<table>
  <tr>
    <td>Contributing Authors</td>
    <td>vii</td>
    <td>General Acknowledgments</td>
    <td>xiii</td>
  </tr>
  <tr>
    <td>Associate Authors</td>
    <td>viii</td>
    <td>How to Contribute</td>
    <td>xv</td>
  </tr>
  <tr>
    <td>Faculty Advisors</td>
    <td></td>
    <td>How to Use This Book</td>
    <td>xvii</td>
  </tr>
  <tr>
    <td>Preface</td>
    <td>xi</td>
    <td>Selected USMLE Laboratory Values</td>
    <td>xviii</td>
  </tr>
  <tr>
    <td>Special Acknowledgments</td>
    <td>xii</td>
    <td>First Aid Checklist for the USMLE Step 1</td>
    <td>XX</td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>Introduction</td>
    <td>2</td>
    <td>Test-Taking Strategies</td>
    <td>19</td>
  </tr>
  <tr>
    <td>USMLE Step 1—The Basics</td>
    <td>2</td>
    <td>Clinical Vignette Strategies</td>
    <td>21</td>
  </tr>
  <tr>
    <td>Learning Strategies</td>
    <td>11</td>
    <td>If You Think You Failed</td>
    <td>22</td>
  </tr>
  <tr>
    <td>Timeline for Study</td>
    <td>14</td>
    <td>Testing Agencies</td>
    <td>22</td>
  </tr>
  <tr>
    <td>Study Materials</td>
    <td>18</td>
    <td>References</td>
    <td>23</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>&gt; SECTION Il</th>
    <th>HIGH-YIELD</th>
    <th>GENERAL PRINCIPLES</th>
    <th>27</th>
  </thead>
  <tr>
    <td>How to Use the Database</td>
    <td>28</td>
    <td>Pathology</td>
    <td>201</td>
  </tr>
  <tr>
    <td>Biochemistry</td>
    <td>31</td>
    <td>Pharmacology</td>
    <td>227</td>
  </tr>
  <tr>
    <td>Immunology</td>
    <td>93</td>
    <td>Public Health Sciences</td>
    <td>255</td>
  </tr>
  <tr>
    <td>Microbiology</td>
    <td>121</td>
    <td></td>
    <td></td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>&gt; SECTION III</td>
    <td>HIGH-YIELD</td>
    <td>ORGAN SYSTEMS</td>
    <td></td>
  </tr>
  <tr>
    <td>Approaching the Organ Systems.</td>
    <td>280</td>
    <td>Neurology and Special Senses</td>
    <td>499</td>
  </tr>
  <tr>
    <td>Cardiovascular</td>
    <td>283</td>
    <td>Psychiatry</td>
    <td>571</td>
  </tr>
  <tr>
    <td>Endocrine</td>
    <td>329</td>
    <td>Renal</td>
    <td>597</td>
  </tr>
  <tr>
    <td>Gastrointestinal</td>
    <td>363</td>
    <td>Reproductive</td>
    <td>631</td>
  </tr>
  <tr>
    <td>Hematology and Oncology</td>
    <td>409</td>
    <td>Respiratory</td>
    <td>679</td>
  </tr>
  <tr>
    <td>Musculoskeletal, Skin, and Connective Tissue</td>
    <td>449</td>
    <td>Rapid Review</td>
    <td>709</td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>How to Use the Database</td>
    <td>742</td>
    <td>Biochemistry</td>
    <td>746</td>
  </tr>
  <tr>
    <td>Question Banks</td>
    <td>744</td>
    <td>Cell Biology and Histology</td>
    <td>746</td>
  </tr>
  <tr>
    <td>Web and Mobile Apps</td>
    <td>744</td>
    <td>Microbiology and Immunology</td>
    <td>746</td>
  </tr>
  <tr>
    <td>Comprehensive</td>
    <td>745</td>
    <td>Pathology</td>
    <td>747</td>
  </tr>
  <tr>
    <td>Anatomy, Embryology, and Neuroscience</td>
    <td>745</td>
    <td>Pharmacology</td>
    <td>747</td>
  </tr>
  <tr>
    <td>Behavioral Science</td>
    <td>746</td>
    <td>Physiology</td>
    <td>748</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>Louisville</th>
    <th>‘Tao Le</th>
    <th></th>
  </thead>
  <tr>
    <td colspan="3">Boracay Vikas Bhushan</td>
  </tr>
  <tr>
    <td colspan="3">Baltimore Connie Qiu</td>
  </tr>
  <tr>
    <td colspan="3">Kathmandu Anup Chalise</td>
  </tr>
  <tr>
    <td colspan="3">Athens Panagiotis Kaparaliotis</td>
  </tr>
  <tr>
    <td colspan="3">Atlanta Caroline Coleman</td>
  </tr>
  <tr>
    <td>San Francisco</td>
    <td>Kimberly</td>
    <td>Kallianos</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>Louisville</th>
    <th>‘Tao Le</th>
    <th></th>
  </thead>
  <tr>
    <td colspan="3">Boracay Vikas Bhushan</td>
  </tr>
  <tr>
    <td colspan="3">Baltimore Connie Qiu</td>
  </tr>
  <tr>
    <td colspan="3">Kathmandu Anup Chalise</td>
  </tr>
  <tr>
    <td colspan="3">Athens Panagiotis Kaparaliotis</td>
  </tr>
  <tr>
    <td colspan="3">Atlanta Caroline Coleman</td>
  </tr>
  <tr>
    <td>San Francisco.</td>
    <td>Kimberly</td>
    <td>Kallianos</td>
  </tr>
</table>
<table>
  <thead>
    <th>lood, Plasma, Serum</th>
    <th>Reference Range</th>
    <th>SI Reference Intervals</th>
  </thead>
  <tr>
    <td>Alanine aminotransferase (ALT, GPT at 30°C)</td>
    <td>10-40 U/L</td>
    <td>10-40 U/L</td>
  </tr>
  <tr>
    <td>Alkaline phosphatase</td>
    <td>25-100 U/L</td>
    <td>25-100 U/L</td>
  </tr>
  <tr>
    <td>Amylase, serum</td>
    <td>25-125 U/L</td>
    <td>25-125 U/L</td>
  </tr>
  <tr>
    <td>Aspartate aminotransferase (AST, GOT at 30°C)</td>
    <td>12-38 U/L</td>
    <td>12-38 U/L</td>
  </tr>
  <tr>
    <td>Bilirubin, serum (adult) Total // Direct</td>
    <td>0.1-1.0 mg/dL // 0.0-0.3 mg/dL</td>
    <td>2-17 umol/L // 0-5 umol/L</td>
  </tr>
  <tr>
    <td>Calcium, serum (Total)</td>
    <td>8.4-10.2 mg/dL</td>
    <td>2.1-2.6 mmol/L</td>
  </tr>
  <tr>
    <td>Cholesterol, serum (Total)</td>
    <td>Rec: &lt; 200 mg/dL</td>
    <td>&lt;5.2 mmol/L</td>
  </tr>
  <tr>
    <td>Creatinine, serum (Total)</td>
    <td>0.6-1.2 mg/dL</td>
    <td>53-106 umol/L</td>
  </tr>
  <tr>
    <td colspan="3"></td>
  </tr>
  <tr>
    <td>
      Electrolytes, serum Sodium (Na‘*) Chloride (Cl) otassium (K*) Bicarbonate
      (HCO,&gt;)
    </td>
    <td>136-146 mEq/L 95-105 mEq/L 3.5-5.0 mEq/L 22-28 mEq/L 15-2 mEq/L</td>
    <td>
      136-146 mmol/L 95-105 mmol/L, 3.5-5.0 mmol/L 22-28 mmol/L 0.75-1.0 mmol/L
    </td>
  </tr>
  <tr>
    <td>Magnesium (Mg**)</td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td colspan="3">
      Gases, arterial blood (room air) 75-105 Hg 10.0-14.0 kPa
    </td>
  </tr>
  <tr>
    <td>Glucose,</td>
    <td>33-45 mm Hg 735-745 70-100</td>
    <td>44-59 kPa [H"] 36-44 nmol/L 3.8-6.1 mmol/L</td>
  </tr>
  <tr>
    <td>serum Growth hormone ~ stimulation</td>
    <td>Fasting: mg/dL &lt; 5</td>
    <td>&lt;5</td>
  </tr>
  <tr>
    <td>arginine</td>
    <td>Fasting: ng/mL Provocative stimuli: &gt; 7 ng/mL</td>
    <td>ug/L &gt;7 ug/L</td>
  </tr>
  <tr>
    <td>Osmolality, serum</td>
    <td>275-295 mOsmol/kg H,O</td>
    <td>275-295 mOsmol/kg H,O</td>
  </tr>
  <tr>
    <td>Phosphorus (inorganic), serum Prolactin, (hPRL)</td>
    <td>3.0-4.5 mg/dL Male: 17</td>
    <td>1.0-1.5 mmol/L 17</td>
  </tr>
  <tr>
    <td>serum Proteins, serum</td>
    <td>&lt; ng/mL. Female: &lt; 25 ng/mL</td>
    <td>&lt; pg/L &lt;25 pg/L</td>
  </tr>
  <tr>
    <td>Total (recumbent) Albumin Globulins</td>
    <td>6.0-78 g/dL. 35-55 gidL. 23-35 gidL,</td>
    <td>60-78 g/L. 35-55 g/L. 23-35 g/L.</td>
  </tr>
  <tr>
    <td>Thyroid-stimulating hormone, serum or plasma</td>
    <td>0.4-4.0 wU/nL</td>
    <td>0.4—4.0 mIU/L</td>
  </tr>
  <tr>
    <td>Urea nitrogen, serum (BUN)</td>
    <td>7-18 mg/dL</td>
    <td>25-64 nmol/L</td>
  </tr>
  <tr>
    <td>Uric acid, serum</td>
    <td>3.0-8.2 mg/dL</td>
    <td>0.18—0.48 mmol/L</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>Yell count</th>
    <th>0-5/mm?</th>
    <th>0-5 x 10°/L</th>
  </thead>
  <tr>
    <td>xlucose</td>
    <td>40-70 mg/dL</td>
    <td>2.2-3.9 mmol/L</td>
  </tr>
  <tr>
    <td>roteins, total</td>
    <td>&lt;40 mg/dL</td>
    <td>&lt; 040 g/L</td>
  </tr>
  <tr>
    <td colspan="3">natologic</td>
  </tr>
  <tr>
    <td>itythrocyte count</td>
    <td>Male: 4.3-5.9 million/mm* Female: 3.5-5.5 million/mm?</td>
    <td>435.9 x 10?/L, 3.5-5.5 x 10?/L,</td>
  </tr>
  <tr>
    <td>itythrocyte sedimentation rate (Westergen)</td>
    <td>Male: 0-15 mm/hr Female: 0-20 mm/hr</td>
    <td>0-15 mm/hr 0-20 mm/hr</td>
  </tr>
  <tr>
    <td>[ematocrit</td>
    <td>Male: 41-53%</td>
    <td>0.41-0.53</td>
  </tr>
  <tr>
    <td>Iemoglobin, blood</td>
    <td>Female: 36-46% Male: 13.5-17.5 g/dL.</td>
    <td>0.36-0.46 135-175 g/L</td>
  </tr>
  <tr>
    <td>Iemoglobin, plasma</td>
    <td>Female: 12.0-16.0 g/dL &lt;4mg/dL</td>
    <td>120-160 g/L &lt; 0.62 umol/L</td>
  </tr>
  <tr>
    <td>seukocyte count and differential</td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td>Leukocyte count</td>
    <td>4,500—11,000/mm?</td>
    <td>4.5-11.0 x 10°/L</td>
  </tr>
  <tr>
    <td></td>
    <td></td>
    <td>0.54-0.62</td>
  </tr>
  <tr>
    <td>Segmented neutrophils</td>
    <td>54-62%</td>
    <td></td>
  </tr>
  <tr>
    <td>Band forms</td>
    <td>35%</td>
    <td>0.03-0.05</td>
  </tr>
  <tr>
    <td>Eosinophils</td>
    <td>13%</td>
    <td>0.01—0.03</td>
  </tr>
  <tr>
    <td>Basophils</td>
    <td>0-0.75%</td>
    <td>0-0.0075</td>
  </tr>
  <tr>
    <td>Lymphocytes</td>
    <td>25-33%</td>
    <td>0.25-0.33</td>
  </tr>
  <tr>
    <td>Monocytes</td>
    <td>37%</td>
    <td>0.03—0.07</td>
  </tr>
  <tr>
    <td>Jean corpuscular hemoglobin</td>
    <td>25-35 pg/cell</td>
    <td>0.39-0.54 fmol/cell</td>
  </tr>
  <tr>
    <td>lean corpuscular hemoglobin concentration</td>
    <td>31%-36% Hb/cell</td>
    <td>4.8-5.6 mmol Hb/L</td>
  </tr>
  <tr>
    <td>Jean corpuscular volume</td>
    <td>80-100 um?</td>
    <td>80-100 fL</td>
  </tr>
  <tr>
    <td>artial thromboplastin time (activated)</td>
    <td>25-40 sec</td>
    <td>25-40 sec</td>
  </tr>
  <tr>
    <td>latelet count</td>
    <td>150,000-400,000/mm?</td>
    <td>150-400 x 10°/L</td>
  </tr>
  <tr>
    <td>rothrombin time</td>
    <td>11-15 sec</td>
    <td>11-15 sec</td>
  </tr>
  <tr>
    <td>eticulocyte count</td>
    <td>0.5-1.5% of RBCs</td>
    <td>0.005—0.015</td>
  </tr>
  <tr>
    <td colspan="3">le</td>
  </tr>
  <tr>
    <td>Yreatinine clearance</td>
    <td>Male: 97-137 mL/min Female: 88-128 mL/min</td>
    <td>97-137 mL/min 88-128 mL/min</td>
  </tr>
  <tr>
    <td>)smolality</td>
    <td>50-1200 mOsmol/kg H,O</td>
    <td>50-1200 mOsmol/kg H,O</td>
  </tr>
  <tr>
    <td>roteins, total</td>
    <td>&lt; 150 mg/24 hr</td>
    <td>&lt;0.15 g/24 hr</td>
  </tr>
</table>
<table>
  <tr>
    <td>Years Prior —</td>
    <td>
      © Use top-rated review resources for first-year medical school courses. 0
      Ask for advice from those who have recently taken the USMLE Step 1.
    </td>
  </tr>
  <tr>
    <td>Months Prior</td>
    <td>
      CO Review computer test format and registration information. O Register
      six months in advance. O Carefully verify name and address printed on
      scheduling permit. Make sure the name on scheduling permit matches the
      name printed on your photo ID. 0 Go online for test date ASAP. O Set up a
      realistic timeline for study. Cover less crammable subjects first. 0
      Evaluate and choose study materials (review books, question banks). O Use
      a question bank to simulate the USMLE Step 1 to pinpoint strengths and
    </td>
  </tr>
  <tr>
    <td>Weeks Prior</td>
    <td>
      weaknesses in knowledge and test-taking skills from early on. 0 Do test
      simulations in question banks.
    </td>
  </tr>
  <tr>
    <td>One Week Prior</td>
    <td>
      1 Remember comfort measures (eg, loose clothing, earplugs). 0 Work out
      test site logistics (eg, location, transportation, parking, lunch). O
      Print or download your Scheduling Permit and Scheduling Confirmation to
      your phone.
    </td>
  </tr>
  <tr>
    <td>One Day Prior</td>
    <td>
      O Relax. Lightly review short-term material if necessary. Skim high-yield
      facts. O Get a good night’s sleep.
    </td>
  </tr>
  <tr>
    <td>Day of Exam</td>
    <td>
      0 Relax. 0 Eat breakfast. 0 Minimize bathroom breaks during exam by
      avoiding excessive morning caffeine.
    </td>
  </tr>
  <tr>
    <td>After Exam</td>
    <td>
      O Celebrate, regardless of how well you feel you did. O Send feedback to
      us on our website at www.firstaidteam.com firstaid@scholarrx.com.
    </td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td></td>
    <td>&gt; Introduction</td>
    <td></td>
    <td>2</td>
  </tr>
  <tr>
    <td>USMLE</td>
    <td>&gt;» Step</td>
    <td>1—The</td>
    <td></td>
  </tr>
  <tr>
    <td>Basics</td>
    <td></td>
    <td></td>
    <td>2</td>
  </tr>
  <tr>
    <td>Learning</td>
    <td>&gt; Strategies</td>
    <td></td>
    <td>= 1</td>
  </tr>
  <tr>
    <td>Failed</td>
    <td></td>
    <td></td>
    <td>22</td>
  </tr>
  <tr>
    <td></td>
    <td>&gt; Testing Agencies</td>
    <td></td>
    <td>22</td>
  </tr>
  <tr>
    <td></td>
    <td>» References</td>
    <td></td>
    <td>23</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>Competency</th>
    <th>Range, %</th>
    <th>System</th>
    <th>Range, %</th>
  </thead>
  <tr>
    <td>Medical knowledge: applying foundational science concepts</td>
    <td>— 60-70</td>
    <td>General principles</td>
    <td>12-16</td>
  </tr>
  <tr>
    <td>Patient care: diagnosis</td>
    <td>20-25</td>
    <td>Behavioral health &amp; nervous systems/special senses</td>
    <td></td>
  </tr>
  <tr>
    <td>Communication and interpersonal skills</td>
    <td>6-9</td>
    <td>Respiratory &amp; rena /urinary systems</td>
    <td>Www</td>
  </tr>
  <tr>
    <td rowspan="2">Practice-based learning &amp; improvement Discipline</td>
    <td>4-6</td>
    <td>Reproductive &amp; en docrine systems</td>
    <td></td>
  </tr>
  <tr>
    <td></td>
    <td>Range, %</td>
    <td>Blood &amp; lymphore icular/immune systems</td>
    <td>~~ Il F</td>
  </tr>
  <tr>
    <td>Pathology</td>
    <td>44-52</td>
    <td>Multisystem processes &amp; disorders</td>
    <td>CO</td>
  </tr>
  <tr>
    <td>Physiology</td>
    <td>25-35</td>
    <td>Musculoskeletal, skin &amp; subcutaneous tissue</td>
    <td></td>
  </tr>
  <tr>
    <td>Pharmacology</td>
    <td>15-22</td>
    <td>Cardiovascular sys em</td>
    <td></td>
  </tr>
  <tr>
    <td>Biochemistry &amp; nutrition</td>
    <td>14-24</td>
    <td>Gastrointestinal system</td>
    <td>5-9</td>
  </tr>
  <tr>
    <td>Microbiology</td>
    <td>10-15</td>
    <td>Biostatistics &amp; epid emiology/population health</td>
    <td>4-6</td>
  </tr>
  <tr>
    <td>Immunology</td>
    <td>6-11</td>
    <td>Social sciences: communication skills/ethics</td>
    <td>6-9</td>
  </tr>
  <tr>
    <td>Gross anatomy &amp; embryology</td>
    <td>11-15</td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td>Histology &amp; cell biology</td>
    <td>8-13</td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td>Behavioral sciences</td>
    <td>8-13</td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td>Genetics</td>
    <td>5-9</td>
    <td></td>
    <td></td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th></th>
    <th>No. Tested</th>
    <th>% Passing</th>
    <th>No. Tested</th>
    <th>% Passing</th>
  </thead>
  <tr>
    <td>Allopathic Ist takers</td>
    <td>19,772</td>
    <td>98%</td>
    <td>22,280</td>
    <td>96%</td>
  </tr>
  <tr>
    <td>Repeaters</td>
    <td>571</td>
    <td>67%</td>
    <td>798</td>
    <td>66%</td>
  </tr>
  <tr>
    <td>Allopathic total</td>
    <td>20,343</td>
    <td>95%</td>
    <td>23,078</td>
    <td>95%</td>
  </tr>
  <tr>
    <td>Osteopathic Ist takers</td>
    <td>5,235</td>
    <td>96%</td>
    <td>5,309</td>
    <td>94%</td>
  </tr>
  <tr>
    <td>Repeaters</td>
    <td>39</td>
    <td>74%</td>
    <td>56</td>
    <td>75%</td>
  </tr>
  <tr>
    <td>Osteopathic total</td>
    <td>5,274</td>
    <td>95%</td>
    <td>5,365</td>
    <td>94%</td>
  </tr>
  <tr>
    <td>Total US/Canadian</td>
    <td>25,617</td>
    <td>97%</td>
    <td>28,443</td>
    <td>95%</td>
  </tr>
  <tr>
    <td>IMG Ist takers</td>
    <td>11,742</td>
    <td>87%</td>
    <td>16,952</td>
    <td>82%</td>
  </tr>
  <tr>
    <td>Repeaters</td>
    <td>1,375</td>
    <td>50%</td>
    <td>2,258</td>
    <td>45%</td>
  </tr>
  <tr>
    <td>IMG total</td>
    <td>13,117</td>
    <td>83%</td>
    <td>19,210</td>
    <td>77%</td>
  </tr>
  <tr>
    <td>Total Step 1 examinees</td>
    <td>38,734</td>
    <td>92%</td>
    <td>47,653</td>
    <td>87%</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>Efficacy</th>
    <th>Strategy</th>
    <th>Example Resources</th>
  </thead>
  <tr>
    <td></td>
    <td></td>
    <td>Anki</td>
  </tr>
  <tr>
    <td></td>
    <td></td>
    <td>Firecracker</td>
  </tr>
  <tr>
    <td></td>
    <td></td>
    <td>Memorang</td>
  </tr>
  <tr>
    <td>Moderate efficacy</td>
    <td>Mnemonics</td>
    <td>Osmosis Pre-made: SketchyMedical Picmonic Self-made: Mullen Memory</td>
  </tr>
  <tr>
    <td></td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td></td>
    <td>Elaborative interrogation/ selfexplanation</td>
    <td></td>
  </tr>
  <tr>
    <td></td>
    <td>Concept mapping</td>
    <td>Coggle</td>
  </tr>
  <tr>
    <td></td>
    <td></td>
    <td>FreeMind</td>
  </tr>
  <tr>
    <td></td>
    <td></td>
    <td>XMind</td>
  </tr>
  <tr>
    <td></td>
    <td></td>
    <td>MindNode</td>
  </tr>
  <tr>
    <td>Low efficacy</td>
    <td>Rereading</td>
    <td></td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>» How to</td>
    <td>Use</td>
    <td></td>
    <td>the</td>
    <td></td>
  </tr>
  <tr>
    <td>Database</td>
    <td></td>
    <td></td>
    <td></td>
    <td>28</td>
  </tr>
  <tr>
    <td>&gt; Biochemistry</td>
    <td></td>
    <td></td>
    <td></td>
    <td>31</td>
  </tr>
  <tr>
    <td>&gt; Microbiology</td>
    <td></td>
    <td></td>
    <td></td>
    <td>121</td>
  </tr>
  <tr>
    <td>»</td>
    <td></td>
    <td></td>
    <td></td>
    <td>201</td>
  </tr>
  <tr>
    <td>Pathology</td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td>» Pharmacology</td>
    <td></td>
    <td></td>
    <td></td>
    <td>227</td>
  </tr>
  <tr>
    <td>» Public</td>
    <td>Health</td>
    <td></td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td>Sciences</td>
    <td></td>
    <td></td>
    <td></td>
    <td>255</td>
  </tr>
</table>
<table>
  <tr>
    <td>Histone methylation</td>
    <td>
      Usually causes reversible transcriptional suppression, but can also cause
      activation depending on location of methyl groups.
    </td>
    <td>
      Fragile syndrome. Histone methylation mostly makes DNA mute. Lysine and
      arginine residues of histones can be methylated.
    </td>
  </tr>
  <tr>
    <td>Histone acetylation</td>
    <td>
      Removal of histone’s ® charge + relaxed DNA coiling &gt; t transcription.
    </td>
    <td>
      Thyroid hormone synthesis is altered by acetylation of thyroid hormone
      receptor. Histone acetylation makes DNA active.
    </td>
  </tr>
  <tr>
    <td>Histone deacetylation</td>
    <td>
      Removal of acetyl groups &gt; tightened DNA coiling &gt; $ transcription.
    </td>
    <td>
      Histone deacetylation may be responsible for altered gene expression in
      Huntington disease.
    </td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>Unambiguous</td>
    <td>Each codon specifies only | amino acid.</td>
    <td></td>
  </tr>
  <tr>
    <td>Degenerate/ redundant</td>
    <td>
      Most amino acids are coded by multiple codons. Wobble hypothesis—first 2
      nucleotides of codon are essential for anticodon recognition while the 3rd
      nucleotide can differ (“wobble”).
    </td>
    <td>
      Exceptions: methionine (AUG) and tryptophan (UGG) encoded by only 1 codon.
    </td>
  </tr>
  <tr>
    <td>Commaless, nonoverlapping</td>
    <td>Read from a fixed starting point as a continuous sequence of bases.</td>
    <td>Exceptions: some viruses.</td>
  </tr>
  <tr>
    <td>Universal</td>
    <td>Genetic code is conserved throughout evolution.</td>
    <td>Exception in humans: mitochondria.</td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>Origin of replication EY</td>
    <td>
      Particular consensus sequence in genome where DNA replication begins. May
      be single
    </td>
    <td>
      AT-rich sequences (eg, TATA box regions) are found in promoters (often
      upstream) and
    </td>
  </tr>
  <tr>
    <td>Replication fork FJ</td>
    <td>
      (prokaryotes) or multiple (eukaryotes). Y-shaped region along DNA template
      where
    </td>
    <td>origins of replication (ori).</td>
  </tr>
  <tr>
    <td>Helicase [4</td>
    <td>
      leading and lagging strands are synthesized. Unwinds DNA template at
      replication fork.
    </td>
    <td>Helicase halves DNA.</td>
  </tr>
  <tr>
    <td>Single-stranded</td>
    <td>Prevent strands from reannealing or degradation</td>
    <td>Deficient in Bloom syndrome (BLM gene mutation).</td>
  </tr>
  <tr>
    <td>binding proteins B) DNA topoisomerases [3</td>
    <td>
      by nucleases. Creates a single- (topoisomerase I) or double-
      (topoisomerase II) stranded break in the helix to add or remove supercoils
      (as needed due to underwinding or overwinding of DNA).
    </td>
    <td>
      In eukaryotes: irinotecan/topotecan inhibit topoisomerase (‘T'OP) I,
      etoposide/teniposide inhibit TOP IL. In prokaryotes: fluoroquinolones
      inhibit TOP II
    </td>
  </tr>
  <tr>
    <td>Primase [9</td>
    <td>Makes RNA primer for DNA polymerase III to initiate replication.</td>
    <td>(DNA gyrase)</td>
  </tr>
  <tr>
    <td>DNA polymerase III [4]</td>
    <td>
      Prokaryotes only. Elongates leading strand by adding deoxynucleotides to
      the 3’ end. Elongates lagging strand until it reaches primer of preceding
      fragment.
    </td>
    <td>
      DNA polymerase III has 5’ + 3’ synthesis and proofreads with 3’ + 5’
      exonuclease. Drugs blocking DNA replication often have a modified 3’ OH,
      thereby preventing addition of the next nucleotide (“chain termination”).
    </td>
  </tr>
  <tr>
    <td>DNA polymerase | [J</td>
    <td>Prokaryotes only. Degrades RNA primer; replaces it with DNA.</td>
    <td>
      Same functions as DNA polymerase III, also excises RNA primer with 5’ + 3’
      exonuclease.
    </td>
  </tr>
  <tr>
    <td>DNA ligase {J</td>
    <td>
      Catalyzes the formation of a phosphodiester bond within a strand of
      double-stranded DNA.
    </td>
    <td>Joins Okazaki fragments. Ligase links DNA.</td>
  </tr>
  <tr>
    <td>Telomerase</td>
    <td>
      Eukaryotes only. A reverse transcriptase (RNA- dependent DNA polymerase)
      that adds DNA (TTAGGG) to 3’ ends of chromosomes to avoid
    </td>
    <td>
      Upregulated in progenitor cells and also often in cancer; downregulated in
      aging and progeria. Telomerase TAGs for Greatness and Glory.
    </td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td></td>
    <td>
      lost or translocated. May be dysfunctional in ataxia telangiectasia.
    </td>
  </tr>
  <tr>
    <td></td>
    <td>
      strand from damaged dsDNA is repaired using a complementary strand from
      intact
    </td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>Enhancer</td>
    <td>
      activity. DNA locus w here regulatory pro eins (“activators”) bind,
      increasing expression of a gene on the same chromosome.
    </td>
    <td>
      Enhancers and silencers may be located close to, far from, or even within
      (in an intron) the gene whose expression they regulate.
    </td>
  </tr>
  <tr>
    <td>Silencer</td>
    <td>
      DNA locus w here regulatory pro eins (“repressors”) bind, decreasing
      expression of a gene on the same chromosome.
    </td>
    <td></td>
  </tr>
  <tr>
    <td>Epigenetics</td>
    <td>
      Changes mad mitotically/meiotically) withou le to gene expressio n
      (heritable underlying DNA sequence. a change in
    </td>
    <td>
      Primary mechanisms of epigenetic change include DNA methylation, histone
      modification, and noncoding RNA.
    </td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>ukaryotes</td>
    <td>RNA polymerase I makes r RNA, the most</td>
    <td>I, I, and III are numbered in the same order</td>
  </tr>
  <tr>
    <td>rokaryotes</td>
    <td>
      promoter 1 RNA polymerase (multisubunit complex) makes all 3 kinds of RNA.
    </td>
    <td>
      Rifamycins (rifampin, rifabutin) inhibit DNA- dependent RNA polymerase in
      prokaryotes.
    </td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>mRNA start codon</th>
    <th>AUG.</th>
    <th>AUG inAUGurates protein synthesis.</th>
  </thead>
  <tr>
    <td>Eukaryotes</td>
    <td>
      Codes for methionine, which may be removed before translation is
      completed.
    </td>
    <td></td>
  </tr>
  <tr>
    <td>Prokaryotes</td>
    <td>Codes for N-formylmethionine (fMet).</td>
    <td>fMet stimulates neutrophil chemotaxis.</td>
  </tr>
  <tr>
    <td rowspan="2">mRNA stop codons</td>
    <td>UGA, UAA, UAG.</td>
    <td>UGA = U Go Away.</td>
  </tr>
  <tr>
    <td></td>
    <td>Recognized by release factors.</td>
    <td>UAA = U Are Away.</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>TYPE OF FILAMENT</th>
    <th>PREDOMINANT FUNCTION</th>
    <th>EXAMPLES</th>
  </thead>
  <tr>
    <td>Microfilaments</td>
    <td>Muscle contraction, cytokinesis</td>
    <td>Actin, microvilli.</td>
  </tr>
  <tr>
    <td>Intermediate filaments</td>
    <td>Maintain cell structure</td>
    <td>
      Vimentin, desmin, cytokeratin, lamins, glial fibrillary acidic protein
      (GFAP), neurofilaments.
    </td>
  </tr>
  <tr>
    <td>Microtubules</td>
    <td>Movement, cell division</td>
    <td>Cilia, flagella, mitotic spindle, axonal trafficking, centrioles.</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th></th>
    <th>Extensively modified by posttranslational</th>
    <th>Type II - Cartilage</th>
  </thead>
  <thead>
    <th></th>
    <th>modification.</th>
    <th>‘Type III - Arteries</th>
  </thead>
  <thead>
    <th></th>
    <th>
      Organizes and strengthens extracellular matrix. ‘Types I to IV are the
      most common types in humans.
    </th>
    <th>‘Type IV - Basement membrane SCAB</th>
  </thead>
  <tr>
    <td>Typel</td>
    <td>
      Most common (90%)—Bone (made by osteoblasts), Skin, Tendon, dentin,
      fascia, cornea, late wound repair.
    </td>
    <td>
      Type L: bone, tendone. + production in osteogenesis imperfecta type I.
    </td>
  </tr>
  <tr>
    <td>Type ll</td>
    <td>Cartilage (including hyaline), vitreous body, nucleus pulposus.</td>
    <td>Type II: cartwolage.</td>
  </tr>
  <tr>
    <td>Type lll</td>
    <td>
      Reticulin—skin, blood vessels, uterus, fetal tissue, early wound repair.
    </td>
    <td>
      Type LIL deficient in vascular type of Ehlers- Danlos syndrome (threE D).
    </td>
  </tr>
  <tr>
    <td>Type lV</td>
    <td>Basement membrane/basal lamina (glomerulus, cochlea), lens.</td>
    <td>
      Type IV: under the floor (basement membrane). Defective in Alport
      syndrome; targeted by autoantibodies in Goodpasture syndrome.
      Myofibroblasts are responsible for secretion (proliferative stage) and
      wound contraction.
    </td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>INHERITANCE</td>
    <td>Autosomal dominant</td>
    <td>Autosomal recessive</td>
  </tr>
  <tr>
    <td>INTELLECT</td>
    <td>Normal</td>
    <td>Decreased</td>
  </tr>
  <tr>
    <td>VASCULAR COMPLICATIONS</td>
    <td>Aortic root dilatation</td>
    <td>Thrombosis</td>
  </tr>
  <tr>
    <td>LENS DISLOCATION</td>
    <td>Upward/temporal (Marfan fans out)</td>
    <td>Downward/nasal</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>Gene expression modifications</th>
    <th>
      Transgenic strategies in mice involve: * Random insertion of gene into
      mouse genome * Targeted insertion or deletion of gene through homologous
      recombination with mouse gene
    </th>
    <th>
      Knock-out = removing a gene, taking it out. Knock-in = inserting a gene.
      Random insertion—constitutive expression. Targeted insertion—conditional
      expression.
    </th>
  </thead>
  <tr>
    <td>RNA interference</td>
    <td>Process whereby small non-coding RNA molecules</td>
    <td>target mRNAs to inhibit gene expression.</td>
  </tr>
  <tr>
    <td>MicroRNA</td>
    <td>
      Naturally produced by cell as hairpin structures. Loose nucleotide pairing
      allows broad targeting of related mRNAs. When miRNA binds to mRNA, it
      blocks translation of mRNA and sometimes facilitates its degradation.
    </td>
    <td>
      Abnormal expression of miRNAs contributes to certain malignancies (eg, by
      silencing an mRNA from a tumor suppressor gene).
    </td>
  </tr>
  <tr>
    <td>Small interfering RNA</td>
    <td>
      Usually derived from exogenous dsRNA source (eg, virus). Once inside a
      cell, siRNA requires complete nucleotide pairing, leading to highly
      specific mRNA targeting. Results in mRNA cleavage prior to translation.
    </td>
    <td>
      Can be produced by transcription or chemically synthesized for gene
      “knockdown” experiments.
    </td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>TERM</th>
    <th>DEFINITION</th>
    <th>EXAMPLE</th>
  </thead>
  <tr>
    <td>Codominance</td>
    <td>Both alleles contribute to the phenotype of the heterozygote.</td>
    <td>Blood groups A, B, AB; oy-antitrypsin deficiency; HLA groups.</td>
  </tr>
  <tr>
    <td>Variable expressivity</td>
    <td>Patients with the same genotype have varying phenotypes.</td>
    <td>
      ‘Two patients with neurofibromatosis type 1 (NF 1) may have varying
      disease severity.
    </td>
  </tr>
  <tr>
    <td>Incomplete penetrance</td>
    <td>
      Not all individuals with a disease show the disease. % penetrance x
      probability of inheriting genotype = risk of expressing phenotype.
    </td>
    <td>
      BRCAI gene mutations do not always result in breast or ovarian cancer.
    </td>
  </tr>
  <tr>
    <td>Pleiotropy</td>
    <td>One gene contributes to multiple phenotypic effects.</td>
    <td>
      Untreated phenylketonuria (PKU) manifests with light skin, intellectual
      disability, musty body odor.
    </td>
  </tr>
  <tr>
    <td>Anticipation</td>
    <td>
      Increased severity or earlier onset of disease in succeeding generations.
    </td>
    <td>Trinucleotide repeat diseases (eg, Huntington disease).</td>
  </tr>
  <tr>
    <td>Loss of heterozygosity</td>
    <td>
      Ifa patient inherits or develops a mutation in a tumor suppressor gene,
      the wild type allele must be deleted/mutated/eliminated before cancer
      develops. This is not true of oncogenes.
    </td>
    <td>
      Retinoblastoma and the “two-hit hypothesis,” Lynch syndrome (HNPCC),
      Li-Fraumeni syndrome.
    </td>
  </tr>
  <tr>
    <td>Epistasis</td>
    <td>
      The allele of one gene affects the phenotypic expression of alleles in
      another gene.
    </td>
    <td>Albinism, alopecia.</td>
  </tr>
  <tr>
    <td>Aneuploidy</td>
    <td>
      An abnormal number of chromosomes; due to chromosomal nondisjunction
      during mitosis or meiosis.
    </td>
    <td>Down syndrome, ‘Turner syndrome, oncogenesis.</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>TERM</th>
    <th>DEFINITION</th>
    <th>EXAMPLE</th>
  </thead>
  <tr>
    <td>Dominant negative mutation</td>
    <td>
      Exerts a dominant effect. A heterozygote produces a nonfunctional altered
      protein that also prevents the normal gene product from functioning.
    </td>
    <td>
      A single mutated p53 tumor suppressor gene results in a protein that is
      able to bind DNA and block the wild type p53 from binding to the promoter.
    </td>
  </tr>
  <tr>
    <td>Linkage disequilibrium</td>
    <td>
      Tendency for certain alleles to occur in close proximity on the same
      chromosome more or less often than expected by chance. Measured in a
      population, not in a family, and often varies in different populations.
    </td>
    <td></td>
  </tr>
  <tr>
    <td>Mosaicism</td>
    <td>
      Presence of genetically distinct cell lines in the same individual.
      Somatic mosaicism—mutation arises from mitotic errors after fertilization
      and propagates through multiple tissues or organs. Germline (gonadal)
      mosaicism—mutation only in egg or sperm cells. If parents and relatives do
      not have the disease, suspect gonadal (or germline) mosaicism.
    </td>
    <td>
      McCune-Albright syndrome—due to G-protein activating mutation. Presents
      with unilateral café-au-lait spots [J with ragged edges, polyostotic
      fibrous dysplasia (bone is replaced by collagen and fibroblasts), and at
      least one endocrinopathy (eg, precocious puberty). Lethal if mutation
      occurs before fertilization (affecting all cells), but survivable in
      patients with mosaicism.
    </td>
  </tr>
  <tr>
    <td>Locus heterogeneity</td>
    <td>Mutations at different loci result in the same disease.</td>
    <td>Albinism, retinitis pigmentosa, familial hypercholesteremia.</td>
  </tr>
  <tr>
    <td>Allelic heterogeneity</td>
    <td>Different mutations in the same locus result in the same disease.</td>
    <td>B-thalassemia.</td>
  </tr>
  <tr>
    <td>Heteroplasmy</td>
    <td>
      Presence of both normal and mutated mtDNA, resulting in variable
      expression in mitochondrially inherited disease.
    </td>
    <td>mtDNA passed from mother to all children.</td>
  </tr>
  <tr>
    <td>Uniparental disomy</td>
    <td>
      Offspring receives 2 copies of a chromosome from 1 parent and no copies
      from the other parent. HeterodIsomy (heterozygous) indicates a meiosis
      Terror. IsodIsomy (homozygous) indicates a meiosis II error or postzygotic
      chromosomal duplication of one of a pair of chromosomes,
    </td>
    <td>
      Uniparental is euploid (correct number of chromosomes). Most occurrences
      of uniparental disomy (UPD) &gt; normal phenotype. Consider isodisomy in
      an individual manifesting a recessive disorder when only one parent is a
      carrier. Examples: Prader-Willi and Angelman
    </td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>CONCEPT</th>
    <th>DESCRIPTION</th>
    <th>EXAMPLE</th>
  </thead>
  <tr>
    <td>Bottleneck effect</td>
    <td>
      Fitness equal across alleles &gt; natural disaster that removes certain
      alleles by chance — new allelic frequency (by chance, not naturally
      selected).
    </td>
    <td>
      The founder effect is a type of bottleneck when cause is due to calamitous
      population separation.
    </td>
  </tr>
  <tr>
    <td>Natural selection</td>
    <td>
      Alleles that increase species fitness are more likely to be passed down to
      offspring and vice versa.
    </td>
    <td>Human evolution.</td>
  </tr>
  <tr>
    <td>Genetic drift</td>
    <td>
      Also called allelic drift or Wright effect. A dramatic shift in allelic
      frequency that occurs
    </td>
    <td>
      Founder effect and bottleneck effect are both examples of genetic drift.
    </td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>Alp)</th>
    <th>a(q)</th>
  </thead>
  <tr>
    <td>AA</td>
    <td>Aa</td>
  </tr>
  <tr>
    <td>(p’)</td>
    <td>(pq)</td>
  </tr>
  <tr>
    <td>Aa</td>
    <td>aa</td>
  </tr>
  <tr>
    <td>(pq)</td>
    <td>(2)</td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>WHICH GENE IS SILENT?</td>
    <td>
      Maternally derived genes are silenced Disease occurs when the paternal or
      mutated
    </td>
    <td>
      Paternally derived UBE3A is silenced Disease occurs when the maternal
      allele is deleted or mutated
    </td>
  </tr>
  <tr>
    <td>SIGNS AND SYMPTOMS</td>
    <td>Hyperphagia, obesity, intellectual hypogonadism, hypotonia</td>
    <td>
      Hand-flapping, Ataxia, severe Intellectual disability, inappropriate
      Laughter, Seizures. HAILS the Angels.
    </td>
  </tr>
  <tr>
    <td>CHROMOSOMES INVOLVED</td>
    <td>Chromosome 15 of paternal origin</td>
    <td>UBE3A on maternal copy of chromosome 15</td>
  </tr>
  <tr>
    <td rowspan="8">NOTES</td>
    <td>25% of cases are due to maternal disomy</td>
    <td>5% of cases are due to paternal uniparental disomy</td>
  </tr>
  <tr>
    <td></td>
    <td>POP: Prader-Willi, Obesity/overeating, allele deleted</td>
    <td>
      MAMAS: Maternal allele deleted, Angelman syndrome, Mood, Ataxia, Seizures
    </td>
  </tr>
  <tr>
    <td></td>
    <td></td>
    <td>P = Paternal M = Maternal</td>
  </tr>
  <tr>
    <td></td>
    <td>Normal</td>
    <td>Active gene i</td>
  </tr>
  <tr>
    <td></td>
    <td>P M</td>
    <td>Silenced gene (imprinting)</td>
  </tr>
  <tr>
    <td></td>
    <td></td>
    <td>Gene deletion/mutation ©</td>
  </tr>
  <tr>
    <td></td>
    <td></td>
    <td>Prader-Willi syndrome</td>
  </tr>
  <tr>
    <td></td>
    <td></td>
    <td>Angelman syndrome</td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td rowspan="3">Autosomal dominant on06 HOU 00a</td>
    <td colspan="5">
      Often due to defects in structural genes. Many generations, both males and
      females are affected.
    </td>
    <td rowspan="3">
      Often pleiotropic (multiple apparently unrelated effects) and variably
      expressive (different between individuals). Family history crucial to
      diagnosis. With one affected (heterozygous) parent, each child has a 50%
      chance of being affected.
    </td>
  </tr>
  <tr>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td>Autosomal recessive O</td>
    <td>With of</td>
    <td>2 each 50% not</td>
    <td>carrier child has chance being</td>
    <td>(heterozygous) a 25% of being affected</td>
    <td>
      parents, on average: chance of being affected, carrier, and 25% chance
      carrier.
    </td>
    <td rowspan="3">
      Often due to enzyme deficiencies. Usually seen in only 1 generation.
      Commonly more severe than dominant disorders; patients often present in
      childhood. t risk in consanguineous families. Unaffected individual with
      affected sibling has 2/3 probability of being a carrier.
    </td>
  </tr>
  <tr>
    <td>OO OOH a</td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td>X-linked recessive &lt;q O</td>
    <td>Sons</td>
    <td>of chance</td>
    <td>heterozygous of being</td>
    <td>affected.</td>
    <td>mothers have a 50% No male-to-male</td>
    <td>
      Commonly more severe in males. Females usually must be homozygous to be
      affected.
    </td>
  </tr>
  <tr>
    <td>ou</td>
    <td>Y</td>
    <td>XX XY</td>
    <td>XY</td>
    <td>Y</td>
    <td>wn</td>
    <td rowspan="2"></td>
    <td></td>
  </tr>
  <tr>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td>X-linked dominant</td>
    <td></td>
    <td>Transmitted affected</td>
    <td>mothers</td>
    <td>through each</td>
    <td>parents. Children of a 50% chance of</td>
    <td rowspan="4">
      Examples: fragile X syndrome, Alport syndrome, hypophosphatemic rickets
      (also called X-linked hypophosphatemia)—phosphate wasting at proximal
      tubule — ricketslike presentation.
    </td>
  </tr>
  <tr>
    <td>[0 O O Oo:</td>
    <td></td>
    <td>being sons of x</td>
    <td>affected. affected Xx</td>
    <td>100% fathers</td>
    <td>daughters and 0% of be affected.</td>
    <td></td>
  </tr>
  <tr>
    <td>Xe orale)</td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td></td>
    <td>Y</td>
    <td>XY</td>
    <td>XY</td>
    <td>Y</td>
    <td>ww</td>
    <td></td>
  </tr>
  <tr>
    <td>Mitochondrial inheritance</td>
    <td colspan="5" rowspan="4">
      Transmitted only through the mother. All offspring of affected females may
      show signs of disease. Variable expression in a population or even within
      a family due to heteroplasmy.
    </td>
    <td colspan="5"></td>
    <td rowspan="4">
      Caused by mutations in mtDNA. Examples: mitochondrial myopathies, Leber
      hereditary optic neuropathy.
    </td>
    <td></td>
  </tr>
  <tr>
    <td></td>
    <td colspan="5"></td>
    <td></td>
  </tr>
  <tr>
    <td>6 to</td>
    <td colspan="5"></td>
    <td></td>
  </tr>
  <tr>
    <td></td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>GENETICS</td>
    <td>
      Autosomal recessive; defect in CFTR gene on chromosome 7 (deletion;
      AF508). Most common lethal genetic disease in patients with European
      ancestry.
    </td>
  </tr>
  <tr>
    <td>PATHOPHYSIOLOGY</td>
    <td>
      CFTR encodes an ATP-gated Cl channel (secretes Cl in lungs/GI tract,
      reabsorbs CI in sweat glands). Phe508 deletion + misfolded protein +
      improper protein trafficking + protein absent from cell membrane &gt; + Cl
      (and H2O) secretion + compensatory t Na* reabsorption via epithelial Na*
      channels (ENaC) + t HO reabsorption + abnormally thick mucus secreted into
      lungs/GI tract. t Na* reabsorption = more negative transepithelial
      potential difference.
    </td>
  </tr>
  <tr>
    <td>DIAGNOSIS</td>
    <td>
      t Cl concentration in pilocarpine-induced sweat test. Can present with
      contraction alkalosis and hypokalemia (ECF effects analogous loop diuretic
      effect) due to ECF H,O/Na* losses via sweating and concomitant renal K*/H*
      wasting. t immunoreactive trypsinogen (newborn screening) due to clogging
      of pancreatic duct.
    </td>
  </tr>
  <tr>
    <td rowspan="2">COMPLICATIONS</td>
    <td>
      Recurrent pulmonary infections (eg, S aureus [infancy and early
      childhood], P aeruginosa [adulthood], allergic bronchopulmonary
      aspergillosis [ABPA]), chronic bronchitis and bronchiectasis &gt;
      reticulonodular pattern on CXR, opacification of sinuses. Nasal polyps,
      nail clubbing. Pancreatic with steatorrhea, and fat-soluble vitamin
      deficiencies D,
    </td>
  </tr>
  <tr>
    <td></td>
    <td>
      insufficiency, malabsorption (A, E, K) progressing to endocrine
      dysfunction (CF-related diabetes), biliary cirrhosis, liver disease.
      Meconium ileus in newborns. Infertility in males (absence of vas deferens,
      spermatogenesis may be unaffected) and subfertility in females
      (amenorrhea, abnormally thick cervical mucus). Multifactorial: chest
      physiotherapy, aerosolized dornase alfa (DNase), and inhaled hypertonic
      saline
    </td>
  </tr>
  <tr>
    <td>TREATMENT</td>
    <td>
      &gt; mucus clearance. Azithromycin prevents acute exacerbations. Ibuprofen
      for anti-inflammatory effect. Pancreatic enzyme replacement therapy
      (pancrelipase) for pancreatic insufficiency. CFTR modulators can be used
      alone or in combination. Efficacy varies by different genetic mutations
      (pharmacogenomics). Are either potentiators (hold gate of CFTR channel
      open + Cl” flows through cell membrane; eg, ivacaftor) or correctors (help
      CF'TR protein to form right 3-D shape + moves to the cell surface; eg,
      lumacaftor, tezacaftor).
    </td>
  </tr>
  <tr>
    <td></td>
    <td>Nat QA a- Na* CFTR VL ENaC</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>DISEASE</th>
    <th>TRINUCLEOTIDE REPEAT</th>
    <th>MODE OF INHERITANCE</th>
    <th>MNEMONIC</th>
  </thead>
  <tr>
    <td>Huntington disease</td>
    <td>(CAG),</td>
    <td>AD</td>
    <td>Caudate has | ACh and GABA</td>
  </tr>
  <tr>
    <td>Myotonic dystrophy</td>
    <td>(CTG),</td>
    <td>AD</td>
    <td>
      Cataracts, Toupee (early balding in males), Gonadal atrophy in males,
      reduced fertility in females
    </td>
  </tr>
  <tr>
    <td>Fragile X syndrome Friedreich ataxia</td>
    <td>(CGG), (GAA),</td>
    <td>XD AR</td>
    <td>Chin (protruding), Giant Gonads Ataxic GAAit</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th colspan="3">1st trimester screening</th>
  </thead>
  <thead>
    <th>Trisomy</th>
    <th>B-hcG</th>
    <th>PAPP-A</th>
  </thead>
  <tr>
    <td>21</td>
    <td>t</td>
    <td>4</td>
  </tr>
  <tr>
    <td>18</td>
    <td>+</td>
    <td>4</td>
  </tr>
  <tr>
    <td>B</td>
    <td>+</td>
    <td>1</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th colspan="4">2nd trimester (quadruple) screening</th>
  </thead>
  <thead>
    <th>Trisomy</th>
    <th>hCG</th>
    <th>Inhibin A</th>
    <th>© AFP</th>
  </thead>
  <tr>
    <td>21</td>
    <td>t</td>
    <td>t</td>
    <td>4</td>
  </tr>
  <tr>
    <td>18</td>
    <td>4</td>
    <td>—ort</td>
    <td>+</td>
  </tr>
  <tr>
    <td>13</td>
    <td>_</td>
    <td>=_</td>
    <td>_</td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>3</td>
    <td>von Hippel-Lindau disease, renal cell carcinoma</td>
  </tr>
  <tr>
    <td>4</td>
    <td>ADPKD (PKD2), achondroplasia, Huntington disease</td>
  </tr>
  <tr>
    <td>5</td>
    <td>Cri-du-chat syndrome, familial adenomatous polyposis</td>
  </tr>
  <tr>
    <td>6</td>
    <td>Hemochromatosis (HF'E)</td>
  </tr>
  <tr>
    <td></td>
    <td>Williams syndrome, cystic fibrosis</td>
  </tr>
  <tr>
    <td></td>
    <td>Friedreich ataxia, tuberous sclerosis (TSC1)</td>
  </tr>
  <tr>
    <td></td>
    <td>
      Wilms tumor, B-globin gene defects (eg, sickle cell disease,
      B-thalassemia), MEN1
    </td>
  </tr>
  <tr>
    <td></td>
    <td>Patau syndrome, Wilson disease, retinoblastoma (RBI), BRCA2</td>
  </tr>
  <tr>
    <td></td>
    <td>Prader-Willi syndrome, Angelman syndrome, Marfan syndrome</td>
  </tr>
  <tr>
    <td></td>
    <td>
      ADPKD (PKDI), a-globin gene defects (eg, o-thalassemia), tuberous
      sclerosis (TSC2)
    </td>
  </tr>
  <tr>
    <td></td>
    <td>Neurofibromatosis type 1, BRCAI, TP53 (Li-Fraumeni syndrome)</td>
  </tr>
  <tr>
    <td></td>
    <td>Edwards syndrome</td>
  </tr>
  <tr>
    <td></td>
    <td>Down syndrome</td>
  </tr>
  <tr>
    <td></td>
    <td>Neurofibromatosis type 2, DiGeorge syndrome (22q11)</td>
  </tr>
  <tr>
    <td></td>
    <td>
      Fragile X syndrome, X-linked agammaglobulinemia, Klinefelter syndrome
      (XXY)
    </td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>amins: water</td>
    <td>B, (thiamine: TPP)</td>
    <td></td>
  </tr>
  <tr>
    <td>uble</td>
    <td>2 (riboflavin: FAD, le]</td>
    <td>FMN)</td>
  </tr>
  <tr>
    <td colspan="3">B; (niacin: NAD*)</td>
  </tr>
  <tr>
    <td></td>
    <td>B; (pantothenic acid:</td>
    <td>CoA)</td>
  </tr>
  <tr>
    <td colspan="3">Bg (pyridoxine: PLP)</td>
  </tr>
  <tr>
    <td colspan="3">( biotin)</td>
  </tr>
  <tr>
    <td colspan="3">Bo ( g folate)</td>
  </tr>
  <tr>
    <td colspan="3">By (cobalamin)</td>
  </tr>
  <tr>
    <td></td>
    <td>C (ascorbic acid)</td>
    <td></td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th></th>
    <th>DIET</th>
    <th>SUPPLEMENTATION REQUIRED</th>
  </thead>
  <tr>
    <td>nentation</td>
    <td>Vegetarian/vegan</td>
    <td>Vitamin By2</td>
  </tr>
  <tr>
    <td></td>
    <td></td>
    <td>
      Frequently, vitamin D (although this is commonly deficient in many diets)
    </td>
  </tr>
  <tr>
    <td></td>
    <td>High egg white (raw)</td>
    <td>
      Vitamin B; (avidin in egg whites binds biotin and prevents absorption)
    </td>
  </tr>
  <tr>
    <td></td>
    <td>Untreated corn</td>
    <td>Vitamin B; (deficiency is common in resource-limited areas)</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th></th>
    <th></th>
    <th>
      Use oral isotretinoin to treat severe cystic acne. Use all-trans retinoic
      acid to treat acute promyelocytic leukemia.
    </th>
  </thead>
  <tr>
    <td></td>
    <td>
      Acute toxicity—nausea, vomiting, t ICP (eg, vertigo, blurred vision).
    </td>
    <td>
      Teratogenic (interferes with homeobox gene; clef palate, cardiac
      abnormalities), therefore a ©
    </td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>Wernicke encephalopathy</td>
    <td colspan="2">
      Acute, reversible, life-threatening neurologic condition. Symptoms:
      Confusion, Ophthalmoplegia/ Nystagmus, Ataxia (CorONA beer).
    </td>
  </tr>
  <tr>
    <td>Korsakoff syndrome</td>
    <td colspan="2">
      Amnestic disorder due to chronic alcohol overuse; presents with
      confabulation, personality changes, memory loss (permanent).
    </td>
  </tr>
  <tr>
    <td>Wernicke-Korsakoff syndrome</td>
    <td colspan="2">
      Damage to medial dorsal nucleus of thalamus, mammillary bodies.
      Presentation is combination of Wernicke encephalopathy and Korsakoff
      syndrome.
    </td>
  </tr>
  <tr>
    <td>Dry beriberi</td>
    <td>Polyneuropathy, symmetric muscle wasting.</td>
    <td>Spell beriberi as Berl Berl to remember</td>
  </tr>
  <tr>
    <td>Wet beriberi</td>
    <td>High-output cardiac failure (due to systemic vasodilation).</td>
    <td>vitamin By.</td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>FUNCTION</td>
    <td>
      Component of flavins FAD and FMN, used as cofactors in redox reactions,
      eg, the succinate dehydrogenase reaction in the TCA cycle.
    </td>
    <td>FAD and FMN are derived from riboFlavin (Bz ~ 2 ATP).</td>
  </tr>
  <tr>
    <td>DEFICIENCY</td>
    <td>
      Cheilosis (inflammation of lips, scaling and fissures at the corners of
      the mouth), “magenta” tongue, corneal vascularization.
    </td>
    <td>The 2 C’s of Bo.</td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>DEFICIENCY</td>
    <td>
      Convulsions, hyperirritability, peripheral neuropathy (deficiency
      inducible by isoniazid and oral contraceptives), sideroblastic anemia (due
      to impaired hemoglobin synthesis and iron excess).
    </td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>Vitamin By</td>
    <td>Also called folate.</td>
    <td></td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>FUNCTION</td>
    <td>
      Antioxidant; also facilitates iron absorption by reducing it to Fe**
      state. Necessary for hydroxylation of proline and lysine in collagen
      synthesis. Necessary for dopamine B-hydroxylase (converts dopamine to NE).
    </td>
    <td>
      Found in fruits and vegetables. Pronounce “absorbic” acid. Ancillary
      treatment for methemoglobinemia by reducing Fe** to Fe**.
    </td>
  </tr>
  <tr>
    <td>DEFICIENCY</td>
    <td>
      Scurvy—swollen gums, easy bruising, petechiae, hemarthrosis, anemia, poor
      wound healing, perifollicular and subperiosteal hemorrhages, “corkscrew”
      hair. Weakened immune response.
    </td>
    <td>
      Deficiency may be precipitated by tea and toast diet. Vitamin C deficiency
      causes sCurvy due to a Collagen hydroCylation defect.
    </td>
  </tr>
  <tr>
    <td>EXCESS</td>
    <td>
      Nausea, vomiting, diarrhea, fatigue, calcium oxalate nephrolithiasis
      (excess oxalate from vitamin C metabolism). Can t iron toxicity in
      predisposed individuals by increasing dietary iron absorption (ie, can
      worsen hemochromatosis transfusion-related iron overload).
    </td>
    <td></td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>FUNCTION</td>
    <td>
      Antioxidant (protects RBCs and neuronal membranes from free radical
      damage).
    </td>
    <td></td>
  </tr>
  <tr>
    <td>DEFICIENCY</td>
    <td>
      Hemolytic anemia, acanthocytosis, muscle weakness, demyelination of
      posterior columns (+ proprioception and vibration sensation) and
      spinocerebellar tract (ataxia). Closely mimics Friedreich ataxia.
    </td>
    <td>
      Neurologic presentation may appear similar to vitamin Bj deficiency, but
      without megaloblastic anemia, hypersegmented neutrophils, or t serum
      methylmalonic acid levels.
    </td>
  </tr>
  <tr>
    <td>EXCESS</td>
    <td>
      Risk of enterocolitis in enfants (infants) with excess of vitamin E.
    </td>
    <td>
      High-dose supplementation may alter metabolism of vitamin K &gt; enhanced
      anticoagulant effects
    </td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>Enzyme terminology</td>
    <td>
      An enzyme’s name often describes its function. For example, glucokinase is
      an enzyme that catalyzes the phosphorylation of glucose using a molecule
      of ATP. The following are commonly used enzyme descriptors.
    </td>
  </tr>
  <tr>
    <td>Kinase</td>
    <td>
      Catalyzes transfer of a phosphate group from a high-energy molecule
      (usually ATP) to a substrate (eg, phosphofructokinase).
    </td>
  </tr>
  <tr>
    <td>Phosphorylase</td>
    <td>
      Adds inorganic phosphate onto substrate without using ATP (eg, glycogen
      phosphorylase).
    </td>
  </tr>
  <tr>
    <td>Phosphatase</td>
    <td>
      Removes phosphate group from substrate (eg, fructose-1,6-bisphosphatase
      1).
    </td>
  </tr>
  <tr>
    <td>Dehydrogenase</td>
    <td>
      Catalyzes oxidation-reduction reactions (eg, pyruvate dehydrogenase).
    </td>
  </tr>
  <tr>
    <td>Hydroxylase</td>
    <td>
      Adds hydroxyl group (-OH) onto substrate (eg, tyrosine hydroxylase).
    </td>
  </tr>
  <tr>
    <td>Carboxylase</td>
    <td>
      Transfers carboxyl groups (-COOH) with the help of biotin (eg, pyruvate
      carboxylase).
    </td>
  </tr>
  <tr>
    <td>Mutase</td>
    <td>
      Relocates a functional group within a molecule (eg, vitamin B).-dependent
      methylmalonyl-CoA mutase).
    </td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>PROCESS</th>
    <th>ENZYME</th>
    <th>REGULATORS</th>
  </thead>
  <tr>
    <td>Glycolysis</td>
    <td>Phosphofructokinase-1 (PF'K-1)</td>
    <td>AMP @, fructose-2,6-bisphosphate © ATP ©, citrate ©</td>
  </tr>
  <tr>
    <td>Gluconeogenesis</td>
    <td>Fructose-l,6-bisphosphatase 1</td>
    <td>AMP ©, fructose-2,6-bisphosphate ©</td>
  </tr>
  <tr>
    <td>TCA cycle</td>
    <td>Isocitrate dehydrogenase</td>
    <td>ADP ® ‘TP ©, NADH © es</td>
  </tr>
  <tr>
    <td>Glycogenesis</td>
    <td>Glycogen synthase</td>
    <td>
      ucose-6-phosphate ©, insulin ©, cortisol ® pinephrine O, glucagon © G E
    </td>
  </tr>
  <tr>
    <td>Glycogenolysis</td>
    <td>Glycogen phosphorylase</td>
    <td>
      pinephrine , glucagon ®, AMP © ucose-6-phosphate ©, insulin ©, ATP © E G
    </td>
  </tr>
  <tr>
    <td>HMP shunt</td>
    <td>Glucose-6-phosphate dehydrogenase (G6PD)</td>
    <td>ADP* ® ADPH © N. N.</td>
  </tr>
  <tr>
    <td>De novo pyrimidine synthesis</td>
    <td>Carbamoy] phosphate synthetase II</td>
    <td>ATP ©, PRPP ® UTP O</td>
  </tr>
  <tr>
    <td>De novo purine synthesis</td>
    <td>Glutamine-phosphoribosylpyrophosphate (PRPP) amidotransferase</td>
    <td>AMP ©, inosine monophosphate (IMP) ©, GMP ©</td>
  </tr>
  <tr>
    <td>Urea cycle</td>
    <td>Carbamoy] phosphate synthetase I</td>
    <td>N-acetylglutamate ©</td>
  </tr>
  <tr>
    <td>Fatty acid synthesis</td>
    <td>Acetyl-CoA carboxylase (ACC)</td>
    <td>Insulin @, citrate ® Glucagon ©, palmitoyl-CoA ©</td>
  </tr>
  <tr>
    <td>Fatty acid oxidation</td>
    <td>Carnitine acyltransferase I</td>
    <td>Malonyl-CoA ©</td>
  </tr>
  <tr>
    <td>Ketogenesis</td>
    <td>HMG-CoA synthase (HOMG! I’m starving!)</td>
    <td></td>
  </tr>
  <tr>
    <td>Cholesterol synthesis</td>
    <td>HMG-CoA reductase</td>
    <td>Insulin ®, thyroxine ®, estrogen ®</td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>Mitochondria</td>
    <td>
      Fatty acid oxidation (B-oxidation), acetyl-CoA production, TCA cycle,
      oxidative phosphorylation, ketogenesis.
    </td>
  </tr>
  <tr>
    <td>Cytoplasm</td>
    <td>
      Glycolysis, HMP shunt, and synthesis of cholesterol (SER), proteins
      (ribosomes, RER), fatty acids, and nucleotides.
    </td>
  </tr>
  <tr>
    <td>Both</td>
    <td>Heme synthesis, urea cycle, gluconeogenesis. Hugs take two (both).</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>ATP</th>
    <th>Phosphoryl groups</th>
  </thead>
  <tr>
    <td>NADH, NADPH, FADH,</td>
    <td>Electrons</td>
  </tr>
  <tr>
    <td>CoA, lipoamide</td>
    <td>Acyl groups</td>
  </tr>
  <tr>
    <td>Biotin</td>
    <td>CO;</td>
  </tr>
  <tr>
    <td>Tetrahydrofolates</td>
    <td>l-carbon units</td>
  </tr>
  <tr>
    <td>S-adenosylmethionine (SAM)</td>
    <td>CH; groups</td>
  </tr>
  <tr>
    <td>TPP</td>
    <td>Aldehydes</td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>Location</td>
    <td>Most tissues, except liver and pancreatic B cells</td>
    <td>Liver, B cells of pancreas</td>
  </tr>
  <tr>
    <td>Km</td>
    <td>Lower (t affinity)</td>
    <td>Higher (+ affinity)</td>
  </tr>
  <tr>
    <td>Vimax</td>
    <td>Lower (+ capacity)</td>
    <td>Higher (t capacity)</td>
  </tr>
  <tr>
    <td>Induced by insulin</td>
    <td>No</td>
    <td>Yes</td>
  </tr>
  <tr>
    <td>Feedback inhibition by</td>
    <td>Glucose-6-phosphate</td>
    <td>Fructose-6-phosphate</td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>rreversible enzymes Pyruvate carboxylase</td>
    <td>
      glucagon in fasting state. In mitochondria. Pyruvate + oxaloacetate.
    </td>
    <td>Requires biotin, ATP. Activated by acetyl-CoA.</td>
  </tr>
  <tr>
    <td>Phosphoenolpyruvate carboxykinase</td>
    <td>In cytosol. Oxaloacetate = phosphoenolpyruvate (PEP).</td>
    <td>Requires GTP.</td>
  </tr>
  <tr>
    <td>Fructose-1,6- bisphosphatase 1</td>
    <td>In cytosol. Fructose-1,6-bisphosphate + fructose-6-phosphate.</td>
    <td>Citrate ©, AMP ©, fructose 2,6-bisphosphate ©.</td>
  </tr>
  <tr>
    <td>Glucose-6-</td>
    <td>In ER. Glucose-6-phosphate — glucose.</td>
    <td></td>
  </tr>
  <tr>
    <td>phosphatase</td>
    <td>Occurs primarily in liver; serves to maintain</td>
    <td>euglycemia during fasting. Enzymes also found in</td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>ENZYME DEFICIENCY</td>
    <td>Fructokinase (autosomal recessive)</td>
    <td>Aldolase B (autosomal recessive)</td>
  </tr>
  <tr>
    <td>PATHOPHYSIOLOGY</td>
    <td>
      not trapped into cells. Hexokinase 1° pathway for converting fructose
      fructose-6-phosphate.
    </td>
    <td>
      Fructose-1-phosphate accumulates + 4 available phosphate + inhibition of
      glycogenolysis and gluconeogenesis.
    </td>
  </tr>
  <tr>
    <td>PRESENTATION (SIGNS/SYMPTOMS)</td>
    <td>
      Asymptomatic, benign. Fructose appears urine (fructokinase deficiency
    </td>
    <td>
      Hypoglycemia, jaundice, cirrhosis, vomiting. Symptoms only present
      following consumption of fruit, juice, or honey.
    </td>
  </tr>
  <tr>
    <td>ADDITIONAL REMARKS</td>
    <td>
      dipstick will be © (tests for glucose (nonspecific test for inborn errors
      of
    </td>
    <td>
      reducing sugar can be detected in the urine carbohydrate metabolism).
    </td>
  </tr>
  <tr>
    <td rowspan="3">TREATMENT</td>
    <td></td>
    <td>
      + intake of fructose, sucrose (glucose + fructose), and sorbitol
      (metabolized to fructose).
    </td>
  </tr>
  <tr>
    <td></td>
    <td>Fructokinase Fructose-1-P Aldolase ™</td>
    <td>
      Triose phosphate Dihydroxyacetone-P —SOMETAS€ yuoe Glyceraldehyde-3-P
      ——&gt; Glycolysis Hose Glyceraldehyde , ” ATP ADP NADH
    </td>
  </tr>
  <tr>
    <td></td>
    <td></td>
    <td>NAD*</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th></th>
    <th colspan="2">Galactokinase deficiency</th>
    <th>Classic</th>
    <th>galactosemia</th>
  </thead>
  <tr>
    <td>ENZYME DEFICIENCY</td>
    <td colspan="2">Galactokinase (autosomal recessive).</td>
    <td>(autosomal</td>
    <td>Galactose-1-phosphate uridyltransferase recessive).</td>
  </tr>
  <tr>
    <td>PATHOPHYSIOLOGY</td>
    <td colspan="2">Galactitol accumulates if diet has galactose.</td>
    <td>Damage substances</td>
    <td>caused by accumulation of toxic (eg, galacitol).</td>
  </tr>
  <tr>
    <td>PRESENTATION (SIGNS/SYMPTOMS)</td>
    <td colspan="2">
      Relatively mild/benign condition (galactokinase deficiency is kinder).
      Galactose appears in blood (galactosemia) urine (galactosuria); infantile
      cataracts. present as failure to track objects or social smile.
    </td>
    <td>Symptoms or breast hepatomegaly, deposition Can</td>
    <td>
      start when infant is fed formula milk &gt; failure to thrive, jaundice,
      infantile cataracts (galacitol in eye lens), intellectual disability.
      predispose neonates to E' coli sepsis.
    </td>
  </tr>
  <tr>
    <td rowspan="5">TREATMENT</td>
    <td></td>
    <td></td>
    <td>Exclude glucose)</td>
    <td>galactose and lactose (galactose + from diet.</td>
  </tr>
  <tr>
    <td></td>
    <td>Galactose</td>
    <td>Galactokinase</td>
    <td></td>
    <td>Uridylyltransferase Glucose-1-P</td>
  </tr>
  <tr>
    <td></td>
    <td>Aldose reductase</td>
    <td>ATP ADP</td>
    <td>UDP-Glu —_</td>
    <td>UDP-Gal</td>
  </tr>
  <tr>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td>4-Epimerase —_Glycolysis/glycogenesis</td>
  </tr>
  <tr>
    <td></td>
    <td colspan="2">Galactitol</td>
    <td></td>
    <td></td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td rowspan="4">Lactase deficiency</td>
    <td>
      Insufficient lactase enzyme — dietary lactose in olerance. Lactase
      functions on the intestinal brush border to digest lactose (in milk and
      milk products) into glucose and galactose.
    </td>
  </tr>
  <tr>
    <td></td>
    <td>
      Primary: age-dependent decline after childhood of Asian, African, Native
      American (absence of lactase-persistent allele), common in escent.
    </td>
  </tr>
  <tr>
    <td></td>
    <td>
      eople or d Secondary: loss of intestinal brush border due to
      gastroenteritis (eg, rotavirus), autoimmune disease. Congenital lactase
      deficiency: rare, due to defective gene.
    </td>
  </tr>
  <tr>
    <td></td>
    <td>
      Stool demonstrates + pH and breath shows t hyd (H* is produced when
      colonic bacteria fermen rogen content with lactose hydrogen breath test
      undigested lactose). Intestinal biopsy reveals
    </td>
  </tr>
  <tr>
    <td>FINDINGS</td>
    <td>
      normal mucosa in patients with hereditary lac ose intolerance. Bloating,
      cramps, flatulence (all due to fermentation of lactose by colonic bacteria
      &gt; gas), and
    </td>
  </tr>
  <tr>
    <td>TREATMENT</td>
    <td>
      osmotic diarrhea (undigested lactose). Avoid dairy products or add lactase
      pills to diet; lactose-free milk.
    </td>
  </tr>
  <tr>
    <td>Amino acids</td>
    <td>Only L-amino acids are found in proteins.</td>
  </tr>
  <tr>
    <td>Essential</td>
    <td>
      PVT TIM HaLL: Phenylalanine, Valine, Tryptophan, Threonine, Isoleucine,
      Methionine, Histidine, Leucine, Lysine. Glucogenic: Methionine, histidine,
      valine. We met his valentine, who is so sweet (glucogenic).
      Glucogenic/ketogenic: Isoleucine, phenylalanine, threonine, tryptophan.
      Ketogenic: leucine, lysine. The only purely ketogenic amino acids.
    </td>
  </tr>
  <tr>
    <td>Acidic</td>
    <td>Aspartic acid, glutamic acid. Negatively charged at body pH.</td>
  </tr>
  <tr>
    <td>Basic</td>
    <td>
      Arginine, histidine, lysine. Arginine is most basic. Histidine has no
      charge at body pH. Arginine and histidine are required during perio
      Arginine and lysine are t in histones which bind ds of growth. negatively
      charged DNA.
    </td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>DISEASE</th>
    <th>FINDINGS</th>
    <th>DEFICIENT ENZYME</th>
    <th>COMMENTS</th>
  </thead>
  <tr>
    <td>Von Gierke disease (type I)</td>
    <td>
      Severe fasting hypoglycemia, tt Glycogen in liver and kidneys, t blood
      lactate, t triglycerides, t uric acid (Gout), and hepatomegaly,
      renomegaly. Liver does not regulate blood glucose.
    </td>
    <td>Glucose-6-phosphatase.</td>
    <td>
      Treatment: frequent oral glucose/cornstarch; avoidance of fructose and
      galactose. Impaired gluconeogenesis and glycogenolysis.
    </td>
  </tr>
  <tr>
    <td>Pompe disease (type Il)</td>
    <td>
      Cardiomyopathy, hypotonia, exercise intolerance, enlarged tongue, and
      systemic findings lead to early death.
    </td>
    <td>Lysosomal acid o-1,4- glucosidase (acid maltase).</td>
    <td>
      Pompe trashes the pump (Ist and 4th letter; heart, liver, and muscle).
    </td>
  </tr>
  <tr>
    <td>Cori disease (type III)</td>
    <td>
      Similar to von Gierke disease, but milder symptoms and normal blood
      lactate levels. Can lead to cardiomyopathy. Limit dextrin—like structures
      accumulate in cytosol.
    </td>
    <td>
      Debranching enzymes (a-1,6-glucosidase and 4-o-p-glucanotransferase).
    </td>
    <td>Gluconeogenesis is intact.</td>
  </tr>
  <tr>
    <td>Andersen disease (type IV)</td>
    <td>
      Most commonly presents with hepatosplenomegaly and failure to thrive in
      early infancy. Other findings include infantile cirrhosis, muscular
      weakness, hypotonia, cardiomyopathy early childhood death.
    </td>
    <td>Branching enzyme. Neuromuscular form can present at any age.</td>
    <td>Hypoglycemia occurs late in the disease.</td>
  </tr>
  <tr>
    <td>McArdle disease (type V)</td>
    <td>
      t glycogen in muscle, but muscle cannot break it down — painful muscle
      cramps, myoglobinuria (red urine) with strenuous exercise, and arrhythmia
      from electrolyte abnormalities. Second-wind phenomenon noted during
      exercise due to f muscular
    </td>
    <td>
      Skeletal muscle glycogen phosphorylase (myophosphorylase). Characterized
      by a flat venous lactate curve with normal rise in ammonia levels during
      exercise.
    </td>
    <td>Blood glucose levels typically unaffected. McArdle = muscle.</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th colspan="5">Sphingolipidoses</th>
  </thead>
  <tr>
    <td>Tay-Sachs disease A</td>
    <td>
      Progressive neurodegeneration, developmental delay, hyperreflexia,
      hyperacusis, “cherry-red” spot on macula fi (lipid accumulation in
      ganglion cell layer), lysosomes with onion skin, no hepatosplenomegaly (vs
      Niemann-Pick).
    </td>
    <td>@ Hexosaminidase A (“TAy-Sax”).</td>
    <td>GM ganglioside.</td>
    <td>AR</td>
  </tr>
  <tr>
    <td>Fabry disease B “|</td>
    <td>
      Early: triad of episodic peripheral neuropathy, angiokeratomas [5,
      hypohidrosis. Late: progressive renal failure, cardiovascular disease.
    </td>
    <td>@ o-galactosidase A.</td>
    <td>Ceramide trihexoside (globotriaosylce- ramide).</td>
    <td>XR</td>
  </tr>
  <tr>
    <td>Metachromatic leukodystrophy</td>
    <td>Central and peripheral demyelination with ataxia, dementia.</td>
    <td>© Arylsulfatase A.</td>
    <td>Cerebroside sulfate.</td>
    <td>AR</td>
  </tr>
  <tr>
    <td>Krabbe disease</td>
    <td>
      Peripheral neuropathy, destruction of oligodendrocytes, developmental
      delay, CN II atrophy, globoid cells.
    </td>
    <td>@ Galactocerebrosi-_ _ dase (galactosylce- ramidase).</td>
    <td>Galactocerebroside, psychosine.</td>
    <td>AR</td>
  </tr>
  <tr>
    <td>Gaucher disease</td>
    <td>
      Most common. Hepatosplenomegaly, pancytopenia, osteoporosis, avascular
      necrosis of femur, bone crises, Gaucher cells (lipid-laden macrophages
      resembling crumpled tissue paper).
    </td>
    <td>
      © Glucocerebrosidase (B-glucosidase); treat with recombinant
      glucocerebrosidase.
    </td>
    <td>Glucocerebroside.</td>
    <td>| AR</td>
  </tr>
  <tr>
    <td>Niemann-Pick disease</td>
    <td>
      _ Progressive neurodegeneration, hepatosplenomegaly, foam cells
      (lipid-laden macrophages) [, “cherry-red” spot on macula EN.
    </td>
    <td>© Sphingomyelinase.</td>
    <td>Sphingomyelin.</td>
    <td>AR</td>
  </tr>
  <tr>
    <td colspan="5">Mucopolysaccharidoses</td>
  </tr>
  <tr>
    <td>Hurler syndrome</td>
    <td>
      Developmental delay, hirsutism, skeletal anomalies, airway obstruction,
      clouded cornea, hepatosplenomegaly.
    </td>
    <td>o-L-iduronidase.</td>
    <td>Heparan sulfate, dermatan sulfate.</td>
    <td>AR</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>Hurler syndrome</th>
    <th>
      Developmental delay, hirsutism, skeletal anomalies, airway obstruction,
      clouded cornea, hepatosplenomegaly.
    </th>
    <th>o-L-iduronidase.</th>
    <th>Heparan sulfate, dermatan sulfate.</th>
    <th>AR</th>
  </thead>
  <tr>
    <td>Hunter syndrome</td>
    <td>Mild Hurler + aggressive behavior, no corneal clouding.</td>
    <td>Iduronate-2 (two)- sulfatase.</td>
    <td>Heparan sulfate, dermatan sulfate.</td>
    <td>XR</td>
  </tr>
  <tr>
    <td></td>
    <td>GM, Ceramide trihexoside o GM, (2)</td>
    <td>Hunters see aggressively</td>
    <td>clearly (no corneal aim for the X (X-linked</td>
    <td>clouding) and recessive).</td>
  </tr>
  <tr>
    <td>Sulfatides</td>
    <td>Glucocerebroside</td>
    <td></td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td>(3) Galactocerebroside</td>
    <td>® © Ceramide Sphingomyelin</td>
    <td></td>
    <td></td>
    <td></td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th rowspan="4">nn S Ss BS % Maximal energy by source</th>
    <th colspan="2" rowspan="3">
      — Stored ATP — Creatine phosphate — Anaerobic metabolism — Aerobic
      metabolism Overall
    </th>
    <th colspan="2" rowspan="4">
      lg carb/protein = 4 kcal 1g alcohol = 7 kcal lg fatty acid = 9 kcal (#
      letters = # kcal)
    </th>
    <th></th>
  </thead>
  <thead>
    <th></th>
    <th colspan="2"></th>
    <th colspan="2"></th>
    <th></th>
  </thead>
  <thead>
    <th></th>
    <th colspan="2"></th>
    <th colspan="2"></th>
    <th></th>
  </thead>
  <thead>
    <th></th>
    <th></th>
    <th>— performance</th>
    <th colspan="2"></th>
    <th></th>
  </thead>
  <tr>
    <td>2 sec</td>
    <td>10 sec</td>
    <td>1min 2hr</td>
    <td></td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td></td>
    <td>Duration of</td>
    <td>exercise 1}</td>
    <td></td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td>Fasting and starvation</td>
    <td>Priorities are to</td>
    <td>supply sufficient glucose to the</td>
    <td>brain and RBCs and to preserve protein.</td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td>Fed state (after a meal)</td>
    <td>Glycolysis and</td>
    <td>aerobic respiration.</td>
    <td>Insulin stimulates storage of lipids, glycogen.</td>
    <td>proteins,</td>
    <td>and</td>
  </tr>
  <tr>
    <td>Fasting (between meals)</td>
    <td colspan="2" rowspan="2">
      Hepatic glycogenolysis (major); hepatic gluconeogenesis, adipose release
      of FFA (minor).
    </td>
    <td>Glucagon and epinephrine stimulate reserves.</td>
    <td>use</td>
    <td>of fuel</td>
  </tr>
  <tr>
    <td></td>
    <td colspan="2"></td>
    <td></td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td>Starvation days 1-3</td>
    <td>
      _ Blood glucose = Hepatic = Adipose = Muscle and glucose to * Hepatic
      tissue adipose CoA (from triacylglycerol to
    </td>
    <td>
      levels maintained by: glycogenolysis release of FFA liver, which shift
      fuel use from FFA gluconeogenesis from peripheral lactate and alanine, and
      from tissue glycerol and propionyl- odd-chain FFA—the only component that
      contributes gluconeogenesis)
    </td>
    <td>
      Glycogen reserves depleted after day RBCs lack mitochondria and therefore
      use ketone bodies. Protein 0 a Stored energy (kd) ~~
    </td>
    <td>1.</td>
    <td>cannot</td>
  </tr>
  <tr>
    <td>Starvation after day 3</td>
    <td>Adipose stores source of depleted, vital leading to Amount of time.</td>
    <td>
      (ketone bodies become the main energy for the brain). After these are
      protein degradation accelerates, organ failure and death. excess stores
      determines survival
    </td>
    <td>0 1 2 3 4 5 6 Weeks of starvation</td>
    <td>7</td>
    <td>8 i]</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>APOLIPOPROTEIN</th>
    <th>FUNCTION</th>
    <th>CHYLOMICRON</th>
    <th>REMNANT</th>
    <th>VLDL</th>
    <th>IDL</th>
    <th>LOL</th>
    <th>HDL</th>
  </thead>
  <tr>
    <td>E</td>
    <td>Mediates remnant uptake (everything except LDL)</td>
    <td>v</td>
    <td>v</td>
    <td>v</td>
    <td>v</td>
    <td></td>
    <td>v</td>
  </tr>
  <tr>
    <td>Al</td>
    <td>Found only on alpha- lipoproteins (HDL), activates LCAT</td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td>v</td>
  </tr>
  <tr>
    <td>cll</td>
    <td>Lipoprotein lipase cofactor that catalyzes cleavage</td>
    <td>v</td>
    <td></td>
    <td>v</td>
    <td>v</td>
    <td></td>
    <td>v</td>
  </tr>
  <tr>
    <td>Bag</td>
    <td>
      Mediates chylomicron secretion into lymphatics Only on particles
      originating from the intestines
    </td>
    <td>v</td>
    <td>v</td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td>Bioo</td>
    <td>
      Binds LDL receptor Only on particles originating from the liver (I hope I
      live to Be 100)
    </td>
    <td></td>
    <td></td>
    <td>v</td>
    <td>v</td>
    <td>v</td>
    <td></td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>TYPE</th>
    <th>INHERITANCE</th>
    <th>PATHOGENESIS</th>
    <th>t BLOOD LEVEL</th>
    <th>CLINICAL</th>
  </thead>
  <tr>
    <td>|—Hyper- chylomicronemia</td>
    <td>AR</td>
    <td>Lipoprotein lipase or apo CII deficiency</td>
    <td>| Chylomicrons, TG, cholesterol</td>
    <td>
      Pancreatitis, hepatosplenomegaly, and eruptive/pruritic xanthomas (no t
      risk for atherosclerosis). Creamy layer in supernatant.
    </td>
  </tr>
  <tr>
    <td>ll—Hyper- cholesterolemia</td>
    <td>AD</td>
    <td>Absent or defective LDL receptors, or defective apo Bioo</td>
    <td>Ila: LDL, cholesterol IIb: LDL, cholesterol, VLDL</td>
    <td>
      Heterozygotes (1:500) have cholesterol ~ 300 mg/dL; homozygotes (very
      rare) have cholesterol 2 700 mg/dL. Accelerated atherosclerosis (may have
      MI before age 20), tendon (Achilles) xanthomas, and corneal arcus.
    </td>
  </tr>
  <tr>
    <td>III—Dysbeta- lipoproteinemia</td>
    <td>AR</td>
    <td>ApoE (defective in type thrEE)</td>
    <td>Chylomicrons, VLDL</td>
    <td>— Premature atherosclerosis, uberoeruptive and palmar xanthomas.</td>
  </tr>
  <tr>
    <td>IV—Hyper- triglyceridemia</td>
    <td>AD</td>
    <td>Hepatic overproduction of VLDL</td>
    <td>VLDL, TG</td>
    <td>
      Hypertriglyceridemia (&gt; 1000 mg/dL) can cause acute pancreatitis.
      Related to insulin
    </td>
  </tr>
</table>
<table><thead><th></th><th>Submandibular, submental</th><th>Oral cavity, anterior tongue, lower lip</th><th>Malignancy of and metastasis to the oral cavity</th></thead><tr><td rowspan="2"></td><td>Deep cervical</td><td>Head, neck, oropharynx</td><td>Upper respiratory tract infection Infectious mononucleosis Kawasaki disease Malignancy of head, neck, oropharynx</td></tr><tr><td></td><td>; Supraclavicular</td><td>Right: right hemithorax Left (Virchow node): left hemithorax, abdomen, pelvis</td><td rowspan="2">Malignancies of thorax, abdomen, pelvis Pulmonary TB (unilateral hilar) Sarcoidosis (bilateral hilar)</td></tr><tr><td></td><td>Mediastinal</td><td>Trachea, esophagus</td><td></td></tr><tr><td></td><td>Hilar</td><td>Lungs</td><td>Lung cancer Granulomatous disease</td></tr><tr><td></td><td>Axillary</td><td>Upper limb, breast, skin above umbilicus</td><td>Mastitis Metastasis (especially breast cancer)</td></tr><tr><td></td><td>Epitrochlear</td><td>Hand, forearm</td><td>Secondary syphilis</td></tr><tr><td></td><td></td><td>Liver, stomach, spleen, pancreas, upper duodenum</td><td rowspan="3">Mesenteric lymphadenitis Inflammatory bowel disease Celiac disease</td><td></td></tr><tr><td></td><td>Superior mesenteric</td><td>Lower duodenum, jejunum, ileum, colon to splenic flexure</td></tr><tr><td rowspan="5">at A</td><td>Inferior mesenteric</td><td>Colon from splenic flexure to upper rectum</td><td></td></tr><tr><td></td><td>Periumbilical (Sister Mary Joseph node)</td><td>Abdomen, pelvis</td><td>Gastric cancer</td></tr><tr><td></td><td>Para-aortic</td><td>Pair of testes, ovaries, kidneys, fallopian tubes, fundus of uterus</td><td>Metastasis</td></tr><tr><td></td><td>External iliac</td><td>Body of uterus, cervix, superior bladder</td><td rowspan="3">Sexually transmitted infections Medial foot/leg cellulitis (superficial inguinal)</td></tr><tr><td></td><td>Internal iliac</td><td>Cervix, proximal vagina, corpus cavernosum, prostate, inferior bladder, lower rectum to anal canal (above pectinate line)</td><td></td></tr><tr><td rowspan="2">@ Palpable lymph node © Nonpalpable lymph node</td><td>Superficial inguinal</td><td>Distal vagina, vulva, scrotum, urethra, anal canal (below pectinate line), skin below umbilicus (except popliteal area)</td><td></td></tr><tr><td></td><td>Popliteal (‘pop-lateral’)</td><td>| Dorsolateral foot, posterior calf</td><td>Lateral foot/leg cellulitis</td></tr></table>
======================================
<table><tr><td>COMPONENTS</td><td>Neutrophils, macrophages, monocytes, dendritic cells, natural killer (NK) cells (lymphoid origin), complement, physical epithelial barriers, secreted enzymes</td><td>T cells, B cells, circulating antibodies</td></tr><tr><td>MECHANISM</td><td>Germline encoded</td><td>Variation through V(D)J recombination during lymphocyte development</td></tr><tr><td>RESPONSE TO PATHOGENS</td><td>Nonspecific Occurs rapidly (minutes to hours) No memory response</td><td>Highly specific, refined over time Develops over long periods; memory response is faster and more robust</td></tr><tr><td>SECRETED PROTEINS</td><td>Lysozyme, complement, C-reactive protein (CRP), defensins, cytokines</td><td>Immunoglobulins, cytokines</td></tr><tr><td>KEY FEATURES IN PATHOGEN RECOGNITION</td><td>Toll-like receptors (TLRs): pattern recognition receptors that recognize pathogen-associated molecular patterns (PAMPs) and lead to activation of NF-«B. Examples of PAMPs: LPS (gram © bacteria), flagellin (bacteria), nucleic acids (viruses)</td><td>Memory cells: activated B and T cells; subsequent exposure to a previously encountered antigen + stronger, quicker immune response</td></tr></table>
======================================
<table><thead><th>HLA SUBTYPE</th><th>DISEASE</th><th>MNEMONIC</th></thead><tr><td>B27</td><td>Psoriatic arthritis, Ankylosing spondylitis, IBD-associated arthritis, Reactive arthritis</td><td>PAIR</td></tr><tr><td>B57</td><td>Abacavir hypersensitivity</td><td></td></tr><tr><td>DQ2/DQ8</td><td>Celiac disease</td><td>Late (8) too (2) much gluten at Dairy Queen</td></tr><tr><td>DR3</td><td>DM type 1, SLE, Graves disease, Hashimoto thyroiditis, Addison disease</td><td>DM type 1: HLA-3 and -4 (1 + 3 = 4) SL3 (SLE)</td></tr><tr><td>DR4</td><td>Rheumatoid arthritis, DM type 1, Addison disease</td><td>There are 4 walls in 1 “rheum” (room)</td></tr></table>
======================================
<table><tr><td>B cells</td><td>Humoral immunity.</td></tr></table>
======================================
<table><thead><th>Terminal complement _ deficiencies (C5-C9)</th><th>tf susceptibility to recurrent Neisseria bacteremia.</th></thead><tr><td colspan="2">Complement regulatory protein deficiencies</td></tr><tr><td>Clesterase inhibitor deficiency</td><td>Causes hereditary angioedema due to unregulated activation of kallikrein &gt; t bradykinin. Characterized by + C4 levels. ACE inhibitors are contraindicated (also t bradykinin).</td></tr><tr><td>Paroxysmal nocturnal hemoglobinuria</td><td>A defect in the PIGA gene prevents the formation of glycosylphosphatidylinositol (GPI) anchors for complement inhibitors, such as decay-accelerating factor (DAF/CD55) and membrane inhibitor of</td></tr><tr><td>Al ' Li</td><td>reactive lysis (MIRL/CD59). Causes complement-mediated intravascular hemolysis &gt; 4 haptoglobin, dark urine £3. Can cause atypical venous thrombosis (eg, Budd-Chiari syndrome; portal vein, cerebral, or dermal thrombosis).</td></tr></table>
======================================
<table><tr><td>Interleukin-1</td><td>Causes fever, acute inflammation. Activates endothelium to express adhesion molecules. Induces chemokine secretion to recruit WBCs. Also called osteoclast-activating factor.</td><td>“Hot T-bone stEAK”: IL-1: fever (hot). IL-2: stimulates T cells. IL-3: stimulates bone marrow.</td></tr><tr><td>Interleukin-6</td><td>Causes fever and stimulates production of acute- phase proteins.</td><td>IL-4: stimulates IgE. production. IL-5: stimulates IgA production. IL-6: stimulates aKute-phase protein production.</td></tr><tr><td>Tumor necrosis factor-a</td><td>Activates endothelium. Causes WBC recruitment, vascular leak.</td><td>Causes cachexia in malignancy. Maintains granulomas in TB. IL-1, IL-6, TNF-a can mediate fever and sepsis.</td></tr><tr><td>Interleukin-8</td><td>Major chemotactic factor for neutrophils.</td><td>“Clean up on aisle 8.” Neutrophils are recruited by IL-8 to clear infections.</td></tr><tr><td>Interleukin-12</td><td>Induces differentiation of T cells into Thl cells. Activates NK cells.</td><td>Facilitates granuloma formation in TB.</td></tr><tr><td colspan="3">Secreted by T cells</td></tr><tr><td>Interleukin-2</td><td>Stimulates growth of helper, cytotoxic, and regulatory T cells, and NK cells.</td><td></td></tr><tr><td>Interleukin-3</td><td>Supports growth and differentiation of bone marrow stem cells. Functions like GM-CSF.</td><td></td></tr><tr><td colspan="3">From Thi cells</td></tr><tr><td>Interferon-y</td><td>Secreted by NK cells and T cells in response to antigen or IL-12 from macrophages; stimulates macrophages to kill phagocytosed pathogens. Inhibits differentiation of Th2 cells. Induces IgG isotype switching in B cells.</td><td>Increases MHC expression and antigen presentation by all cells. Activates macrophages to induce granuloma formation.</td></tr><tr><td colspan="3">From Th2 cells</td></tr><tr><td>Interleukin-4</td><td>Induces differentiation of T cells into Th (helper) 2 cells. Promotes growth of B cells. Enhances class switching to Ig: and IgG.</td><td>Ain’t too proud 2 BEG 4 help.</td></tr><tr><td>Interleukin-5</td><td>Promotes growth and differentiation of B cells. Enhances class switching to IgA. Stimulates growth and differentiation of Eosinophils.</td><td>Thave 5 BAEs.</td></tr><tr><td>Interleukin-10</td><td>Attenuates inflammatory response. Decreases expression of MHC class II and Th] cytokines. Inhibits activated macrophages and dendritic cells. Also secreted by regulatory T cells.</td><td>TGF-B and IL-10 both attenuate the immune response.</td></tr></table>
======================================
<table><tr><td>T cells</td><td>TCR (binds antigen-MHC complex), CD3 associated with TCR for signal transduction), CD28 (binds B7 on APC)</td><td></td></tr><tr><td>Helper T cells</td><td>CD4, CD40L, CXCR4/CCRS (coreceptors for HIV)</td><td></td></tr><tr><td>Cytotoxic T cells</td><td>CD8</td><td></td></tr><tr><td>Regulatory T cells</td><td>CD4, CD25</td><td></td></tr><tr><td>B cells</td><td>Ig (binds antigen), CD19, CD20, CD21 (receptor for Epstein-Barr virus), CD40, MHC II, B7 (CD80/86)</td><td>Must be 21 to drink at a Barr</td></tr><tr><td>NK cells</td><td>CD16 (binds Fe of IgG), CD56 (suggestive marker for NK cells)</td><td></td></tr><tr><td>Macrophages</td><td>CD14 (receptor for PAMPs [eg, LPS]), CD40, CCR5, MHC IIL, B7, Fc and C3b receptors (enhanced phagocytosis)</td><td></td></tr><tr><td>Hematopoietic stem cells</td><td>CD34</td><td></td></tr></table>
======================================
<table><tr><td>MEANS OF ACQUISITION</td><td>Receiving preformed antibodies</td><td>Exposure to exogenous antigens</td></tr><tr><td>ONSET</td><td>Rapid</td><td>Slow</td></tr><tr><td>DURATION</td><td>Short span of antibodies (halflife = 3 weeks)</td><td>Long-lasting protection (memory)</td></tr><tr><td>EXAMPLES</td><td>IgA in breast milk, maternal IgG crossing placenta, antitoxin, humanized monoclonal antibody</td><td>Natural infection, vaccines, toxoid</td></tr><tr><td>NOTES</td><td>IVIG and other immune globulin preparations can be administered to provide temporary but specific passive immunity to a target pathogen.</td><td>Combined passive and active immunizations can be given for hepatitis B or rabies exposure</td></tr></table>
======================================
<table><thead><th>VACCINE TYPE</th><th>response DESCRIPTION</th><th>(humoral cellular) PROS/CONS</th><th>specific pathogens. EXAMPLES</th></thead><tr><td>Live attenuated vaccine</td><td>Microorganism rendered nonpathogenic but retains capacity for transient growth within inoculated host. MMR and varicella vaccines can be given to people living with HIV without evidence of immunity if CD4+ cell count &gt; 200 cells/mm’.</td><td>Pros: induces cellular and humoral responses. Induces strong, often lifelong immunity. Cons: may revert to virulent form. Contraindicated in pregnancy and patients with immunodeficiency.</td><td>Adenovirus (nonattenuated, given to military recruits), typhoid (‘Ty2la, oral), polio (Sabin), varicella (chickenpox), smallpox, BCG, yellow fever, influenza (intranasal), MMR, rotavirus. “Attention teachers! Please vaccinate small, Beautiful young infants with MMR routinely!”</td></tr><tr><td>Killed or inactivated vaccine</td><td>Pathogen is inactivated by heat or chemicals. Maintaining epitope structure on surface antigens is important for immune response. Mainly induces a humoral response.</td><td>Pros: safer than live vaccines. Cons: weaker cell-mediated immune response; mainly induces a humoral response. Booster shots usually needed.</td><td>Hepatitis A, Typhoid (Vi polysaccharide, intramuscular), Rabies, Influenza (intramuscular), Polio (Salk). A TRIP could Kill you.</td></tr><tr><td>Subunit, recombinant, polysaccharide, and conjugate</td><td>All use specific antigens that best stimulate the immune system.</td><td>Pros: targets specific epitopes of antigen; lower chance of adverse reactions. Cons: expensive; weaker immune response.</td><td>HBV (antigen = HBsAg), HPV, acellular pertussis (aP), Neisseria meningitidis (various strains), Streptococcus pneumoniae (PPSV23 polysaccharide primarily ‘T-cell-independent response; PCV13, PCVI5, and PCV20 polysaccharide produces ‘T-cell-dependent response), Haemophilus influenzae type b, herpes zoster.</td></tr><tr><td>Toxoid</td><td>Denatured bacterial toxin with an intact receptor binding site. Stimulates immune system to make antibodies without potential for causing disease.</td><td>Pros: protects against the bacterial toxins. Cons: antitoxin levels decrease with time, thus booster shots may be needed.</td><td>Clostridium tetani, Corynebacterium diphtheriae.</td></tr><tr><td>mRNA</td><td>A lipid nanoparticle delivers mRNA, causing cells to synthesize foreign protein (eg, spike protein of SARS-CoV-2).</td><td>Pros: high efficacy; induces cellular and humoral immunity. Safe in pregnancy. Cons: local and transient systemic (fatigue, headache, myalgia) reactions are common. Rare myocarditis, pericarditis particularly in</td><td>SARS-CoV-2</td></tr></table>
======================================
<table><tr><td>Type lV hypersensitivity</td><td>‘Two mechanisms, each involving T cells: 1. Direct cell cytotoxicity: CD8+ cytotoxic T cells kill targeted cells.</td><td>Response does not involve antibodies (vs types I, IL, and III). Examples:</td></tr><tr><td>Delayed-type hypersensitivity</td><td></td><td>Fourth (type) and last (delayed).</td></tr></table>
======================================
<table><thead><th>TYPE</th><th>PATHOGENESIS</th><th>TIMING</th><th>CLINICAL PRESENTATION</th><th>DONOR BLOOD</th><th>HOST BLOOD</th></thead><tr><td>Allergic/ anaphylactic reaction</td><td>‘Type | hypersensitivity reaction against plasma proteins in transfused blood IgA-deficient individuals should receive blood . products without IgA</td><td>Within minutes to 2-3 hr (due to release of preformed inflammatory mediators in degranulating mast cells)</td><td>Allergies: urticaria, pruritus Anaphylaxis: wheezing, hypotension, _ respiratory arrest, shock</td><td>S 4 4 &gt; is Donor plasma proteins, including IgA</td><td>ivan ma y ortisal -ve° Ley +e . e oe Host mast cell a</td></tr><tr><td>Acute hemolytic transfusion reaction</td><td>‘Type II hypersensitivity reaction ‘Typically causes intravascular hemolysis (ABO blood group . aan incompatibility)</td><td>During transfusion or within 24 hr (due to preformed antibodies)</td><td>Fever, hypotension, tachypnea, tachycardia, flank pain, hemoglobinuria . (intravascular), jaundice (extravascular)</td><td>Donor RBC with A and/ or B group antigens</td><td>Wa We ra Suga + 4 Host anti-A, anti-B IgG, IgM Ba</td></tr><tr><td>Febrile nonhemolytic transfusion reaction</td><td>Cytokines created by — donor WBCs accumulate during storage of blood products Reactions prevented by leukoreduction of blood products</td><td>Within 1-6 hr (due _to preformed cytokines)</td><td>Fever, headaches, chills, flushing More common in children</td><td>Donor WBC releases preformed cytokines Et</td><td></td></tr><tr><td>Transfusion- related acute lung injury</td><td>‘Two-hit mechanism: = Neutrophils are sequestered and primed in pulmonary vasculature due to recipient risk factors = Neutrophils are activated by a product (eg, antileukocyte antibodies) in the transfused blood and release inflammatory mediators &gt; t capillary permeability &gt; pulmonary edema</td><td>Within minutes to 6hr</td><td>Respiratory distress, noncardiogenic pulmonary edema</td><td>2 neutrophils Donor antileukocyte antibody</td><td>&amp;</td></tr></table>
======================================
<table><tr><td>Anti-postsynaptic ACh receptor</td><td>Myasthenia gravis</td></tr><tr><td>Anti-presynaptic voltage-gated Ca** channel</td><td>Lambert-Eaton myasthenic syndrome</td></tr><tr><td>Anti-B2 glycoprotein |</td><td>Antiphospholipid syndrome</td></tr><tr><td>Antinuclear (ANA)</td><td>Nonspecific screening antibody, often associated with SLE</td></tr><tr><td>Anticardiolipin, lupus anticoagulant</td><td>SLE, antiphospholipid syndrome</td></tr><tr><td>Anti-dsDNA, anti-Smith</td><td>SLE</td></tr><tr><td>Antihistone</td><td>Drug-induced lupus</td></tr><tr><td>Anti-U1] RNP (ribonucleoprotein)</td><td>Mixed connective tissue disease</td></tr><tr><td>Rheumatoid factor (IgM antibody against IgG Fc region), anti-cyclic citrullinated peptide (anti-CCP, more specific)</td><td>Rheumatoid arthritis</td></tr><tr><td>Anti-Ro/SSA, anti-La/SSB</td><td>Sjégren syndrome</td></tr><tr><td>Anti-Scl-70 (anti-DNA topoisomerase I)</td><td>Scleroderma (diffuse)</td></tr><tr><td>Anticentromere</td><td>Limited scleroderma (CREST syndrome)</td></tr><tr><td>Antisynthetase (eg, anti-Jo-1), anti-SRP, anti- helicase (anti-Mi-2)</td><td>Polymyositis, dermatomyositis</td></tr><tr><td>Antimitochondrial</td><td>1° biliary cholangitis</td></tr><tr><td>Anti-smooth muscle, anti-liver/kidney</td><td>Autoimmune hepatitis</td></tr><tr><td>microsomal-] Myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)/perinuclear ANCA</td><td>Microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, ulcerative</td></tr><tr><td>(p-ANCA)</td><td>colitis, 1° sclerosing cholangitis</td></tr><tr><td>PR3-ANCA/cytoplasmic ANCA (c-ANCA)</td><td>Granulomatosis with polyangiitis</td></tr><tr><td>Anti-phospholipase Az receptor</td><td>1° membranous nephropathy</td></tr><tr><td>Anti-hemidesmosome</td><td>Bullous pemphigoid</td></tr><tr><td>Anti-desmoglein (anti-desmosome)</td><td>Pemphigus vulgaris</td></tr><tr><td>Antithyroglobulin, antithyroid peroxidase (antimicrosomal)</td><td>Hashimoto thyroiditis</td></tr><tr><td>Anti-T’SH receptor</td><td>Graves disease</td></tr><tr><td>IgA anti-endomysial, IgA anti-tissue transglutaminase, IgA and IgG deamidated gliadin peptide</td><td>Celiac disease</td></tr><tr><td>Anti-glutamic acid decarboxylase, islet cell cytoplasmic antibodies</td><td>Type | diabetes mellitus</td></tr><tr><td>Antiparietal cell, anti-intrinsic factor</td><td>Pernicious anemia</td></tr><tr><td>Anti-glomerular basement membrane</td><td>Goodpasture syndrome</td></tr></table>
======================================
<table><thead><th>DISEASE</th><th>DEFECT</th><th>PRESENTATION</th><th>FINDINGS</th></thead><tr><td colspan="4">B-cell disorders</td></tr><tr><td>X-linked (Bruton) agammaglobulinemia</td><td>Defect in BTK, a tyrosine kinase gene &gt; no B-cell maturation; X-linked recessive (t in Boys)</td><td>Recurrent bacterial and enteroviral infections after 6 months ($ maternal IgG)</td><td>Absent B cells in peripheral blood, 4 Ig of all classes. Absent/scanty lymph nodes and tonsils (1° follicles and germinal centers absent) — live vaccines contraindicated</td></tr><tr><td>Selective IgA deficiency</td><td>Cause unknown Most common 1° immunodeficiency</td><td>Majority Asymptomatic Can see Airway and GI infections, Autoimmune disease, Atopy, Anaphylaxis to IgA in blood products</td><td>+ IgA with normal IgG, IgM levels t susceptibility to giardiasis Can cause false-negative celiac disease test and false-positive serum pregnancy test</td></tr><tr><td>Common variable immunodeficiency</td><td>Defect in B-cell differentiation. Cause unknown in most cases</td><td>May present in childhood but usually diagnosed after puberty t risk of autoimmune disease, bronchiectasis, lymphoma, sinopulmonary infections</td><td>+ plasma cells, + immunoglobulins</td></tr><tr><td colspan="4">T-cell disorders</td></tr><tr><td>Thymic aplasia</td><td>22q11 microdeletion; failure to develop 3rd and 4th pharyngeal pouches &gt; absent thymus and parathyroids DiGeorge syndrome—thymic, parathyroid, cardiac defects Velocardiofacial syndrome— palate, facial, cardiac defects</td><td>CATCH-22: Cardiac defects (conotruncal abnormalities eg, tetralogy of Fallot, truncus arteriosus]), Abnormal facies, Thymic hypoplasia + T-cell deficiency (recurrent viral/ fungal infections), Cleft palate, Hypocalcemia 2° to parathyroid aplasia &gt; tetany</td><td>4 T cells, | PTH, + Ca’* Thymic shadow absent on CXR</td></tr><tr><td>IL-12 receptor deficiency</td><td>+ Thl response; autosomal recessive</td><td>Disseminated mycobacterial and fungal infections; may present after administration of BCG vaccine</td><td>yIFN-y Most common cause of Mendelian susceptibility to mycobacterial diseases (MSMD)</td></tr><tr><td>Autosomal dominant hyper-IgE syndrome (Job syndrome)</td><td>Deficiency of Th17 cells due to STAT3 mutation &gt; impaired recruitment of neutrophils to sites of infection</td><td>Cold (noninflamed) staphylococcal Abscesses, retained Baby teeth, Coarse facies, Dermatologic problems (eczema), t IgE, bone</td><td>tlgE t eosinophils Learn the ABCDEF’s to get a Job STAT!</td></tr></table>
======================================
<table><tr><td>Severe combined immunodeficiency</td><td>Several types including defective IL-2R gamma chain (most common, X-linked recessive); adenosine deaminase deficiency (autosomal recessive); RAG mutation + VDJ</td><td>Failure to thrive, chronic diarrhea, thrush Recurrent viral, bacterial, fungal, and protozoal infections</td><td>+ T-cell receptor excision circles (TRECs) Part of newborn screening for SCID Absence of thymic shadow (CXR), germinal centers (lymph node biopsy), and</td></tr><tr><td>Ataxia-telangiectasia A *</td><td>recombination defect Defects in ATM gene &gt; failure to detect DNA damage &gt; failure to halt progression of cell cycle &gt; mutations accumulate; autosomal recessive</td><td>Triad: cerebellar defects (Ataxia), spider Angiomas (telangiectasia fi), IgA deficiency tt sensitivity to radiation (limit x-ray exposure)</td><td>T cells (flow cytometry) t AFP + IgA, IgG, and Igk Lymphopenia, cerebellar atrophy t risk of lymphoma and leukemia</td></tr><tr><td>Hyper-IgM syndrome</td><td>Most commonly due to defective CD40L on Th cells + class switching defect; X-linked recessive</td><td>Severe pyogenic infections early in life; opportunistic infection with Pneumocystis, Cryptosporidium, CMV</td><td>Normal or t IgM. 44 IgG, IgA, IgE Failure to make germinal centers</td></tr><tr><td>Wiskott-Aldrich syndrome</td><td>Mutation in WAS gene; leukocytes and platelets unable to reorganize actin cytoskeleton + defective antigen presentation; X-linked recessive</td><td>WATER: Wiskott-Aldrich: Thrombocytopenia, Eczema, Recurrent (pyogenic) infections _ t risk of autoimmune disease and malignancy</td><td>+ to normal IgG, IgM t IgE, IgA Fewer and smaller platelets</td></tr><tr><td>Phagocyte dysfunction</td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>PATHOGEN</th><th>+ TCELLS</th><th>+ BCELLS</th><th>4 GRANULOCYTES</th><th>+ COMPLEMENT</th></thead><tr><td>Bacteria</td><td>Sepsis</td><td>Encapsulated (Please SHINE my SKiS): Pseudomonas deruginosa, Streptococcus pneumoniae, Haemophilus Influenzae type b, Neisseria meningitidis, Escherichia coli, Salmonella, Klebsiella pneumoniae, group B Streptococcus</td><td>— Some Bacteria Produce No Serious granules: Staphylococcus, Burkholderia cepacia, Pseudomonas aeruginosa, Nocardia, Serratia</td><td>Encapsulated species with early complement deficiencies Neisseria with late complement (C5— C9) deficiencies</td></tr><tr><td>Viruses</td><td>CMV, EBV, JC virus, VZV, chronic infection with respiratory/GI viruses</td><td>Enteroviral encephalitis, poliovirus (live vaccine contraindicated)</td><td></td><td></td></tr><tr><td>Fungi/parasites</td><td>Cryptococcus Candida (local), PCP,</td><td>GI giardiasis (no IgA)</td><td>Aspergillus, Mucor — Candida (systemic),</td><td></td></tr></table>
======================================
<table><thead><th>TYPE OF REJECTION</th><th>ONSET</th><th>PATHOGENESIS</th><th>FEATURES</th></thead><tr><td>Hyperacute</td><td>Within minutes</td><td>Pre-existing recipient antibodies react to donor antigen (type II hypersensitivity reaction), activate complement</td><td>Widespread thrombosis of graft vessels (arrows within glomerulus 53) — ischemia and fibrinoid necrosis Graft must be removed</td></tr><tr><td>Acute</td><td>Weeks to months</td><td>Cellular: CD8+ T cells and/or CD4+ T cells activated against donor MHCs (ty Humoral: similar to hyperacute, except pe IV hypersensitivity reaction) antibodies develop after transplant (associated with C4d deposition)</td><td>Vasculitis of graft vessels with dense interstitial lymphocytic infiltrate 5} Prevent/reverse with immunosuppressants</td></tr><tr><td>Chronic</td><td>Months to years</td><td>CD4+ T cells respond to recipient APCs presenting donor peptides, including allogeneic MHC Both cellular and humoral components (ty reactions) pe II and IV hypersensitivity</td><td>Dominated by arteriosclerosis Recipient T cells react and secrete cytokines — proliferation of vascular smooth muscle, parenchymal atrophy, interstitial fibrosis Organ-specific examples: * Chronic allograft nephropathy * Bronchiolitis obliterans = Accelerated atherosclerosis (heart) * Vanishing bile duct syndrome</td></tr><tr><td>Graft-versus-host disease</td><td>Varies</td><td>Grafted immunocompetent T cells proliferate in the immunocompromised host and reject host cells with “foreign” proteins &gt; severe organ dysfunction HLA mismatches (most importantly HLA-A, -B, and -DR antigens) t the risk for GVHD ‘Type IV hypersensitivity reaction</td><td>Maculopapular rash, jaundice, diarrhea, hepatosplenomegaly Usually in bone marrow and liver transplants (rich in lymphocytes) Potentially beneficial in bone marrow transplant for leukemia (graft-versus- tumor effect) For patients who are immunocompromised, irradiate blood products prior to transfusion</td></tr></table>
======================================
<table><thead><th>cyclosporine</th><th>Calcineurin inhibitor; binds cyclophilin Blocks T-cell activation by preventing IL-2 transcription</th><th>Psoriasis, rheumatoid arthritis</th><th>Nephrotoxicity, hypertension, hyperlipidemia, neurotoxicity, gingival hyperplasia, hirsutism</th><th>Both calcineurin inhibitors are</th></thead><tr><td>Tacrolimus (FK506)</td><td>Calcineurin inhibitor; binds F'K506 binding rotein (KBP) Blocks ‘T-cell activation by preventing IL-2 transcription</td><td>Immunosuppression after solid organ transplant</td><td>Similar to cyclosporine, t risk of diabetes and neurotoxicity; no gingival hyperplasia or hirsutism</td><td>highly nephrotoxic, especially in higher doses or in patients with $ renal function</td></tr><tr><td>sirolimus (Rapamycin)</td><td>mTOR inhibitor; binds FKBP Blocks T-cell activation and B-cell differentiation by preventing response to IL-2</td><td>Kidney transplant specifically Sir Basil’s kidney transplant rejection prophylaxis</td><td>“Pansirtopenia” (pancytopenia), insulin resistance, hyperlipidemia; not nephrotoxic</td><td>Kidney “sir-vives.” Synergistic with cyclosporine Also used in drug- eluting stents</td></tr><tr><td>3asiliximab</td><td>Monoclonal antibody; blocks IL-2R</td><td></td><td>Edema, hypertension, tremor</td><td></td></tr></table>
======================================
<table><thead><th>DRUG</th><th>MECHANISM</th><th>INDICATIONS</th><th>TOXICITY</th><th>NOTES</th></thead><tr><td>Azathioprine</td><td>Antimetabolite recursor of 6-mercaptopurine Inhibits lymphocyte roliferation by blocking nucleotide synthesis</td><td>Rheumatoid arthritis, Crohn disease, glomerulonephritis, other autoimmune conditions</td><td>Pancytopenia</td><td>6-MP degraded by xanthine oxidase; toxicity t by allopurinol Pronounce “azathio- purine”</td></tr><tr><td>Mycophenolate mofetil</td><td>Reversibly inhibits IMP dehydrogenase, reventing purine synthesis of B and T’ cells</td><td>Glucocorticoid-sparing agent in rheumatic disease</td><td>GI upset, pancytopenia, hypertension Less nephrotoxic and neurotoxic</td><td>Associated with invasive CMV infection</td></tr><tr><td>Glucocorticoids</td><td>Inhibit NF-«B Suppress both B- and ‘T-cell function by 4 transcription of many cytokines Induce T cell apoptosis</td><td>Many autoimmune and inflammatory disorders, adrenal insufficiency, asthma, CLL, non-Hodgkin lymphoma</td><td>Cushing syndrome, osteoporosis, hyperglycemia, diabetes, amenorrhea, adrenocortical atrophy, peptic ulcers, psychosis, cataracts, avascular necrosis (femoral head)</td><td>Demargination of WBCs causes artificial leukocytosis Adrenal insufficiency may develop if drug is stopped abruptly after chronic use</td></tr></table>
======================================
<table><thead><th>CYTOKINE</th><th>AGENT</th><th>CLINICAL USES</th></thead><tr><td colspan="3">Bone marrow stimulation</td></tr><tr><td>Erythropoietin</td><td>Epoetin alfa (EPO analog)</td><td>Anemias (especially in renal failure) Associated with t risk of hypertension, thromboembolic events</td></tr><tr><td>Colony stimulating factors</td><td>Filgrastim (G-CSF), Sargramostim (GM-CSF)</td><td>Leukopenia; recovery of granulocyte and monocyte counts</td></tr><tr><td>Thrombopoietin</td><td>Romiplostim (TPO analog), eltrombopag (think “elthrombopag.” TPO receptor agonist)</td><td>Autoimmune thrombocytopenia Platelet stimulator</td></tr><tr><td colspan="3">Immunotherapy</td></tr><tr><td>Interleukin-2</td><td>Aldesleukin</td><td>Renal cell carcinoma, metastatic melanoma</td></tr><tr><td rowspan="3">Interferons</td><td></td><td>IFN-o</td><td>Chronic hepatitis C (not preferred) and B, rena cell carcinoma</td></tr><tr><td>IFN-B</td><td>Multiple sclerosis</td></tr><tr><td></td><td>IFN-y</td><td>Chronic granulomatous disease</td></tr></table>
======================================
<table><thead><th>AGENT</th><th>TARGET</th><th>CLINICAL USE</th><th>NOTES</th></thead><tr><td colspan="4">Autoimmune disease therapy</td></tr><tr><td>Adalimumab, certolizumab, golimumab, infliximab</td><td>Soluble TNF-o</td><td>IBD, rheumatoid arthritis, ankylosing spondylitis, psoriasis</td><td>Pretreatment screening (TB, HBV, HCV, VZV, EBV, CMV) due to risk of reactivation Etanercept is a decoy TNF-o receptor and not a monoclonal antibody</td></tr><tr><td>Eculizumab</td><td>Complement protein C5</td><td>Paroxysmal nocturnal hemoglobinuria</td><td>Associated with t risk of meningococcal infection</td></tr><tr><td>Guselkumab</td><td>IL-23</td><td>Psoriasis</td><td></td></tr><tr><td>Ixekizumab, secukinumab</td><td>IL-I7A</td><td>Psoriasis, psoriatic arthritis</td><td></td></tr><tr><td>Ustekinumab</td><td>IL-12/IL-23</td><td>Psoriasis, psoriatic arthritis</td><td></td></tr><tr><td>Vedolizumab</td><td>o4-integrin</td><td>IBD</td><td>Gut-specific anti-integrin, preventing migration of leukocytes to the gastrointestinal tract</td></tr><tr><td colspan="4">Other applications</td></tr><tr><td>Denosumab</td><td>RANKL</td><td>Osteoporosis; inhibits osteoclast maturation (mimics osteoprotegerin)</td><td>Denosumab helps make dense bones</td></tr><tr><td>Emicizumab</td><td>Factor [Xa and X</td><td>Hemophilia A</td><td>Bispecific; mimics factor VIII</td></tr><tr><td>Omalizumab</td><td>Igk</td><td>Refractory allergic asthma; prevents IgE binding to FceRI</td><td></td></tr><tr><td>Palivizumab</td><td>RSV F protein</td><td>RSV prophylaxis for high-risk infants</td><td>Palivizumab—virus</td></tr></table>
======================================
<table><thead><th>STRUCTURE</th><th>CHEMICAL COMPOSITION</th><th>FUNCTION</th></thead><tr><td colspan="3">Appendages</td></tr><tr><td>Flagellum</td><td>Proteins</td><td>Motility</td></tr><tr><td>Pilus/fimbria</td><td>Glycoprotein</td><td>Mediate adherence of bacteria to cell surface; sex pilus forms during conjugation</td></tr><tr><td colspan="3">Specialized structures</td></tr><tr><td>Spore</td><td>Keratinlike coat; dipicolinic acid; peptidoglycan, DNA</td><td>Gram @ only Survival: resist dehydration, heat, chemicals</td></tr><tr><td colspan="3">Cell envelope</td></tr><tr><td>Capsule</td><td>Discrete layer usually made of polysaccharides (and rarely proteins)</td><td>_ Protects against phagocytosis</td></tr><tr><td>(S) layer</td><td>of polysaccharides</td><td>surfaces, plays biofilm formation (eg, indwelling catheters)</td></tr><tr><td>Outer membrane</td><td>Outer leaflet: contains endotoxin (LPS/LOS) Embedded proteins: porins and other outer membrane proteins (OMPs) Inner leaflet: phospholipids</td><td>Gram © only Endotoxin: lipid A induces TNF and IL-1; antigenic O polysaccharide component Most OMPs are antigenic Porins: transport across outer membrane</td></tr><tr><td>Periplasm</td><td>Space between cytoplasmic membrane and outer membrane in gram © bacteria (peptidoglycan in middle)</td><td>Accumulates components exiting gram © cells, including hydrolytic enzymes (eg, B-lactamases)</td></tr><tr><td>Cell wall</td><td>Peptidoglycan is a sugar backbone with peptide side chains cross-linked by transpeptidase</td><td>Netlike structure gives rigid support, protects against osmotic pressure damage</td></tr><tr><td>Cytoplasmic membrane</td><td>Phospholipid bilayer sac with embedded proteins (eg, penicillin-binding proteins [PBPs]) and other enzymes</td><td>Site of oxidative and transport enzymes; PBPs involved in cell wall synthesis Lipoteichoic acids induce ‘TNF-a and IL-1</td></tr><tr><td></td><td>Lipoteichoic acids (gram positive) only extend</td><td></td></tr></table>
======================================
<table><tr><td rowspan="5">Gram stain</td><td colspan="2">First-line lab test in bacterial identification. Bacteria with thick peptidoglycan layer retain crystal violet dye (gram ®); bacteria with thin peptidoglycan layer turn red or pink (gram ©) with counterstain. These bugs do not Gram stain well (These Little Microbes May Unfortunately Lack Real Color But Are</td></tr><tr><td></td><td>Everywhere): Treponema, Leptospira</td><td>Too thin to be visualized</td></tr><tr><td></td><td>Mycobacteria</td><td>Cell wall has high lipid content</td></tr><tr><td></td><td>Mycoplasma, Ureaplasma</td><td>No cell wall</td></tr><tr><td></td><td>Legionella, Rickettsia, Chlamydia, Bartonella, Anaplasma, Ehrlichia</td><td>Primarily intracellular; also, Chlamydia lack classic peptidoglycan because of 4 muramic acid</td></tr><tr><td>Giemsa stain</td><td>Chlamydia, Rickettsia, Trypanosomes [N, Borrelia, Helicobacter pylori, Plasmodium</td><td>Clumsy Rick Tripped on a Borrowed Helicopter Plastered in Gems</td></tr><tr><td>Periodic acid-Schiff stain</td><td>Stains glycogen, mucopolysaccharides; used to diagnose Whipple disease (Tropheryma whipplei E))</td><td>PaSs the sugar</td></tr><tr><td>(carbol fuchsin) India ink stain</td><td>Nocardia; stains mycolic acid in cell wall); protozoa (eg, Cryptosporidium oocysts) Cryptococcus neoformans [); mucicarmine</td><td>for screening (inexpensive, more sensitive)</td></tr><tr><td>Silver stain</td><td>can also be used to stain thick polysaccharide capsule red Helicobacter pylori, Legionella, Bartonella henselae, and fungi Coccidioides (3,</td><td>HeLiCoPters Are silver</td></tr><tr><td>Fluorescent antibody stain</td><td>(eg, Pneumocystis jirovecii, Aspergillus fumigatus) Used to identify many bacteria, viruses, Pneumocystis jirovecii, Giardia, and</td><td>Example is F'TA-ABS for syphilis</td></tr></table>
======================================
<table><thead><th>BUG</th><th>MEDIA USED FOR ISOLATION</th><th>MEDIA CONTENTS/OTHER</th></thead><tr><td>H influenzae</td><td>Chocolate agar</td><td>Factors V (NAD*) and X (hematin)</td></tr><tr><td>N gonorrhoeae, N meningitidis</td><td>Thayer-Martin agar</td><td>Selectively favors growth of Neisseria by inhibiting growth of gram © organisms with vancomycin, gram © organisms except Neisseria with trimethoprim and colistin, and fungi with nystatin Very typically cultures Neisseria</td></tr><tr><td>B pertussis</td><td>Bordet-Gengou agar (Bordet for Bordetella) Regan-Lowe medium</td><td>Potato extract Charcoal, blood, and antibiotic</td></tr><tr><td>Cdiphtheriae</td><td>Tellurite agar, Loffler medium</td><td></td></tr><tr><td>M tuberculosis</td><td>Léwenstein-Jensen medium, Middlebrook medium, rapid automated broth cultures</td><td></td></tr><tr><td>M pneumoniae</td><td>Eaton agar</td><td>Requires cholesterol</td></tr><tr><td>Lactose-fermenting enterics</td><td>MacConkey agar</td><td>Fermentation produces acid, causing colonies to turn pink</td></tr><tr><td>E coli</td><td>Eosin-methylene blue (EMB) agar</td><td>Colonies with green metallic sheen</td></tr><tr><td>Brucella, Francisella, Legionella, Pasteurella</td><td>Charcoal yeast extract agar buffered with cysteine and iron</td><td>The Ella siblings, Bruce, Francis, a legionnaire, and a pasteur (pastor), built the Sistine (cysteine) chapel out of charcoal and iron</td></tr></table>
======================================
<table><tr><td>ment-producing teria</td><td>Actinomyces israelii—yellow “sulfur” granules, which are composed of filaments of bacteria</td><td>Israel has yellow sand</td><td></td></tr><tr><td></td><td>S aureus—golden yellow pigment</td><td>Aureus (Latin) = gold</td><td></td></tr><tr><td></td><td>P aeruginosa—blue-green pigment (pyocyanin and pyoverdin) Serratia marcescens—red pigment</td><td>Aerugula is green Think red Sriracha</td><td>hot sauce</td></tr></table>
======================================
<table><tr><td>producing bacteria</td><td>Viridans streptococci (S mutans, S sanguinis)</td><td>Dental plaques, infective endocarditis</td></tr><tr><td></td><td>Nontypeable (unencapsulated) H influenzae</td><td>Otitis media</td></tr></table>
======================================
<table><tr><td>SOURCE</td><td>Certain species of gram ® and gram O bacteria</td><td>Outer cell membrane of most gram © bacteria</td></tr><tr><td>SECRETED FROM CELL</td><td>Yes</td><td>No</td></tr><tr><td>CHEMISTRY</td><td>Polypeptide</td><td>Lipid A component of LPS (structural part of bacteria; released when lysed)</td></tr><tr><td>LOCATION OF GENES</td><td>Plasmid or bacteriophage</td><td>Bacterial chromosome</td></tr><tr><td>TOXICITY</td><td>High (fatal dose on the order of 1 jg)</td><td>Low (fatal dose on the order of hundreds of micrograms)</td></tr><tr><td>CLINICAL EFFECTS</td><td>Various effects (see following pages)</td><td>Fever, shock (hypotension), DIC</td></tr><tr><td>MODE OF ACTION</td><td>Various modes (see following pages)</td><td>Induces TNF, IL-1, and IL-6</td></tr><tr><td>VACCINES</td><td>Toxoids used as vaccines</td><td>No toxoids formed and no vaccine available</td></tr><tr><td>HEAT STABILITY</td><td>Destroyed rapidly at 60°C (except staphylococcal enterotoxin and E coli heat- stable toxin)</td><td>Stable at 100°C for | hr</td></tr><tr><td rowspan="4">TYPICAL DISEASES</td><td>Tetanus, botulism, diphtheria, cholera</td><td>Meningococcemia; sepsis by gram © rods</td></tr><tr><td></td><td>Exotoxin</td><td></td></tr><tr><td></td><td>@ t, e@ Ce</td><td>a J &amp; fs?</td></tr><tr><td></td><td>Downstream cellular reaction Ne Host</td><td>L TNF, IL-1, IL-6 cell 7</td></tr></table>
======================================
<table><thead><th>BACTERIA</th><th>TOXIN</th><th>MECHANISM</th><th>MANIFESTATION</th></thead><tr><td colspan="4">Inhibit protein synthesis</td></tr><tr><td>Corynebacterium diphtheriae</td><td>Diphtheria toxin*</td><td>Inactivate elongation factor (EF-2) through</td><td>Pharyngitis with pseudomembranes in throat and severe lymphadenopathy (bull neck), myocarditis</td></tr><tr><td>Pseudomonas aeruginosa</td><td>Exotoxin A*</td><td>ADP-ribosylation</td><td>Host cell death</td></tr><tr><td>Shigella spp</td><td>Shiga toxin*</td><td>Inactivate 60S ribosome by</td><td>Damages GI mucosa &gt; dysentery</td></tr><tr><td>Enterohemorrhagic Ecoli</td><td></td><td>removing adenine from tRNA</td><td>Enhances cytokine release + hemolytic-uremic syndrome (HUS; prototypically in EHEC serotype O157:H7) Unlike Shigella, EHEC does not invade host cells</td></tr><tr><td>Increase fluid secretion Enterotoxigenic Ecoli</td><td>Heat-labile toxin</td><td>Overactivates adenylate &gt; t Cl</td><td>Watery diarrhea: “labile in the Air (Adenylate stable on the Ground</td></tr><tr><td></td><td>(LT)* Heat-stable toxin (ST)</td><td>cyclase (t cAMP) secretion in gut and H,O efflux Overactivates guanylate cyclase (t cGMP)</td><td>cyclase), (Guanylate cyclase)” Bacteria that t cAMP include Cholera, Anthracis, Pertussis, E coli; “Increase cAMP with CAPE</td></tr><tr><td></td><td></td><td>— 4 resorption of NaCl and H,O in gut</td><td></td></tr><tr><td>Bacillus anthracis</td><td>Anthrax toxin*</td><td>Mimics adenylate cyclase (t cAMP)</td><td>Likely responsible for characteristic edematous borders of black eschar in cutaneous anthrax</td></tr><tr><td>Vibrio cholerae</td><td>Cholera toxin®</td><td>Overactivates adenylate cyclase (t cAMP) by permanently activating G,</td><td>Voluminous “rice-water” diarrhea</td></tr><tr><td colspan="4">Inhibit phagocytic ability</td></tr><tr><td>Bordetella pertussis</td><td>Pertussis toxin*</td><td>Activates adenylate cyclase (t cAMP) by inactivating inhibitory subunit (G)).</td><td>Whooping cough—child coughs on expiration and “whoops” on inspiration; can cause “100-day cough” in adults; associated with posttussive emesis</td></tr><tr><td colspan="4">Inhibit release of neurotransmitter</td></tr><tr><td>Clostridium tetani</td><td>Tetanospasmin*</td><td>Both are proteases that cleave SNARE (soluble NSF attachment</td><td>Toxin prevents release of inhibitory (GABA and glycine) neurotransmitters from Renshaw cells in spinal cord &gt; spastic paralysis, risus sardonicus, trismus (lockjaw), opisthotonos</td></tr><tr><td>Clostridium botulinum</td><td>Botulinum toxin*</td><td>protein receptor), a set of proteins required for neurotransmitter release via vesicular fusion</td><td>Infant botulism—caused by ingestion of spores (eg, from soil, raw honey). Toxin produced in vivo Foodborne botulism—caused by of</td></tr></table>
======================================
<table><thead><th>BACTERIA</th><th>TOXIN</th><th>MECHANISM</th><th>MANIFESTATION</th></thead><tr><td colspan="4">Lyse cell membranes</td></tr><tr><td>Clostridium perfringens</td><td>Alpha toxin</td><td>Phospholipase (lecithinase) that degrades tissue and cell membranes</td><td>Degradation of phospholipids + myonecrosis (“gas gangrene”) and hemolysis (“double zone’ of hemolysis on blood agar)</td></tr><tr><td>Streptococcus pyogenes</td><td>Streptolysin O</td><td>Protein that degrades cell membrane</td><td>Lyses RBCs; contributes to B-hemolysis; host antibodies against toxin (ASO) used to diagnose rheumatic fever (do not confuse with immune complexes of poststreptococcal glomerulonephritis)</td></tr><tr><td colspan="4">Superantigens causing shock</td></tr><tr><td>Staphylococcus aureus</td><td>Toxic shock syndrome toxin (TSST-1)</td><td>Cross-links B region of TCR to MHC class II on APCs outside of the antigen binding site</td><td>Toxic shock syndrome: fever, rash, shock; other toxins cause scalded skin syndrome (exfoliative toxin) and food poisoning (heat-stable enterotoxin)</td></tr><tr><td>Streptococcus pyogenes</td><td>Erythrogenic exotoxin A</td><td>&gt; overwhelming release of IL-1, IL-2, IF'N-y, and TNF-a &gt; shock</td><td>Toxic shock-like syndrome: fever, rash, shock; scarlet fever</td></tr></table>
======================================
<table><tr><td>Aerobe</td><td>Anaerobe</td></tr><tr><td>Acid fast (weak) EN</td><td>Not acid fast [J</td></tr><tr><td>Found in soil</td><td>Normal oral, reproductive, and GI microbiota</td></tr><tr><td>Causes pulmonary infections in immunocompromised (can mimic TB but</td><td>Causes oral/facial abscesses that drain through sinus often associated with dental caries/</td></tr><tr><td>Treat with sulfonamides (TMP-SMX)</td><td>Treat with penicillin</td></tr></table>
======================================
<table><thead><th>Gonococci</th><th>Meningococci</th></thead><tr><td>No polysaccharide capsule</td><td>Polysaccharide capsule</td></tr><tr><td>No maltose acid detection</td><td>Maltose acid detection</td></tr><tr><td>No vaccine due to antigenic variation of pilus proteins</td><td>Vaccine (type B vaccine available for at-risk individuals)</td></tr><tr><td>Sexually or perinatally transmitted</td><td>Transmitted via respiratory and oral secretions More common among individuals in close quarters (eg, army barracks, college dorms)</td></tr><tr><td>Causes gonorrhea, septic arthritis, neonatal conjunctivitis (2-5 days after birth), pelvic inflammatory disease (PID), and Fitz-Hugh- Curtis syndrome</td><td>Causes meningococcemia with petechial hemorrhages and gangrene of toes 5, meningitis, Waterhouse-Friderichsen syndrome (acute hemorrhagic adrenal</td></tr><tr><td>Diagnosed with NAAT</td><td>insufficiency) Diagnosed via culture-based tests or PCR</td></tr><tr><td>Condoms 4 sexual transmission, erythromycin eye ointment prevents neonatal blindness</td><td>Rifampin, ciprofloxacin, or ceftriaxone prophylaxis in close contacts</td></tr><tr><td>Treatment: single dose IM ceftriaxone; if chlamydial coinfection not excluded by</td><td>Treatment: ceftriaxone or penicillin G</td></tr></table>
======================================
<table><thead><th></th><th>Salmonella typhi (ty-Vi)</th><th>Salmonella spp. except S typhi</th><th>Shigella</th></thead><tr><td>RESERVOIRS</td><td>Humans only</td><td>Humans and animals</td><td>Humans only</td></tr><tr><td>SPREAD</td><td>Hematogenous spread</td><td>Hematogenous spread</td><td>Cell to cell; no hematogenous spread</td></tr><tr><td>H,S PRODUCTION</td><td>Yes</td><td>Yes</td><td>No</td></tr><tr><td>FLAGELLA</td><td>Yes (salmon swim)</td><td>Yes (salmon swim)</td><td>No</td></tr><tr><td>VIRULENCE FACTORS</td><td>Endotoxin; Vi capsule (pronounce “tyVi”)</td><td>Endotoxin</td><td>Endotoxin; Shiga toxin (enterotoxin)</td></tr><tr><td>INFECTIOUS DOSE (IDso)</td><td>High—large inoculum required; acid-labile (inactivated by gastric acids)</td><td>High</td><td>Low—very small inoculum required; acid stable (resistant to gastric acids)</td></tr><tr><td>EFFECT OF ANTIBIOTICS ON FECAL EXCRETION</td><td>Prolongs duration</td><td>Prolongs duration</td><td>Shortens duration (shortens Shigella)</td></tr><tr><td>IMMUNE RESPONSE</td><td>Primarily monocytes</td><td>PMNs in disseminated disease</td><td>Primarily PMN infiltration</td></tr><tr><td>GI MANIFESTATIONS</td><td>Constipation, followed by diarrhea</td><td>Diarthea (possibly bloody)</td><td>Crampy abdominal pain &gt; tenesmus, bloody mucoid stools (bacillary dysentery)</td></tr><tr><td>VACCINE UNIQUE PROPERTIES</td><td>Oral vaccine contains live attenuated S typhi IM vaccine contains Vi capsular polysaccharide Causes typhoid fever (salmon-</td><td>No vaccine Poultry, pets, and</td><td>No vaccine 4 F's: fingers, flies, food, feces</td></tr><tr><td></td><td>colored truncal macular rash, abdominal pain, fever [pulse-temperature dissociation]; later GI ulceration and hemorrhage); treat with ceftriaxone or fluoroquinolone Carrier state with gallbladder</td><td>eggs, turtles are common sources ‘Treatment is supportive; antibiotics are not indicated in immunocompetent individuals</td><td>In order of decreasing severity (less toxin produced): S dysenteriae, S flexneri, S boydii, S sonnei Invasion of M cells is key to pathogenicity; infectious dose is low</td></tr></table>
======================================
<table><tr><td>Enteroinvasive E coli</td><td>Microbe invades intestinal mucosa and causes necrosis and inflammation.</td><td>EIEC is Invasive; dysentery. Clinical manifestations similar to Shigella.</td></tr><tr><td>Enterotoxigenic E coli</td><td>Produces heat-labile and heat-stable enteroToxins. No inflammation or invasion.</td><td>ETEC; Traveler’s diarrhea (watery).</td></tr><tr><td>Enteropathogenic E coli</td><td>No toxin produced. Adheres to apical surface, flattens villi, prevents absorption.</td><td>Diarrhea, usually in children (think EPEC and Pediatrics).</td></tr><tr><td>Enterohemorrhagic E coli</td><td>O157:H7 is most common serotype in US. Often ransmitted via undercooked meat, raw leafy vegetables. Shiga toxin causes hemolytic-uremic syndrome—triad of anemia, thrombocytopenia, and acute kidney injury due to microthrombi forming on damaged endothelium &gt; mechanical hemolysis (with schistocytes on ripheral blood smear), platelet consumption, and $ renal blood flow.</td><td>Dysentery (toxin alone causes necrosis and inflammation). Does not ferment sorbitol (vs other E coli). EHEC associated with hemorrhage, hamburgers, hemolytic-uremic syndrome.</td></tr></table>
======================================
<table><thead><th></th><th colspan="2">Serologic testing</th><th></th><th colspan="2"></th></thead><tr><td>(nonspecific)</td><td>Nontreponemal</td><td>Treponemal (specific)</td><td></td><td>Darkfield microscopy</td><td>PCR</td></tr><tr><td>J</td><td>|</td><td>af</td><td>|</td><td></td><td></td></tr><tr><td>RPR</td><td>VDRL</td><td>FTA-ABS</td><td>TPPA</td><td></td><td></td></tr></table>
======================================
<table><thead><th>SPECIES</th><th>DISEASE</th><th>TRANSMISSION AND SOURCE</th></thead><tr><td>Anaplasma spp</td><td>Anaplasmosis</td><td>Ixodes ticks (live on deer and mice)</td></tr><tr><td>Bartonella spp</td><td>Cat scratch disease, bacillary angiomatosis</td><td>Cat scratch</td></tr><tr><td>Borrelia burgdorferi</td><td>Lyme disease</td><td>Ixodes ticks (live on deer and mice)</td></tr><tr><td>Borrelia recurrentis</td><td>Relapsing fever</td><td>Louse (recurrent due to variable surface antigens)</td></tr><tr><td>Brucella spp</td><td>Brucellosis/undulant fever</td><td>Unpasteurized dairy; inhalation of or contact with infected animal tissue or fluids</td></tr><tr><td>Campylobacter</td><td>Bloody diarrhea</td><td>Feces from infected pets/animals; contaminated meats/foods/hands</td></tr><tr><td>Chlamydophila psittaci</td><td>Psittacosis</td><td>Parrots, other birds</td></tr><tr><td>Coxiella burnetii</td><td>Q fever</td><td>Aerosols of cattle/sheep amniotic fluid</td></tr><tr><td>Ehrlichia chaffeensis</td><td>Ehrlichiosis</td><td>Amblyomma (Lone Star tick)</td></tr><tr><td>Francisella tularensis</td><td>Tularemia</td><td>Ticks, rabbits, deer flies</td></tr><tr><td>Leptospira spp</td><td>Leptospirosis</td><td>Animal urine in water; recreational water use</td></tr><tr><td>Mycobacterium leprae</td><td>Leprosy</td><td>Humans with lepromatous leprosy; armadillo (rare)</td></tr><tr><td>Pasteurella multocida</td><td>Cellulitis, osteomyelitis</td><td>Animal bite, cats, dogs</td></tr><tr><td>Rickettsia prowazekii</td><td>Epidemic typhus</td><td>Human to human via human body louse</td></tr><tr><td>Rickettsia rickettsii</td><td>Rocky Mountain spotted fever</td><td>Dermacentor (dog tick)</td></tr><tr><td>Rickettsia typhi</td><td>Endemic typhus</td><td>Fleas</td></tr><tr><td>Salmonella spp (except S typhi)</td><td>Diarrhea (which may be bloody), vomiting, fever, abdominal cramps</td><td>Reptiles and poultry</td></tr></table>
======================================
<table><tr><td>Rocky Mountain</td><td>Rickettsia rickettsii, vector is tick. Despite its</td><td>Classic triad—headache, fever, rash (vasculitis).</td></tr><tr><td>spotted fever</td><td>name, disease occurs primarily in the South Atlantic states, especially North Carolina. Rash typically starts at wrists [J and ankles and then spreads to trunk, palms, and soles.</td><td>Palms and soles rash is seen in Coxsackievirus A infection (hand, foot, and mouth disease), Rocky Mountain spotted fever, and 2° Syphilis (you drive CARS using your palms and soles).</td></tr><tr><td>Typhus</td><td>Endemic (fleas)—R typhi. Epidemic (human body louse)—R prowazekii. Rash starts centrally and spreads out, sparing palms and soles.</td><td>Rickettsii on the wrists, typhus on the trunk.</td></tr><tr><td colspan="3">RASH RARE</td></tr><tr><td>Ehrlichiosis</td><td>Ehrlichia, vector is tick. Monocytes with morulae [J (mulberrylike inclusions) in cytoplasm.</td><td>MEGA: Monocytes = Ehrlichiosis Granulocytes = Anaplasmosis</td></tr><tr><td>Anaplasmosis</td><td>Anaplasma, vector is tick. Granulocytes with morulae [@ in cytoplasm.</td><td></td></tr><tr><td>Q fever</td><td>Coxiella burnetii, no arthropod vector. Bacterium inhaled as aerosols from cattle/ sheep amniotic fluid. Presents with headache, cough, flulike symptoms, pneumonia, possibly in combination with hepatitis. Common cause of culture © endocarditis.</td><td>QO fever is caused by a Quite Complicated bug because it has no rash or vector and its causative organism can survive outside in its endospore form. Not in the Rickettsia genus, but closely related.</td></tr></table>
======================================
<table><thead><th>DISEASE</th><th>ENDEMIC LOCATION</th><th>PATHOLOGIC FEATURES</th><th>UNIQUE SIGNS/SYMPTOMS</th><th>NOTES</th></thead><tr><td>Histoplasmosis</td><td>Mississippi and Ohio River Valleys</td><td>Macrophage filled with Histoplasma (smaller than RBC) EY</td><td>Palatal/tongue ulcers, splenomegaly, pancytopenia, erythema nodosum</td><td>Histo hides (within macrophages) Associated with bird or bat droppings (eg, caves) Diagnosis via urine/ serum antigen</td></tr><tr><td></td><td>Eastern and Central US, Great Lakes</td><td>Broad-based budding of Blastomyces (same size as RBC) FE}</td><td>Inflammatory lung disease Disseminates to bone/ skin (verrucous lesions [@, may mimic SCC).</td><td>Blasto buds broadly</td></tr><tr><td></td><td>Southwestern US, California</td><td>Spherule filled with endospores of Coccidioides (much larger than RBC) B)</td><td>Disseminates to bone/ skin Erythema nodosum (desert bumps) or multiforme Arthralgias (desert rheumatism) Can cause meningitis</td><td>Associated with dust exposure in endemic areas (eg, archeological excavations, earthquakes)</td></tr><tr><td>Para- coccidioidomycosis SS</td><td>Latin America</td><td>Budding yeast of Paracoccidioides with “captain’s wheel” formation (much larger than RBC) &amp;</td><td>Similar to blastomycosis, males &gt; females</td><td>Paracoccidio parasails with the captain’s wheel all the way to Latin America</td></tr></table>
======================================
<table><tr><td>Candida albicans</td><td>alba = white. Dimorphic; forms pseudohyphae and budding yeasts at 20°C [N, germ tubes at 37°C Bh. superficial fungal infection. oral and esophageal thrush</td></tr><tr><td rowspan="2">Aspergillus fumigatus</td><td>Acute angle (45°) 3) branching of septate hyphae. 1 Causes invasive aspergillosis in immunocompromised patients, especially those with neutroph dysfunction (eg, chronic granulomatous disease) because Aspergillus is catalase @. Can cause aspergillomas [9 in pre-existing lung cavities, especially after TB infection. Some species of Aspergillus produce aflatoxins (induce TP53 mutations leading to hepatocellular carcinoma). Treatment: voriconazole or echinocandins (2nd-line). Allergic bronchopulmonary aspergillosis (ABPA)—hypersensitivity response to Aspergillus growing in</td></tr><tr><td></td><td>lung mucus. Associated with asthma and cystic fibrosis; may cause bronchiectasis and eosinophilia.</td></tr><tr><td>Cryptococcus neoformans</td><td>5-10 um with narrow budding. Heavily encapsulated yeast. Not dimorphic. © PAS staining. Found in soil, pigeon droppings. Acquired through inhalation with hematogenous dissemination to meninges. Highlighted with India ink (clear halo [) and mucicarmine (red inner capsule [@). Latex agglutination test detects polysaccharide capsular antigen and is more sensitive and specific. Causes cryptococcosis, which can manifest with meningitis, pneumonia, and/or encephalitis (“soap bubble” lesions in brain), primarily in immunocompromised. Treatment: amphotericin B + flucytosine followed by fluconazole for cryptococcal meningitis.</td></tr><tr><td>Mucor and Rhizopus spp</td><td>Irregular, broad, nonseptate hyphae branching at wide angles [i]. Causes mucormycosis, mostly in patients with DKA and/or neutropenia (eg, leukemia). Inhalation of spores + fungi proliferate in blood vessel walls, penetrate cribriform plate, and enter brain. Rhinocerebral, frontal lobe abscess; cavernous sinus thrombosis. Headache, facial pain, black necrotic eschar on face [[; may have cranial nerve involvement. Treatment: surgical debridement, amphotericin B or isavuconazole.</td></tr></table>
======================================
<table><thead><th colspan="5">Protozoa—gastrointestinal infections</th></thead><thead><th>ORGANISM</th><th>DISEASE</th><th>TRANSMISSION</th><th>DIAGNOSIS</th><th>TREATMENT</th></thead><tr><td>Giardia lamblia</td><td>Giardiasis—bloating, flatulence, foul-smelling, nonbloody, fatty diarrhea (often seen in campers/hikers)—think fat-rich Ghirardelli chocolates for fatty stools of Giardia</td><td>Cysts in water</td><td>Multinucleated trophozoites [iJ or cysts [J in stool, antigen detection, PCR</td><td>Tinidazole, nitazoxanide, or metronidazole</td></tr><tr><td>Entamoeba histolytica</td><td>Amebiasis—bloody diarrhea (dysentery), liver abscess (“anchovy paste” exudate), RUQ pain; histology of colon biopsy shows flask-shaped ulcers [@</td><td>Cysts in water</td><td>Serology, antigen testing, PCR, and/ or trophozoites (with engulfed RBCs fi) in the cytoplasm) or cysts with up to 4 nuclei in stool A; Entamoeba Eats Erythrocytes</td><td>Metronidazole; paromomycin for asymptomatic cyst passers</td></tr><tr><td rowspan="2">Cryptosporidium —</td><td>Severe diarrhea in AIDS Mild disease (watery diarrhea) in immunocompetent hosts</td><td>Oocysts in water</td><td>Oocysts on acid-fast stain [jJ, antigen detection, PCR</td><td>— Prevention (by filtering city water supplies); nitazoxanide in immunocom-</td></tr><tr><td></td><td></td><td></td><td></td><td>promised hosts</td></tr></table>
======================================
<table><thead><th>ORGANISM</th><th>DISEASE</th><th>TRANSMISSION</th><th>DIAGNOSIS</th><th>TREATMENT</th></thead><tr><td>Toxoplasma gondii</td><td>Immunocompetent: mononucleosis-like symptoms, © heterophile antibody test Reactivation in AIDS — brain abscesses usually seen as multiple ring-enhancing lesions on MRI EY Congenital toxoplasmosis: classic triad of chorioretinitis, hydrocephalus, and intracranial calcifications</td><td>Cysts in meat (most common); oocysts in cat feces; crosses placenta (pregnant patients should avoid cats)</td><td>Serology, biopsy (tachyzoite) FE; PCR of amniotic —_fluid for possible intrauterine disease</td><td>Sulfadiazine + pyrimethamine Prophylaxis with TMP-SMX when | CD4+ cell count &lt; 100 cells/mm?</td></tr><tr><td>Naegleriafowleri</td><td>Rapidly fatal meningoencephalitis</td><td>Swimming in warm freshwater; enters CNS through olfactory nerve via cribriform plate</td><td>Amoebas in CSF [|</td><td>— Amphotericin B has been effective for a few survivors</td></tr><tr><td>Trypanosoma brucei</td><td>African sleeping sickness— enlarged lymph nodes, recurring fever (due to antigenic variation), somnolence, coma</td><td>Tsetse fly, a painful _ bite</td><td>—‘Trypomastigote in blood smear [)</td><td>Suramin for blood- borne disease or melarsoprol for CNS penetration (“I sure am mellow when I’m sleeping”)</td></tr></table>
======================================
<table><thead><th>ORGANISM</th><th>DISEASE</th><th>TRANSMISSION</th><th>DIAGNOSIS</th><th>TREATMENT</th></thead><tr><td>Plasmodium</td><td>Malaria—cyclic fevers, headache, anemia, splenomegaly; hypoglycemia in severe disease</td><td>Anopheles mosquito</td><td></td><td>If sensitive, chloroquine; if resistant, mefloquine, doxycycline or atovaquone/proguanil If life threatening, use intravenous quinine or artesunate (test for GOPD deficiency)</td></tr><tr><td>P malariae</td><td>72-hr fever cycle (quartan)</td><td></td><td>Blood smear with trophozoite ring within RBC</td><td></td></tr><tr><td>P vivax/ovale</td><td>48-hr fever cycle (tertian); dormant form (hypnozoite) in liver</td><td></td><td>Blood smear with trophozoites and Schiiffner stippling (small red granules) within RBC cytoplasm [iN</td><td>Add primaquine to target hypnozoites</td></tr><tr><td>P falciparum</td><td>Severe, irregular fever pattern; parasitized RBCs may occlude capillaries in brain (cerebral malaria), kidneys, lungs</td><td></td><td>Blood smear with trophozoite ring (headphone shaped) within RBC &amp;}; crescent-shaped gametocytes [@</td><td></td></tr><tr><td>Babesia</td><td>Babesiosis—fever and hemolytic anemia; predominantly in northeastern and north central United States; asplenia t risk of severe disease due to inability to clear infected RBCs</td><td>_Ixodes tick (also vector for Borrelia burgdorferi and Anaplasma spp)</td><td>Blood smear: ring form BYI, “Maltese cross” [py]; PCR</td><td>Atovaquone + azithromycin</td></tr></table>
======================================
<table><thead><th>ORGANISM</th><th>DISEASE</th><th>TRANSMISSION</th><th>DIAGNOSIS</th><th>TREATMENT</th></thead><tr><td colspan="5">Visceral infections</td></tr><tr><td>Trypanosoma cruzi</td><td>Chagas disease — dilated cardiomyopathy with apical atrophy, megacolon, megaesophagus; (T cruzi causes big problems); predominantly in South America Unilateral periorbital swelling (Romaiia sign) characteristic of acute stage</td><td>‘Triatomine insect (kissing bug) bites and defecates around the mouth or eyes &gt; fecal transmission into bite site or mucosa</td><td>Trypomastigote in blood smear [iy</td><td>Benznidazole or nifurtimox</td></tr><tr><td colspan="5">[J Sexually transmitted infections</td></tr><tr><td>Trichomonas vaginalis</td><td>discharge; itching and burning; do not confuse with Gardnerella vaginalis, a gram-variable bacterium associated with bacterial vaginosis Vaginitis—foul-smelling, greenish</td><td>Sexual (cannot exist outside human because it cannot form cysts)</td><td>Trophozoites (motile) DP) on wet mount; punctate cervical hemorrhages (“strawberry «oy cervix”)</td><td>Metronidazole for patient and partner(s) (prophylaxis; check for STI)</td></tr></table>
======================================
<table><thead><th>ORGANISM</th><th>DISEASE</th><th>TRANSMISSION</th><th>TREATMENT</th></thead><tr><td colspan="4">Intestinal</td></tr><tr><td>Enterobius vermicularis (pinworm)</td><td>Causes anal pruritus, worse at night (eggs [AN visualized via tape test).</td><td>Fecal-oral.</td><td>Bendazoles, pyrantel pamoate.</td></tr><tr><td>Ascaris lumbricoides (giant roundworm)</td><td>May cause obstruction at ileocecal valve, biliary obstruction, intestinal perforation, migrates from nose/mouth. Migration of larvae to alveoli + Léeffler syndrome (pulmonary eosinophilia).</td><td>Fecal-oral; knobby-coated, oval eggs seen in feces under microscope [J.</td><td>Bendazoles.</td></tr><tr><td>Strongyloides stercoralis (threadworm)</td><td>GI (eg, duodenitis), pulmonary (eg, dry cough, hemoptysis), and cutaneous (eg, pruritus) symptoms. Hyperinfection syndrome can be caused by accelerated autoinfection in the immunocompromised.</td><td>Larvae in soil penetrate skin; thabditiform larvae seen in feces under microscope.</td><td>Ivermectin or bendazoles.</td></tr><tr><td>Ancylostoma spp, Necator americanus (hookworms)</td><td>Cause microcytic anemia by sucking blood from intestinal wall. Cutaneous larva migrans—pruritic, serpiginous rash [@.</td><td>Larvae penetrate skin from walking barefoot on contaminated beach/soil.</td><td>Bendazoles or pyrantel pamoate.</td></tr><tr><td>Trichinella spiralis</td><td>Larvae enter bloodstream, encyst in striated muscle 5) &gt; myositis. Trichinosis—fever, vomiting, nausea, periorbital edema, myalgia.</td><td>Undercooked meat (especially pork); fecal-oral (less likely).</td><td>Bendazoles.</td></tr><tr><td>Trichuris trichiura (whipworm)</td><td>Often asymptomatic; loose stools, anemia, rectal prolapse in children.</td><td>Fecal-oral.</td><td>Bendazoles.</td></tr><tr><td colspan="4">Tissue</td></tr><tr><td>Toxocara canis</td><td>Visceral larva migrans—migration into blood &gt; inflammation of liver, eyes (visual impairment), CNS (seizures, coma), heart (myocarditis). Patients often asymptomatic.</td><td>Fecal-oral.</td><td>Bendazoles.</td></tr><tr><td>Onchocerca volvulus</td><td>Black skin nodules, river blindness (“black sight”).</td><td>Female black fly.</td><td>Ivermectin (ivermectin for river blindness).</td></tr><tr><td>Loaloa</td><td>Swelling in skin, worm in conjunctiva.</td><td>Deer fly, horse fly, mango fly.</td><td>Diethylcarbamazine.</td></tr><tr><td>Wuchereria bancrofti, Brugia malayi</td><td>Lymphatic filariasis (elephantiasis) — worms invade lymph nodes = inflammation + lymphedema 3; symptom onset after 9 mo-l yr.</td><td>Female mosquito.</td><td>Diethylcarbamazine.</td></tr></table>
======================================
<table><thead><th>ORGANISM</th><th>DISEASE</th><th>TRANSMISSION</th><th>TREATMENT</th></thead><tr><td rowspan="2">Taenia solium [\</td><td>Intestinal tapeworm</td><td>ngestion of larvae encysted in undercooked pork</td><td>Praziquantel</td></tr><tr><td></td><td>Cysticercosis, neurocysticercosis (cystic CNS lesions, seizures) EJ</td><td>ngestion of eggs in food contaminated with human feces</td><td>Praziquantel; albendazole for neurocysticercosis</td></tr><tr><td>Diphyllobothrium latum</td><td>Vitamin Bj deficiency (tapeworm competes for By in intestine) + megaloblastic anemia</td><td>ngestion of larvae in raw freshwater fish</td><td>Praziquantel, niclosamide</td></tr><tr><td>Echinococcus granulosus [4</td><td>Hydatid cysts B) (“eggshell calcification”) most commonly in liver [J and lungs; cyst rupture can cause anaphylaxis</td><td>ngestion of eggs in food contaminated with dog feces Sheep are an intermediate host</td><td>Albendazole; surgery for complicated cysts</td></tr></table>
======================================
<table><thead><th>ORGANISM</th><th>DISEASE</th><th>TRANSMISSION</th><th>TREATMENT</th></thead><tr><td>Schistosoma</td><td>Liver and spleen enlargement (EN shows S mansoni egg with lateral spine), fibrosis, inflammation, portal hypertension; S mansoni and S</td><td>_ Snails are intermediate host; cercariae penetrate skin of humans in contact with contaminated fresh water (eg, swimming or bathing)</td><td>Praziquantel</td></tr><tr><td></td><td>schistosomiasis, presenting with diarrhea, abdominal pain, iron deficiency anemia Chronic infection with S haematobium (egg with terminal spine J) can lead to squamous cell carcinoma of the bladder (painless hematuria) and pulmonary hypertension</td><td></td><td></td></tr><tr><td>Clonorchis sinensis</td><td>Biliary tract inflammation — pigmented gallstones Associated with cholangiocarcinoma</td><td>Undercooked fish</td><td>Praziquantel</td></tr></table>
======================================
<table><thead><th>‘asite hints</th><th>ASSOCIATIONS</th><th>ORGANISM</th></thead><tr><td></td><td>Biliary tract disease, cholangiocarcinoma</td><td>Clonorchis sinensis</td></tr><tr><td></td><td>Brain cysts, seizures</td><td>Taenia solium (neurocysticercosis)</td></tr><tr><td></td><td>Hematuria, squamous cell bladder cancer</td><td>Schistosoma haematobium</td></tr><tr><td></td><td>Liver (hydatid) cysts, exposure to infected dogs</td><td>Echinococcus granulosus</td></tr><tr><td></td><td>Iron deficiency anemia</td><td>Ancylostoma, Necator</td></tr><tr><td></td><td>Myalgias, periorbital edema</td><td>Trichinella spiralis</td></tr><tr><td></td><td>Nocturnal perianal pruritus</td><td>Enterobius</td></tr><tr><td></td><td>Portal hypertension</td><td>Schistosoma mansoni, Schistosoma japonicum</td></tr><tr><td></td><td>Vitamin Bj deficiency</td><td>Diphyllobothrium latum</td></tr></table>
======================================
<table><tr><td>Recombination</td><td>Exchange of genes between 2 chromosomes by crossing over within regions of significant base SsIng i i sequence homology.</td><td>. . * Ff IIR, + e o 6 . .</td><td>. 7 _f DIK = INI o 6 eo</td><td>, .</td></tr><tr><td>Reassortment</td><td>When viruses with segmented genomes (eg, influenza virus) exchange genetic material Be § . For example, the 2009 novel HIN influenza A pandemic emerged via complex viral reassortment of genes from human, swine, and avian viruses. Has potential to cause antigenic shift. Reassortment of genome segments.</td><td>*. 2. f rf VV tI CAl( D&gt; ME . .</td><td>* 7 _f CAO DS BE CAG .</td><td>, ASS</td></tr><tr><td>Complementation</td><td>When 1 of 2 viruses that infect the cell has a mutation that results in a nonfunctional . . . protein, the nonmutated virus “complements” , ey 1 the mutated one by making a functional protein that serves both viruses. For example, hepatitis D virus requires the presence of replicating hepatitis B virus to supply HBsAg, the envelope protein for HDV.</td><td>° ° f 7 f DINIX, + «4s e e Functional</td><td>° 7 Ff DINIX = ef AX e Nonfunctional Functional</td><td>+f e</td></tr><tr><td>Phenotypic mixing</td><td>Occurs with simultaneous infection of a cell with 2 viruses. For progeny 1, genome ; SBOP Progeny 1, 8 of virus A can be partially or completely : ee i coated (forming pseudov irion) with the surface proteins of virus B. ‘Type B protein coat determines the tropism (infectivity) of the hybrid virus. Progeny from subsequent infection of a cell by progeny 1 will have a type A coat that is encoded by its type A</td><td>° * f , f IININ + E2OSS ° ° Virus A Virus</td><td>* | f DININ = NINN OOS OSS ° B Progeny</td><td>° | ¢ i DINK ILO e 1 Progeny2</td></tr></table>
======================================
<table><thead><th></th><th colspan="2">viruses are infectious. Naked nucleic acids of © strand ssRNA and dsRNA viruses are not infectious because they lack the required polymerases to replicate. Virions of © strand ssRNA viruses carry RNA-dependent RNA polymerases to transcribe © strand to @.</th><th colspan="2" rowspan="2">CHARACTERISTICS MNEMONIC</th></thead><tr><td></td><td colspan="2"></td></tr><tr><td>DNA viruses</td><td>All have dsDNA genomes (like our cells) except Parvoviridae (ssDNA). All are linear except papilloma-, polyoma-, and hepadnaviruses (circular).</td><td>Part of a virus</td></tr><tr><td rowspan="3">RNA viruses</td><td>All have ssRNA genomes except Reoviridae (dsRNA).</td><td>Repeato-virus</td></tr><tr><td></td><td>© stranded ( mRNA): retro-, toga-, flavi-, corona-, hepe-, calici-, and picornaviruses. O stranded: arena-, bunya-, paramyxo-, orthomyxo-, filo-, and rhabdoviruses.</td><td>While at a retro toga party, I drank flavored Corona and ate hippie California pickles. Always bring polymerase or fail replication.</td></tr><tr><td></td><td>Segmented: Bunya-, Orthomyxo-, Arena-, and Reoviruses.</td><td>BOAR</td></tr></table>
======================================
<table><thead><th>VIRAL FAMILY</th><th>ENVELOPE</th><th>DNA STRUCTURE</th><th>MEDICAL IMPORTANCE</th></thead><tr><td>Herpesviruses</td><td>Yes</td><td>DS and linear</td><td>See Herpesviruses entry</td></tr><tr><td>Poxvirus</td><td>Yes</td><td>DS and linear (largest DNA virus)</td><td>Smallpox eradicated world wide by use of the live- attenuated vaccine Cowpox (“milkmaid blisters”) Molluscum contagiosum—flesh-colored papule with central umbilication; keratinocytes contain molluscum bodies [5</td></tr><tr><td>Hepadnavirus</td><td>Yes</td><td>Partially DS and circular.</td><td>~~ HBV: = Acute or chronic hepatitis = Nota retrovirus but has reverse transcriptase</td></tr><tr><td>Adenovirus</td><td>No</td><td>DS and linear</td><td>Febrile pharyngitis [J—sore throat Acute hemorrhagic cystitis Pneumonia Conjunctivitis—“pink eye” Gastroenteritis Myocarditis</td></tr><tr><td>Papillomavirus</td><td>No</td><td>DS and circular</td><td>HPV—warts, cancer (cervical, anal, penile, or oropharyngeal); serotypes 1, 2, 6, 11 associated with warts; serotypes 16, 18 associated with cancer</td></tr><tr><td>Polyomavirus</td><td>No</td><td>DS and circular</td><td>JC virus—progressive multifocal leukoencephalopathy (PML) in immunocompromised patients (eg, HIV) BK virus—transplant patients, commonly targets kidney JC: Junky Cerebrum; BK: Bad Kidney</td></tr><tr><td>Parvovirus</td><td>No</td><td>SS and linear (smallest DNA virus; parvus = small)</td><td>B19 virus—aplastic crises in sickle cell disease, “slapped cheek” rash in children (erythema infectiosum, or fifth disease); infects RBC precursors and endothelial cells + RBC destruction + hydrops fetalis and death in fetus, pure RBC aplasia and</td></tr></table>
======================================
<table><thead><th>VIRUS</th><th>ROUTE OF TRANSMISSION</th><th>CLINICAL SIGNIFICANCE</th><th>NOTES</th></thead><tr><td>Herpes simplex virus-1</td><td>Respiratory secretions, saliva</td><td>Gingivostomatitis, keratoconjunctivitis [N, herpes labialis (cold sores) [, herpetic whitlow on finger, temporal lobe encephalitis, esophagitis, erythema multiforme. Responsible for a growing percentage of herpes genitalis.</td><td>Most commonly latent in trigeminal ganglia | Most common cause of sporadic encephalitis, can present as altered mental status, seizures, and/or aphasia</td></tr><tr><td>Herpes simplex virus-2</td><td>Sexual contact, perinatal</td><td>Herpes genitalis, neonatal herpes [§</td><td>Most commonly latent in sacral ganglia Viral meningitis more common with HSV-2 than with HSV-1</td></tr><tr><td>Varicella- zoster virus (HHV-3)</td><td>Respiratory secretions, contact with fluid from vesicles</td><td>Varicella-zoster (chickenpox [3), shingles [§), encephalitis, pneumonia Most common complication of shingles is post- herpetic neuralgia</td><td>Latent in dorsal root or trigeminal ganglia; CN V, branch involvement can cause herpes zoster ophthalmicus</td></tr><tr><td>Epstein-Barr virus (HHV-4)</td><td>Respiratory secretions, saliva; also called “kissing disease,” (common in teens, young adults)</td><td>Mononucleosis—fever, hepatosplenomegaly [i, pharyngitis, and lymphadenopathy (especially posterior cervical nodes); avoid contact sports until resolution due to risk of splenic rupture Associated with lymphomas (eg, endemic Burkitt lymphoma), nasopharyngeal carcinoma (especially Asian adults), lymphoproliferative disease in transplant patients</td><td>Infects B cells through CD21, “Must be 21 to drink Beer in a Barr” Atypical lymphocytes on peripheral blood smear [&amp;|—not infected B cells but reactive cytotoxic T cells ® Monospot test—heterophile antibodies detected by agglutination of sheep or horse RBCs Use of amoxicillin (eg, for presumed strep pharyngitis) can cause maculopapular rash</td></tr><tr><td>Cytomegalo- virus (HHV-5)</td><td>Congenital, transfusion, sexual contact, saliva, urine, transplant</td><td>Mononucleosis (© Monospot) in immunocompetent patients; infection in immunocompromised, especially pneumonia patients; esophagitis; AIDS retinitis (“sightomegalovirus”): hemorrhage, in transplan cotton-wool exudates, vision loss CMV Congenita</td><td>Infected cells have characteristic “owl eye” intranuclear inclusions [J Latent in mononuclear cells</td></tr><tr><td>Human herpes- viruses 6 and7</td><td>Saliva</td><td>Roseola infantum (exanthem subitum): high fevers for several days that can cause seizures, followed by diffuse macular rash (starts on trunk then spreads to extremities) [fj usually seen in children &lt;2 years old</td><td>Roseola: fever first, Rosy (rash) later Self-limited illness HHV-7—less common cause of roseola</td></tr><tr><td>Human herpesvirus 8</td><td>Sexual contact</td><td>Kaposi sarcoma (neoplasm of endothelial cells). Seen in HIV/AIDS and transplant patients. Dark/violaceous plaques or nodules [J]</td><td>Can also affect GI tract and lungs</td></tr></table>
======================================
<table><thead><th>VIRUS</th><th>RECEPTOR(S)</th></thead><tr><td>CMV</td><td>Integrins (heparan sulfate)</td></tr><tr><td>EBV</td><td>CD21</td></tr><tr><td>HIV</td><td>CD4, CXCR4, CCR5</td></tr><tr><td>Parvovirus B19</td><td>P antigen on RBCs</td></tr><tr><td>Rabies</td><td>Nicotinic AChR</td></tr><tr><td>Rhinovirus</td><td>ICAM-1 (I CAMe to see the rhino)</td></tr><tr><td>SARS-CoV-2</td><td>ACE2</td></tr></table>
======================================
<table><thead><th>VIRAL FAMILY</th><th>ENVELOPE</th><th>RNA STRUCTURE</th><th>CAPSID SYMMETRY</th><th>MEDICAL IMPORTANCE</th></thead><tr><td>Reoviruses</td><td>No</td><td>DS linear Multisegmented</td><td>Icosahedral (double)</td><td>—_ Rotavirus—important cause of diarrhea in young children; may be fatal.</td></tr><tr><td>Picornaviruses</td><td>No</td><td>SS @ linear</td><td>Icosahedral</td><td>—_- Poliovirus—polio-Salk/Sabin vaccines—IPV/OPV Echovirus—aseptic meningitis Rhinovirus—“common cold” Coxsackievirus—aseptic meningitis; herpangina (mouth blisters, fever); hand, foot, and mouth disease; myocarditis; pericarditis HAV—acute viral hepatitis PERCH</td></tr><tr><td>Hepevirus</td><td>No</td><td>SS @ linear</td><td>Icosahedral</td><td>HEV</td></tr><tr><td>Caliciviruses</td><td>No</td><td>SS @ linear</td><td>Icosahedral</td><td>Norovirus—viral gastroenteritis</td></tr><tr><td>Flaviviruses</td><td>Yes</td><td>SS © linear</td><td>Icosahedral</td><td>= HCV Yellow fever" Dengue* West Nile virus*—meningoencephalitis, acute asymmetric flaccid paralysis Zika virus*</td></tr><tr><td>Togaviruses</td><td>Yes</td><td>SS @ linear</td><td>Icosahedral |</td><td>Toga CREW—Chikungunya virus’ (co-infection with dengue virus can occur), Rubella (formerly a togavirus), Eastern and Western equine encephalitis*</td></tr><tr><td>Matonavirus</td><td>Yes</td><td>SS @ linear</td><td>Icosahedral</td><td>Rubella</td></tr><tr><td>Retroviruses</td><td>Yes</td><td>SS @ linear</td><td>Icosahedral (HTLY), conical (HIV)</td><td>— Have reverse transcriptase HTLV—Tcell leukemia HIV—AIDS</td></tr><tr><td>Coronaviruses</td><td>Yes</td><td>SS @ linear</td><td>Helica’</td><td>“Common cold,” SARS, COVID-19, MERS</td></tr><tr><td>Orthomyxoviruses</td><td>Yes</td><td>SS © linear Multisegmented</td><td>Helica</td><td>Influenza virus</td></tr><tr><td>Paramyxoviruses</td><td>Yes</td><td>SS © linear</td><td>Helica</td><td>PaRaMyxovirus: Parainfluenza—croup RSV—bronchiolitis in babies Measles, Mumps</td></tr><tr><td>Rhabdoviruses</td><td>Yes</td><td>SS © linear</td><td>Helica’</td><td>Rabies</td></tr><tr><td>Filoviruses</td><td>Yes</td><td>SS © linear</td><td>Helica’</td><td>Ebola/Marburg hemorrhagic fever—often fatal.</td></tr><tr><td>Arenaviruses</td><td>Yes</td><td>SS @ and © circular Multisegmented</td><td>Helica'</td><td>LCMV-—lymphocytic choriomeningitis virus Lassa fever encephalitis—spread by rodents</td></tr><tr><td>Bunyaviruses</td><td>Yes</td><td>SS © circular Multisegmented</td><td>Helica</td><td>California encephalitis* Sandfly/Rift Valley fevers*</td></tr></table>
======================================
<table><thead><th></th><th>Chikungunya virus</th><th>Dengue virus</th></thead><tr><td rowspan="5">VIRUS TYPE SYMPTOMS DIAGNOSIS</td><td>Alphavirus/togavirus</td><td>Flavivirus</td></tr><tr><td></td><td>High fever, maculopapular rash, headache, lymphadenopathy, and inflammatory</td><td>Dengue fever: fever, rash, headache, myalgias, arthralgias, retro-orbital pain, neutropenia.</td></tr><tr><td></td><td>polyarthritis Arthralgias are more commonly reported (vs dengue); joint swelling is highly specific for</td><td>Dengue hemorrhagic fever: dengue fever + bleeding and plasma leakage due to severe thrombocytopenia and RBC perturbations.</td></tr><tr><td></td><td>Chikungunya. Thrombocytopenia, leukopenia, and hemorrhagic manifestations are less common.</td><td>Most common if infected with a different serotype after initial infection due to antibody- dependent enhancement of disease. May progress to dengue shock syndrome: plasma leakage &gt; circulatory collapse.</td></tr><tr><td></td><td>RT-PCR, serology</td><td></td></tr><tr><td>TREATMENT</td><td>Supportive. Steroids or DMARDs for chronic arthritis.</td><td>Supportive. Intravascular volume repletion or blood transfusion if severe shock.</td></tr><tr><td>PREVENTION</td><td>Minimize mosquito exposure. No vaccine currently available.</td><td>Live, recombinant vaccine available. Derived from the yellow fever virus backbone with insertion of genes for the envelope and pre- membrane proteins of dengue virus.</td></tr><tr><td colspan="3">Yellow fever virus A flavivirus (also an arbovirus) transmitted by Aedes mosquito bites. Virus has monkey or human</td></tr><tr><td colspan="3">reservoir. Flavi = yellow, jaundice. Symptoms: high fever, black vomitus, jaundice, hemorrhage, backache. May see Councilman</td></tr></table>
======================================
<table><thead><th>Virus</th><th>HAV</th><th>HBV</th><th>HCV</th><th>HDV</th><th>HEV</th></thead><tr><td>FAMILY</td><td>RNA picornavirus</td><td>= DNA hepadnavirus</td><td>— RNA flavivirus</td><td>RNA deltavirus</td><td>RNA hepevirus</td></tr><tr><td>TRANSMISSION</td><td>Fecal-oral (shellfish, travelers, day care)</td><td>Parenteral (Blood), sexual (Bedroom), perinatal (Birthing)</td><td>— Primarily blood _ (injection drug use, posttransfusion)</td><td>Parenteral, sexual, — perinatal</td><td>Fecal-oral, especially waterborne</td></tr><tr><td>INCUBATION</td><td>Short (weeks)</td><td>Long (months)</td><td>Long</td><td>Superinfection (HDV after HBV) = short Coinfection (HDV with HBV) = long</td><td>Short</td></tr><tr><td>CLINICAL COURSE</td><td>Acute and self limiting (adults), Asymptomatic (children)</td><td>Initially like serum sickness (fever, arthralgias, rash); may progress to carcinoma</td><td>— May progress to Cirrhosis or Carcinoma</td><td>Similar to HBV</td><td>Fulminant hepatitis in Expectant (pregnant) patients</td></tr><tr><td>PROGNOSIS</td><td>Good</td><td>Adults + mostly full resolution; neonates &gt; worse prognosis</td><td>Majority develop stable, Chronic hepatitis C</td><td>Superinfection &gt; worse prognosis</td><td>High mortality in _ pregnant patients</td></tr><tr><td>HCCRISK</td><td>No</td><td>Yes</td><td>Yes</td><td>Yes</td><td>No</td></tr><tr><td>LIVER BIOPSY</td><td>Hepatocyte swelling, monocyte infiltration, Councilman bodies</td><td>Granular eosinophilic “ground glass” appearance due to accumulation of surface antigen within infected hepatocytes; cytotoxic T cells mediate damage</td><td>Lymphoid aggregates with focal areas of macrovesicular steatosis</td><td>Similar to HBV</td><td>Patchy necrosis</td></tr><tr><td>NOTES</td><td>Absent (no) carrier state</td><td>— Carrier state common</td><td>Carrier state very common</td><td>Defective virus, Depends on HBV HBsAg coat for entry into</td><td>Enteric, Epidemic (eg, in parts of Asia, Africa, Middle East), no</td></tr></table>
======================================
<table><tr><td>HEMATOLOGIC</td><td>Aplastic anemia</td><td>Essential mixed cryoglobulinemia, t risk B-cell NHL, ITP, autoimmune hemolytic anemia</td></tr><tr><td>RENAL</td><td>Membranous GN &gt; membranoproliferative GN</td><td>Membranoproliferative GN &gt; membranous GN</td></tr><tr><td>VASCULAR</td><td>Polyarteritis nodosa</td><td>Leukocytoclastic vasculitis</td></tr><tr><td>DERMATOLOGIC</td><td></td><td>Sporadic porphyria cutanea tarda, lichen planus</td></tr><tr><td>ENDOCRINE</td><td></td><td>t risk of diabetes mellitus, autoimmune</td></tr></table>
======================================
<table><tr><td>Anti-HAV (IgM)</td><td>IgM antibody to HAV; best test to detect acute hepatitis A.</td></tr><tr><td>Anti-HAV (IgG)</td><td>IgG antibody indicates prior HAV infection and/or prior vaccination; protects against reinfection.</td></tr><tr><td>HBsAg</td><td>Antigen found on surface of HBV; indicates hepatitis B infection.</td></tr><tr><td>Anti-HBs</td><td>Antibody to HBsAg; indicates immunity to hepatitis B due to vaccination or recovery from infection.</td></tr><tr><td>HBcAg</td><td>Antigen associated with core of HBV.</td></tr><tr><td>Anti-HBc</td><td>Antibody to HBcAg; IgM = acute/recent infection; IgG = prior exposure or chronic infection. IgM</td></tr></table>
======================================
<table><thead><th></th><th>oe</th><th>eo</th><th></th></thead><tr><td colspan="4">Incubation +</td></tr><tr><td>Acute infection</td><td>+</td><td>+ (IgM)</td><td>+</td></tr><tr><td>Window</td><td></td><td>+ (IgM)</td><td></td></tr><tr><td>Recovery</td><td></td><td>+ (IgG)</td><td></td></tr><tr><td>Chronic infection (high infectivity)</td><td></td><td>+ (IgG)</td><td></td></tr><tr><td>Chronic infection (low infectivity)</td><td></td><td>+ (IgG)</td><td></td></tr><tr><td>Immunized</td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>PATHOGEN</th><th>PRESENTATION</th><th>FINDINGS</th></thead><tr><td colspan="3">CD4+ cell count &lt; 500/mm?</td></tr><tr><td>Candida albicans</td><td>Oral thrush</td><td>Scrapable white plaque, pseudohyphae on microscopy</td></tr><tr><td>EBV</td><td>Oral hairy leukoplakia</td><td>Unscrapable white plaque on lateral tongue</td></tr><tr><td>HHV-8</td><td>Kaposi sarcoma, localized cutaneous disease</td><td>Perivascular spindle cells invading and forming vascular tumors on histology</td></tr><tr><td>HPV</td><td>Squamous cell carcinoma at site(s) of sexual contact (most commonly anus, cervix, oropharynx)</td><td></td></tr><tr><td>Mycobacterium tuberculosis</td><td>Increased risk of reactivation of latent TB infection</td><td></td></tr><tr><td colspan="3">CD4+ cell count &lt; 200/mm?</td></tr><tr><td>Histoplasma capsulatum</td><td>Fever, weight loss, fatigue, cough, dyspnea, nausea, vomiting, diarrhea</td><td>Oval yeast cells within macrophages</td></tr><tr><td>HIV</td><td>Dementia, HIV-associated nephropathy</td><td>Cerebral atrophy on neuroimaging</td></tr><tr><td>JC virus (reactivation)</td><td>Progressive multifocal leukoencephalopathy</td><td>Nonenhancing areas of demyelination on MRI</td></tr><tr><td>HHV-8</td><td>Kaposi sarcoma, disseminated disease</td><td></td></tr><tr><td></td><td>(pulmonary, GI, lymphatic)</td><td>chest</td></tr><tr><td>Pneumocystis jirovecii</td><td>Pneumocystis pneumonia</td><td>“Ground-glass” opacities on imaging</td></tr><tr><td colspan="3">CD4+ cell count &lt; 100/mm? Bartonella red nodules</td></tr><tr><td>spp</td><td>Bacillary angiomatosis</td><td>Multiple to purple papules or Biopsy with neutrophilic inflammation</td></tr><tr><td>Candida albicans</td><td>Esophagitis</td><td>White plaques on endoscopy; yeast and pseudohyphae on biopsy</td></tr><tr><td>CMV</td><td>Colitis, Retinitis, Esophagitis, Encephalitis, Pneumonitis (CREEP)</td><td>Linear ulcers on endoscopy, cotton-wool spots on fundoscopy Biopsy reveals cells with intranuclear (owl eye) inclusion bodies</td></tr><tr><td>Cryptococcus neoformans</td><td>Meningitis</td><td>Encapsulated yeast on India ink stain or capsular antigen ©</td></tr><tr><td>Cryptosporidium spp</td><td>Chronic, watery diarrhea</td><td>Acid-fast oocysts in stool</td></tr><tr><td>EBV</td><td>B-cell lymphoma (eg, non-Hodgkin lymphoma, CNS lymphoma)</td><td>CNS lymphoma—ring enhancing, may be solitary (vs Toxoplasma)</td></tr><tr><td>Mycobacterium avium-intracellulare,</td><td>Nonspecific systemic symptoms (fever, night sweats, weight loss) or focal lymphadenitis</td><td>Most common if CD4+ cell count &lt; 50/mm?</td></tr></table>
======================================
<table><thead><th>LOCATION</th><th>MICROORGANISM</th></thead><tr><td>Skin</td><td>S epidermidis</td></tr><tr><td>Nose</td><td>S epidermidis; colonized by S aureus</td></tr><tr><td>Oropharynx</td><td>Viridans group streptococci</td></tr><tr><td>Dental plaque</td><td>S mutans</td></tr><tr><td>Colon</td><td>B fragilis &gt; E coli</td></tr><tr><td>Vagina</td><td>Lactobacillus; colonized by E coli and group B</td></tr><tr><td></td><td>strep</td></tr></table>
======================================
<table><tr><td>B cereus</td><td>Reheated rice. “Food poisoning from reheated tice? Be serious!” (B cereus)</td></tr><tr><td>C botulinum</td><td>Improperly canned foods (toxins), raw honey (spores)</td></tr><tr><td>C perfringens</td><td>Reheated meat</td></tr><tr><td>E coli O157:H7</td><td>Undercooked meat</td></tr><tr><td>L monocytogenes</td><td>Deli meats, soft cheeses</td></tr><tr><td>Salmonella</td><td>Poultry, meat, and eggs</td></tr><tr><td>S aureus</td><td>Meats, mayonnaise, custard; preformed toxin</td></tr><tr><td>V parahaemolyticus and V yulnificus*</td><td>Raw/undercooked seafood</td></tr></table>
======================================
<table><tr><td>Campylobacter</td><td>Comma- or S-shaped organisms; growth at 42°C</td></tr><tr><td>E histolytica</td><td>Protozoan; amebic dysentery; liver abscess</td></tr><tr><td>Enterohemorrhagic E coli</td><td>O157:H7; can cause HUS; makes Shiga toxin</td></tr><tr><td>Enteroinvasive E coli</td><td>Invades colonic mucosa</td></tr><tr><td>Salmonella (non- typhoidal)</td><td>Lactose ©; flagellar motility; has animal reservoir, especially poultry and eggs</td></tr><tr><td>Shigella</td><td>Lactose ©; very low IDs»; produces Shiga toxin; human reservoir only; bacillary dysentery</td></tr><tr><td>Yenterocolitica</td><td>Day care outbreaks; pseudoappendicitis</td></tr><tr><td colspan="2">Watery diarrhea</td></tr><tr><td>Cdifficile</td><td>Pseudomembranous colitis; associated with antibiotics and PPIs; occasionally bloody diarrhea</td></tr><tr><td>Cperfringens</td><td>Also causes gas gangrene</td></tr><tr><td>Enterotoxigenic E coli</td><td>Travelers’ diarrhea; produces heat-labile (LT’) and heat-stable (ST) toxins</td></tr><tr><td>Protozoa</td><td>Giardia, Cryptosporidium</td></tr><tr><td>V cholerae</td><td>Comma-shaped organisms; rice-water diarrhea; often from infected seafood</td></tr><tr><td>Viruses</td><td>Norovirus (most common cause in developed countries), rotavirus ({ incidence in developed countries due to vaccination), enteric adenovirus</td></tr></table>
======================================
<table><thead><th>NEONATES (&lt; 4 WK)</th><th>CHILDREN (4 WK-18 YR)</th><th>ADULTS (18-40 YR)</th><th>ADULTS (40-65 YR)</th><th>ADULTS (65 YR +)</th></thead><tr><td rowspan="8">Group B streptococci E coli</td><td>Viruses (RSV)</td><td>Mycoplasma</td><td>S pneumoniae</td><td>S pneumoniae</td></tr><tr><td></td><td>Mycoplasma</td><td>C pneumoniae</td><td>H influenzae</td><td>Influenza virus</td></tr><tr><td></td><td>C trachomatis</td><td>S pneumoniae</td><td>Anaerobes</td><td>Anaerobes</td></tr><tr><td></td><td>(infants—3 yr)</td><td>Viruses (eg, influenza)</td><td>Viruses</td><td>H influenzae</td></tr><tr><td></td><td>C pneumoniae (school-</td><td></td><td>Mycoplasma</td><td>Gram © rods</td></tr><tr><td></td><td>S pneumoniae</td><td></td><td></td><td></td></tr><tr><td></td><td>Runts May Cough</td><td></td><td></td><td></td></tr><tr><td></td><td>Chunky Sputum</td><td></td><td></td><td></td></tr><tr><td colspan="5">Special groups</td></tr><tr><td>Alcohol overuse</td><td>Klebsiella, anaerobes Bacteroides)</td><td>usually due to aspiration (eg,</td><td>Peptostreptococcus,</td><td>Fusobacterium, Prevotella,</td></tr><tr><td>Injection drug use</td><td>S pneumoniae, S aureus</td><td></td><td></td><td></td></tr><tr><td>Aspiration</td><td>Anaerobes</td><td></td><td></td><td></td></tr><tr><td>Atypical</td><td>Mycoplasma, Chlamydophila,</td><td>Legionella, viruses</td><td>(RSV, CMV, influenza,</td><td>adenovirus)</td></tr><tr><td>Cystic fibrosis</td><td>Pseudomonas, S aureus,</td><td>S pneumoniae, Burkholderia</td><td>cepacia</td><td></td></tr><tr><td>Immunocompromised</td><td>S aureus, enteric gram ©</td><td>rods, fungi, viruses, P</td><td>jirovecii (with HIV)</td><td></td></tr><tr><td>Healthcare-associated</td><td>S aureus, Pseudomonas,</td><td>other enteric gram © rods</td><td></td><td></td></tr><tr><td>Postviral</td><td>S pneumoniae, S aureus,</td><td>H influenzae</td><td></td><td></td></tr><tr><td>COPD</td><td colspan="4">S pneumoniae, H influenzae, M catarrhalis, Pseudomonas</td></tr></table>
======================================
<table><thead><th>NEWBORN (0-6 MO)</th><th>CHILDREN (6 MO-6 YR)</th><th>6-60 YR</th><th>60YR+</th></thead><tr><td>Group B Streptococcus</td><td>S pneumoniae</td><td>S pneumoniae</td><td>S pneumoniae</td></tr><tr><td>E coli</td><td>N meningitidis</td><td>N meningitidis</td><td>N meningitidis</td></tr><tr><td rowspan="2">Listeria</td><td>H influenzae type b</td><td>Enteroviruses</td><td>H influenzae type b</td></tr><tr><td></td><td>Group B Streptococcus</td><td>HSV</td><td>Group B Streptococcus</td></tr></table>
======================================
<table><thead><th></th><th>OPENING PRESSURE</th><th>CELL TYPE</th><th>PROTEIN</th><th>GLUCOSE</th></thead><tr><td>Bacterial</td><td>t</td><td>t PMNs</td><td>t</td><td>1</td></tr><tr><td>Fungal/TB</td><td>t</td><td>t lymphocytes</td><td>t</td><td>1</td></tr><tr><td>Viral</td><td>Normal/t</td><td>t lymphocytes</td><td>Normal/t</td><td>Normal</td></tr></table>
======================================
<table><thead><th>RISK FACTOR</th><th>ASSOCIATED INFECTION</th></thead><tr><td>Assume if no other information is available</td><td>S aureus (most common overall)</td></tr><tr><td>Sexually active</td><td>Neisseria gonorrhoeae (rare), septic arthritis more common</td></tr><tr><td>Sickle cell disease</td><td>Salmonella and S aureus</td></tr><tr><td>Prosthetic joint replacement</td><td>S aureus and S epidermidis</td></tr><tr><td>Vertebral involvement</td><td>S aureus, M tuberculosis (Pott disease)</td></tr><tr><td>Cat and dog bites</td><td>Pasteurella multocida</td></tr><tr><td>Injection drug use</td><td>S aureus; also Pseudomonas, Candida</td></tr></table>
======================================
<table><thead><th>AGENT</th><th>ASSOCIATED SYNDROME/DISEASE</th><th>CLINICAL PRESENTATION</th></thead><tr><td>Coxsackievirus type A</td><td>Hand-foot-mouth disease</td><td>Oval-shaped vesicles on palms and soles fN; vesicles and ulcers in oral mucosa (herpangina)</td></tr><tr><td>Human herpesvirus 6</td><td>Roseola (exanthem subitum)</td><td>Asymptomatic rose-colored macules appear on body after several days of high fever; can present with febrile seizures; usually affects infants</td></tr><tr><td>Measles virus</td><td>Measles (rubeola)</td><td>Confluent rash beginning at head and moving down fj; preceded by cough, coryza, conjunctivitis, and blue-white (Koplik) spots on buccal mucosa</td></tr><tr><td>Parvovirus B19</td><td>Erythema infectiosum (fifth disease)</td><td>“Slapped cheek” rash on face [@</td></tr><tr><td>Rubella virus</td><td>Rubella</td><td>Pink macules and papules begin at head and move down, remain discrete &gt; fine desquamating truncal rash; postauricular lymphadenopathy</td></tr><tr><td>Streptococcus pyogenes</td><td>Scarlet fever</td><td>Sore throat, Circumoral pallor, group A strep, Rash (sandpaperlike DJ, from neck to trunk and extremities), Lymphadenopathy, Erythrogenic toxin, strawberry Tongue (SCARLET)</td></tr><tr><td>Varicella-zoster virus</td><td>Chickenpox</td><td>Vesicular rash begins on trunk [, spreads to face and extremities with lesions of different stages</td></tr><tr><td></td><td></td><td>FA</td></tr></table>
======================================
<table><thead><th>Urinary tract infections</th><th colspan="2">Cystitis presents with dysuria, frequency, urgency, suprapubic pain, and WBCs (but not WBC casts) in urine. Primarily caused by ascension of microbes from urethra to bladder. Ascension to kidney results in pyelonephritis, which presents with fever, chills, flank pain, costovertebral angle tenderness, hematuria, and WBC casts. Ten times in females (shorter urethras colonized by fecal microbiota).</th></thead><tr><td>SPECIES Escherichia coli</td><td>FEATURES Leading cause of UTI. Colonies show strong</td><td>COMMENTS Diagnostic markers: =</td></tr><tr><td></td><td>pink lactose-fermentation on MacConkey agar.</td><td>© Leukocyte esterase evidence of WBC activity. © Nitrite test = reduction of urinary nitrates</td></tr><tr><td>Staphylococcus saprophyticus</td><td>2nd leading cause of UTI, particularly in young, sexually active females.</td><td>by gram © bacterial species (eg, F coli).</td></tr><tr><td>Klebsiella pneumoniae</td><td>3rd leading cause of UTI. Large mucoid capsule and viscous colonies.</td><td></td></tr><tr><td>Serratia marcescens</td><td>Some strains produce a red pigment; often healthcare-associated and drug resistant.</td><td></td></tr><tr><td>Enterococcus</td><td>Often healthcare-associated and drug resistant.</td><td></td></tr><tr><td>Proteus mirabilis</td><td>Motility causes “swarming” on agar; associated with struvite stones. Produces urease.</td><td></td></tr><tr><td>Pseudomonas aeruginosa</td><td>Blue-green pigment and fruity odor; usually healthcare-associated and drug resistant.</td><td></td></tr></table>
======================================
<table><thead><th>DISEASE</th><th>CLINICAL FEATURES</th><th>PATHOGEN</th></thead><tr><td>AIDS</td><td>Opportunistic infections, Kaposi sarcoma, lymphoma</td><td>HIV</td></tr><tr><td>Chancroid</td><td>Painful genital ulcer(s) with exudate, inguinal adenopathy [i</td><td>Haemophilus ducreyi (it’s so painful, you “do cry”)</td></tr><tr><td>Chlamydia</td><td>Urethritis, cervicitis, epididymitis, conjunctivitis, reactive arthritis, PID</td><td>Chlamydia trachomatis (D-K)</td></tr><tr><td>Condylomata acuminata</td><td>Genital warts [, koilocytes</td><td>HPV-6 and -11</td></tr><tr><td>Herpes genitalis</td><td>Painful penile, vulvar, or cervical vesicles and ulcers [@ with bilateral tender inguinal lymphadenopathy; can cause systemic symptoms such as fever, headache, myalgia</td><td>HSV-2, less commonly HSV-1</td></tr><tr><td>Gonorrhea</td><td>Urethritis, cervicitis, PID, prostatitis, epididymitis, arthritis, creamy purulent discharge</td><td>Neisseria gonorrhoeae</td></tr><tr><td>Granuloma inguinale (Donovanosis)</td><td>Painless, beefy red ulcer that bleeds readily on contact [) Uncommon in US</td><td>Klebsiella (Calymmatobacterium) granulomatis; cytoplasmic Donovan bodies (bipolar staining) seen on microscopy</td></tr><tr><td>Hepatitis B</td><td>Jaundice</td><td>HBV</td></tr><tr><td>Lymphogranuloma venereum</td><td>Infection of lymphatics; painless genital ulcers, painful lymphadenopathy (ie, buboes [§)</td><td>C trachomatis (L1—L3)</td></tr><tr><td>Primary syphilis</td><td>Painless chancre {j, regional lymphadenopathy</td><td>Treponema pallidum</td></tr><tr><td rowspan="2">Secondary syphilis Tertiary syphilis</td><td>Fever, diffuse lymphadenopathy, skin rashes, condylomata lata</td><td></td></tr><tr><td></td><td>Gummas, tabes dorsalis, general paresis, aortitis,</td><td></td></tr></table>
======================================
<table><tr><td>AGENT Toxoplasma gondii</td><td>MATERNAL ACQUISITION Cat feces or ingestion of</td><td>MATERNAL MANIFESTATIONS sually asymptomatic;</td><td>NEONATAL MANIFESTATIONS Classic triad: chorioretinitis,</td></tr><tr><td>Rubella</td><td>undercooked meat Respiratory droplets</td><td>lymphadenopathy (rarely) Rash, lymphadenopathy,</td><td>hydrocephalus, and intracranial calcifications, +/— “blueberry muffin” rash [y Classic triad: abnormalities</td></tr><tr><td>Cytomegalovirus</td><td>Sexual contact, organ transplants</td><td>Usually asymptomatic; mononucleosis-like illness</td><td>muffin” rash. “I (eye) ¥ ruby (rubella) earrings” Hearing loss, seizures, petechial rash, “blueberry muffin” rash, chorioretinitis, periventricular calcifications [@</td></tr><tr><td>HIV</td><td>Sexual contact, needlestick</td><td>Variable presentation depending on CD4+ cell count</td><td>calcifications Recurrent infections, chronic diarrhea</td></tr><tr><td>Herpes simplex virus-2</td><td>Skin or mucous membrane contact</td><td>Usually asymptomatic; herpetic (vesicular) lesions</td><td>Meningoencephalitis, herpetic (vesicular) lesions</td></tr><tr><td>Syphilis</td><td>Sexual contact</td><td>Chancre (1°) and disseminated rash (2°) are the two stages likely to result in fetal infection</td><td>Often results in stillbirth, hydrops fetalis; if child survives, presents with facial abnormalities (eg, notched teeth, saddle nose, short maxilla), saber shins, CN VIII deafness</td></tr></table>
======================================
<table><tr><td>Antibiotic use</td><td>Clostridioides difficile</td><td>Watery diarrhea, leukocytosis</td></tr><tr><td>Aspiration (2° to altered mental status, old age)</td><td>Polymicrobial, gram © bacteria, often anaerobes</td><td>Right lower lobe infiltrate or right upper/ middle lobe (patient recumbent); purulent malodorous sputum</td></tr><tr><td>Decubitus ulcers, surgical wounds, drains</td><td>S aureus (including MRSA), gram © anaerobes (Bacteroides, Prevotella, Fusobacterium)</td><td>Erythema, tenderness, induration, drainage from surgical wound sites</td></tr><tr><td>Intravascular catheters</td><td>S aureus (including MRSA), S epidermidis (long term)</td><td>Erythema, induration, tenderness, drainage from access sites</td></tr><tr><td>Mechanical ventilation, endotracheal intubation</td><td>Late onset: P aeruginosa, Klebsiella, Acinetobacter, S aureus</td><td>New infiltrate on CXR, ft sputum production; sweet odor (Pseudomonas)</td></tr><tr><td>Renal dialysis unit, needlestick</td><td>HBV, HCV</td><td></td></tr><tr><td>Urinary catheterization</td><td>Proteus spp, E coli, Klebsiella (PEcK)</td><td>Dysuria, leukocytosis, flank pain or costovertebral angle tenderness</td></tr><tr><td>Water aerosols</td><td>Legionella</td><td>Signs of pneumonia, GI symptoms (diarrhea, nausea, vomiting), neurologic abnormalities</td></tr></table>
======================================
<table><thead><th>CLINICAL PRESENTATION</th><th>FINDINGS/LABS</th><th>PATHOGEN</th></thead><tr><td colspan="3">Dermatologic</td></tr><tr><td rowspan="2">Rash</td><td>Beginning at head and moving down with postauricular, posterior cervical, and suboccipital lymphadenopathy</td><td>Rubella virus</td></tr><tr><td></td><td>Beginning at head and moving down; preceded by cough, coryza, conjunctivitis, and Koplik spots</td><td>Measles virus</td></tr><tr><td colspan="3">Neurologic</td></tr><tr><td>Meningitis</td><td>Microbe colonizes nasopharynx Can also lead to myalgia and paralysis</td><td>H influenzae type b Poliovirus</td></tr><tr><td>Tetanus</td><td>Muscle spasms and spastic paralysis (eg, lockjaw, opisthotonus)</td><td>Clostridium tetani</td></tr><tr><td colspan="3">Respiratory</td></tr><tr><td>Epiglottitis</td><td>Fever with dysphagia, drooling, inspiratory stridor, and difficulty breathing due to edema</td><td>H influenzae type b (also capable of causing epiglottitis in fully immunized children)</td></tr><tr><td>Pertussis</td><td>Low-grade fevers, coryza + whooping cough, posttussive vomiting + gradual recovery</td><td>Bordetella pertussis</td></tr><tr><td>Pharyngitis</td><td>Grayish pseudomembranes (may obstruct airways)</td><td>Corynebacterium diphtheriae</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>D-Ala-D-Ala structural analog. Bind penicil in-binding proteins (transpeptidases).</td></tr><tr><td>CLINICAL USE</td><td>Mostly used for gram ® organisms (S pneumoniae, S pyogenes, Actinomyces). Also used for gram © cocci (mainly N meningitidis) and spiroche es (mainly T pallidum). Bactericidal for gram ® cocci, gram @ rods, gram © cocci, and spirochetes. B-lactamase sensitive.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Hypersensitivity reactions, direct Coombs ® hemolytic anemia, drug-induced interstitial nephritis.</td></tr><tr><td>RESISTANCE</td><td>B-lactamase cleaves the B-lactam ring. Mutal ions in PBPs.</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Same as penicillin. Wider spectrum; penicillinase sensitive. Also combine with clavulanic acid to protect against destruction by B-lactamase.</td><td>Aminopenicillins are amped-up penicillin. Amoxicillin has greater oral bioavailability than ampicillin.</td></tr><tr><td>CLINICAL USE</td><td>Extended-spectrum penicillin—H influenzae, H pylori, E coli, Enterococci, Listeria monocytogenes, Proteus mirabilis, Salmonella, Shigella.</td><td>Coverage: ampicillin/amoxicillin HHEELPSS kill enterococci.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Hypersensitivity reactions, rash, pseudomembranous colitis.</td><td></td></tr><tr><td>MECHANISM OF RESISTANCE</td><td>Penicillinase (a type of B-lactamase) cleaves B-lactam ring.</td><td></td></tr><tr><td>Penicillinase-resistant penicillins</td><td>Dicloxacillin, nafcillin, oxacillin.</td><td></td></tr><tr><td>MECHANISM</td><td>Same as penicillin. Narrow spectrum; penicillinase resistant because bulky R group blocks access of B-lactamase to B-lactam ring.</td><td></td></tr><tr><td>CLINICAL USE</td><td>S aureus (except MRSA).</td><td>“Use naf (nafcillin) for staph.”</td></tr><tr><td>ADVERSE EFFECTS</td><td>Hypersensitivity reactions, interstitial nephritis.</td><td></td></tr><tr><td>MECHANISM OF RESISTANCE</td><td>MRSA has altered penicillin-binding protein target site.</td><td></td></tr></table>
======================================
<table><thead><th>Piperacillin</th><th>Antipseudomonal penicillin.</th></thead><tr><td>MECHANISM</td><td>Same as penicillin. Extended spectrum. Penicillinase sensitive; use with B-lactamase inhibitors.</td></tr><tr><td>CLINICAL USE</td><td>Pseudomonas spp., gram © rods, anaerobes.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Hypersensitivity reactions.</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>B-lactam drugs that inhibit cell wall synthesis but are less susceptible to penicillinases. Bactericidal.</td><td>Organisms typically not covered by Ist-4th generation cephalosporins are LAME: Listeria, Atypicals (Chlamydia, Mycoplasma), MRSA, and Enterococci.</td></tr><tr><td rowspan="5">CLINICAL USE</td><td>Ist generation (cefazolin, cephalexin)—gram © cocci, Proteus mirabilis, E coli, Klebsiella pneumoniae. Cefazolin used prior to surgery to prevent S aureus wound infections.</td><td>Ist generation—©® PEcK.</td></tr><tr><td></td><td>2nd generation (cefaclor, cefoxitin, cefuroxime, cefotetan)—gram © cocci, H influenzae, Enterobacter aerogenes, Neisseria spp., Serratia marcescens, Proteus mirabilis, E. coli, Klebsiella pneumoniae.</td><td>2nd graders wear fake fox fur to tea parties. 2nd generation—® HENS PEcK.</td></tr><tr><td></td><td>3rd generation (ceftriaxone, cefpodoxime, ceftazidime, cefixime)—serious gram © infections resistant to other B-lactams.</td><td>Can cross blood-brain barrier. Ceftriaxone—meningitis, gonorrhea, disseminated Lyme disease. Ceftazidime for</td></tr><tr><td></td><td>4th generation (cefepime)—gram © organisms, with t activity against Pseudomonas and gram © organisms.</td><td>pseudomonaz.</td></tr><tr><td></td><td>5th generation (ceftaroline)—broad gram ® and gram © organism coverage; unlike Ist-4th generation cephalosporins, ceftaroline covers MRSA, and Enterococcus faecalis—does not cover Pseudomonas.</td><td></td></tr><tr><td>ADVERSE EFFECTS</td><td>Hypersensitivity reactions, autoimmune hemolytic anemia, disulfiram-like reaction, vitamin K deficiency. Low rate of cross- reactivity even in penicillin-allergic patients. t nephrotoxicity of aminoglycosides.</td><td></td></tr><tr><td>MECHANISM OF RESISTANCE</td><td>Inactivated by cephalosporinases (a type of B-lactamase). Structural change in penicillin-</td><td></td></tr></table>
======================================
<table><tr><td></td><td>resistant carbapenem. Binds penicillin-binding</td><td>_cilastatin.”</td></tr><tr><td></td><td>proteins &gt; inhibition of cell wall synthesis + cell death. Always administered with cilastatin (inhibitor of renal dehydropeptidase I) to + inactivation of drug in renal tubules.</td><td>Unlike other carbapenems, ertapenem is not active against Pseudomonas.</td></tr><tr><td>CLINICAL USE</td><td>Gram © cocci, gram © rods, and anaerobes. Wide spectrum and significant adverse effects limit use to life-threatening infections or after other drugs have failed. Meropenem has a 4 risk of seizures and is stable to dehydropeptidase I.</td><td></td></tr><tr><td>ADVERSE EFFECTS</td><td>GI distress, rash, and CNS toxicity (seizures) at high plasma levels.</td><td></td></tr><tr><td>MECHANISM OF RESISTANCE</td><td>Inactivated by carbapenemases produced by, eg, K pneumoniae, E coli, E aerogenes.</td><td></td></tr><tr><td>Aztreonam</td><td></td><td></td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Less susceptible to B-lactamases. Prevents peptidoglycan cross-linking by binding to penicillin- binding protein 3. Synergistic with aminoglycosides. No cross-allergenicity with penicillins.</td></tr><tr><td>CLINICAL USE</td><td>Gram © rods only—no activity against gram © rods or anaerobes. For penicillin-allergic patients and those with renal insufficiency who cannot tolerate aminoglycosides.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Usually nontoxic; occasional GI upset.</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Inhibits cell wall peptidoglycan formation by binding D-Ala-D-Ala portion of cell wall precursors. Bactericidal against most bacteria (bacteriostatic against C difficile). Not susceptible to B-lactamases.</td></tr><tr><td>CLINICAL USE</td><td>Gram © bugs only—for serious, multidrug-resistant organisms, including MRSA, S epidermidis, sensitive Enterococcus species, and Clostridium difficile (oral route).</td></tr><tr><td>ADVERSE EFFECTS</td><td>Well tolerated in general but not trouble free: nephrotoxicity, ototoxicity, thrombophlebitis, diffuse flushing (vancomycin infusion reaction [;)—idiopathic reaction largely preventable by pretreatment with antihistamines and slower infusion rate), DRESS syndrome.</td></tr><tr><td>MECHANISM OF RESISTANCE</td><td>Occurs in bacteria (eg, Enterococcus) via amino acid modification of D-Ala-D-Ala to D-Ala-D-Lac.</td></tr></table>
======================================
<table><tr><td>CLINICAL USE</td><td>drugs’ absorption gut. Borrelia burgdorferi, M pneumoniae. Drugs’ ability to accumulate intracellularly makes them very effective against Rickettsia and Chlamydia. Also used to treat acne. Doxycycline effective against community-acquired MRSA.</td></tr><tr><td>ADVERSE EFFECTS</td><td>GI distress, discoloration of teeth and inhibition of bone growth in children, photosensitivity. “Teratocylines” are teratogenic; generally avoided in pregnancy and in children (except doxycycline).</td></tr><tr><td>MECHANISM OF RESISTANCE</td><td>+ uptake or t efflux out of bacterial cells by plasmid-encoded transport pumps.</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Tetracycline derivative. Binds to 30S, inhibiting protein synthesis. Generally bacteriostatic.</td></tr><tr><td>CLINICAL USE</td><td>Broad-spectrum anaerobic, gram ©, and gram © coverage. Multidrug-resistant organisms (eg, MRSA, VRE).</td></tr><tr><td>ADVERSE EFFECTS</td><td>Nausea, vomiting.</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Blocks peptidyltransferase at 50S ribosomal subunit. Bacteriostatic.</td></tr><tr><td>CLINICAL USE</td><td>Meningitis (Haemophilus influenzae, Neisseria meningitidis, Streptococcus pneumoniae) and rickettsial diseases (eg, Rocky Mountain spotted fever [Rickettsia rickettsii]). Limited use due to toxicity but often still used in developing countries because of low cost.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Anemia (dose dependent), aplastic anemia (dose independent), gray baby syndrome (in prematur infants because they lack liver UDP-glucuronosyltransferase).</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Blocks peptide transfer (translocation) at 50S ribosomal subunit. Bacteriostatic.</td></tr><tr><td>CLINICAL USE</td><td>Anaerobic infections (eg, Bacteroides spp., Clostridium perfringens) in aspiration pneumonia, lung abscesses, and oral infections. Also effective against invasive group A streptococcal infection. Treats anaerobic infections above the diaphragm vs metronidazole (anaerobic infections below diaphragm).</td></tr></table>
======================================
<table><tr><td>Macrolides</td><td>Azil hromycin, clarithromycin, erythromycin.</td></tr><tr><td>MECHANISM</td><td>Inhibit protein synthesis by blocking translocation (“macroslides”); bind to the 50S ribosomal subunit. Bacteriostatic.</td></tr><tr><td>CLINICAL USE</td><td>Aty ical pneumonias (Mycoplasma, Chlamydia, Legionella), STIs (Chlamydia), gram ® cocci (streptococcal infections in patients allergic to penicillin), and B pertussis.</td></tr><tr><td>ADVERSE EFFECTS</td><td>MACRO: Gastrointestinal Motility issues, Arrhythmia caused by prolonged QT interval, acute Cc holestatic hepatitis, Rash, eOsinophilia. Increases serum concentration of theophylline, oral anticoagulants. Clarithromycin and erythromycin inhibit cytochrome P-450.</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Cation polypeptides that bind to phospholipids on cell membrane of gram © bacteria. Disrupt cell membrane integrity + leakage of cellular components — cell death.</td></tr><tr><td>CLINICAL USE</td><td>Salvage therapy for multidrug-resistant gram © bacteria (eg, P aeruginosa, E coli, K pneumoniae). Polymyxin B is a component of a triple antibiotic ointment used for superficial skin infections.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Nephrotoxicity, neurotoxicity (eg, slurred speech, weakness, paresthesias), respiratory failure.</td></tr></table>
======================================
<table><thead><th></th><th>(SMX), sulfadiazine.</th></thead><tr><td>MECHANISM</td><td>Inhibit dihydropteroate synthase, thus inhibiting folate synthesis. Bacteriostatic (bactericidal when combined with trimethoprim).</td></tr><tr><td>CLINICAL USE</td><td>Gram ©, gram ©, Nocardia. TMP-SMX for simple UTI.</td></tr></table>
======================================
<table><thead><th></th><th>Il (DNA gyrase) and topoisomerase IV. Bactericidal. Concurrent ingestion of divalent cations (eg, dairy, antacids) markedly decreases oral absorption.</th><th></th></thead><tr><td>CLINICAL USE</td><td>Gram © rods of urinary and GI tracts (including Pseudomonas), some gram © organisms, otitis externa.</td><td></td></tr><tr><td>ADVERSE EFFECTS</td><td>GI upset, superinfections, skin rashes, headache, dizziness. Less commonly, can cause leg cramps and myalgias. Contraindicated during pregnancy or breastfeeding and in children &lt; 18 years old due to possible damage to cartilage. Some may prolong OT interval.</td><td>May cause tendonitis or tendon rupture in people &gt; 60 years old and in patients taking prednisone. Ciprofloxacin inhibits cytochrome P-450. Fluoroquinolones hurt attachments to your bones.</td></tr><tr><td colspan="3">Daptomycin</td></tr><tr><td>MECHANISM</td><td>Lipopeptide that disrupts cell membranes of gram ® cocci by creating transmembrane channels.</td><td></td></tr><tr><td>CLINICAL USE</td><td>S aureus skin infections (especially MRSA), bacteremia, infective endocarditis, VRE.</td><td>Not used for pneumonia (avidly binds to and is inactivated by surfactant). “Dapto-myo-skin” is used for skin infections but can cause myopathy.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Myopathy, rhabdomyolysis.</td><td></td></tr><tr><td>Metronidazole</td><td></td><td></td></tr></table>
======================================
<table><thead><th>DRUG</th><th>MECHANISM</th><th>ADVERSE EFFECTS</th><th>NOTES</th><th></th></thead><tr><td>Rifamycins Rifampin, rifabutin, rifapentine</td><td>Inhibit DNA-dependent RNA polymerase &gt; 4 mRNA synthesis Rifamycin resistance arises due to mutations in gene encoding RNA polymerase</td><td>Minor hepatotoxicity, drug interactions (CYP450 induction), red-orange discoloration of body fluids (nonhazardous adverse effect)</td><td>Rifabutin favored over in patients with HIV due to less CYP450 Monotherapy rapidly resistance</td><td>rifampin infection induction leads to</td></tr><tr><td>Isoniazid</td><td>Inhibits mycolic acid synthesis &gt; 4 cell wall synthesis Bacterial catalase-peroxidase (encoded by katG) is needed to convert INH to active form INH resistance arises due to mutations in katG</td><td>Vitamin Bg deficiency (peripheral neuropathy, sideroblastic anemia), hepatotoxicity, drug interactions (CYP450 inhibition), drug-induced lupus overdose can lead to seizures (often refractory to benzodiazepines)</td><td>Administer with (vitamin Bg) INH Injures Neurons Hepatocytes (t risk hepatotoxicity with t alcohol overuse) Different INH half-lives vs slow acetylators</td><td>pyridoxine and of age and in fast</td></tr><tr><td>Pyrazinamide</td><td>Mechanism uncertain</td><td>Hepatotoxicity, hyperuricemia —</td><td>Works best at acidic</td><td>pH (eg, in</td></tr><tr><td>Ethambutol</td><td rowspan="2">Inhibits arabinosyltransferase = 4 arabinogalactan synthesis &gt; 4 cell wall synthesis</td><td>Optic neuropathy (red-green $</td><td colspan="2" rowspan="2">host phagolysosomes) Pronounce “eyethambutol”</td></tr><tr><td></td><td></td><td>color blindness or visual acuity, typically reversible)</td><td colspan="2"></td></tr><tr><td>MYCOBACTERIAL CELL</td><td>Cell wall</td><td>Plasma membrane</td><td colspan="2">Interior of cell</td></tr><tr><td></td><td>Oey sf 2 Ge F ae eo e I &amp; SS</td><td></td><td>mRNA SYNTHESIS (DNA-dependent</td><td></td></tr><tr><td>MYCOLIC ACID SYNTHESIS</td><td>ae? a? a — os &amp;_ &gt;</td><td></td><td>RNA polymerase) Rifabutin</td><td></td></tr><tr><td>~</td><td>= — Ss — eo =</td><td></td><td>Rifampin en Rifapentine</td><td></td></tr><tr><td>ARABINOGALACTAN SYNTHESIS (arabinosyltransferase)</td><td rowspan="2">(= ar &gt; o— = ae } = —_&gt; e— =. —_— = - (= at -— a:</td><td></td><td>INTRACELLULAR (unclear mechanism)</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>BACTERIUM</th><th>PROPHYLAXIS</th><th>TREATMENT</th></thead><tr><td>M tuberculosis</td><td>Rifamycin-based regimen for 3-4 months</td><td>Rifampin, Isoniazid, Pyrazinamide, Ethambutol (RIPE for treatment)</td></tr><tr><td>Mavium-intracellulare</td><td>Azithromycin, rifabutin</td><td>Azithromycin or clarithromycin + ethambutol Can add rifabutin or ciprofloxacin</td></tr><tr><td>Mleprae</td><td></td><td>Long-term treatment with dapsone and rifampin for tuberculoid form Add clofazimine for lepromatous form</td></tr><tr><td rowspan="8">Antimicrobial prophylaxis</td><td>CLINICAL SCENARIO Exposure to meningococcal infection</td><td>MEDICATION Ceftriaxone, ciprofloxacin, or rifampin</td></tr><tr><td></td><td>High risk for infective endocarditis and undergoing surgical or dental procedures</td><td>Amoxicillin</td></tr><tr><td></td><td>History of recurrent UTIs</td><td>TMP-SMX</td></tr><tr><td></td><td>Malaria prophylaxis for travelers</td><td>Atovaquone-proguanil, mefloquine, doxycycline, primaquine, or chloroquine (for areas with sensitive species)</td></tr><tr><td></td><td>Pregnant patients carrying group B strep</td><td>Intrapartum penicillin G or ampicillin</td></tr><tr><td></td><td>Prevention of gonococcal conjunctivitis in newborn</td><td>Erythromycin ointment on eyes</td></tr><tr><td></td><td>Prevention of postsurgical infection due to S aureus</td><td>Cefazolin; vancomycin if ® for MRSA</td></tr><tr><td></td><td>Prophylaxis of strep pharyngitis in child with prior rheumatic fever</td><td>Benzathine penicillin G or oral penicillin V</td></tr></table>
======================================
<table><tr><td>CELL COUNT</td><td>PROPHYLAXIS</td><td>INFECTION</td></tr><tr><td>CD4+ &lt; 200 cells/mm?</td><td>‘TMP-SMX</td><td>Pneumocystis pneumonia</td></tr><tr><td>CD4+ &lt; 100 cells/mm?</td><td>TMP-SMX</td><td>Pneumocystis pneumonia and toxoplasmosis</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Binds ergosterol (unique to fungi); forms membrane pores that allow leakage of electrolytes.</td><td>Amphotericin “tears” holes in the fungal membrane by forming pores.</td></tr><tr><td>CLINICAL USE</td><td>Serious, systemic mycoses. Cryptococcus (amphotericin B +/— flucytosine for cryptococcal meningitis), Blastomyces, Coccidioides, Histoplasma, Candida, Mucor. Intrathecally for coccidioidal meningitis.</td><td>Supplement K* and Mg** because of altered renal tubule permeability.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Fever/chills (“shake and bake”), hypotension, nephrotoxicity, arrhythmias, anemia, IV phlebitis (“amphoterrible”).</td><td>Hydration + nephrotoxicity. Liposomal amphotericin $ toxicity.</td></tr><tr><td colspan="3">Nystatin</td></tr><tr><td>MECHANISM</td><td>Same as amphotericin B. Topical use only as</td><td>toxic for systemic use.</td></tr><tr><td>CLINICAL USE</td><td>“Swish and swallow” for oral candidiasis (thrush);</td><td>topical for diaper rash or vaginal candidiasis.</td></tr><tr><td colspan="3">Flucytosine</td></tr><tr><td>MECHANISM</td><td>Inhibits DNA and RNA biosynthesis by conversion</td><td>to 5-fluorouracil by cytosine deaminase.</td></tr><tr><td>CLINICAL USE</td><td colspan="2">Systemic fungal infections (especially meningitis caused by Cryptococcus) in combination with amphotericin B.</td></tr><tr><td>ADVERSE EFFECTS</td><td colspan="2">Myelosuppression.</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Interferes with microtubule function; disrupts mitosis. Deposits in keratin-containing tissues (eg, nails).</td></tr><tr><td>CLINICAL USE</td><td>Oral treatment of superficial infections; inhibits growth of dermatophytes (tinea, ringworm).</td></tr><tr><td>ADVERSE EFFECTS</td><td>Teratogenic, carcinogenic, confusion, headaches, disulfiram-like reaction, t cytochrome P-450 and warfarin metabolism.</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Blocks detoxification of heme into hemozoin. Heme accumulates and is toxic to plasmodia.</td></tr><tr><td>CLINICAL USE</td><td>Treatment of plasmodial species other than P falciparum (due to drug resistance from membrane pump that $ intracellular concentration of drug).</td></tr><tr><td>ADVERSE EFFECTS</td><td>Retinopathy (dependent on cumulative dose); pruritus (especially in dark-skinned individuals).</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Inhibits the “cap snatching” (transfer of the 5’ cap from cell mRNA onto viral mRNA) endonuclease activity of the influenza virus RNA polymerase &gt; $ viral replication.</td></tr><tr><td>CLINICAL USE</td><td>Treatment within 48 hours of symptom onset shortens duration of illness.</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Prodrug of an ATP analog. The active metabolite inhibits viral RNA-dependent RNA polymerase and evades proofreading by viral exoribonuclease (ExoN) + $ viral RNA production.</td></tr><tr><td>CLINICAL USE</td><td>Recently approved for treatment of COVID-19 requiring hospitalization.</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Viral DNA/RNA polymerase inhibitor and HIV reverse transcriptase inhibitor. Binds to pyrophosphate-binding site of enzyme. Does not require any kinase activation.</td><td>Foscarnet = pyrofosphate analog.</td></tr><tr><td>CLINICAL USE</td><td>CMV retinitis in immunocompromised patients when ganciclovir fails; acyclovir-resistant HSV.</td><td></td></tr><tr><td>ADVERSE EFFECTS</td><td>Nephrotoxicity, multiple electrolyte abnormalities can lead to seizures.</td><td></td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Preferentially inhibits viral DNA polymerase. Does not require phosphorylation by viral kinase</td></tr><tr><td>CLINICAL USE</td><td>CMV retinitis in immunocompromised patients. Long half-life.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Nephrotoxicity (coadminister cidofovir with probenecid and IV saline to 4 toxicity).</td></tr></table>
======================================
<table><thead><th>DRUG</th><th>MECHANISM</th><th>ADVERSE EFFECTS</th></thead><tr><td colspan="3">NRTIs</td></tr><tr><td>Abacavir (ABC) Emtricitabine (FTC) Lamivudine (3TC) Tenofovir (TDF) Zidovudine (ZDV, formerly AZT)</td><td>Competitively inhibit nucleotide binding to reverse transcriptase and terminate the DNA chain (lack a 3’ OH group). Tenofovir is a nucleoTiide; the others are nucleosides. All need to be phosphorylated to be active. ZDV can be used for general prophylaxis and during pregnancy to 4 risk of fetal transmission. Have you dined (vudine) with my nuclear (nucleosides) family?</td><td>Myelosuppression (can be reversed with granulocyte colony-stimulating factor [G-CSF] and erythropoietin), nephrotoxicity. Abacavir contraindicated if patient has HLA-B*5701 mutation due to t risk of hypersensitivity.</td></tr><tr><td colspan="3">NNRTIs</td></tr><tr><td>Doravirine Efavirenz Rilpivirine</td><td>Bind to reverse transcriptase at site different from NRTIs. Do not require phosphorylation to be active or compete with nucleotides.</td><td>Rash and hepatotoxicity are common to all NNRIIs. Vivid dreams and CNS symptoms are common with efavirenz.</td></tr><tr><td colspan="3">Integrase strand transfer inhibitors</td></tr><tr><td>Bictegravir Dolutegravir</td><td>Also called integrase inhibitors. Inhibit HIV genome integration into host cell chromosome by reversibly HIV</td><td>t creatine kinase, weight gain.</td></tr><tr><td colspan="3">inhibiting integrase. Protease inhibitors</td></tr><tr><td></td><td>Prevents maturation of virions. Maturation</td><td>— Hyperglycemia, GI intolerance (nausea,</td></tr><tr><td>Atazanavir Darunavir Lopinavir Ritonavir</td><td>new depends on HIV-1 protease (pol gene), which cleaves the polypeptide products of HIV mRNA into their functional parts. Thus, protease inhibitors prevent maturation of new viruses. All protease inhibitors require boosting with either ritonavir or cobicistat. Navir (never) tease a protease.</td><td>diarrhea). Rifampin (potent CYP/UGT inducer) § protease inhibitor concentrations; use rifabutin instead. _ Ritonavir (cytochrome P-450 inhibitor) is only used as a boosting agent.</td></tr><tr><td colspan="3">Entry inhibitors</td></tr><tr><td>Enfuvirtide</td><td>Binds gp4l, inhibiting viral entry. Enfuvirtide inhibits fusion.</td><td>Skin reaction at injection sites.</td></tr><tr><td>Maraviroc</td><td>Binds CCR-5 on surface of T cells/monocytes, inhibiting interaction with gp120.</td><td></td></tr></table>
======================================
<table><tr><td colspan="3">NSSA inhibitors</td></tr><tr><td>Elbasvir</td><td>nhibits NS5A, a viral phosphoprotein that plays</td><td>| Headache, diarrhea</td></tr><tr><td>Ledipasvir Pibrentasvir Velpatasvir</td><td>a key role in RNA replication Exact mechanism unknown</td><td></td></tr><tr><td>NSSB inhibitors Sofosbuvir</td><td>nhibits NS5B, an RNA-dependent RNA</td><td>Fatigue, headache</td></tr><tr><td></td><td>polymerase acting as a chain terminator revents viral RNA replication</td><td></td></tr><tr><td colspan="3">NS3/4A inhibitors</td></tr><tr><td>Glecaprevir</td><td>nhibits NS3/4A, a viral protease, preventing viral</td><td>Headache, fatigue</td></tr><tr><td>Grazoprevir</td><td>replication</td><td></td></tr><tr><td>Alternative drugs</td><td></td><td></td></tr><tr><td>Ribavirin</td><td>nhibits synthesis of guanine nucleotides by com petitively inhibiting IMP dehydrogenase</td><td>Hemolytic anemia, severe teratogen</td></tr><tr><td></td><td></td><td></td></tr><tr><td>Disinfection and sterilization</td><td>Goals inac include the reduction of pathogenic organism ivation of all microbes including spores</td><td>counts to safe levels (disinfection) and the (sterilization).</td></tr><tr><td>Autoclave*</td><td colspan="2">ressurized steam at &gt; 120°C. May not reliably inactivate prions.</td></tr><tr><td>Alcohols</td><td>Denature proteins and disrupt cell membranes.</td><td></td></tr><tr><td>Chlorhexidine</td><td colspan="2">Disruy pts cell membranes and coagulates intracellular components.</td></tr><tr><td>Chlorine?</td><td colspan="2">Oxidizes and denatures proteins.</td></tr><tr><td>Ethylene oxide?</td><td colspan="2">Alkylating agent.</td></tr><tr><td>Hydrogen peroxide?</td><td colspan="2">Free radical oxidation.</td></tr><tr><td>lodine and iodophors</td><td colspan="2">lalogenation of DNA, RNA, and proteins. May be sporicidal.</td></tr><tr><td>Quaternary amines</td><td colspan="2">mpair permeability of cell membranes.</td></tr><tr><td>*Sporicidal.</td><td colspan="2"></td></tr></table>
======================================
<table><tr><td rowspan="8">ntimicrobials to void in pregnancy</td><td>ANTIMICROBIAL</td><td>ADVERSE EFFECT</td></tr><tr><td></td><td>Sulfonamides</td><td>Kernicterus</td></tr><tr><td></td><td>Aminoglycosides</td><td>Ototoxicity</td></tr><tr><td></td><td>Fluoroquinolones</td><td>Cartilage damage</td></tr><tr><td></td><td>Clarithromycin</td><td>Embryotoxic</td></tr><tr><td></td><td>Tetracyclines</td><td>Discolored teeth, inhibition of bone growth</td></tr><tr><td></td><td>Ribavirin</td><td>Teratogenic</td></tr><tr><td></td><td>Griseofulvin</td><td>Teratogenic</td></tr></table>
======================================
<table><thead><th></th><th>Intrinsic, extrinsic, and perforin/granzyme B pathways — activate caspases (cytosolic proteases)</th></thead><tr><td rowspan="3">Intrinsic (mitochondrial) pathway</td><td>DNA laddering (fragments in multiples of 180 bp) is a sensitive indicator of apoptosis. Involved in tissue remodeling in embryogenesis. Occurs when a regulating factor is withdrawn from a proliferating cell population (eg, + IL-2 after a completed immunologic reaction — apoptosis of proliferating effector cells). Also occurs after exposure to injurious stimuli (eg,</td></tr><tr><td></td><td>Bel-2 and Bcl-xL are antiapoptotic (Be clever, live). BAX and BAK form pores in the mitochondrial membrane &gt; release of cytochrome C from inner mitochondrial membrane into the cytoplasm &gt; activation of caspases.</td></tr><tr><td></td><td>Bcl-2 keeps the mitochondrial membrane impermeable, thereby preventing cytochrome C release. Bcl-2 overexpression (eg, follicular lymphoma t{14;18]}) + 4 caspase activation + tumorigenesis.</td></tr><tr><td>Extrinsic (death receptor) pathway</td><td>Ligand receptor interactions: FasL binding to Fas (CD95) or TNF-a binding to its receptor. Fas-FasL interaction is necessary in thymic medullary negative selection. Autoimmune lymphoproliferative syndrome—caused by defective Fas-FasL interaction &gt; failure of clonal deletion + t numbers of selfreacting lymphocytes. Presents with lymphadenopathy, hepatosplenomegaly, autoimmune cytopenias.</td></tr><tr><td>Perforin/granzyme B pathway</td><td>Release of granules containing perforin and granzyme B by immune cells (cytotoxic ‘T-cell and natural killer cell) + perforin forms a pore for granzyme B to enter the target cell.</td></tr><tr><td>Intrinsic pathway (mitochondrial)</td><td>Extrinsic pathway Cytotoxic T cell (death receptor) — —~</td></tr></table>
======================================
<table><thead><th>TYPE</th><th>SEEN IN</th><th>DUETO</th><th>HISTOLOGY</th></thead><tr><td>Coagulative</td><td>Ischemia/infarcts in most tissues (except brain)</td><td>Ischemia or infarction; injury denatures enzymes — proteolysis blocked</td><td>Preserved cellular architecture (cell outlines seen), but nuclei disappear; t cytoplasmic binding of eosin stain (&gt; t eosinophilia; red/pink color) EY</td></tr><tr><td>Liquefactive</td><td>Bacterial abscesses, CNS infarcts</td><td>Neutrophils release lysosomal enzymes that digest the tissue</td><td>Early: cellular debris and macrophages Late: cystic spaces and cavitation (CNS) Ej Neutrophils and cell debris seen with bacterial infection</td></tr><tr><td>Caseous</td><td>TB, systemic fungi (eg, Histoplasma capsulatum), Nocardia</td><td>Macrophages wall off the infecting microorganism = granular debris</td><td>Fragmented cells and debris surrounded by lymphocytes and macrophages (granuloma) Cheeselike gross appearance [@</td></tr><tr><td>Fat</td><td>Enzymatic: acute pancreatitis (saponification of peripancreatic fat) Nonenzymatic: traumatic (eg, injury to breast tissue)</td><td>Damaged pancreatic cells release lipase, which breaks down triglycerides; liberated fatty acids bind calcium — saponification (chalky- white appearance)</td><td>Outlines of dead fat cells without peripheral nuclei; saponification of fat (combined with Ca’*) appears dark blue on H&amp;E stain DB)</td></tr><tr><td>Fibrinoid</td><td>Immune vascular reactions (eg, PAN) Nonimmune vascular reactions (eg, hypertensive emergency, preeclampsia)</td><td>Immune complex deposition (type III hypersensitivity reaction) and/or plasma protein (eg, fibrin) leakage from damaged vessel</td><td>Vessel walls contain eosinophilic layer of P y proteinaceous material</td></tr><tr><td>Gangrenous</td><td>Distal extremity and GI tract, after chronic ischemia</td><td>Dry: ischemia y Wet: superinfection</td><td>Coagulative Liquefactive superimposed on coagulative</td></tr></table>
======================================
<table><tr><td>Brain</td><td>ACA/MCA/PCA boundary areas*?</td></tr><tr><td>Heart</td><td>Subendocardium of LV (yellow lines in EY outline a subendocardial infarction)</td></tr><tr><td>Kidney</td><td>Straight segment of proximal tubule (medulla) Thick ascending limb (medulla)</td></tr><tr><td>Liver</td><td>Area around central vein (zone III)</td></tr><tr><td>Colon</td><td>Splenic flexure (Griffith point),* rectosigmoid junction (Sudeck point)*</td></tr></table>
======================================
<table><thead><th></th><th>Dystrophic calcification</th><th>Metastatic calcification</th></thead><tr><td>Ca®* DEPOSITION</td><td>In abnormal (diseased) tissues</td><td>In normal tissues</td></tr><tr><td>EXTENT</td><td>Tends to be localized (eg, calcific aortic stenosis)</td><td>Widespread (ie, diffuse, metastatic)</td></tr><tr><td>ASSOCIATED CONDITIONS</td><td>TB (lung and pericardium) and other</td><td>Predominantly in interstitial tissues of kidney,</td></tr><tr><td></td><td>granulomatous infections, liquefactive necrosis of chronic abscesses, fat necrosis, infarcts, thrombi, schistosomiasis, congenital CMV, toxoplasmosis, rubella, psammoma bodies, CREST syndrome, atherosclerotic plaques can become calcified</td><td>lung, and gastric mucosa (these tissues lose acid quickly; t pH favors Ca** deposition) Nephrocalcinosis of collecting ducts may lead to nephrogenic diabetes insipidus and renal failure</td></tr><tr><td>ETIOLOGY</td><td>2° to injury or necrosis</td><td>2° to hyperphosphatemia (eg, chronic kidney disease) or hypercalcemia (eg, 1° hyperparathyroidism, sarcoidosis, hypervitaminosis D)</td></tr><tr><td>Psammoma bodies 2</td><td>Concentrically laminated calcified spherules [J. Usually seen in certain types of tumors:</td><td>Please, MOM, don’t forget the Milk!</td></tr></table>
======================================
<table><thead><th></th><th>* Cardiac—restrictive cardiomyopathy.</th><th rowspan="4"></th></thead><thead><th></th><th>= GlI—hepatosplenomegaly.</th><th></th></thead><thead><th></th><th>» Neurologic—peripheral neuropathy.</th><th></th></thead><thead><th></th><th>* Skin—waxy thickening, easy bruising.</th><th></th></thead><tr><td>COMMON TYPES</td><td>FIBRIL PROTEIN</td><td>NOTES</td></tr><tr><td colspan="3">Systemic AL Seen in cell</td></tr><tr><td>Primary amyloidosis</td><td>(from Ig Light chains)</td><td>plasma dyscrasias (eg, multiple myeloma)</td></tr><tr><td>Secondary amyloidosis</td><td>AA (serum Amyloid A)</td><td>Seen in chronic inflammatory conditions, (eg, rheumatoid arthritis, IBD, familial</td></tr><tr><td></td><td></td><td>Mediterranean fever, protracted infection)</td></tr><tr><td>Transthyretin amyloidosis</td><td>Transthyretin</td><td>Sporadic (wild-type TTR)—slowly progressive, associated with aging; mainly affects the heart Hereditary (mutated TTR)—familial amyloid polyneuropathy and/or cardiomyopathy</td></tr><tr><td>Dialysis-related amyloidosis</td><td>B-microglobulin</td><td>Seen in patients with ESRD on long-term dialysis</td></tr><tr><td colspan="3">Localized</td></tr><tr><td>Alzheimer disease</td><td>B-amyloid protein</td><td>Cleaved from amyloid precursor protein</td></tr><tr><td>Isolated atrial amyloidosis</td><td>ANP</td><td>Common, associated with aging; t risk for atrial fibrillation</td></tr><tr><td>Type 2 diabetes mellitus</td><td>Islet amyloid polypeptide</td><td>Caused by deposition of amylin in pancreatic islets</td></tr><tr><td>Medullary thyroid cancer</td><td>Calcitonin</td><td>Secreted from tumor cells</td></tr></table>
======================================
<table><tr><td>Inflammation</td><td>Response to eliminate initial cause of cell injury, to remove necrotic cells resulting from the original insult, and to initiate tissue repair. Divided into acute and chronic. The inflammatory response itself can be harmful to the host if the reaction is excessive (eg, septic shock), prolonged (eg, persistent infections such as TB), or inappropriate (eg, autoimmune diseases such as SLE).</td></tr><tr><td>SIGN</td><td>MECHANISM</td></tr><tr><td colspan="2">Cardinal signs</td></tr><tr><td>Rubor and calor</td><td>Redness and warmth. Vasodilation (relaxation of arteriolar smooth muscle) &gt; t blood flow. Mediated by histamine, prostaglandins, bradykinin, NO.</td></tr><tr><td>Tumor</td><td>Swelling. Endothelial contraction/disruption (eg, from tissue damage) &gt; t vascular permeability + leakage of protein-rich fluid from postcapillary venules into interstitial space (exudate) &gt; t interstitial oncotic pressure. Endothelial contraction is mediated by leukotrienes (C4, D4, E4), histamine, serotonin.</td></tr><tr><td>Dolor</td><td>Pain. Sensitization of sensory nerve endings. Mediated by bradykinin, PGE, histamine.</td></tr><tr><td>Functio laesa</td><td>Loss of function. Inflammation impairs function (eg, inability to make fist due to hand cellulitis).</td></tr><tr><td colspan="2">Systemic manifestations (acute-phase reaction)</td></tr><tr><td>Fever</td><td>Pyrogens (eg, LPS) induce macrophages to release IL-1 and TNF &gt; t COX activity in perivascular cells of anterior hypothalamus &gt; t PGE, &gt; t temperature set point.</td></tr><tr><td>Leukocytosis</td><td>t WBC count; type of predominant cell depends on inciting agent or injury (eg, bacteria &gt; t neutrophils).</td></tr><tr><td>t plasma acute-phase reactants</td><td>Serum concentrations significantly change in response to acute and chronic inflammation. Produced by liver. Notably induced by IL-6.</td></tr></table>
======================================
<table><tr><td>C-reactive protein</td><td>Opsonin; fixes complement and facilitates phagocytosis. Measured clinically as a nonspecific sign of ongoing inflammation.</td></tr><tr><td>Ferritin</td><td>Binds and sequesters iron to inhibit microbial iron scavenging.</td></tr><tr><td>Fibrinogen</td><td>Coagulation factor; promotes endothelial repair; correlates with ESR.</td></tr><tr><td>Haptoglobin</td><td>Binds extracellular hemoglobin, protects against oxidative stress.</td></tr><tr><td>Hepcidin</td><td>+ iron absorption (by degrading ferroportin) and $ iron release (from macrophages) + anemia of chronic disease.</td></tr><tr><td>Procalcitonin</td><td>Increases in bacterial infections; normal in viral infections.</td></tr><tr><td>Serum amyloid A</td><td>Prolonged elevation can lead to secondary amyloidosis.</td></tr><tr><td colspan="2">NEGATIVE (DOWNREGULATED)</td></tr><tr><td>Albumin</td><td>Reduction conserves amino acids for positive reactants.</td></tr><tr><td>Transferrin</td><td>Internalized by macrophages to sequester iron.</td></tr><tr><td>Transthyretin</td><td>Also called prealbumin. Reduction conserves amino acids for positive reactants.</td></tr></table>
======================================
<table><tr><td>Most anemias</td><td>Sickle cell anemia (altered shape)</td></tr><tr><td>Infections</td><td>Polycythemia (t RBCs “dilute” aggregation</td></tr><tr><td>Inflammation (eg, giant cell [temporal] arteritis,</td><td>factors)</td></tr><tr><td>polymyalgia rheumatica)</td><td>HF</td></tr><tr><td>Cancer (eg, metastases, multiple myeloma)</td><td>Microcytosis</td></tr><tr><td>Renal disease (end-stage or nephrotic syndrome)</td><td>— Hypofibrinogenemia</td></tr><tr><td>Pregnancy</td><td></td></tr></table>
======================================
<table><thead><th>STIMULI</th><th>Infections, trauma, necrosis, foreign bodies.</th><th></th></thead><tr><td>MEDIATORS</td><td>Toll-like receptors, arachidonic acid metabolites, neutrophils, eosinophils, antibodies (pre- existing), mast cells, basophils, complement, Hageman factor (factor XII).</td><td>Inflammasome—Cytoplasmic protein complex that recognizes products of dead cells, microbial products, and crystals (eg, uric acid crystals) &gt; activation of IL-1 and inflammatory response.</td></tr><tr><td>COMPONENTS</td><td>= Vascular: vasodilation (+ t blood flow and stasis) and t endothelial permeability (contraction of endothelial cells opens interendothelial junctions) ® Cellular: extravasation of leukocytes (mainly neutrophils) from postcapillary venules &gt; accumulation of leukocytes in focus of injury + leukocyte activation</td><td>To bring cells and proteins to site of injury or infection. Leukocyte extravasation has 4 steps: margination and rolling, adhesion, transmigration, and migration (chemoattraction).</td></tr><tr><td></td><td></td><td></td></tr><tr><td>OUTCOMES</td><td>* Resolution and healing (IL-10, TGF-B) = Persistent acute inflammation (IL-8) = Abscess (acute inflammation walled off by fibrosis) * Chronic inflammation (antigen presentation by macrophages and other APCs — activation of CD4+ Th cells)</td><td>Macrophages predominate in the late stages of acute inflammation (peak 2-3 days after onset) and influence outcome by secreting cytokines.</td></tr></table>
======================================
<table><tr><td rowspan="8">Tissue mediators PHASE OF WOUND HEALING</td><td>MEDIATOR</td><td>ROLE</td></tr><tr><td></td><td>FGF</td><td>Stimulates angiogenesis</td></tr><tr><td></td><td>TGE-B</td><td>Angiogenesis, fibrosis</td></tr><tr><td></td><td>VEGF</td><td>Stimulates angiogenesis</td></tr><tr><td></td><td>PDGF</td><td>Secreted by activated platelets and macrophages Induces vascular remodeling and smooth muscle cell migration Stimulates fibroblast growth for collagen synthesis</td></tr><tr><td></td><td>etalloproteinases</td><td>Tissue remodeling</td></tr><tr><td></td><td>EGF</td><td>Stimulates cell growth via tyrosine kinases (eg, EGFR/ErbB1)</td></tr><tr><td></td><td>EFFECTOR CELLS</td><td>CHARACTERISTICS</td></tr><tr><td>Inflammatory (up to 3 days after wound)</td><td>Platelets, neutrophils, macrophages</td><td>Clot formation, t vessel permeability and neutrophil migration into tissue; macrophages clear debris 2 days later</td></tr><tr><td>Proliferative (day 3-weeks after wound)</td><td>fe] ibroblasts, myofibroblasts, endothelial cells, eratinocytes, macrophages</td><td>Deposition of granulation tissue and type III collagen, angiogenesis, epithelial cell proliferation, dissolution of clot, and wound contraction (mediated by myofibroblasts) Delayed second phase of wound healing in vitamin C and copper deficiency</td></tr><tr><td>Remodeling (1 week-6+ months after wound)</td><td>Fibroblasts</td><td>Type III collagen replaced by type I collagen, t tensile strength of tissue Collagenases (require zinc to function) break down type III collagen</td></tr></table>
======================================
<table><thead><th>Granulomatous inflammation</th><th>A pattern of chronic inflammation. Can be induced by persistent T-cell response to certain infections (eg, TB), immune-mediated diseases, and foreign bodies. Granulomas “wall off” a resistant stimulus without completely eradicating or degrading it &gt; persistent inflammation — fibrosis, organ damage.</th></thead><tr><td>HISTOLOGY</td><td>Focus of epithelioid cells (activated macrophages with abundant pink cytoplasm) surrounded by lymphocytes and multinucleated giant cells (formed by fusion of several activated macrophages). ‘Two types: Caseating: associated with central necrosis [-. Seen with infectious etiologies (eg, TB, fungal). Noncaseating: no central necrosis. Seen with noninfectious etiologies (eg, sarcoidosis, Crohn disease).</td></tr><tr><td rowspan="3"></td><td>@ Thl secretes IFN-y &gt; macrophage activation © Macrophages t cytokine secretion (eg, TNF) &gt; formation of epithelioid macrophages and giant cells</td></tr><tr><td></td><td>therapy sequestering granulomas Always test for latent TB before starting anti-TNF therapy. Associated with hypercalcemia due to t lo-hydroxylase activity in activated macrophages, resulting in t vitamin D activity. Lymphocyte</td></tr><tr><td></td><td>Fibroblast IL-12 Epithelioid cell y -N e</td></tr></table>
======================================
<table><tr><td>Tumor nomenclature</td><td>Carcinoma implies epithelial origin, whereas sarcoma denotes mesenchymal origin. Both terms</td></tr><tr><td></td><td>generally imply malignancy. Benign tumors are usually well-differentiated and well-demarcated, with low mitotic activity, no metastases, and necrosis.</td></tr><tr><td></td><td>no Malignant tumors (cancers) may show poor differentiation, erratic growth, local invasion, metastasis, and $ apoptosis.</td></tr><tr><td></td><td>for non-neoplastic malformations include hamartoma (disorganized overgrowth of tissues in native location, eg, Peutz-Jeghers polyps) and choristoma (normal tissue in a foreign location, tissue located in distal ileum in Meckel diverticulum).</td></tr><tr><td></td><td>gastric</td></tr><tr><td>CELL TYPE</td><td>MALIGNANT</td></tr><tr><td>Epithelium</td><td>Adenoma, papilloma Adenocarcinoma, papillary carcinoma</td></tr><tr><td>Mesenchyme</td><td></td></tr><tr><td>Blood cells</td><td>Leukemia, lymphoma</td></tr><tr><td>Blood vessels</td><td>Hemangioma Angiosarcoma</td></tr><tr><td>Smooth muscle</td><td>Leiomyoma Leiomyosarcoma</td></tr><tr><td>Striated muscle</td><td>Rhabdomyoma Rhabdomyosarcoma</td></tr><tr><td>Connective tissue</td><td>Fibroma Fibrosarcoma</td></tr><tr><td>Bone</td><td>Osteoma Osteosarcoma</td></tr><tr><td>Fat</td><td>Lipoma Liposarcoma</td></tr><tr><td>Melanocyte</td><td>Nevus/mole Melanoma</td></tr></table>
======================================
<table><thead><th>Hallmarks of cancer</th><th>Cancer is caused by (mostly acquired) DNA mutations that affect fundamental cellular processes (eg, growth, DNA repair, survival).</th></thead><tr><td>HALLMARK</td><td>MECHANISM</td></tr><tr><td>Growth signal self-sufficiency</td><td>Mutations in genes encoding: * Proto-oncogenes + t growth factors + autocrine loop (eg, t PDGF in brain tumors) * Growth factor receptors + constitutive signaling (eg, HER2 in breast cancer) * Signaling molecules (eg, RAS) » ‘Transcription factors (eg, MYC) * Cell cycle regulators (eg, cyclins, CDKs)</td></tr><tr><td>Anti-growth signal insensitivity</td><td>* Mutations in tumor suppressor genes (eg, Rb) ® Loss of E-cadherin function &gt; loss of contact inhibition (eg, NF'2 mutations)</td></tr><tr><td>Evasion of apoptosis</td><td>Mutations in genes that regulate apoptosis (eg, TP53, BCL2 &gt; follicular B cell lymphoma).</td></tr><tr><td>Limitless replicative potential</td><td>Reactivation of telomerase + maintenance and lengthening of telomeres &gt; prevention of chromosome shortening and cell aging.</td></tr><tr><td>Sustained angiogenesis</td><td>t pro-angiogenic factors (eg, VEGF) or + inhibitory factors. Factors may be produced by tumor or stromal cells. Vessels can sprout from existing capillaries (neoangiogenesis) or endothelial cells are recruited from bone marrow (vasculogenesis). Vessels may be leaky and/or dilated.</td></tr><tr><td>Warburg effect</td><td>Shift of glucose metabolism away from mitochondrial oxidative phosphorylation toward glycolysis, even in the presence of oxygen. Aerobic glycolysis provides rapidly dividing cancer cells with the carbon needed for synthesis of cellular structures.</td></tr><tr><td>Immune evasion in cancer</td><td>Normally, immune cells can recognize and attack tumor cells. For successful tumorigenesis, tumor cells must evade the immune system. Multiple escape mechanisms exist: * 4 MHC class I expression by tumor cells + cytotoxic T cells are unable to recognize tumor cells. = Tumor cells secrete immunosuppressive factors (eg, T'GF-B) and recruit regulatory T cells to down regulate immune response. * Tumor cells up regulate immune checkpoint molecules, which inhibit immune response.</td></tr><tr><td>Tissue invasion</td><td>Loss of E-cadherin function &gt; loosening of intercellular junctions + metalloproteinases degrade basement membrane and ECM = cells attach to ECM proteins (eg, laminin, fibronectin) — cells migrate through degraded ECM (“locomotion”) &gt; vascular dissemination.</td></tr><tr><td>Metastasis</td><td>Tumor cells or emboli spread via lymphatics or blood adhesion to endothelium &gt; extravasation and homing. Site of metastasis can be predicted by site of 1° tumor, as the target organ is often the first-encountered capillary bed. Some cancers show organ tropism (eg, lung cancers commonly</td></tr></table>
======================================
<table><thead><th></th><th>MALES</th><th>FEMALES</th><th>CHILDREN (AGE 0-14)</th><th>NOTES</th></thead><tr><td rowspan="3">Cancer incidence</td><td>1. Prostate</td><td>1. Breast</td><td>1. Leukemia</td><td>Lung cancer incidence has $ in</td></tr><tr><td></td><td>2. Lung</td><td>2. Lung</td><td>2. CNS</td><td>males, but has not changed</td></tr><tr><td></td><td>3. Colon/rectum</td><td>3. Colon/rectum</td><td>3. Neuroblastoma</td><td>significantly in females.</td></tr><tr><td rowspan="3">Cancer mortality</td><td>1. Lung</td><td>1. Lung</td><td>1. Leukemia</td><td>Cancer is the 2nd leading cause</td></tr><tr><td></td><td>2. Prostate</td><td>2. Breast</td><td>2. CNS</td><td>of death in the United States</td></tr><tr><td></td><td>3. Colon/rectum</td><td>3. Colon/rectum</td><td>3. Neuroblastoma</td><td>(heart disease is Ist).</td></tr></table>
======================================
<table><thead><th></th><th colspan="2">renal cell carcinoma, and hepatocellular carcinoma. Metastasis to bone, liver, lung, and brain is more common than 1° malignancy in these organs. Metastases often appear as multiple lesions (vs 1° tumors which generally appear as solitary lesions).</th></thead><thead><th>SITE OF METASTASIS</th><th>1° TUMOR</th><th>NOTES</th></thead><tr><td>Bone</td><td>Prostate, breast &gt;&gt; lung &gt; kidney, colon</td><td>Predilection for axial skeleton Bone metastasis can be: * Blastic (eg, prostate, small cell lung cancer) = Mixed (eg, breast) ® Lytic (eg, kidney, colon, non-small cell lung</td></tr><tr><td></td><td></td><td>cancer)</td></tr><tr><td>Liver</td><td>Colon &gt; breast &gt;&gt; pancreas, lung, prostate</td><td>Scattered throughout liver parenchyma [i</td></tr><tr><td>Lung</td><td>Colon, breast &gt;&gt; kidney, prostate</td><td>Typically involve both lungs</td></tr><tr><td>Brain</td><td>Lung &gt; breast &gt;&gt; melanoma &gt; colon, prostate</td><td>Usually seen at gray/wvhite matter junction</td></tr></table>
======================================
<table><thead><th>GENE</th><th>GENE PRODUCT</th><th>ASSOCIATED NEOPLASM</th></thead><tr><td>ALK</td><td>Receptor tyrosine kinase</td><td>Lung adenocarcinoma</td></tr><tr><td>EGFR (ERBB1)</td><td>Receptor tyrosine kinase</td><td>Lung adenocarcinoma</td></tr><tr><td>HER2 (ERBB2)</td><td>Receptor tyrosine kinase</td><td>Breast and gastric carcinomas</td></tr><tr><td>RET</td><td>REceptor ‘Tyrosine kinase</td><td>MENZ2A and 2B, medullary and papillary thyroid carcinoma, pheochromocytoma</td></tr><tr><td>BCR-ABL</td><td>Non-receptor tyrosine kinase</td><td>CML, ALL</td></tr><tr><td>JAK2</td><td>Non-receptor tyrosine kinase</td><td>Myeloproliferative neoplasms</td></tr><tr><td>BRAF</td><td>Serine/threonine kinase</td><td>Melanoma, non-Hodgkin lymphoma, colorectal carcinoma, papillary thyroid carcinoma, hairy cell leukemia</td></tr><tr><td>cKIT</td><td>CytoKIne receptor (CD117)</td><td>Gastrointestinal stromal tumor (GIST), mastocytosis</td></tr><tr><td>MYCC (c-myc)</td><td>Transcription factor</td><td>Burkitt lymphoma</td></tr><tr><td>MYCN (N-myc)</td><td>Transcription factor</td><td>Neuroblastoma</td></tr><tr><td>KRAS</td><td>RAS GTPase</td><td>Colorectal, lung, pancreatic cancers</td></tr><tr><td>BCL-2</td><td>Antiapoptotic molecule (inhibits apoptosis)</td><td>Follicular and diffuse large B-Cell Lymphomas</td></tr></table>
======================================
<table><thead><th rowspan="2">Tumor suppressor genes GENE</th><th colspan="2">Loss of function + t cancer risk; both (two) alleles of a tumor suppressor gene must be lost for expression of disease (the Knudson 2-hit hypothesis).</th></thead><thead><th></th><th>GENE PRODUCT</th><th>ASSOCIATED CONDITION</th></thead><tr><td>APC</td><td>Negative regulator of B-catenin/WNT pathway</td><td>Colorectal cancer (associated with FAP)</td></tr><tr><td>BRCA1/BRCA2</td><td>BRCAI/BRCA2 proteins</td><td>BReast, ovarian, prostate, pancreatic CAncers</td></tr><tr><td>CDKN2A</td><td>pl6, blocks G, + S phase</td><td>Many cancers (eg, melanoma, lung, pancreatic)</td></tr><tr><td>DCC</td><td>DCC—Deleted in Colorectal Cancer</td><td>Colorectal cancer</td></tr><tr><td>SMAD4 (DPC4)</td><td>DPC — Deleted in Pancreatic Cancer</td><td>Pancreatic cancer, colorectal cancer</td></tr><tr><td>MEN1</td><td>MENin</td><td>Multiple Endocrine Neoplasia type 1</td></tr><tr><td>NF1</td><td>Neurofibromin (Ras GTPase activating protein)</td><td>| Neurol’ibromatosis type 1</td></tr><tr><td>NF2</td><td>Merlin (schwannomin) protein</td><td>NeuroFibromatosis type 2</td></tr><tr><td>PTEN</td><td>Negative regulator of PI3kK/AKT pathway</td><td>Prostate, breasT’, and ENdometrial cancers</td></tr><tr><td>RB1</td><td>Inhibits E2F; blocks G, + S phase</td><td>Retinoblastoma, osteosarcoma (Bone cancer)</td></tr><tr><td>TP53</td><td>p53, activates p21, blocks G; &gt; S phase</td><td>Most cancers, Li-Fraumeni (SBLA) syndrome (multiple malignancies at early age; Sarcoma, Breast/Brain, Lung/Leukemia, Adrenal gland)</td></tr><tr><td>TSC1</td><td>Hamartin protein</td><td>Tuberous sclerosis</td></tr><tr><td>TSC2</td><td>Tuberin (“2berin”)</td><td>Tuberous sclerosis</td></tr><tr><td>VHL</td><td>Inhibits hypoxia-inducible factor la</td><td>von Hippel-Lindau disease</td></tr><tr><td>WT1</td><td>Urogenital development transcription factor</td><td>Wilms Tumor (nephroblastoma)</td></tr></table>
======================================
<table><thead><th>TOXIN</th><th>EXPOSURE</th><th>ORGAN</th><th>IMPACT</th></thead><tr><td>Aflatoxins (Aspergillus)</td><td>Stored grains and nuts</td><td>Liver</td><td>Hepatocellular carcinoma</td></tr><tr><td>Alkylating agents</td><td>Oncologic chemotherapy</td><td>Blood</td><td>Leukemia/lymphoma</td></tr><tr><td>Aromatic amines (eg, benzidine, 2-naphthylamine)</td><td>Textile industry (dyes), tobacco smoke (2-naphthylamine)</td><td>Bladder</td><td>Transitional cell carcinoma</td></tr><tr><td>Arsenic</td><td>Herbicides (vineyard workers), metal smelting, wood preservation</td><td>Liver Lung Skin</td><td>Hepatic angiosarcoma Lung cancer Squamous cell carcinoma</td></tr><tr><td>Asbestos</td><td>Old roofing material, shipyard workers</td><td>— Lung</td><td>Bronchogenic carcinoma &gt; mesothelioma</td></tr><tr><td rowspan="2">Tobacco smoke</td><td rowspan="2"></td><td>Bladder Cervix Esophagus idney</td><td>Transitional cell carcinoma Squamous cell carcinoma Squamous cell carcinoma/ adenocarcinoma Renal cell carcinoma Squamous carcinoma</td></tr><tr><td></td><td></td><td>Larynx Lung Oropharynx ancreas</td><td>cell Squamous cell and small cell carcinoma Squamous cell carcinoma Pancreatic adenocarcinoma</td></tr><tr><td>Ethanol</td><td></td><td>Esophagus Liver Breast</td><td>Squamous cell carcinoma Hepatocellular carcinoma Breast cancer</td></tr><tr><td>lonizing radiation</td><td></td><td>Blood Thyroid</td><td>Leukemia Papillary thyroid carcinoma</td></tr><tr><td>Nickel, chromium, beryllium, silica</td><td>Occupational exposure</td><td>Lung</td><td>Lung cancer</td></tr><tr><td>Nitrosamines</td><td>Smoked foods</td><td>Stomach</td><td>Gastric cancer (intestinal type)</td></tr><tr><td>Radon</td><td>Byproduct of uranium decay, accumulates in basements</td><td>Lung</td><td>Lung cancer (2nd leading cause after tobacco smoke)</td></tr><tr><td>Vinyl chloride</td><td>Used to make PVC pipes</td><td>LiVer</td><td>Hepatic angiosarcoma</td></tr></table>
======================================
<table><thead><th>MICROBE</th><th>ASSOCIATED CANCER</th></thead><tr><td>EBV</td><td>Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma, 1° CNS lymphoma (in immunocompromised patients)</td></tr><tr><td>HBV, HCV</td><td>Hepatocellular carcinoma</td></tr><tr><td>HHV-8</td><td>Kaposi (“Kacesi”) sarcoma</td></tr><tr><td>HPV (usually types 16, 18)</td><td>Cervical and penile/anal carcinoma, head and neck cancer</td></tr><tr><td>H pylori</td><td>Gastric adenocarcinoma and MALT lymphoma</td></tr><tr><td>HTLV-1</td><td>Adult T-cell Leukemia/Lymphoma</td></tr><tr><td>Liver fluke (Clonorchis sinensis)</td><td>Cholangiocarcinoma</td></tr><tr><td>Schistosoma haematobium</td><td>Squamous cell bladder cancer</td></tr></table>
======================================
<table><thead><th rowspan="2">Serum tumor markers</th><th>Tumor markers should not be used as the 1° tool</th><th>for cancer diagnosis or screening. They may be</th></thead><thead><th></th><th>used to monitor tumor recurrence and response biopsy. Some can be associated with non-neoplastic</th><th>to therapy, but definitive diagnosis is made via conditions.</th></thead><tr><td>MARKER Alkaline</td><td>IMPORTANT ASSOCIATIONS Metastases bone disease of</td><td>NOTES Exclude LFTs and</td></tr><tr><td>phosphatase a-fetoprotein</td><td>to or liver, Paget bone, seminoma (PLAP). Hepatocellular carcinoma, endodermal sinus</td><td>hepatic origin by checking GGT levels. Normally made by fetus. Transiently elevated in</td></tr><tr><td>hcG</td><td>(yolk sac) tumor, mixed germ cell tumor, ataxia-telangiectasia, neural tube defects. Hydatidiform moles and Choriocarcinomas</td><td>pregnancy. High levels associated with neural tube and abdominal wall defects, low levels associated with Down syndrome. Produced by syncytiotrophoblasts of the</td></tr><tr><td></td><td>(Gestational trophoblastic disease), testicular cancer, mixed germ cell tumor.</td><td>placenta.</td></tr><tr><td>CA 15-3/CA 27-29</td><td>Breast cancer.</td><td></td></tr><tr><td>CA 19-9</td><td>Pancreatic adenocarcinoma.</td><td></td></tr><tr><td>CA 125 Calcitonin</td><td>Epithelial ovarian cancer. Medullary thyroid carcinoma (alone and in</td><td>Calci2nin.</td></tr><tr><td></td><td>MEN2A, MEN2B).</td><td></td></tr><tr><td>CEA</td><td>Colorectal and pancreatic cancers. Minor associations: gastric, breast, and medullary thyroid carcinomas.</td><td>CarcinoEmbryonic Antigen. Very nonspecific.</td></tr><tr><td>Chromogranin</td><td>Neuroendocrine tumors.</td><td></td></tr><tr><td>LDH</td><td>Testicular germ cell tumors, ovarian dysgerminoma, other cancers.</td><td>Can be used as an indicator of tumor burden.</td></tr><tr><td>Neuron-specific enolase</td><td>Neuroendocrine tumors (eg, small cell lung cancer, carcinoid tumor, neuroblastoma).</td><td></td></tr><tr><td>PSA</td><td>Prostate cancer.</td><td>Prostate-Specific Antigen. Also elevated in BPH and prostatitis. Questionable risk/benefit for</td></tr></table>
======================================
<table><tr><td rowspan="2">immunohistochemical stains STAIN</td><td colspan="2">classify. Can have prognostic and predictive value.</td></tr><tr><td></td><td>TARGET</td><td>TUMORS IDENTIFIED</td></tr><tr><td>Chromogranin and synaptophysin</td><td>Neuroendocrine cells</td><td>Small cell carcinoma of the lung, carcinoid tumor, neuroblastoma</td></tr><tr><td>Cytokeratin</td><td>Epithelial cells</td><td>Epithelial tumors (eg, squamous cell carcinoma)</td></tr><tr><td>Desmin</td><td>Muscle</td><td>Muscle tumors (eg, rhabdomyosarcoma)</td></tr><tr><td>GFAP</td><td>NeuroGlia (eg, astrocytes, Schwann cells, oligodendrocytes)</td><td>Astrocytoma, Glioblastoma</td></tr><tr><td>Neurofilament</td><td>Neurons</td><td>Neuronal tumors (eg, neuroblastoma)</td></tr><tr><td>PSA</td><td>Prostatic epithelium</td><td>Prostate cancer</td></tr><tr><td>PECAM-1/CD-31</td><td>Endothelial cells</td><td>Vascular tumors (eg, angiosarcoma)</td></tr><tr><td>S-100</td><td>Neural crest cells</td><td>Melanoma, schwannoma, Langerhans cell histiocytosis</td></tr><tr><td>TRAP</td><td>‘Tartrate-resistant acid phosphatase</td><td>Hairy cell leukemia</td></tr><tr><td>Vimentin</td><td>Mesenchymal tissue (eg, fibroblasts, endothelial cells, macrophages)</td><td>Mesenchymal tumors (eg, sarcoma), but also many other tumors (eg, endometrial carcinoma, renal cell carcinoma, meningioma)</td></tr><tr><td>P-glycoprotein</td><td>ATP-dependent efflux pump also called multidrug some cancer cells to pump out toxins, including of + responsiveness or resistance to chemotherapy</td><td>resistance protein 1 (MDRI1). Expressed in chemotherapeutic agents (one mechanism over time).</td></tr><tr><td>Cachexia</td><td colspan="2">Weight loss, muscle atrophy, and fatigue that occur in chronic disease (eg, cancer, AIDS, heart failure, COPD). Mediated by TNF-a, IF'N-y, IL-1, and IL-6.</td></tr></table>
======================================
<table><thead><th>MANIFESTATION</th><th>DESCRIPTION/MECHANISM</th><th>MOST COMMONLY ASSOCIATED TUMOR(S)</th></thead><tr><td colspan="3">Musculoskeletal and cutaneous</td></tr><tr><td>Dermatomyositis</td><td>Progressive proximal muscle weakness, Gottron papules, heliotrope rash</td><td>Adenocarcinomas, especially ovarian</td></tr><tr><td>Acanthosis nigricans</td><td>Hyperpigmented velvety plaques in axilla and neck</td><td>Gastric adenocarcinoma and other visceral malignancies</td></tr><tr><td>Sign of Leser-Trélat</td><td>Sudden onset of multiple seborrheic keratoses</td><td>GI adenocarcinomas and other visceral malignancies</td></tr><tr><td>Hypertrophic osteoarthropathy</td><td>Abnormal proliferation of skin and bone at distal extremities + clubbing, arthralgia, joint effusions, periostosis of tubular bones</td><td>Adenocarcinoma of the lung</td></tr><tr><td colspan="3">Endocrine</td></tr><tr><td rowspan="2">Hypercalcemia</td><td></td><td>PTHrP</td><td>SCa**mous cell carcinomas of lung, head, and neck; renal, bladder, breast, and ovarian carcinomas</td></tr><tr><td>t 1,25-(OH), vitamin D; (calcitriol)</td><td>Lymphoma</td></tr><tr><td>Cushing syndrome</td><td>t ACTH</td><td rowspan="2">Small cell lung cancer</td></tr><tr><td>Hyponatremia (SIADH)</td><td>t ADH</td><td></td></tr><tr><td>Polycythemia</td><td>t Erythropoietin Paraneoplastic rise to High hematocrit levels</td><td>Pheochromocytoma, renal cell carcinoma, HCC, hemangioblastoma, leiomyoma</td></tr><tr><td>Pure red cell aplasia</td><td>Anemia with low reticulocytes</td><td rowspan="2">Thymoma</td></tr><tr><td>Good syndrome</td><td>Hypogammaglobulinemia</td><td></td></tr><tr><td>Trousseau syndrome</td><td>Migratory superficial thrombophlebitis</td><td></td></tr><tr><td>Nonbacterial thrombotic endocarditis</td><td>Deposition of sterile platelet thrombi on heart valves</td><td>Adenocarcinomas, especially pancreatic</td></tr><tr><td colspan="3">Neuromuscular</td></tr><tr><td>Anti-NMDA receptor encephalitis</td><td>Psychiatric disturbance, memory deficits, seizures, dyskinesias, autonomic instability, language dysfunction</td><td>Ovarian teratoma</td></tr><tr><td>Opsoclonus- myoclonus ataxia syndrome</td><td>“Dancing eyes, dancing feet”</td><td>Neuroblastoma (children), small cell lung cancer (adults)</td></tr><tr><td>Paraneoplastic cerebellar degeneration</td><td>Antibodies against antigens in Purkinje cells</td><td>Small cell lung cancer (anti-Hu), gynecologic and breast cancers (anti-Yo), and Hodgkin lymphoma (anti-Ir)</td></tr><tr><td>Paraneoplastic encephalomyelitis</td><td>Antibodies against Hu antigens in neurons</td><td rowspan="2">Small cell lung cancer</td></tr><tr><td>Lambert-Eaton myasthenic syndrome</td><td>Antibodies against presynaptic (P/Q-type) Ca** channels at NMJ</td><td></td></tr></table>
======================================
<table><tr><td>Normal aging</td><td>Time-dependent progressive decline in organ function resulting in t susceptibility to disease. Associated with genetic (eg, telomere shortening), epigenetic (eg, DNA methylation), and metabolic (eg, mitochondrial dysfunction) alterations.</td></tr><tr><td>Cardiovascular</td><td>4 arterial compliance (t stiffness), t aortic diameter, 4 left ventricular cavity size and sigmoid- shaped interventricular septum (due to myocardial hypertrophy), t left atrial cavity size, aortic and mitral valve calcification, } maximum heart rate.</td></tr><tr><td>Gastrointestinal</td><td>+ LES tone, $ gastric mucosal protection, + colonic motility.</td></tr><tr><td>Hematopoietic</td><td>+ bone marrow mass, t bone marrow fat; less vigorous response to stressors (eg, blood loss).</td></tr><tr><td>Immune</td><td>Predominant effect on adaptive immunity: 4 naive B cells and T cells, preserved memory B cells and T' cells. Immunosenescence impairs response to new antigens (eg, pathogens, vaccines).</td></tr><tr><td>Musculoskeletal</td><td>+ skeletal muscle mass (sarcopenia), | bone mass (osteopenia), joint cartilage thinning.</td></tr><tr><td>Nervous</td><td>+ brain volume (neuronal loss), $ cerebral blood flow; function is preserved despite mild cognitive decline.</td></tr><tr><td>Special senses</td><td>Impaired accommodation (presbyopia), + hearing (presbycusis), } smell and taste.</td></tr><tr><td>Skin</td><td>Atrophy with flattening of dermal-epidermal junction; + dermal collagen and $ elastin (wrinkles, senile purpura), + sweat glands (heat stroke), 4 sebaceous glands (xerosis cutis). « Intrinsic aging (chronological aging)—+ biosynthetic capacity of dermal fibroblasts. * Extrinsic aging (photoaging)—degradation of dermal collagen and elastin from sun exposure (UVA); degradation products accumulate in dermis (solar elastosis).</td></tr><tr><td>Renal</td><td>+ GFR (4 nephrons), | RBF, 4 hormonal function. Voiding dysfunction (eg, urinary incontinence).</td></tr><tr><td>Reproductive</td><td>Males—testicular atrophy (+ spermatogenesis), prostate enlargement, slower erection/ejaculation, longer refractory period. Less pronounced 4 in libido as compared to females. Females—vulvovaginal atrophy; vaginal shortening, thinning, dryness, t pH.</td></tr><tr><td>Respiratory</td><td>t lung compliance (4 elastic recoil), 4 chest wall compliance (t stiffness), | respiratory muscle strength; | FEV), } FVC, t RV (TLC is unchanged); t A-a gradient, t V/Q mismatch.</td></tr></table>
======================================
<table><tr><td>Michaelis-Menten</td><td>K,, is inversely related to the affinity of the</td></tr><tr><td rowspan="8">kinetics</td><td>enzyme for its substrate.</td></tr><tr><td></td><td>Vinax is directly proportional to the enzyme</td></tr><tr><td></td><td>concentration.</td></tr><tr><td></td><td>Most enzymatic reac ions follow a hyperboli</td></tr><tr><td></td><td>curve (ie, Michaelis-Menten kinetics);</td></tr><tr><td></td><td>however, enzymatic reactions that exhibit a</td></tr><tr><td></td><td>sigmoid curve usua ly indicate cooperative</td></tr><tr><td></td><td>kinetics (eg, hemog obin).</td></tr></table>
======================================
<table><thead><th></th><th>inhibitors, reversible</th><th>inhibitors, irreversible</th><th>Noncompetitive inhibitors</th></thead><tr><td>Resemble substrate</td><td>Yes</td><td>Yes</td><td>No</td></tr><tr><td>Overcome by t [S]</td><td>Yes</td><td>No</td><td>No</td></tr><tr><td>Bind active site</td><td>Yes</td><td>Yes</td><td>No</td></tr><tr><td>Effect on Vinax</td><td>Unchanged</td><td>t</td><td>4</td></tr><tr><td>Effect on Km</td><td>t</td><td>Unchanged</td><td>Unchanged</td></tr><tr><td>Pharmacodynamics</td><td>+ potency</td><td>+ efficacy</td><td>+ efficacy</td></tr></table>
======================================
<table><thead><th colspan="3">~ plasma drug concentration</th></thead><thead><th></th><th>COMPARTMENT</th><th>DRUG TYPES</th></thead><tr><td>w</td><td>Intravascular</td><td>Large/charged molecules; plasma protein bo</td></tr><tr><td>dium</td><td>ECF</td><td>Small hydrophilic molecules</td></tr><tr><td>yh</td><td>All tissues including</td><td>Small lipophilic molecules, especially if bou</td></tr><tr><td></td><td>fat</td><td>to tissue protein</td></tr></table>
======================================
<table><thead><th></th><th>DEFINITION</th><th>EXAMPLE</th></thead><tr><td>Additive</td><td>Effect of substances A and B together is equal to he sum of their individual effects</td><td>Aspirin and acetaminophen 24+2=4</td></tr><tr><td>Permissive</td><td>Presence of substance A is required for the full effects of substance B</td><td>Cortisol on catecholamine responsiveness</td></tr><tr><td>Synergistic</td><td>Effect of substances A and B together is greater han the sum of their individual effects</td><td>Clopidogrel with aspirin “‘24+2&gt;4"</td></tr><tr><td>Potentiation</td><td>Si milar to synergism, but drug B with no herapeutic action enhances the therapeutic action of drug A</td><td>Carbidopa only blocks enzyme to prevent peripheral conversion of levodopa “24+0&gt;2”</td></tr><tr><td>Antagonistic</td><td>Effect of substances A and B together is less han the sum of their individual effects</td><td>Morphine with naloxone</td></tr><tr><td>Tachyphylactic</td><td>Acute decrease in response to a drug after initial/repeated administration</td><td>Repeat use of intranasal decongestant (eg, oxymetazoline) &gt; 4 therapeutic response (with rebound congestion)</td></tr></table>
======================================
<table><tr><td></td><td>Heart Kidney</td><td>contractility t renin secretion</td></tr><tr><td>Bo</td><td>Bronchioles</td><td>Bronchodilation</td></tr></table>
======================================
<table><tr><td colspan="3">Adrenergic</td></tr><tr><td>%</td><td>q</td><td>t vascular smooth muscle contraction, t pupillary dilator muscle contraction (mydriasis), t intestinal and bladder sphincter muscle contraction</td></tr><tr><td>Ol</td><td>i</td><td>+ sympathetic (adrenergic) outflow, 4 insulin release, $ lipolysis, t platelet aggregation, + aqueous humor production</td></tr><tr><td>Bi</td><td>s</td><td>t heart rate, t contractility (one heart), t renin release, t lipolysis</td></tr><tr><td>B.</td><td>s</td><td>Vasodilation, bronchodilation (two lungs), t lipolysis, t insulin release, t glycogenolysis, 4 uterine tone (tocolysis), t aqueous humor production, t cellular K* uptake</td></tr><tr><td>Bs</td><td>s</td><td>t lipolysis, t thermogenesis in skeletal muscle, t bladder relaxation</td></tr><tr><td colspan="3">Cholinergic</td></tr><tr><td>M,</td><td>q</td><td>Mediates higher cognitive functions, stimulates enteric nervous system</td></tr><tr><td>M,</td><td>i</td><td>+ heart rate and contractility of atria</td></tr><tr><td>M3</td><td>q</td><td>t exocrine gland secretions, gut peristalsis, bladder contraction, bronchoconstriction, vasodilation, t pupillary sphincter muscle contraction (miosis), ciliary muscle contraction (accommodation)</td></tr><tr><td colspan="3">Dopamine</td></tr><tr><td>D,</td><td>s</td><td>Relaxes renal vascular smooth muscle, activates direct pathway of striatum</td></tr><tr><td>D,</td><td>i</td><td>Modulates transmitter release, especially in brain, inhibits indirect pathway of striatum</td></tr><tr><td colspan="3">Histamine</td></tr><tr><td>H,</td><td>q</td><td>t bronchoconstriction, airway mucus production, t vascular permeability/vasodilation, pruritus</td></tr><tr><td>H,</td><td>s</td><td>t gastric acid secretion</td></tr><tr><td colspan="3">Vasopressin</td></tr><tr><td>vr</td><td>q</td><td>t vascular smooth muscle contraction</td></tr><tr><td>V2</td><td>s</td><td>t HO permeability and reabsorption via upregulating aquaporin-2 in collecting twobules (tubules) of kidney, t release of VWF</td></tr></table>
======================================
<table><thead><th>DRUG</th><th>ACTION</th><th>APPLICATIONS</th></thead><tr><td colspan="3">Direct agonists</td></tr><tr><td>Bethanechol</td><td>Activates bladder smooth muscle; resistant to AChE. Acts on muscarinic receptors; no nicotinic activity. “Bethany, call me to activate your bladder.”</td><td>Urinary retention.</td></tr><tr><td>Carbachol</td><td>Carbon copy of acetylcholine (but resistant to AChE).</td><td>Constricts pupil. Used for intraoperative miosis induction.</td></tr><tr><td>Methacholine</td><td>Stimulates muscarinic receptors in airway when inhaled.</td><td>Challenge test for diagnosis of asthma.</td></tr><tr><td>Pilocarpine</td><td>Contracts ciliary muscle of eye (open-angle glaucoma), pupillary sphincter (closed-angle glaucoma); resistant to AChE, can cross blood- brain barrier. “You cry, drool, and sweat on your ‘pilow.”</td><td>Potent stimulator of sweat, tears, and saliva Open-angle and closed-angle glaucoma, xerostomia (Sjégren syndrome).</td></tr><tr><td colspan="3">Indirect agonists (anticholinesterases)</td></tr><tr><td>Donepezil, rivastigmine, galantamine</td><td>t ACh.</td><td>Ist line for Alzheimer disease (Don Riva forgot the gala).</td></tr><tr><td>Neostigmine</td><td>t ACh. Neo CNS = no CNS penetration due to positive charge.</td><td>Postoperative and neurogenic ileus and urinary retention, myasthenia gravis, reversal of neuromuscular junction blockade (postoperative).</td></tr><tr><td>Pyridostigmine</td><td>t ACh; t muscle strength. Does not penetrate CNS. Pyridostigmine gets rid of myasthenia gravis.</td><td>Myasthenia gravis (long acting). Used with glycopyrrolate or hyoscyamine to control pyridostigmine adverse effects.</td></tr><tr><td>Physostigmine</td><td>t ACh. Phreely (freely) crosses blood-brain barrier as not charged + CNS.</td><td>Antidote for anticholinergic toxicity; physostigmine “phyxes” atropine overdose.</td></tr></table>
======================================
<table><thead><th></th><th>ORGAN SYSTEMS</th><th>APPLICATIONS</th></thead><tr><td>Atropine, homatropine, tropicamide</td><td>Eye</td><td>Produce mydriasis and cycloplegia</td></tr><tr><td>Benztropine, trihexyphenidyl</td><td>CNS</td><td>Parkinson disease (“park my Benz”) Acute dystonia</td></tr><tr><td>Glycopyrrolate</td><td>GI, respiratory</td><td>Parenteral: preoperative use to reduce airway secretions Oral: reduces drooling, peptic ulcer</td></tr><tr><td>Hyoscyamine, dicyclomine</td><td>Gl</td><td>Antispasmodics for irritable bowel syndrome</td></tr><tr><td>Ipratropium, tiotropium</td><td>Respiratory</td><td>COPD, asthma Duration: tiotropium &gt; ipratropium</td></tr><tr><td>Solifenacin, Oxybutynin, Flavoxate, Tolterodine</td><td>Genitourinary</td><td>Reduce bladder spasms and urge urinary incontinence (overactive bladder) Make bladder SOFT</td></tr><tr><td>Scopolamine</td><td>CNS</td><td>Motion sickness</td></tr></table>
======================================
<table><thead><th>ORGAN SYSTEM</th><th>ACTION</th><th>NOTES</th></thead><tr><td>Eye</td><td>t pupil dilation, cycloplegia</td><td rowspan="5">Blocks muscarinic effects (DUMBBELSS) of anticholinesterases, but not the nicotinic effects</td></tr><tr><td>Airway</td><td>Bronchodilation, + secretions</td><td></td></tr><tr><td>Stomach</td><td>+ acid secretion</td><td></td></tr><tr><td>Gut</td><td>+ motility</td><td></td></tr><tr><td>Bladder</td><td>+ urgency in cystitis</td><td></td></tr><tr><td rowspan="8">ADVERSE EFFECTS</td><td>t body temperature (due to } sweating); t HR;</td><td>Adverse effects:</td></tr><tr><td></td><td>dry mouth; dry, flushed skin; cycloplegia;</td><td>Hot as a hare</td></tr><tr><td></td><td>constipation; disorientation</td><td>Fast as a fiddle</td></tr><tr><td></td><td>Can cause acute angle-closure glaucoma</td><td>Dry as a bone</td></tr><tr><td></td><td>in older adults (due to mydriasis), urinary</td><td>Red as a beet</td></tr><tr><td></td><td>retention in men with prostatic hyperplasia,</td><td>Blind as a bat</td></tr><tr><td></td><td>and hyperthermia in infants</td><td>Mad as a hatter</td></tr><tr><td></td><td></td><td>Jimson weed (Datura) + gardener’s pupil (mydriasis)</td></tr></table>
======================================
<table><thead><th>DRUG</th><th>SITE</th><th>HEMODYNAMIC CHANGES</th><th>APPLICATIONS</th></thead><tr><td colspan="4">Direct sympathomimetics</td></tr><tr><td>Albuterol, salmeterol, terbutaline</td><td>8, &gt; By</td><td>t HR (little effect)</td><td>Albuterol for acute asthma/COPD. Salmeterol for serial (long-term) asthma/COPD. ‘Terbutaline for acute bronchospasm in asthma and tocolysis.</td></tr><tr><td>Dobutamine</td><td>B) &gt; Bo, a</td><td>-/1 BP, t HR, t CO</td><td>Cardiac stress testing, acute decompensated heart failure (HF) with cardiogenic shock (inotrope)</td></tr><tr><td>Dopamine</td><td>D, =D, &gt;B&gt;oa</td><td>t BP (high dose), t HR tCco</td><td>Unstable bradycardia, shock; inotropic and chronotropic effects at lower doses via B effects; vasoconstriction at high doses via o effects.</td></tr><tr><td>Epinephrine</td><td>B&gt;a</td><td>t BP (high dose), t HR tCco</td><td>Anaphylaxis, asthma, shock, open-angle glaucoma; o effects predominate at high doses. Stronger effect at B)-receptor than norepinephrine.</td></tr><tr><td>Fenoldopam</td><td>D,</td><td>+ BP (vasodilation), t HR, tCco</td><td>Postoperative hypertension, hypertensive crisis. Vasodilator (coronary, peripheral, renal, and splanchnic). Promotes natriuresis. Can cause headache.</td></tr><tr><td>Isoproterenol</td><td>B, = B</td><td>+ BP (vasodilation), t HR, tCco</td><td>hypotension, tachycardia, flushing, Electrophysiologic evaluation of tachyarrhythmias. Can worsen ischemia. Has negligible o effect.</td></tr><tr><td>Midodrine</td><td>[on</td><td>t w (vasoconstriction), + HR, -4 CO</td><td>Autonomic insufficiency and postural hypotension. May exacerbate supine hypertension.</td></tr><tr><td>Mirabegron</td><td>Bs</td><td></td><td>Urinary urgency or incontinence or overactive bladder. Think “mirab3gron.”</td></tr><tr><td>Norepinephrine</td><td>O &gt; O&amp; &gt; Bi</td><td>t BP, -/+ HR (may have minor reflexive change in response to t BP due to 0% agonism outweighing direct B, chronotropic effect), -/t CO</td><td>Hypotension, septic shock.</td></tr><tr><td>Phenylephrine</td><td>OQ &gt; Ob</td><td>t BP (vasoconstriction), + HR, -/4 CO</td><td>Hypotension (vasoconstrictor), ocular procedures (mydriatic), rhinitis (decongestant), ischemic priapism.</td></tr></table>
======================================
<table><thead><th>DRUG</th><th>APPLICATIONS</th><th>ADVERSE EFFECTS</th></thead><tr><td>Clonidine, guanfacine</td><td>— Hypertensive urgency (limited situations), ADHD, Tourette syndrome, symptom control in opioid withdrawal</td><td>CNS depression, bradycardia, hypotension, respiratory depression, miosis, rebound hypertension with abrupt cessation</td></tr><tr><td>a-methyldopa</td><td>Hypertension in pregnancy</td><td>Direct Coombs © hemolysis, drug-induced lupus, hyperprolactinemia</td></tr><tr><td>Tizanidine</td><td>Relief of spasticity</td><td>Hypotension, weakness, xerostomia</td></tr><tr><td colspan="3">a-blockers</td></tr><tr><td>DRUG</td><td>APPLICATIONS</td><td>ADVERSE EFFECTS</td></tr><tr><td colspan="3">Nonselective</td></tr><tr><td>Phenoxybenzamine</td><td>Irreversible. Pheochromocytoma (used preoperatively) to prevent catecholamine (hypertensive) crisis.</td><td rowspan="2">Orthostatic hypotension, reflex tachycardia.</td><td></td></tr><tr><td>Phentolamine</td><td>Reversible. Given to patients on MAO inhibitors who eat tyramine-containing foods and for severe cocaine-induced hypertension (2nd line). Also used to treat norepinephrine extravasation.</td></tr><tr><td colspan="3">Qt, selective (-osin ending)</td></tr><tr><td>Prazosin, terazosin, doxazosin, tamsulosin</td><td>Urinary symptoms of BPH; PTSD (prazosin); hypertension (except tamsulosin).</td><td>Ist-dose orthostatic hypotension, dizziness, headache.</td></tr><tr><td>Oz selective</td><td></td><td></td></tr></table>
======================================
<table><thead><th>APPLICATION</th><th>ACTIONS</th><th>NOTES/EXAMPLES</th></thead><tr><td>Angina pectoris</td><td>+ heart rate and contractility + +O; consumption</td><td></td></tr><tr><td>Glaucoma</td><td>+ production of aqueous humor</td><td>Timolol</td></tr><tr><td>Heart failure</td><td>Blockade of neurohormonal stress &gt; prevention of deleterious cardiac remodeling &gt; 4 mortality</td><td>Bisoprolol, carvedilol, metoprolol (B-blockers curb mortality)</td></tr><tr><td>Hypertension</td><td>+ cardiac output, + renin secretion (due to By- receptor blockade on JG cells)</td><td></td></tr><tr><td>Hyperthyroidism/ thyroid storm</td><td>Symptom control ($ heart rate, $ tremor)</td><td>Propranolol</td></tr><tr><td>Hypertrophic cardiomyopathy</td><td>+ heart rate + t filling time, relieving obstruction</td><td></td></tr><tr><td>Myocardial infarction</td><td>+O; demand (short-term), + mortality (long- term)</td><td></td></tr><tr><td>Supraventricular tachycardia</td><td>+ AV conduction velocity (class II antiarrhythmic)</td><td>Metoprolol, esmolol</td></tr><tr><td>Variceal bleeding</td><td>+ hepatic venous pressure gradient and portal hypertension (prophylactic use)</td><td>Nadolol, propranolol, carvedilol for no portal circulation</td></tr><tr><td>ADVERSE EFFECTS</td><td>Erectile dysfunction, cardiovascular (bradycardia, AV block, HF), CNS (seizures, sleep alterations), dyslipidemia (metoprolol), masked hypoglycemia, asthma/COPD exacerbations</td><td>Use of B-blockers for acute cocaine-associated chest pain remains controversial due to unsubstantiated concern for unopposed o-adrenergic stimulation</td></tr><tr><td rowspan="4">SELECTIVITY</td><td>Bj-selective antagonists (B; &gt; B,)—atenolol, betaxolol, bisoprolol, esmolol, metoprolol</td><td>Selective antagonists mostly go from A to M (B) with Ist half of alphabet)</td></tr><tr><td></td><td>B)—nadolol, Nonselective ant agonists (B) = propranolol, timolol</td><td>NonZelective antagonists mostly go from N to Z (Bp with 2nd half of alphabet)</td></tr><tr><td></td><td>Nonselective a and B-antagonists—carvedilol, labetalol</td><td>Nonselective o- and B-antagonists have modified suffixes (instead of “-olol”)</td></tr><tr><td></td><td>Nebivolol combines cardiac-selective Bi-adrenergic blockade with stimulation of B3-receptors (activate NO synthase in the</td><td>NebivOlol increases NO</td></tr></table>
======================================
<table><thead><th>TYPE OF INHIBITOR</th><th>MECHANISM OF ACTION</th><th>CLINICAL USES</th><th>ADVERSE EFFECTS</th></thead><tr><td>Nonspecific PDE inhibitor Theophylline</td><td>+ cAMP hydrolysis + t cAMP — bronchial smooth muscle relaxation &gt; bronchodilation</td><td>COPDaasthma (rarely used)</td><td>Cardiotoxicity (eg, tachycardia, arrhythmia), neurotoxicity (eg, seizures, headache), abdominal pain</td></tr><tr><td>PDE-5 inhibitors Sildenafil, vardenafil, tadalafil, avanafil</td><td>+ hydrolysis of cGMP &gt; t cGMP &gt; t smooth muscle relaxation by enhancing NO activity &gt; pulmonary vasodilation and t blood flow in corpus cavernosum fills the penis</td><td>Erectile dysfunction Pulmonary hypertension Benign prostatic hyperplasia (tadalafil only)</td><td>Facial flushing, headache, dyspepsia, hypotension in patients taking nitrates; “hot and sweaty,” then headache, heartburn, hypotension Sildenafil only: cyanopia (blue- tinted vision) via inhibition of PDE-6 (six) in retina</td></tr><tr><td>PDE-4 inhibitor Roflumilast</td><td>t cAMP in neutrophils, granulocytes, and bronchial epithelium</td><td>Severe COPD</td><td>Abdominal pain, weight loss, depression, anxiety, insomnia</td></tr><tr><td>PDE-3 inhibitor Milrinone</td><td>In cardiomyocytes: t cAMP &gt; t Ca”* influx &gt; t ionotropy and chronotropy In vascular smooth muscle: t cAMP &gt; MLCK inhibition &gt; vasodilation + 4 preload and afterload</td><td>Acute decompensated HF with cardiogenic shock (inotrope)</td><td>Tachycardia, ventricular arrhythmias, hypotension</td></tr><tr><td>“Platelet inhibitors” Cilostazol? Dipyridamole?</td><td>In platelets: t cAMP + inhibition of platelet aggregation</td><td>Intermittent claudication Stroke or TIA prevention (with aspirin) Cardiac stress testing (dipyridamole only, due to coronary vasodilation) Prevention of coronary stent restenosis</td><td>Nausea, headache, facial flushing, hypotension, abdominal pain</td></tr></table>
======================================
<table><thead><th>TOXIN</th><th>SOURCE</th><th>ACTION</th><th>SYMPTOMS</th><th>TREATMENT</th></thead><tr><td>Histamine (scombroid poisoning)</td><td>Spoiled dark-meat fish such as tuna, mahi-mahi, mackerel, and bonito</td><td>Bacterial histidine decarboxylase converts histidine to histamine Frequently misdiagnosed as fish allergy</td><td>Mimics anaphylaxis: oral burning sensation, facial flushing, erythema, urticaria, itching; may progress to bronchospasm, angioedema, hypotension</td><td>Antihistamines Albuterol +/— epinephrine</td></tr><tr><td>Tetrodotoxin</td><td>Pufferfish</td><td>Binds fast voltage-gated Na* channels in nerve tissue, preventing depolarization</td><td>— Nausea, diarrhea, paresthesias, weakness, dizziness, loss of reflexes</td><td>Supportive</td></tr><tr><td>Ciguatoxin</td><td>Reef fish such as barracuda, snapper, and moray eel</td><td>Opens Na* channels, causing depolarization</td><td>Nausea, vomiting, diarrhea; perioral numbness; reversal of hot and cold sensations; bradycardia,</td><td>Supportive</td></tr></table>
======================================
<table><thead><th>TOXIN</th><th>TREATMENT</th></thead><tr><td>Acetaminophen</td><td>N-acetylcysteine (replenishes glutathione)</td></tr><tr><td>AChE inhibitors, organophosphates</td><td>Atropine &gt; pralidoxime</td></tr><tr><td>Antimuscarinic, anticholinergic agents</td><td>Physostigmine (crosses BBB), control hyperthermia</td></tr><tr><td>Arsenic</td><td>Dimercaprol, succimer</td></tr><tr><td>Benzodiazepines</td><td>Flumazenil</td></tr><tr><td>B-blockers</td><td>Atropine, glucagon, saline</td></tr><tr><td>Carbon monoxide</td><td>100% Oz, hyperbaric Oz</td></tr><tr><td>Copper</td><td>“Penny’cillamine (penicillamine), trientine (3 copper pennies)</td></tr><tr><td>Cyanide</td><td>Hydroxocobalamin, nitrites + sodium thiosulfate</td></tr><tr><td>Dabigatran</td><td>Idarucizumab</td></tr><tr><td>Digoxin</td><td>Digoxin-specific antibody fragments</td></tr><tr><td>Direct factor Xa inhibitors (eg, apixaban)</td><td>Andexanet alfa</td></tr><tr><td>Heparin</td><td>Protamine sulfate</td></tr><tr><td>Iron (Fe)</td><td>Deferoxamine, deferasirox, deferiprone</td></tr><tr><td>Lead</td><td>Penicillamine, calcium disodium EDTA, Dimercaprol, Succimer, (correct lead poisoning in PEDS patients)</td></tr><tr><td>Mercury</td><td>Dimercaprol, succimer</td></tr><tr><td>Methanol, ethylene glycol (antifreeze)</td><td>Fomepizole &gt; ethanol, dialysis</td></tr><tr><td>Methemoglobin</td><td>Methylene blue, vitamin C (reducing agent)</td></tr><tr><td>Methotrexate</td><td>Leucovorin</td></tr><tr><td>Opioids</td><td>Naloxone</td></tr><tr><td>Salicylates</td><td>NaHCO; (alkalinize urine), dialysis</td></tr><tr><td>TCAs</td><td>NaHCO; (stabilizes cardiac cell membrane)</td></tr><tr><td>Warfarin</td><td>Vitamin K (delayed effect), PCC (prothrombin</td></tr></table>
======================================
<table><thead><th>DRUG REACTION</th><th>CAUSAL AGENTS</th></thead><tr><td>Coronary vasospasm</td><td>Cocaine, Amphetamines, Sumatriptan, Ergot alkaloids (CASE)</td></tr><tr><td rowspan="2">Cutaneous flushing</td><td>Vancomycin, Adenosine, Niacin, Ca”* channel blockers, Echinocandins, Nitrates (flushed from VANCEN [dancing])</td></tr><tr><td></td><td>Vancomycin infusion reaction (formerly called red man syndrome)—rate-dependent infusion reaction to vancomycin causing widespread pruritic erythema due to histamine release. Manage with diphenhydramine, slower infusion rate.</td></tr><tr><td>Dilated cardiomyopathy</td><td>Alcohol, anthracycline (eg, doxorubicin, daunorubicin; prevent with dexrazoxane), trastuzumab</td></tr><tr><td>Torsades de pointes</td><td>Agents that prolong OT interval: antiArrhythmics (class IA, III), antiBiotics (eg, macrolides, fluoroquinolones), anti“C”ychotics (eg, ziprasidone), antiDepressants (eg, TCAs), antiEmetics (eg ondansetron), antiFungals (eg, fluconazole) (ABCDEF)</td></tr></table>
======================================
<table><thead><th>DRUG REACTION</th><th>CAUSAL AGENTS</th><th>NOTES</th></thead><tr><td>Adrenocortical insufficiency</td><td>HPA suppression 2° to glucocorticoid withdrawal</td><td></td></tr><tr><td>Diabetes insipidus</td><td>Lithium, demeclocycline</td><td></td></tr><tr><td>Gynecomastia</td><td>Ketoconazole, cimetidine, spironolactone, GnRH analogs/antagonists, androgen receptor inhibitors, 5ot-reductase inhibitors</td><td></td></tr><tr><td>Hot flashes</td><td>SERMs (eg, tamoxifen, clomiphene, raloxifene)</td><td></td></tr><tr><td>Hyperglycemia</td><td>Tacrolimus, protease inhibitors, niacin, HCTZ, glucocorticoids</td><td>The people need High glucose</td></tr><tr><td>Hyperprolactinemia</td><td>Typical antipsychotics (eg, haloperidol), atypical antipsychotics (eg, risperidone), metoclopramide, methyldopa, verapamil</td><td>Presents with hypogonadism (eg, infertility, amenorrhea, erectile dysfunction) and galactorrhea</td></tr><tr><td>Hyperthyroidism</td><td>Amiodarone, iodine, lithium</td><td></td></tr><tr><td>Hypothyroidism</td><td>Amiodarone, lithium</td><td>Lam lethargic</td></tr><tr><td>SIADH</td><td>Carbamazepine, Cyclophosphamide, SSRIs</td><td>Can't Concentrate Serum Sodium</td></tr></table>
======================================
<table><thead><th>DRUG REACTION</th><th>CAUSAL AGENTS</th><th>NOTES</th></thead><tr><td>Acute cholestatic hepatitis, jaundice</td><td>Macrolides (eg, erythromycin)</td><td></td></tr><tr><td>Constipation</td><td>Antimuscarinics (eg, atropine), antipsychotics, opioids, non-dihydropyridine CCBs, ranolazine, amiodarone, aluminum hydroxide, loperamide, 5HT3 receptor antagonist (ondansetron), vincristine</td><td></td></tr><tr><td>Diarrhea</td><td>Acamprosate, antidiabetic agents (acarbose, metformin, pramlintide), colchicine, cholinesterase inhibitors, lipid-lowering agents (eg, ezetimibe, orlistat), macrolides (eg, erythromycin), SSRIs, chemotherapy (eg, irinotecan)</td><td></td></tr><tr><td>Focal to massive hepatic necrosis</td><td>Amanita phalloides (death cap mushroom), valproate, acetaminophen</td><td></td></tr><tr><td>Hepatitis</td><td>Rifampin, isoniazid, pyrazinamide, statins, fibrates</td><td></td></tr><tr><td>Pancreatitis</td><td>Diuretics (eg, furosemide, HCTZ), glucocorticoids, alcohol, valproate, azathioprine</td><td>Drugs generate a violent abdominal distress</td></tr><tr><td>Medication-induced esophagitis</td><td>Potassium chloride, NSAIDs, bisphosphonates, ferrous sulfate, tetracyclines Pills Not beneficial for food tube</td><td>Usually occurs at anatomic sites of esophageal narrowing (eg, near level of aortic arch); caustic effect minimized with upright posture and adequate water ingestion</td></tr><tr><td>Pseudomembranous colitis</td><td>Ampicillin, cephalosporins, clindamycin, fluoroquinolones, PPIs</td><td>Antibiotics predispose to superinfection by resistant C difficile</td></tr></table>
======================================
<table><thead><th>DRUG REACTION</th><th>CAUSAL AGENTS</th><th>NOTES</th></thead><tr><td>Agranulocytosis</td><td>Dapsone, clozapine, carbamazepine, propylthiouracil, methimazole, ganciclovir, colchicine</td><td>Drugs can cause pretty major granulocytes collapse</td></tr><tr><td>Aplastic anemia</td><td>Carbamazepine, methimazole, NSAIDs, benzene, chloramphenicol, propylthiouracil</td><td>Can't make New blood cells properly</td></tr><tr><td>Direct Coombs © hemolytic anemia</td><td>Penicillin, methylDopa, Cephalosporins</td><td>P Diddy Coombs</td></tr><tr><td>Drug Reaction with Eosinophilia and Systemic Symptoms</td><td>Phenytoin, carbamazepine, minocycline, sulfa drugs, allopurinol, vancomycin</td><td>DRESS is a delayed (type IV) hypersensitivity reaction DRESSes partially cover my skin and viscera</td></tr><tr><td>Gray baby syndrome</td><td>Chloramphenicol</td><td></td></tr><tr><td>Hemolysis in G6PD deficiency</td><td>Sulfonamides, dapsone, primaquine, aspirin, nitrofurantoin</td><td></td></tr><tr><td>Megaloblastic anemia</td><td>Hydroxyurea, Phenytoin, Methotrexate, Sulfa drugs</td><td>You're having a mega blast with PMS</td></tr><tr><td>Thrombocytopenia</td><td>Heparin, quinidine, ganciclovir, vancomycin, linezolid</td><td></td></tr><tr><td>Thrombotic complications</td><td>Combined oral contraceptives, hormone replacement therapy, SERMs, epoetin alfa</td><td>Estrogen-mediated adverse effect</td></tr></table>
======================================
<table><thead><th>Drug-induced lupus</th><th>Hydralazine, procainamide, quinidine</th><th></th></thead><tr><td>Fat redistribution</td><td>Protease inhibitors, glucocorticoids</td><td>Fat protects glutes</td></tr><tr><td>Gingival hyperplasia</td><td>Cyclosporine, Ca?* channel blockers, phenytoin</td><td>Can Cause puffy gums</td></tr><tr><td>Hyperuricemia (gout)</td><td>Pyrazinamide, thiazides, furosemide, niacin, cyclosporine</td><td>Painful tophi and feet need care</td></tr><tr><td>Myopathy</td><td>Statins, fibrates, niacin, colchicine, daptomycin, hydroxychloroquine, interferon-a, penicillamine, glucocorticoids</td><td></td></tr><tr><td>Osteoporosis</td><td>Glucocorticoids, depot medroxyprogesterone acetate, GnRH agonists, aromatase inhibitors,</td><td></td></tr><tr><td>Photosensitivity</td><td>anticonvulsants, heparin, PPIs Sulfonamides, amiodarone, tetracyclines, 5-FU</td><td>Sat For photo</td></tr><tr><td>Rash (Stevens-Johnson syndrome)</td><td>Anti-epileptic drugs (especially lamotrigine), allopurinol, sulfa drugs, penicillin</td><td>Steven Johnson has epileptic allergy to sulfa drugs and penicillin</td></tr><tr><td>Teeth discoloration</td><td>Tetracyclines</td><td>Teethracyclines</td></tr><tr><td>Tendon/cartilage damage</td><td>Fluoroquinolones</td><td></td></tr></table>
======================================
<table><thead><th>DRUG REACTION</th><th>CAUSAL AGENTS</th><th>NOTES</th></thead><tr><td>Cinchonism</td><td>Quinidine, quinine</td><td>Can present with tinnitus, hearing/vision loss, psychosis, and cognitive impairment</td></tr><tr><td>Parkinson-like syndrome</td><td>Antipsychotics, metoclopramide</td><td>Cogwheel rigidity of arm</td></tr><tr><td>Peripheral neuropathy</td><td>Platinum agents (eg, cisplatin), isoniazid, vincristine, paclitaxtel, phenytoin</td><td>Cis, it’s very painful peripherally</td></tr><tr><td>Idiopathic intracranial hypertension</td><td>Vitamin A, growth hormones, tetracyclines</td><td>Always grow head tension</td></tr><tr><td>Seizures</td><td>Isoniazid, bupropion, imipenem/cilastatin, tramadol</td><td>With seizures, I bit my tongue</td></tr><tr><td>Tardive dyskinesia</td><td>Antipsychotics, metoclopramide</td><td></td></tr><tr><td>Visual disturbances</td><td>Topiramate (blurred vision/diplopia, haloes), hydroxychloroquine ($ visual acuity, visual field defects), digoxin (yellow-tinged vision), isoniazid (optic neuritis), ivabradine (luminous phenomena), PDE-5 inhibitors (blue-tinged</td><td>These horrible drugs iirritate Precious eyes</td></tr></table>
======================================
<table><thead><th>DRUG REACTION</th><th>CAUSAL AGENTS.</th><th>NOTES</th></thead><tr><td>Fanconi syndrome</td><td>Cisplatin, ifosfamide, expired tetracyclines, tenofovir</td><td></td></tr><tr><td>Hemorrhagic cystitis</td><td>Cyclophosphamide, ifosfamide</td><td>Prevent by coadministering with mesna</td></tr><tr><td>Interstitial nephritis</td><td>Diuretics (Pee), NSAIDs (Pain-free), Penicillins and cephalosporins, PPIs, rifamPin, sulfa drugs</td><td>Remember the 5 P’s</td></tr></table>
======================================
<table><thead><th>DRUG REACTION</th><th>CAUSAL AGENTS</th><th>NOTES</th></thead><tr><td>Dry cough</td><td>ACE inhibitors</td><td></td></tr><tr><td>Pulmonary fibrosis</td><td>Methotrexate, nitrofurantoin, carmustine, bleomycin, busulfan, amiodarone</td><td>My nose cannot breathe bad air</td></tr></table>
======================================
<table><thead><th>DRUG REACTION</th><th>CAUSAL AGENTS</th><th>NOTES</th></thead><tr><td>Antimuscarinic</td><td>Atropine, TCAs, H)-blockers, antipsychotics</td><td></td></tr><tr><td>Disulfiram-like reaction</td><td>_ Ist-generation sulfonylureas, procarbazine, certain cephalosporins, griseofulvin, metronidazole</td><td>Sorry pals, can’t go mingle</td></tr><tr><td>Nephrotoxicity/ ototoxicity</td><td>Loop diuretics, cisplatin, aminoglycosides, amphotericin, vancomycin</td><td>Listen cis, always adjust vancomycin in CKD. Cisplatin toxicity may respond to amifostine</td></tr></table>
======================================
<table><tr><td rowspan="14">interactions (selected)</td><td>cy John’s wort</td><td rowspan="14">Anti-epileptics are anti-war</td><td>Sodium valproate</td></tr><tr><td></td><td>Phenytoin</td><td></td><td>Isoniazid</td></tr><tr><td></td><td>Phenobarbital</td><td></td><td>Cimetidine</td></tr><tr><td></td><td>Modafinil</td><td></td><td>Ketoconazole</td></tr><tr><td></td><td>Nevirapine</td><td></td><td>Fluconazole</td></tr><tr><td></td><td>Rifampin</td><td></td><td>Acute alcohol overuse</td></tr><tr><td></td><td>Griseofulvin</td><td></td><td>Chloramphenicol</td></tr><tr><td></td><td>Carbamazepine Chronic alcohol overuse</td><td></td><td>Erythromycin/clarithromycin Sulfonamides</td></tr><tr><td></td><td></td><td></td><td>Ciprofloxacin</td></tr><tr><td></td><td></td><td></td><td>Omeprazole</td></tr><tr><td></td><td></td><td></td><td>Amiodarone</td></tr><tr><td></td><td></td><td></td><td>Ritonavir</td></tr><tr><td></td><td></td><td></td><td>Grapefruit juice</td></tr><tr><td></td><td>St. John’s funny funny (phen- phen) mom never refuses greasy carbs and chronic alcohol</td><td></td><td>am really drinking grapefruit juice</td></tr><tr><td>Sulfa drugs</td><td>Sulfonamide antibiotics, Sulfasalazine, Probenecid, Furosemide, Acetazolamide, Celecoxib, Thiazides, Sulfonylureas. Patients with su fever, urinary Johnson syndr thrombocytop' fa allergies may ract infection, Stevens- ome, hemolytic anemia, enia, agranulocytosis, interstitial nephritis, and urticaria photosensitivi y.</td><td>Scary Sulfa</td><td>Pharm FACTS</td></tr></table>
======================================
<table><thead><th>ENDING</th><th>CATEGORY</th><th>EXAMPLE</th></thead><tr><td colspan="3">Antimicrobial</td></tr><tr><td>-asvir</td><td>NSSA inhibitor</td><td>Ledipasvir</td></tr><tr><td>-bendazole</td><td>Antiparasitic/antihelminthic</td><td>Mebendazole</td></tr><tr><td>-buvir</td><td>NS5B inhibitor</td><td>Sofosbuvir</td></tr><tr><td>-cillin</td><td>Transpeptidase inhibitor</td><td>Ampicillin</td></tr><tr><td>-conazole</td><td>Ergosterol synthesis inhibitor</td><td>Ketoconazole</td></tr><tr><td>-cycline</td><td>Protein synthesis inhibitor</td><td>Tetracycline</td></tr><tr><td>-floxacin</td><td>Fluoroquinolone</td><td>Ciprofloxacin</td></tr><tr><td>-mivir</td><td>Neuraminidase inhibitor</td><td>Oseltamivir</td></tr><tr><td>-navir</td><td>Protease inhibitor</td><td>Ritonavir</td></tr><tr><td>-ovir</td><td>Viral DNA polymerase inhibitor</td><td>Acyclovir</td></tr><tr><td>-previr</td><td>NS3/4A inhibitor</td><td>Grazoprevir</td></tr><tr><td>-tegravir</td><td>Integrase inhibitor</td><td>Dolutegravir</td></tr><tr><td>-thromycin</td><td>Macrolide</td><td>Azithromycin</td></tr><tr><td colspan="3">Antineoplastic</td></tr><tr><td>-case</td><td>Recombinant uricase</td><td>Rasburicase</td></tr><tr><td>-mustine</td><td>Nitrosourea</td><td>Carmustine</td></tr><tr><td>-platin</td><td>Platinum compound</td><td>Cisplatin</td></tr><tr><td>-poside</td><td>Topoisomerase II inhibitor</td><td>Etoposide</td></tr><tr><td>-rubicin</td><td>Anthracycline</td><td>Doxorubicin</td></tr><tr><td>-taxel</td><td>‘Taxane</td><td>Paclitaxel</td></tr><tr><td>-tecan</td><td>Topoisomerase | inhibitor</td><td>Irinotecan</td></tr><tr><td colspan="3">CNS</td></tr><tr><td>-flurane</td><td>Inhaled anesthetic</td><td>Sevoflurane</td></tr><tr><td>-apine, -idone</td><td>Atypical antipsychotic</td><td>Quetiapine, risperidone</td></tr><tr><td>-azine</td><td>Typical antipsychotic</td><td>Thioridazine</td></tr><tr><td>-barbital</td><td>Barbiturate</td><td>Phenobarbital</td></tr><tr><td>-benazine</td><td>VMAT inhibitor</td><td>Tetrabenazine</td></tr><tr><td>-caine</td><td>Local anesthetic</td><td>Lidocaine</td></tr><tr><td>-capone</td><td>COMT inhibitor</td><td>Entacapone</td></tr><tr><td>-curium, -curonium</td><td>Nondepolarizing neuromuscular blocker</td><td>Atracurium, pancuronium</td></tr><tr><td>-giline</td><td>MAO-B inhibitor</td><td>Selegiline</td></tr><tr><td>-ipramine, -triptyline</td><td>TCA</td><td>Imipramine, amitriptyline</td></tr><tr><td>-triptan</td><td>5-HT pnp agonist</td><td>Sumatriptan</td></tr><tr><td>-zepam, -zolam</td><td>Benzodiazepine</td><td>Diazepam, alprazolam</td></tr></table>
======================================
<table><thead><th>ENDING</th><th>CATEGORY</th><th>EXAMPLE</th></thead><tr><td colspan="3">Autonomic</td></tr><tr><td>-chol</td><td>Cholinergic agonist</td><td>Bethanechol</td></tr><tr><td>-olol</td><td>B-blocker</td><td>Propranolol</td></tr><tr><td>-stigmine</td><td>AChE inhibitor</td><td>Neostigmine</td></tr><tr><td>-terol</td><td>Bo-agonist</td><td>Albuterol</td></tr><tr><td>-zosin</td><td>on-blocker</td><td>Prazosin</td></tr><tr><td colspan="3">Cardiovascular</td></tr><tr><td>-afil</td><td>PDE-5 inhibitor</td><td>Sildenafil</td></tr><tr><td>-dipine</td><td>Dihydropyridine Ca’* channel blocker</td><td>Amlodipine</td></tr><tr><td>-parin</td><td>Low-molecular-weight heparin</td><td>Enoxaparin</td></tr><tr><td>-plase</td><td>Thrombolytic</td><td>Alteplase</td></tr><tr><td>-pril</td><td>ACE inhibitor</td><td>Captopril</td></tr><tr><td>-sartan</td><td>Angiotensin-II receptor blocker</td><td>Losartan</td></tr><tr><td>-xaban</td><td>Direct factor Xa inhibitor</td><td>Apixaban</td></tr><tr><td>Metabolic</td><td></td><td></td></tr><tr><td>-gliflozin</td><td>SGLT-2 inhibitor</td><td>Dapagliflozin</td></tr><tr><td>-glinide</td><td>Meglitinide</td><td>Repaglinide</td></tr><tr><td>-gliptin</td><td>DPP-4 inhibitor</td><td>Sitagliptin</td></tr><tr><td>-glitazone</td><td>PPAR-Y activator</td><td>Pioglitazone</td></tr><tr><td>-glutide</td><td>GLP-1 analog</td><td>Liraglutide</td></tr><tr><td>-statin</td><td>HMG-CoA reductase inhibitor</td><td>Lovastatin</td></tr><tr><td colspan="3">Other</td></tr><tr><td>-caftor</td><td>CFTR modulator</td><td>Lumacaftor</td></tr><tr><td>-dronate</td><td>Bisphosphonate</td><td>Alendronate</td></tr><tr><td>-lukast</td><td>CysLT1 receptor blocker</td><td>Montelukast</td></tr><tr><td>-lutamide</td><td>Androgen receptor inhibitor</td><td>Flutamide</td></tr><tr><td>-pitant</td><td>Nk, blocker</td><td>Aprepitant</td></tr><tr><td>-prazole</td><td>Proton pump inhibitor</td><td>Omeprazole</td></tr><tr><td>-prost</td><td>Prostaglandin analog</td><td>Latanoprost</td></tr><tr><td>-sentan</td><td>Endothelin receptor antagonist</td><td>Bosentan</td></tr><tr><td>-setron</td><td>5-HT; blocker</td><td>Ondansetron</td></tr><tr><td>-steride</td><td>5a-reductase inhibitor</td><td>Finasteride</td></tr><tr><td>-tadine</td><td>H)-antagonist</td><td>Loratadine</td></tr><tr><td>-tidine</td><td>H-antagonist</td><td>Cimetidine</td></tr><tr><td>-trozole</td><td>Aromatase inhibitor</td><td>Anastrozole</td></tr><tr><td>-vaptan</td><td>ADH antagonist</td><td>Tolvaptan</td></tr></table>
======================================
<table><thead><th>ENDING</th><th>CATEGORY</th><th>EXAMPLE</th></thead><tr><td colspan="3">Monoclonal antibodies (-mab)—target overexpressed cell surface receptors</td></tr><tr><td>-ximab</td><td>Chimeric human-mouse monoclonal antibody</td><td>—_ Rituximab</td></tr><tr><td>-zumab</td><td>Humanized monoclonal antibody</td><td>Bevacizumab</td></tr><tr><td>-umab</td><td>Human monoclonal antibody</td><td>Denosumab</td></tr><tr><td colspan="3">Small molecule inhibitors (-ib)—target intracellular molecules</td></tr><tr><td>-ciclib</td><td>Cyclin-dependent kinase inhibitor</td><td>Palbociclib</td></tr><tr><td>-coxib</td><td>COX-2 inhibitor</td><td>Celecoxib</td></tr><tr><td>-parib</td><td>Poly(ADP-ribose) polymerase inhibitor</td><td>Olaparib</td></tr><tr><td>-rafenib</td><td>BRAF inhibitor</td><td>Vemurafenib</td></tr><tr><td>-tinib</td><td>‘Tyrosine kinase inhibitor</td><td>Imatinib</td></tr><tr><td>-zomib</td><td>Proteasome inhibitor</td><td>Bortezomib</td></tr><tr><td colspan="3">Interleukin receptor modulators (-kin)—agonists and antagonists of interleukin receptors</td></tr><tr><td>-leukin</td><td>Interleukin-2 agonist/analog</td><td>Aldesleukin</td></tr><tr><td>-kinra</td><td>Interleukin receptor antagonist</td><td>Anakinra</td></tr></table>
======================================
<table><thead><th>STUDY TYPE</th><th colspan="4">DESIGN</th><th colspan="4">MEASURES/EXAMPLE</th></thead><tr><td>Case series</td><td colspan="4">Describes several individual patients with the same diagnosis, treatment, or outcome.</td><td colspan="4">Description of clinical findings and symptoms. Has no comparison group, thus cannot show risk factor association with disease.</td></tr><tr><td>Cross-sectional study</td><td colspan="4">Frequency of disease and frequency of risk- related factors are assessed in the present. Asks, “What is happening?”</td><td colspan="4">Disease prevalence. Can show risk factor association with disease, but does not establish causality.</td></tr><tr><td>Case-control study</td><td colspan="3">Retrospectively compares a group of people disease to a group without disease. Looks to see if odds of prior exposure or factor differ by disease state. Asks, “What happened?”</td><td>with risk</td><td colspan="4">Odds ratio (OR). Control the case in the OR. Patients with COPD had higher odds of a smoking history than those without COPD.</td></tr><tr><td>Cohort study</td><td colspan="4">Compares a group with a given exposure or risk factor to a group without such exposure. Looks to see if exposure or risk factor is associated with later development of disease. Can be prospective or retrospective, but risk factor has to be present prior to disease development.</td><td colspan="4">Disease incidence. Relative risk (RR). People who smoke had a higher risk of developing COPD than people who do not. Cohort = relative risk.</td></tr><tr><td>Twin concordance study</td><td colspan="4" rowspan="2">Compares the frequency with which both monozygotic twins vs both dizygotic twins develop the same disease. Compares behavioral traits/genetics in siblings raised by biological vs adoptive parents.</td><td colspan="4">Measures heritability and influence of environmental factors (“nature vs nurture”).</td></tr><tr><td>Adoption study</td><td colspan="4"></td><td colspan="4">Measures heritability and influence of environmental factors.</td></tr><tr><td rowspan="6">Ecological study</td><td colspan="4" rowspan="2">Compares frequency of disease and frequency of risk-related factors across populations. Measures population data not necessarily applicable to individuals (ecological fallacy). Cross-sectional study Case-control study</td><td colspan="4"></td><td colspan="3">Used to monitor population health. COPD prevalence was higher in more cities.</td><td colspan="4" rowspan="2">polluted Retrospective cohort study Prospective cohort study</td><td colspan="4"></td></tr><tr><td></td></tr><tr><td></td><td>s &amp;</td><td></td><td>Compare risk frequency</td><td>factor</td><td colspan="2">Risk factor)” Risk factor)!</td><td></td><td></td></tr><tr><td></td><td colspan="4" rowspan="2">= Riskfactor © Risk actor 5 I I</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="4"></td><td colspan="2">|</td><td></td><td></td></tr><tr><td></td><td colspan="4">3 ° Cae |</td><td colspan="2">=</td><td>BRIER)</td><td>RskaaGRS)</td></tr></table>
======================================
<table><thead><th></th><th>between presumed cause and effect.</th></thead><tr><td>Strength</td><td>Association does not necessarily imply causation, but the stronger the association, the more evidence for causation.</td></tr><tr><td>Consistency</td><td>Repeated observations of the findings in multiple distinct samples. The the the the the evidence for</td></tr><tr><td>Specificity</td><td>more specific presumed cause is to effect, stronger causation.</td></tr><tr><td>Temporality</td><td>The presumed cause precedes the effect by an expected amount of time.</td></tr><tr><td>Biological gradient</td><td>Greater effect observed with greater exposure to the presumed cause (dose-response relationship).</td></tr><tr><td>Plausibility</td><td>A conceivable mechanism exists by which the cause may lead to the effect.</td></tr><tr><td>Coherence</td><td>The presumed cause and effect do not conflict with existing scientific consensus.</td></tr><tr><td>Experiment</td><td>Empirical evidence supporting the presumed cause and effect (eg, animal studies, in vitro studies).</td></tr></table>
======================================
<table><thead><th></th><th>outcome iS)</th></thead><tr><td>uonuansayut aunsodx3</td><td>b</td></tr><tr><td>® oO</td><td>d</td></tr></table>
======================================
<table><thead><th>TERM Odds ratio</th><th>DEFINITION ‘Typically used in case-control</th><th>EXAMPLE If in case-control study, 20/30</th><th colspan="3">FORMULA _ad</th></thead><tr><td rowspan="5"></td><td>studies. Represents the odds of exposure among cases (a/c) vs odds</td><td>a patients with lung cancer and 5/25 healthy individuals report smoking, the OR is</td><td>OR</td><td>_alce “bid be</td><td></td></tr><tr><td></td><td>of exposure among controls (b/d).</td><td>8; so the patients with lung cancer are</td><td></td><td></td><td></td></tr><tr><td></td><td>OR = 1 &gt; odds of ex osure are</td><td>8 times more likely to have a history of</td><td></td><td></td><td></td></tr><tr><td></td><td>equal in cases and controls. OR &gt; 1 &gt; odds of ex osure are</td><td>smoking. You take a case to the OR.</td><td></td><td></td><td></td></tr><tr><td></td><td>OR &lt; 1 odds of ex greater in controls. osure are</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="2">Relative risk</td><td rowspan="2">‘Typically used in cohort studies. Risk of developing disease in the exposed group divided by risk in the unexposed group. RR = 1 &gt; no association between</td><td>If 5/10 people exposed to radiation are diagnosed with cancer, and 1/10 people</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>not exposed to radiation are diagnosed with cancer, the RR is 5; so people exposed to radiation have a 5 times</td><td></td><td></td><td></td></tr><tr><td>Relative risk reduction</td><td>The proportion of risk reduction attributable to the intervention (ARI) as compared to a control (ARC).</td><td>f 2% of patients who receive a flu shot develop the flu, while 8% of unvaccinated patients develop the flu, then RR = 2/8 = 0.25, and RRR = 0.75.</td><td>_ RRR=</td><td>(ARC</td><td>- ART) ARC</td></tr><tr><td>Attributable risk</td><td>(he difference in risk between exposed and unexposed groups.</td><td>f risk of lung cancer in people who smoke is 21% and risk in people who don’t smoke is 1%, then the attributable risk is 20%.</td><td>AR= AR% =</td><td>a a+b RR-1 Re</td><td>c c+d * 100</td></tr><tr><td>Absolute risk reduction</td><td>[he difference in risk (not the proportion) attributable to the intervention as compared to a control.</td><td>f 8% of people who receive a placebo vaccine develop the flu vs 2% of people who receive a flu vaccine, then ARR = 8% 2% = 6% = 0.06.</td><td>ARR =</td><td>c ct+d</td><td>a a+b</td></tr><tr><td>Number needed to treat</td><td>Number of patients who need to be treated for | patient to benefit. Lower number = better treatment.</td><td></td><td colspan="3">NNT = I/ARR</td></tr><tr><td>Number needed to harm</td><td>Number of patients who need to be exposed to a risk factor for 1 patient to be harmed. Higher number = safer exposure.</td><td></td><td colspan="3">NNH = 1/AR</td></tr><tr><td>Case fatality rate</td><td>Percentage of deaths occurring among those with disease.</td><td>If 4 patients die among 10 cases of meningitis, case fatality rate is 40%.</td><td colspan="3">CFR% = deaths x 100 cases</td></tr></table>
======================================
<table><thead><th>TERM</th><th>DEFINITION</th><th>EXAMPLE</th><th>FORMULA</th></thead><tr><td>Attackrate</td><td>Proportion of exposed people who become ill.</td><td>_If 80 people in a town are exposed and 60 people become ill, attack rate is 75%.</td><td>People who become ill Total people exposed</td></tr></table>
======================================
<table><tr><td>+</td><td>probability of positive result in</td><td>sensitivity _</td><td>TP rate</td></tr><tr><td></td><td>___ probability of negative result in ~ probability of negative result in</td><td>1 =sensitivity _ specificity</td><td>FN rate TN rate</td></tr></table>
======================================
<table><thead><th>diagnostic</th><th rowspan="3">a vary depending disease prevalence in population being tested. Test efficiency = (TP + TN)(TP + FN + FP + TN)</th><th rowspan="3">a © © O|</th><th>rP</th><th>PPV =TP/(TP + FP)</th><th></th></thead><tr><td></td><td></td><td></td><td>IN</td><td>NPV =TN/(TN +FN)</td><td></td></tr><tr><td></td><td></td><td></td><td>Sensitivity | Specificity =TPA(TP +N) | =TN/(TN</td><td>Prevalence FP) | (P+ EN FP + TN)</td><td>oy</td></tr><tr><td>Sensitivity (true- positive rate)</td><td>Proportion of all people with disease who test positive, or the ability of a test to correctly identify those with the disease. Value approaching 100% is desirable for ruling out disease and indicates low false-negative</td><td>= TP/(TP + = 1-FN rate SN-N-OUT Negative, High sensitivity</td><td>FN) highly SeNsitive rules OUT disease test used</td><td>test, when screening</td><td></td></tr><tr><td>Specificity (true- negative rate)</td><td>rate. Proportion of all people without disease who test negative, or the ability of a test to correctly identify those without the disease. Value approaching 100% is desirable for ruling in disease and indicates a low</td><td>= TN/(TN = 1-FP rate SP-P-IN = tules IN</td><td>FP) highly SPecific disease test used</td><td>test, when confirmation</td><td>Positive, after a</td></tr><tr><td></td><td>false-positive rate.</td><td>High specificity positive</td><td>screening test</td><td></td><td></td></tr><tr><td>Positive predictive value</td><td>Probability that a person who has a positive test result actually has the disease.</td><td>PPV = TP/(TP PPV varies (baseline risk, high pretest</td><td>+ FP) directly with such as probability</td><td>pretest probability prevalence of disease): high PPV</td><td></td></tr><tr><td rowspan="4">Negative predictive value</td><td></td><td>Probability that a person with a negative test result actually does not have the disease.</td><td colspan="4">NPV =TN/(TN + FN) NPV varies inversely with prevalence or pretest probability</td></tr><tr><td rowspan="2">Disease Disease absent ‘N a present TN TP Number of people FN FP en Bene</td><td colspan="4">Possible cutoff values for @) vs © test result 100% sensitivity cutoff value practical compromise between specificity and sensitivity 100% specificity cutoff value</td></tr><tr><td></td><td></td><td>Lowering the B-&gt;A(TFP</td><td>cutoff value: 1 FN) J</td><td>Sensitivity T NPV Specificity | PPV</td><td></td></tr><tr><td></td><td>| B Test results | A TP</td><td>Raising the cutoff B—&gt;C(TEN</td><td>value: * FP) J</td><td>Specificity T PPV Sensitivity | NPV</td><td></td></tr></table>
======================================
<table><thead><th>survival time</th><th>_—</th><th>t</th></thead><tr><td>mortality</td><td>_</td><td>+</td></tr><tr><td>Faster recovery time</td><td>_—</td><td>M</td></tr><tr><td>Extensive vaccine administration</td><td>4</td><td>t</td></tr><tr><td>risk factors</td><td>4</td><td>t</td></tr><tr><td>diagnostic sensitivity</td><td>t</td><td>t</td></tr><tr><td>New effective treatment started</td><td>_</td><td>t</td></tr><tr><td>contact between infected and noninfected patients with airborne</td><td>1</td><td>t</td></tr><tr><td>infectious disease</td><td></td><td></td></tr></table>
======================================
<table><thead><th>TYPE</th><th>DEFINITION</th><th>EXAMPLES</th><th>STRATEGIES TO REDUCE BIAS</th></thead><tr><td colspan="4">Recruiting participants</td></tr><tr><td>Selection bias</td><td>Nonrandom sampling or treatment allocation of subjects such that study population is not representative of target population Most commonly a sampling bias Convenience sampling— patients are enrolled on basis of ease of contact</td><td>Berkson bias—cases and/ or controls selected from hospitals (bedside bias) are less healthy and have different exposures Attrition bias—participants lost to follow up have a different prognosis than those who complete the study</td><td>Randomization (creates groups with similar distributions of known and unknown variables) Ensure the choice of the right comparison/reference group</td></tr><tr><td colspan="4">Performing study</td></tr><tr><td>Recall bias</td><td>Awareness of disorder alters recall by subjects; common in retrospective studies</td><td>Patients with disease recall exposure after learning of similar cases</td><td>Decrease time from exposure to follow-up; use medical records as sources</td></tr><tr><td>Measurement bias</td><td>Information is gathered in a systemically distorted manner</td><td>Jsing a faulty automatic a phygmomanometer Hawthorne effect—participants change behavior upon awareness of being observed</td><td>Use objective, standardized, and previously tested methods of data collection that are planned ahead of time Use placebo group</td></tr><tr><td>Procedure bias</td><td>Subjects in different groups are not treated the same</td><td>p. rs) ients in treatment group a pend more time in highly pecialized hospital units a</td><td>Blinding (masking) and use of placebo reduce influence of participants and</td></tr><tr><td>Observer-expectancy bias</td><td>Researcher’s belief in the efficacy of a treatment changes the outcome of that treatment (also called Pygmalion effect)</td><td>An observer expecting treatment group to show signs of recovery is more likely to document positive outcomes</td><td>researchers on procedures and interpretation of outcomes as neither are aware of group assignments</td></tr><tr><td colspan="4">Interpreting results</td></tr><tr><td>Lead-time bias</td><td>Early detection interpreted as t survival, but the disease course has not changed</td><td>Breast cancer diagnosed ear! &lt; by mammography may appear to exaggerate survival time because patients are known to have the cancer for longer</td><td>Measure “back-end” survival (adjust survival according to the severity of disease at the time of diagnosis)</td></tr><tr><td>Length-time bias</td><td>Screening test detects diseases with long latency period, while those with shorter latency period become symptomatic earlier</td><td>A slowly progressive cancer is more likely detected by a screening test than a rapidly progressive cancer</td><td>A randomized controlled trial assigning subjects to the screening program or to no screening</td></tr></table>
======================================
<table><tr><td colspan="2">Stratified analysis</td></tr><tr><td></td><td>&gt; Lung cancer</td></tr><tr><td></td><td>-&gt; Lung cancer</td></tr></table>
======================================
<table><tr><td colspan="3">stratified analysis OCP use</td></tr><tr><td>Smokers. ©</td><td>——-—————&gt;</td><td>DVT</td></tr><tr><td>Nonsmokers ~ocPuse</td><td>---- ---&gt;</td><td>DVT</td></tr></table>
======================================
<table><thead><th rowspan="2">tendency</th><th rowspan="2">Median = middle value of a list of data sorted from least to greatest. Mode = most common value.</th><th>If there is an even will be the average of</th><th>number of values, the median the middle two values.</th></thead><thead><th></th><th></th><th>Least affected by outliers.</th><th></th></thead><tr><td>Measures of dispersion</td><td>Standard deviation = how much variability exists in a set of values, around the mean of these values. Standard error = an estimate of how much variability exists in a (theoretical) set of sample means around the true population mean.</td><td>6 = SD; n = sample size. Variance = (SD). SE = on. SE ¢asn t.</td><td></td></tr><tr><td>Normal distribution</td><td>Gaussian, also called bell-shaped. Mean = median = mode. For normal distribution, mean is the best measure of central tendency. For skewed data, median is a better measure of central tendency than mean.</td><td>2</td><td>68% Bo ee) 884 95% 99.7% 15}</td></tr><tr><td colspan="4">Nonnormal distributions</td></tr><tr><td>Bimodal distribution</td><td>Suggests two different populations (eg, metabolic polymorphism such as fast vs slow acetylators; age at onset of Hodgkin lymphoma; suicide rate by age).</td><td></td><td></td></tr><tr><td>Positive skew</td><td>Typically, mean &gt; median &gt; mode. Asymmetry with longer tail on right; mean falls closer to tail.</td><td></td><td></td></tr><tr><td>Negative skew</td><td>Typically, mean &lt; median &lt; mode. h longer tail on left; mean falls Asymmetry wi oser to tail. °</td><td></td><td></td></tr></table>
======================================
<table><thead><th>Correct result</th><th>Stating that there is an effect or difference when</th><th></th><th colspan="2">Reality</th></thead><thead><th></th><th>one exists (Hp rejected in favor of H)).</th><th></th><th>H,</th><th>H,</th></thead><tr><td></td><td>Stating that there is no effect or difference when none exists (Ho not rejected).</td><td>Study rejects H,</td><td>POWen (1-8)</td><td>o Type | error</td></tr><tr><td></td><td></td><td>Study does not reject H,</td><td>B Type ll error</td><td></td></tr></table>
======================================
<table><thead><th>Testing errors</th><th></th><th></th></thead><tr><td rowspan="2">Type | error (a)</td><td>Stating that there is an effect or difference when none exists (Hp incorrectly rejected in favor of H)).</td><td>Also called false-positive error. Ist time boy cries wolf, the town believes there is a wolf, but there is not (false positive).</td></tr><tr><td></td><td>o is the probability of making a type I error (usually 0.05 is chosen). If P&lt;, then assuming Hp is true, the probability of obtaining the test results would be less than the probability of making a type I error. Hp is therefore rejected as false. Statistical significance # clinical significance.</td><td>You can never “prove” Hj, but you can reject the Ho as being very unlikely.</td></tr><tr><td>Type Il error (8)</td><td>Stating that there is not an effect or difference when one exists (Hp is not rejected when it is in fact false). B is the probability of making a type II error. B is related to statistical power (1 — B), which is the probability of rejecting Hy when it is false. t power and $ B by: = t sample size = t expected effect size * t precision of measurement = t a level (t statistical significance level).</td><td>Also called false-negative error. 2nd time boy cries wolf, the town believes there is no wolf, but there is one. Ifyou t sample size, you t power. There is power in numbers. Generally, when type I error increases, type II error decreases.</td></tr><tr><td>Statistical vs clinical significance</td><td colspan="2">Statistical significance—defined by the likelihood of study results being due to chance. If there is a high statistical significance, then there is a low probability that the results are due to chance.</td></tr></table>
======================================
<table><tr><td>t-test</td><td>Checks d ifferences between means of 2 groups.</td><td>Tea is meant for 2. Example: comparing the blood</td></tr><tr><td>Fisher's exact test</td><td>Checks d proport Use ins popula ifferences between 2 percentages or ions of categorical, nominal outcomes. ead of chi-square test with small ions.</td><td>of groups. Example: comparing the percentage of 20 men and 20 women with hypertension.</td></tr><tr><td>Chi-square (x)</td><td>Checks d ifferences between 2 or more percen' outcom ages or proportions of categorical es (not mean values).</td><td>Pronounce chi-tegorical. Example: comparing the proportion of members of 3 age groups who have essential</td></tr></table>
======================================
<table><thead><th>Core ethical principles</th><th></th><th></th></thead><tr><td>Autonomy</td><td colspan="2">Obligation to respect patients as individuals (truth-telling, confidentiality), to create conditions necessary for autonomous choice (informed consent), and to honor their preference in accepting or not accepting medical care.</td></tr><tr><td>Beneficence</td><td colspan="2">Physicians have a special ethical (fiduciary) duty to act in the patient’s best interest. May conflict with autonomy (an informed patient has the right to decide) or what is best for society (eg, mandatory TB treatment). Traditionally, patient interest supersedes. Principle of double effect—facilitating comfort is prioritized over potential side effects (eg, respiratory depression with opioid use) for patients receiving end-of-life care.</td></tr><tr><td>Nonmaleficence</td><td>“Do no harm.” Must be balanced against beneficence; may make an informed decision to proceed (most</td><td>if the benefits outweigh the risks, a patient surgeries and medications fall into this category).</td></tr><tr><td>Justice</td><td>‘To treat persons fairly and equitably. This does not</td><td>always imply equally (eg, triage).</td></tr><tr><td>Decision-making capacity</td><td>Physician must determine whether the patient is psychologically and legally capable of making a healthcare decision.</td><td>Four major components of decision-making: * Understanding (what do you know about</td></tr><tr><td></td><td>particular Note that decisions made with capacity cannot be revoked simply if the patient later loses capacity. Intellectual disabilities and mental illnesses are not exclusion criteria unless the patient’s condition presently impairs their ability to make healthcare decisions. Capacity is determined by a physician for a specific healthcare-related decision (eg, to refuse medical care). Competency is determined by a judge and usually refers to more global categories of decision-making (eg, legally unable to make any healthcare-related decision).</td><td>your condition/proposed procedure/ treatment?) = Appreciation (what does your condition mean to you? why do you think your doctor is recommending this course of treatment?) * Reasoning (how are you weighing your options?) = Expressing a choice (what would you like to do?)</td></tr></table>
======================================
<table><tr><td>Partnership</td><td>Work together with patient to identify primary concerns and develop preferred solutions.</td></tr><tr><td>Empathy</td><td>Acknowledge the emotions displayed and demonstrate understanding of why the patient is feeling that way.</td></tr><tr><td>Apology</td><td>Take personal responsibility when appropriate.</td></tr><tr><td>Respect</td><td>Commend the patient for coming in to discuss a problem, pushing through challenging circumstances, keeping a positive attitude, or other constructive behaviors.</td></tr><tr><td>Legitimization</td><td>Assure patient that emotional responses are understandable or common.</td></tr><tr><td>Support</td><td>Reassure patient that you will work together through difficult times and offer appropriate resources.</td></tr></table>
======================================
<table><tr><td>Setting</td><td>Offer in advance for the patient to bring support. Eliminate distractions, ensure privacy, and sit down with the patient to talk.</td></tr><tr><td>Perception</td><td>Determine the patient’s understanding and expectations of the situation.</td></tr><tr><td>Invitation</td><td>Obtain the patient’s permission to disclose the news and what level of detail is desired.</td></tr><tr><td>Knowledge</td><td>Share the information in small pieces without medical jargon, allowing time to process. Assess the patient’s understanding.</td></tr><tr><td>Emotions</td><td>Acknowledge the patient’s emotions, and provide opportunity to express them. Listen and offer empathetic responses.</td></tr><tr><td>Strategy</td><td>If the patient feels ready, discuss treatment options and goals of care. Offer an agenda for the next appointment. Giving control to the patient may be empowering. Ask how they feel a problem might be solved and what they would like do about the plan of</td></tr></table>
======================================
<table><thead><th></th><th>or more of the principles of autonomy, beneficence, nonmaleficence, and justice. Appropriate responses are respectful of patients and other members of the healthcare</th></thead><tr><td>SITUATION</td><td>eam. &gt; PPROPRIATE RESPONSE</td></tr><tr><td>Patient does not follow the medical plan.</td><td>Determine whether there are financial, logistical, or other obstacles preventing the patient’s adherence. Do not coerce the patient into adhering or refer the patient to another physician. Schedule regular follow-up visits to track patient progress.</td></tr><tr><td>Patient desires an unnecessary procedure.</td><td>Attempt to understand why the patient wants the procedure and address underlying concerns. Do not refuse to see the patient or refer to another physician. Avoid performing unnecessary procedures.</td></tr><tr><td>Patient has difficulty taking medications.</td><td>Determine what factors are involved in the patient’s difficulties. If comprehension or memory are issues, use techniques such as providing written instructions, using the each-back method, or simplifying treatment regimens.</td></tr><tr><td>Family members ask for information about patient’s prognosis.</td><td>Avoid discussing issues with relatives without the patient’s permission.</td></tr><tr><td>A patient’s family member asks you not to disclose the results of a test f the prognosis is poor because i he patient will be “unable to handle it.”</td><td>Explore why the family member believes this would be detrimental, including possible cultural factors. Explain that if the patient would like to know information concerning care, it will not be withheld. However, if you believe the patient might seriously harm self or others if informed, you may invoke therapeutic privilege and withhold the information.</td></tr><tr><td>A 17-year-old is pregnant and requests an abortion.</td><td>Many states require parental notification or consent for minors for an abortion. Unless here are specific medical risks associated with pregnancy, a physician should not sway the patient’s decision for, or against, an elective abortion (regardless of patient’s age or fetal condition). Discuss options for terminating the pregnancy and refer to abortion care, if needed.</td></tr><tr><td>A 15-year-old is pregnant and wants to raise the child. The patient’s parents want you to tell the patient to give the child up for adoption.</td><td>The patient retains the right to make decisions regarding the child, even if the patient’s parents disagree. Provide information to the teenager about the practical aspects ° f caring for a baby. Discuss options for terminating the pregnancy, if requested. Encourage discussion between the patient and parents to reach the best decision.</td></tr><tr><td>A terminally ill patient requests physician-assisted dying.</td><td>The overwhelming majority of states prohibit most forms of physician-assisted dying. Physicians may, however, prescribe medically appropriate analgesics even if they potentially shorten the patient's life.</td></tr><tr><td>Patient is suicidal.</td><td>Assess the seriousness of the threat. If patient is actively suicidal with a plan, suggest remaining in the hospital voluntarily; patient may be hospitalized involuntarily if needed.</td></tr><tr><td>Patient states that you are attractive and asks if you would go on a date.</td><td>Use a chaperone if necessary. Romantic relationships with patients are never appropriate. Set firm professional boundaries with direct communication. ‘Transition care to another physician if necessary.</td></tr><tr><td>A woman who had a mastectomy says she now feels “ugly.”</td><td>Find out why the patient feels this way. Do not offer falsely reassuring statements (eg, “You still look good”).</td></tr><tr><td>Patient is angry about the long time spent in the waiting room.</td><td>Acknowledge the patient’s anger, but do not take a patient’s anger personally. ‘Thank the patient for being patient and
======================================
 apologize for any inconvenience. Stay away from efforts to explain the delay.</td></tr></table>
======================================
<table><thead><th>SITUATION</th><th>APPROPRIATE RESPONSE</th></thead><tr><td>An invasive test is performed on the wrong patient.</td><td>Regardless of the outcome, a physician is ethically obligated to inform a patient that a mistake has been made.</td></tr><tr><td>A patient requires a treatment not covered by insurance.</td><td>Discuss all treatment options with patients, even if some are not covered by their insurance companies. Inform patient of financ ial assistance programs.</td></tr><tr><td>A 7-year-old boy loses a sister to cancer and now feels responsible.</td><td>At ages 5-7, children begin to understand that d end completely at dea concrete description of his sister’s death. Avoid play and healthy coping behaviors eath is permanent, all life functions h, and everything that is alive eventually dies. Provide a direct, clichés and euphemisms. Reassure the boy that he is not responsible. Identify and normalize fears and feelings. Encourage (eg, remembering her in his own way).</td></tr><tr><td>Patient is victim of intimate partner violence.</td><td>Ask i direct, open-ended questions abou patient is safe and help devise exam findings and summarize patient’s answers back to them. Ask if patient has any questions. eave a partner or disc an emergency plan if there isn’t one. Ask patient Do not necessarily pressure patient to lose the incident to the authorities (unless required by state law).</td></tr><tr><td>Patient wants to try alternative or holistic medicine.</td><td>Explore any underlying reasons with the patient i na supportive, nonjudgmental manner. s and risks o' Advise the raindications, and medication interactions. atient of known benefil con complementary or alternative medicine provide f treatment, including adverse effects, Consider referral to an appropriate Tr.</td></tr><tr><td>Physician colleague presents to work impaired.</td><td>This obligation o report impaired colleagues so the approprial and applicable law vary by institution and state. resents a potential risk to patient safety. You have an ethical and usually a legal y can cease patient care and receive e assistance in a timely manner. Seek guidance in reporting as procedures</td></tr><tr><td>Patient’s family insists on maintaining life support after brain death has occurred, citing patient's movements when touched.</td><td>Gently explain to family that there is no chance of recovery, and that brain death is equivalent to death. Movement is due to spinal arc reflex and is not voluntary. Bring case to appropriate ethics board regarding futility of care and withdrawal of life support.</td></tr><tr><td>A pharmaceutical company offers you a sponsorship in exchange for advertising its new drug.</td><td>Reject this offer. Generally, decline gifts and sponsorships to avoid any conflict of interest. ‘The AMA Code of Ethics does make exceptions for gifts directly benefitting patients; special funding for medical education of students, residents, fellows; grants whose recipients are chosen by independent institutional criteria; and funds that are distributed without attribution to sponsors.</td></tr><tr><td>Patient requests a nonemergent procedure that is against your personal or religious beliefs.</td><td>Provide accurate and unbiased information so p atients can make an informed decision. Ina neutral, nonjudgmental manner, explain to the patient that you do not perform the procedure but offer to refer to another physician.</td></tr><tr><td>Mother and 15-year-old daughter are unresponsive and bleeding</td><td>Transfuse daughter, but do not transfuse mother. Emergent care can be refused by the healthcare proxy for an adult, particularly when patient preferences are known or</td></tr></table>
======================================
<table><thead><th>PLAN</th><th>PROVIDERS</th><th>PAYMENTS</th><th>SPECIALIST CARE</th></thead><tr><td>Exclusive provider organization</td><td>Restricted to limited panel (except emergencies)</td><td></td><td>No referral required</td></tr><tr><td>Health maintenance organization</td><td>__ Restricted to limited panel (except emergencies)</td><td>Most affordable</td><td>Requires referral from primary care provider</td></tr><tr><td>Point of service</td><td>Patient can see providers outside network</td><td>Higher copays and deductibles for out-of-network services</td><td>Requires referral from primary care provider</td></tr><tr><td>Preferred provider organization</td><td>Patient can see providers outside network</td><td>Higher copays and deductibles for all services</td><td>No referral required</td></tr><tr><td>Accountable care</td><td>Providers voluntarily enroll</td><td>Medicare</td><td>Specialists voluntarily enroll</td></tr></table>
======================================
<table><tr><td>Medicaid</td><td>healthcare programs that originated from</td></tr><tr><td></td><td>Medicare is available to patients 2 65 years old</td></tr><tr><td></td><td>&lt; 65 with certain disabilities, and those with</td></tr><tr><td></td><td>end-stage renal disease.</td></tr><tr><td></td><td>Medicaid is joint federal and state health</td></tr><tr><td></td><td>assistance for people with limited income an</td></tr><tr><td></td><td>or resources.</td></tr></table>
======================================
<table><thead><th></th><th>&lt;1YR</th><th>1-14 YR</th><th>15-34YR</th><th>35-44 YR</th><th>45-64 YR</th><th>65+ YR*</th></thead><tr><td>#1</td><td>Congenital malformations</td><td>Unintentional injury</td><td>Unintentional injury</td><td>Unintentional injury</td><td>Cancer</td><td>Heart disease</td></tr><tr><td>#2</td><td>Preterm birth</td><td>Cancer</td><td>Suicide</td><td>Cancer</td><td>Heart disease</td><td>Cancer</td></tr><tr><td>#3</td><td>Sudden unexpected infant death</td><td>Congenital malformations</td><td>Homicide</td><td>Heart disease</td><td>Unintentional injury</td><td>Chronic lower respiratory disease</td></tr></table>
======================================
<table><thead><th></th><th>MEASURE</th><th>EXAMPLE</th></thead><tr><td>Structural</td><td>Physical equipment, resources, facilities</td><td>Number of diabetes educators</td></tr><tr><td>Process</td><td>Performance of system as planned</td><td>Percentage of patients with diabetes whose HbA,, was measured in the past 6 months</td></tr><tr><td>Outcome</td><td>Impact on patients</td><td>Average HbA,, of patients with diabetes</td></tr><tr><td>Balancing</td><td>Impact on other systems/outcomes</td><td>Incidence of hypoglycemia among patients who tried an intervention to lower HbA\.</td></tr></table>
======================================
<table><thead><th rowspan="2">Types errors Active error</th><th colspan="2">May patient diagnosis, monitoring, medications, procedures, devices, documentation, handoffs. Medical errors should be disclosed to patients, independent of immediate outcome (harmful or not). Burnout—prolonged, excessive stress + medical errors due to reduced professional efficacy. Fatigue—sleep/rest deprivation + medical errors due to cognitive impairment.</th></thead><thead><th></th><th>Occurs at level of frontline operator (eg, wrong IV pump dose programmed).</th><th>Immediate impact.</th></thead><tr><td>Latent error</td><td>Occurs in processes indirect from operator but impacts patient care (eg, different types of IV pumps used within same hospital).</td><td>Accident waiting to happen.</td></tr><tr><td>Never event</td><td>Adverse event that is identifiable, serious, and usually preventable (eg, scalpel retained in a surgical patient’s abdomen).</td><td>Major error that should never occur. Sentinel event—a never event that leads to death, permanent harm, or severe temporary harm.</td></tr><tr><td>Near miss</td><td>Unplanned event that does not result in harm but has the potential to do so (eg, pharmacist recognizes a medication interaction and cancels the order).</td><td>Narrow prevention of harm that exposes dangers.</td></tr><tr><td colspan="3">Medical error analysis</td></tr><tr><td colspan="3">DESIGN METHODS</td></tr><tr><td>Root cause analysis</td><td>Retrospective approach. Applied after failure event to prevent recurrence.</td><td>Uses records and participant interviews (eg, 5 whys approach, fishbone/cause-and- effect diagrams, process maps) to identify all the underlying problems (eg, process, people, environment, equipment, materials, management) that led to an error.</td></tr><tr><td>Failure mode and effects analysis</td><td>Forward-looking approach. Applied before process implementation to prevent failure occurrence.</td><td>Uses inductive reasoning to identify all the ways a process might fail and prioritizes them by their probability of occurrence and impact on patients.</td></tr></table>
======================================
<table><tr><td>» Approaching Organ Systems</td><td>the</td><td>280</td></tr><tr><td>Hematology Oncology &gt; Musculoskeletal,</td><td></td><td>409</td></tr><tr><td>» Neurology Special Senses</td><td>and</td><td>499</td></tr></table>
======================================
<table><tr><td>Cardiovascular</td><td></td></tr><tr><td>“As for me, except for an occasional heart attack, I feel as young as I ever did.”</td><td>» Embryology</td></tr><tr><td>—Robert Benchley</td><td>» Anatomy</td></tr><tr><td>“Hearts will never be practical until they are made unbreakable.”</td><td>» Physiology</td></tr><tr><td>—The Wizard of Oz</td><td>»</td></tr><tr><td>“As the arteries grow hard, the heart grows soft.” —H. L. Mencken</td><td>Pathology »</td></tr><tr><td>“Nobody has ever measured, not even poets, how much the heart can</td><td>Pharmacology</td></tr><tr><td colspan="2">hold.” —Zelda Fitzgerald</td></tr><tr><td colspan="2">“The art of medicine has its roots in the heart.” —Paracelsus</td></tr><tr><td colspan="2">“Tt is not the size of the man but the size of his heart that matters.”</td></tr><tr><td>—Evander Holyfield</td><td></td></tr></table>
======================================
<table><tr><td>Ist</td><td>Part of maxillary artery (branch of external carotid). Ist arch is maximal.</td><td>External——s_¢</td><td>“Right recurrent</td></tr><tr><td>2nd</td><td>: . Stapedial artery and hyoid artery. Second = stapedial.</td><td>artery Internal 4 )) J artery 1 |</td><td>laryngeal nerve loops around product of 4th arch (subclavian artery)</td></tr><tr><td>3rd Ath</td><td>Common carotid artery and proximal part of internal carotid artery. C is 3rd letter of alphabet. On aortic on of</td><td>Common ~ 4 cart —_ artery ) WS / A&gt; 6 ;</td><td>7 Left recurrent laryngeal nerve loops around product of 6th arch</td></tr><tr><td></td><td>left, arch; right, proximal part : : : right subclavian artery. 4th arch (4 limbs) = systemic.</td><td>e )</td><td>(ductus arteriosus) 3rd</td></tr><tr><td>6th</td><td>: : Proximal part of pulmonary arteries and (on left only) ductus arteriosus. 6th arch = pulmonary and the pulmonary-to-systemic shunt (ductus arteriosus).</td><td>{ :</td><td>4th léth</td></tr></table>
======================================
<table><tr><td>‘Truncus arteriosus</td><td>Ascending aorta and pulmonary trunk</td></tr><tr><td>Bulbus cordis</td><td>Smooth parts (outflow tract) of left and right ventricles</td></tr><tr><td>Primitive ventricle</td><td>Trabeculated part of left and right ventricles</td></tr><tr><td>Primitive atrium</td><td>Trabeculated part of left and right atria</td></tr><tr><td>Left horn of sinus venosus</td><td>Coronary sinus</td></tr><tr><td>Right horn of sinus venosus</td><td>Smooth part of right atrium (sinus venarum)</td></tr><tr><td>Endocardial cushion</td><td>Atrial septum, membranous interventricular septum; AV and semilunar valves</td></tr><tr><td>Right common cardinal vein and right anterior cardinal vein</td><td>Superior vena cava (SVC)</td></tr><tr><td>Posterior cardinal, subcardinal, and supracardinal veins</td><td>Inferior vena cava (IVC)</td></tr></table>
======================================
<table><thead><th></th><th>(dysphagia) and/or the left recurrent laryngeal nerve, a branch of the vagus nerve, causing hoarseness (Ortner syndrome). RV is the most anterior part of the heart and most commonly injured in trauma. LV is about 2/3 and RV is about 1/3 of the inferior (diaphragmatic) cardiac surface EJ.</th><th>svc vein</th><th></th></thead><tr><td>ericardium</td><td>Consists of 3 layers (from outer to inner): * Fibrous pericardium ® Parietal pericardium * Epicardium (visceral pericardium) Pericardial space lies between parietal | ; 7 : pericardium and epicardium. Pericardium innervated by phrenic nerve. Pericarditis can cause referred pain to the neck, arms, or one or both shoulders (often left).</td><td></td><td>Fibrous pericardium Parietal pericardium +—— Pericardial space Epicardium (visceral pericardium) essels Coronary vs Myocardium == Endocardium</td></tr><tr><td></td><td>posteromedial papillary muscle. RCA supplies AV node and SA node. Infarct may cause nodal dysfunction (bradycardia or heart block). Right (acute) marginal artery supplies RV.</td><td>both LCX and RCA Coronary blood flow to LV septum peaks in early Coronary sinus runs in the into the RA.</td><td>and interventricular diastole. left AV groove and</td></tr></table>
======================================
<table><tr><td>Stroke volume</td><td>Stroke Volume affected by Contractility,</td><td>SV CAP.</td></tr><tr><td></td><td>Afterload, and Preload. t SV with: = t Contractility (eg, anxiety, exercise) ® t Preload (eg, early pregnancy) ® 4 Afterload</td><td>Stroke work (SW) is work done by ventricle to eject SV. SW « SV x MAP A failing heart has 4 SV (systolic and/or diastolic dysfunction).</td></tr><tr><td>Contractility</td><td>Contractility (and SV) t with: = Catecholamine stimulation via B; receptor: * Activated protein kinase A &gt; phospholamban phosphorylation = active Ca** ATPase &gt; t Ca”* storage in sarcoplasmic reticulum = Activated protein kinase A &gt; Ca** channel phosphorylation &gt; t Ca** entry = t Ca’*-induced Ca” release ® ft intracellular Ca** = 4 extracellular Na* (4 activity of Na*/Ca?* exchanger) * Digoxin (blocks Na*/K* pump — t intracellular Na* + } Na*/Ca?* exchanger activity &gt; t intracellular Ca**)</td><td>Contractility (and SV) $ with: = B-blockade (+ cAMP) * Heart failure (HF) with systolic dysfunction = Acidosis * Hypoxia/hypercapnia (4 Po2/t Pco2) = Nondihydropyridine Ca** channel blockers</td></tr><tr><td>Preload Afterload</td><td>Preload approximated by ventricular end- diastolic volume (EDV); depends on venous tone and circulating blood volume. Afterload approximated by MAP.</td><td>Venous vasodilators (eg, nitroglycerin) 4 preload. Arterial vasodilators (eg, hydralazine)</td></tr><tr><td></td><td>t wall tension per Laplace’s law &gt; t pressure &gt; t afterload. LV compensates for t afterload by thickening (hypertrophy) in order to + wall stress.</td><td>4 afterload. ACE inhibitors and ARBs $ both preload and afterload. Chronic hypertension (t MAP) &gt; LV hypertrophy.</td></tr><tr><td>Cardiac oxygen demand</td><td>Myocardial O, demand is t by: = t contractility = t afterload (proportional to arterial pressure) = t heart rate = t diameter of ventricle (t wall tension) Coronary sinus contains most deoxygenated blood in body.</td><td>Wall tension follows Laplace’s law: Wall tension = pressure x radius Wall stress = Pressure radius ~~ 2.x wall thickness</td></tr></table>
======================================
<table><thead><th></th><th>EQUATION</th><th>NOTES</th></thead><tr><td>Stroke volume</td><td>SV = EDV - ESV</td><td>ESV = end-systolic volume.</td></tr><tr><td>Ejection fraction</td><td>pp =_SV__EDV-ESV “EDV EDV</td><td>EF is an index of ventricular contractility (+ in systolic HF; usually normal in diastolic HF).</td></tr><tr><td rowspan="2">Cardiac output</td><td>CO=Q=SVxHR</td><td>In early stages of exercise, CO maintained by t HR and t SV. In later stages, CO maintained</td></tr><tr><td></td><td>Fick principle: rate of O) consumption (arterial O2 content — venous O; content)</td><td>by t HR only (SV plateaus). Diastole is shortened with tt HR (eg, ventricular achycardia) + 4 diastolic filling time + + SV &gt;4CO.</td></tr></table>
======================================
<table><tr><td>© Inotropy</td><td>Changes in contractility + altered SV &gt; altered CO/VR and RA pressure (RAP)</td><td>@Q Catecholamines, dobutamine, milrinone, digoxin, exercise ® @ HF with reduced EF, narcotic overdose, sympathetic inhibition ©</td></tr><tr><td>© Venous return</td><td>Changes in circulating volume &gt; altered RAP = altered SV &gt; change in CO</td><td>© Fluid infusion, sympathetic activity, arteriovenous shunt ® O Acute hemorrhage, spinal anesthesia O</td></tr><tr><td>@ Total peripheral resistance</td><td>Changes in TPR + altered CO Change in RAP unpredictable</td><td>© Vasopressors ® © Exercise, arteriovenous shunt ©</td></tr></table>
======================================
<table><tr><td rowspan="2">Physiologic splitting</td><td>Inspiration &gt; drop in intrathoracic pressure</td><td>E</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>+ pulmonary impedance (t capacity of the ulmonary circulation) also occurs during inspiration, which contributes to delayed closure of pulmonic valve.</td><td></td><td colspan="4">E = Expiration ! = Inspiration</td></tr><tr><td>Fixed splitting</td><td>splitting. Heard in ASD. ASD = left-to-right shunt &gt; t RAand RV volumes &gt; ¢ flow through ulmonic valve + delayed pulmonic valve closure (independent of respiration).</td><td>E |</td><td colspan="4">2, | | SL AZ P2 | |_| a</td></tr><tr><td rowspan="2">Paradoxical splitting</td><td>Heard in conditions that delay aortic valve closure aortic left bundle branch</td><td>E</td><td>|</td><td></td><td>|</td><td></td></tr><tr><td></td><td>(eg, stenosis, block). Normal order of semilunar valve closure is reversed: in paradoxical splitting P2 occurs before A2. On inspiration, P2 closes ater and moves closer to A2, “paradoxically” io} iminating the split. On expiration, the split hea hbaaned fannnctte nhectalacin onlitbhinc)</td><td>\</td><td>SL |</td><td>P2</td><td>Ad I</td><td></td></tr></table>
======================================
<table><thead><th>Standing, Valsalva (strain phase)</th><th>+ preload ($ LV volume)</th><th>VP (+ LV volume) with earlier midsystolic click HCM (4 LV volume)</th><th>Most murmurs (+ flow through stenotic or regurgitant valve)</th></thead><tr><td>Passive leg raise</td><td>t preload (t LV volume)</td><td>flow</td><td rowspan="2">MVP (t LV volume) with later midsystolic click HCM (t LV volume)</td></tr><tr><td>Squatting</td><td>t preload, t afterload (t LV volume)</td><td>ost murmurs (t through stenotic or regurgitant valve)</td><td></td></tr><tr><td>Hand grip</td><td>tt afterload &gt; t reverse flow across aortic valve (t LV volume)</td><td>ost other left-sided murmurs (AR, MR, VSD)</td><td>AS (4 transaortic valve pressure gradient) HCM (t LV volume)</td></tr><tr><td>Inspiration</td><td>t venous return to right heart, + venous return to left heart</td><td>ost right-sided murmurs</td><td>Most left-sided murmurs</td></tr></table>
======================================
<table><thead><th></th><th>AUSCULTATION</th><th>CLINICAL ASSOCIATIONS</th><th>NOTES</th></thead><tr><td colspan="4">Systolic</td></tr><tr><td>Aortic stenosis St I | s2</td><td>Crescendo-decrescendo ejection murmur, loudest at heart base, radiates to carotids Soft $2 +/ ejection click “Pulsus parvus et tardus”—</td><td>In older (+60 years old) patients, most commonly due to age- related calcification In younger patients, most commonly due to early-onset calcification of bicuspid aortic</td><td>Can lead to Syncope, Angina, Dyspnea on exertion (SAD) LV pressure &gt; aortic pressure during systole</td></tr><tr><td>Mitral/tricuspid regurgitation SL 82 | |</td><td>weak pulses with delayed peak “blowing” murmur MR: loudest at apex, radiates toward axilla TR: loudest at tricuspid area Holosystolic, high-pitched</td><td>valve MR: often due to ischemic heart disease (post-MI), MVP, LV dilatation, rheumatic fever TR: often due to RV dilatation Either MR or TR: infective endocarditis</td><td></td></tr><tr><td>Mitral valve prolapse SL MC 32 Lawl</td><td>Late crescendo murmur with midsystolic click (MC) that occurs after carotid pulse Best heard over apex Loudest just before S2</td><td>Usually benign, but can predispose to infective endocarditis Can be caused by rheumatic fever, chordae rupture, or myxomatous degeneration (1° or</td><td>MC due to sudden tensing of chordae tendineae as mitral leaflets prolapse into LA (chordae cause crescendo with click)</td></tr><tr><td>Ventricular septal defect St s2 I |</td><td>Holosystolic, harsh-sounding murmur Loudest at tricuspid area</td><td>Congenital</td><td>Larger VSDs have lower intensity murmur than smaller VSDs</td></tr><tr><td colspan="4">Diastolic</td></tr><tr><td>Aortic regurgitation SL 2 bein</td><td>Early diastolic, decrescendo, high-pitched “blowing” murmur best heard at base (aortic root dilation) or left sternal border (valvular disease)</td><td>Causes include BEAR: = Bicuspid aortic valve = Endocarditis = Aortic root dilation = Rheumatic fever Wide pulse pressure, pistol shot femoral pulse, pulsing nail bed (Quincke pulse)</td><td>Hyperdynamic pulse and head bobbing when severe and chronic = Can progress to le HF</td></tr><tr><td>Mitral stenosis SL 52 OS | Ds</td><td>Follows opening snap (OS) Delayed rumbling mid-to-late murmur (} interval between S82 and OS correlates with t severity)</td><td>Late and highly specific sequelae of rheumatic fever Chronic MS can result in LA dilation and pulmonary congestion, atrial fibrillation, Ortner syndrome, hemoptysis, right HF</td><td>OS due to abrupt halt in leaflet motion in diastole after rapid opening due to fusion at leaflet tips LA &gt;&gt; LV pressure during diastole</td></tr></table>
======================================
<table><thead><th>ORGAN</th><th>FACTORS DETERMINING AUTOREGULATION</th><th></th></thead><tr><td>Lungs</td><td>Hypoxia causes vasoconstriction</td><td>The pulmonary vasculature is unique in that</td></tr><tr><td>Heart</td><td>Local metabolites (vasodilatory): NO, CO2, + Oz</td><td>alveolar hypoxia causes vasoconstriction so</td></tr><tr><td>Brain</td><td>Local metabolites (vasodilatory): CO2 (pH)</td><td>that only well-ventilated areas are perfused. In other hypoxia causes vasodilation</td></tr><tr><td>Kidneys</td><td>Myogenic (stretch-dependent response of afferent arteriole) and tubuloglomerular feedback</td><td>organs,</td></tr><tr><td>Skeletal muscle</td><td>Local metabolites during exercise (vasodilatory): CO,, H*, Adenosine, Lactate, K* At rest: sympathetic tone in arteries</td><td>CHALK</td></tr><tr><td>Skin</td><td>Sympathetic vasoconstriction most important mechanism for temperature control</td><td></td></tr></table>
======================================
<table><tr><td rowspan="9">genital cardiac associations</td><td>ASSOCIATION</td><td>DEFECT</td></tr><tr><td></td><td>Prenatal alcohol exposure (fetal alcohol syndrome)</td><td>VSD, PDA, ASD, tetralogy of Fallot</td></tr><tr><td></td><td>Congenital rubella</td><td>PDA, pulmonary artery stenosis, septal defects</td></tr><tr><td></td><td>Down syndrome</td><td>AV septal defect (endocardial cushion defect), VSD, ASD</td></tr><tr><td></td><td>Infant of patient with diabetes during pregnancy</td><td>Transposition of great arteries, truncus arteriosus, tricuspid atresia, VSD</td></tr><tr><td></td><td>Marfan syndrome</td><td>MVP, thoracic aortic aneurysm and dissection, aortic regurgitation</td></tr><tr><td></td><td>Prenatal lithium exposure</td><td>Ebstein anomaly</td></tr><tr><td></td><td>Turner syndrome</td><td>Bicuspid aortic valve, coarctation of aorta</td></tr><tr><td></td><td>Williams syndrome</td><td>Supravalvular aortic stenosis</td></tr></table>
======================================
<table><thead><th></th><th>Stable angina</th><th>STEMI</th></thead><tr><td>PAIN</td><td>On exertion</td><td>At rest</td></tr><tr><td>TROPONIN LEVEL</td><td>No elevation</td><td>Elevated</td></tr><tr><td>INFARCTION</td><td></td><td>wh w Transmural</td></tr><tr><td>ECG CHANGES</td><td></td><td>ST elevation</td></tr><tr><td>Coronary steal syndrome</td><td>Distal to coronary stenosis, (eg, dipyridamole, regadenoson) areas + ischemia in myocardium stress tests with coronary</td><td>Administration of vasodilators toward well-perfused behind pharmacologic</td></tr><tr><td>Sudden cardiac death</td><td>Unexpected death due to to lethal arrhythmia (eg, cardiomyopathy (hypertrophic, Brugada syndrome). Prevent</td><td>most commonly due (up to 70% of cases), (eg, long OT syndrome,</td></tr><tr><td>Chronic ischemic heart disease</td><td>Progressive onset of HF Myocardial hibernation—potentially ischemia. Contrast with episode of acute ischemia.</td><td>myocardial damage. the setting of chronic dysfunction after a brief</td></tr><tr><td rowspan="2">Myocardial infarction</td><td>Most often due to rupture biomarkers (CK-MB, troponins)</td><td>acute thrombosis. t cardiac</td></tr><tr><td></td><td>NSTEMI</td><td></td></tr><tr><td>INFARCT LOCATION</td><td>Subendocardial</td><td></td></tr><tr><td>LAYERS INVOLVED</td><td>Subendocardium (inner vulnerable to ischemia</td><td>myocardial wall</td></tr><tr><td>ECG CHANGES</td><td>ST-segment depression,</td><td>pathologic Q waves</td></tr></table>
======================================
<table><thead><th>ARRHYTHMIA</th><th>DESCRIPTION</th><th>ECG FINDINGS</th><th></th><th></th><th></th><th></th></thead><tr><td>Atrial fibrillation</td><td>Irregularly irregular rate and rhythm with no discrete P waves. Arrhythmogenic activity usually originates from automatic foci near pulmonary vein ostia in left atrium. Common risk factors include hypertension and CAD. May predispose to ° “ thromboembolic events, particularly stroke. Management: rate and rhythm control, cardioversion. Definitive treatment is ablation of pulmonary vein ostia. Consider anticoagulation based on stroke risk.</td><td>RR, # Uo</td><td>RR, Pinney Irregular</td><td># tL baseline</td><td>RR, # RR, (absent P waves)</td><td>15}</td></tr><tr><td>Multifocal atrial tachycardia</td><td>Irregularly irregular rate and rhythm with at least 3 distinct P wave morphologies, due to multiple ectopic foci in atria. Associated with underlying conditions such as COPD, pneumonia, HF.</td><td>| ~N t t</td><td>|</td><td>| t</td><td>~ A | i: | t t</td><td></td></tr><tr><td>Atrial flutter</td><td>Rapid succession of identical, consecutive atrial depolarization waves causing “sawtooth” appearance of P waves. Arrhythmogenic activity usually originates from reentry circuit around tricuspid annulus in right atrium. : * Tele: : : . Treat like atrial fibrillation +/— catheter ablation of region between tricuspid annulus and IVC.</td><td>RR =) |</td><td>RR, peseateeeeeere 41 sanooth</td><td>th</td><td>= RR, Lo. patt pattern</td><td></td></tr><tr><td>Paroxysmal supraventricular tachycardia Wolff-Parkinson-White</td><td>Most often due to a reentrant tract between atrium and ventricle, most commonly in AV node. Commonly presents with sudden- onset palpitations, lightheadedness, diaphoresis. Treatment: terminate reentry rhythm by slowing AV node conduction (eg, vagal maneuvers, IV adenosine), electrica cardioversion if hemodynamically unstable. Definitive treatment is catheter ablation of reentry tract. — Most common type of ventricular preexcitation</td><td>|</td><td></td><td></td><td></td><td>th</td></tr></table>
======================================
<table><thead><th>ARRHYTHMIA</th><th>DESCRIPTION</th><th>ECG FINDINGS</th><th></th><th></th></thead><tr><td>Ventricular tachycardia</td><td>‘Typically regular rhythm, rate &gt; 100. Most commonly due to structural heart disease (eg, cardiomyopathy, scarring after myocardial infarction). High risk of sudden cardiac death.</td><td></td><td></td><td></td></tr><tr><td>Torsades de pointes</td><td>Polymorphic ventricular tachycardia. Shifting sinusoidal waveforms. May progress to ventricular fibrillation. Long OT interval predisposes to torsades de poin| VK’, Mg2*, § Ca", Torsad Treatment: defibrillation for unstable pa jes de pointes = twisting of the poi for stable patients. Drug-induced long OT (ABCDEF+NO ani ani a 5 ani a nN ani i-Arrhythmics (Ia and III), Arsenic i-Biotics (macrolides, fluoroquino es. Caused by drugs, nts ients, magnesium sulfate ): ones) i-Cychotics (haloperidol), Chloroquine i-Depressants (TCAs), Diuretics (| i-Emetics (ondansetron) i-Fungals (Fluconazole) Navir (protease inhibitors) hiazides)</td><td>Ais</td><td></td><td>le</td></tr><tr><td>Ventricular fibrillation</td><td>Opioids (methadone) Disorganized rhythm with no identifiable waves. Treatment: fatal without immediate CPR and defibrillation.</td><td>NAV ACAVAUAVN No discernible</td><td>VAG rhythm</td><td>il 1]</td></tr><tr><td>Hereditary channelopathies</td><td>Inherited mutations of cardiac ion channels + abnormal ventricular tachyarrhythmias and sudden cardiac death (SCD).</td><td>myocardial action potential</td><td>&gt; t risk</td><td>of</td></tr><tr><td>Brugada syndrome</td><td colspan="4">Autosomal dominant; most commonly due to loss of function mutation of Na* channels. t prevalence in Asian males. ECG pattern of pseudo-right bundle branch block and ST-segment</td></tr></table>
======================================
<table><thead><th rowspan="2">ARRHYTHMIA Premature atrial contraction</th><th>DESCRIPTION</th><th>ECG</th><th>FINDINGS</th><th></th></thead><thead><th></th><th>Extra beats arising from ectopic foci in atria instead of the SA node. Often 2° to t adrenergic drive (eg, caffeine consumption). Benign, but may increase risk for atrial fibrillation and flutter. Narrow ORS complex with preceding P wave on ECG.</th><th></th><th></th><th>oh 4</th></thead><tr><td>Premature ventricular contraction</td><td>Ectopic beats arising from ventricle instead of the SA node. Shortened diastolic filling time + 4 SV compared to a normal beat. Prognosis is largely influenced by underlying heart disease. Wide ORS complex with no preceding P wave on ECG.</td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>COMPLICATION</th><th>TIMEFRAME</th><th>FINDINGS</th><th>NOTES</th></thead><tr><td>Cardiac arrhythmia</td><td>First few days to several months</td><td>Can be supraventricular arrhythmias, ventricular arrhythmias, or conduction blocks.</td><td>Due to myocardial death and scarring. Important cause of death before reaching the hospital and within the first 48 hours post-MI.</td></tr><tr><td>Peri-infarction pericarditis</td><td>1-3 days</td><td>Pleuritic chest pain, pericardial friction rub, ECG changes, and/or small pericardial effusion.</td><td>Usually self-limited.</td></tr><tr><td>Papillary muscle rupture</td><td>2-7 days</td><td>Can result in acute mitral regurgitation &gt; cardiogenic shock, severe pulmonary edema.</td><td>Posteromedial &gt;&gt; anterolateral papillary muscle rupture [, as the posteromedial has single artery blood supply (PDA) whereas anterolateral has dual (LAD, LCX).</td></tr><tr><td>Interventricular septal rupture</td><td>3-5 days</td><td>Symptoms can range from mild to severe with cardiogenic shock and pulmonary edema.</td><td>Macrophage-mediated degradation + VSD = t O, saturation and tf pressure in RV.</td></tr><tr><td>Ventricular pseudoaneurysm</td><td>3-14 days</td><td>May be asymptomatic. Symptoms may include chest pain, murmur, arrhythmia, syncope, HF, embolus from mural thrombus. Rupture &gt; cardiac tamponade.</td><td>Free wall rupture contained by adherent pericardium or scar tissue—does not contain endocardium or myocardium. More likely to rupture than true aneurysm.</td></tr><tr><td>Ventricular free wall rupture</td><td>5-14 days</td><td>Free wall rupture [3] + cardiac tamponade; acute form usually leads to sudden death.</td><td>LV hypertrophy and previous MI protect against free wall rupture.</td></tr><tr><td>True ventricular aneurysm</td><td>2 weeks to several months</td><td>Similar to pseudoaneurysm.</td><td>Outward bulge with contraction (“dyskinesia”). Associated with fibrosis.</td></tr><tr><td>Postcardiac injury syndrome</td><td>Weeks to several months</td><td>Fibrinous pericarditis due to autoimmune reaction.</td><td>Also called Dressler syndrome. Cardiac antigens released after injury + deposition of immune complexes in pericardium</td></tr></table>
======================================
<table><thead><th>Hypovolemic shock</th><th>Hemorrhage, dehydration, burns</th><th>Volume depletion</th><th rowspan="4">Cold, clammy</th><th>t</th><th>4</th><th>t</th><th>t</th><th>1</th></thead><tr><td>Cardiogenic shock</td><td>MI, HF, valvular dysfunction, arrhythmia</td><td>— Left heart dysfunction</td><td></td><td>t</td><td>t</td><td>4</td><td>t</td><td>t</td></tr><tr><td>Obstructive shock</td><td>PE, tension pneumothorax</td><td>meted</td><td></td><td>t</td><td>1</td><td>1</td><td>t</td><td>t</td></tr><tr><td></td><td>: Cardiac tamponade</td><td>7 cardiopulmonary blood flow</td><td></td><td>t</td><td>t</td><td>t</td><td>t</td><td>t</td></tr><tr><td rowspan="2">Distributive shock</td><td>Sepsis (early), hylaxi anaphylaxis</td><td>; Systemic a,</td><td>Warm,</td><td>+</td><td>4</td><td>t</td><td>4</td><td>t</td></tr><tr><td></td><td>CNS injury</td><td>vasodilation</td><td>dry ,</td><td>t</td><td>1</td><td>1</td><td>4</td><td>normal/</td></tr></table>
======================================
<table><tr><td>Primary (essential) hypertension</td><td>Thiazide diuretics, ACE inhibitors, angiotensin II receptor blockers (ARBs), dihydropyridine Ca™* channel blockers.</td><td></td></tr><tr><td>Hypertension with heart failure</td><td>Diuretics, ACE inhibitors/ARBs, B-blockers (compensated HF), aldosterone antagonists.</td><td>B-blockers must be used cautiously in decompensated HF and are contraindicated in cardiogenic shock. In HF, ARBs may be combined with the neprilysin inhibitor sacubitril.</td></tr><tr><td>Hypertension with diabetes mellitus</td><td>ACE inhibitors/ARBs, Ca”* channel blockers, thiazide diuretics, B-blockers.</td><td>ACE inhibitors/ARBs are protective against diabetic nephropathy. B-blockers can mask hypoglycemia symptoms.</td></tr><tr><td>Hypertension in asthma</td><td>ARBs, Ca** channel blockers, thiazide diuretics, cardioselective B-blockers.</td><td>Avoid nonselective B-blockers to prevent B&gt;-receptor—induced bronchoconstriction. Avoid ACE inhibitors to prevent confusion between drug or asthma-related cough.</td></tr><tr><td>Hypertension in</td><td>Nifedipine, methyldopa, labetalol, hydralazine.</td><td>New moms love hugs.</td></tr></table>
======================================
<table><thead><th>blockers</th><th>smooth muscle); diltiazem, verapamil (nondihydropyridines, act on heart).</th></thead><tr><td>MECHANISM</td><td>Block voltage-dependent L-type calcium channels of cardiac and smooth muscle &gt; + muscle contractility. Vascular smooth muscle—amlodipine = nifedipine &gt; diltiazem &gt; verapamil. Heart—verapamil &gt; diltiazem &gt; amlodipine = nifedipine.</td></tr><tr><td>CLINICAL USE</td><td>Dihydropyridines (except nimodipine): hypertension, angina (including vasospastic type), Raynaud phenomenon. Dihydropyridine mainly dilates arteries. Nimodipine: subarachnoid hemorrhage (prevents cerebral vasospasm). Nicardipine, clevidipine: hypertensive urgency or emergency. Nondihydropyridines: hypertension, angina, atrial fibrillation/flutter.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Gingival hyperplasia. Dihydropyridine: peripheral edema, flushing, dizziness.</td></tr></table>
======================================
<table><thead><th>COMPONENT</th><th>NITRATES</th><th>B-BLOCKERS</th><th>NITRATES + B-BLOCKERS</th></thead><tr><td>End-diastolic volume</td><td>4</td><td>No effect or t</td><td>No effect or $</td></tr><tr><td>Blood pressure</td><td>t</td><td>4</td><td>+</td></tr><tr><td>Contractility</td><td>t (reflex response)</td><td>1</td><td>Little/no effect</td></tr><tr><td>Heart rate</td><td>t (reflex response)</td><td>1</td><td>No effect or $</td></tr><tr><td>Ejection time</td><td>1</td><td>t</td><td>Little/no effect</td></tr><tr><td>MVO,</td><td>1</td><td>1</td><td>uy</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Inhibits the late phase of inward sodium current thereby reducing diastolic wall tension and oxygen consumption. Does not affect heart rate or blood pressure.</td></tr><tr><td>CLINICAL USE</td><td>Refractory angina.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Constipation, dizziness, headache, nausea.</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>A neprilysin inhibitor; prevents degradation of bradykinin, natriuretic peptides, angiotensin II, and substance P &gt; tf vasodilation, | ECF volume.</td></tr><tr><td>CLINICAL USE</td><td>Used in combination with valsartan (an ARB) to treat HFYEF.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Hypotension, hyperkalemia, cough, dizziness; contraindicated with ACE inhibitors</td></tr></table>
======================================
<table><thead><th>DRUG</th><th>LDL</th><th>HDL</th><th>TRIGLYCERIDES</th><th>MECHANISM</th><th>ADVERSE EFFECTS</th></thead><tr><td>Atorvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin</td><td></td><td></td><td></td><td>&gt; 4 cholesterol synthesis; + 4 intrahepatic cholesterol &gt; t LDL receptor recycling &gt; t LDL catabolism + in mortality in patients with CAD</td><td>Hepatotoxicity (t LFTs), myopathy (especially when used with fibrates or niacin)</td></tr><tr><td>Bile acid resins Cholestyramine, colesevelam, colestipol</td><td>Mh</td><td>tslightly</td><td>t slightly</td><td>Disrupt enterohepatic bile acid circulation + compensatory t conversion of cholesterol to bile + $ intrahepatic cholesterol &gt; t LDL receptor recycling</td><td>GI upset, } absorption of other drugs and fat- soluble vitamins</td></tr><tr><td>Ezetimibe</td><td>ut</td><td>ti-</td><td>V—</td><td>Prevents cholesterol absorption at small intestine brush border</td><td>Rare t LFTs, diarrhea</td></tr></table>
======================================
<table><thead><th>DRUG</th><th>LDL</th><th>HDL</th><th>TRIGLYCERIDES</th><th>MECHANISM</th><th>ADVERSE EFFECTS</th></thead><tr><td>Fibrates Fenofibrate, gemfibrozil</td><td>+</td><td>t</td><td>Ve</td><td>Activate PPAR-o &gt; upregulate LPL &gt; t TG clearance Activate PPAR-a &gt; induce HDL synthesis</td><td>Myopathy (¢ risk with statins), cholesterol gallstones (via inhibition of cholesterol 7a-hydroxylase)</td></tr><tr><td>Niacin</td><td>44</td><td>tt</td><td>1</td><td>Inhibits lipolysis (hormone- sensitive lipase) in adipose tissue; reduces hepatic VLDL synthesis</td><td>Flushed face (prostaglandin mediated; + by NSAIDs or long- term use) Hyperglycemia Hyperuricemia</td></tr><tr><td>PCSK9 inhibitors Alirocumab, evolocumab</td><td>tht</td><td>t</td><td>1</td><td>Inactivation of LDL-receptor degradation + t removal of LDL from bloodstream</td><td>— Myalgias, delirium, dementia, other neurocognitive effects</td></tr><tr><td>Fish oil and marine omega-3 fatty acids</td><td>t slightly</td><td>t slightly</td><td>4 at high doses</td><td>Believed to decrease FFA delivery to liver and decrease activity of T'G-synthesizing</td><td>Nausea, fishlike taste</td></tr></table>
======================================
<table><tr><td>blockers (class I)</td><td>resting state (drugs dissociate during this state) Effect most pronounced in IC&gt;IA&gt;IB due to relative</td><td>less time for drug to binding strength.</td><td>dissociate from receptor. Fast taxi CAB.</td></tr><tr><td>Class IA</td><td>Quinidine, procainamide, disopyramide. “The queen proclaims Diso’s pyramid.”</td><td>mV</td><td></td></tr><tr><td>MECHANISM</td><td>Moderate Na* channel blockade. t AP duration, t effective refractory period (ERP) in ventricular action potential, t OT interval, some K* channel blocking effects.</td><td>Sl pf phase 0 Ina</td><td></td></tr><tr><td>CLINICAL USE</td><td>Both atrial and ventricular arrhythmias, especially reentrant and ectopic SVT and VT.</td><td></td><td></td></tr><tr><td>ADVERSE EFFECTS</td><td>Cinchonism (headache, tinnitus with quinidine), reversible SLE-like syndrome (procainamide), HF (disopyramide), thrombocytopenia, torsades de pointes due to t interval.</td><td></td><td></td></tr><tr><td></td><td>OT</td><td></td><td></td></tr><tr><td>Class IB</td><td>Lidocaine, phenytoin, mexiletine. “Td Buy Liddy’s phine Mexican tacos.”</td><td>Omv Slope of</td><td></td></tr><tr><td>MECHANISM</td><td>Weak Na* channel blockade. + AP duration. Preferentially affect ischemic or depolarized Purkinje and ventricular tissue.</td><td>pase 0</td><td></td></tr><tr><td>CLINICAL USE</td><td>Acute ventricular arrhythmias (especially post- MI), digitalis-induced arrhythmias. IB is Best post-MI.</td><td></td><td></td></tr><tr><td>ADVERSE EFFECTS</td><td>CNS stimulation/depression, cardiovascular</td><td></td><td></td></tr></table>
======================================
<table><thead><th></th><th>Flecainide, propafenone. “Can I have fries, please?”</th><th>Omv</th><th></th></thead><tr><td>MECHANISM</td><td>Strong Na* channel blockade. Significantly prolongs ERP in AV node and accessory bypass tracts. No effect on ERP in Purkinje and ventricular tissue. Minimal effect on AP duration.</td><td>Slope of phase 0</td><td></td></tr><tr><td>CLINICAL USE</td><td>SVTs, including atrial fibrillation. Only as a last resort in refractory VT.</td><td></td><td></td></tr><tr><td>ADVERSE EFFECTS</td><td>Proarrhythmic, especially post-MI (contraindicated). IC is Contraindicated in structural and ischemic heart disease.</td><td></td><td></td></tr><tr><td>Antiarrhythmics— B-blockers (class II)</td><td>Metoprolol, propranolol, esmolol, atenolol, timolol,</td><td>carvedilol.</td><td></td></tr><tr><td>MECHANISM</td><td>Decrease SA and AV nodal activity by } cAMP, $ + slope of phase 4. AV node particularly sensitive—t PR interval.</td><td>Ca** currents. Suppress Esmolol very short acting.</td><td>abnormal pacemakers by</td></tr><tr><td>CLINICAL USE</td><td>SVT, ventricular rate control for atrial fibrillation post-MI.</td><td>and atrial flutter,</td><td>prevent ventricular arrhythmia</td></tr><tr><td>ADVERSE EFFECTS</td><td>Impotence, exacerbation of COPD and asthma, CNS effects (sedation, sleep alterations). May mask Metoprolol can cause dyslipidemia. Propranolol B-blockers (except the nonselective o- and -agonism if given alone for pheochromocytoma B-blocker overdose with saline, atropine, glucagon.</td><td>cardiovascular effects the signs of can exacerbate vasospasm B-antagonists carvedilol and or for cocaine toxicity</td><td>(bradycardia, AV block, HF), hypoglycemia. in vasospastic angina. labetalol) cause unopposed (unsubstantiated). ‘Treat</td></tr><tr><td></td><td>60-} Decrease slope of phase 4 30-} depolarization ntial (mv)</td><td>Prolonged repolarization {at AV node)</td><td></td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>TIVabradine prolongs slow depolarization (phase “IV”) by selectively inhibiting “funny” sodium channels (Ip).</td></tr><tr><td>CLINICAL USE</td><td>Chronic HFYEF.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Luminous phenomena/Vvisual brightness, hypertension, bradycardia.</td></tr></table>
======================================
<table><thead><th>HORMONE</th><th></th><th>FUNCTION</th><th>CLINICAL NOTES</th></thead><tr><td>ADH</td><td></td><td>t water permeability and collecting reabsorption</td><td>— Alcohol consumption + 4 ADH secretion = polyuria and dehydration</td></tr><tr><td>CRH</td><td></td><td>t ACTH, t MSH,</td><td>+ in chronic glucocorticoid use</td></tr><tr><td>Dopamine</td><td></td><td>4 prolactin,</td><td>Also called prolactin-inhibiting factor Dopamine antagonists (eg, antipsychotics) can cause galactorrhea due to hyperprolactinemia</td></tr><tr><td>GHRH</td><td></td><td>t GI</td><td>Analog (tesamorelin) used to treat HIV-associated lipodystrophy</td></tr><tr><td>GnRH</td><td></td><td>t FSH, t LH</td><td>Suppressed by hyperprolactinemia Tonic GnRH analog (eg, leuprolide) suppresses hypothalamic-pituitary-gonadal axis. Pulsatile GnRH leads to puberty, fertility</td></tr><tr><td>MSH Oxytocin</td><td></td><td>t melanogenesis Causes uterine</td><td>Causes hyperpigmentation in Cushing disease, as MSH and ACTH share the same precursor molecule, proopiomelanocortin Modulates fear, anxiety, social bonding, mood,</td></tr><tr><td>Prolactin</td><td></td><td>to suckling. + GnRH Stimulates lactogenesis.</td><td>Pituitary prolactinoma + amenorrhea, osteoporosis, hypogonadism, galactorrhea &gt; t + 4 GnRH</td></tr><tr><td>Somatostatin</td><td></td><td>4 GH, + TSH</td><td>Breastfeeding prolactin — delayed postpartum ovulation (natural contraception) Also called growth hormone inhibiting hormone</td></tr><tr><td rowspan="4">TRH</td><td></td><td>t TSH, t prolactin</td><td>(GHIH) t TRH (eg, in 1°/2° hypothyroidism) may increase prolactin secretion &gt; galactorrhea</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Hypothalamus</td><td>CRH</td><td>6</td></tr><tr><td></td><td>Anterior pituitary</td><td>ACTH</td><td>7.</td></tr></table>
======================================
<table><tr><td>SOURCE</td><td>Chief cells of parathyroid</td></tr><tr><td rowspan="5">FUNCTION</td><td>t free Ca”* in the blood (1° function)</td></tr><tr><td></td><td>t Ca** and PO,* absorption in GI system</td></tr><tr><td></td><td>t Ca** and PO,*- from bone resorption</td></tr><tr><td></td><td>t Ca* reabsorption from DCT 4 PO,* reabsorption in PCT</td></tr><tr><td></td><td>1,25-(OH)2D; (calcitriol) production by activating 1o-hydroxylase in PCT (tri to</td></tr></table>
======================================
<table><tr><td>SOURCE</td><td>Made by o cells of pancreas.</td></tr><tr><td>FUNCTION</td><td>Promotes glycogenolysis, gluconeogenesis, lipolysis, ketogenesis. Elevates blood sugar levels to maintain homeostasis when bloodstream glucose levels fall too low (ie, fasting state).</td></tr><tr><td>REGULATION</td><td>Secreted in response to hypoglycemia. Inhibited by insulin, amylin, somatostatin, hyperglycemi:</td></tr></table>
======================================
<table><tr><td>ON</td><td>Binds insulin receptors (tyrosine kinase</td><td>Insulin-dependent glucose transporters:</td></tr><tr><td></td><td>Unlike glucose, insulin does not cross placenta.</td><td>BRICK LIPS (insulin-independent glucose</td></tr><tr><td></td><td>In mothers with diabetes, excess glucose can placenta and fetal insulin.</td><td>uptake): Brain, RBCs, Intestine, Cornea, Kidney,</td></tr></table>
======================================
<table><thead><th>ENZYME DEFICIENCY</th><th>MINERALOCORTICOIDS</th><th>(K]</th><th>BP</th><th>HORMONES</th><th>LABS</th><th>PRESENTATION</th></thead><tr><td>@ 170-hydroxylase?¢</td><td></td><td>+</td><td>of</td><td>t</td><td>4 androstenedione</td><td>XY: atypical genitalia, undescended testes XX: lacks 2° sexual development</td></tr><tr><td>@ 21-hydroxylase*</td><td>1</td><td>t</td><td>oof</td><td>t</td><td>t renin activity t 17-hydroxy- progesterone</td><td>Most common Presents in infancy (salt wasting) or childhood (precocious puberty) XX: virilization</td></tr><tr><td>@ 118-hydroxylase*</td><td>+ aldosterone t 11-deoxycorti- costerone (results in t BP)</td><td>+</td><td>ft</td><td>t</td><td>+ renin activity</td><td>Presents in infancy (severe hypertension) or childhood (precocious puberty) XX: virilization</td></tr></table>
======================================
<table><tr><td>NCTION</td><td>t Appetite</td></tr><tr><td></td><td>t Blood pressure:</td></tr><tr><td></td><td>= Upregulates o4-receptors on arterioles</td></tr><tr><td></td><td>= t sensitivity to norepinephrine and</td></tr><tr><td></td><td>epinephrine (permissive action)</td></tr><tr><td></td><td>* At high concentrations, can bind to</td></tr><tr><td></td><td>mineralocorticoid (aldosterone) receptors</td></tr><tr><td></td><td>t Insulin resistance (diabetogenic)</td></tr><tr><td></td><td>t Gluconeogenesis, lipolysis, and proteolysis (+ glucose utilization)</td></tr><tr><td></td><td>+ Fibroblast activity (poor wound healing,</td></tr><tr><td></td><td>+ collagen synthesis, t striae)</td></tr><tr><td></td><td>+ Inflammatory and Immune responses:</td></tr><tr><td></td><td>* Inhibits production of leukotrienes and</td></tr><tr><td></td><td>prostaglandins * Inhibits WBC adhesion &gt; neutrophilia</td></tr><tr><td></td><td>* Blocks histamine release from mast cells</td></tr><tr><td></td><td>* Eosinopenia, lymphopenia</td></tr><tr><td></td><td>* Blocks IL-2 production</td></tr><tr><td></td><td>+ Bone formation (+ osteoblast activity)</td></tr></table>
======================================
<table><tr><td>Ghrelin</td><td>Stimulates hunger (orexigenic effect) and GH release (via GH secretagog receptor). Produced by stomach. Sleep deprivation, fasting, or Prader-Willi syndrome &gt; t ghrelin production. Ghrelin makes you ghrow hunghry. Acts on lateral area of hypothalamus (hunger center) to t appetite.</td></tr><tr><td>Leptin</td><td>Satiety hormone. Produced by adipose tissue. Mutation of leptin gene &gt; severe obesity. Obese people have t leptin due to t adipose tissue but are tolerant or resistant to leptin’s anorexigenic effect. Sleep deprivation or starvation + } leptin production. Leptin keeps you thin. Acts on ventromedial area of hypothalamus (satiety center) to + appetite.</td></tr><tr><td>Endocannabinoids</td><td>Act at cannabinoid receptors in hypothalamus and nucleus accumbens, two key brain areas for the homeostatic and hedonic control of food intake + t appetite. Exogenous cannabinoids cause “the munchies.”</td></tr></table>
======================================
<table><thead><th>cAMP</th><th>FSH, LH, ACTH, TSH, CRH, hCG, ADH (V&gt;- receptor), MSH, PTH, Calcitonin, Histamine (H2-receptor), Glucagon, GHRH</th><th>FLAT ChAMPs CHuGG</th></thead><tr><td>cGMP</td><td>BNP, ANP, EDRF (NO)</td><td>BAD GraMPa Think vasodilation and diuresis</td></tr><tr><td>IP3</td><td>GnRH, Oxytocin, ADI (V)-receptor), TRH, Histamine (Hj-receptor), Angiotensin II, Gastrin</td><td>GOAT HAG</td></tr><tr><td>Intracellular receptor</td><td>Progesterone, Estrogen, Aldosterone, T;/T4, Vi Testosterone, Cortisol, amin D</td><td>PET CAT in TV</td></tr><tr><td>Receptor tyrosine kinase</td><td>IGF-1, FGF, PDGF, EGF, Insulin</td><td>MAP kinase pathway Get Found In the MAP</td></tr><tr><td>Nonreceptor tyrosine kinase</td><td>G-CSF, Erythropoietin, Thrombopoietin Prolactin, Immunomod IL-2, IL-6, IFN), GH ulators (eg, cytokines</td><td>JAK/STAT pathway Think acidophils and cytokines GET a JAKed PIG</td></tr></table>
======================================
<table><tr><td>DEFINITION</td><td>Excessive water intake</td><td>1 ADH release</td><td>ADH resistance</td></tr><tr><td>CAUSES</td><td>Psychiatric illnesses, hypothalamic lesions affecting thirst center</td><td>Idiopathic, brain injury (trauma, hypoxia, tumor, surgery, infiltrative diseases)</td><td>Hereditary (ADH receptor mutation), drugs (eg, lithium, demeclocycline), hypercalcemia, hypokalemia</td></tr><tr><td>SERUM OSMOLALITY</td><td>t</td><td>t</td><td>t</td></tr><tr><td>ADH LEVEL</td><td>+ or normal</td><td>1</td><td>Normal or t</td></tr><tr><td>WATER RESTRICTION?</td><td>Significant t in urine osmolality (&gt; 700 mOsm/kg)</td><td>No change or slight t in urine osmolality</td><td>No change or slight t in urine osmolality</td></tr><tr><td>DESMOPRESSIN ADMINISTRATION?</td><td></td><td>Significant t in urine osmolality (&gt; 50%)</td><td>Minimal change in urine osmolality</td></tr><tr><td>TREATMENT</td><td>Water restriction</td><td>Desmopressin (DDAVP)</td><td>Manage the underlying cause; low-solute diet, HCTZ,</td></tr></table>
======================================
<table><tr><td>METABOLIC</td><td>Cold intolerance, } sweating, weight gain (4 basal metabolic rate + $ calorigenesis), hyponatremia (+ free water clearance)</td><td>Heat intolerance, t sweating, weight loss (t synthesis of Na*/K*-ATPase — tf basal metabolic rate + t calorigenesis)</td></tr><tr><td>SKIN/HAIR</td><td>Dry, cool skin (due to $ blood flow); coarse, brittle hair; diffuse alopecia; brittle nails; puffy facies and generalized nonpitting edema (myxedema) due to t GAGs in interstitial spaces &gt; t osmotic pressure &gt; water retention</td><td>Warm, moist skin (due to vasodilation); fine hair; onycholysis (G3); pretibial myxedema in Graves disease [J</td></tr><tr><td>OCULAR</td><td>Periorbital edema [@</td><td>Ophthalmopathy in Graves disease (including periorbital edema, exophthalmos), lid lag/ retraction (t sympathetic stimulation of superior tarsal muscle)</td></tr><tr><td>GASTROINTESTINAL</td><td>Constipation ($ GI motility), } appetite</td><td>Hyperdefecation/diarrhea (t GI motility), t appetite</td></tr><tr><td>MUSCULOSKELETAL</td><td>Hypothyroid myopathy (proximal weakness, t CK), carpal tunnel syndrome, myoedema (small lump rising on the surface of a muscle when struck with hammer)</td><td>Thyrotoxic myopathy (proximal weakness, normal Ck), osteoporosis/t fracture rate (‘T directly stimulates bone resorption)</td></tr><tr><td>REPRODUCTIVE</td><td>a Abnormal uterine bleeding, $ libido, infertility</td><td>Abnormal uterine bleeding, gynecomastia, 4 libido, infertility</td></tr><tr><td>NEUROPSYCHIATRIC</td><td>Hypoactivity, lethargy, fatigue, weakness, depressed mood, $ reflexes (delayed/slow relaxing)</td><td>Hyperactivity, restlessness, anxiety, insomnia, fine tremors (due to t B-adrenergic activity), t reflexes (brisk)</td></tr><tr><td>CARDIOVASCULAR</td><td>Bradycardia, dyspnea on exertion ($ cardiac output)</td><td>Tachycardia, palpitations, dyspnea, arrhythmias (eg, atrial fibrillation), chest pain and systolic HTN due to t number and sensitivity of B-adrenergic receptors, t expression of cardiac sarcolemmal ATPase and 4 expression of phospholamban</td></tr><tr><td>LABS</td><td>t TSH (if 1°)</td><td>+ TSH (if 1°)</td></tr></table>
======================================
<table><tr><td>Hashimoto thyroiditis</td><td>Also called chronic autoimmune thyroiditis. Most common cause of hypothyroidism in iodine- sufficient regions. Associated with HLA-DR3 (differs by ethnicity), t risk of primary thyroid lymphoma (typically diffuse large B-cell lymphoma). Findings: moderately enlarged, nontender thyroid. May be preceded by transient hyperthyroid state (“Hashitoxicosis”) due to follicular rupture and thyroid hormone release. Serology: ® antithyroid peroxidase (antimicrosomal) and antithyroglobulin antibodies. Histology: Hiirthle cells [-, lymphoid aggregates with germinal centers FJ. Postpartum thyroiditis—mild, self-limited variant of Hashimoto thyroiditis arising &lt; | year after</td></tr><tr><td>Subacute granulomatous thyroiditis</td><td>delivery. Also called de Quervain thyroiditis. Usually, a selflimited disease. Natural history: transient hyperthyroidism &gt; euthyroid state + hypothyroidism + euthyroid state. Often preceded by viral infection. Findings: t ESR, jaw pain, very tender thyroid (de Quervain is associated with pain).</td></tr><tr><td></td><td>Histology: granulomatous inflammation [.</td></tr><tr><td>Riedel thyroiditis</td><td>Also called invasive fibrous thyroiditis. May occur as part of IgGy-related disease spectrum (eg, autoimmune pancreatitis, retroperitoneal fibrosis, noninfectious aortitis). Hypothyroidism occurs in ¥% of patients. Fibrosis may extend to local structures (eg, trachea, esophagus), mimicking anaplastic carcinoma. Findings: slowly enlarging, hard (rocklike), fixed, nontender thyroid. Histology: thyroid replaced by fibrous tissue and inflammatory infiltrate [).</td></tr><tr><td>Congenital hypothyroidism</td><td>Formerly called cretinism. Most commonly caused by thyroid dysgenesis (abnormal thyroid gland development; eg, agenesis, hypoplasia, ectopy) or dyshormonogenesis (abnormal thyroid hormone synthesis; eg, mutations in thyroid peroxidase) in iodine-sufficient regions. Findings (6 P’s): pot-bellied, pale, puffy-faced child with protruding umbilicus, protuberant tongue ff, and poor brain development.</td></tr><tr><td>Other causes</td><td>Iodine deficiency (most common cause worldwide; typically presents with goiter [€]), iodine excess (Wolff-Chaikoff effect), drugs (eg, amiodarone, lithium), nonthyroidal illness syndrome (also called euthyroid sick syndrome; $ 'T’; with normal/+ 'T, and TSH in critically ill patients).</td></tr></table>
======================================
<table><tr><td></td><td>= t cytokines (eg, TNF-a, IFN-y) + t fibroblast secretion of hydrophilic GAGs + t osmotic muscle swelling, muscle inflammation, and adipocyte count + exophthalmos J. Often presents during stress (eg, pregnancy). Associated with HLA-DR3 and HLA-B8. Histology: tall, crowded follicular epithelial cells; scalloped colloid.</td></tr><tr><td>Toxic multinodular goiter</td><td>Focal patches of hyperfunctioning follicular cells distended with colloid working independently of TSH (due to TSH receptor mutations in 60% of cases). t release of T3 and Ty. Hot nodules (hyperfunctioning nodules visualized on radioactive iodine scan) are rarely malignant.</td></tr><tr><td>Thyroid storm</td><td>Uncommon but serious complication that occurs when hyperthyroidism is incompletely treated/ untreated and then significantly worsens in the setting of acute stress such as infection, trauma, surgery. Presents with agitation, delirium, fever, diarrhea, coma, and tachyarrhythmia (cause f death). May see t LFTs. ‘Treat with the 4 P’s: B-blockers (eg, propranolol), propylthiouracil, ucocorticoids (eg, prednisolone), potassium iodide (Lugol iodine). Iodide load + $ Ty synthesis Wolff-Chaikoff effect. je] ga 1</td></tr><tr><td>Jod-Basedow phenomenon</td><td>lodine-induced hyperthyroidism. Occurs when a patient with iodine deficiency and partially autonomous thyroid tissue (eg, autonomous nodule) is made iodine replete. Can happen after iodine IV contrast or amiodarone use. Opposite to Wolff-Chaikoff effect. 2</td></tr><tr><td>Causes of goiter</td><td>Smooth/diffuse: Graves disease, Hashimoto thyroiditis, iodine deficiency, TSH-secreting pituitary adenoma. Nodular: toxic multinodular goiter, thyroid adenoma, thyroid cancer, thyroid cyst.</td></tr></table>
======================================
<table><thead><th>DISORDER</th><th>@</th><th>Poe”</th><th>PTH</th><th>ALP</th><th>25(0H) VITAMIN D</th><th>1,25(0H), VITAMIN D</th></thead><tr><td>Vitamin D deficiency</td><td>ht</td><td>i</td><td>t</td><td>t</td><td>t</td><td>—/t</td></tr><tr><td>2° hyperpara- thyroidism (CKD)</td><td>t</td><td>t</td><td>t</td><td>t</td><td>_</td><td>1</td></tr><tr><td>Hypoparathyroidism</td><td>t</td><td>t</td><td>1</td><td>_</td><td>_</td><td>hh</td></tr><tr><td>Pseudohypo-</td><td>1</td><td>t</td><td>t</td><td>t</td><td>—</td><td>hh</td></tr></table>
======================================
<table><tr><td>ACUTE MANIFESTATIONS</td><td>Polydipsia, polyuria, polyphagia (3 state (type 2). Rarely, can be caused by unopposed</td><td>P’s), weight loss, DKA secretion of GH and</td><td>(type 1), hyperosmolar hyperglycemic epinephrine. Also seen in patients on</td></tr><tr><td rowspan="3">CHRONIC COMPLICATIONS.</td><td>glucocorticoid therapy (steroid Nonenzymatic glycation: * Small vessel disease (hyaline</td><td>diabetes). arteriolosclerosis) +</td><td>retinopathy, neuropathy, nephropathy.</td></tr><tr><td></td><td>= Large vessel disease (atherosclerosis) disease. MI is the most common Osmotic damage (sorbitol accumulation</td><td>+ CAD, cerebrovascular cause of death. in organs with aldose</td><td>disease, peripheral vascular reductase and 4 or absent sorbitol</td></tr><tr><td></td><td>dehydrogenase): » Neuropathy: motor, sensory (glove GERD, gastroparesis, diabetic = Cataracts.</td><td>and stocking distribution), diarrhea).</td><td>autonomic degeneration (eg,</td></tr><tr><td rowspan="4">DIAGNOSIS</td><td>TEST HbA.</td><td>DIAGNOSTIC CUTOFF 26.5%</td><td>NOTES Reflects average blood glucose over prior 3 months (influenced by RBC turnover)</td></tr><tr><td></td><td>Fasting plasma glucose</td><td>2 126 mg/dL</td><td>Fasting for &gt; 8 hours</td></tr><tr><td></td><td>2-hour oral glucose tolerance test</td><td>= 200 mg/dL</td><td>2 hours after consumption of 75 g of glucose in water</td></tr><tr><td></td><td>Random plasma glucose</td><td>= 200 mg/dL</td><td>Presence of hyperglycemic</td></tr></table>
======================================
<table><tr><td>1° DEFECT</td><td>Autoimmune T-cell—mediated destruction of B cells</td><td>t resistance to insulin, progressive pancreatic B-cell failure</td></tr><tr><td>INSULIN NECESSARY IN TREATMENT</td><td>Always</td><td>Sometimes</td></tr><tr><td>AGE (EXCEPTIONS COMMON)</td><td>&lt;30yr</td><td>&gt; 40 yr</td></tr><tr><td>ASSOCIATION WITH OBESITY</td><td>No</td><td>Yes</td></tr><tr><td>GENETIC PREDISPOSITION</td><td>Relatively weak (50% concordance in identical twins), polygenic</td><td>Relatively strong (90% concordance in identical twins), polygenic</td></tr><tr><td>ASSOCIATION WITH HLA SYSTEM</td><td>Yes, HLA-DR4 and -DR3 (4 —3 = type 1)</td><td>No</td></tr><tr><td>GLUCOSE INTOLERANCE</td><td>Severe</td><td>Mild to moderate</td></tr><tr><td>INSULIN SENSITIVITY</td><td>High</td><td>Low</td></tr><tr><td>KETOACIDOSIS</td><td>Common</td><td>Rare</td></tr><tr><td>B-CELL NUMBERS IN THE ISLETS</td><td>1</td><td>Variable (with amyloid deposits)</td></tr><tr><td>SERUM INSULIN LEVEL</td><td>1</td><td>t initially, but } in advanced disease</td></tr><tr><td>CLASSIC SYMPTOMS OF POLYURIA, POLYDIPSIA, POLYPHAGIA, WEIGHT LOSS</td><td>Common</td><td>Sometimes</td></tr><tr><td>HISTOLOGY</td><td>Islet leukocytic infiltrate</td><td>Islet amyloid polypeptide deposits</td></tr></table>
======================================
<table><thead><th></th><th>Diabetic ketoacidosis</th><th>Hyperosmolar hyperglycemic state</th></thead><tr><td>PATHOGENESIS</td><td>Insulin noncompliance or t requirements due to f stress (eg, infection) &gt; lipolysis and oxidation of free fatty acids + t ketone bodies (B-hydroxybutyrate &gt; acetoacetate). Insulin deficient, ketones present.</td><td>Profound hyperglycemia + excessive osmotic diuresis + dehydration and t serum osmolality &gt; HHS. Classically seen in older patients with type 2 DM and limited ability to drink. Insulin present, ketones deficient.</td></tr><tr><td>SIGNS/SYMPTOMS</td><td>DKA is Deadly: Delirium/psychosis, Kussmaul respirations (rapid, deep breathing), Abdominal pain/nausea/vomiting, Dehydration. Fruity breath odor due to exhaled acetone.</td><td>Thirst, polyuria, lethargy, focal neurologic deficits, seizures.</td></tr><tr><td>LABS</td><td>Hyperglycemia, t H*, 4 HCO; (t anion gap metabolic acidosis), t urine and blood ketone levels, leukocytosis. Normal/t serum K*, but depleted intracellular K* due to transcellular shift from $ insulin and acidosis. Osmotic diuresis + t K* loss in urine &gt; total body K* depletion.</td><td>Hyperglycemia (often &gt; 600 mg/dL), t serum osmolality (&gt; 320 mOsm/kg), normal pH (no acidosis), no ketones. Normal/t serum Kk’, + intracellular K*.</td></tr><tr><td>COMPLICATIONS</td><td>Life-threatening mucormycosis, cerebral edema, cardiac arrhythmias.</td><td>Can progress to coma and death if untreated.</td></tr><tr><td>TREATMENT</td><td colspan="2">IV fluids, TV insulin, and k* (to replete intracellular stores). Glucose may be required to prevent hypoglycemia from insulin therapy.</td></tr></table>
======================================
<table><tr><td>ETIOLOGY</td><td>Most common tumor of the adrenal medulla</td><td>Rule of 1 0's:</td></tr><tr><td></td><td>(black J; points to bone metastases). De rived from chromaffin cells (arise from neural crest). May be associated with germline mutations (eg, NF-1, VHL, RET [MEN 2A, 2B)).</td><td>10% bi alignant ateral 10% extra-adrenal (eg, bladder wall, organ of Zuckerkandl) 10% ca 10% kids cify</td></tr><tr><td>SYMPTOMS</td><td>Most tumors secrete epinephrine, norepinephrine, and do amine, which can cause episodic hypertension. May also secrete EPO = polycythemia. Symptoms occur in “spel s”—relapse and remit.</td><td>Episodic hyperadrenergic symptoms (5 P’s): Pressure (t BP) Pain (headache) Perspiration Palpita' Pallor ions (tachycardia)</td></tr><tr><td>FINDINGS</td><td>t catecholamines and metanephrines (eg, homovanillic acid, vani urine and plasma. lylmandelic acid) in</td><td>Chromogranin, synaptophysin and NSE @.</td></tr><tr><td>TREATMENT</td><td>Irreversible o-antagonists (eg, phenoxybenzamine) fol prior to tumor resection. owed by B-blockers . o-blockade must be achieved before giving B-blockers to avoid a</td><td>Phenoxybenzamine for pheochromocytoma.</td></tr></table>
======================================
<table><thead><th>neoplasias</th><th>The X-MEN are dominant over villains.</th></thead><tr><td>SUBTYPE</td><td>CHARACTERISTICS</td></tr><tr><td>MEN2A</td><td>Parathyroid hyperplasia Medullary thyroid carcinoma—neoplasm of parafollicular C cells; secretes calcitonin; prophylactic thyroidectomy required Pheochromocytoma (secretes catecholamines) Associated with mutation in RET codes for chromosome</td></tr><tr><td>MEN2B</td><td>(protooncogene, receptor tyrosine kinase, 10) Medullary thyroid carcinoma</td></tr><tr><td></td><td>Pheochromocytoma Mucosal neuromas [i (oral/intestinal ganglioneuromatosis) Associated with marfanoid habitus; mutation in RET gene</td></tr></table>
======================================
<table><tr><td>Glucagonoma</td><td>Tumor of surgical pancreatic &amp; cells + overproduction of glucagon. Presents with 6 D’s: dermatitis (necrolytic migratory erythema), diabetes (hyperglycemia), DVT, declining weight, depression, diarrhea. ‘Treatmeni : octreotide, surgical resection.</td></tr><tr><td>Somatostatinoma</td><td>Tumor of cholecys May prese pancreatic 8 cells + overproduction of somatostatin + 4 secretion of secretin, okinin, glucagon, insulin, gastrin, gastric inhibitory peptide (GIP). nt with diabetes/glucose intolerance, steatorrhea, gallstones, achlorhydria.</td></tr></table>
======================================
<table><thead><th>DRUG</th><th>MECHANISM</th><th>ADVERSE EFFECTS</th></thead><tr><td colspan="3">Increase insulin sensitivity</td></tr><tr><td>Metformin</td><td>Inhibits mitochondrial glycerol-3-phosphate dehydrogenase (mGPD) =&gt; inhibition of hepatic gluconeogenesis and the action of glucagon. t glycolysis, peripheral glucose uptake (t insulin sensitivity).</td><td>GI upset, lactic acidosis (use with caution in renal insufficiency), vitamin Bj deficiency. Weight loss (often desired).</td></tr><tr><td>Pioglitazone</td><td>Activate PPAR-y (a nuclear receptor) &gt; f insulin sensitivity and levels of adiponectin = regulation of glucose metabolism and fatty acid storage.</td><td>Weight gain, edema, HF, t risk of fractures. Delayed onset of action (several weeks).</td></tr><tr><td colspan="3">Increase insulin secretion</td></tr><tr><td>Sulfonylureas (1st gen) Chlorpropamide, tolbutamide</td><td>Close K* channels in cell</td><td rowspan="3">Disulfiram-like reaction with first-generation sulfonylureas only (rarely used). Hypoglycemia (t risk in renal insufficiency), weight gain.</td></tr><tr><td>Sulfonylureas (2nd gen) Glipizide, glyburide a Meglitinides</td><td>pancreatic B membrane &gt; cell depolarizes &gt; insulin release via t Ca** influx.</td><td></td></tr><tr><td>Nateglinide, repaglinide</td><td></td><td></td></tr><tr><td colspan="3">Increase glucose-induced insulin secretion</td></tr><tr><td>GLP-1 analogs Exenatide, liraglutide, semaglutide</td><td>+ glucagon release, } gastric emptying, t glucose-dependent insulin release.</td><td>Nausea, vomiting, pancreatitis. Weight loss (often desired). t satiety (often desired).</td></tr><tr><td>DPP-4 inhibitors Linagliptin, saxagliptin, sitagliptin</td><td>Inhibit DPP-4 enzyme that deactivates GLP-1 + 4 glucagon release, + gastric emptying. t glucose-dependent insulin release.</td><td>Respiratory and urinary infections, weight neutral. t satiety (often desired).</td></tr><tr><td colspan="3">Decrease glucose absorption</td></tr><tr><td>Sodium-glucose co-transporter 2 inhibitors Canagliflozin, dapagliflozin, empadgliflozin</td><td>Block reabsorption of glucose in proximal convoluted tubule.</td><td>Glucosuria (UTIs, vulvovaginal candidiasis), dehydration (orthostatic hypotension), weight loss. Glucose flows in urine. Use with caution in renal insufficiency (4 efficacy with + GFR).</td></tr><tr><td>a-glucosidase inhibitors Acarbose, miglitol</td><td>Inhibit intestinal brush-border o-glucosidases = delayed carbohydrate hydrolysis and glucose absorption &gt; $ postprandial hyperglycemia.</td><td>GI upset, bloating. Not recommended in renal insufficiency.</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Block thyroid peroxidase, inhibiting the oxidation of iodide as well as the organification and coupling of iodine &gt; inhibition of thyroid hormone synthesis. PTU also blocks 5’-deiodinase &gt; 4 Peripheral conversion of Ty to T3.</td></tr><tr><td>CLINICAL USE</td><td>Hyperthyroidism. PTU used in Primary (first) trimester of pregnancy (due to methimazole teratogenicity); methimazole used in second and third trimesters of pregnancy (due to risk of PTU-induced hepatotoxicity). Not used to treat Graves ophthalmopathy (treated with glucocorticoids).</td></tr><tr><td>ADVERSE EFFECTS</td><td>Skin rash, agranulocytosis (rare), aplastic anemia, hepatotoxicity. PTU use has been associated with ANCA-positive vasculitis. Methimazole is a possible teratogen (can cause aplasia cutis).</td></tr></table>
======================================
<table><thead><th>DRUG</th><th>CLINICAL USE</th></thead><tr><td>Conivaptan, tolvaptan</td><td>ADH antagonists SIADH (block action of ADH at V2-receptor)</td></tr><tr><td>Demeclocycline</td><td>ADH antagonist, a tetracycline SIADH (interferes with ADH signaling)</td></tr><tr><td>Desmopressin</td><td>ADH analog Central DI, von Willebrand disease, sleep enuresis, hemophilia A</td></tr><tr><td>GH</td><td>GH deficiency, Turner syndrome</td></tr><tr><td>Oxytocin</td><td>Induction of labor (stimulates uterine contractions), control uterine hemorrhage</td></tr><tr><td>Somatostatin (octreotide)</td><td>Acromegaly, carcinoid syndrome, gastrinoma, glucagonoma, esophageal varices</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Synthetic analog of aldosterone with glucocorticoid effects. Fluidrocortisone retains fluid.</td></tr><tr><td>CLINICAL USE</td><td>Mineralocorticoid replacement in 1° adrenal insufficiency.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Similar to glucocorticoids; also edema, exacerbation of heart failure, hyperpigmentation.</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Sensitizes calcium-sensing receptor (CaSR) in parathyroid gland to circulating Ca** + $ PTH.</td></tr><tr><td>CLINICAL USE</td><td>2° hyperparathyroidism in patients with CKD receiving hemodialysis, hypercalcemia in 1° hyperparathyroidism (if parathyroidectomy fails), or in parathyroid carcinoma.</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Nonabsorbable phosphate binder that prevents phosphate absorption from the GI tract.</td></tr><tr><td>CLINICAL USE</td><td>Hyperphosphatemia in CKD.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Hypophosphatemia, GI upset.</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Bind K* in colon in exchange for other cations (eg, Na*, Ca’*) &gt; K* excreted in feces.</td></tr><tr><td>CLINICAL USE</td><td>Hyperkalemia.</td></tr></table>
======================================
<table><tr><td>Gastrointestinal</td></tr><tr><td>“A good set of bowels is worth more to a man than any quantity of brains.” —Josh Billings » Embryology » Anatomy</td></tr><tr><td>“Man should strive to have his intestines relaxed all the</td></tr><tr><td>days of his life.” —Moses Maimonides » Physiology</td></tr><tr><td>“All right, let’s not panic. I'll make the money by selling one of my livers. I can get by with one.” » Pathology</td></tr><tr><td>—Homer Simpson, The Simpsons » Pharmacology</td></tr><tr><td>“The truth does not change according to our ability to stomach it emotionally.”</td></tr><tr><td>—Flannery O’Connor</td></tr></table>
======================================
<table><tr><td rowspan="3">Spleen Kid raney</td><td></td><td>Gastrosplenic ligament</td><td></td><td rowspan="4">Transverse colon NOTES</td></tr><tr><td></td><td></td><td>Splenorenal ligament</td><td></td><td></td></tr><tr><td></td><td></td><td>Gastrocolic ligament</td><td></td><td></td></tr><tr><td>LIGAMENT</td><td>CONNECTS</td><td>STRUCTURES CONTAINED</td><td></td><td></td></tr><tr><td>Falciform ligament</td><td>Liver to anterior abdominal wall</td><td>Ligamentum teres hepatis (derivative of fetal vein), patent veins</td><td>umbilical paraumbilical</td><td>Derivative of ventral mesentery</td></tr><tr><td>Hepatoduodenal ligament</td><td>Liver to duodenum</td><td>Portal triad: proper hepatic artery, portal vein, bile duct</td><td>common</td><td>Derivative of ventral mesentery Pringle maneuver—ligament is compressed manually or with a vascular clamp in omental foramen to control bleeding from hepatic inflow source (portal vein, hepatic artery) vs outflow (hepatic veins, 1VC) Borders the omental foramen, which connects the greater and lesser sacs Part of lesser omentum</td></tr><tr><td>Hepatogastric ligament</td><td>Liver to lesser curvature of stomach</td><td>Gastric vessels</td><td></td><td>Derivative of ventral mesentery Separates greater and lesser sacs on the right May be cut during surgery to access lesser sac Part of lesser omentum</td></tr><tr><td>Gastrocolic ligament</td><td>Greater curvature and transverse colon</td><td>Gastroepiploic arteries</td><td></td><td>Derivative of dorsal mesentery Part of greater omentum</td></tr><tr><td>Gastrosplenic ligament</td><td>Greater curvature and spleen</td><td>Short gastrics, left gastroepiploic vessels</td><td></td><td>Derivative of dorsal mesentery Separates greater and lesser sacs on the left Part of greater omentum</td></tr></table>
======================================
<table><thead><th rowspan="2">EMBRYONIC GUT REGION</th><th rowspan="2">ARTERY</th><th rowspan="2">PARASYMPATHETIC INNERVATION</th><th>VERTEBRAL</th><th rowspan="2">STRUCTURES SUPPLIED.</th></thead><thead><th></th><th></th><th></th><th>LEVEL</th><th></th></thead><tr><td>Foregut</td><td>Celiac</td><td>Vagus</td><td>T12/L1</td><td>Pharynx (vagus nerve only) and lower esophagus (celiac artery only) to proximal duodenum; liver, gallbladder, pancreas, spleen (mesoderm)</td></tr><tr><td>Midgut</td><td>SMA</td><td>Vagus</td><td>Ll</td><td>Distal duodenum to proximal 2/3 of transverse colon</td></tr><tr><td>Hindgut</td><td>IMA</td><td>Pelvic</td><td>L3</td><td>Distal 1/3 of transverse colon to upper portion of</td></tr></table>
======================================
<table><thead><th>REGULATORY SUBSTANCE</th><th>SOURCE</th><th>ACTION</th><th>REGULATION</th><th>NOTES</th></thead><tr><td>Gastrin</td><td>G cells (antrum of stomach, duodenum)</td><td>t gastric H* secretion t growth of gastric mucosa t gastric motility</td><td>t by stomach distention/ alkalinization, amino acids, peptides, vagal stimulation via gastrin-releasing peptide (GRP) + bypH&lt;15</td><td>t by chronic PPI use t in chronic atrophic gastritis (eg, H pylori) tt in Zollinger-Ellison syndrome (gastrinoma)</td></tr><tr><td>Somatostatin</td><td>D cells (pancreatic islets, GI mucosa)</td><td>+ gastric acid and pepsinogen secretion + pancreatic and small intestine fluid secretion 4 gallbladder contraction + insulin and glucagon release</td><td>t by acid + by vagal stimulation</td><td>Inhibits secretion of various hormones (encourages somato-stasis) Octreotide is an analog used to treat acromegaly, carcinoid syndrome, VIPoma, and variceal bleeding</td></tr><tr><td>Cholecystokinin</td><td>Icells (duodenum, jejunum)</td><td>t pancreatic secretion t gallbladder contraction + gastric emptying t sphincter of Oddi relaxation</td><td>t by fatty acids, amino acids</td><td>Acts on neural muscarinic pathways to cause pancreatic secretion</td></tr><tr><td>Secretin</td><td>S cells (duodenum)</td><td>t pancreatic HCO,- secretion + gastric acid secretion</td><td>t by acid, fatty acids in lumen of duodenum</td><td>t HCO, neutralizes gastric acid in duodenum, allowing pancreatic enzymes to</td></tr><tr><td>Glucose- dependent insulinotropic peptide</td><td>K cells (duodenum, jejunum)</td><td>t bile secretion Exocrine: + gastric H* secretion Endocrine: t insulin release</td><td>t by fatty acids, amino acids, oral glucose</td><td>function Also called gastric inhibitory peptide (GIP) Oral glucose load t insulin compared to IV equivalent</td></tr><tr><td>Motilin</td><td>Small intestine</td><td>Produces migrating motor complexes (MMCs)</td><td>fin fasting state</td><td>due to GIP secretion Motilin receptor agonists (eg, erythromycin) are used to stimulate intestinal</td></tr><tr><td>Vasoactive intestinal polypeptide</td><td>Parasympathetic ganglia in sphincters, gallbladder, small intestine</td><td>t intestinal water and electrolyte secretion t relaxation of intestinal smooth muscle and sphincters</td><td>t by distention and vagal stimulation + by adrenergic input</td><td>peristalsis. ViPoma—non-a, non-f islet cell pancreatic tumor that secretes VIP; associated with Watery Diarrhea, Hypokalemia, Achlorhydria</td></tr><tr><td>Nitric oxide</td><td></td><td>t smooth muscle relaxation, including lower esophageal sphincter (LES)</td><td></td><td>(WDHA syndrome) Loss of NO secretion is implicated in t LES tone of achalasia</td></tr><tr><td>Ghrelin</td><td>Stomach</td><td>t appetite (“ghrowlin’</td><td>t in fasting state</td><td>tf in Prader-Willi syndrome</td></tr></table>
======================================
<table><thead><th>PRODUCT</th><th>SOURCE</th><th>ACTION</th><th>REGULATION</th><th>NOTES</th></thead><tr><td>Gastric acid</td><td>Parietal cells (stomach fi)</td><td>+ stomach pH</td><td>t by histamine, vagal</td><td>Autoimmune destruction of parietal cells + chronic</td></tr><tr><td>Intrinsic factor</td><td>Parietal cells (stomach)</td><td>Vitamin B,,—-binding protein (required for B,, uptake in terminal ileum)</td><td>stimulation (ACh), gastrin + by somatostatin, GIP, prostaglandin, secretin</td><td>gastritis and pernicious anemla</td></tr><tr><td>Pepsin</td><td>Chief cells (stomach)</td><td>Protein digestion</td><td>t by vaga stimulation (ACh), local acid</td><td>Pepsinogen (inactive) is converted to pepsin (active) in the presence of H*</td></tr><tr><td>Bicarbonate</td><td>Mucosal cells (stomach, duodenum, salivary glands, pancreas) and Brunner glands</td><td>Neutralizes acid</td><td>t by pancreatic and biliary secretion with secretin</td><td>Trapped in mucus that covers the gastric epithelium</td></tr></table>
======================================
<table><tr><td>Aphthous ulcers</td><td>Also called canker sores. Common oral lesions that appear as painful, shallow, round to oval ulcers covered by yellowish exudate fi. Recurrent aphthous stomatitis is associated with celiac disease, IBD, SLE, Behcet syndrome, HIV infection.</td></tr><tr><td>Squamous cell carcinoma</td><td>Most common malignancy of oral cavity. Usually affects the tongue. Associated with tobacco, alcohol, IPV-16. Presents as nonhealing ulcer with irregular margins and raised borders. Leukoplakia (white patch [)) and erythroplakia (red patch) are precursor lesions.</td></tr><tr><td>Sialolithiasis</td><td>Stone formation in ducts of major salivary glands (parotid [@, submandibular, or sublingual). Associated with salivary stasis (eg, dehydration) and trauma. Presents as recurrent pre-/periprandial pain and swelling in affected gland.</td></tr><tr><td>Sialadenitis</td><td>Inflamma ion of salivary gland due to obstruction, infection (eg, S aureus, mumps virus), or immune-mediated mechanisms (eg, Sjégren syndrome).</td></tr><tr><td>Salivary gland tumors</td><td>Usually benign and most commonly affect the parotid gland. Submandibular, sublingual, and minor sa swelling. ivary gland tumors are more likely to be malignant. Typically present as painless mass/ Facial paralysis or pain suggests malignant involvement. ® Pleomorphic adenoma (benign mixed tumor)—most common salivary gland tumor [3). Composed of chondromyxoid stroma and epithelium and recurs if incompletely excised or ruptured intraoperatively. May undergo malignant transformation. ® Warthin tumor (papillary cystadenoma lymphomatosum)—benign cystic tumor with germinal centers. May be bilateral or multifocal. Typically found in people who smoke. “Warriors from Germany love smoking.” » Mucoepidermoid carcinoma—most common malignant tumor. Mucinous and squamous components.</td></tr></table>
======================================
<table><tr><td>Gastroesophageal reflux disease</td><td>Transient decreases in LES tone. Commonly presents as heartburn, regurgitation, dysphagia. May also present as chronic cough, hoarseness (laryngopharyngeal reflux). Associated with asthma. Complications include erosive esophagitis, strictures, and Barrett esophagus.</td></tr><tr><td>Plummer-Vinson syndrome</td><td>esophagitis—2° ingestion. Triad of dysphagia, iron deficiency anemia, esophageal webs. t risk of esophageal squamous cell carcinoma ("Plumber dies"). May be associated with glossitis.</td></tr><tr><td>Mallory-Weiss syndrome</td><td>Partial thickness, longitudinal lacerations of gastroesophageal junction, confined to mucosa/ submucosa, due to severe vomiting. Often presents with hematemesis +/— abdominal/back pain. Usually found in patients with alcohol use disorder, bulimia nervosa.</td></tr><tr><td>Esophageal varices</td><td>Dilated submucosal veins (red arrows in [)) in lower 1/3 of esophagus 2° to portal hypertension. Common in patients with cirrhosis, may be source of life-threatening hematemesis.</td></tr><tr><td>Distal esophageal spasm</td><td>Formerly called diffuse esophageal spasm. Spontaneous, nonperistaltic (uncoordinated) contractions of the esophagus with normal LES pressure. Presents with dysphagia and anginali chest pain. Barium swallow may reveal “corkscrew” esophagus. Manometry is diagnostic. Treatment includes nitrates and CCBs.</td></tr><tr><td>Scleroderma esophageal involvement</td><td>Esophageal smooth muscle atrophy + 4 LES pressure and distal esophageal dysmotility + acid reflux and dysphagia &gt; stricture, Barrett esophagus, and aspiration. Part of CREST syndrome.</td></tr><tr><td>Esophageal perforation</td><td>Most commonly iatrogenic following esophageal instrumentation. Noniatrogenic causes include spontaneous rupture, foreign body ingestion, trauma, malignancy. May present with pneumomediastinum (arrows in [@). Subcutaneous emphysema may be due</td></tr></table>
======================================
<table><thead><th>CANCER</th><th>PART OF ESOPHAGUS AFFECTED</th><th>RISK FACTORS</th><th>PREVALENCE</th></thead><tr><td>Squamous cell carcinoma</td><td>Upper 2/3</td><td>Alcohol, hot liquids, caustic strictures, smoking, achalasia, nitrosamine-rich foods</td><td>More common worldwide</td></tr><tr><td>Adenocarcinoma</td><td>Lower 1/3</td><td>Chronic GERD, Barrett esophagus, obesity, tobacco smoking</td><td>More common in America</td></tr></table>
======================================
<table><tr><td>Acute gastritis</td><td>Erosions can be caused by: » NSAIDs—4 PGE, &gt; $ gastric mucosa protection</td><td>Especially common among patients with alcohol use disorder and those taking daily NSAIDs (eg, for rheumatoid arthritis)</td></tr><tr><td>Chronic gastritis</td><td>production Mucosal inflammation, often leading to atrophy (hypochlorhydria + hypergastrinemia) and intestinal metaplasia (t risk of gastric cancers)</td><td></td></tr><tr><td>H pylori</td><td>Most common. t risk of peptic ulcer disease, MALT lymphoma</td><td>Affects antrum first and spreads to body of stomach</td></tr><tr><td>Autoimmune</td><td>Autoantibodies (T-cell induced) to the H*/K*-ATPase on parietal cells and to intrinsic</td><td>Affects body/fundus of stomach</td></tr></table>
======================================
<table><thead><th></th><th>Gastric ulcer</th><th>Duodenal ulcer</th></thead><tr><td>PAIN</td><td>Can be greater with meals—weight loss</td><td>Decreases with meals—weight gain</td></tr><tr><td>H PYLORI INFECTION</td><td>~ 70%</td><td>~ 90%</td></tr><tr><td>MECHANISM</td><td>+ mucosal protection against gastric acid</td><td>+ mucosal protection or t gastric acid secretion</td></tr><tr><td>OTHER CAUSES</td><td>NSAIDs</td><td>Zollinger-Ellison syndrome</td></tr><tr><td rowspan="2">RISK OF CARCINOMA</td><td>t</td><td>Generally benign</td></tr><tr><td></td><td>Biopsy margins to rule out malignancy</td><td>Not routinely biopsied</td></tr></table>
======================================
<table><tr><td>Hemorrhage</td><td>Gastric, duodenal (posterior &gt; anterior). Most common complication. Ruptured ulcer the lesser of stomach bleeding from left</td></tr><tr><td>Obstruction</td><td>Pyloric channel, duodenal. Duodenal</td></tr><tr><td></td><td>Anterior duodenal ulcers can perforate into the anterior abdominal cavity, potentially leading to pneumoperitoneum. May see free air under diaphragm (pneumoperitoneum) [iN with referred pain to the shoulder via irritation of phrenic nerve.</td></tr></table>
======================================
<table><tr><td>LOCATION</td><td>Any portion of the GI tract, usually the terminal ileum and colon. Skip lesions, rectal sparing.</td><td>— Colitis = colon inflammation. Continuous colonic lesions, always with rectal involvement.</td></tr><tr><td>GROSS MORPHOLOGY</td><td>Transmural inflammation &gt; fistulas. Cobblestone mucosa, creeping fat, bowel wall thickening (“string sign” on small bowel follow-through [¥), linear ulcers, fissures.</td><td>Mucosal and submucosal inflammation only. Friable mucosa with superficial and/or deep ulcerations (compare normal [J with diseased [). Loss of haustra &gt; “lead pipe” appearance on imaging.</td></tr><tr><td>MICROSCOPIC MORPHOLOGY</td><td>Noncaseating granulomas, lymphoid aggregates.</td><td>Crypt abscesses/ulcers, bleeding, no granulomas.</td></tr><tr><td>COMPLICATIONS</td><td>Malabsorption/malnutrition, colorectal cancer (t</td><td>risk with pancolitis).</td></tr><tr><td>INTESTINAL MANIFESTATION</td><td>obstruction), Diarrhea that may or may not be bloody.</td><td>Bloody diarrhea (usually painful).</td></tr><tr><td rowspan="2">EXTRAINTESTINAL MANIFESTATIONS</td><td>Rash (pyoderma gangrenosum, erythema nodosum), ulcerations (aphthous stomatitis), arthritis</td><td>eye inflammation (episcleritis, uveitis), oral (peripheral, spondylitis).</td></tr><tr><td></td><td>Kidney stones (usually calcium oxalate), gallstones. May be © for anti-Saccharomyces cerevisiae antibodies (ASCA).</td><td>1° sclerosing cholangitis. Associated with MPO- ANCA/p-ANCA.</td></tr><tr><td>TREATMENT</td><td>Glucocorticoids, azathioprine, antibiotics (eg, ciprofloxacin, metronidazole), biologics (eg, infliximab, adalimumab).</td><td>5-aminosalicylic acid preparations (eg, mesalamine), 6-mercaptopurine, infliximab, colectomy.</td></tr><tr><td>DISEASE ACTIVITY</td><td>Fecal calprotectin used to monitor activity and</td><td>distinguish from noninflammatory diseases</td></tr></table>
======================================
<table><thead><th>Acute mesenteric ischemia</th><th>Critical blockage of intestinal blood flow (often embolic occlusion of SMA) — small bowel necrosis [5) + abdominal pain out of proportion to physical findings. May see red “currant jelly” stools. Risk factors: atrial fibrillation, peripheral arterial disease, recent MI, CHF.</th></thead><tr><td>Angiodysplasia</td><td>Tortuous dilation of vessels + hematochezia. Most often found in the right-sided colon. More common in older patients. Confirmed by angiography. Associated with end-stage renal disease, von Willebrand disease, aortic stenosis.</td></tr><tr><td>Chronic mesenteric ischemia</td><td>“Intestinal angina”: atherosclerosis of celiac artery, SMA (most commonly affected), or IMA &gt; intestinal hypoperfusion &gt; postprandial epigastric pain &gt; food aversion and weight loss.</td></tr><tr><td>Colonic ischemia</td><td>Crampy abdominal pain followed by hematochezia. Commonly occurs at watershed areas (splenic flexure, rectosigmoid junction). Typically affects older adults. Thumbprint sign on imaging due to mucosal edema/hemorthage.</td></tr><tr><td>lleus</td><td>Intestinal hypomotility without obstruction &gt; constipation and 4 flatus; distended/tympanic abdomen with 4 bowel sounds. Associated with abdominal surgeries, opiates, hypokalemia, sepsis. No transition zone on imaging. Treatment: bowel rest, electrolyte correction, cholinergic drugs (stimulate intestinal motility).</td></tr><tr><td>Necrotizing enterocolitis</td><td>Seen in premature, formula-fed infants with immature immune system. Necrosis of intestinal mucosa (most commonly terminal ileum and proximal colon), which can lead to pneumatosis intestinalis (arrows in [), pneumoperitoneum, portal venous gas.</td></tr><tr><td>Proctitis</td><td>Inflammation of rectal mucosa, usually associated with infection (N gonorrhea, Chlamydia, Campylobacter, Shigella, Salmonella, HSV, CMV), IBD, and radiation. Patients report tenesmus, rectal bleeding, and rectal pain. Proctoscopy reveals inflamed rectal mucosa (ulcers/vesicles in the case of HSV). Rectal swabs are used to detect other infectious etiologies.</td></tr><tr><td>Small bowel obstruction</td><td>Normal flow of intraluminal contents is interrupted + fluid accumulation and intestinal dilation proximal to blockage and intestinal decompression distal to blockage. Presents with abrupt onset of abdominal pain, nausea, vomiting, abdominal distension. Compromised blood flow due to excessive dilation or strangulation may lead to ischemia, necrosis, or perforation. Most commonly caused by intraperitoneal adhesions (fibrous band of scar tissue), tumors, and hernias (in rare cases, meconium plug in newborns + meconium ileus). Upright abdominal x-ray shows air-fluid levels [§. Management: gastrointestinal decompression, volume resuscitation, bowel rest.</td></tr><tr><td>Small intestinal bacterial overgrowth</td><td>Abnormal bacterial overgrowth in the small intestine (normally low bacterial colony count). Risk factors: altered pH (eg, achlorhydria, PPI use), anatomical (eg, small bowel obstruction, adhesions, fistula, gastric bypass surgery, blind loop), dysmotility (eg, gastroparesis), immune mediated (IgA deficiency, HIV). Presents with bloating, flatulence, abdominal pain, chronic watery diarrhea, malabsorption (vitamin B,,) in Diagnosis: carbohydrate breath test small bowel</td></tr></table>
======================================
<table><thead><th>Generally nonneoplastic</th><th></th></thead><tr><td>Hamartomatous polyps</td><td>Solitary lesions do not have significant risk of transformation. Growths of normal colonic tissue with distorted architecture. Associated with Peutz-Jeghers syndrome and juvenile polyposis.</td></tr><tr><td>Hyperplastic polyps</td><td>Most common; generally smaller and predominantly located in rectosigmoid region. Occasionally evolves into serrated polyps and more advanced lesions.</td></tr><tr><td>Inflammatory pseudopolyps</td><td>Due to mucosal erosion in inflammatory bowel disease.</td></tr><tr><td>Mucosal polyps</td><td>Small, usually &lt; 5 mm. Look similar to normal mucosa. Clinically insignificant.</td></tr><tr><td>Submucosal polyps</td><td>May include lipomas, leiomyomas, fibromas, and other lesions.</td></tr><tr><td colspan="2">Potentially malignant</td></tr><tr><td>Adenomatous polyps</td><td>—_ Neoplastic, via chromosomal instability pathway with mutations in APC and KRAS. ‘Tubular Fj</td></tr></table>
======================================
<table><tr><td>Familialadenomatous polyposis</td><td>Autosomal dominant mutation of APC tumor suppressor gene on chromosome 5q21-q22. 2-hit hypothesis. Thousands of polyps arise starting after puberty; pancolonic; always involves rectum. Prophylactic colectomy or else 100% progress to CRC.</td></tr><tr><td>Gardner syndrome</td><td>FAP + osseous and soft tissue tumors (eg, osteomas of skull or mandible), congenital hypertrophy of retinal pigment epithelium, impacted/supernumerary teeth.</td></tr><tr><td>Turcot syndrome</td><td>FAP or Lynch syndrome + malignant CNS tumor (eg, medulloblastoma, glioma). Turcot = Turban.</td></tr><tr><td>Peutz-Jeghers syndrome</td><td>Autosomal dominant syndrome featuring numerous hamartomatous polyps throughout GI tract, along with hyperpigmented macules on mouth, lips, hands, genitalia. Associated with t risk of breast and GI cancers (eg, colorectal, stomach, small bowel, pancreatic).</td></tr><tr><td>Juvenile polyposis syndrome</td><td>Autosomal dominant syndrome in children (typically &lt;5 years old) featuring numerous hamartomatous polyps in the colon, stomach, small bowel. Associated with t risk of CRC.</td></tr><tr><td>MUTYH-associated polyposis syndrome</td><td>Autosomal recessive disorder of the MUTYH gene responsible for DNA repair. Associated with significantly t risk of CRC, polyps (adenomatous; may be hyperplastic or serrated), and serrated</td></tr></table>
======================================
<table><tr><td>EPIDEMIOLOGY</td><td>Most patients are &gt; 50 years old. ~ 25% have a family history.</td></tr><tr><td>RISK FACTORS</td><td>Adenomatous and serrated polyps, familial cancer syndromes, IBD, tobacco use, diet of processed meat with low fiber.</td></tr><tr><td>PRESENTATION</td><td>Rectosigmoid &gt; ascending &gt; descending. Most are asymptomatic. Right side (cecal, ascending) associated with occult bleeding; left side (rectosigmoid) associated with hematochezia and obstruction (narrower lumen — } stool caliber). Ascending—exophytic mass, iron deficiency anemia, weight loss. Descending—infiltrating mass, partial obstruction, colicky pain, hematochezia. Can present with S bovis (gallolyticus) bacteremia/endocarditis or as an episode of diverticulitis.</td></tr><tr><td></td><td>FIT-fecal DNA, CT colonography. * Patients with a first-degree relative who has colon cancer: screen at age 40 with colonoscopy, or 10 years prior to the relative’s presentation. * Patients with IBD: screen 8 years after onset. “Apple core” lesion seen on barium enema x-ray 5). CEA tumor marker: good for monitoring recurrence, should not be used for screening.</td></tr></table>
======================================
<table><tr><td colspan="3">ENZYMES RELEASED IN LIVER DAMAGE</td></tr><tr><td>Aspartate aminotransferase and alanine aminotransferase</td><td colspan="2">t in most liver disease: ALT &gt; AST t in alcoholic liver disease: AST &gt; ALT (ratio usually &gt; 2:1, AST does not typically exceed 500 U/L in alcoholic hepatitis). Make a toAST with alcohol AST &gt; ALT in nonalcoholic liver disease suggests progression to advanced fibrosis or cirrhosis ttt aminotransferases (&gt;1000 U/L): differential includes drug-induced liver injury (eg, acetaminophen toxicity), ischemic hepatitis, acute viral hepatitis, autoimmune hepatitis</td></tr><tr><td>Alkaline phosphatase</td><td>__t in cholestasis (eg, biliary obstruction), infiltrative</td><td>disorders, bone disease</td></tr><tr><td>y-glutamyl transpeptidase</td><td colspan="2">t in various liver and biliary diseases (just as ALP can), but not in bone disease (located in canalicular membrane of hepatocytes like ALP); associated with alcohol use</td></tr><tr><td colspan="3">FUNCTIONAL LIVER MARKERS</td></tr><tr><td>Bilirubin</td><td>t in various liver diseases (eg, biliary obstruction,</td><td>alcoholic or viral hepatitis, cirrhosis), hemolysis</td></tr><tr><td>Albumin</td><td>+ in advanced liver disease (marker of liver’s</td><td>biosynthetic function)</td></tr><tr><td>Prothrombin time</td><td>t in advanced liver disease (4 production of clotting biosynthetic function)</td><td>factors, thereby measuring the liver’s</td></tr><tr><td>Platelets</td><td colspan="2">+ in advanced liver disease ($ thrombopoietin, liver sequestration) and portal hypertension (splenomegaly/splenic sequestration)</td></tr><tr><td>Reye syndrome</td><td>Rare, often fatal childhood hepatic encephalopathy. Associated with viral infection (especially VZV and influenza) that has been treated with aspirin. Aspirin metabolites + B-oxidation by reversible inhibition of mitochondrial enzymes. Findings: mitochondrial abnormalities, fatty liver (microvesicular fatty changes), hypoglycemia, vomiting, hepatomegaly, coma. t ICP t morbidity and mortality. Renal and cardiac failure may also occur. Requires expert review.</td><td>Avoid aspirin (ASA) in children, except in KawASAki disease. Salicylates aren’t a ray (Reye) of sunSHINE for kids: Steatosis of liver/hepatocytes Hypoglycemia/Hepatomegaly Infection (VZV, influenza) Not awake (coma) Encephalopathy</td></tr></table>
======================================
<table><tr><td>Conjugated (direct) hyperbilirubinemia</td><td>Biliary tract obstruction: gallstones, cholangiocarcinoma, pancreatic or liver cancer, liver fluke. Biliary tract disease: 1° sclerosing cholangitis, 1° biliary cholangitis Excretion defect: Dubin-Johnson syndrome, Rotor syndrome.</td></tr><tr><td>Unconjugated (indirect) hyperbilirubinemia</td><td>Hemolytic, benign (neonates), Crigler-Najjar, Gilbert syndrome.</td></tr><tr><td>Mixed hyperbilirubinemia</td><td>Both direct and indirect hyperbilirubinemia. Hepatitis, cirrhosis.</td></tr><tr><td rowspan="7">3enign neonatal ayperbilirubinemia</td><td>Formerly called physiologic neonatal jaundice. Mild unconjugated hyperbiliru = t fetal RBC turnover (t hematocrit and $ fetal RBC lifespan). * Immature newborn liver (} UDP-glucuronosyltransferase activity). ® Sterile newborn gut (+ conversion to urobilinogen &gt; t deconjugation by in B-glucuronidase &gt; t enterohepatic circulation). binemia caused by: estinal brush border</td></tr><tr><td></td><td>B-glucuronidase—lysosomal enzyme for direct biliru May lead to pigment stone formation. bin deconjugation. Also found in breast milk.</td></tr><tr><td></td><td>Occurs in near! 1-2 weeks. Exaggerated forms: y all newborns after first 24 hours of li fe and usually resolves wi hout treatment in</td></tr><tr><td></td><td>Breastfeeding failure jaundice—insufficient breast milk intake &gt; 4 bilirubin e t enterohepatic circulation. imination in stool +</td></tr><tr><td></td><td>Breast milk jaundice—t B-glucuronidase in breast mi circulation. k + t deconjugation &gt; t enterohepatic</td></tr><tr><td></td><td>Severe cases may lead to kernicterus (deposition of un brain, particularly basal ganglia). conjugated, lipid-soluble bilirubin in the</td></tr><tr><td></td><td>Treatment: phototherapy (non-UV) isomerizes unconj ugated bilirubin to water-soluble form.</td></tr></table>
======================================
<table><thead><th>Hereditary hyperbilirubinemias</th><th>All autosomal recessive.</th></thead><tr><td>O Gilbert syndrome</td><td>Mildly | UDP-glucuronosyltransferase conjugation. Asymptomatic or mild jaundice usually with stress, illness, or fasting. t unconjugated bilirubin without overt hemolysis. Relatively common, benign condition.</td></tr><tr><td>@ Crigler-Najjar syndrome, type |</td><td>Absent UDP-glucuronosyltransferase. Presents early in life, but some patients may not have neurologic signs until later in life. Findings: jaundice, kernicterus (unconjugated bilirubin deposition in brain), t unconjugated bilirubin Treatment: plasmapheresis and phototherapy (does not conjugate UCB; but does t polarity and t water solubility to allow excretion). Liver transplant is curative.</td></tr><tr><td></td><td>‘Type II is less severe and responds to phenobarbital, which t liver enzyme synthesis.</td></tr><tr><td>© Dubin-Johnson syndrome</td><td>Conjugated hyperbilirubinemia due to defective liver excretion. Grossly black (Dark) liver due to impaired excretion of epinephrine metabolites. Benign.</td></tr><tr><td>© Rotor syndrome</td><td>Phenotypically similar to Dubin-Johnson, but milder in presentation without black (Regular) liver. Due to impaired hepatic storage of conjugated bilirubin.</td></tr></table>
======================================
<table><thead><th></th><th>PATHOLOGY</th><th>EPIDEMIOLOGY</th><th>ADDITIONAL FEATURES</th></thead><tr><td>Primary sclerosing cholangitis</td><td>Unknown cause of concentric “onion skin” bile duct fibrosis + alternating strictures and dilation with “beading” of intra- and extrahepatic bile ducts on ERCP iN, magnetic resonance cholangiopancreatography (MRCP).</td><td>Classically in middle-aged males with ulcerative colitis.</td><td>Associated with ulcerative colitis. MPO-ANCA/ p-ANCA @. t IgM. Can lead to 2° biliary cirrhosis. t risk of cholangiocarcinoma and gallbladder cancer.</td></tr><tr><td>Primary biliary cholangitis</td><td>Autoimmune reaction &gt; lymphocytic infiltrate +/— granulomas — destruction of lobular bile ducts.</td><td>Classically in middle-aged females.</td><td>Antimitochondrial antibody ©, t IgM. Associated with other autoimmune conditions (eg, Hashimoto thyroiditis, rheumatoid arthritis, celiac disease). Treatment: ursodiol.</td></tr><tr><td>Secondary biliary cirrhosis</td><td>Extrahepatic biliary obstruction — t pressure in intrahepatic ducts &gt; injury/ fibrosis and bile stasis.</td><td>Patients with known obstructive lesions (gallstones, biliary strictures, pancreatic carcinoma).</td><td>May be complicated by acute cholangitis.</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Irreversibly inhibit H*/K'-ATPase in stomach parietal</td><td>cells.</td></tr><tr><td>CLINICAL USE</td><td>Peptic ulcer, gastritis, esophageal reflux, Zollinger-Ellison H pylori, stress ulcer prophylaxis.</td><td>syndrome, component of therapy for</td></tr><tr><td>ADVERSE EFFECTS</td><td colspan="2">t risk of C difficile infection, pneumonia, acute interstitial nephritis. Vitamin B,, malabsorption; + serum Mg?'/Ca** absorption (potentially leading to increased fracture risk in older adults).</td></tr><tr><td>Antacids</td><td>Can affect absorption, bioavailability, or urinary urinary pH or by delaying gastric emptying. All</td><td>excretion of other drugs by altering gastric and can cause hypokalemia.</td></tr><tr><td>Aluminum hydroxide</td><td>Constipation, Hypophosphatemia, Osteodystrophy, Proximal muscle weakness, Seizures</td><td>Aluminimum amount of feces CHOPS</td></tr><tr><td>Calcium carbonate</td><td>Hypercalcemia (milk-alkali syndrome), rebound — acid t</td><td>Can chelate and $ effectiveness of other drugs (eg, tetracycline)</td></tr><tr><td>Magnesium hydroxide</td><td>Diarrhea, hyporeflexia, hypotension, cardiac arrest</td><td>Mg* = Must go 2 the bathroom</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>PGE, analog. t production and secretion of gastric mucous barrier, + acid production.</td></tr><tr><td>CLINICAL USE</td><td>Prevention of NSAID-induced peptic ulcers (NSAIDs block PGE, production). Also used offal for induction of labor (ripens cervix).</td></tr><tr><td>ADVERSE EFFECTS</td><td>Diarrhea. Contraindicated in patients of childbearing potential (abortifacient).</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Long-acting somatostatin analog; inhibits secretion of various splanchnic vasodilatory hormones.</td></tr><tr><td>CLINICAL USE</td><td>Acute variceal bleeds, acromegaly, VIPoma, carcinoid tumors.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Nausea, cramps, steatorrhea. tf risk of cholelithiasis due to CCK inhibition.</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>A combination of sulfapyridine (antibacterial) and 5-aminosalicylic acid (anti-inflammatory). Activated by colonic bacteria.</td></tr><tr><td>CLINICAL USE</td><td>Ulcerative colitis, Crohn disease (colitis component).</td></tr></table>
======================================
<table><thead><th>DRUG</th><th>MECHANISM</th><th>CLINICAL USE</th><th>ADVERSE EFFECTS</th></thead><tr><td>Ondansetron, granisetron</td><td>5-HT,-receptor antagonists Also act peripherally (4 vagal stimulation)</td><td>Nausea and vomiting after chemotherapy, radiotherapy, or surgery</td><td>Headache, constipation, OT interval prolongation, serotonin syndrome</td></tr><tr><td>Prochlorperazine, metoclopramide</td><td>D,-receptor antagonists Metoclopramide also causes t gastric emptying and t LES tone</td><td>Nausea and vomiting Metoclopramide is also used in gastroparesis (eg, diabetic), persistent GERD</td><td>Extrapyramidal symptoms, hyperprolactinemia, anxiety, drowsiness, restlessness, depression, GI distress</td></tr><tr><td>Aprepitant, fosaprepitant</td><td>NK, (neurokinin-1) receptor antagonists NK, receptor = substance P</td><td>Chemotherapy-induced nausea and vomiting</td><td>Fatigue, GI distress</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Inhibits gastric and pancreatic lipase + $+ breakdown and absorption of dietary fats. Taken with fat-containing meals.</td></tr><tr><td>CLINICAL USE</td><td>Weight loss.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Abdominal pain, flatulence, bowel urgency/frequent bowel movements, steatorrhea; } absorption of</td></tr></table>
======================================
<table><thead><th>DRUG</th><th>MECHANISM</th><th>ADVERSE EFFECTS</th></thead><tr><td>Bulk-forming laxatives Methylcellulose, psyllium</td><td>Soluble fibers that draw water into gut lumen, forming viscous liquid that promotes peristalsis</td><td>Bloating</td></tr><tr><td>Osmotic laxatives Lactulose, magnesium citrate, magnesium hydroxide, polyethylene glycol</td><td>Provide osmotic load to draw water into GI lumen Lactulose also treats hepatic encephalopathy: gut microbiota degrades lactulose into metabolites (lactic acid, acetic acid) that promote nitrogen excretion as NH," by trapping it in colon</td><td>Diarrhea, dehydration; may be misused by patients with bulimia</td></tr><tr><td>Stimulant laxatives Bisacodyl, senna</td><td>Enteric nerve stimulation &gt; colonic contraction</td><td>Diarrhea</td></tr><tr><td>Emollient laxatives Docusate</td><td>Surfactants that 4 stool surface tension, promoting water entry into stool</td><td>Diarrhea</td></tr><tr><td>Lubiprostone</td><td>Chloride channel activator &gt; ¢ intestinal fluid secretion</td><td>Diarrhea, nausea</td></tr><tr><td>Guanylate cyclase-C agonists Linaclotide, plecanatide</td><td>Activate intracellular cGMP signaling &gt; t fluid and electrolyte secretion in the intestinal lumen</td><td>Diarrhea, bloating, abdominal discomfort, flatulence</td></tr><tr><td>Serotonergic agonists Prucalopride</td><td>SHT, agonism &gt; enteric nerve stimulation &gt; t peristalsis, intestinal secretion</td><td>Diarrhea, abdominal pain, nausea, headache</td></tr><tr><td>NHE, inhibitor</td><td>Inhibits Na‘/H* exchanger &gt; 4 Na’ absorption</td><td>Diarrhea, abdominal pain, nausea</td></tr></table>
======================================
<table><tr><td>INTERACTION</td><td>Rh © pregnant patient; Rh @ fetus.</td><td>‘Type O pregnant patient; type A or B fetus.</td></tr><tr><td>MECHANISM</td><td>First pregnancy: patient exposed to fetal blood (often during delivery) + formation of maternal anti-D IgG. Subsequent pregnancies: anti-D IgG crosses lacenta &gt; attacks fetal and newborn RBCs &gt; hemolysis.</td><td>Preexisting pregnant patient anti-A and/or anti-B IgG antibodies cross the placenta &gt; attack fetal and newborn RBCs &gt; hemolysis.</td></tr><tr><td>PRESENTATION</td><td>ydrops fetalis, jaundice shortly after birth, kernicterus.</td><td>Mild jaundice in the neonate within 24 hours of birth. Unlike Rh hemolytic disease, can occur in firstborn babies and is usually less severe.</td></tr><tr><td>TREATMENT/PREVENTION</td><td>Prevent by administration of anti-D IgG to Rh © pregnant patients during third trimester and early postpartum period (if fetus Rh @).</td><td>Treatment: phototherapy or exchange transfusion.</td></tr></table>
======================================
<table><thead><th></th><th>lron deficiency</th><th>Chronic disease</th><th>Hemochromatosis</th><th>Pregnancy/ OCP use</th></thead><tr><td>Serum iron</td><td>1</td><td>4</td><td>t</td><td></td></tr><tr><td>Transferrin or TIBC</td><td>t</td><td>ve</td><td>t</td><td>t</td></tr><tr><td>Ferritin</td><td>1</td><td>t</td><td>t</td><td></td></tr><tr><td>% transferrin saturation (serum iron/TIBC)</td><td>Mh</td><td>hi</td><td>tt</td><td></td></tr></table>
======================================
<table><thead><th>asst Folate deficiency</th><th>Causes: malnutrition (eg, chronic alcohol overuse), malabsorption, drugs (eg, methotrexate, trimethoprim, phenytoin), t requirement (eg, hemolytic anemia, pregnancy).</th><th>t homocysteine, normal methylmalonic acid. No neurologic symptoms (vs B,, deficiency).</th></thead><tr><td>Vitamin B,, (cobalamin) deficiency</td><td>Causes: pernicious anemia, malabsorption (eg, Crohn disease), pancreatic insufficiency, gastrectomy, insufficient intake (eg, veganism), Diphyllobothrium latum (fish tapeworm).</td><td>t homocysteine, t methylmalonic acid. Neurologic symptoms: reversible dementia, subacute combined degeneration (due to involvement of B,, in fatty acid pathways and myelin synthesis): spinocerebellar tract, lateral corticospinal tract, dorsal column dysfunction. Folate supplementation in vitamin B,, deficiency can correct the anemia, but worsens neurologic symptoms. Historically diagnosed with the Schilling test, a test that determines if the cause is dietary insufficiency vs malabsorption. Anemia 2° to insufficient intake may take several years to develop due to liver’s ability to store B,, (vs folate deficiency, which takes weeks to months).</td></tr><tr><td>Orotic aciduria Nonmegaloblastic</td><td>Inability to convert orotic acid to UMP (de novo pyrimidine synthesis pathway) because of defect in UMP synthase. Autosomal recessive. Presents in children as failure to thrive, developmental delay, and megaloblastic anemia refractory to folate and B,,. No hyperammonemia (vs ornithine transcarbamylase deficiency—t orotic acid with hyperammonemia). Macrocytic anemia in which DNA synthesis is</td><td>Orotic acid in urine. Treatment: uridine monophosphate or uridine triacetate to bypass mutated enzyme. RBC macrocytosis without hypersegmented</td></tr><tr><td>anemia</td><td>normal. Causes: chronic alcohol overuse, liver disease.</td><td>neutrophils.</td></tr><tr><td>Diamond-Blackfan anemia</td><td>A congenital form of pure red cell aplasia (vs Fanconi anemia, which causes pancytopenia). Rapid-onset anemia within Ist year of life due to intrinsic defect in erythroid progenitor cells.</td><td>t % HbF (but $ total Hb). Short stature, craniofacial abnormalities, and upper extremity malformations (triphalangeal thumbs) in up to 50% of cases.</td></tr></table>
======================================
<table><thead><th></th><th>DESCRIPTION</th><th>FINDINGS</th></thead><tr><td>tereditary spherocytosis</td><td>Primarily autosomal dominant. Due to defect in proteins interacting with RBC membrane skeleton and plasma membrane (eg, ankyrin, band 3, protein 4.2, spectrin). Small, round RBCs with no central pallor. + surface area/dehydration + t MCHC &gt; premature removal by spleen (extravascular hemolysis).</td><td>Splenomegaly, pigmented gallstones, aplastic crisis (parvovirus B19 infection). Labs: | mean fluorescence of RBCs in eosin (EMA) binding test, t fragility in osmotic fragility test (RBC hemolysis with 5-maleimide exposure to hypotonic solution). Normal to + MCV with abundance of RBCs. Treatment: splenectomy.</td></tr><tr><td>&gt;aroxysmal nocturnal hemoglobinuria</td><td>Hematopoietic stem cell mutation &gt; t complement-mediated intravascular hemolysis, especially at night. Acquired PIGA mutation &gt; impaired GPI anchor synthesis for decay-accelerating factor (DAF/CD55) and membrane inhibitor of reactive lysis (MIRL/ CD59), which protect RBC membrane from complement.</td><td>Triad: Coombs © hemolytic anemia (mainly intravascular), pancytopenia, venous thrombosis (eg, Budd-Chiari syndrome). Pink/red urine in morning. Associated with aplastic anemia, acute leukemias. Labs: CD55/59 © RBCs on flow cytometry. Treatment: eculizumab (targets terminal complement protein C5).</td></tr><tr><td>G6PD deficiency</td><td>X-linked recessive. G6PD defect &gt; 4 NADPH = $ reduced glutathione &gt; t RBC susceptibility to oxidative stress (eg, sulfa drugs, antimalarials, fava beans) &gt; hemolysis. Causes extravascular and intravascular hemolysis.</td><td>Back pain, hemoglobinuria a few days after oxidant stress. Labs: 4 G6PD activity (may be falsely normal during acute hemolysis), blood smear shows RBCs with Heinz bodies and bite cells. “Stress makes me eat bites of fava beans with Heinz ketchup.”</td></tr><tr><td>&gt;yruvate kinase deficiency Sickle cell anemia</td><td>Autosomal recessive. Pyruvate kinase defect &gt; 4 ATP = rigid RBCs &gt; extravascular hemolysis. Increases levels of 2,3-BPG &gt; 4 hemoglobin affinity for O,. Point mutation in B-globin gene &gt; single amino acid substitution (glutamic acid valine)</td><td>Hemolytic anemia in a newborn. Labs: blood smear shows burr cells. Complications: Aplastic crisis (transient arrest of</td></tr><tr><td>&gt; 02 6 be</td><td>&gt; aggregation of hemoglobin. Causes extravascular and intravascular hemolysis. Pathogenesis: low O,, high altitude, or acidosis recipitates sickling (deoxygenated HbS olymerizes) + vaso-occlusive disease. Newborns are initially asymptomatic because of t HbF and + HbS. Heterozygotes (sickle cell trait) have resistance o malaria. Sickle cells are crescent-shaped RBCs [N. “Crew cut” on skull x-ray due to marrow expansion from tf erythropoiesis (also seen in halassemias).</td><td>= Autosplenectomy (Howell-Jolly bodies) = t risk of infection by encapsulated organisms (eg, Salmonella osteomyelitis). ® Splenic infarct/sequestration crisis. = Painful vaso-occlusive crises: dactylitis (painful swelling of hands/feet), priapism, acute chest syndrome (respiratory distress, new pulmonary infiltrates on CXR, common cause of death), avascular necrosis, stroke. * Sickling in renal medulla (4 Po,) + renal papillary necrosis + hematuria (also seen in sickle cell trait). Hb electrophoresis: $4 HbA, t HbF, tt HbS.</td></tr></table>
======================================
<table><tr><td>Autoimmune hemolytic anemia</td><td>A normocytic anemia that is usually idiopathic and Coombs ®. Two types: = Warm AIHA-chronic anemia in which primarily extravascular</td><td>Spherocytes and agglutinated RBCs [J on peripheral blood smear. Warm AIHA treatment: steroids, rituximab, splenectomy (if refractory).</td></tr><tr><td></td><td>hemolysis. Seen in SLE and CLL and with certain drugs (eg, B-lactams, o&amp;-methyldopa). “Warm weather is Good.” * Cold AIHA-acute anemia in which primarily IgM + complement cause RBC agglutination and extravascular hemolysis upon exposure to cold &gt; painful, blue fingers and toes. Seen in CLL, Mycoplasma pneumoniae infections, infectious mononucleosis.</td><td>Cold AIHA treatment: cold avoidance, rituximab.</td></tr><tr><td>Drug-induced hemolytic anemia</td><td>Most commonly due to antibody-mediated immune destruction of RBCs or oxidant injury via free radical damage (may be exacerbated in GOPD deficiency). Common causes include antibiotics (eg, penicillins, cephalosporins), NSAIDs, immunotherapy, chemotherapy.</td><td>Spherocytes suggest immune hemolysis. Bite cells suggest oxidative hemolysis. Can cause both extravascular and intravascular hemolysis.</td></tr><tr><td>Microangiopathic hemolytic anemia</td><td>RBCs are damaged when passing through obstructed or narrowed vessels. Causes intravascular hemolysis. Seen in DIC, TTP/HUS, SLE, HELLP syndrome, hypertensive emergency.</td><td>Schistocytes (eg, “helmet cells”) are seen on peripheral blood smear due to mechanical destruction (schisto = to split) of RBCs.</td></tr><tr><td>Macroangiopathic hemolytic anemia</td><td>Prosthetic heart valves and aortic stenosis may also cause hemolytic anemia 2° to mechanical destruction of RBCs.</td><td>Schistocytes on peripheral blood smear.</td></tr><tr><td>Hemolytic anemia due to infection</td><td>¢ destruction of RBCs (eg, malaria, Babesia).</td><td></td></tr></table>
======================================
<table><thead><th>CELL TYPE</th><th>CELL COUNT</th><th>CAUSES</th></thead><tr><td>Neutropenia</td><td>Absolute neutrophil count &lt; 1500 cells/mm’ Severe infections typical when &lt; 500 cells/mm</td><td>Sepsis/postinfection, drugs (including chemotherapy), aplastic anemia, SLE, radiation, congenital</td></tr><tr><td>Lymphopenia</td><td>Absolute lymphocyte count &lt; 1500 cells/mm? (&lt; 3000 cells/mm? in children)</td><td>HIV, DiGeorge syndrome, SCID, SLE, glucocorticoids’, radiation, sepsis, postoperative</td></tr><tr><td>Eosinopenia</td><td>Absolute eosinophil count &lt; 30 cells/mm?</td><td>Cushing syndrome, glucocorticoids*</td></tr></table>
======================================
<table><thead><th>CONDITION</th><th>AFFECTED ENZYME</th><th>ACCUMULATED SUBSTRATE</th><th>PRESENTING SYMPTOMS</th></thead><tr><td>Lead poisoning</td><td>Ferrochelatase and ALA dehydratase</td><td>Protoporphyrin, ALA (blood)</td><td>Microcytic anemia (basophilic stippling in peripheral smear [[N, ringed sideroblasts in bone marrow), GI and kidney disease. Children—exposure to lead paint + mental deterioration. Adults—environmental exposure (eg, batteries, ammunition) &gt; headache, memory loss, demyelination (peripheral neuropathy).</td></tr><tr><td>Acute intermittent porphyria cutanea</td><td>Porphobilinogen deaminase (autosomal dominant mutation)</td><td>Porphobilinogen, ALA</td><td>Symptoms (5 P’s): = Painful abdomen * Port wine-colored Pee * Polyneuropathy ® Psychological disturbances * Precipitated by factors that t ALA synthase (eg, drugs [CYP450 inducers}, alcohol, starvation) Treatment: hemin and glucose. cutaneous and</td></tr><tr><td>Porphyria tarda</td><td>Uroporphyrinogen decarboxylase</td><td>Uroporphyrin (tea- colored urine)</td><td>Blistering photosensitivity hyperpigmentation EJ. Most common porphyria. Exacerbated with alcohol consumption. Causes: familial, hepatitis C. Treatment: phlebotomy, sun avoidance, antimalarials (eg, hydroxychloroquine).</td></tr></table>
======================================
<table><tr><td>FINDINGS</td><td colspan="2">High mortality rate associated with accidental ingestion by children (adult iron tablets may look like candy).</td><td>Seen in patients with 1° (hereditary) or 2° (eg, chronic blood transfusions for thalassemia or sickle cell disease) hemochromatosis.</td></tr><tr><td>MECHANISM</td><td colspan="2">Cell death due to formation of free radicals and peroxidation of membrane lipids.</td><td></td></tr><tr><td>SYMPTOMS/SIGNS</td><td>Abdominal Radiopaque anion failure.</td><td>pain, vomiting, GI bleeding. pill seen on x-ray. May progress to gap metabolic acidosis and multiorgan Leads to scarring with GI obstruction.</td><td>Arthropathy, cirrhosis, cardiomyopathy, diabetes mellitus and skin pigmentation (“bronze diabetes”), hypogonadism.</td></tr><tr><td>TREATMENT</td><td>Chelation gastric</td><td>(eg, deferoxamine, deferasirox), lavage.</td><td>Phlebotomy (patients without anemia) or chelation.</td></tr><tr><td rowspan="3">Coagulation disorders DISORDER</td><td colspan="2" rowspan="3">(Play Tennis outside [extrinsic pathway)). &gt; t PTT (Play Table Tennis inside). PT—tests function of common and extrinsic pathway INR (international normalized ratio) = patient common test used to follow patients on warfarin, PT'T—tests function of common and intrinsic TT—measures the rate of conversion of fibrinogen hypofibrinogenemia, DIC, liver disease. Coagulation disorders can be due to clotting factor commonly against factor VIII). Diagnosed with to patient’s plasma. Clotting factor deficiencies the appropriate normal range), whereas factor PT PIT MECHANISM AND COMMENTS</td><td>(factors I, I, V, VIL, and X). Defect &gt; t PT P'T/control PT. 1 = normal, &gt; | = prolonged. Most which prolongs INR. pathway (all factors except VII and XIII). Defect</td></tr><tr><td></td><td colspan="2"></td><td>deficiencies or acquired factor inhibitors (most a mixing study, in which normal plasma is added should correct (the PT or PT'T returns to within inhibitors will not correct.</td></tr><tr><td></td><td colspan="2"></td><td></td></tr><tr><td>Hemophilia A, B, or C</td><td></td><td>Intrinsic pathway coagulation = A: deficiency of factor VIII, (eight).” * B: deficiency of factor IX; * C: deficiency of factor XI; Hemorrhage in easy bruising, bleeding after Treatment: desmopressin, factor concentrate (B); factor XI</td><td>defect (t PTT). X-linked recessive. Pronounce “hemophilia Ate X-linked recessive. autosomal recessive. hemophilia—hemarthroses (bleeding into joints, eg, knee [i¥), trauma or surgery (eg, dental procedures). VIII concentrate, emicizumab (A); factor IX concentrate (C).</td></tr><tr><td>Vitamin K deficiency</td><td colspan="3">General coagulation defect. Bleeding time normal. + activity of factors II, VII, [X, X, protein C, protein S.</td></tr></table>
======================================
<table><thead><th>DISORDER</th><th>PC</th><th colspan="3">qualitative BT NOTES</th></thead><tr><td>Bernard-Soulier syndrome</td><td>lt</td><td>t</td><td>Autosomal recessive defect in Labs: | platelet aggregation,</td><td>adhesion. | GpIb &gt; 4 platelet-to-vWF adhesion. Big platelets.</td></tr><tr><td>Glanzmann thrombasthenia</td><td>-</td><td>t</td><td>Autosomal recessive defect in platelet-to-platelet aggregation Labs: blood smear shows no</td><td>aggregation. } GpIIb/Illa (4 integrin o,,,B,) + + and defective platelet plug formation. platelet clumping.</td></tr><tr><td>Immune thrombocytopenia</td><td>+</td><td>t</td><td>Destruction of platelets in macrophages phagocytose disorders (eg, SLE), viral drug reactions. Labs: t megakaryocytes on Treatment: glucocorticoids, eltrombopag, romiplostim),</td><td>spleen. Anti-GplIb/IIIa antibodies &gt; splenic platelets. May be idiopathic or 2° to autoimmune illness (eg, HIV, HCV), malignancy (eg, CLL), or bone marrow biopsy, + platelet count. IVIG, rituximab, ‘TPO receptor agonists (eg, or splenectomy for refractory ITP.</td></tr><tr><td>Uremic platelet dysfunction</td><td>-</td><td>t</td><td>n patients with renal failure, platelet adhesion.</td><td>uremic toxins accumulate and interfere with</td></tr><tr><td>Thrombotic microangiopathies</td><td>Disorders findings involve</td><td>overlap of a</td><td>significantly in symptomatology. consumptive coagulopathy (eg, t widespread clotting factor activation.</td><td>May resemble DIC, but do not exhibit lab PT, t PTT, + fibrinogen), as etiology does not</td></tr><tr><td></td><td>Thrombotic</td><td></td><td>thrombocytopenic purpura</td><td>Hemolytic-uremic syndrome</td></tr><tr><td>EPIDEMIOLOGY</td><td>Typically</td><td>females</td><td></td><td>Typically children</td></tr><tr><td>PATHOPHYSIOLOGY</td><td>Inhibition vWF vWF = t</td><td>or multimers platelet (microthrombi</td><td>deficiency of ADAMTS]3 (a metalloprotease) + + degradation of &gt; t large WWF multimers adhesion and aggregation formation)</td><td>Predominately caused by Shiga toxin—producing Escherichia coli (STEC) infection (serotype O157:H7), which causes profound endothelial dysfunction.</td></tr><tr><td>PRESENTATION</td><td colspan="4">Triad of throm bocytopenia (t platelets), microangiopathic hemolytic anemia (+ Hb, schistocytes, t LDH), acute kidney injury (t Cr)</td></tr><tr><td>DIFFERENTIATING SYMPTOMS</td><td>Triad</td><td>+ fever +</td><td>neurologic symptoms</td><td>Triad + bloody diarrhea</td></tr><tr><td>LABS</td><td colspan="4">Normal PT and PTT helps distinguish TTP and HUS (coagulation pathway is not activated) from DIC (coagulation pathway is activated)</td></tr></table>
======================================
<table><thead><th>DISORDER</th><th>PC</th><th>BT</th><th>PT</th><th>PIT</th><th>NOTES</th></thead><tr><td></td><td></td><td></td><td></td><td></td><td>Labs: schistocytes, t fibrin degradation products (p-dimers), $ fibrinogen, 4 factors V</td></tr></table>
======================================
<table><thead><th>DISEASE</th><th>DESCRIPTION</th></thead><tr><td>Antithrombin deficiency</td><td>Has no direct effect on the PT, PTT, or thrombin time but diminishes the increase in PTT following standard heparin dosing. Can also be acquired: renal failure/nephrotic syndrome &gt; antithrombin loss in urine = 4 inhibition of factors Ila and Xa.</td></tr><tr><td>Factor V Leiden</td><td>Production of mutant factor V (guanine + adenine DNA point mutation &gt; Arg506GIn mutation near the cleavage site) that is resistant to degradation by activated protein C. Complications include DVT, cerebral vein thrombosis, recurrent pregnancy loss.</td></tr><tr><td>Protein Cor S deficiency</td><td>+ ability to inactivate factors Va and VIIa. t risk of warfarin-induced skin necrosis. Together, protein C Cancels, and protein S Stops, coagulation.</td></tr><tr><td>Prothrombin G20270A mutation</td><td>Point mutation in 3” untranslated region &gt; t production of prothrombin &gt; t plasma levels and venous clots.</td></tr></table>
======================================
<table><thead><th>COMPONENT</th><th>DOSAGE EFFECT</th><th>CLINICAL USE</th></thead><tr><td>Packed RBCs</td><td>t Hb and O, binding (carrying) capacity, t hemoglobin ~1 g/dL per unit, t hematocrit ~3% per unit</td><td>Acute blood loss, severe anemia</td></tr><tr><td>Platelets</td><td>t platelet count ~30,000/microL per unit (t ~5000/mm?/unit)</td><td>Stop significant bleeding (thrombocytopenia, qualitative platelet defects)</td></tr><tr><td>Fresh frozen plasma/ prothrombin complex concentrate</td><td>t coagulation factor levels; FFP contains all coagulation factors and plasma proteins; PCC generally contains factors II, VII, IX, and X, as well as protein C and S</td><td>Cirrhosis, immediate anticoagulation reversal</td></tr><tr><td>Cryoprecipitate</td><td>Contains fibrinogen, factor VIII, factor XIII, vWF, and fibronectin</td><td>Coagulation factor deficiencies involving fibrinogen and factor VIII</td></tr><tr><td>Albumin</td><td>t intravascular volume and oncotic pressure</td><td>Post-paracentesis, therapeutic plasmapheresis</td></tr></table>
======================================
<table><tr><td>»n-Hodgkin mphoma</td><td colspan="2">Both may have constitutional (“B”) signs/symptoms: low-grade fever, night sweats, weight loss.</td></tr><tr><td></td><td>Bimodal distribution: young adults, &gt; 55 years.</td><td>— Can occur in children and adults.</td></tr><tr><td></td><td>Associated with EBV.</td><td>May be associated with autoimmune diseases and viral infections (eg, HIV, EBV, HTLV).</td></tr></table>
======================================
<table><thead><th>SUBTYPE</th><th>NOTES</th></thead><tr><td>Nodular sclerosis</td><td>Most common</td></tr><tr><td>Mixed cellularity</td><td>Eosinophilia; seen in immunocompromised patients</td></tr><tr><td>Lymphocyte rich</td><td>Best prognosis (the rich have better bank accounts</td></tr><tr><td>Lymphocyte depleted</td><td>Worst prognosis (the poor have worse bank accounts); seen in immunocompromised patients</td></tr></table>
======================================
<table><thead><th>TYPE</th><th>OCCURS IN</th><th>GENETICS</th><th>COMMENTS</th></thead><tr><td colspan="4">Neoplasms of mature B cells</td></tr><tr><td>Burkitt lymphoma</td><td>Adolescents or young adults “Burkid” lymphoma (more common in kids)</td><td>t(8;14) translocation of c-myc (8) and heavy-chain Ig (14)</td><td>“Starry sky” appearance (StarBurst), sheets of lymphocytes with interspersed “tingible body” macrophages (arrows in fi). Associated with EBV. Jaw lesion [J in endemic form in Africa; pelvis or abdomen in sporadic form.</td></tr><tr><td>Diffuse large B-cell lymphoma</td><td>Usually older adults, but 20% in children</td><td>Mutations in BCL-2, BCL-6</td><td>Most common type of non-Hodgkin lymphoma in adults.</td></tr><tr><td>Follicular lymphoma</td><td>Adults</td><td>t(14;18) translocation of heavy-chain Ig (14) and BCL-2 (18)</td><td>Indolent course with painless “waxing and waning” lymphadenopathy. Bcl-2 normally inhibits apoptosis.</td></tr><tr><td>Mantle cell lymphoma</td><td>Adult males &gt;&gt; adult females</td><td>t(11;14) translocation of cyclin D1 (11) and heavy-chain Ig (14), CD5+</td><td>Very aggressive, patients typically present with late-stage disease.</td></tr><tr><td>Marginal zone lymphoma</td><td>Adults</td><td>t(11;18)</td><td>Associated with chronic inflammation (eg, Sjégren syndrome, chronic gastritis [MALT lymphoma; may regress with H pylori eradication]).</td></tr><tr><td>Primary central nervous system lymphoma</td><td>Adults</td><td>EBV related; associated with HIV/ AIDS</td><td>Considered an AIDS-defining illness. Variable _ presentation: confusion, memory loss, seizures. CNS mass (often single, ring-enhancing lesion on MRI) in immunocompromised patients [@, needs to be distinguished from toxoplasmosis via CSF analysis or other lab tests.</td></tr><tr><td colspan="4">Neoplasms of mature T cells</td></tr><tr><td>Adult T-celllymphoma</td><td>Adults</td><td>Caused by HTLV (associated with IV drug use)</td><td>Adults present with cutaneous lesions; common in Japan (‘T-cell in Tokyo), West Africa, and the Caribbean. Lytic bone lesions, hypercalcemia.</td></tr><tr><td>Mycosis fungoides/ Sézary syndrome</td><td>Adults</td><td></td><td>Mycosis fungoides: skin patches and plaques [3 (cutaneous T-cell lymphoma), characterized by atypical CD4+ cells with “cerebriform” nuclei and intraepidermal neoplastic cell aggregates (Pautrier microabscess). May progress to Sézary syndrome (‘T-cell leukemia).</td></tr></table>
======================================
<table><tr><td></td><td></td><td>overproducing a monoclonal immunoglobulin (also called paraprotein). Seen in older adults.</td></tr><tr><td>Albumin</td><td>o, o BY</td><td>Diagnostic confirmation with bone marrow biopsy. Peripheral blood smear may show rouleaux formation [iJ (RBCs stacked like poker chips).</td></tr><tr><td>Multiple</td><td>myeloma</td><td>Overproduction of IgG (most common) &gt; IgA &gt; Ig light c hains. Clinical features (CRAB): hyperCalcemia (t cytokine secretion [eg, IL-1, TNF-a, RANK-L] by malignant plasma cells</td></tr><tr><td></td><td></td><td>— t osteoclast activity), Renal insufficiency, Anemia, Bone lytic lesions (“punched out” on x-ray (5) — back pain). Complications: t infection risk, 1° amyloidosis (AL). Urinalysis may show Ig light chains (Bence Jones proteinuria) with © urine dipstick. Bone marrow biopsy shows &gt;10% monoclonal plasma cells with clock-face chromatin [@ and intracytoplasmic inclusions containing Ig.</td></tr><tr><td></td><td>Waldenstr6m macroglobulinemia</td><td>Overproduction of IgM (macroglobulinemia because IgM is the largest Ig). Clinical features include anemia, constitutional (“B”) signs/symptoms, lymphadenopathy, hepatosplenomegaly, hyperviscosity (eg, headache, bleeding, blurry vision, ataxia), peripheral neuropathy. Funduscopy shows dilated, segmented, and tortuous retinal veins (sausage link appearance). Bone marrow biopsy shows &gt;10% monoclonal B lymphocytes with plasma cell features (lymphoplasmacytic lymphoma) and intranuclear pseudoinclusions containing IgM.</td></tr><tr><td></td><td>Monoclonal gammopathy of undetermined significance</td><td>Overproduction of any Ig type (M spike &lt;3 g/dL). Asymptomatic (no CRAB findings). 1%-2% risk per year of progressing to multiple myeloma. Bone marrow biopsy shows &lt;10% monoclonal plasma cell S.</td></tr></table>
======================================
<table><thead><th></th><th>t circulating WBCs (malignant leukocytes in blood), although some cases present with normal/! WBCs. Leukemic cell infiltration of liver, spleen, lymph nodes, and skin (leukemia cutis) possible.</th></thead><tr><td colspan="2">TYPE NOTES</td></tr><tr><td colspan="2">Lymphoid neoplasms</td></tr><tr><td>Acute lymphoblastic leukemia/lymphoma</td><td>Most frequently occurs in children; less common in adults (worse prognosis). T-cell ALL can present as mediastinal mass (presenting as SVC-like syndrome). Associated with Down syndrome. Peripheral blood and bone marrow have ttt lymphoblasts [iN. Td T+ (marker of pre-T and pre-B cells), CD10+ (marker of pre-B cells). Most responsive to therapy. May spread to CNS and testes. + better chromosome) ~ worse</td></tr><tr><td>Chronic lymphocytic leukemia/small lymphocytic lymphoma</td><td>t(12;21) prognosis; t(9;22) (Philadelphia prognosis. Age &gt; 60 years. Most common adult leukemia. CD20+, CD23+, CD5+ B-cell neoplasm. Often asymptomatic, progresses slowly; smudge cells [J in peripheral blood smear; autoimmune hemolytic anemia. CLL = Crushed Little Lymphocytes (smudge cells). Richter transformation—CLL/SLL transformation into an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL).</td></tr><tr><td>Hairy cell leukemia</td><td>Adult males. Mature B-cell tumor. Cells have filamentous, hairlike projections (fuzzy appearing on LM [@). Peripheral lymphadenopathy is uncommon. Causes marrow fibrosis &gt; dry tap on aspiration. Patients usually present with massive splenomegaly and pancytopenia. Stains TRAP (Tartrate-Resistant Acid Phosphatase) ® (TRAPped in a hairy situation). ‘TRAP stain largely replaced with flow cytometry. Associated with BRAF mutations. Treatment: purine analogs (cladribine, pentostatin).</td></tr><tr><td colspan="2">Myeloid neoplasms</td></tr><tr><td>Acute myelogenous leukemia</td><td>Median onset 65 years. Auer rods [5); myeloperoxidase ® cytoplasmic inclusions seen mostly in APL (formerly M3 AML); ttt circulating myeloblasts on peripheral smear. May present with leukostasis (capillary occlusion by malignant, nondistensible cells + organ damage). Risk factors: prior exposure to alkylating chemotherapy, radiation, benzene, myeloproliferative disorders, Down syndrome (typically acute megakaryoblastic leukemia [formerly M7 AML])). APL: t(15;17), responds to all-trans retinoic acid (vitamin A) and arsenic trioxide, which induce differentiation of promyelocytes; DIC is a common presentation.</td></tr><tr><td>Chronic myelogenous leukemia</td><td>Peak incidence: 45-85 years; median age: 64 years. Defined by the Philadelphia chromosome (t{9;22], BCR-ABL) and myeloid stem cell proliferation. Presents with dysregulated production of mature and maturing granulocytes (eg, neutrophils, metamyelocytes, myelocytes, basophils [3)) and splenomegaly. May accelerate and transform to AML or ALL (“blast crisis”). Responds to BCR-ABL tyrosine kinase inhibitors (eg, imatinib).</td></tr></table>
======================================
<table><tr><td>DEFINITION</td><td>Reactive neutrophilia &gt; 50,000 cells/mm’</td><td>Myeloproliferative neoplasm ® for BCR-ABL</td></tr><tr><td>NEUTROPHIL MORPHOLOGY</td><td>Toxic granulation, Déhle bodies, cytoplasmic vacuoles</td><td>Pseudo-Pelger-Huét anomaly</td></tr><tr><td>LAP SCORE</td><td>t</td><td>4 (LAP enzyme } in malignant neutrophils)</td></tr></table>
======================================
<table><thead><th></th><th>PLASMAVOLUME</th><th>— RBCMASS</th><th>0, SATURATION</th><th>EPOLEVELS</th><th>ASSOCIATIONS</th></thead><tr><td>Relative</td><td>+</td><td>-</td><td>-</td><td>-</td><td>Dehydration, burns.</td></tr><tr><td>Appropriate absolute</td><td>= —</td><td>t</td><td>4</td><td>t</td><td>Lung disease, congenital heart disease, high altitude, obstructive sleep apnea.</td></tr><tr><td>Inappropriate absolute</td><td>= —</td><td>t</td><td>-</td><td>t</td><td>Exogenous EPO (athlete misuse, also called “blood doping”), androgen supplementation. Inappropriate EPO secretion: malignancy (eg, RCC, HCC).</td></tr><tr><td>Polycythemia vera</td><td>t</td><td>tt</td><td>-</td><td>+</td><td>EPO 4 in PCV due to negative feedback suppressing renal EPO production.</td></tr></table>
======================================
<table><thead><th>TRANSLOCATION</th><th>ASSOCIATED DISORDER</th><th>NOTES</th></thead><tr><td>t(8;14)</td><td>Burkitt (Burk-8) lymphoma (c-myc activation)</td><td>The Ig heavy chain genes on chromosome 14</td></tr><tr><td>t(11,14)</td><td>Mantle cell lymphoma (cyclin D1 activation)</td><td>are constitutively expressed. When other</td></tr><tr><td>t(11;18)</td><td>Marginal zone lymphoma</td><td>genes (eg, c-myc and BCL-2) are translocated</td></tr><tr><td></td><td></td><td>next to this heavy chain gene region, they are</td></tr><tr><td>t(14;18)</td><td>Follicular lymphoma (BCL-2 activation)</td><td>overexpressed.</td></tr><tr><td>t(15;17)</td><td>APL (formerly M3 type of AML)</td><td></td></tr><tr><td>t(9;22) (Philadelphia chromosome)</td><td>CML (BCR-ABL hybrid), ALL (less common); Philadelphia CreaML cheese</td><td></td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Inhibits vitamin K epoxide reductase by competing with vitamin K &gt; inhibition of vitamin K- dependent y-carboxylation of clotting factors II, VII, IX, and X and proteins C and S. Metabolism affected by polymorphisms in the gene for vitamin K epoxide reductase complex (VKORCI). In laboratory assay, has effect on extrinsic pathway and t P'T. Long halflife. “The ex-PresidenT went to war(farin).”</td></tr><tr><td>CLINICAL USE</td><td>Chronic anticoagulation (eg, venous thromboembolism prophylaxis and prevention of stroke in atrial fibrillation). Not used in pregnant patients (because warfarin, unlike heparin, crosses placenta). Monitor P'T/INR.</td></tr><tr><td></td><td>production hypercoagulation. days large believed to be due to small vessel microthrombosis. leparin “bridging”: heparin frequently used when starting warfarin. Heparin’s activation of antithrombin enables anticoagulation during initial, transient hypercoagulable state caused by warfarin. Initial heparin therapy reduces risk of recurrent venous thromboembolism and skin/ - issue necrosis.</td></tr></table>
======================================
<table><thead><th></th><th>Heparin</th><th>Warfarin</th></thead><tr><td>ROUTE OF ADMINISTRATION</td><td>Parenteral (IV, SC)</td><td>Oral</td></tr><tr><td>SITE OF ACTION</td><td>Blood</td><td>Liver</td></tr><tr><td>ONSET OF ACTION</td><td>Rapid (seconds)</td><td>Slow, limited by half-lives of normal clotting factors</td></tr><tr><td>DURATION OF ACTION</td><td>Hours</td><td>Days</td></tr><tr><td>MONITORING</td><td>PTT (intrinsic pathway)</td><td>PT/INR (extrinsic pathway)</td></tr><tr><td>CROSSES PLACENTA</td><td>No</td><td>Yes (teratogenic)</td></tr></table>
======================================
<table><thead><th>DRUG</th><th>MECHANISM</th><th>CLINICAL USE</th><th>ADVERSE EFFECTS</th></thead><tr><td>Bivalirudin, argatroban, dabigatran</td><td>Directly inhibit thrombin (factor Ha)</td><td>Venous thromboembolism, atrial fibrillation. Can be used in HIT, when heparin is BAD for the patient</td><td>Bleeding (idarucizumab can be _used to inhibit dabigatran)</td></tr><tr><td>Apixaban, edoxaban, rivaroxaban</td><td>Directly inhibit (ban) factor Xa</td><td>Oral agents. DVT/PE treatment and prophylaxis; stroke prophylaxis in patients</td><td>Bleeding (reverse with andexanet alfa)</td></tr></table>
======================================
<table><thead><th>ANTICOAGULANT</th><th>REVERSAL AGENT</th><th>NOTES</th></thead><tr><td>Heparin</td><td>Protamine sulfate</td><td>© charged peptide that binds © charged heparin</td></tr><tr><td>Warfarin</td><td>Vitamin K (slow) +/— FFP or PCC (rapid)</td><td></td></tr><tr><td>Dabigatran</td><td>Idarucizumab</td><td>Monoclonal antibody Fab fragments</td></tr><tr><td>Direct factor Xa</td><td>Andexanet alfa</td><td>Recombinant modified factor Xa (inactive)</td></tr></table>
======================================
<table><thead><th>DRUG</th><th>MECHANISM</th><th>CLINICAL USE</th><th>ADVERSE EFFECTS</th></thead><tr><td>Aspirin</td><td>Irreversibly blocks COX &gt; 1 TXA, release</td><td>Acute coronary syndrome; coronary stenting. } incidence or recurrence of thrombotic stroke</td><td>Gastric ulcers, tinnitus, allergic reactions, renal injury, Reye syndrome (in children)</td></tr><tr><td>Clopidogrel, prasugrel, ticagrelor</td><td>Block ADP (P2Y,,) receptor — | ADP-induced expression of GplIb/IIIa</td><td>Same as aspirin; dual antiplatelet therapy</td><td>Bleeding</td></tr><tr><td>Eptifibatide, tirofiban</td><td>Block GplIb/IIla (fibrinogen receptor) on activated platelets</td><td>Unstable angina, percutaneous coronary intervention</td><td>Bleeding, thrombocytopenia</td></tr><tr><td>Cilostazol, dipyridamole</td><td>Block phosphodiesterase &gt; 4 cAMP hydrolysis &gt; t cAMP in platelets</td><td>Intermittent claudication, stroke prevention, cardiac stress testing, prevention of</td><td>Nausea, headache, facial flushing, hypotension, abdominal pain</td></tr></table>
======================================
<table><thead><th>DRUG</th><th>MECHANISM</th><th>CLINICAL USE</th><th>ADVERSE EFFECTS</th></thead><tr><td>Bleomycin</td><td>Induces free radical formation — breaks in DNA strands</td><td>Testicular cancer, Hodgkin lymphoma</td><td>Pulmonary fibrosis, skin hyperpigmentation</td></tr><tr><td>Dactinomycin (actinomycin D)</td><td>Intercalates into DNA, preventing RNA synthesis</td><td>Wilms tumor, Ewing sarcoma, thabdomyosarcoma</td><td>Myelosuppression</td></tr><tr><td>Anthracyclines Doxorubicin, daunorubicin</td><td>Generate free radicals Intercalate in DNA &gt; breaks in DNA &gt; $ replication Inhibit topoisomerase II</td><td>Solid tumors, leukemias, lymphomas</td><td>Dilated cardiomyopathy (often irreversible; prevent with dexrazoxane), myelosuppression</td></tr></table>
======================================
<table><thead><th>Antimetabolites DRUG</th><th>All are S-phase specific except MECHANISM</th><th>cladribine, which is cell cycle CLINICAL USE</th><th>nonspecific. ADVERSE EFFECTS</th></thead><tr><td>Azathioprine, 6-mercaptopurine</td><td>+ 4 de novo purine synthesis AZA is converted to 6-MP, which is then activated by HGPRT</td><td>SLE, ALL; steroid-refractory disease Prevention of organ rejection Weaning from glucocorticoids</td><td>toxicity 6-MP is inactivated by xanthine oxidase (t toxicity with allopurinol or febuxostat)</td></tr><tr><td>Cladribine, pentostatin</td><td>Purine analogs + unable to be processed by ADA, interfering with DNA synthesis</td><td>Hairy cell leukemia</td><td>Myelosuppression</td></tr><tr><td>Cytarabine (arabinofuranosyl cytidine)</td><td>Pyrimidine analog + DNA chain termination Inhibits DNA polymerase</td><td>Leukemias (AML), lymphomas</td><td>Myelosuppression</td></tr><tr><td>5-Fluorouracil</td><td>Pyrimidine analog bioactivated to 5-FUUMP — thymidylate synthase inhibition &gt; 4dTMP &gt;4DNA synthesis Capecitabine is a prodrug</td><td>Colon cancer, pancreatic cancer, actinic keratosis, basal cell carcinoma (topical) Effects enhanced with the addition of leucovorin</td><td>Myelosuppression, palmar- plantar erythrodysesthesia (hand-foot syndrome)</td></tr><tr><td>Hydroxyurea</td><td>Inhibits ribonucleotide reductase + 4 DNA synthesis</td><td>Myeloproliferative disorders (eg, CML, vera), sickle cell disease (t HbF) olycythemia</td><td>Severe myelosuppression, megaloblastic anemia</td></tr><tr><td>Methotrexate</td><td>Folic acid analog that competitively inhibits dihydrofolate reductase &gt; 4dTMP &gt; 4DNA synthesis</td><td>Cancers: leukemias (ALL), lymphomas, choriocarcinoma, sarcomas Nonneoplastic: ectopic pregnancy, medical abortion (with misoprostol), theumatoid arthritis, psoriasis,</td><td>Myelosuppression (reversible with leucovorin “rescue”), hepatotoxicity, mucositis (eg, mouth ulcers), pulmonary fibrosis, folate deficiency (teratogenic), nephrotoxicity</td></tr></table>
======================================
<table><thead><th>DRUG</th><th>MECHANISM</th><th>CLINICAL USE</th><th>ADVERSE EFFECTS</th></thead><tr><td>Busulfan</td><td>Cross-links DNA</td><td>Used to ablate patient’s bone marrow before bone marrow transplantation</td><td>Severe myelosuppression (in almost all cases), pulmonary fibrosis, hyperpigmentation</td></tr><tr><td>Nitrogen mustards Cyclophosphamide, ifosfamide</td><td>Cross-link DNA Require bioactivation by liver</td><td>Solid tumors, leukemia, lymphomas, rheumatic disease (eg, SLE, granulomatosis with polyangiitis)</td><td>Myelosuppression, SIADH, Fanconi syndrome (ifosfamide), hemorrhagic cystitis and bladder cancer (prevent with mesna)</td></tr><tr><td>Nitrosoureas Carmustine, lomustine</td><td>Cross-link DNA Require bioactivation by liver Cross blood-brain barrier &gt; CNS entry</td><td>Brain tumors (including glioblastoma multiforme) Put nitro in your Mustang and travel the globe</td><td>CNS toxicity (convulsions, dizziness, ataxia)</td></tr><tr><td>Procarbazine</td><td>Mechanism unknown Weak MAO inhibitor</td><td>Hodgkin lymphoma, brain tumors</td><td>Myelosuppression, pulmonary toxicity, leukemia, disulfiram-</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Cross-link DNA. Cell cycle nonspecific.</td><td></td></tr><tr><td>CLINICAL USE</td><td>Solid tumors (eg, testicular, bladder, ovarian, GI, lung), lymphomas.</td><td></td></tr></table>
======================================
<table><thead><th>DRUG</th><th>MECHANISM</th><th>CLINICAL USE</th><th>ADVERSE EFFECTS</th></thead><tr><td>Taxanes Docetaxel, paclitaxel</td><td>Hyperstabilize polymerized microtubules &gt; prevent mitotic spindle breakdown</td><td>Various tumors (eg, ovarian and breast carcinomas)</td><td>Myelosuppression, neuropathy, hypersensitivity Taxes stabilize society</td></tr><tr><td>Vinca alkaloids Vincristine, vinblastine</td><td>Bind B-tubulin and inhibit its polymerization into microtubules + prevent mitotic spindle formation</td><td>Solid tumors, leukemias, Hodgkin and non-Hodgkin lymphomas</td><td>Vincristine (crisps the nerves): neurotoxicity (axonal neuropathy), constipation (including ileus) Vinblastine (blasts the marrow): myelosuppression</td></tr></table>
======================================
<table><thead><th>DRUG</th><th>MECHANISM</th><th>CLINICAL USE</th><th>ADVERSE EFFECTS</th></thead><tr><td>lrinotecan, topotecan</td><td>—_ Inhibit topoisomerase I “tecone”</td><td>Colon, ovarian, small cell ling cancer</td><td>— Severe myelosuppression, diarrhea</td></tr><tr><td>Etoposide, teniposide</td><td>— Inhibit topoisomerase II “bothside”</td><td>Testicular, small cell lung cancer, leukemia, lymphoma</td><td>Myelosuppression, alopecia</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Selective estrogen receptor modulator with complex mode of action: antagonist in breast tissue, partial agonist in endometrium and bone. Blocks the binding of estrogen to ER in ER @ cells.</td></tr><tr><td>CLINICAL USE</td><td>Prevention and treatment of breast cancer, prevention of gynecomastia in patients undergoing cancer</td></tr><tr><td></td><td>prostate therapy.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Hot flashes, t risk of thromboembolic events (eg, DVT, PE) and endometrial cancer.</td></tr></table>
======================================
<table><thead><th>AGENT</th><th>TARGET</th><th>CLINICAL USE</th><th>ADVERSE EFFECTS</th></thead><tr><td>Alemtuzumab</td><td>CD52</td><td>Chronic lymphocytic leukemia (CLL), multiple sclerosis.</td><td>t risk of infections and autoimmunity (eg, ITP)</td></tr><tr><td>Bevacizumab</td><td>VEGF (inhibits blood vessel formation)</td><td>Colorectal cancer (CRC), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), angioproliferative retinopathy</td><td>Hemorrhage, blood clots, impaired wound healing</td></tr><tr><td>Cetuximab, panitumumab</td><td>EGFR</td><td>Metastatic CRC (wild-type RAS), head and neck cancer</td><td>Rash, elevated LF'Ts, diarrhea</td></tr><tr><td>Rituximab</td><td>CD20</td><td>Non-Hodgkin lymphoma, CLL, rheumatoid arthritis, ITP, TTP, AIHA, multiple sclerosis</td><td>Infusion reaction due to cytokine release following interaction of rituximab with its target on B cells</td></tr><tr><td>Trastuzumab</td><td>HER2 (“trust HER”)</td><td>Breast cancer, gastric cancer</td><td>Dilated cardiomyopathy (often reversible)</td></tr><tr><td>Pembrolizumab, nivolumab, cemiplimab</td><td>PD-1</td><td>Various tumors (eg, NSCLC,</td><td>t risk of autoimmunity (eg,</td></tr><tr><td>Atezolizumab, durvalumab, avelumab</td><td>PD-L1</td><td>RCC, melanoma, urothelial carcinoma)</td><td>dermatitis, enterocolitis, hepatitis, pneumonitis, endocrinopathies)</td></tr></table>
======================================
<table><thead><th>AGENT</th><th>TARGET</th><th>CLINICAL USE</th><th>ADVERSE EFFECTS</th></thead><tr><td>Alectinib, crizotinib</td><td>ALK</td><td>Non-small cell lung cancer</td><td>Edema, rash, diarrhea</td></tr><tr><td>Erlotinib, gefitinib, afatinib</td><td>EGFR</td><td>Non-small cell lung cancer</td><td>Rash, diarrhea</td></tr><tr><td>Imatinib, dasatinib, nilotinib</td><td>BCR-ABL (also other tyrosine kinases [eg, c-KIT])</td><td>CML, ALL, GISTs</td><td>Myelosuppression, t LFTs, edema, myalgias</td></tr><tr><td>Ruxolitinib</td><td>JAKI/2</td><td>Polycythemia vera</td><td>Bruises, t LFTs</td></tr><tr><td>Bortezomib, ixazomib, carfilzomib</td><td>Proteasome (induce arrest at G2-M phase via accumulation of abnormal proteins + apoptosis)</td><td>Multiple myeloma, mantle cell lymphoma</td><td>Peripheral neuropathy, herpes zoster reactivation (4 T-cell activation + $ cell-mediated immunity)</td></tr><tr><td>Vemurafenib, encorafenib, dabrafenib</td><td>BRAF</td><td>Melanoma Often co-administered with MEK inhibitors (eg, trametinib)</td><td>Rash, fatigue, nausea, diarrhea</td></tr><tr><td>Palbociclib</td><td>Cyclin-dependent kinase 4/6 (induces arrest at G1-S phase — apoptosis)</td><td>Breast cancer</td><td>Myelosuppression, pneumonitis</td></tr><tr><td>Olaparib</td><td>Poly(ADP-ribose) polymerase (+ DNA repair)</td><td>Breast, ovarian, pancreatic, and prostate cancers</td><td>Myelosuppression, edema, diarrhea</td></tr></table>
======================================
<table><thead><th>DRUG</th><th>MECHANISM</th><th>CLINICAL USE</th></thead><tr><td>Amifostine</td><td>Free radical scavenger</td><td>Nephrotoxicity from platinum compounds</td></tr><tr><td>Dexrazoxane</td><td>Tron chelator</td><td>Cardiotoxicity from anthracyclines</td></tr><tr><td>Leucovorin (folinic acid)</td><td>Tetrahydrofolate precursor</td><td>Myelosuppression from methotrexate (leucovorin “tescue”); also enhances the effects of 5-FU</td></tr><tr><td>Mesna</td><td>Sulfhydryl compound that binds acrolein (toxic metabolite of cyclophosphamide/ifosfamide)</td><td>Hemorrhagic cystitis from cyclophosphamide/ ifosfamide</td></tr><tr><td>Rasburicase</td><td>Recombinant uricase that catalyzes metabolism of uric acid to allantoin</td><td>Tumor lysis syndrome</td></tr><tr><td>Ondansetron, granisetron</td><td>5-HT, receptor antagonists</td><td rowspan="2">Acute nausea and vomiting (usually within 1-2 hr after chemotherapy)</td></tr><tr><td>Prochlorperazine, metoclopramide</td><td>D, receptor antagonists</td><td></td></tr><tr><td>Aprepitant, fosaprepitant</td><td>NK, receptor antagonists</td><td>Delayed nausea and vomiting (&gt;24 hr after chemotherapy)</td></tr><tr><td>Filgrastim, sargramostim</td><td>Recombinant G(M)-CSF</td><td>Neutropenia</td></tr></table>
======================================
<table><thead><th>NERVE</th><th>CAUSES OF INJURY</th><th>PRESENTATION</th></thead><tr><td>Axillary (C5-C6)</td><td>Fractured surgical neck of humerus Anterior dislocation of humerus</td><td>Flattened deltoid Loss of arm abduction at shoulder (&gt; 15°) Loss of sensation over deltoid and lateral arm</td></tr><tr><td>Musculocutaneous (C5-C7)</td><td>Upper trunk compression</td><td>+ biceps (C5-C6) reflex Loss of forearm flexion and supination Loss of sensation over radial and dorsal forearm</td></tr><tr><td>Radial (C5-T1)</td><td>Compression of axilla, eg, due to crutches or sleeping with arm over chair (“Saturday night palsy”) Midshaft fracture of humerus Repetitive pronation/supination of forearm, eg, due to screwdriver use (“finger drop”)</td><td>Injuries above the elbow cause loss of sensation over posterior arm/forearm and dorsal hand, wrist drop (loss of elbow, wrist, and finger extension) with 4 grip strength (wrist extension necessary for maximal action of flexors) Injuries below the elbow can cause paresthesias of the dorsal forearm (superficial radial nerve) or wrist drop (posterior interosseus nerve) Tricep function and posterior arm sensation spared in midshaft fracture</td></tr><tr><td>Median (C5-T1)</td><td>Supracondylar fracture of humerus &gt; proximal lesion of the nerve Carpal tunnel syndrome and wrist laceration — distal lesion of the nerve</td><td>“Ape hand” and “Hand of benediction” Loss of wrist flexion and function of the lateral wo Lumbricals, Opponens pollicis, Abductor ollicis brevis, Flexor pollicis brevis (LOAF) Loss of sensation over thenar eminence and dorsal and palmar aspects of lateral 3 1/2 fingers with proximal lesion</td></tr><tr><td>Ulnar (C8-T1)</td><td>Fracture of medial epicondyle of humerus (proximal lesion) Fractured hook of hamate (distal lesion) from fall on outstretched hand Compression of nerve against hamate as the wrist rests on handlebar during cycling</td><td>“Ulnar claw” on digit extension Radial deviation of wrist upon flexion (proximal esion) 4 flexion of ulnar fingers, abduction and adduction of fingers (interossei), thumb adduction, actions of ulnar 2 lumbrical muscles Loss of sensation over ulnar | 1/2 fingers including hypothenar eminence</td></tr><tr><td>Recurrent branch of median nerve (C5-T1)</td><td>Superficial laceration of palm</td><td>“Ape hand” Loss of thenar muscle group: opposition, abduction, and flexion of thumb No loss of sensation</td></tr></table>
======================================
<table><tr><td>DEGREE</td><td>MUSCLE</td><td>NERVE</td></tr><tr><td>0°-15°</td><td>Supraspinatus</td><td>Suprascapular</td></tr><tr><td>15°-90°</td><td>Deltoid</td><td>Axillary</td></tr><tr><td>&gt; 90°</td><td>Trapezius</td><td>Accessory</td></tr><tr><td>&gt; 90°</td><td>Serratus Anterior</td><td>Long Thoracic (SALT)</td></tr></table>
======================================
<table><thead><th>CONDITION</th><th>INJURY</th><th>CAUSES</th><th>MUSCLE DEFICIT</th><th>FUNCTIONAL DEFICIT</th><th>PRESENTATION</th></thead><tr><td rowspan="3">Erb palsy (“waiter’s tip”)</td><td rowspan="3">‘Traction or tear of upper trunk: C5-C6 roots</td><td>Infants—lateral traction on neck</td><td>Deltoid, _ supraspinatus</td><td>Abduction (arm hangs by side)</td><td></td></tr><tr><td></td><td></td><td>during delivery Adults—trauma</td><td>Infraspinatus, supraspinatus</td><td>Lateral rotation (arm medially rotated)</td><td></td></tr><tr><td></td><td></td><td>leading to neck traction (eg, falling on head and shoulder in motorcycle accident)</td><td>Biceps brachii Herb gets DIBs on tips</td><td>Flexion, supination (arm extended and pronated)</td><td></td></tr><tr><td>Klumpke palsy</td><td>‘Traction or tear of lower trunk: C8-T'l roots</td><td>Infants—upward force on arm during delivery Adults—trauma (eg, grabbing a tree branch to break a fall)</td><td>Intrinsic hand muscles: lumbricals, interossei, thenar, hypothenar</td><td>Claw hand: lumbricals normally flex MCP joints and extend DIP and PIP joints</td><td></td></tr><tr><td>Thoracic outlet syndrome</td><td>Compression of lower trunk and subclavian vessels, most commonly within the scalene triangle</td><td>Cervical/ anomalous first ribs (arrows in EY), Pancoast tumor</td><td>Same as Klumpke palsy</td><td>Atrophy of intrinsic hand muscles; ischemia, pain, and edema due to vascular compression</td><td></td></tr><tr><td>Winged scapula</td><td>Lesion of long thoracic nerve, roots C5-C7 (“wings of</td><td>Axillary node dissection after mastectomy, stab wounds</td><td>Serratus anterior</td><td>Inability to anchor scapula to thoracic cage &gt; cannot abduct arm</td><td></td></tr></table>
======================================
<table><thead><th>Actions of hip muscles</th><th colspan="4"></th></thead><tr><td colspan="5">ACTION MUSCLES.</td></tr><tr><td>Abductors</td><td colspan="4">Gluteus medius, gluteus minimus</td></tr><tr><td>Adductors</td><td colspan="4">Adductor magnus, adductor longus, adductor brevis</td></tr><tr><td>Extensors</td><td>Gluteus maximus, semitendinosus, semimembranosus,</td><td>long head of</td><td>biceps femoris</td><td></td></tr><tr><td>Flexors</td><td>Iliopsoas (iliacus and psoas), rectus femoris, tensor</td><td>fascia lata, pectineus,</td><td>sartorius</td><td></td></tr><tr><td>Internal rotation</td><td>Gluteus medius, gluteus minimus, tensor fascia latae</td><td></td><td></td><td></td></tr><tr><td>External rotation</td><td>Iliopsoas, gluteus maximus, piriformis, obturator</td><td>internus, obturator</td><td>externus</td><td></td></tr><tr><td colspan="5">Knee exam Lateral femoral condyle to anterior tibia: ACL. Medial femoral condyle to posterior tibia: PCL.</td></tr><tr><td>TEST</td><td>PROCEDURE</td><td></td><td></td><td></td></tr><tr><td>Anterior drawer sign</td><td colspan="4" rowspan="2">_ Positive in ACL tear. Tibia glides anteriorly (relative to femur) when knee is at 90° angle. Alternatively, Lachman test done (places knee at 30° angle).</td></tr><tr><td></td><td colspan="4"></td></tr><tr><td>Posterior drawer sign</td><td>_ Bending knee at 90° angle, t posterior gliding of tibia due to PCL injury.</td><td></td><td></td><td></td></tr><tr><td>Valgus stress test</td><td>Abnormal passive abduction. Knee either extended or at ~ 30° angle, lateral (valgus) force + medial space widening of tibia &gt; MCL injury.</td><td>Lateral condyle</td><td></td><td>Medial condyle</td></tr><tr><td>Varus stress test</td><td>Abnormal passive adduction. Knee either extended or at ~ 30° angle, medial (varus) force &gt; lateral space widening of tibia + LCL injury.</td><td>ACL LcL—&gt; Lateral</td><td></td><td></td></tr><tr><td>McMurray test</td><td>During flexion and extension of knee with rotation of tibia/foot (LIME): * Pain, “popping” on internal rotation and varus force + Lateral meniscal tear (Internal rotation stresses lateral meniscus) * Pain, “popping” on external rotation and valgus force + Medial meniscal tear (External rotation stresses medial meniscus)</td><td>meniscus Fibula</td><td></td><td></td></tr></table>
======================================
<table><thead><th>Lower extremity nerves</th><th></th><th></th><th></th></thead><thead><th>NERVE</th><th>INNERVATION</th><th>CAUSE OF INJURY</th><th>PRESENTATION/COMMENTS</th></thead><tr><td>lliohypogastric (T12-L1)</td><td>Sensory—suprapubic region Motor—transversus abdominis and internal oblique</td><td>Abdominal surgery</td><td>Burning or tingling pain in surgical incision site radiating o inguinal and suprapubic region</td></tr><tr><td>Genitofemoral nerve (L1-L2)</td><td>— Sensory—scrotum/labia majora, medial thigh Motor—cremaster</td><td>Laparoscopic surgery</td><td>- upper medial thigh and anterior thigh sensation beneath the inguinal igament (lateral part of the femoral triangle); absent cremasteric reflex</td></tr><tr><td>Lateral femoral cutaneous (L2-L3)</td><td>Sensory—anterior and lateral thigh</td><td>Tight clothing, obesity, pregnancy, pelvic procedures</td><td>- thigh sensation (anterior and ateral) Meralgia paresthetica— compression of lateral femoral cutaneous nerve — tingling, numbness, burning pain in anterolateral thigh</td></tr><tr><td>Obturator (L2-L4)</td><td>Sensory—medial thigh Motor—obturator externus, adductor longus, adductor brevis, gracilis, pectineus, adductor magnus</td><td>Pelvic surgery</td><td>+ thigh sensation (medial) and adduction</td></tr><tr><td>Femoral (L2-L4)</td><td>Sensory—anterior thigh, medial leg Motor—quadriceps, iliacus, pectineus, sartorius</td><td>Pelvic fracture, compression from retroperitoneal hematoma or psoas abscess</td><td>+ leg extension (+ patellar reflex)</td></tr><tr><td>Sciatic (L4-S3)</td><td>Motor—semitendinosus, semimembranosus, biceps femoris, adductor magnus</td><td>Herniated disc, posterior hip dislocation, piriformis syndrome</td><td>Splits into common peroneal and tibial nerves</td></tr></table>
======================================
<table><thead><th>NERVE</th><th>INNERVATION</th><th>CAUSE OF INJURY</th><th>PRESENTATION/COMMENTS</th></thead><tr><td>Common (fibular) peroneal (L4-S2) U</td><td>Superficial peroneal nerve: * Sensory—dorsum of foot (except webspace between hallux and 2nd digit) » Motor—peroneus longus and brevis Deep peroneal nerve: * Sensory—webspace between hallux and 2nd digit * Motor—tibialis anterior</td><td>Trauma or compression of lateral aspect of leg, fibular neck fracture</td><td>PED = Peroneal Everts and Dorsiflexes; if injured, foot dropPED Loss of sensation on dorsum of foot Foot drop—inverted and plantarflexed at rest, loss of eversion and dorsiflexion; “steppage gait”</td></tr><tr><td>Tibial (L4-S3)</td><td>Sensory—sole of foot Motor—biceps femoris (long head), triceps surae, plantaris, popliteus, flexor muscles of foot</td><td>Knee trauma, Baker cyst (proximal lesion); tarsal tunnel syndrome (distal lesion)</td><td>TIP = Tibial Inverts and Plantarflexes; if injured, can’t stand on TIPtoes Inability to curl toes and loss of sensation on sole; in proximal esions, foot everted at rest with weakened inversion and plantar flexion</td></tr><tr><td>Superior gluteal (L4-S1) "</td><td>minimus, tensor fascia latae Motor—gluteus medius, gluteus</td><td>Iatrogenic injury during intramuscular injection to superomedial gluteal region (prevent by choosing superolateral quadrant, preferably anterolateral region)</td><td>Trendelenburg sign/gait— pelvis tilts because weight- bearing leg cannot maintain alignment of pelvis through hip abduction Lesion is contralateral to the side of the hip that drops, ipsilateral to extremity on which the patient stands</td></tr><tr><td>Tene Normal sign</td><td></td><td></td><td></td></tr><tr><td>Inferior gluteal (L5-S2)</td><td>Motor—gluteus maximus</td><td>Posterior hip dislocation</td><td>Difficulty climbing stairs, rising from seated position; loss of hip extension</td></tr><tr><td>Pudendal (S2-S4)</td><td>Sensory—perineum</td><td>Stretch injury during</td><td>+ sensation in perineum and</td></tr></table>
======================================
<table><tr><td>Axilla/lateral thorax</td><td>Long thoracic</td><td>Lateral thoracic</td></tr><tr><td>Surgical neck of humerus</td><td>Axillary</td><td>Posterior circumflex</td></tr><tr><td>Midshaft of humerus</td><td>Radial</td><td>Deep brachial</td></tr><tr><td>Distal humerus/cubital fossa</td><td>Median</td><td>Brachial</td></tr><tr><td>Popliteal fossa</td><td>Tibial</td><td>Popliteal</td></tr><tr><td>Posterior to medial malleolus</td><td>Tibial</td><td>Posterior tibial</td></tr></table>
======================================
<table><thead><th></th><th>Typel</th><th>Type ll</th></thead><tr><td>CONTRACTION VELOCITY</td><td>Slow</td><td>Fast</td></tr><tr><td>FIBER COLOR</td><td>Red</td><td>White</td></tr><tr><td>PREDOMINANT METABOLISM</td><td>Oxidative phosphorylation &gt; sustained contraction</td><td>Anaerobic glycolysis</td></tr><tr><td>MITOCHONDRIA, MYOGLOBIN</td><td>t</td><td>1</td></tr><tr><td>TYPE OF TRAINING</td><td>Endurance training</td><td>Weight/resistance training, sprinting</td></tr></table>
======================================
<table><thead><th></th><th>Atrophy</th><th>Hypertrophy</th></thead><tr><td>MYOFIBRILS</td><td>+ (removal via ubiquitin-proteasome system)</td><td>t (addition of sarcomeres in parallel)</td></tr><tr><td>MYONUCLEI</td><td>+ (selective apoptosis)</td><td>t (fusion of satellite cells, which repair damaged myofibrils; absent in cardiac muscles)</td></tr></table>
======================================
<table><tr><td>Medial (golfer’s) elbow tendinopathy</td><td>Repetitive wrist flexion or idiopathic + pain near medial epicondyle.</td></tr><tr><td>Lateral (tennis) elbow</td><td>_ Repetitive wrist extension (backhand shots) or idiopathic &gt; pain near lateral epicondyle.</td></tr></table>
======================================
<table><tr><td>Guyon canal syndrome</td><td>Compression of ulnar nerve at wrist. Classically seen in cyclists due to pressure from handlebars.</td><td>| May also be seen with fracture/dislocation of he hook of hamate.</td></tr><tr><td>Carpal tunnel syndrome</td><td>Entrapment of median nerve in carpal tunnel (between transverse carpal ligament and carpal bones) &gt; nerve compression — paresthesia, pain, and numbness in distribution of median nerve. Thenar eminence atrophies but sensation spared, because palmar cutaneous branch enters hand external to carpal tunnel.</td><td>Suggested by ® Tinel sign (percussion of wrist _ causes tingling) and Phalen maneuver (90° flexion of wrist causes tingling). Associated with pregnancy (due to edema), theumatoid arthritis, hypothyroidism, diabetes, acromegaly, dialysis-related amyloidosis; may be associated with repetitive use.</td></tr><tr><td>Metacarpal neck fracture</td><td>Also called boxer’s fracture. Common fracture caused by direct blow with a closed fist (eg,</td><td></td></tr><tr><td></td><td>from punching a wall). Most commonly seen in the 5th metacarpal [iN.</td><td></td></tr></table>
======================================
<table><tr><td>De Quervain tenosynovitis</td><td>(eg, MI) or pulmonary (eg, pulmonary embolism) Noninflammatory thickening of abductor Lo we A pollicis longus and extensor pollicis brevis tendons &gt; pain or tenderness at radial styloid.</td><td>diseases. Extensor retinaculum Extensor pollicis raiis</td></tr><tr><td>Dupuytren contracture</td><td>® Finkelstein test (pain at radial styloid with active or passive stretch of thumb tendons). t risk in new mothers (lifting baby), golfers, racquet sport players, “thumb” texters. Caused by fibroblastic proliferation and thickening of the fascia at the base of the ring and little fingers.</td><td>inflamed Abductor tendon sheaths iaHOUES\ongus superficial palmar fascia. Typically involves Unknown etiology; most frequently seen in</td></tr><tr><td>Ganglion cyst</td><td>males &gt; 50 years old of Northern European descent. Fluid-filled swelling overlying joint or tendon sheath,</td><td>most commonly at dorsal side of wrist.</td></tr><tr><td>lliotibial band syndrome</td><td>Usually resolves spontaneously. Overuse injury of lateral knee that occurs primarily in iliotibial band against lateral femoral epicondyle.</td><td>runners. Pain develops 2° to friction of</td></tr><tr><td>Limb compartment syndrome</td><td>t pressure within fascial compartment of a limb &gt; collapse + anoxia, necrosis, rhabdomyolysis + acute long bone fractures (eg, tibia), reperfusion injury, and tense, swollen compartments with passive Increased serum creatine kinase and motor deficits damage. 5 P’s: pain, pallor, paresthesia, pulselessness,</td><td>venous outflow obstruction and arteriolar tubular necrosis. Causes include significant animal venoms. Presents with severe pain stretch of muscles in the affected compartment. are late signs of irreversible muscle and nerve paralysis.</td></tr><tr><td>Medial tibial stress syndrome</td><td>Also called shin splints. Common cause of shin pain recruits. Caused by bone resorption that outpaces</td><td>and diffuse tenderness in runners and military bone formation in tibial cortex.</td></tr><tr><td>Plantar fasciitis</td><td>Inflammation of plantar aponeurosis characterized by morning or after period of inactivity) and tenderness. or jumping (eg, dancers, runners), and flat feet. Heel</td><td>heel pain (worse with first steps in the Associated with obesity, prolonged standing spurs often coexist.</td></tr><tr><td>Temporomandibular disorders</td><td>Group of disorders that involve the temporomandibular Multifactorial etiology; associated with TMJ trauma, trigeminal nerve pain processing, psychological facial pain that worsens with jaw movement, otalgia, range of motion).</td><td>joint (‘TMJ) and muscles of mastication. poor head and neck posture, abnormal factors. Present with dull, constant unilateral headache, ‘TMJ dysfunction (eg, limited</td></tr></table>
======================================
<table><thead><th>DISORDER</th><th>SERUM Ca’</th><th>PO*</th><th>ALP</th><th>PTH</th><th>COMMENTS</th></thead><tr><td>Osteoporosis</td><td></td><td></td><td></td><td></td><td>+ bone mass</td></tr><tr><td>Osteopetrosis</td><td>It</td><td></td><td></td><td></td><td>Dense, brittle bones. Ca** | in severe, malignant disease</td></tr><tr><td>Paget disease ofbone</td><td>—</td><td>_</td><td>t</td><td>_</td><td>Abnormal “mosaic” bone architecture</td></tr><tr><td>Osteitis fibrosa cystica Primary hyperparathyroidism</td><td>t</td><td>+</td><td>t</td><td>t</td><td>“Brown tumors” due to fibrous replacement of bone, subperiosteal thinning Idiopathic or parathyroid hyperplasia, adenoma,</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>carcinoma</td></tr><tr><td>Secondary hyperparathyroidism</td><td>1</td><td>t</td><td>t</td><td>t</td><td>Often as compensation for CKD (+ PO,’ excretion and production of activated vitamin D)</td></tr><tr><td>Osteomalacia/rickets</td><td>|</td><td>4</td><td>t</td><td>t</td><td>Soft bones; vitamin D deficiency also causes 2° hyperparathyroidism</td></tr><tr><td>Hypervitaminosis D</td><td>t</td><td>t</td><td>_</td><td>1</td><td>Caused by oversupplementation or granulomatous disease (eg, sarcoidosis)</td></tr></table>
======================================
<table><thead><th>TUMOR TYPE</th><th>EPIDE! MIOLOGY</th><th>LOCATION</th><th>CHARACTERISTICS</th></thead><tr><td colspan="4">Benign tumors</td></tr><tr><td>Osteochondroma</td><td>Most common benign bone tumor Ma les &lt; 25 years old</td><td>Metaphysis of long bones</td><td>Lateral bony projection of growth plate (continuous with marrow space) covered by cartilaginous cap [iN Rarely transforms to chondrosarcoma</td></tr><tr><td>Osteoma</td><td>Middle age</td><td>Surface of facial bones</td><td>Associated with Gardner syndrome</td></tr><tr><td>Osteoid osteoma</td><td>Adults &lt; 25 years old Ma les &gt; females</td><td>Cortex of long bones</td><td>Presents as bone pain (worse at night) that is relieved by NSAIDs Bony mass (&lt; 2 cm) with radiolucent osteoid core EJ</td></tr><tr><td>Osteoblastoma</td><td>Ma les &gt; females</td><td>Vertebrae</td><td>Similar histology to osteoid osteoma Larger size (&gt; 2 cm), pain unresponsive to NSAIDs</td></tr><tr><td>Chondroma</td><td></td><td>Medulla of small bones of hand and feet</td><td>Benign tumor of cartilage</td></tr><tr><td>Giant cell tumor</td><td>20- 40 years old</td><td>Epiphysis of long bones (often in knee region)</td><td>Locally aggressive benign tumor Neoplastic mononuclear cells that express RANKL and reactive multinucleated giant (osteoclastlike) cells. “Osteoclastoma”</td></tr></table>
======================================
<table><thead><th>TUMOR TYPE</th><th>EPIDEMIOLOGY</th><th>LOCATION</th><th>CHARACTERISTICS</th></thead><tr><td colspan="4">Malignant tumors</td></tr><tr><td>Osteosarcoma (osteogenic sarcoma)</td><td>Accounts for 20% of 1° _ bone cancers. Peak incidence of 1° tumor in males &lt; 20 years. Less common in older adults; usually 2° to predisposing factors, such as Paget disease of bone, bone infarcts, radiation, familial retinoblastoma, Li-Fraumeni syndrome.</td><td>Metaphysis of long bones (often in knee region).</td><td>Pleomorphic osteoid-producing cells (malignant osteoblasts). Presents as painful enlarging mass or pathologic fractures. Codman triangle ) (from elevation of periosteum) or sunburst pattern on x-ray [J (think of an osteocod [bone fish] swimming in the sun). Aggressive. 1° usually responsive to treatment (surgery, chemotherapy), poor prognosis for 2°.</td></tr><tr><td>Chondrosarcoma</td><td>Most common in adults &gt; 50 years old.</td><td>Medulla of pelvis, proximal femur and humerus.</td><td>‘Tumor of malignant chondrocytes. Lytic (&gt; 50%) cases with intralesional calcifications, endosteal erosion, cortex breach.</td></tr><tr><td>Ewing sarcoma</td><td>Most common in White —_ patients, generally males &lt; 15 years old.</td><td>Diaphysis of long bones —_ (especially femur), pelvic flat bones.</td><td>Anaplastic small blue cells of neuroectodermal (mesenchymal) origin (resemble lymphocytes) [. Differentiate from conditions with similar morphology (eg, lymphoma, chronic osteomyelitis) by testing for t(11;22) (fusion protein EWS-FLII). “Onion skin” periosteal reaction. Aggressive with early metastases, but responsive to chemotherapy. 11 + 22 = 33 (Patrick Ewing’s jersey number).</td></tr><tr><td colspan="4">Round cell lesions Ewing sarcoma Myeloma Fibrous dysplasia</td></tr><tr><td>Diaphysis Osteoid osteoma _Metaphysis</td><td>Simple bone cyst Osteochondroma Physis</td><td></td><td></td></tr></table>
======================================
<table><tr><td>PATHOGENESIS</td><td>Mechanical—wear and tear destroys articular cartilage (degenerative joint disorder) =&gt; inflammation with inadequate repair (mediated by chondrocytes).</td><td>Autoimmune—inflammation [@ induces formation of pannus (proliferative granulation tissue), which erodes articular cartilage and bone.</td></tr><tr><td>PREDISPOSING FACTORS</td><td>Age, female, obesity, joint trauma.</td><td>Female, HLA-DR¢4 (4-walled “rheum”), HLA- DRBI, tobacco smoking. ® rheumatoid factor (IgM antibody that targets IgG Fe region; in 80%), anti-cyclic citrullinated peptide antibody (more specific).</td></tr><tr><td>PRESENTATION</td><td>Pain in weight-bearing joints after use (eg, at the end of the day), improving with rest. Asymmetric joint involvement. Knee cartilage loss begins medially (“bowlegged”). No systemic symptoms.</td><td>Pain, swelling, and morning stiffness lasting &gt; | hour, improving with use. Symmetric joint involvement. Systemic symptoms (fever, fatigue, weight loss). Extraarticular manifestations common.”</td></tr><tr><td>JOINT FINDINGS</td><td>Osteophytes (bone spurs), joint space narrowing (asymmetric), subchondral sclerosis and cysts, loose bodies. Synovial fluid noninflammatory (WBC &lt; 2000/mm’). Development of Heberden nodes [3 (at DIP) and Bouchard nodes [J (at PIP), and Ist CMC; not MCP.</td><td>Erosions, juxta-articular osteopenia, soft tissue swelling, subchondral cysts, joint space narrowing (symmetric). Deformities: cervical subluxation, ulnar finger deviation, swan neck {, boutonniere [J. Involves MCP, PIP, wrist; not DIP or Ist CMC.</td></tr><tr><td>TREATMENT</td><td>Activity modification, acetaminophen, NSAIDs, intra-articular glucocorticoids.</td><td>NSAIDs, glucocorticoids, disease-modifying agents (eg, methotrexate, sulfasalazine),</td></tr></table>
======================================
<table><tr><td>Giant cell (temporal) arteritis</td><td>Females &gt; 50 years old. Unilateral headache, possible temporal artery tenderness, jaw claudication. May lead to irreversible blindness due to anterior ischemic optic neuropathy. Associated with polymyalgia rheumatica. Most commonly affects carotid artery branches.</td><td>May also cause aortitis or vertebral artery infarct. Focal granulomatous inflammation [N. tt ESR. IL-6 levels correlate with disease activity. Treat with high-dose glucocorticoids prior to temporal artery biopsy to prevent blindness.</td></tr><tr><td>Takayasu arteritis</td><td>Usually Asian females &lt; 40 years old. “Pulseless disease” (weak upper extremity P skin nodules, ocular disturbances. z ilses), fever, night sweats, arthritis, myalgias,</td><td>Granulomatous thickening and narrowing of aortic arch and proximal great vessels [FJ. t ESR. Treatment: glucocorticoids.</td></tr><tr><td colspan="3">Medium-vessel vasculitis</td></tr><tr><td rowspan="2">Buerger disease (thromboangiitis obliterans)</td><td>Heavy tobacco smoking history, males &lt; 40 years old.</td><td>Raynaud phenomenon is often present. Segmental thrombosing vasculitis with vein and</td></tr><tr><td></td><td>Intermittent claudication. May lead to gangrene [@, autoamputation of digits, superficial nodular phlebitis.</td><td>nerve involvement. Treatment: smoking cessation.</td></tr><tr><td>Kawasaki disease</td><td>Usually Asian children &lt; 4 years old. Bilateral nonexudative bulbar Conjunctivitis, Rash (polymorphous &gt; desquamating), Adenopathy (cervical), Strawberry tongue (oral mucositis) J, Hand-foot changes (edema, erythema), fever.</td><td>Formerly called mucocutaneous lymph node syndrome. CRASH and burn on a Kawasaki. May deve thrombosis or rupture can cause death. op coronary artery aneurysms [4; Treatment: IV immunoglobulin and aspirin.</td></tr><tr><td>Polyarteritis nodosa</td><td>Usually middle-aged males. Hepatitis B seropositivity in 30% of patients. Fever, weight loss, malaise, headache. GI: abdominal pain, melena. Hypertension, neurologic dysfunction, cutaneous eruptions, renal damage. ‘Typically involves renal and visceral vessels, spares pulmonary arteries.</td><td>Different stages of transmural inflammation with fibrinoid necrosis. Innumerable renal microaneurysms [jj and spasms on arteriogram (string of pearls appearance). Treatment: glucocorticoids, cyclophosphamide. PAN usually affects the SKIN: Skin, Kidneys, Intestines (GI), Nerves.</td></tr><tr><td colspan="3">Small-vessel vasculitis</td></tr><tr><td>Behcet syndrome</td><td>t incidence in people of Turkish and eastern Mediterranean descent. Recurrent aphthous ulcers, genital ulcerations, uveitis, erythema nodosum. Can be precipitated by HSV or parvovirus. Flares last 1-4 weeks.</td><td>Immune complex vasculitis. Associated with HLA-B51.</td></tr><tr><td>Cutaneous small- vessel vasculitis</td><td>Occurs 7-10 days after certain medications (penicillins, cephalosporins, sulfonamides, phenytoin, allopurinol) or infections (eg, HCV, HIV).</td><td>Immune complex—mediated leukocytoclastic vasculitis; late involvement indicates systemic vasculitis.</td></tr></table>
======================================
<table><tr><td colspan="3">Small-vessel vasculitis (continued)</td></tr><tr><td>Eosinophilic granulomatosis with polyangiitis</td><td>Asthma, sinusitis, skin nodules or purpura, peripheral neuropathy (eg, wrist/foot drop). Can also involve heart, GI, kidneys (pauci- immune glomerulonephritis).</td><td>Formerly called Churg-Strauss syndrome. Granulomatous, necrotizing vasculitis with eosinophilia [&amp;. MPO-ANCA/p-ANCA, t IgE level.</td></tr><tr><td>Granulomatosis with polyangiitis</td><td>Upper respiratory tract: perforation of nasal septum, chronic sinusitis, otitis media, mastoiditis. O° Lower respiratory tract: hemoptysis, cough, dyspnea. Renal: pauci-immune rapidly progressive glomerulonephritis (hematuria, red cell casts).</td><td>Triad: * Focal necrotizing vasculitis » Necrotizing granulomas in lung and upper airway » Necrotizing glomerulonephritis PR3-ANCA/c-ANCA [7] (anti-proteinase 3). CXR: large nodular densities. Treatment: glucocorticoids in combination with rituximab or cyclophosphamide.</td></tr><tr><td>Immunoglobulin A vasculitis</td><td>Most common childhood systemic vasculitis. Often follows URI. Classic triad: * Hinge pain (arthralgias) = Stomach pain (abdominal pain associated with intussusception) * Palpable purpura on buttocks/legs</td><td>Formerly called Henoch-Schénlein purpura. Vasculitis 2° to IgA immune complex deposition. Associated with IgA nephropathy (Berger disease). Treatment: supportive care, possibly glucocorticoids.</td></tr><tr><td>Microscopic polyangiitis</td><td>Necrotizing vasculitis commonly involving lung, kidneys, and skin with pauci-immune glomerulonephritis [J and palpable purpura. Presentation similar to granulomatosis with polyangiitis but without nasopharyngeal involvement.</td><td>No granulomas. MPO-ANCA/p-ANCA (anti-myeloperoxidase). Treatment: cyclophosphamide, glucocorticoids.</td></tr><tr><td>Mixed cryoglobulinemia</td><td>Often due to viral infections, especially HCV. Triad of palpable purpura, weakness, arthralgias. May also have peripheral neuropathy and renal disease (eg, glomerulonephritis).</td><td>Cryoglobulins are immunoglobulins that precipitate in the Cold. Vasculitis due to mixed IgG and IgM immune complex deposition.</td></tr></table>
======================================
<table><tr><td>FREQUENCY</td><td>Most common NMJ disorder</td><td>Uncommon</td></tr><tr><td>PATHOPHYSIOLOGY</td><td>Autoantibodies to postsynaptic ACh receptor</td><td>Autoantibodies to presynaptic Ca®* channel &gt; 4 ACh release; L comes before M</td></tr><tr><td rowspan="2">CLINICAL</td><td>Fatigable muscle weakness—ptosis; diplopia; proximal weakness; respiratory muscle involvement — dyspnea; bulbar muscle involvement — dysphagia, difficulty chewing Spared reflexes</td><td>Proximal muscle weakness, autonomic symptoms (dry mouth, constipation, impotence) Hyporeflexia</td></tr><tr><td></td><td>Worsens with muscle use</td><td>Improves with muscle use</td></tr><tr><td>ASSOCIATED WITH</td><td>Thymoma, thymic hyperplasia</td><td>Small cell lung cancer</td></tr><tr><td>AChE INHIBITOR ADMINISTRATION</td><td>Reverses symptoms (pyridostigmine for</td><td>Minimal effect</td></tr></table>
======================================
<table><thead><th>LESION</th><th>CHARACTERISTICS</th><th>EXAMPLES</th></thead><tr><td>Macule</td><td>Flat lesion with well-circumscribed change in skin color &lt; 1 cm</td><td>Freckle (ephelis), labial macule [i</td></tr><tr><td>Patch</td><td>Macule &gt; 1 cm</td><td>Vitiligo FE</td></tr><tr><td>Papule</td><td>Elevated solid skin lesion &lt; 1 cm</td><td>Neurofibroma [@, acne</td></tr><tr><td>Plaque</td><td>Papule &gt; 1 cm</td><td>Psoriasis [5)</td></tr><tr><td>Vesicle</td><td>Small fluid-containing blister &lt; 1 cm</td><td>Chickenpox (varicella), shingles (zoster) 5)</td></tr><tr><td>Bulla</td><td>Large fluid-containing blister &gt; 1 cm</td><td>Bullous pemphigoid [9</td></tr><tr><td>Pustule</td><td>Vesicle containing pus</td><td>Pustular psoriasis [=]</td></tr><tr><td>Wheal</td><td>Transient smooth papule or plaque</td><td>Hives (urticaria) [7]</td></tr><tr><td>Scale</td><td>Flaking off of stratum corneum</td><td>Eczema, psoriasis, SCC [J</td></tr></table>
======================================
<table><thead><th>LESION</th><th>CHARACTERISTICS</th><th>EXAMPLES</th></thead><tr><td>Dyskeratosis</td><td>Abnormal premature keratinization</td><td>Squamous cell carcinoma</td></tr><tr><td>Hyperkeratosis</td><td>hickness of stratum corneum t</td><td>Psoriasis, calluses</td></tr><tr><td>Parakeratosis</td><td>Retention of nuclei in stratum corneum</td><td>Psoriasis, actinic keratosis</td></tr><tr><td>Hypergranulosis</td><td>t thickness of stratum granulosum</td><td>Lichen planus</td></tr><tr><td>Spongiosis</td><td>E pidermal accumulation of edematous fluid in intercellular spaces</td><td>Eczematous dermatitis</td></tr><tr><td>Acantholysis</td><td>Separation of epidermal cells</td><td>Pemphigus vulgaris</td></tr><tr><td>Acanthosis</td><td>Epidermal hyperplasia (t spinosum)</td><td>Acanthosis nigricans, psoriasis</td></tr></table>
======================================
<table><tr><td>Acne</td><td>Multifactorial etiology—t sebum/androgen production, abnormal keratinocyte desquamation, Cutibacterium acnes colonization of the pilosebaceous unit (comedones), and inflammation (papules/pustules FN, nodules, cysts). Treatment: retinoids, benzoyl peroxide, and antibiotics.</td></tr><tr><td>Atopic dermatitis (eczema)</td><td>Pruritic eruption associated with ichthyosis vulgaris and other atopic diseases (asthma, allergic rhi- nitis, food allergies); t serum IgE. Often appears on face in infancy [FJ and then on flexural surfaces {in children and adults.</td></tr><tr><td>Allergic contact dermatitis</td><td>‘Type IV hypersensitivity reaction secondary to contact allergen (eg, nickel ), poison ivy [3], neomycin).</td></tr><tr><td>Keratosis pilaris</td><td>Follicular-based papules from keratin plugging, most often on extensor surfaces of arms and thighs.</td></tr><tr><td>Melanocytic nevus</td><td>Common mole. Benign, but melanoma can arise in congenital or atypical moles. Intradermal nevi are papular ff. Junctional nevi are flat macules (4.</td></tr><tr><td>Pseudofolliculitis barbae</td><td>Inflammatory reaction to hair penetrating the skin characterized by firm papules and pustules that are painful and pruritic. Commonly occurs near jawline as a result of shaving (“razor bumps”), more common with naturally curly hair.</td></tr><tr><td>Rosacea</td><td>spinosum, $ stratum granulosum. Auspitz sign (§]])—pinpoint bleeding spots from exposure of dermal papillae when scales are scraped off. Associated with nail pitting and psoriatic arthritis. Inflammatory facial skin disorder characterized by erythematous papules and pustules Jj, but no comedones. May be associated with facial flushing in response to external stimuli (eg, alcohol,</td></tr><tr><td>Seborrheic keratosis</td><td>heat). Complications include ocular involvement, rhinophyma (bulbous deformation of nose). Well-demarcated, verrucous, benign squamous epithelial proliferation of immature keratinocytes with keratin-filled cysts (horn cysts) [[. Looks “stuck on.” Leser-Irélat sign [J]—rapid onset of</td></tr><tr><td>Verrucae</td><td>multiple seborrheic keratoses, indicates possible malignancy (eg, GI adenocarcinoma). Warts; caused by low-risk HPV strains. Soft, tan-colored, cauliflowerlike papules [J]. Epidermal</td></tr><tr><td>Urticaria</td><td>hyperplasia, hyperkeratosis, koilocytosis. Condyloma acuminatum on anus or genitals [J Hives. Pruritic wheals that form after mast cell degranulation [@). Characterized by superficial dermal edema and lymphatic channel dilation.</td></tr></table>
======================================
<table><thead><th colspan="2">Bacterial infections</th></thead><tr><td>Impetigo</td><td>Skin infection involving superficial epidermis. Usually from S aureus or S pyogenes. Highly contagious. Honey-colored crusting [N. Bullous impetigo [J has bullae and is usually caused by S aureus.</td></tr><tr><td>Erysipelas</td><td>Infection involving upper dermis and superficial lymphatics, usually from S pyogenes. Presents with well-defined, raised demarcation between infected and normal skin [@.</td></tr><tr><td>Cellulitis</td><td>Acute, painful, spreading infection of deeper dermis and subcutaneous tissues. Usually from S pyogenes or S aureus. Often starts with a break in skin from trauma or another infection fi).</td></tr><tr><td>Abscess</td><td>Collection of pus from a walled-off infection within deeper layers of skin []. Offending organism is almost always S aureus.</td></tr><tr><td>Necrotizing fasciitis</td><td>Deeper tissue injury, usually from anaerobic bacteria or S pyogenes. Pain may be out of proportion to exam findings. Results in crepitus from methane and CO, production. “Flesh-eating bacteria.” Causes bullae and skin necrosis + violaceous color of bullae, surrounding skin [. Surgical emergency.</td></tr><tr><td>Staphylococcal scalded skin syndrome</td><td>Exotoxin destroys keratinocyte attachments in stratum granulosum only (vs toxic epidermal necrolysis, which destroys epidermal-dermal junction). No mucosal involvement. Characterized by fever and generalized erythematous rash with sloughing of the upper layers of the epidermis [=] that heals completely. ® Nikolsky sign (separation of epidermis upon manual stroking of skin). Commonly seen in newborns and children/adults with renal insufficiency.</td></tr><tr><td colspan="2">Viral infections</td></tr><tr><td>Herpes</td><td>Herpes virus infections (HSV-1 and HSV-2) of skin can occur anywhere from mucosal surfaces to normal skin. These include herpes labialis, herpes genitalis, herpetic whitlow [J (finger).</td></tr><tr><td>Molluscum contagiosum</td><td>Umbilicated papules [fj caused by a poxvirus. While frequently seen in children, it may be sexually transmitted in adults.</td></tr><tr><td>Varicella zoster</td><td>Causes varicella (chickenpox) and zoster (shingles). Varicella presents with multiple crops of lesions in various stages from vesicles to crusts. Zoster is a reactivation of the virus in dermatomal distribution (unless it is disseminated).</td></tr><tr><td>Hairy leukoplakia</td><td>Irregular, white, painless plaques on lateral tongue that cannot be scraped off [J]. EBV mediated. Occurs in patients living with HIV, organ transplant recipients. Contrast with thrush (scrapable) and leukoplakia (precancerous).</td></tr></table>
======================================
<table><tr><td>GROSS MORPHOLOGY</td><td>Flaccid intraepidermal bullae [J caused by acantholysis (separation of keratinocytes, “row of tombstones” on H&amp;E stain); oral mucosa is involved. Nikolsky sign ®.</td><td>Tense blisters [§ containing eosinophils; oral mucosa spared. Nikolsky sign ©.</td></tr></table>
======================================
<table><thead><th></th><th>Venous ulcer</th><th>Arterial ulcer</th><th>Neuropathic ulcer</th><th>Pressure injury</th></thead><tr><td>ETIOLOGY</td><td>Chronic venous insufficiency; most common ulcer type</td><td>Peripheral artery disease (eg, atherosclerotic stenosis)</td><td>Peripheral neuropathy (eg, diabetic foot)</td><td>Prolonged unrelieved pressure (eg, immobility)</td></tr><tr><td>LOCATION</td><td>Gaiter area (ankle to midcalf), typically over malleoli</td><td>Distal toes, anterior shin, pressure points</td><td>Bony prominences (eg, metatarsal heads, heel)</td><td>Weightbearing points (eg, sacrum, ischium, calcaneus)</td></tr><tr><td>APPEARANCE</td><td>Irregular border, shallow, exudative [J</td><td>Symmetric with well- defined punched-out appearance [:]</td><td>Hyperkeratotic edge with undermined borders [@]</td><td>Varies based on stage from non-blanchable erythema to full- thickness skin loss B)</td></tr><tr><td>PAIN</td><td>Mild to moderate</td><td>Severe</td><td>Absent</td><td>Present</td></tr><tr><td>ASSOCIATED SIGNS</td><td>Telangiectasias, varicose veins, edema, stasis dermatitis (erythematous eczematous patches)</td><td>Arterial insufficiency, cold and pale atrophic skin, hair loss, absent pulses</td><td>Claw toes, Charcot joints, absent reflexes</td><td>Soft tissue infection and osteomyelitis are frequent complications</td></tr></table>
======================================
<table><thead><th>DEPTH</th><th>INVOLVEMENT</th><th>APPEARANCE</th><th>SENSATION</th></thead><tr><td>Superficial burn</td><td>pidermis only sal</td><td>Similar to sunburn; histamine release causes localized, dry, blanching redness without blisters</td><td>Painful</td></tr><tr><td>Superficial partial- thickness burn</td><td>Di fat ermis and papillary dermis sal</td><td>Blisters, blanches with pressure, swollen, warm</td><td>Painful to temperature and air</td></tr><tr><td>Deep partial- thickness burn</td><td>dermis and reticular dermis p! sal</td><td>Blisters (easily unroofed), does not blanch with pressure</td><td>Painless; perception of pressure only</td></tr><tr><td>Full-thickness burn</td><td>dermis and full-thickness p! sal dermis</td><td>White, waxy, dry, inelastic, leathery, does not blanch with pressure</td><td>Painless; perception of deep pressure only</td></tr><tr><td>Deeper injury burn</td><td>fv. of underlying tissue (eg, fascia, muscle) dermis, dermis, and involvement</td><td>White, dry, inelastic, does not blanch with pressure</td><td>Painless; some perception of deep pressure</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Reversibly inhibits cyclooxygenase, mostly in CNS. Inactivated peripherally.</td></tr><tr><td>CLINICAL USE</td><td>Antipyretic, analgesic, but not anti-inflammatory. Used instead of aspirin to avoid Reye syndrome in children with viral infection.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Overdose produces hepatic necrosis; acetaminophen metabolite (NAPQI) depletes glutathione and forms toxic tissue byproducts in liver. N-acetylcysteine is antidote—regenerates glutathione.</td></tr></table>
======================================
<table><thead><th>Celecoxib</th><th></th></thead><tr><td>MECHANISM</td><td>Reversibly and selectively inhibits the cyclooxygenase (COX) isoform 2 (“Selecoxib”), which is found in inflammatory cells and vascular endothelium and mediates inflammation and pain; spares COX-1, which helps maintain gastric mucosa. Thus, does not have the corrosive effects of other NSAIDs on the GI lining. Spares platelet function as T'XA, production is dependent on COX-1.</td></tr><tr><td>CLINICAL USE</td><td>Rheumatoid arthritis, osteoarthritis.</td></tr><tr><td>ADVERSE EFFECTS</td><td>t risk of thrombosis, sulfa allergy.</td></tr><tr><td>Nonsteroidal anti-inflammatory drugs</td><td>Ibuprofen, naproxen, indomethacin, ketorolac, diclofenac, meloxicam, piroxicam.</td></tr><tr><td>MECHANISM</td><td>Reversibly inhibit cyclooxygenase (both COX-1 and COX-2). Block prostaglandin synthesis.</td></tr><tr><td>CLINICAL USE</td><td>Antipyretic, analgesic, anti-inflammatory. Indomethacin is used to close a PDA.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Interstitial nephritis, gastric ulcer (prostaglandins protect gastric mucosa), renal ischemia (prostaglandins vasodilate afferent arteriole), aplastic anemia.</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Recombinant PTH analog. t osteoblastic activity when administered in pulsatile fashion.</td></tr><tr><td>CLINICAL USE</td><td>Osteoporosis. Causes t bone growth compared to antiresorptive therapies (eg, bisphosphonates)</td></tr></table>
======================================
<table><thead><th colspan="2">Chronic gout drugs (preventive)</th><th colspan="6"></th></thead><thead><th>Allopurinol</th><th>Competitive inhibitor of xanthine oxidase &gt; 4 conversion of hypoxanthine and xanthine . . to urate. Also used in lymphoma and leukemia</th><th>All painful flares are</th><th>preventable. . Purines</th><th></th><th></th></thead><tr><td>. Pegloticase</td><td>6-MP. . . . . . Recombinant uricase catalyzing uric acid to</td><td></td><td>y Xanthine</td><td>oxidase . Xanthine</td><td>Allopurinol, Febuxostat</td></tr><tr><td></td><td>allantoin (a more water-soluble product). ° I .</td><td></td><td></td><td>oxidase</td><td></td></tr><tr><td>Febuxostat</td><td>Inhibits xanthine oxidase. Think, “febu-xo-stat makes Xanthine Oxidase static.”</td><td></td><td>Plasma uric acid</td><td></td><td></td></tr><tr><td>Probenecid</td><td>Inhibits reabsorption of uric acid in proximal convoluted tubule (also inhibits secretion of penicillin). Can precipitate uric acid calculi or lead to sulfa allergy.</td><td>Tubular secretion</td><td></td><td>Tubular</td><td>reabsorption</td></tr><tr><td>Acute gout drugs</td><td></td><td>)</td><td></td><td></td><td></td></tr><tr><td>NSAIDs</td><td>. . . Any NSAID. Use salicylates with caution (may decrease uric acid excretion, particularly at low doses).</td><td>Diuretics, low-dose salicylates</td><td>Urine</td><td>high-dose</td><td>Probenecid, salicylates</td></tr><tr><td>Glucocorticoids</td><td>Oral, intra-articular, or parenteral.</td><td></td><td></td><td></td><td></td></tr><tr><td>Colchicine</td><td>Binds and stabilizes tubulin to inhibit microtubule polymerization, impairing neutrophil chemotaxis and degranulation. Acute and prophylactic value. GI, neuromyopathic adverse effects. Can also</td><td></td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>DRUG</th><th>MECHANISM</th><th>CLINICAL USE</th><th>ADVERSE EFFECTS</th></thead><tr><td>Etanercept</td><td>Fusion protein (decoy receptor for TNF-a + IgG, Fe), produced by recombinant DNA. Etanercept intercepts TNF.</td><td>Rheumatoid arthritis, psoriasis, ankylosing spondylitis.</td><td>Predisposition to infection, including reactivation of latent TB, since T'NF is important in granuloma</td></tr><tr><td>Adalimumab, certolizumab, golimumab,</td><td>Anti-TNF-o monoclonal antibody.</td><td>Inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis,</td><td>formation and stabilization. Can also lead to drug-induced lupus.</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Binds toll-like receptor 7 (‘TLR-7) of macrophages, monocytes, and dendritic cells to activate them = topical antitumor immune response modifier.</td></tr><tr><td>CLINICAL USE</td><td>Anogenital warts, actinic keratosis.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Itching, burning pain at site of application, rashes.</td></tr></table>
======================================
<table><tr><td>Neurology and</td><td></td></tr><tr><td colspan="2">Special Senses</td></tr><tr><td>“We are all now connected by the Internet, like neurons in a giant brain.” —Stephen Hawking</td><td>&gt;» Embryology » Anatomy and</td></tr><tr><td>“Exactly how [the brain] operates remains one of the biggest unsolved</td><td>Physiology</td></tr><tr><td>mysteries, and it seems the more we probe its secrets, the more surprises we find.”</td><td>» Pathology</td></tr><tr><td>—Neil deGrasse Tyson</td><td></td></tr><tr><td>“Tt’s not enough to be nice in life. You’ve got to have nerve.” —Georgia O'Keeffe</td><td>» Otology &gt; Ophthalmology</td></tr><tr><td>“I not only use all the brains that I have, but all that I can borrow.” —Woodrow Wilson</td><td>» Pharmacology</td></tr><tr><td colspan="2">“The chief function of the body is to carry the brain around.” —Thomas Edison</td></tr><tr><td>“I opened two gifts this morning. They were my eyes.” —Hilary Hinton “Zig” Ziglar</td><td></td></tr></table>
======================================
<table><thead><th>RECEPTOR TYPE</th><th>SENSORY NEURON FIBER TYPE</th><th>LOCATION</th><th>SENSES</th></thead><tr><td>Free nerve endings</td><td>Aé—fast, myelinated fibers C—slow, unmyelinated A Delta plane is fast, but a taxC is slow</td><td>All tissues except cartilage and eye lens; numerous in skin</td><td>Pain, temperature</td></tr><tr><td>Meissner corpuscles</td><td>Large, myelinated fibers; adapt quickly</td><td>Glabrous (hairless) skin</td><td>Dynamic, fine/light touch, low-frequency vibration, skin indentation</td></tr><tr><td>Pacinian corpuscles</td><td>Large, myelinated fibers; adapt quickly</td><td>Deep skin layers, ligaments, joints</td><td>High-frequency vibration, pressure</td></tr><tr><td>Merkel discs</td><td>Large, myelinated fibers; adapt slowly</td><td>Finger tips, superficial skin</td><td>Pressure, deep static touch (eg, shapes, edges)</td></tr><tr><td>Ruffini corpuscles</td><td>Large, myelinated fiber intertwined among collagen fiber bundles; adapt slowly</td><td>Finger tips, joints</td><td>Stretch, joint angle change</td></tr></table>
======================================
<table><thead><th></th><th rowspan="2">LOCATION OF SYNTHESIS</th><th rowspan="2">ANXIETY</th><th rowspan="2">DEPRESSION</th><th rowspan="2">SCHIZOPHRENIA</th><th rowspan="2">ALZHEIMER DISEASE</th><th rowspan="2">HUNTINGTON DISEASE</th><th rowspan="2">PARKINSON DISEASE</th></thead><thead><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></thead><tr><td>Acetylcholine</td><td>Basal nucleus of Meynert (forebrain)</td><td></td><td></td><td></td><td>1</td><td>+</td><td>t</td></tr><tr><td>Dopamine</td><td>Ventral tegmentum, SNe (midbrain)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>GABA</td><td>Nucleus accumbens (basal ganglia)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Norepinephrine</td><td>Locus ceruleus (pons)</td><td>t</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Serotonin</td><td>Raphe nuclei (brainstem)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>Sleep physiology</th><th>Sleep cycle is regulated by the circadian rhythm, of the hypothalamus. Circadian rhythm controls norepinephrine: SCN &gt; norepinephrine release by environment (eg, light). ‘Two stages: rapid-eye movement (REM) and Alcohol, benzodiazepines, and barbiturates are norepinephrine also | REM</th><th>which is driven by suprachiasmatic nucleus (SCN) nocturnal release of ACTH, prolactin, melatonin, + pineal gland + t melatonin. SCN is regulated non-REM. associated with | REM sleep and N3 sleep;</th></thead><thead><th></th><th>sleep. Benzodiazepines are useful for night terrors and</th><th>sleepwalking by | N3 and REM sleep.</th></thead><tr><td>SLEEP STAGE (% OF TOTAL SLEEP TIME IN YOUNG ADULTS)</td><td>DESCRIPTION</td><td>EEG WAVEFORM AND NOTES</td></tr><tr><td>Awake (eyes open)</td><td>Alert, active mental concentration.</td><td>Beta (highest frequency, lowest amplitude).</td></tr><tr><td>Awake (eyes closed)</td><td></td><td>Alpha.</td></tr><tr><td colspan="3">Non-REM sleep</td></tr><tr><td>Stage N1 (5%) Stage N2 (45%)</td><td>Light sleep. Deeper sleep; when bruxism (“twoth” [tooth]</td><td>Theta. Sleep spindles and K complexes.</td></tr><tr><td>Stage N3 (25%)</td><td>grinding) occurs. Deepest non-REM sleep (slow-wave sleep);</td><td>Delta (lowest frequency, highest amplitude),</td></tr><tr><td>REM sleep (25%)</td><td>sleepwalking, night terrors, and bedwetting occur (wee and flee in N3). Loss of motor tone, t brain O, use, variable</td><td>deepest sleep stage. Beta.</td></tr><tr><td></td><td>pulse/BP, t ACh. REM is when dreaming, nightmares, and penile/clitoral tumescence occur, May serve Memory. processing function. Extraocular movements due to activity of PPRF (paramedian pontine reticular formation/ conjugate gaze center). Occurs every 90 minutes, and duration t through the night.</td><td>Changes in older adults: | REM, + N3, t sleep latency, t early awakenings. Changes in depression: t REM sleep time, + REM latency, + N3, repeated nighttime awakenings, early morning awakening (terminal insomnia). Change in narcolepsy: | REM latency. At night, BATS Drink Blood.</td></tr></table>
======================================
<table><tr><td>Lateral nucleus</td><td>Hunger. Stimulated by ghrelin, inhibited by leptin.</td><td>Lateral injury makes you lean. Destruction &gt; anorexia, failure to thrive (infants)</td></tr><tr><td>Ventromedial nucleus</td><td>Satiety. Stimulated by leptin.</td><td>Ventromedial injury makes you very massive. Destruction (eg, craniopharyngioma) — hyperphagia.</td></tr><tr><td>Anterior nucleus</td><td>Cooling, parasympathetic.</td><td>A/C = Anterior Cooling.</td></tr><tr><td>Posterior nucleus</td><td>Heating, sympathetic.</td><td>Heating controlled by posterior nucleus (“hot pot”).</td></tr><tr><td>Suprachiasmatic nucleus</td><td>Circadian rhythm.</td><td>SCN is a Sun-Censing Nucleus.</td></tr><tr><td>Supraoptic and paraventricular nuclei</td><td>Synthesize ADH and oxytocin.</td><td>SAD POX: Supraoptic = ADH, Paraventricular = OXytocin. ADH and oxytocin are carried by neurophysins down axons to posterior pituitary, where these hormones are stored and released.</td></tr><tr><td>Preoptic nucleus</td><td>Thermoregulation, sexual behavior. Releases GnRH.</td><td>Failure of GnRH-producing neurons to migrate from olfactory pit &gt; Kallmann syndrome.</td></tr></table>
======================================
<table><thead><th>NUCLEI</th><th>INPUT</th><th>SENSES</th><th>DESTINATION</th><th>MNEMONIC</th></thead><tr><td>Ventral posterolateral nucleus</td><td>Spinothalamic and dorsal columns/medial emmniscus</td><td>Vibration, pain, pressure, proprioception (conscious), light touch, temperature</td><td>° somatosensory cortex (parietal lobe)</td><td></td></tr><tr><td>Ventral postero- medial nucleus</td><td>Trigeminal and gustatory athway</td><td>Face sensation, taste</td><td>° somatosensory cortex (parietal lobe)</td><td>Very pretty makeup goes on the face</td></tr><tr><td>Medial geniculate nucleus</td><td>Superior olive and inferior colliculus of tectum</td><td>Hearing</td><td>(occipital ° auditory cortex</td><td>Medial = music</td></tr><tr><td></td><td></td><td></td><td>(temporal lobe)</td><td>(hearing)</td></tr><tr><td>Ventral anterior and ventral lateral nuclei</td><td>Basal ganglia, cerebellum</td><td>Motor</td><td>Motor cortices (frontal lobe)</td><td>Venus astronauts vow to love</td></tr></table>
======================================
<table><thead><th>NUCLEUS</th><th>FUNCTION</th><th>CRANIAL NERVES</th></thead><tr><td>Nucleus tractus solitarius</td><td>Visceral sensory information (eg, taste, baroreceptors, gut distention) May play a role in vomiting</td><td>VII, IX, X</td></tr><tr><td>Nucleus ambiguus</td><td>Motor innervation of pharynx, larynx, upper esophagus (eg, swallowing, palate elevation)</td><td>IX, X</td></tr><tr><td>Dorsal motor nucleus</td><td>Sends autonomic (parasympathetic) fibers to heart, lungs, upper GI</td><td>xX</td></tr></table>
======================================
<table><thead><th>NERVE</th><th>CN</th><th>FUNCTION</th><th>TYPE</th><th>MNEMONIC</th></thead><tr><td>Olfactory</td><td>I</td><td>Smell (only CN without thalamic relay to cortex)</td><td>Sensory</td><td>Some</td></tr><tr><td>Optic</td><td>I</td><td>Sight</td><td>Sensory</td><td>— Say</td></tr><tr><td>Oculomotor</td><td>Il</td><td>Eye movement (SR, IR, MR, IO), pupillary constriction (sphincter pupillae), accommodation (ciliary muscle), eyelid opening (levator palpebrae)</td><td>— Motor</td><td>Marry</td></tr><tr><td>Trochlear</td><td>IV</td><td>Eye movement (SO)</td><td>Motor</td><td>Money</td></tr><tr><td>Trigeminal</td><td>Vv</td><td>Mastication, facial sensation (ophthalmic, maxillary, mandibular divisions), somatosensation from anterior 2/3 of tongue, dampening of loud noises (tensor tympani)</td><td>Both</td><td>But</td></tr><tr><td>Abducens</td><td>VI</td><td>Eye movement (LR)</td><td>Motor</td><td>My</td></tr><tr><td>Facial</td><td>VII</td><td>Facial movement, eye closing (orbicularis oculi), auditory volume modulation (stapedius), taste from anterior 2/3 of tongue (chorda tympani), lacrimation, salivation (submandibular and sublingual glands are innervated by CN seven)</td><td>Both</td><td>Brother</td></tr><tr><td>Vestibulocochlear</td><td>VII</td><td>Hearing, balance</td><td>Sensory</td><td>— Says</td></tr><tr><td>Glossopharyngeal</td><td>IX</td><td>‘Taste and sensation from posterior 1/3 of tongue, swallowing, salivation (parotid gland), monitoring carotid body and sinus chemo- and baroreceptors, and elevation of pharynx/larynx (stylopharyngeus)</td><td>Both</td><td>Big</td></tr><tr><td>Vagus</td><td>xX</td><td>‘Taste from supraglottic region, swallowing, soft palate elevation, midline uvula, talking, cough reflex, parasympathetics to thoracoabdominal viscera, monitoring aortic arch chemo- and baroreceptors</td><td>Both</td><td>Brains</td></tr><tr><td>Accessory</td><td>XI</td><td>Head turning, shoulder shrugging (SCM, trapezius)</td><td>Motor</td><td>Matter</td></tr><tr><td>Hypoglossal</td><td>XII</td><td>‘Tongue movement</td><td>Motor</td><td>Most</td></tr></table>
======================================
<table><thead><th>REFLEX</th><th>AFFERENT</th><th>EFFERENT</th></thead><tr><td>Accommodation</td><td>I</td><td>Ul</td></tr><tr><td>Corneal</td><td>V, ophthalmic (nasociliary branch)</td><td>Bilateral VII (temporal and zygomatic branches—orbicularis oculi)</td></tr><tr><td>Cough</td><td>xX</td><td>X (also phrenic and spinal nerves)</td></tr><tr><td>Gag</td><td>IX</td><td>xX</td></tr><tr><td>Jaw jerk</td><td>V, (sensory—muscle spindle from masseter)</td><td>V, (motor—masseter)</td></tr><tr><td>Lacrimation</td><td>V, (loss of reflex does not preclude emotional tears)</td><td>VII</td></tr><tr><td>Pupillary</td><td>I</td><td>Ul</td></tr></table>
======================================
<table><thead><th></th><th>Spinothalamic tract</th><th>Dorsal column</th><th>Corticospinal tract</th></thead><tr><td>FUNCTION</td><td>Pain, temperature</td><td>Pressure, vibration, fine touch, proprioception (conscious)</td><td>Voluntary movement</td></tr><tr><td>1ST-ORDER NEURON</td><td>Sensory nerve ending (Aé and C fibers) of pseudounipolar neuron in dorsal root ganglion + enters spinal cord</td><td>Sensory nerve ending of pseudounipolar neuron in dorsal root ganglion &gt; enters spinal cord + ascends ipsilaterally in dorsal columns</td><td>UMN: 1° motor cortex + descends ipsilaterally (through posterior limb of internal capsule and cerebral peduncle), decussates at caudal medulla (pyramidal decussation) + descends contralaterally</td></tr><tr><td>1ST SYNAPSE</td><td>Posterior horn (spinal cord)</td><td>Nucleus gracilis, nucleus cuneatus (ipsilateral medulla)</td><td>Anterior horn (spinal cord)</td></tr><tr><td>2ND-ORDER NEURON</td><td>Decussates in spinal cord as the anterior white commissure &gt; ascends contralaterally</td><td>Decussates in medulla &gt; ascends contralaterally as the medial lemniscus</td><td>LMN: leaves spinal cord</td></tr><tr><td>2ND SYNAPSE</td><td>VPL (thalamus)</td><td>VPL (thalamus)</td><td>NMJ (skeletal muscle)</td></tr><tr><td>3RD-ORDER NEURON</td><td>Projects to 1° somatosensory cortex</td><td>Projects to 1° somatosensory cortex</td><td></td></tr></table>
======================================
<table><tr><td>bold):</td><td>Cremasteric r</td></tr><tr><td>Achilles reflex = S1, S2 (“buckle my shoe”)</td><td>Anal wink ref</td></tr><tr><td>Patellar reflex = L2-L4 (“kick the door’)</td><td>Reflex grading:</td></tr><tr><td>Biceps and brachioradialis reflexes = C5, C6</td><td>0: absent</td></tr><tr><td colspan="2">(“pick up sticks”) 1+: hypoactive</td></tr><tr><td>Triceps reflex = C6, C7, C8 (“lay them</td><td>2+: normal</td></tr><tr><td>straight”)</td><td>34: hyperactiv</td></tr></table>
======================================
<table><thead><th>AREA OF LESION</th><th>COMPLICATIONS</th></thead><tr><td>Prefrontal cortex</td><td>Frontal lobe syndrome—disinhibition, hyperphagia, impulsivity, loss of empathy, impaired executive function, akinetic mutism. Seen in frontotemporal dementia.</td></tr><tr><td>Frontal eye fields</td><td>Eyes look toward brain lesion (ie, away from side of hemiplegia). Seen in MCA stroke.</td></tr><tr><td>Paramedian pontine reticular formation</td><td>Eyes look away from brain lesion (ie, toward side of hemiplegia).</td></tr><tr><td>Dominant parietal cortex</td><td>Gerstmann syndrome—agraphia, acalculia, finger agnosia, left-right disorientation.</td></tr><tr><td>Nondominant parietal cortex</td><td>Hemispatial neglect syndrome—agnosia of the contralateral side of the world.</td></tr><tr><td>Basal ganglia</td><td>Tremor at rest, chorea, athetosis. Seen in Parkinson disease, Huntington disease.</td></tr><tr><td>Subthalamic nucleus</td><td>Contralateral hemiballismus.</td></tr><tr><td>Mammillary bodies</td><td>Bilateral lesions + Wernicke-Korsakoff syndrome (due to thiamine deficiency).</td></tr><tr><td>Amygdala</td><td>Bilateral lesions + Kliiver-Bucy syndrome—disinhibition (eg, hyperphagia, hypersexuality, hyperorality). Seen in HSV-] encephalitis.</td></tr><tr><td>Hippocampus</td><td>Bilateral lesions + anterograde amnesia (no new memory formation). Seen in Alzheimer disease.</td></tr><tr><td>Dorsal midbrain</td><td>Parinaud syndrome (often due to pineal gland tumors).</td></tr><tr><td>Reticular activating system</td><td>Reduced levels of arousal and wakefulness, coma.</td></tr><tr><td>Medial longitudinal fasciculus</td><td>Internuclear ophthalmoplegia (impaired adduction of ipsilateral eye; nystagmus of contralateral eye with abduction). Seen in multiple sclerosis.</td></tr><tr><td>Cerebellar hemisphere</td><td>Intention tremor, limb ataxia, loss of balance; damage to cerebellum = ipsilateral deficits; fall toward side of lesion. Cerebellar hemispheres are laterally located—affect lateral limbs.</td></tr><tr><td>Cerebellar vermis</td><td>Truncal ataxia (wide-based, “drunken sailor” gait), nystagmus, dysarthria. Degeneration associated with chronic alcohol overuse. Vermis is centrally located—affects central body.</td></tr></table>
======================================
<table><thead><th>TIME SINCE ISCHEMIC</th><th></th><th></th><th></th><th></th><th></th></thead><thead><th>EVENT</th><th>12-24 HOURS</th><th>24-72 HOURS</th><th>3-5 DAYS</th><th>1-2 WEEKS</th><th>&gt; 2 WEEKS</th></thead><tr><td>Histologic</td><td>Eosinophilic</td><td>Necrosis +</td><td>Macrophages</td><td>_ Reactive gliosis</td><td>Glial scar</td></tr><tr><td rowspan="4">features</td><td>cytoplasm</td><td>neutrophils</td><td>(microglia)</td><td>(astrocytes)</td><td></td></tr><tr><td></td><td>+ pyknotic</td><td></td><td></td><td>+ vascular</td><td></td></tr><tr><td></td><td>nuclei (red</td><td></td><td></td><td>proliferation</td><td></td></tr><tr><td></td><td>neurons)</td><td></td><td></td><td></td><td></td></tr></table>
======================================
<table><tr><td>Anterior circulation</td><td>OF</td><td></td><td></td></tr><tr><td>Anterior cerebral artery</td><td>Motor and sensory cortices—lower imb.</td><td>Contralateral paralysis and sensory loss—lower limb, urinary incontinence.</td><td></td></tr><tr><td>Middle cerebral artery</td><td>imb and face. Temporal lobe (Wernicke area); frontal lobe (Broca area). Motor and sensory cortices [J—upper</td><td>Contralateral paralysis and sensory loss—lower face and upper limb. Aphasia if in dominant (usually left) hemisphere. Hemineglect if lesion affects nondominant (usually right) hemisphere.</td><td>Wernicke aphasia is associated with right superior quadrant visual field de temporal lobe fect due to involvement.</td></tr><tr><td>Lenticulo- striate artery</td><td>n riatum, internal capsule.</td><td>Contralateral paralysis. Absence of cortical signs (eg, neglect, aphasia, visual field loss).</td><td>Pure motor stro! e (most common). Common location of lac 5, due to mic unar infarcts roatheroma and hyaline ar eriosclerosis (lipohyalinosis) 2° to unmanaged hypertension.</td></tr><tr><td>Posterior circulation</td><td></td><td></td><td></td></tr><tr><td>Posterior cerebral artery</td><td>Occipital lobe [.</td><td>Contralateral hemianopia with macular sparing; alexia without agraphia (dominant hemisphere, extending to splenium of corpus callosum); prosopagnosia (nondominant hemisphere).</td><td></td></tr><tr><td>Basilar artery</td><td>Pons, medulla, lower midbrain.</td><td>If RAS spared, consciousness is</td><td>Locked-in synd: rome (locked</td></tr><tr><td rowspan="2"></td><td></td><td>Corticospinal and corticobulbar tracts.</td><td>preserved. Quadriplegia; loss of voluntary facial (except blinking), mouth, and</td><td>in the baseme nt).</td></tr><tr><td>Ocular cranial nerve nuclei, paramedian pontine reticular formation.</td><td>tongue movements. Loss of horizontal, but not vertical, eye movements.</td><td></td></tr><tr><td rowspan="3">Anterior inferior cerebellar artery</td><td>Facial nerve nuclei.</td><td>Paralysis of face (LMN lesion vs UMN lesion in cortical stroke), 4 lacrimation, 4 salivation, + taste</td><td rowspan="3">Lateral pontine syndrome. Facial nerve nuclei effects are specific to AICA lesions. Supplied by labyrinthine artery,</td></tr><tr><td></td><td>Vestibular nuclei. Spinothalamic tract, spinal trigeminal nucleus.</td><td>from anterior 2/3 of tongue. Vomiting, vertigo, nystagmus + pain and temperature sensation from contralateral body, ipsilateral face.</td><td></td></tr><tr><td></td><td>Sympathetic fibers. Middle and inferior cerebellar peduncles. Inner ear.</td><td>Ipsilateral Horner syndrome. Ipsilateral ataxia, dysmetria. Ipsilateral sensorineural deafness,</td><td></td></tr></table>
======================================
<table><tr><td>Epidural hematoma</td><td>Rupture of middle meningeal artery (branch of maxillary artery), often 2° to skull fracture (circle in [N) involving the pterion (thinnest area of the lateral skull). Might present with ransient loss of consciousness</td></tr><tr><td>Subduralhematoma</td><td>(lentiform), hyperdense blood collection [J not crossing suture lines. Rupture of bridging veins. Can be acute (traumatic, high-energy impact + hyperdense on CT) or chronic (associated with mild rauma, cerebral atrophy, t age, chronic alcohol overuse + hypodense on CT). Also seen in shaken babies. Crescent-shaped hemorrhage (red arrows in [@ and [9)) that crosses suture lines. Can cause midline shift, findings of “acute on chronic” hemorrhage (blue arrows in 5).</td></tr><tr><td>Subarachnoid hemorrhage</td><td>Bleeding [9 { due to trauma, or rupture of an aneurysm (such as a saccular aneurysm) or arteriovenous malformation. Rapid time course. Patients complain of “worst headache of my life.” Bloody or yellow (xanthochromic) umbar puncture. Vasospasm can occur due to blood breakdown or rebleed 3-10 days after hemorrhage — ischemic infarct; nimodipine used o prevent/reduce vasospasm. ¢ risk of developing communicating and/or obstructive hydrocephalus.</td></tr><tr><td>Intraparenchymal hemorrhage</td><td>Most commonly caused by systemic hypertension. Also seen with amyloid angiopathy (recurrent lobar hemorrhagic stroke in older adults), arteriovenous malformations, vasculitis, neoplasm. May be 2° to reperfusion injury in ischemic stroke. Hypertensive hemorrhages (Charcot- Bouchard microaneurysm) most often occur in putamen/globus pallidus of basal ganglia (lenticulostriate vessels []), followed by internal capsule, thalamus, and</td></tr></table>
======================================
<table><thead><th></th><th>— NIE Ud ee use caused by pathology in dominant cerebral hemisphere (usually left). Dysarthria—motor inability to produce speech (movement deficit).</th></thead><tr><td>TYPE</td><td>COMMENTS</td></tr><tr><td>Broca (expressive)</td><td>Broca area in inferior frontal gyrus of frontal lobe. Associated with defective language production. Patients appear frustrated, insight intact. Broca = broken boca (boca = mouth in Spanish).</td></tr><tr><td>Wernicke (receptive)</td><td>| Wernicke area in superior temporal gyrus of temporal lobe. Associated with impaired language comprehension. Patients do not have insight. Wernicke is a word salad and makes no sense.</td></tr><tr><td>Conduction</td><td>Can be caused by damage to arcuate fasciculus.</td></tr><tr><td>Global</td><td>Broca and Wernicke areas affected.</td></tr></table>
======================================
<table><thead><th></th><th>Fever</th><th>Heat stroke</th></thead><tr><td>PATHOPHYSIOLOGY</td><td>Cytokine activation during inflammation (eg, infection)</td><td>Inability of body to dissipate heat (eg, exertion)</td></tr><tr><td>TEMPERATURE</td><td>Usually &lt; 40°C (104°F)</td><td>Usually &gt; 40°C (104°F)</td></tr><tr><td>COMPLICATIONS</td><td>Febrile seizure (benign, usually self-limiting)</td><td>CNS dysfunction (eg, confusion), rhabdomyolysis, acute kidney injury, ARDS, DIC</td></tr><tr><td>MANAGEMENT</td><td>Acetaminophen or ibuprofen for comfort (does not prevent future febrile seizures), antibiotic</td><td>Rapid external cooling, rehydration and electrolyte correction</td></tr></table>
======================================
<table><thead><th>CLASSIFICATION</th><th></th><th>LOCALIZATION</th><th>DURATION</th><th>DESCRIPTION</th><th>TREATMENT</th></thead><tr><td>Tension-type</td><td></td><td>Bilateral</td><td>&gt; 30 min (typically 4-6 hr); constant</td><td>Steady, “bandlike” pain. No nausea or vomiting. No more than one of photophobia or —_ phonophobia. No aura. Most common primary headache; more common in females.</td><td>Acute: analgesics, NSAIDs, acetaminophen. Prophylaxis: TCAs (eg, —_ amitriptyline), behavioral therapy.</td></tr><tr><td></td><td></td><td>Unilateral</td><td>4-72 hr</td><td>Pulsating pain with nausea, photophobia, and/or phonophobia. May have “aura.” Due to irritation of CN V, meninges, or blood vessels (release of vasoactive</td><td>Acute: NSAIDs, triptans, dihydroergotamine, antiemetics (eg, prochlorperazine, metoclopramide). Prophylaxis: lifestyle changes</td></tr><tr><td></td><td>a</td><td></td><td></td><td>neuropeptides [eg, substance P, calcitonin gene-related peptide]). More common in females. POUND-Pulsatile, One-day duration, Unilateral, Nausea,</td><td>(eg, sleep, exercise, diet), B-blockers, amitriptyline, topiramate, valproate, botulinum toxin, anti-CGRP monoclonal antibodies.</td></tr><tr><td>Cluster</td><td></td><td>Unilateral</td><td>15 min-3 hr; repetitive</td><td>Disabling. Excruciating periorbital pain (“suicide headache”) with autonomic symptoms (eg, lacrimation, rhinorrhea,</td><td>Acute: sumatriptan, 100% O,,. Prophylaxis: verapamil.</td></tr><tr><td></td><td></td><td></td><td></td><td>conjunctival injection). May present with Horner syndrome. More common in males.</td><td></td></tr></table>
======================================
<table><thead><th>DISORDER</th><th>PRESENTATION</th><th>NOTES</th></thead><tr><td>Akathisia</td><td>Restlessness and intense urge to move</td><td>Can be seen with neuroleptic use or as an adverse effect of Parkinson disease treatment</td></tr><tr><td>Asterixis</td><td>“Flapping” motion upon extension of wrists</td><td>Associated with hepatic encephalopathy, Wilson disease, and other metabolic derangements</td></tr><tr><td>Athetosis</td><td>Slow, snakelike, writhing movements; especially seen in the fingers</td><td>| Caused by lesion to basal ganglia Seen in Huntington disease</td></tr><tr><td>Chorea</td><td>Sudden, jerky, purposeless movements</td><td>Chorea (Greek) = dancing Caused by lesion to basal ganglia Seen in Huntington disease and acute theumatic fever (Sydenham chorea).</td></tr><tr><td>Dystonia</td><td>Sustained, involuntary muscle contractions</td><td>Writers cramp, blepharospasm, torticollis Treatment: botulinum toxin injection</td></tr><tr><td>Essential tremor</td><td>High-frequency tremor with sustained posture (eg, outstretched arms); worsened with movement or anxiety</td><td>Often familial Patients often self-medicate with alcohol, which + tremor amplitude Treatment: nonselective B-blockers (eg, propranolol), barbiturates (primidone)</td></tr><tr><td>Intention tremor</td><td>Slow, zigzag motion when pointing/extending toward a target</td><td>Caused by cerebellar dysfunction</td></tr><tr><td>Resting tremor</td><td>Uncontrolled movement of distal appendages (most noticeable in hands); tremor alleviated by intentional movement</td><td>Caused by lesion to substantia nigra Occurs at rest; “pill-rolling tremor” of Parkinson disease; when you park your car, it is at rest</td></tr><tr><td>Hemiballismus</td><td>Sudden, wild flailing of one side of the body</td><td>Caused by lesion to contralateral subthalamic nucleus (eg, due to lacunar stroke) In hemiballismus, half-of-body is going ballistic</td></tr><tr><td>Myoclonus</td><td>Sudden, brief, uncontrolled muscle contraction</td><td>Jerks; hiccups; common in metabolic abnormalities (eg, renal and liver failure), Creutzfeldt-Jakob disease</td></tr></table>
======================================
<table><tr><td></td><td>amyloid precursor protein (APP) is located . 4 ACh in brain. Associated with the following altered chromosome 2 * ApoE-2: $ risk of sporadic form * ApoE-4: t risk of sporadic form » APP, presenilin-1, presenilin-2: familial forms (10%) with earlier onset ApoE.-2 is “protwoctive,” ApoE-4 is “four” Alzheimer disease.</td><td>on proteins:</td><td>B-amyloid core; may cause amyloid angiopathy = intraparenchymal hemorrhage; AB (amyloid-B) is derived from cleavage of APP. Neurofibrillary tangles [}: intracellular, hyperphosphorylated tau protein = insoluble cytoskeletal elements; number of tangles correlates with degree of dementia. Hirano bodies: intracellular eosinophilic proteinaceous rods in hippocampus.</td></tr><tr><td>Frontotemporal dementia</td><td>Pick disease. Early changes personality and behavior (behavioral Formerly called or aphasia (primary progressive aphasia). May have associated movement disorders.</td><td>in variant),</td><td>Frontal and/or temporal lobe atrophy. Inclusions of hyperphosphorylated tau (round Pick bodies [@) or ubiquitinated TDP-43.</td></tr><tr><td>Lewy body dementia</td><td>Visual hallucinations (“haLewycinations”), dementia with fluctuating cognition/ alertness, REM sleep behavior disorder, and parkinsonism.</td><td></td><td>Intracellular Lewy bodies primarily in cortex. Called Lewy body dementia if cognitive and motor symptom onset &lt; | year apart, otherwise considered dementia 2° to Parkinson disease.</td></tr></table>
======================================
<table><thead><th>Vascular</th><th></th><th></th></thead><tr><td>Vascular dementia</td><td>2nd most common cause of dementia in older adults. Result of multiple arterial infarcts and/ or chronic ischemia. Step-wise decline in cognitive ability with late- onset memory impairment.</td><td>MRI or CT shows multiple cortical and/or subcortical infarcts Bi).</td></tr><tr><td colspan="3">Infective</td></tr><tr><td>Creutzfeldt-Jakob disease</td><td>Rapidly progressive (weeks to months) dementia with myoclonus (“startle myoclonus”) and ataxia. Fatal. Caused by prions: PrP* + PrP** (B-pleated sheet resistant to proteases). ‘Typically sporadic, but may be transmitted by contaminated materials (eg, corneal transplant, neurosurgical equipment).</td><td>Spongiform cortex [J (vacuolation without inflammation). Associated with periodic sharp waves on EEG and t 14-3-3 protein in CSF,</td></tr><tr><td>HIV-associated dementia ee</td><td>Big ae Te Subcortical dysfunction associated with advanced HIV infection. Characterized by cognitive deficits, gait disturbance, irritability, depressed mood.</td><td>Diffuse gray matter and subcortical atrophy. Microglial nodules with multinucleated giant cells.</td></tr></table>
======================================
<table><thead><th>we *</th><th></th></thead><tr><td>Acute inflammatory demyelinating polyneuropathy</td><td>Most common subtype of Guillain-Barré syndrome. Autoimmune condition that destroys Schwann cells via inflammation and demyelination of motor fibers, sensory fibers, peripheral nerves (including CN III-XII). Likely facilitated by m olecular mimicry and triggered by inoculations or stress. Despite association with infections (eg, Campylobacter jejuni, viruses [eg, Zika]), no definitive causal link to any pathogen. Results in symmetric ascending muscle weakness/paralysis and depressed/absent DTRs beginning in lower extremities. Facial paralysis (usually bilateral) and respiratory failure are common. May see autonomic dysregulation (eg, cardiac irregularities, hypertension, hypotension) or abnormalities. Most patients survive with good functional recovery. t CSF protein with normal cell count (albuminocytologic dissociation). Respiratory support is critical until recovery. Disease-modifying treatment: plasma exc IV immunoglobulins. No role for steroids. sensory hange Or</td></tr><tr><td>Acute disseminated (postinfectious) encephalomyelitis</td><td>Multifocal inflammation and demyelination after infection or vaccination. Presents wi progressive multifocal neurologic symptoms, altered mental status. h rapidly</td></tr><tr><td>Charcot-Marie-Tooth disease</td><td>Also called hereditary motor and sensory neuropathy. Group of progressive hereditary nerve disorders related to the defective production of proteins involved in the structure and peripheral nerves or the myelin sheath. Typically autosomal dominant and associated deformities (eg, pes cavus, hammer toe), lower extremity weakness (eg, foot drop), and deficits (Can’t Move Toes). Most common type, CMT1A, is caused by PMP22 gene d function of with foot sensory uplication.</td></tr><tr><td>Progressive multifocal leukoencephalopathy</td><td>Demyelination of CNS [5] due to destruction of oligodendrocytes (2° to reactivation of virus infection). Associated with severe immunosuppression (eg, lymphomas and leuk atent JC emias, AIDS, organ transplantation). Rapidly progressive, usually fatal. Predominantly involves parietal and occipital areas; visual symptoms are common. t risk associated with natalizumab.</td></tr><tr><td>Other disorders</td><td>Krabbe disease, metachromatic leukodystrophy, adrenoleukodystrophy.</td></tr></table>
======================================
<table><thead><th>DISORDER</th><th>GENETICS</th><th>PRESENTATION</th><th>NOTES</th></thead><tr><td>Sturge-Weber syndrome</td><td>Congenital nonhereditary anomaly of neural crest derivatives. Somatic mosaicism of an activating mutation in one copy of the GNAQ gene.</td><td>Capillary vascular malformation &gt; port- wine stain [J (nevus flammeus or non- neoplastic birthmark) in CN V/V, distribution; ipsilateral leptomeningeal angioma with calcifications [] &gt; seizures/ epilepsy; intellectual disability; episcleral hemangioma &gt; t IOP = early-onset glaucoma.</td><td>Also called encephalotrigeminal angiomatosis.</td></tr><tr><td>Tuberous sclerosis</td><td>AD, variable expression. Mutation in tumor suppressor genes TSC] on chromosome 9 (hamartin), TSC2 on chromosome 16 (tuberin; pronounce “twoberin”).</td><td>Hamartomas in CNS and skin, angiofibromas {S, mitral regurgitation, ash-leaf spots D, cardiac rhabdomyoma, intellectual disability, renal angiomyolipoma [&amp;, seizures, shagreen patches.</td><td>t incidence of subependymal giant cell astrocytomas and ungual fibromas.</td></tr><tr><td>Neurofibromatosis typel</td><td>AD, 100% penetrance. Mutation in NF! tumor suppressor gene on chromosome 17 (encodes neurofibromin, a negative RAS</td><td>Café-au-lait spots [j, Intellectual disability, Cutaneous neurofibromas [4], Lisch nodules (pigmented iris hamartomas [i]), Optic gliomas, Pheochromocytomas, Seizures/focal neurologic Signs (often from meningioma), bone lesions (eg,</td><td>Also called von Recklinghausen disease. 17 letters in “von Recklinghausen.” CICLOPSS.</td></tr><tr><td>Neurofibromatosis type ll</td><td>regulator). AD. Mutation in NF2 tumor suppressor gene (merlin) on chromosome 22.</td><td>sphenoid dysplasia). Bilateral vestibular schwannomas, juvenile cataracts, meningiomas, ependymomas.</td><td>NF 2 affects 2 ears, 2 eyes.</td></tr><tr><td>von Hippel-Lindau disease</td><td>AD. Deletion of VHL gene on chromosome 3p. pVHL ubiquitinates hypoxia- inducible factor la.</td><td>Hemangioblastomas (high vascularity with hyperchromatic nuclei ff) in retina, brainstem, cerebellum, spine [J; Angiomatosis; bilateral Renal cell carcinomas; Pheochromocytomas.</td><td>Numerous tumors, benign and malignant. HARP. VHL = 3 letters = chromosome 3; associated with RCC (also 3 letters)</td></tr></table>
======================================
<table><tr><td>Glioblastoma</td><td>Grade IV astrocytoma. Common, highly malignant 1° brain tumor with ~ 1-year median survival. Found in cerebral hemispheres. Can cross corpus callosum (“butterfly glioma” iN). Associated with EGFR amplification.</td><td>Astrocyte origin, GFAP @. “Pseudopalisading” pleomorphic tumor cells [J border central areas of necrosis, hemorrhage, and/or microvascular proliferation.</td></tr><tr><td>Oligodendroglioma</td><td>Relatively rare, slow growing. Most often in frontal lobes [. Often calcified.</td><td>Oligodendrocyte origin. “Fried egg” cells—round nuclei with clear cytoplasm [5). “Chicken-wire” capillary pattern.</td></tr><tr><td>Meningioma</td><td>Common, typically benign. Females &gt; males. Occurs along surface of brain or spinal cord. Extra-axial (external to brain parenchyma) and may have a dural attachment (“tail” 9). Often asymptomatic; may present with seizures or focal neurologic signs. Resection and/or radiosurgery.</td><td>Arachnoid cell origin. Spindle cells concentrically arranged in a whorled pattern; psammoma bodies (laminated calcifications, arrow in [fj).</td></tr><tr><td>Hemangioblastoma</td><td>Most often cerebellar (J. Associated with von Hippel-Lindau syndrome when found with retinal angiomas. Can produce erythropoietin &gt; 2° polycythemia.</td><td>Blood vessel origin. Closely arranged, thin- walled capillaries with minimal intervening parenchyma [§].</td></tr><tr><td>Pituitary adenoma</td><td>May be nonfunctioning (silent) or hyperfunctioning (hormone-producing). Nonfunctional tumors present with mass effect (eg, bitemporal hemianopia [due to pressure on optic chiasm [ff])). Pituitary apoplexy — hypopituitarism. Prolactinoma classically presents as galactorrhea, amenorrhea, + bone density due to suppression of estrogen in females and as $ libido, infertility in males. Treatment: dopamine agonists (eg, bromocriptine, cabergoline), transsphenoidal resection.</td><td>Hyperplasia of only one type of endocrine cells found in pituitary. Most commonly from lactotrophs (prolactin) [{]] &gt; hyperprolactinemia. Less commonly, from somatotrophs (GH) — acromegaly, gigantism; corticotrophs (ACTH) &gt; Cushing disease. Rarely, from thyrotrophs (TSH), gonadotrophs (FSH, LH).</td></tr><tr><td>Schwannoma</td><td>Classically at the cerebellopontine angle [/, benign, involving CNs V, VII, and VIII, but can be along any peripheral nerve. Often localized to CN VIII in internal acoustic meatus &gt; vestibular schwannoma (can present as hearing loss and tinnitus). Bilateral vestibular schwannomas found in NF-2.</td><td>Schwann cell origin, S-100 ®. Biphasic, dense, hypercellular areas containing spindle cells alternating with hypocellular, myxoid areas [§.</td></tr></table>
======================================
<table><tr><td>Pilocytic astrocytoma</td><td>Low-grade astrocytoma. Most common 1° brain tumor in childhood. Usually well circumscribed. In children, most often found in posterior fossa [iN (eg, cerebellum). May be supratentorial. Benign; good prognosis.</td><td>Astrocyte origin, GFAP ®. Bipolar neoplastic cells with hairlike projections. Associated with microcysts and Rosenthal fibers (eosinophilic, corkscrew fibers [EJ). Cystic + solid (gross).</td></tr><tr><td>Medulloblastoma</td><td>Most common malignant brain tumor in childhood. Commonly involves cerebellum {S. Can compress 4th ventricle, causing noncommunicating hydrocephalus — headaches, papilledema. Can involve the cerebellar vermis &gt; truncal ataxia. Can send “drop metastases” to spinal cord.</td><td>Form of primitive neuroectodermal tumor (PNET). Homer-Wright rosettes (small blue cells surrounding central area of neuropil 5). Synaptophysin ®.</td></tr><tr><td>Ependymoma</td><td>Most commonly found in 4th ventricle [3]. Can cause hydrocephalus. Poor prognosis.</td><td>Ependymal cell origin. Characteristic perivascular pseudorosettes [J]. Rod-shaped blepharoplasts (basal ciliary bodies) found near the nucleus.</td></tr><tr><td>Craniopharyngioma</td><td>Most common childhood supratentorial tumor. Calcification is common [&amp;j. May be confused with pituitary adenoma (both cause bitemporal hemianopia). Associated with a high recurrence rate.</td><td>Derived from remnants of Rathke pouch (ectoderm) [7]. Cholesterol crystals found in “motor oil”-like fluid within tumor.</td></tr><tr><td>Pineal gland tumors</td><td>Most commonly extragonadal germ cell tumors. t incidence in males. Present with obstructive hydrocephalus (compression of cerebral aqueduct), Parinaud syndrome (compression of dorsal midbrain) —triad of upward gaze palsy, convergence-retraction nystagmus, and light-near dissociation.</td><td>Similar to testicular seminomas.</td></tr></table>
======================================
<table><thead><th>SIGN</th><th>UMN LESION</th><th>LMN LESION</th><th>COMMENTS</th></thead><tr><td>Weakness</td><td>+</td><td>+</td><td>Lower motor neuron (LMN) = everything</td></tr><tr><td>Atrophy</td><td>_</td><td>+</td><td>lowered (less muscle mass, + muscle tone, $</td></tr><tr><td>Fasciculati ascicurations</td><td>—</td><td>+</td><td>reflexes, downgoing toes) Upper motor neuron (UMN) = everything up</td></tr><tr><td>Reflexes</td><td>t</td><td>+</td><td>(tone, DTRs, toes)</td></tr><tr><td>viene</td><td>t</td><td>4</td><td>Fasciculations = muscle twitching</td></tr><tr><td>Babinski</td><td>+</td><td>-</td><td>Positive Babinski is normal in infants</td></tr><tr><td>Spastic paresis</td><td>+</td><td>-</td><td></td></tr><tr><td>Flaccid paralysis</td><td>-</td><td>+</td><td></td></tr><tr><td>Clasp knife spasticity</td><td>+</td><td>-</td><td></td></tr></table>
======================================
<table><tr><td>CN X lesion</td><td>Uvula deviates away from side of lesion. Weak side collapses and uvula points away.</td></tr><tr><td>CN XI lesion</td><td>Weakness turning head to contralateral side of lesion (SCM). Shoulder droop on side of lesion (trapezius).</td></tr><tr><td>CN Xil lesion</td><td>LMN lesion. Tongue deviates toward side of lesion (“lick your wounds”) due to weakened tongue</td></tr></table>
======================================
<table><thead><th>Noise-induced hearing loss</th><th>extremely loud noises can produce hearing</th><th>loss due to tympanic membrane rupture.</th></thead><tr><td>Presbycusis</td><td>Aging-related progressive bilateral/symmetric due to destruction of hair cells at the cochlear</td><td>sensorineural hearing loss (often of higher frequencies base (preserved low-frequency hearing at apex).</td></tr></table>
======================================
<table><thead><th>Refractive errors</th><th>Common cause of impaired vision, correctable with glasses.</th></thead><tr><td>Hyperopia</td><td>Also called “farsightedness.” Eye too short for refractive power of cornea and lens &gt; light focused behind retina. Correct with convex (converging) lenses.</td></tr><tr><td>Myopia</td><td>Also called “nearsightedness.” Eye too long for refractive power of cornea and lens &gt; light focuse in front of retina. Correct with concave (diverging) lens.</td></tr><tr><td>Astigmatism</td><td>Abnormal curvature of cornea &gt; different refractive power at different axes. Correct with</td></tr></table>
======================================
<table><tr><td>-resbyopia</td><td>Aging-related impaired accommodation (focusing on near objects), primarily due to + lens elasticity. Patients often need reading glasses or magnifiers.</td></tr><tr><td></td><td>night, and loss of the red Acquired risk factors: t age, tobacco smoking, alcohol overuse, excessive sunlight, prolonged glucocorticoid use, diabetes mellitus, trauma, infection. Congenital risk factors: classic galactosemia, galactokinase deficiency, trisomies (13, 18, 21), TORCH infections (eg, rubella), Marfan syndrome, Alport syndrome, myotonic dystrophy, NF-2. Treatment: surgical removal of lens and replacement with an artificial lens.</td></tr></table>
======================================
<table><thead><th>AGES degeneration</th><th>Vegenerauion * Dry (most common)—gradual 4 in vision with subretinal deposits (drusen, arrow in [i§). * Wet—rapid 4 in vision due to bleeding 2° to choroidal neovascularization. Distortion of straight lines (metamorphopsia) is an early symptom.</th></thead><tr><td>Diabetic retinopathy</td><td>Chronic hyperglycemia &gt; t permeability and occlusion of retinal vessels. ‘Two types: * Nonproliferative (most common)—microaneurysms, hemorrhages (arrows in [5J), cotton-wool spots, hard exudates. Vision loss mainly due to macular edema. ® Proliferative—retinal neovascularization due to chronic hypoxia. Abnormal new vessels may cause vitreous hemorrhage and tractional retinal detachment.</td></tr><tr><td>Hypertensive retinopathy</td><td>Chronic hypertension &gt; spasm, sclerosis, and fibrinoid necrosis of retinal vessels. Funduscopy: arteriovenous nicking, microaneurysms, hemorrhages, cotton-wool spots (blue arrow in [@), hard exudates (may form macular “star,” red arrow in [@). Presence of papilledema is indicative of hypertensive emergency and warrants immediate lowering of blood pressure.</td></tr><tr><td>Retinal artery occlusion</td><td>Blockage of central or branch retinal artery usually due to embolism (carotid artery atherosclerosis &gt; cardiogenic); less commonly due to giant cell arteritis. Presents with acute, painless monocular vision loss. Funduscopy: cloudy retina with “cherry-red” spot at fovea [5), identifiable retinal emboli (eg, cholesterol crystals appear as small, yellow, refractile deposits in arterioles).</td></tr><tr><td>Retinal vein occlusion</td><td>Central retinal vein occlusion is due to 1° thrombosis; branch retinal vein occlusion is due to 2° thrombosis at arteriovenous crossings (sclerotic arteriole compresses adjacent venule causing turbulent blood flow). Funduscopy: retinal hemorrhage and venous engorgement (“blood and thunder” appearance; arrows in 9), retinal edema in affected areas.</td></tr><tr><td>Retinal detachment</td><td>Separation of neurosensory retina from underlying retinal pigment epithelium — loss of choroidal blood supply + hypoxia and degeneration of photoreceptors. ‘Two types: = Rhegmatogenous (most common)—due to retinal tears; often associated with posterior vitreous detachment (t risk with advanced age, high myopia), less frequently traumatic. = Nonrhegmatogenous—tractional or exudative (fluid accumulation). resents with symptoms of posterior vitreous detachment (eg, floaters, light flashes) Commonly followed by painless monocular vision loss (“dark curtain”). Funduscopy: opacification and wrinkling of detached retina [, change in vessel direction. Surgical emergency.</td></tr><tr><td>Retinitis pigmentosa</td><td>Group of inherited dystrophies causing progressive degeneration of photoreceptors and retinal pigment epithelium. May be associated with abetalipoproteinemia. Early symptoms: night blindness (nyctalopia) and peripheral vision loss. Funduscopy: triad of optic disc pallor, retinal vessel attenuation, and retinal pigmentation with bone spicule-shaped deposits [&amp;.</td></tr><tr><td>Retinopathy of prematurity</td><td>Preterm birth + loss of normal hypoxic environment in utero &gt; relative hyperoxia (t with supplemental O, for NRDS) + 4 VEGF ~ arrest of normal retinal vascularization. As the eyes grow &gt; hypoxia of avascular retina &gt; t VEGF = retinal neovascularization (may cause tractional retinal detachment). Common cause of childhood blindness.</td></tr><tr><td>Papilledema</td><td>Optic disc swelling (usually bilateral) due to t ICP (eg, 2° to mass effect). Results from impaired elevated optic disc with blurred margins [FJ. axoplasmic flow in optic Funduscop</td></tr></table>
======================================
<table><thead><th></th><th>MECHANISM</th><th>COMMON ADVERSE EFFECTS</th><th>RARE BUT SERIOUS ADVERSE EFFECTS</th></thead><tr><td colspan="4">Narrow spectrum (focal seizures)</td></tr><tr><td>Phenytoin</td><td></td><td>Sedation, dizziness, diplopia, gingival hypertrophy, rash, hirsutism, drug interactions (CYP450 induction)</td><td>SJS, DRESS, hepatotoxicity, neuropathy, osteoporosis, folate depletion, teratogenicity</td></tr><tr><td>Carbamazepine</td><td>Block Na‘ channel</td><td>; _ a Sedation, dizziness, diplopia, vomiting, diarrhea, SIADH, rash, drug interactions (CYP450 induction)</td><td>- SJS, DRESS, hepatotoxicity, agranulocytosis, aplastic anemia, folate depletion, teratogenicity</td></tr><tr><td>Gabapentinoids Gabapentin, pregabalin</td><td>Block Ca?* channel</td><td>Sedation, dizziness, ataxia, weight gain</td><td></td></tr><tr><td colspan="4">Narrow spectrum (absence seizures only)</td></tr><tr><td>Ethosuximide</td><td>Blocks Ca** channel</td><td>Sedation, dizziness, vomiting</td><td></td></tr><tr><td colspan="4">Broad spectrum (focal and generalized seizures)</td></tr><tr><td>Valproate</td><td>Blocks Na* channe Blocks Ca** channel Blocks GABA transaminase</td><td>Sedation, dizziness, vomiting, weight gain, hair loss, easy bruising, drug interactions (CYP450 inhibition)</td><td>| Hepatotoxicity, pancreatitis, teratogenicity</td></tr><tr><td>Lamotrigine</td><td>Blocks Na* channe</td><td>Sedation, dizziness, rash</td><td>SJS, DRESS</td></tr><tr><td>Levetiracetam</td><td>Blocks Synaptic Vesicle protein 2A (SV2A)</td><td>Sedation, dizziness, fatigue</td><td>Neuropsychiatric (eg, psychosis)</td></tr><tr><td>Topiramate</td><td>Blocks Na* channe Potentiates GABA, receptor</td><td>Sedation, dizziness, mood disturbance (eg, depression),</td><td>Kidney stones, angle-closure glaucoma</td></tr></table>
======================================
<table><thead><th>AGENT</th><th>MECHANISM</th><th>ADVERSE EFFECTS</th><th>NOTES</th></thead><tr><td>Nonbenzodiazepine hypnotics</td><td>Examples: Zolpidem, Zaleplon, esZopiclone Act via the BZ, subtype of GABA receptor</td><td>Ataxia, headaches, confusion Cause only modest day-after psychomotor depression and few amnestic effects (vs older sedative-hypnotics)</td><td>These ZZZs put you to sleep Short duration due to rapid metabolism by liver enzymes; effects reversed by flumazenil + dependency risk and 4 sleep cycle disturbance (vs benzodiazepine hypnotics)</td></tr><tr><td>Suvorexant</td><td>Orexin (hypocretin) receptor antagonist</td><td>CNS depression (somnolence), headache, abnormal sleep- related activities</td><td>Contraindications: narcolepsy, combination with strong CYP3A4 inhibitors Not recommended in patients with liver disease Limited risk of dependency</td></tr><tr><td>Ramelteon</td><td>Melatonin receptor agonist: binds MT and MT2 in</td><td>Dizziness, nausea, fatigue, headache</td><td>No known risk of dependency</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>5-HT),,,, agonists. Inhibit trigeminal nerve activation, prevent vasoactive peptide release, induce vasoconstriction.</td></tr><tr><td>CLINICAL USE</td><td>Acute migraine, cluster headache attacks. A sumo wrestler trips and falls on their head.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Coronary vasospasm (contraindicated in patients with CAD or vasospastic angina), mild</td></tr></table>
======================================
<table><thead><th>therapy</th><th>younger patients, and levodopa (with carbidopa) which is usually started in older patients. Deep brain stimulation of the ST'N or GPi may be helpful in advanced disease.</th></thead><tr><td>STRATEGY</td><td>AGENTS</td></tr><tr><td>Dopamine agonists</td><td>Non-ergot (preferred)—pramipexole, ropinirole; toxicity includes nausea, impulse control disorder (eg, gambling), postural hypotension, hallucinations, confusion, sleepiness, edema. Ergot—bromocriptine; rarely used due to toxicity.</td></tr><tr><td>t dopamine availability</td><td>}Amantadine (t dopamine release and } dopamine reuptake); mainly used to reduce levodopa- induced dyskinesias; toxicity = peripheral edema, livedo reticularis, ataxia.</td></tr><tr><td>t-DOPA availability</td><td>Agents prevent peripheral (pre-BBB) L-DOPA degradation + t L-DOPA entering CNS = tf central L-DOPA available for conversion to dopamine. * Levodopa (L-DOPA)/carbidopa—carbidopa blocks peripheral conversion of L-DOPA to dopamine by inhibiting DOPA decarboxylase. Also reduces adverse effects of peripheral L-DOPA conversion into dopamine (eg, nausea, vomiting). = Entacapone and tolcapone prevent peripheral L-DOPA degradation to 3-O-methyldopa (3-OMD) by inhibiting COMT. Used in conjunction with levodopa.</td></tr><tr><td>Prevent dopamine breakdown</td><td>Agents act centrally (post-BBB) to inhibit breakdown of dopamine. ® Selegiline, rasagiline—block conversion of dopamine into DOPAC by selectively inhibiting MAO-B, which is more commonly found in the Brain than in the periphery. = 'Tolcapone—crosses BBB and blocks conversion of dopamine to 3-methoxytyramine (3-MT) in the brain by inhibiting central COMT.</td></tr><tr><td>Curb excess cholinergic activity</td><td>Benztropine, trihexyphenidyl (Antimuscarinic; improves tremor and rigidity but has little effect on bradykinesia in Parkinson disease). Tri Parking my Mercedes-Benz.</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>t dopamine in brain. Unlike dopamine, L-DOPA can cross BBB and is converted by DOPA decarboxylase in the CNS to dopamine. Carbidopa, a peripheral DOPA decarboxylase inhibitor that cannot cross BBB, is given with L-DOPA to ¢ bioavailability of L.DOPA in the brain and to limit peripheral adverse effects.</td></tr><tr><td>CLINICAL USE</td><td>Parkinson disease.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Nausea, hallucinations, postural hypotension. With progressive disease, L-DOPA can lead to “on- off” phenomenon with improved mobility during “on” periods, then impaired motor function during “off” periods when patient responds poorly to L-DOPA or medication wears off.</td></tr></table>
======================================
<table><thead><th>DISEASE</th><th>AGENT</th><th>MECHANISM</th><th>NOTES</th></thead><tr><td rowspan="2">Alzheimer disease</td><td>Donepezil, rivastigmine, galantamine</td><td>AChE inhibitor</td><td>Ist-line treatment Adverse effects: nausea, dizziness, insomnia; contraindicated in patients with cardiac conduction abnormalities Dona Riva dances at the gala</td></tr><tr><td></td><td>Memantine</td><td>NMDA receptor antagonist; helps prevent excitotoxicity (mediated by Ca**)</td><td>Used for moderate to advanced dementia Adverse effects: dizziness, confusion, hallucinations</td></tr><tr><td>Amyotrophic lateral sclerosis</td><td>Riluzole</td><td>+ neuron glutamate excitotoxicity</td><td>t survival Treat Lou Gehrig disease with riLouzole</td></tr><tr><td>Huntington disease</td><td>Deutetrabenazine, tetrabenazine</td><td>Inhibit vesicular monoamine transporter (VMAT) + 4 dopamine vesicle packaging and release</td><td>May be used for Huntington chorea and tardive dyskinesia</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td colspan="2">Block neurotransmission via binding to voltage-gated Na* channels on inner portion of the channel along nerve fibers. Most effective in rapidly firing neurons. 3° amine local anesthetics penetrate membrane in uncharged form, then bind to ion channels as charged form. Can be given with vasoconstrictors (usually epinephrine) to enhance block duration of action by + systemic absorption. In infected (acidic) tissue, alkaline anesthetics are charged and cannot penetrate membrane effectively + need more anesthetic.</td></tr><tr><td>CLINICAL USE</td><td colspan="2" rowspan="2">Order of loss: (1) pain, (2) temperature, (3) touch, (4) pressure. Minor surgical procedures, spinal anesthesia. If allergic to esters, give amides. CNS excitation, severe cardiovascular toxicity (bupivacaine), hypertension, hypotension, arrhythmias (cocaine), methemoglobinemia (benzocaine, prilocaine).</td></tr><tr><td>ADVERSE EFFECTS</td><td colspan="2"></td></tr><tr><td>General anesthetics</td><td colspan="2">CNS drugs must be lipid soluble (cross the BBB) or be actively transported. Drugs with 4 solubility in blood (eg, nitrous oxide [N,O]) = rapid induction and recovery times. Drugs with t solubility in lipids (eg, isoflurane) = t potency. MAC = Minimum Alveolar Concentration (of inhaled anesthetic) required to prevent 50% of subjects from moving in response to noxious stimulus (eg, skin incision). Potency = 1/MAC. MECHANISM ADVERSE EFFECTS/NOTES</td></tr><tr><td>Inhaled anesthetics</td><td></td><td></td></tr><tr><td>Sevoflurane</td><td rowspan="4">; Mechanism unknown</td><td></td><td>Respiratory depression, + cough reflex</td></tr><tr><td>Desflurane</td><td></td><td>Myocardial depression, + BP</td></tr><tr><td>Isoflurane</td><td></td><td>t cerebral blood flow (t ICP), + metabolic rate + skeletal and smooth muscle tone Pos M operative nausea and vomiting i] ignant hyperthermia</td></tr><tr><td>N,O 2</td><td>Diffusion into and expansion (N,O) of gas-filled cavities (eg, pneumothorax); very low potency</td></tr><tr><td colspan="3">Intravenous anesthetics</td></tr><tr><td>Propofol</td><td>Potentiates GABA, receptor Inhibits NMDA receptor</td><td>Respiratory depression, + BP; most commonly used IV agent for induction of anesthesia</td></tr><tr><td>Etomidate</td><td>Potentiates GABA, receptor</td><td>Acute adrenal insufficiency, postoperative nausea and vomiting; hemodynamically neutral</td></tr><tr><td>Ketamine</td><td>Inhibits NMDA receptor</td><td>Sympathomimetic: t BP, t HR, t cerebral blood flow (t ICP), bronchodilation Psychotomimetic: hallucinations, vivid dreams</td></tr></table>
======================================
<table><thead><th>blocking drugs</th><th>neuromuscular junction but not autonomic N, receptors.</th></thead><tr><td>blocking drugs</td><td>Reversal o = Phase blockade: I (prolonged depolarization) —no antidote. Block potentiated by cholinesterase inhibitors. * Phase II (repolarized but blocked; N_, nicotinic receptors are available, but desensitized) —may be reversed with cholinesterase inhibitors. Complica muscle p ions include hypercalcemia, hyperkalemia, malignant hyperthermia. t risk of prolonged aralysis in patients with pseudocholinesterase deficiency.</td></tr><tr><td>Nondepolarizing neuromuscular blocking drugs</td><td>Atracurium, cisatracurium, pancuronium, rocuronium, vecuronium—competitive N , nicotinic receptor antagonist. Reversal of blockade—sugammadex or cholinesterase inhibitors (eg, neostigmine). Anticholinergics (eg, atropine, glycopyrrolate) are given with cholinesterase inhibitors to prevent muscarinic effects (eg, bradycardia).</td></tr><tr><td>Malignant hyperthermia</td><td>Rare, life-threatening, hypermetabolic condition caused by the administration of potent inhaled anesthetics (sevoflurane, desflurane, isoflurane) or succinylcholine in susceptible individuals. Susceptibility to malignant hyperthermia is caused by de novo or inherited (autosomal dominant) mutation t t Ca** re s to ryanodine (RYR1) or dihydropyridine receptors (DHPR). lease from sarcoplasmic reticulum — sustained muscle contraction + hypercapnia, tachycardia, masseter/generalized muscle rigidity, rhabdomyolysis, hyperthermia. Treatment: dantrolene (ryanodine receptor antagonist).</td></tr></table>
======================================
<table><thead><th>DRUG</th><th>MECHANISM</th><th>CLINICAL USE</th><th>NOTES</th></thead><tr><td>Baclofen</td><td>GABA, receptor agonist in spinal cord</td><td>Muscle spasticity, dystonia, multiple sclerosis</td><td>Acts on the back (spinal cord) May cause sedation</td></tr><tr><td>Cyclobenzaprine</td><td>Acts within CNS, mainly at the brainstem</td><td>Muscle spasms</td><td>Centrally acting Structurally related to TCAs May cause anticholinergic adverse effects, sedation</td></tr><tr><td>Dantrolene</td><td>Prevents release of Ca** from sarcoplasmic reticulum of skeletal muscle by inhibiting the ryanodine receptor</td><td>Malignant hyperthermia (toxicity of inhaled anesthetics and succinylcholine) and neuroleptic malignant syndrome (toxicity of antipsychotics)</td><td>Acts directly on muscle</td></tr><tr><td>Tizanidine</td><td>©, agonist, acts centrally</td><td>Muscle spasticity, multiple sclerosis, ALS, cerebral palsy</td><td></td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Very weak opioid agonist; also inhibits the reuptake of norepinephrine and serotonin.</td></tr><tr><td>CLINICAL USE</td><td>Chronic pain.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Similar to opioids; decreases seizure threshold; serotonin syndrome.</td></tr></table>
======================================
<table><tr><td>Glaucoma therapy</td><td colspan="3">+ IOP via + amount of aqueous humor (inhibit synthesis/secretion or t drainage). “BoD humor may not be politically correct.”</td></tr><tr><td>DRUG CLASS</td><td>EXAMPLES</td><td>MECHANISM</td><td>ADVERSE EFFECTS</td></tr><tr><td>B-blockers</td><td>Timolol, betaxolol, carteolol</td><td>+ aqueous humor synthesis</td><td>No pupillary or vision changes</td></tr><tr><td>a-agonists</td><td>Epinephrine (,), apraclonidine, brimonidine (a)</td><td>+ aqueous humor synthesis via vasoconstriction (epinephrine) + aqueous humor synthesis (apraclonidine, brimonidine) t outflow of aqueous humor via uveoscleral pathway</td><td>Mydriasis (0); do not use in closed-angle glaucoma Blurry vision, ocular hyperemia, foreign body sensation, ocular allergic reactions, ocular pruritus</td></tr><tr><td>Diuretics</td><td>Acetazolamide</td><td>+ aqueous humor synthesis via inhibition of carbonic anhydrase</td><td>No pupillary or vision changes</td></tr><tr><td>Prostaglandins</td><td>Bimatoprost, latanoprost (PGF,,)</td><td>t outflow of aqueous humor via + resistance of flow through uveoscleral pathway</td><td>Darkens color of iris (browning), eyelash growth</td></tr><tr><td>Cholinomimetics (M,)</td><td>Direct: pilocarpine, carbachol Indirect: physostigmine, echothiophate</td><td>t outflow of aqueous humor via contraction of ciliary muscle and opening of trabecular meshwork Use pilocarpine in acute angle closure glaucoma—very effective at opening meshwork into canal of Schlemm</td><td>Miosis (contraction of pupillary sphincter muscles) and cyclospasm (contraction of ciliary muscle)</td></tr></table>
======================================
<table><tr><td>Psychiatry</td><td></td></tr><tr><td>“Words of comfort, skillfully administered, are the oldest therapy known to »</td><td>Psychology</td></tr><tr><td>man.” »</td><td></td></tr><tr><td>—Louis Nizer</td><td>Pathology</td></tr><tr><td>“Psychiatry at its best is what all medicine needs more of — humanity, art, listening, and sympathy.” »</td><td>Pharmacology</td></tr><tr><td colspan="2">—Susannah Cahalan</td></tr><tr><td colspan="2">“Tt’s time to tell everyone who’s dealing with a mental health issue that they're not alone, and that getting support and treatment isn’t a sign of weakness, it’s a sign of strength.”</td></tr><tr><td colspan="2">—Michelle Obama</td></tr><tr><td colspan="2">“T have schizophrenia. I am not schizophrenia. I am not my mental illness. My illness is a part of me.”</td></tr><tr><td>—Jonathan Harnisch</td><td></td></tr></table>
======================================
<table><tr><td rowspan="2">Reinforcement</td><td rowspan="2">Target behavior (response) is followed by desired reward (positive reinforcement) or removal of aversive stimulus (negative reinforcement).</td><td colspan="3">Skinner operant conditioning quadrants:</td></tr><tr><td></td><td></td><td></td><td>Increase behavior</td><td>Decrease behavior</td></tr><tr><td>Punishment</td><td>Repeated application of aversive stimulus (positive punishment) or removal of desired reward (negative punishment) to extinguish</td><td>Adda stimulus</td><td>Positive reinforcement</td><td>Positive punishment</td></tr><tr><td>Extinction</td><td>unwanted behavior. Discontinuation of reinforcement (positive or negative) eventually eliminates behavior. Can occur in operant or classical conditioning.</td><td>Remove a stimulus</td><td>Negative reinforcement</td><td>Negative punishment</td></tr></table>
======================================
<table><thead><th>Countertransference</th><th>—_ Physician projects feelings about formative or other reminds physician of younger sibling).</th><th>important persons onto patient (eg, patient</th></thead><tr><td>Ego defenses</td><td>Thoughts and behaviors (voluntary or involuntary) feelings (eg, anxiety, depression).</td><td>used to resolve conflict and prevent undesirable</td></tr><tr><td>IMMATURE DEFENSES,</td><td>DESCRIPTION</td><td>EXAMPLE</td></tr><tr><td>Acting out</td><td>Subconsciously coping with stressors or emotional conflict using actions rather than reflections or feelings.</td><td>A patient skips therapy appointments after deep discomfort from dealing with his past.</td></tr><tr><td>Denial</td><td>Avoiding the awareness of some painful reality.</td><td>A patient with cancer plans a full-time work schedule despite being warned of significant fatigue during chemotherapy.</td></tr><tr><td>Displacement</td><td>Redirection of emotions or impulses to a neutral person or object (vs projection).</td><td>After being reprimanded by her principal, a frustrated teacher returns home and criticizes her wife’s cooking instead of confronting the principal directly.</td></tr><tr><td>Dissociation</td><td>Temporary, drastic change in personality, memory, consciousness, or motor behavior to avoid emotional stress. Patient has incomplete</td><td>A survivor of sexual abuse sees the abuser and suddenly becomes numb and detached.</td></tr></table>
======================================
<table><thead><th>IMMATURE DEFENSES,</th><th>DESCRIPTION</th><th>EXAMPLE</th></thead><tr><td>Fixation</td><td>Partially remaining at a more childish level of development (vs regression).</td><td>A college student studying for a stressful exam begins sucking her thumb.</td></tr><tr><td>Idealization</td><td>Expressing extremely positive thoughts of self and others while ignoring negative thoughts.</td><td>A patient boasts about his physician and his accomplishments while ignoring any flaws.</td></tr><tr><td>Identification</td><td>Largely unconscious assumption of the characteristics, qualities, or traits of another person or group.</td><td>A resident starts putting her stethoscope in her pocket like her favorite attending, instead of wearing it around her neck like before.</td></tr><tr><td>Intellectualization</td><td>Using facts and logic to emotionally distance oneself from a stressful situation.</td><td>A patient diagnosed with cancer discusses the pathophysiology of the disease.</td></tr><tr><td>Isolation (of affect)</td><td>Separating feelings from ideas and events.</td><td>Describing murder in graphic detail with no emotional response.</td></tr><tr><td>Passive aggression</td><td>Demonstrating hostile feelings in a nonconfrontational manner; showing indirect opposition.</td><td>A disgruntled employee is repeatedly late to work, but won’t admit it is a way to get back at the manager.</td></tr><tr><td>Projection</td><td>Attributing an unacceptable internal impulse to an external source (vs displacement).</td><td>A man who wants to cheat on his wife accuses his wife of being unfaithful.</td></tr><tr><td>Rationalization</td><td>Asserting plausible explanations for events that actually occurred for other reasons, usually to avoid selblame.</td><td>An employee who was recently fired claims that the job was not important anyway.</td></tr><tr><td>Reaction formation</td><td>Replacing a warded-off idea or feeling with an emphasis on its opposite (vs sublimation).</td><td>A stepfather treats a child he resents with excessive nurturing and overprotection.</td></tr><tr><td>Regression</td><td>Involuntarily turning back the maturational clock to behaviors previously demonstrated under stress (vs fixation).</td><td>A previously toilet-trained child begins bedwetting again following the birth of a sibling.</td></tr><tr><td>Repression</td><td>Involuntarily withholding an idea or feeling from conscious awareness (vs suppression).</td><td>A 20-year-old does not remember going to counseling during his parents’ divorce 10 years earlier.</td></tr><tr><td>Splitting</td><td>Believing that people are either all good or all bad at different times due to intolerance of ambiguity. Common in borderline personality disorder. Borders split countries.</td><td>A patient says that all the nurses are cold and insensitive, but the physicians are warm and _ friendly.</td></tr><tr><td colspan="3">MATURE DEFENSES</td></tr><tr><td>Sublimation</td><td>Replacing an unacceptable wish with a course of action that is similar to the wish but socially acceptable (vs reaction formation).</td><td>_A teenager’s aggression toward her parents because of their high expectations is channeled into excelling in sports.</td></tr><tr><td>Altruism</td><td>Alleviating negative feelings via unsolicited generosity, which provides gratification (vs reaction formation).</td><td>A mafia boss makes a large donation to charity.</td></tr><tr><td>Suppression</td><td>Intentionally withholding an idea or feeling from conscious awareness (vs repression); temporary.</td><td>—_ An athlete focuses on other tasks to prevent worrying about an important upcoming match.</td></tr><tr><td>Humor</td><td>Lightheartedly expressing uncomfortable feelings to shift the internal focus away from the distress.</td><td>— A nervous medical student jokes about the boards.</td></tr></table>
======================================
<table><thead><th>AGE</th><th>MOTOR</th><th>SOCIAL</th><th>VERBAL/COGNITIVE</th></thead><tr><td>Infant</td><td>Parents</td><td>Start</td><td>Observing,</td></tr><tr><td>0-12 mo</td><td>Primitive reflexes disappear—__ Moro, rooting, palmar, Babinski (Mr. Peanut Butter) Posture—lifts head up prone (by 1 mo), rolls and sits (by 6 mo), crawls (by 8 mo), stands (by 10 mo), walks (by 12-18 mo) Picks—passes toys hand to hand (by 6 mo), Pincer grasp (by 10 mo) Points to objects (by 12 mo)</td><td>Social smile (by 2 mo) Stranger anxiety (by 6 mo) Separation anxiety (by 9 mo)</td><td>Orients—first to voice (by 4 mo), then to name and gestures (by 9 mo) Object permanence (by 9 mo) Oratory—says “mama” and “dada” (by 10 mo)</td></tr><tr><td>Toddler</td><td>Child</td><td>Rearing</td><td>Working,</td></tr><tr><td>12-36 mo</td><td>Cruises, takes first steps (by 12 mo) Climbs stairs (by 18 mo) Cubes stacked (number) = age (yr) x 3 Cutlery—feeds self with fork and spoon (by 20 mo) Kicks ball (by 24 mo)</td><td>Recreation—parallel play (by | 24-36 mo) Rapprochement—moves away from and returns to parent (by 24 mo) Realization—core gender identity formed (by 36 mo)</td><td>Words—uses 50-200 words (by 2 yr), uses 300+ words (by 3 yr)</td></tr><tr><td>Preschool</td><td>Don’t</td><td>Forget, they’re still</td><td>Learning!</td></tr><tr><td>3-5 yr</td><td>Drive—tricycle (3 wheels at 3 yr) Drawings—copies line or circle, stick figure (by 4 yr) Dexterity—hops on one foot by 4 yr (“4 on one foot”), uses</td><td>Freedom—comfortably spends part of day away from parent (by 3 yr) Friends—cooperative play, has imaginary friends (by 4 yr)</td><td>| Language—understands 1000 (3 zeros) words (by 3 yr), uses complete sentences and prepositions (by 4 yr) Legends—can tell detailed stories (by 4 yr)</td></tr></table>
======================================
<table><thead><th></th><th>Physical abuse</th><th>Sexual abuse</th><th>Emotional abuse</th></thead><tr><td>SIGNS</td><td>Nonaccidental trauma (eg, fractures, bruises, burns). Injuries often in different stages of healing or in patterns resembling possible implements of injury. Includes abusive head trauma (shaken baby syndrome), characterized by subdural hematomas or retinal hemorrhages. Caregivers may delay seeking medical attention for the child or provide explanations inconsistent with the child's developmental stage or pattern of injury.</td><td>STIs, UTIs, and genital, anal, or oral trauma. Most often, there are no physical signs; sexual abuse should not be excluded from a differential diagnosis in the absence of physical trauma. Children often exhibit sexual knowledge or behavior incongruent with their age.</td><td>Babies or young children may ack a bond with the caregiver but are overly affectionate with less familiar adults. They may be aggressive oward children and animals or unusually anxious. Older children are often emotionally labile and prone ‘0 angry outbursts. They may distance themselves from caregivers and other children. They can experience vague somatic symptoms for which a medical cause cannot be found.</td></tr><tr><td>EPIDEMIOLOGY</td><td>40% of deaths related to child abuse or neglect occur in children &lt; 1 year old.</td><td>Peak incidence 9-12 years old.</td><td>~80% of young adult victims of child emotional abuse meet the criteria for 2 1 psychiatric illness by age 21.</td></tr><tr><td>Child neglect</td><td>Failure to provide a child with Most common form of child impaired social/emotional As with other types of child abuse, protective services.</td><td>adequate food, shelter, supervision, maltreatment. Signs: poor hygiene, development, failure to thrive. suspected child neglect must</td><td>education, and/or affection. malnutrition, withdrawal, be reported to local child</td></tr><tr><td>Vulnerable child syndrome</td><td colspan="3">Parents perceive the child as especially susceptible to illness or injury (vs factitious disorder imposed on another). Usually follows a serious illness or life-threatening event. Can result in missed school or overuse of medical services.</td></tr></table>
======================================
<table><tr><td>Attention-deficit hyperactivity disorder</td><td>Onset before age 12, but diagnosis can only be established after age +. Characterized by hyperactivity, impulsivity, and/or inattention in 2 2 settings (eg, school, home, places of worship). Normal intelligence, but commonly coexists with difficulties in school. Often persists into adulthood. Commonly coexists with other behavioral, cognitive, or develo pmental disorders. Treatment: stimulants (eg, methylphenidate) +/- behavioral therapy; alternatives include atomoxetine and ©,-agonists (eg, clonidine, guanfacine).</td></tr><tr><td>Autism spectrum disorder</td><td>Onset in early childhood. Social and communication deficits, repetitive/ritualized behaviors, restricted interests. May be accompanied by intellectual disability and/or al specific skills (eg, music). More common in males. Associated with t head bove average abilities in and/or brain size.</td></tr><tr><td>Conduct disorder</td><td>Repetitive, pervasive behavior violating societal norms or the basic rights of others (eg, aggression toward people and animals, destruction of property, theft). After age 18, often reclassified as antisocial personality disorder. Conduct = children, antisocial = adults. Treatment: psychotherapy (eg, cognitive behavioral therapy [CBT)).</td></tr><tr><td>Disruptive mood dysregulation disorder</td><td>Onset before age 10. Severe, recurrent temper outbursts out of proportion to situation. Child is constantly angry and irritable between outbursts. Treatment: CBT, stimulants, antipsychotics.</td></tr><tr><td>Intellectual disability</td><td>Global cognitive deficits (vs specific learning disorder) hat affect reasoning, memory, abstract thinking, judgment, language, learning. Adaptive functioning is impaired, leading to major difficulties with ed Treatment: psycho herapy, occupational therapy, special education. ucation, employment, communication, socialization, independence.</td></tr><tr><td>Intermittent explosive disorder</td><td>Onset after age 6. Recurrent verbal or physical outbursts re impulses. Outburs' to legal, financial, or social consequences. Episodes a immediate sense of relief, followed by remorse. Trea’ s last &lt; 30 minutes and are out of prop resenting a failure to control aggressive ortion to provocation and may lead re not premeditated and may provide an ment: psychotherapy, SSRIs.</td></tr><tr><td>Oppositional defiant disorder</td><td>Pattern of anger and authority figures la irritability with argumentative, vindic sting = 6 months. Treatment: psychothi ive, and defiant behavior toward erapy (eg, CBT).</td></tr><tr><td>Selective mutism</td><td>Onset before age 5. Anxiety disorder lasting &gt; 1 month involvi situations despite sp eaking in other, usually more comfortab! ng refraining from speech in certain e situations. Development (eg, speech and language) not typically impaired. Interferes with social, academic, and occupational tasks. Commonly coexists with social anxiety disorder. ‘Treatment: behavioral, family, and play therapy; SSRIs.</td></tr><tr><td>Separation anxiety disorder</td><td>Overwhelming fear of separation from home or attachment figure lasting &gt; 4 weeks. Can be normal behavior up to age 3-4. May lead to factitious physical complaints to avoid school. reatment: CBT, play therapy, family therapy.</td></tr><tr><td>Specific learning disorder</td><td>[reatment: academic support, counseling, extracurricular activities. Onset during school-age years. Inability to acquire or use information from a specific subject (eg, math, reading, writing) near age-expected proficiency for &gt; 6 months despite focused intervention. General functioning and intelligence are normal (vs intellectual disability).</td></tr><tr><td>Tourette syndrome</td><td>Onset before age 18. Sudden, recurrent, nonrhythmic, stereotyped motor (eg, grimacing, shrugging) and vocal (eg, grunting, throat clearing) tics that persist for &gt; 1 year. Coprolalia (involuntary obscene speech) f
======================================
ound in some patients. Associated with OCD and ADHD. Treatment: psychoeducation, behavioral therapy. For intractable and distressing tics:</td></tr></table>
======================================
<table><thead><th>Amnesias</th><th></th></thead><tr><td>Retrograde amnesia</td><td>Inability to remember things that occurred before a CNS insult.</td></tr><tr><td>Anterograde amnesia</td><td>_ Inability to remember things that occurred after a CNS insult ($ acquisition of new memory).</td></tr><tr><td>Korsakoff syndrome</td><td>Amnesia (anterograde &gt; retrograde) and disorientation caused by vitamin B, deficiency. Associated with disruption and destruction of the limbic system, especially mammillary bodies and anterior thalamus. Seen in chronic alcohol use as a late neuropsychiatric manifestation of Wernicke encephalopathy. Confabulations are characteristic.</td></tr></table>
======================================
<table><thead><th>Psychosis</th><th>perception reality by disorganized thought/speech. Can occur in patients with psychiatric illness or another medical condition, or secondary to substance or medication use.</th></thead><tr><td>Delusions</td><td>False, fixed, idiosyncratic beliefs that persist despite evidence to the contrary and are not typical of a patient's culture or religion (eg, a patient who believes that others are reading his thoughts). Types include erotomanic, grandiose, jealous, persecutory, somatic, mixed, and unspecified.</td></tr><tr><td>Disorganized thought</td><td>Speech may be incoherent (“word salad”), tangential, or derailed (“loose associations’).</td></tr><tr><td rowspan="5">Hallucinations</td><td>Perceptions in the absence of external stimuli (eg, seeing a light that is not actually present). Contrast with misperceptions (eg, illusions) of real external stimuli. Types include: * Auditory—more commonly due to psychiatric illness (eg, schizophrenia) than neurologic</td></tr><tr><td></td><td>disease. * Visual—more commonly due to neurologic disease (eg, dementia), delirium, or drug</td></tr><tr><td></td><td>i ® Tactile—common in alcohol withdrawal and stimulant use (eg, “cocaine crawlies,” a type of ntoxication than psychiatric illness. delusional parasitosis).</td></tr><tr><td></td><td>* Olfactory—often occur as an aura of temporal lobe epilepsy (eg, burning rubber) and in brain tumors.</td></tr><tr><td></td><td>Contrast with illusions, which are misperceptions of real external stimuli (eg, mistaking a shadow for a black cat).</td></tr></table>
======================================
<table><tr><td>Schizoaffective disorder</td><td>lasting fa sychotic symptoms without a manic or depressive Shares symptoms with both schizophrenia and ifferentiate from a mood disorder with psychotic</td><td>episode. mood disorders (MDD or bipolar disorder). To features, patient must have &gt; 2 weeks of</td></tr><tr><td>Delusional disorder</td><td>IV delusion(s) lasting &gt; 1 month, but without a mood functioning, including socialization, may be impacted unaffected. Can be shared by individuals in close</td><td>disorder or other psychotic symptoms. Daily by the pathological, fixed belief but is otherwise relationships (folie 4 deux).</td></tr><tr><td>Schizotypal personality disorder</td><td>Cluster A personality disorder that also falls on the sychotic episodes (eg, delusions) that are less</td><td>schizophrenia spectrum. May include brief frequent and severe than in schizophrenia.</td></tr><tr><td>Manic episode</td><td>Distinct period of abnormally and persistently or energy. Diagnosis requires marked functional week, or any duration if hospitalization is required * Distractibility * Impulsivity/Indiscretion—seeks pleasure without regard to consequences (hedonistic) = Grandiosity—inflated self-esteem</td><td>elevated, expansive, or irritable mood and t activity impairment with &gt; 3 of the following for &gt; 1 (people with mania DIG FAST): ® Flight of ideas—racing thoughts ® t goal-directed Activity/psychomotor Agitation * 4 need for Sleep ® Talkativeness or pressured speech</td></tr></table>
======================================
<table><tr><td>polar disorder</td><td>Bipolar | (requires 1 type of episode)—&gt; 1 manic episode +/— a hypomanic or depressive episode (may be separated by any length of time).</td></tr><tr><td></td><td>Bipolar Il (requires 2 types of episodes)—a hypomanic and a depressive episode (no history of manic episodes).</td></tr><tr><td></td><td>Patient’s mood and functioning usually normalize between episodes. Use of antidepressants can destabilize mood. High suicide risk. Treatment: mood stabilizers (eg, lithium, valproate, carbamazepine, lamotrigine), atypical antipsychotics.</td></tr><tr><td></td><td>Cyclothymic disorder—milder form of bipolar disorder fluctuating between mild depressive and hypomanic symptoms. Must last 2 2 years with symptoms present at least half of the time, with any remission lasting &lt; 2 months.</td></tr><tr><td rowspan="3">ajor depressive sorder</td><td>Recurrent episodes lasting 2 2 weeks characterized by 2 5 of 9 diagnostic symptoms including depressed mood or anhedonia (or irritability in children). SIG: E CAPS: = Sleep disturbances = 4 Interest in pleasurable activities (anhedonia)</td></tr><tr><td></td><td>Treatment: CBT and SSRIs are first line; alternatives include SNRIs, mirtazapine, bupropion, electroconvulsive therapy (ECT), ketamine.</td></tr><tr><td></td><td>Responses to a significant loss (eg, bereavement, natural disaster, disability) may resemble a depressive episode. Diagnosis of MDD is made if criteria are met.</td></tr><tr><td>ADD with psychotic features</td><td>MDD + hallucinations or delusions. Psychotic features are typically mood congruent (eg, depressive themes of inadequacy, guilt, punishment, nihilism, disease, or death) and occur only</td></tr></table>
======================================
<table><thead><th></th><th>* Cluster C—anxious or fearful (remember as “worried”); genetic association with anxiety disorders.</th></thead><tr><td colspan="2">Cluster A</td></tr><tr><td>Paranoid</td><td>Pervasive distrust (accusatory), suspiciousness, hypervigilance, and a profoundly cynical view of the world.</td></tr><tr><td>Schizoid</td><td>Prefers social withdrawal and solitary activities (vs avoidant), limited emotional expression, indifferent to others’ opinions (aloof).</td></tr><tr><td>Schizotypal</td><td>Eccentric appearance, odd beliefs or magical thinking, interpersonal awkwardness. Included on the schizophrenia spectrum. Pronounce “schizo-type-al” for odd-type thoughts.</td></tr><tr><td colspan="2">Cluster B</td></tr><tr><td>Antisocial</td><td>Disregard for the rights of others with lack of remorse (bad). Involves criminality, impulsivity, hostility, and manipulation (sociopath). Males &gt; females. Must be 2 18 years old with evidence of conduct disorder onset before age 15. If patient is &lt; 18, diagnosis is conduct disorder.</td></tr><tr><td>Borderline</td><td>Unstable mood and interpersonal relationships, fear of abandonment, impulsivity, selfmutilation, suicidality, sense of emotional emptiness (borderline). Females &gt; males. Splitting is a major defense mechanism. ‘Treatment: dialectical behavior therapy.</td></tr><tr><td>Histrionic</td><td>Attention-seeking, dramatic speech and emotional expression, shallow and labile emotions, sexually provocative. May use physical appearance to draw attention (flamboyant).</td></tr><tr><td>Narcissistic</td><td>Grandiosity, sense of entitlement; lacks empathy and requires excessive admiration; often demands the “best” and reacts to criticism with rage and/or defensiveness (must be the best). Fragile self esteem. Often envious of others.</td></tr><tr><td colspan="2">Cluster C</td></tr><tr><td>Avoidant</td><td>Hypersensitive to rejection and criticism, socially inhibited, timid (cowardly), feelings of inadequacy, desires relationships with others (vs schizoid).</td></tr><tr><td>Obsessive-compulsive</td><td>— Preoccupation with order, perfectionism, and control (obsessive-compulsive); egosyntonic: behavior consistent with one’s own beliefs and attitudes (vs OCD).</td></tr><tr><td>Dependent</td><td>Excessive need for support (clingy), submissive, low self-confidence. Patients often get stuck in abusive relationships.</td></tr></table>
======================================
<table><thead><th>Factitious disorders</th><th>Symptoms are intentional, motivation is unconscious. Patient consciously creates physical and/or psychological symptoms in order to assume “sick role” and to get medical attention and sympathy</th></thead><tr><td>Factitious disorder imposed on self</td><td>(1° [internal] gain). Formerly called Munchausen syndrome. Chronic factitious disorder with predominantly physical signs and symptoms. Characterized by a history of multiple hospital admissions and willingness to</td></tr><tr><td>Factitious disorder imposed on another</td><td>undergo invasive procedures. More common in females and healthcare workers. Formerly called Munchausen syndrome by proxy. Illness in an individual being cared for (most often a child, also seen in disabled or older adults) is directly caused (eg, physically harming a child) or fabricated (eg, lying about a child’s symptoms) by the caregiver. Form of child/elder abuse.</td></tr><tr><td>Somatic symptom and related disorders</td><td>Symptoms are unconscious, motivation is unconscious. Category of disorders characterized by physical symptoms causing significant distress and impairment. Symptoms not intentionally produced or feigned.</td></tr><tr><td>Somatic symptom disorder</td><td>&gt; 1 bodily complaints (eg, abdominal pain, fatigue) lasting months to years. Associated with excessive, persistent thoughts and anxiety about symptoms. May co-occur with medical illness. Treatment: regular office visits with the same physician in combination with psychotherapy.</td></tr><tr><td>Conversion disorder</td><td>Also called functional neurologic symptom disorder. Unexplained loss of sensory or motor function (eg, paralysis, blindness, mutism), often following an acute stressor; patient may be aware of but indifferent toward symptoms (“la belle indifférence”); more common in females, adolescents, and young adults.</td></tr><tr><td>IIIness anxiety disorder</td><td>Preoccupation with acquiring or having a serious illness, often despite medical evaluation and reassurance; minimal to no somatic symptoms.</td></tr></table>
======================================
<table><tr><td>SYMPTOMS</td><td>Intentional</td><td>Intentional</td><td>Unconscious</td></tr></table>
======================================
<table><thead><th>Eating disorders</th><th>Most common in young women.</th></thead><tr><td>Anorexia nervosa</td><td>Intense fear of weight gain, overvaluation of thinness, and body image distortion leading to calorie restriction and severe weight loss resulting in inappropriately low body weight (BMI &lt; 18.5 kg/m? for adults). Physiological disturbances may present as bradycardia, hypotension, hypothermia, hypothyroidism, osteoporosis, lanugo, amenorrhea (low calorie intake &gt; 4 leptin + + GnRH + 4LH, FSH — $ estrogen + amenorrhea). Binge-eating/purging type—recurring purging behaviors (eg, laxative or diuretic abuse, sel induced vomiting) or binge eating over the last 3 months. Associated with hypokalemia. Restricting type—primary disordered behaviors include dieting, fasting, and/or over-exercising. No recurring purging behaviors binge eating the last 3 months.</td></tr><tr><td>Bulimia nervosa</td><td>Recurring episodes of binge eating with compensatory purging behaviors at least weekly over the last 3 months. BMI often normal or slightly overweight (vs anorexia). Associated with parotid gland hypertrophy (may see t serum amylase), enamel erosion, Mallory-Weiss syndrome, electrolyte disturbances (eg, | K*, 4 Cl), metabolic alkalosis, dorsal hand calluses from induced vomiting (Russell sign). Treatment: psychotherapy, nutritional rehabilitation, antidepressants (eg, SSRIs). Bupropion is contraindicated due to seizure risk.</td></tr><tr><td>Binge-eating disorder</td><td>Recurring episodes of binge eating without purging behaviors at least weekly over the last 3 months. t diabetes risk. Most common eating disorder in adults. Treatment: psychotherapy (first line); SSRIs; lisdexamfetamine.</td></tr><tr><td>Pica</td><td>Recurring episodes of eating non-food substances (eg, ice, dirt, hair, paint chips) over = 1 month that are not culturally or developmentally recognized as normal. May provide temporary emotional relief. Common in children and during pregnancy. Associated with malnutrition, iron deficiency anemia, developmental disabilities, emotional trauma. Treatment: psychotherapy and nutritional rehabilitation (first line); SSRIs (second line).</td></tr><tr><td>Gender dysphoria</td><td>Significant incongruence between one’s gender identity and one’s gender assigned at birth, lasting &gt; 6 months and leading to persistent distress. Individuals experience marked discomfort with their assigned gender, which interferes with social, academic, and other areas of function. Individuals</td></tr></table>
======================================
<table><thead><th>STAGE</th><th>FEATURES</th><th>MOTIVATIONAL STRATEGIES</th></thead><tr><td>Precontemplation</td><td>Denies problem and its consequences.</td><td>Encourage introspection. Use patient’s personal priorities in explaining risks. Affirm your availability to the patient.</td></tr><tr><td>Contemplation</td><td>Acknowledges problem but is ambivalent or unwilling to change.</td><td>Discuss pros of changing and cons of maintaining current behavior. Suggest means to support behavior changes.</td></tr><tr><td>Preparation/ determination</td><td>Committed to and planning for behavior change.</td><td>Employ motivational interviewing. Encourage initial changes, promote expectations for positive results, provide resources to assist in planning.</td></tr><tr><td>Action/willpower</td><td>Executes a plan and demonstrates a change in behavior.</td><td>Assist with strategies for self-efficacy, contingency management, and coping with situations that trigger old behaviors.</td></tr><tr><td>Maintenance</td><td>New behaviors become sustained, integrate into personal identity and lifestyle.</td><td>Reinforce developing habits. Evaluate and mitigate relapse risk. Praise progress.</td></tr><tr><td>Relapse</td><td>Regression to prior behavior (does not always occur).</td><td>Varies based on degree of regression. Encourage return to changes. Provide reassurance that change remains possible.</td></tr></table>
======================================
<table><thead><th></th><th>CAUSE</th><th>MANIFESTATION</th><th>TREATMENT</th></thead><tr><td>Serotonin syndrome</td><td>Any drug that t 5-HT. Psychiatric drugs: MAO inhibitors, SSRIs, SNRIs, TCAs, vilazodone, vortioxetine, buspirone Nonpsychiatric drugs: tramadol, ondansetron, triptans, linezolid, MDMA, dextromethorphan, meperidine, St. John’s wort</td><td>3 A’s: t activity (neuromuscular; eg, clonus, hyperreflexia, hypertonia, tremor, seizure), autonomic instability (eg, hyperthermia, diaphoresis, diarrhea), altered mental status</td><td>Benzodiazepines and supportive care; cyproheptadine (5-HT, receptor antagonist) if no improvement Prevention: avoid simultaneous serotonergic drugs, and allow a washout period between them</td></tr><tr><td>Hypertensive crisis</td><td>Eating tyramine-rich foods (eg, aged cheeses, cured meats, wine, chocolate) while taking MAO inhibitors, insufficient washout period when switching antidepressants to or from MAO inhibitors</td><td>Hypertensive crisis (tyramine displaces other neurotransmitters leg, NE] in the synaptic cleft — t sympathetic stimulation)</td><td>Phentolamine</td></tr><tr><td>Neuroleptic malignant syndrome</td><td>Antipsychotics (typical &gt; atypical) + genetic redisposition</td><td>Malignant FEVER: Myoglobinuria, Fever, Encephalopathy, Vitals unstable, t Enzymes (eg, Ck), muscle Rigidity (“lead pipe”)</td><td>Dantrolene, dopaminergics (eg, bromocriptine, amantadine), benzodiazepines; discontinue causative agent</td></tr><tr><td>Delirium tremens</td><td>Alcohol withdrawal; occurs 2-4 days after last drink Classically seen in hospital setting when inpatient cannot drink</td><td>Altered mental status, hallucinations, autonomic hyperactivity, anxiety, seizures, tremors, psychomotor agitation, insomnia, nausea</td><td>Longer-acting benzodiazepines</td></tr><tr><td>Acute dystonia</td><td>Typical antipsychotics, anticonvulsants (eg, carbamazepine), metoclopramide</td><td>Sudden onset of muscle spasms, stiffness, and/or oculogyric crisis occurring hours to days after medication use; can lead to laryngospasm requiring intubation</td><td>Benztropine or diphenhydramine</td></tr><tr><td>Lithium toxicity</td><td>t lithium dosage, + renal elimination (eg, acute kidney injury), medications affecting clearance (eg, ACE inhibitors, thiazide diuretics, NSAIDs) Narrow therapeutic window</td><td>Nausea, vomiting, slurred speech, hyperreflexia, seizures, ataxia, nephrogenic diabetes insipidus</td><td>Discontinue lithium, hydrate aggressively with isotonic sodium chloride, consider hemodialysis</td></tr><tr><td>Tricyclic antidepressant toxicity</td><td>TCA overdose</td><td>Respiratory depression, hyperpyrexia, prolonged OT Tricyclic’s: convulsions, coma,</td><td>Supportive treatment, monitor ECG, NaHCO, (prevents arrhythmia), activated</td></tr></table>
======================================
<table><thead><th>DRUG</th><th>MECHANISM</th><th>INTOXICATION</th><th>WITHDRAWAL</th><th></th><th></th></thead><tr><td colspan="6">Depressants</td></tr><tr><td></td><td></td><td>Nonspecific: mood elevation, + anxiety, sedation, behavioral disinhibition, respiratory depression.</td><td colspan="3">Nonspecific: anxiety, tremor, seizures, insomnia.</td></tr><tr><td rowspan="2">Alcohol Barbiturates</td><td>GABA-A receptor positive allosteric modulator.</td><td>Emotional lability, slurred speech, ataxia, coma, blackouts. AST value is 2x ALT value (“ToAST 2 ALcohol”). ‘Treatment: supportive (eg, fluids, antiemetics). I</td><td colspan="3">Treatment: longer-acting benzodiazepines. Alcoholic hallucinosis Sebel Withdrawal seizures fae Isomers “timers agitation, Gl upset t t t t id</td></tr><tr><td></td><td>GABA-A receptor positive</td><td>— Low safety margin, marked respiratory depression. Treatment:</td><td>036 Delirium,</td><td>12 24 36 48 Time from last drink (hours) life-threatening cardiovascular collapse.</td><td>96 a</td></tr><tr><td>Benzodiazepines</td><td>allosteric modulator. GABA-A receptor positive allosteric</td><td>management (eg, respiration, t BP). — Greater safety margin. Ataxia, minor __ respiratory depression. Treatment: flumazenil (benzodiazepine</td><td>Seizures, depression.</td><td>sleep disturbance,</td><td></td></tr><tr><td>Opioids</td><td>Opioid receptor modulator.</td><td>receptor antagonist). Activation of ft receptors causes the prototypic effects of pupillary constriction (pinpoint pupils), + GI motility, respiratory and CNS depression, euphoria, $ gag reflex, seizures. Most common cause of drug overdose death.</td><td>Dilated symptoms, nausea, turkey”), Treatment: methadone,</td><td>pupils, diarrhea, rhinorrhea, sweating, piloerection lacrimation. symptom buprenorphine.</td><td>flulike yawning, (“cold management,</td></tr><tr><td>Inhalants</td><td>Enhanced GABA signaling.</td><td>Overdose treatment: naloxone. _ Disinhibition, euphoria, slurred speech, ataxia, disorientation, drowsiness. Effects often have rapid onset and resolution. Perinasal/perioral rash.</td><td>Irritability, disturbance,</td><td>dysphoria, sleep headache.</td><td></td></tr><tr><td colspan="6">Stimulants</td></tr><tr><td></td><td></td><td>Nonspecific: mood elevation, + appetite, psychomotor agitation, insomnia, cardiac arrhythmias,</td><td>Nonspecific: including appetite,</td><td>post-use “crash,” depression, sleep disturbance,</td><td>lethargy, vivid</td></tr><tr><td>Amphetamines</td><td>Induces reversal</td><td>tachycardia, anxiety. Euphoria, grandiosity, mydriasis,</td><td>nightmares. Meth</td><td>mites</td><td></td></tr></table>
======================================
<table><thead><th>DRUG</th><th>MECHANISM</th><th>INTOXICATION</th><th>WITHDRAWAL</th></thead><tr><td>Caffeine</td><td>Adenosine receptor antagonist.</td><td>Palpitation, agitation, tremor, insomnia.</td><td>Headache, difficulty concentrating, flulike symptoms.</td></tr><tr><td>Cocaine</td><td>Blocks reuptake of dopamine (DAT), serotonin (SERT), and norepinephrine (NET) transporters.</td><td>Impaired judgment, pupillary dilation, diaphoresis, hallucinations (including —_ formication), paranoia, angina, sudden cardiac death. Chronic use may lead to perforated nasal septum due to vasoconstriction and resulting ischemic necrosis. ‘Treatment: benzodiazepines.</td><td>— Restlessness, hunger, severe depression, sleep disturbance.</td></tr><tr><td>Nicotine</td><td>Stimulates central nicotinic acetylcholine receptors.</td><td>Restlessness.</td><td>Irritability, anxiety, restlessness, + concentration, t appetite/weight. Treatment: nicotine replacement therapy (eg, patch, gum, lozenge); bupropion/varenicline.</td></tr><tr><td colspan="4">Hallucinogens</td></tr><tr><td>Lysergic acid diethylamide</td><td>5-HT,, receptor agonist.</td><td>Perceptual distortion (visual, auditory), depersonalization, anxiety, paranoia, psychosis, flashbacks (usually nondisturbing), mydriasis.</td><td></td></tr><tr><td>Cannabis/ cannabinoids</td><td>CBI receptor agonist.</td><td>Euphoria, anxiety, paranoid delusions, erception of slowed time, impaired u dgment, social withdrawal, t appetite, dry mouth, conjunctival injection, hallucinations.</td><td>Irritability, anxiety, depression, insomnia, restlessness, + appetite.</td></tr><tr><td>MDMA</td><td>Induces reversal of transporters for monoamines (SERT &gt; DAT, NET), increasing their neurotransmitter release.</td><td>Also called ecstasy. Euphoria, hallucinations, disinhibition, hyperactivity, f thirst, bruxism, di erception, mydriasis. Life- storted sensory and time hreatening effects include hypertension, tachycardia, hyperthermia, hyponatremia, serotonin syndrome.</td><td>Depression, fatigue, change in appetite, difficulty concentrating, anxiety.</td></tr><tr><td>Phencyclidine</td><td>NMDA receptor antagonist.</td><td>Violence, nystagmus, impulsivity, psychomotor agitation, tachycardia, hypertension, analgesia, psychosis, delirium, seizures.</td><td></td></tr></table>
======================================
<table><thead><th>Psychotherapy</th><th></th></thead><tr><td>Behavioral therapy</td><td>Teaches patients how to identify and change maladaptive behaviors or reactions to stimuli (eg, systematic desensitization for specific phobia).</td></tr><tr><td>Cognitive behavioral therapy</td><td>Teaches patients to recognize distortions in their thought processes, develop constructive coping skills, and + maladaptive coping behaviors + greater emotional control and tolerance of distress (eg, recognizing triggers for alcohol consumption).</td></tr><tr><td>Dialectical behavioral therapy</td><td>Designed for use in borderline personality disorder, but can be used in other psychiatric conditions as well (eg, depression).</td></tr><tr><td>Interpersonal therapy</td><td>Focused on improving interpersonal relationships and communication skills.</td></tr><tr><td>Motivational interviewing</td><td>Enhances intrinsic motivation to change by exploring and resolving ambivalence. Used in substance use disorder and weight loss.</td></tr></table>
======================================
<table><tr><td>ADHD</td><td>Stimulants</td></tr><tr><td>Alcohol withdrawal</td><td>Benzodiazepines</td></tr><tr><td>Bipolar disorder</td><td>Carbamazepine, atypical antipsychotics, lithium, lamotrigine, valproate. Character a — ittle less variable</td></tr><tr><td>Bulimia nervosa</td><td>SSRIs</td></tr><tr><td>Depression</td><td>SSRIs</td></tr><tr><td>Generalized anxiety disorder</td><td>SSRIs, SNRIs</td></tr><tr><td>Obsessive-compulsive disorder</td><td>SSRIs, venlafaxine, clomipramine</td></tr><tr><td>Panic disorder</td><td>SSRIs, venlafaxine, benzodiazepines</td></tr><tr><td>PTSD</td><td>SSRIs, venlafaxine, prazosin (for nightmares)</td></tr><tr><td>Schizophrenia</td><td>A = ypical antipsychotics</td></tr><tr><td>Social anxiety disorder</td><td>SSRIs, venlafaxine Performance only: B-blockers, benzodiazepines</td></tr><tr><td>Tourette syndrome</td><td>A ntipsychotics</td></tr></table>
======================================
<table><tr><td>Antipsychotics</td><td>Typical (Ist-generation) antipsychotics—haloperidol, pimozide, trifluoperazine, fluphenazine,</td></tr><tr><td>MECHANISM CLINICAL USE</td><td>Block dopamine D, receptor (t cAMP). Atypical antipsychotics also block serotonin 5-HT’, receptor. Aripiprazole is a D, partial agonist. Schizophrenia (typical antipsychotics primarily treat positive symptoms; atypical antipsychotics</td></tr><tr><td></td><td>treat both positive and negative symptoms), disorders with concomitant psychosis (eg, bipolar disorder), ‘Tourette syndrome, OCD, Huntington disease. Clozapine is used for treatment- resistant psychotic disorders or those with persistent suicidality (cloze to the edge).</td></tr><tr><td></td><td>Neurologic: neuroleptic malignant syndrome. Ophthalmologic: chlorpromazine—corneal deposits; thioridazine—retinal deposits. Clozapine—agranulocytosis (monitor WBCs clozely), seizures (dose related), myocarditis. Extrapyramidal symptoms—ADAPT: * Hours to days: Acute Dystonia (muscle spasm, stiffness, oculogyric crisis). ‘Treatment: benztropine, diphenhydramine. * Days to months: = Akathisia (restlessness). Treatment: B-blockers, benztropine, benzodiazepines. * Parkinsonism (bradykinesia). ‘Treatment: benztropine, amantadine. * Months to years: Tardive dyskinesia (chorea, especially orofacial). Treatment: benzodiazepines, botulinum toxin injections, valbenazine, deutetrabenazine.</td></tr><tr><td>NOTES</td><td>Lipid soluble — stored in body fat slow to be removed from body. ‘Typical antipsychotics have greater affinity for D, receptor than atypical antipsychotics &gt; t risk for hyperprolactinemia, extrapyramidal symptoms, neuroleptic malignant syndrome. High-potency typical antipsychotics: haloperidol, trifluoperazine, pimozide, fluphenazine (Hal tries pie to fly high)—more neurologic adverse effects (eg, extrapyramidal symptoms).</td></tr></table>
======================================
<table><tr><td>AECHANISM</td><td>Partial 5-H), receptor agonist.</td><td>I get anxious if the bus doesn’t arrive at one, so</td></tr></table>
======================================
<table><thead><th>reuptake MECHANISM</th><th>Inhibit 5-HT reuptake.</th><th>It normally takes 4-8 weeks for antidepressants</th></thead><tr><td>CLINICAL USE</td><td>Depression, generalized anxiety disorder, panic disorder, OCD, bulimia, binge-eating disorder, social anxiety disorder, PTSD, premature</td><td>to show appreciable effect.</td></tr><tr><td>ADVERSE EFFECTS</td><td>ejaculation, premenstrual dysphoric disorder. Fewer than TCAs. Serotonin syndrome, GI distress, SIADH, sexual dysfunction (anorgasmia, erectile dysfunction, $ libido), mania precipitation if underlying bipolar disorder.</td><td></td></tr><tr><td>Serotonin- norepinephrine reuptake inhibitors</td><td>Venlafaxine, desvenlafaxine, duloxetine,</td><td>levomilnacipran, milnacipran.</td></tr><tr><td>MECHANISM</td><td>Inhibit 5-HT and NE reuptake.</td><td></td></tr><tr><td>CLINICAL USE</td><td>Depression, generalized anxiety disorder, diabetic social anxiety disorder, panic disorder, PTSD, indicated for fibromyalgia.</td><td>neuropathy. Venlafaxine is also indicated for OCD. Duloxetine and milnacipran are also</td></tr><tr><td>ADVERSE EFFECTS</td><td>t BP, stimulant effects, sedation, sexual dysfunction,</td><td>nausea.</td></tr><tr><td>Tricyclic antidepressants</td><td>Amitriptyline, nortriptyline, imipramine, desipramine,</td><td>clomipramine, doxepin, amoxapine.</td></tr><tr><td>MECHANISM</td><td>TCAs inhibit 5-HT and NE reuptake.</td><td></td></tr><tr><td>CLINICAL USE</td><td>MDD, peripheral neuropathy, chronic neuropathic (clomipramine), nocturnal enuresis (imipramine).</td><td>pain, migraine prophylaxis, OCD</td></tr><tr><td>ADVERSE EFFECTS</td><td>Sedation, o,-blocking effects including postural adverse effects (tachycardia, urinary retention, anticholinergic effects than 2° TCAs (nortriptyline). Tri-CyCliC’s: Convulsions, Coma, Cardiotoxicity also respiratory depression, hyperpyrexia. Confusion older adults due to anticholinergic adverse effects Treatment: NaHCO, to prevent arrhythmia.</td><td>hypotension, and atropine-like (anticholinergic) dry mouth). 3° TCAs (amitriptyline) have more Can prolong OT interval. (arrhythmia due to Na* channel inhibition); and hallucinations are more common in (2° amines [eg, nortriptyline] better tolerated).</td></tr></table>
======================================
<table><tr><td>Mirtazapine</td><td>g ,-antagonist (t release of NE and 5-H), potent 5-HT, and 5-H, receptor antagonist, and H, antagonist. Adverse effects: sedation (which may be desirable in depressed patients with insomnia), t appetite, weight gain (which may be desirable in underweight patients), dry mouth.</td></tr><tr><td>Trazodone</td><td>Primarily blocks 5-H, o-adrenergic, and H, receptors; also weakly inhibits 5-HT reuptake. Used primarily for insomnia, as high doses are needed for antidepressant effects. Adverse effects: sedation, nausea, priapism, postural hypotension. Think traZZZobone due to sedative and male- specific adverse effects.</td></tr><tr><td>Vilazodone</td><td>Inhibits 5-HT reuptake; 5-HT’, receptor partial agonist. Used for MDD. Adverse effects: headache, diarrhea, nausea, anticholinergic effects. May cause serotonin syndrome if taken with other serotonergic agents.</td></tr><tr><td>Vortioxetine</td><td>Inhibits 5-H'T reuptake; 5-HT’, receptor agonist and 5-H’, receptor antagonist. Used for MDD. Adverse effects: nausea, sexual dysfunction, sleep disturbances, anticholinergic effects. May cause serotonin syndrome if taken with other serotonergic agents.</td></tr><tr><td colspan="2">Pharmacotherapies for smoking cessation</td></tr><tr><td>Nicotine replacement therapy</td><td>Binds to nicotinic ACh receptors. Aim to relieve withdrawal symptoms upon stopping smoking. Long-acting patch and short-acting products (ie, gum, lozenge) can be used in combination. Adverse effects: headache, oral irritation.</td></tr><tr><td>Varenicline</td><td>Nicotinic ACh receptor partial agonist. Diminishes effect on reward system, but also reduces withdrawal. Adverse effects: GI discomfort, sleep disturbance. Varenicline helps nicotine cravings decline.</td></tr><tr><td>Medically supervised opioid withdrawal and relapse prevention</td><td>Injection drug use t risk for HBV, HCV, HIV, skin and soft tissue infections, bacteremia, right- sided infective endocarditis.</td></tr><tr><td>Methadone</td><td>Long-acting oral opioid used for medically supervised opioid (eg, heroin) withdrawal or long-term maintenance therapy.</td></tr><tr><td>Buprenorphine</td><td>Partial opioid agonist. Sublingual form (film) used to suppress withdrawal and for maintenance therapy. Partial agonists can precipitate withdrawal symptoms in opioid-dependent individuals or when administered shortly after use of a full agonist.</td></tr><tr><td>Naloxone</td><td>Short-acting opioid antagonist given IM, IV, or as a nasal spray to treat acute opioid overdose, particularly to reverse respiratory and CNS depression.</td></tr></table>
======================================
<table><tr><td>valves</td><td>urethra in males; its persistence can lead to</td></tr><tr><td></td><td>Diagnosed by bilateral hydronephrosis and dilated</td></tr><tr><td></td><td>or thick-walled bladder on ultrasound.</td></tr><tr><td></td><td>Severe obstruction in fetus associated with</td></tr><tr><td></td><td>oligohydramnios. Most common cause of</td></tr><tr><td></td><td>bladder outlet obstruction in male infants.</td></tr></table>
======================================
<table><thead><th></th><th>GFR</th><th>RPF</th><th>FF (GFR/RPF)</th></thead><tr><td>Afferent arteriole constriction</td><td>se</td><td></td><td>|</td></tr><tr><td>Efferent arteriole constriction</td><td></td><td></td><td></td></tr><tr><td>t plasma protein concentration</td><td>ee</td><td></td><td></td></tr><tr><td>+ plasma protein concentration</td><td></td><td>|</td><td>tee</td></tr><tr><td>Constriction of ureter</td><td></td><td></td><td></td></tr><tr><td>Dehydration</td><td>ee</td><td></td><td></td></tr></table>
======================================
<table><thead><th></th><th>DEFECTS</th><th>EFFECTS</th><th>CAUSES</th><th>NOTES</th></thead><tr><td>Fanconi syndrome</td><td>Generalized reabsorption defect in PCT = ft excretion of amino acids, glucose, HCO,,, and PO,*, and all substances reabsorbed by the PCT</td><td>Metabolic acidosis (proximal RTA), hypophosphatemia, hypokalemia</td><td>Hereditary defects (eg, Wilson disease, tyrosinemia, glycogen storage disease), ischemia, multiple myeloma, drugs (eg, ifosfamide, cisplatin, tenofovir, lead poisoning</td><td>Growth retardation and rickets/osteopenia common due to hypophosphatemia Volume depletion also common</td></tr><tr><td>Bartter syndrome</td><td>Reabsorption defect in thick ascending loop of Henle (affects Na‘/K*/2Cl- cotransporter)</td><td>Metabolic alkalosis, hypokalemia, hypercalciuria</td><td>Autosomal recessive</td><td>Presents similarly to chronic loop diuretic use</td></tr><tr><td>Gitelman syndrome</td><td>Reabsorption defect of NaCl in DCT</td><td>Metabolic alkalosis, hypomagnesemia, hypokalemia, hypocalciuria</td><td>Autosomal recessive</td><td>Presents similarly to chronic thiazide diuretic use Less severe than Bartter syndrome</td></tr><tr><td>Liddle syndrome</td><td>Gain of function mutation &gt; + Na‘ channel degradation &gt; t Na* reabsorption in collecting tubules</td><td>Metabolic alkalosis, hypokalemia, hypertension, 4 aldosterone</td><td>Autosomal dominant</td><td>Presents similarly to hyperaldosteronism, but aldosterone is nearly undetectable Treatment: amiloride</td></tr><tr><td>Syndrome of Apparent Mineralocorticoid Excess</td><td>Cortisol activates mineralocorticoid receptors; 11B-HSD converts cortisol to cortisone (inactive on these receptors) Hereditary 11B-HSD deficiency &gt; t cortisol &gt; t mineralocorticoid receptor activity</td><td>Metabolic alkalosis, hypokalemia, hypertension + serum aldosterone level; cortisol tries to be the SAME as aldosterone</td><td>Autosomal recessive Can acquire disorder from glycyrrhetinic acid (present in licorice), which blocks activity of 11B-hydroxysteroid dehydrogenase</td><td>Treatment: K’-sparing diuretics (+ mineralo- corticoid effects) or corticosteroids (exogenous cortico- steroid + endogenous cortisol production &gt; 4 mineralocorticoid receptor activation)</td></tr></table>
======================================
<table><tr><td>ACE</td><td>Catalyzes conversion of angiotensin I to angiotensin II. Located in many tissues but conversion occurs most extensively in the lung. Produced by vascular endothelial cells in the lung.</td></tr><tr><td>ATII</td><td>Helps maintain bradycardia, w! blood volume and blood pressure. Affects baroreceptor function; limits reflex hich would normally accompany its pressor effects.</td></tr><tr><td>ANP, BNP</td><td>Released from a aldosterone sys arteriole, prom tia (ANP) and ventricles (BNP) in response to t volume; inhibits renin-angiotensin- tem; relaxes vascular smooth muscle via cGMP &gt; t GFR, $ renin. Dilates afferent otes natriuresis.</td></tr><tr><td>ADH (vasopressin)</td><td>Primarily regula reabsorption o' tes serum osmolality; also responds to low blood volume states. Stimulates water in collecting ducts. Also stimulates reabsorption of urea in collecting ducts to maximize corticopapillary osmotic gradient.</td></tr><tr><td>Aldosterone</td><td>Primarily regulates ECF volume and Na* content; t release in hypovolemic states. Responds to</td></tr></table>
======================================
<table><tr><td>Erythropoietin</td><td>Released by interstitial cells in peritubular capillary bed in response to hypoxia.</td><td>Stimulates RBC Administered for kidney disease.</td><td>proliferation in bone marrow. anemia secondary to chronic t risk of HTN.</td></tr><tr><td>Calciferol (vitamin D)</td><td>PCT cells convert 25-OH vitamin D, to 1,25- (OH), vitamin D, (calcitriol, active form). Increases calcium absorption in small bowel.</td><td>25-OH D, (calcidiol)</td><td>———————&gt; 1,25-(OH), D, 1o.-hydroxylase (calcitriol) i PTH</td></tr><tr><td>Prostaglandins</td><td>Paracrine secretion vasodilates afferent arterioles to t RBF.</td><td>NSAIDs block synthesis + and 4 GFR; injury in low</td><td>renal-protective prostaglandin constriction of afferent arteriole this may result in acute kidney renal blood flow states.</td></tr><tr><td>Dopamine</td><td>Secreted by PT cells, promotes natriuresis. At low doses; dilates interlobular arteries, afferent arterioles, efferent arterioles + t RBF, little or no change in GFR. At higher doses; acts as vasoconstrictor.</td><td></td><td></td></tr></table>
======================================
<table><thead><th></th><th>Digoxin (blocks Na'/K'-ATPase)</th></thead><tr><td>Alkalosis (low K*)</td><td>Acidosis</td></tr><tr><td>B-adrenergic agonist (t Na‘/K'-ATPase)</td><td>B-blocker</td></tr><tr><td>Insulin (t Na*/K*-ATPase)</td><td>High blood Sugar (insulin deficiency)</td></tr><tr><td>Insulin shifts K* into cells</td><td>Succinylcholine (t risk in burns/muscle trauma)</td></tr></table>
======================================
<table><tr><td>ELECTROLYTE</td><td>LOW SERUM CONCENTRATION</td><td>HIGH SERUM CONCENTRATION</td></tr><tr><td>Sodium</td><td>Nausea, malaise, stupor, coma, seizures</td><td>Irritability, stupor, coma</td></tr><tr><td>Potassium</td><td>U waves and flattened 'T’ waves on ECG, arrhythmias, muscle cramps, spasm, weakness</td><td>Wide ORS and peaked T waves on ECG, arrhythmias, muscle weakness</td></tr><tr><td>Calcium</td><td>Tetany, seizures, OT prolongation, twitching (eg, Chvostek sign), spasm (eg, Trousseau sign)</td><td>Stones (renal), bones (pain), groans (abdominal pain), thrones (t urinary frequency), psychiatric overtones (anxiety, altered mental status)</td></tr><tr><td>Magnesium</td><td>Tetany, torsades de pointes, hypokalemia, hypocalcemia (when [Mg”'] &lt; 1.0 mEq/L)</td><td>+ DTRs, lethargy, bradycardia, hypotension, cardiac arrest, hypocalcemia</td></tr><tr><td>Phosphate</td><td>Bone loss, osteomalacia (adults), rickets (children)</td><td>Renal stones, metastatic calcifications, hypocalcemia</td></tr></table>
======================================
<table><thead><th>CONDITION</th><th>BLOOD PRESSURE</th><th>PLASMA RENIN</th><th>ALDOSTERONE</th><th>SERUM Mg?</th><th>URINE Ca’*</th></thead><tr><td>SIADH</td><td>—/t</td><td>+</td><td>+</td><td></td><td></td></tr><tr><td>Primary hyperaldosteronism</td><td>t</td><td></td><td></td><td></td><td></td></tr><tr><td>Renin-secreting tumor</td><td>t</td><td></td><td></td><td></td><td></td></tr><tr><td>Bartter syndrome</td><td></td><td>i</td><td>a</td><td></td><td></td></tr><tr><td>Gitelman syndrome</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Liddle syndrome,</td><td>t</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="6">syndrome</td></tr><tr><td colspan="6">of apparent</td></tr><tr><td colspan="6">mineralocorticoid</td></tr><tr><td>excess</td><td></td><td></td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th></th><th>pH</th><th>Poo.</th><th>{HC0,]</th><th>COMPENSATORY RESPONSE</th></thead><tr><td>Metabolic acidosis</td><td>t</td><td>t</td><td>4</td><td>Hyperventilation (immediate)</td></tr><tr><td>Metabolic alkalosis</td><td>t</td><td>t</td><td>t</td><td>Hypoventilation (immediate)</td></tr><tr><td>Respiratory acidosis</td><td>4</td><td>t</td><td>t</td><td>t renal [HCO, ] reabsorption (delayed)</td></tr><tr><td>Respiratory alkalosis</td><td>_—t</td><td>{</td><td>4</td><td>+ renal [HCO,-] reabsorption (delayed)</td></tr></table>
======================================
<table><thead><th></th><th>(RTA type 1)</th><th>acidosis (RTA type 2)</th><th>acidosis (RTA type 4)</th></thead><tr><td>DEFECT</td><td>Inability of o-intercalated cells to secrete Ht &gt; no new HCO, is generated &gt; metabolic acidosis</td><td>Defect in PCT HCO, reabsorption &gt; f excretion of HCO, in urine + metabolic acidosis Urine can be acidified by q-intercalated cells in collecting duct, but not enough to overcome t HCO, excretion</td><td>Hypoaldosteronism or aldosterone resistance; hyperkalemia + 4 NH, synthesis in PCT &gt; + NH,* excretion</td></tr><tr><td>URINE pH</td><td>&gt;5.5</td><td>&lt; 5.5 when plasma HCO, below reduced resorption threshold &gt; 5.5 when filtered HCO,</td><td>&lt;_5.5 (or variable)</td></tr><tr><td></td><td>1</td><td>exceeds resorptive threshold 1</td><td>t</td></tr><tr><td rowspan="3">SERUM K* CAUSES</td><td></td><td></td><td></td></tr><tr><td></td><td>Amphotericin B toxicity, analgesic nephropathy, congenital anomalies of tract,</td><td>Fanconi syndrome, multiple myeloma, carbonic anhydrase inhibitors</td><td>+ aldosterone production (eg, diabetic hyporeninism, ACE, inhibitors, ARB, NSAIDs, adrenal</td></tr><tr><td></td><td>(obstruction) urinary autoimmune diseases (eg, SLE)</td><td></td><td>heparin, cyclosporine, insufficiency) or aldosterone resistance (eg, K*-sparing i an</td></tr></table>
======================================
<table><tr><td>Focal</td><td>&lt; 50% of glomeruli are involved</td><td>Focal segmental glomerulosclerosis</td></tr><tr><td>Diffuse</td><td>&gt; 50% of glomeruli are involved</td><td>Diffuse proliferative glomerulonephritis</td></tr><tr><td>Proliferative</td><td>Hypercellular glomeruli</td><td>Membranoproliferative glomerulonephritis</td></tr><tr><td>Membranous</td><td>Thickening of glomerular basement membrane (GBM)</td><td>Membranous nephropathy</td></tr><tr><td>Primary glomerular disease</td><td>1° disease of the kidney specifically impacting the glomeruli</td><td>Minimal change disease</td></tr><tr><td>Secondary glomerular disease</td><td>Systemic disease or disease of another organ system that also impacts the glomeruli</td><td>SLE, diabetic nephropathy</td></tr></table>
======================================
<table><thead><th>TYPE</th><th>ETIOLOGY</th><th>CLINICAL PRESENTATION</th><th>EXAMPLES</th></thead><tr><td>Nephritic syndrome</td><td>Glomerular inflammation + GBM damage = loss of RBCs into urine — dysmorphic RBCs, hematuria</td><td>Hematuria, RBC casts in urine + GFR = oliguria, azotemia t renin release, HT'N Proteinuria often in the subnephrotic range (&lt; 3.5 g/ day) but in severe cases may be in nephrotic range</td><td>® Infection-associated glomerulonephritis = Goodpasture syndrome * IgA nephropathy (Berger disease) * Alport syndrome * Membranoproliferative glomerulonephritis</td></tr><tr><td>Nephrotic syndrome</td><td>Podocyte damage &gt; impaired charge barrier &gt; proteinuria</td><td>Massive proteinuria (&gt; 3.5 g/day) with edema, hypoalbuminemia — t hepatic lipogenesis &gt; hypercholesterolemia Frothy urine with fatty casts Associated with hypercoagulable state due to antithrombin ILI loss in urine and tf risk of infection (loss of IgGs in urine and soft tissue compromise by edema)</td><td>May be 1° (eg, direct podocyte damage) or 2° (podocyte damage from systemic process): * Focal segmental glomerulosclerosis (1° or 2°) * Minimal change disease (1° or 2°) * Membranous nephropathy (1° or 2°) = Amyloidosis (2°) * Diabetic glomerulonephropathy (2°)</td></tr><tr><td>Nephritic-nephrotic syndrome</td><td>Severe GBM damage = loss of RBCs into urine + impaired charge barrier + hematuria + proteinuria</td><td>Nephrotic-range proteinuria (&gt; 3.5 g/day) and concomitant features of nephritic syndrome</td><td>Can occur with any form of nephritic syndrome, but is most common with: * Diffuse proliferative glomerulonephritis</td></tr></table>
======================================
<table><thead><th></th><th>MECHANISM</th><th>LIGHT MICROSCOPY</th><th>IMMUNOFLUORESCENCE</th><th>ELECTRON MICROSCOPY</th></thead><tr><td>Infection-related glomerulonephritis</td><td>Type III hypersensitivity reaction with consumptive hypocomplimentemia Children: seen ~2—4+ weeks after group A streptococcal pharyngitis or skin infection Adults: Staphylococcus is additional causative agent</td><td>Enlarged and hypercellular glomeruli [J</td><td>Granular (“starry sky”) appearance (“lumpy-bumpy”) fl due to IgG, IgM, and C3 deposition along GBM and mesangium</td><td>Subepithelial IC humps</td></tr><tr><td>IgA nephropathy (Berger disease)</td><td>Occurs concurrently with respiratory or GI tract infections (IgA is secreted by mucosal linings) Renal pathology of IgA vasculitis</td><td>Mesangial proliferation</td><td>IgA-based IC deposits in mesangium</td><td>Mesangial IC deposition</td></tr><tr><td>Rapidly progressive (crescentic) glomerulonephritis</td><td>Poor prognosis Multiple causes: Type II HSR in Goodpasture syndrome</td><td>Crescent moon shape [@; crescents consist of fibrin and plasma proteins (eg, C3b) with glomerular parietal cells, monocytes, macrophages</td><td>Linear IF due to antibodies to GBM and alveolar Goodpasture syndrome— hematuria/ hemoptysis; type I hypersensitivity reaction Negative IF/Pauci- immune (no gC3 deposition): granulomatosis with polyangiitis—PR3- ANCA/c-ANCA, eosinophilic granulomatosis with polyangiitis, or Microscopic polyangiitis—MPO- ANCA/p-ANCA Granular IF—PSGN or DPGN basement membrane:</td><td>Goodpasture syndrome: breaks in GMB, necrosis and crescent formation with no deposits Pauci-immune: usually no deposits; if IC deposits, more severe presentation PSGN: dome-shaped subendothelial and subepithelial electron- dense deposits (humps)</td></tr></table>
======================================
<table><thead><th>Diffuse proliferative glomerulonephritis</th><th>Often due to SLE (think “wire lupus”); DPGN and MPGN often present as nephritic and nephrotic syndromes concurrently</th><th>“Wire looping” of capillaries B)</th><th>Granular</th><th>Subendothelial, sometimes subepithelial or intramembranous IgG-based ICs often with C3 deposition</th></thead><tr><td>Alport syndrome</td><td>Type IV collagen mutation &gt; glomerular basement membrane alterations; X-linked dominant. Eye problems (eg, retinopathy, anterior lenticonus), glomerulonephritis, SNHL (can’t see, can’t pee, can’t hear a bee)</td><td>Irregular thinning and thickening and splitting of glomerular basement membrane</td><td>Initially negative; Irregular deposits of IgG, IgM, and/or C3 may be observed later.</td><td>“Basket-weave” appearance due to irregular thickening and longitudinal splitting of GBM</td></tr><tr><td>Membrano- proliferative glomerulonephritis</td><td>Type I may be 2° to HBV or HCV infection; type II associated with C3 nephritic factor (IgG autoantibody that stabilizes</td><td>Mesangial ingrowth &gt; GBM splitting &gt; “tram-track” on H&amp;E and PAS stains</td><td>Granular</td><td>Type I—Subendothelial IC deposits Type I— Intramembranous deposits, also called dense deposit disease</td></tr><tr><td></td><td>persistent complement activation + $ C3)</td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th></th><th>MECHANISM</th><th>LIGHT MICROSCOPY</th><th>IMMUNOFLUORESCENCE</th><th>ELECTRON MICROSCOPY</th></thead><tr><td>Minimal change disease</td><td>Also called lipoid nephrosis. Often 1° (idiopathic), triggered by recent infection, immunization, immune stimulus (4 Is); rarely 2° to lymphoma (eg, cytokine- mediated damage). Loss of antithrombin Ill + renal vein thrombosis.</td><td>Normal —_ glomeruli (lipid may be seen in PT’ cells)</td><td>iS)</td><td>Effacement of podocyte foot processes [iN</td></tr><tr><td>Focal segmental glomerulosclerosis</td><td>Can be 1° (idiopathic) or 2° (eg, HIV infection, sickle cell disease, heroin use, obesity, INF treatment, or congenital malformations); may progress to CKD. More common in Black people.</td><td>Segmental sclerosis and hyalinosis FJ</td><td>Often © but may be @ for nonspecific focal deposits of IgM, C3, Cl</td><td>Effacement of podocyte foot processes</td></tr><tr><td>Membranous nephropathy</td><td>Also called membranous glomerulo- nephritis. Can be 1° (eg, antibodies to phospholipase A, receptor) or 2° to drugs (eg, NSAIDs, penicillamine, gold), infections (eg, HBV, HCV, syphilis), SLE, or solid tumors. t risk of thromboembolism (eg, DVT, renal vein thrombosis).</td><td>Diffuse capillary and GBM thickening [@]</td><td>Granular due to immune complex (IC) deposition</td><td>“Spike and dome” appearance of subepithelial deposits</td></tr><tr><td>Amyloidosis</td><td>Kidney most commonly involved organ. Associated with chronic conditions that predispose to amyloid deposition (eg, AL amyloid, AA amyloid, prolonged dialysis).</td><td>Congo red stain shows apple-green birefringence under olarized light due to amyloid deposition in he mesangium</td><td>AL amyloidosis: may be positive for lambda and appa light chains AA amyloidosis: positive for AA protein</td><td>| Mesangial expansion by —_ amyloid fibrils</td></tr><tr><td>Diabetic glomerulo- nephropathy</td><td>Most common cause of ESRD in United States. Hyperglycemia &gt; nonenzymatic glycation of tissue proteins + mesangial expansion + GBM thickening and t permeability. Hyperfiltration (glomerular HTN and t GFR) &gt; glomerular hypertrophy and glomerular scarring (glomerulosclerosis) — further progression of nephropathy. Look for albuminuria with t urine albumin-to-creatinine ratio. ACEIs and ARBs renoprotective.</td><td>Mesangial expansion, GBM hickening, eosinophilic nodular glomerulo- sclerosis (Kimmelstiel- Wilson lesions BD)</td><td>Non-specific staining. Jsually negative.</td><td>Prominent thickening of GBM with expanded mesangium, predominantly due to increased mesangial matrix, segmental podocyte effacement</td></tr></table>
======================================
<table><tr><td rowspan="3">CONTENT Calcium</td><td>PRECIPITATES WITH</td><td>X-RAY FINDINGS</td><td>CT FINDINGS</td><td>URINE CRYSTAL</td><td>NOTES</td></tr><tr><td></td><td>Calcium oxalate: hypocitraturia</td><td>Radiopaque</td><td>Hyperdense</td><td>Shaped like envelope [Jor dumbbell</td><td>Calcium stones most common (80%); calcium oxalate more common than calcium phosphate stones. Can result from ethylene glycol (antifreeze) ingestion, vitamin C overuse, hypocitraturia (usually associated with + urine pH), malabsorption (eg, Crohn disease). Treatment: thiazides, citrate, low-sodium diet.</td></tr><tr><td></td><td>Calcium phosphate: t pH</td><td>Radiopaque</td><td>Hyperdense</td><td>Wedge-shaped prism</td><td>‘Treatment: low-sodium diet, thiazides.</td></tr><tr><td>Ammonium _ magnesium phosphate (struvite)</td><td>t pH</td><td>Radiopaque</td><td>Hyperdense</td><td>Coffin lid (“sarcophagus”)</td><td>Account for 15% of stones. Caused by infection with urease ® bugs (eg, Proteus mirabilis, Staphylococcus saprophyticus, Klebsiella) that hydrolyze urea to ammonia &gt; urine alkalinization. Commonly form staghorn calculi EJ. Treatment: eradication of underlying infection, surgical removal of stone.</td></tr><tr><td>Uric acid</td><td>+ pH</td><td>Radiolucent</td><td>Visible</td><td>Rhomboid [§ or rosettes</td><td>About 5% of all stones. Risk factors: } urine volume, arid climates, acidic pH. Strong association with hyperuricemia (eg, gout). Often seen in diseases with t cell urnover (eg, leukemia). Treatment: alkalinization of urine, allopurinol.</td></tr><tr><td>Cystine</td><td>+ pH</td><td>Faintly radi- opaque</td><td>Moderately radiodense</td><td>— Hexagonal B)</td><td>Hereditary (autosomal recessive) condition in which Cystine-reabsorbing PCT ransporter loses function, causing cystinuria. Transporter defect also results in poor reabsorption of Ornithine, Lysine, Arginine (COLA). Cystine is poorly soluble, thus stones form in urine. Usually begins in childhood. Can form staghorn calculi. Sodium cyanide nitroprusside test ®. “Sixtine” stones have six sides. Treatment: low sodium diet, alkalinization of urine, chelating agents (eg, tiopronin, penicillamine) if refractory.</td></tr></table>
======================================
<table><thead><th></th><th>Prerenal azotemia</th><th>Intrinsic renal failure</th><th>Postrenal azotemia</th></thead><tr><td rowspan="3">ETIOLOGY</td><td>Hypovolemia</td><td>Tubules and interstitium:</td><td>Stones</td></tr><tr><td></td><td>+ cardiac output</td><td>= Acute tubular necrosis</td><td>BPH</td></tr><tr><td></td><td>+ effective circulating volume</td><td>(ischemia, nephrotoxins)</td><td>Neoplasm</td></tr><tr><td>PATHOPHYSIOLOGY</td><td>+ RBF + | GFR &gt; t reabsorption of Na*/H,O and urea</td><td>In ATN, patchy necrosis — debris obstructing tubules and fluid backflow + | GFR</td><td>Outflow obstruction (bilateral)</td></tr><tr><td>URINE OSMOLALITY (mOsm/kg)</td><td>&gt;500</td><td>&lt;350</td><td>Varies</td></tr><tr><td>URINE Na* (mEq/L)</td><td>&lt;20</td><td>&gt;40</td><td>Varies</td></tr><tr><td rowspan="2">FE, Na SERUM BUN/Cr</td><td></td><td>&lt;1%</td><td>&gt;2%</td><td>Varies</td></tr><tr><td>&gt;20</td><td>&lt;i5</td><td>Varies</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Osmotic diuretic. t serum osmolality + fluid shift from interstitium to intravascular space &gt; t urine flow, + intracranial/intraocular pressure.</td></tr><tr><td>CLINICAL USE</td><td>Drug overdose, elevated intracranial/intraocular pressure.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Dehydration, hypo- or hypernatremia, pulmonary edema. Contraindicated in anuria, HF.</td></tr></table>
======================================
<table><tr><td>Urine NaCl</td><td>t with all diuretics (concentration varies based on potency of diuretic effect). Serum NaCl may decrease as a result.</td></tr><tr><td>Urine K*</td><td>t especially with loop and thiazide diuretics, excluding K*-sparing diuretics.</td></tr><tr><td>Urine Ca?*</td><td>t with loop diuretics: } paracellular Ca** reabsorption + hypocalcemia. 4 with thiazides: enhanced Ca** reabsorption.</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Inhibit ACE &gt; 4 AT II + $ GFR by preventing constriction of efferent arterioles. t renin due to loss of negative feedback. Inhibition of ACE also prevents inactivation of bradykinin, a potent vasodilator.</td><td></td></tr><tr><td>CLINICAL USE</td><td>Hypertension, HF (} mortality), proteinuria, diabetic nephropathy. Prevent unfavorable heart remodeling as a result of chronic hypertension.</td><td>In chronic kidney disease (eg, diabetic nephropathy), $ intraglomerular pressure, slowing GBM thickening.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Cough, Angioedema (both due to t bradykinin; contraindicated in Cl esterase inhibitor deficiency), Teratogen (fetal renal malformations), t Creatinine (} GFR), Hyperkalemia, and Hypotension. Used with caution in bilateral renal artery stenosis because ACE inhibitors will further } GFR = renal failure.</td><td>Captopril’s CATCHH.</td></tr><tr><td>Angiotensin Il receptor blockers</td><td>Losartan, candesartan, valsartan.</td><td></td></tr><tr><td>MECHANISM</td><td>Selectively block binding of angiotensin II to AT, ARBs do not increase bradykinin.</td><td>receptor. Effects similar to ACE inhibitors, but</td></tr><tr><td>CLINICAL USE</td><td>Hypertension, HF, proteinuria, or chronic kidney intolerance to ACE inhibitors (eg, cough,</td><td>disease (eg, diabetic nephropathy) with angioedema).</td></tr><tr><td>ADVERSE EFFECTS</td><td>Hyperkalemia, | GFR, hypotension; teratogen.</td><td></td></tr><tr><td colspan="3">Aliskiren</td></tr><tr><td>MECHANISM</td><td>Direct renin inhibitor, blocks conversion of</td><td>angiotensinogen to angiotensin I. Aliskiren kills renin.</td></tr><tr><td>CLINICAL USE</td><td>Hypertension.</td><td></td></tr></table>
======================================
<table><thead><th>GENE</th><th>CHARACTERISTICS</th></thead><tr><td>Homeobox (HOX)</td><td>Produced at multiple locations + segmental organization of embryo in cranial-caudal axis.</td></tr><tr><td>genes</td><td>Mutations &gt; limb malformations. Isotretinoin + t HOX gene expression.</td></tr><tr><td>Sonic hedgehog (SHH)</td><td>Produced at notochord, limb buds (zone of polarizing activity) + CNS development, anterior- posterior limb axis patterning. Mutations + holoprosencephaly.</td></tr><tr><td>Wnt-7</td><td>Produced at limb buds (apical ectodermal ridge) + dorsal-ventral limb axis patterning.</td></tr><tr><td>Fibroblast growth</td><td>Produced at limb buds (apical ectodermal ridge) &gt; proximal-distal limb outgrowth.</td></tr></table>
======================================
<table><thead><th>— —</th><th>Endoderm = — Notochord</th><th>ew S Nevr tube</th></thead><tr><td>Ectoderm</td><td></td><td>External/outer layer</td></tr><tr><td>Surface ectoderm</td><td>Epidermis; adenohypophysis (from Rathke pouch); lens of eye; epithelial linings of oral cavity, sensory organs of ear, and olfactory epithelium; anal canal below the pectinate line; parotid, sweat, mammary glands.</td><td>Craniopharyngioma—benign Rathke pouch tumor with cholesterol crystals, calcifications.</td></tr><tr><td>Neural tube</td><td>Brain (neurohypophysis, CNS neurons, oligo- dendrocytes, astrocytes, ependymal cells, pineal gland), retina, spinal cord.</td><td>Neuroectoderm—think CNS.</td></tr><tr><td>Neural crest</td><td>Enterochromaffin cells, Melanocytes, Odontoblasts, PNS ganglia (cranial, dorsal root, autonomic), Adrenal medulla, Schwann cells, Spiral membrane (aorticopulmonary septum), Endocardial cushions (also derived partially from mesoderm), Skull bones.</td><td>EMO PASSES Neural crest—think PNS and non-neural structures nearby.</td></tr><tr><td>Mesoderm</td><td>Muscle, bone, connective tissue, serous linings of body cavities (eg, peritoneum. 8 y &amp; F , pericardium, pleura), spleen (develops within foregut mesentery), cardiovascular structures, lymphatics, blood, wall of gut tube, proximal vagina, kidneys, adrenal cortex, dermis, testes, ovaries, microglia, tracheal cartilage. Notochord induces ectoderm to form neuroectoderm (neural plate); its only ostnatal derivative is the nucleus pulposus of he intervertebral disc.</td><td>Middle/“meat” layer. Mesodermal defects = VACTERL association: Vertebral defects Anal atresia Cardiac defects Tracheo-Esophageal fistula Renal defects Limb defects (bone and muscle)</td></tr><tr><td>Endoderm</td><td>Gut tube epithelium (including anal canal above the pectinate line), most of urethra and distal vagina (derived from urogenital sinus), uminal epithelial derivatives (eg, lungs, iver, gallbladder, pancreas, eustachian tube, hymus, parathyroid, thyroid follicular and arafollicular [C] cells).</td><td>“Enternal” layer.</td></tr></table>
======================================
<table><thead><th>TERATOGEN</th><th>EFFECT ON FETUS</th></thead><tr><td colspan="2">Medications</td></tr><tr><td>ACE inhibitors</td><td>Renal failure, oligohydramnios, hypocalvaria.</td></tr><tr><td>Alkylating agents</td><td>Multiple anomalies (eg, ear/facial abnormalities, absence of digits).</td></tr><tr><td>Aminoglycosides</td><td>Ototoxicity. “A mean guy hit the baby in the ear.”</td></tr><tr><td>Antiepileptic drugs</td><td>Neural tube defects, cardiac defects, cleft palate, skeletal abnormalities (eg, phalanx/nail hypoplasia, facial dysmorphism). Most commonly due to valproate, carbamazepine, phenytoin, phenobarbital; high-dose folate supplementation recommended.</td></tr><tr><td>Diethylstilbestrol</td><td>Vaginal clear cell adenocarcinoma, congenital Miillerian anomalies.</td></tr><tr><td>Fluoroquinolones</td><td>Cartilage damage.</td></tr><tr><td>Folate antagonists</td><td>Neural tube defects. Most commonly due to trimethoprim, methotrexate.</td></tr><tr><td>Isotretinoin</td><td>Craniofacial (eg, microtia, dysmorphism), CNS, cardiac, and thymic defects. Contraception mandatory. Pronounce “isoteratinoin” for its teratogenicity.</td></tr><tr><td>Lithium</td><td>Ebstein anomaly.</td></tr><tr><td>Methimazole</td><td>Aplasia cutis congenita (congenital absence of skin, typically on scalp).</td></tr><tr><td>Tetracyclines</td><td>Discolored teeth, inhibited bone growth. Pronounce “teethracyclines.”</td></tr><tr><td>Thalidomide</td><td>Limb defects (eg, phocomelia—flipperlike limbs). Pronounce “thalimbdomide.”</td></tr><tr><td>Warfarin</td><td>Bone and cartilage deformities (stippled epiphyses, nasal and limb hypoplasia), optic nerve atrophy, cerebral hemorrhage. Use heparin during (does not placenta).</td></tr><tr><td colspan="2">pregnancy Substance use</td></tr><tr><td>Alcohol</td><td>Fetal alcohol syndrome.</td></tr><tr><td>Cocaine</td><td>Preterm birth, low birth weight, fetal growth restriction (FGR). Cocaine &gt; vasoconstriction.</td></tr><tr><td>Tobacco smoking</td><td>Preterm birth, low birth weight (leading cause in resource-rich countries), FGR, sudden infant death syndrome (SIDS), ADHD. Nicotine + vasoconstriction, CO &gt; impaired O, delivery.</td></tr><tr><td colspan="2">Other</td></tr><tr><td colspan="2">lodine lack or excess Congenital hypothyroidism.</td></tr><tr><td>Maternal diabetes</td><td>Caudal regression syndrome, cardiac defects (eg, transposition of great arteries, VSD), neural tube defects, macrosomia, neonatal hypoglycemia (due to islet cell hyperplasia), polycythemia, respiratory distress syndrome.</td></tr><tr><td>Maternal PKU</td><td>Fetal growth restriction, microcephaly, intellectual disability, congenital heart defects.</td></tr><tr><td>Methylmercury</td><td>Neurotoxicity. t concentration in top-predator fish (eg, shark, swordfish, king mackerel, tilefish).</td></tr><tr><td>X-rays</td><td>Microcephaly, intellectual disability. Effects minimized by use of lead shielding.</td></tr></table>
======================================
<table><tr><td>Aplasia</td><td>Absent organ despite presence of primordial tissue.</td></tr><tr><td>Hypoplasia</td><td>Incomplete organ development; primordial tissue present.</td></tr><tr><td>Disruption</td><td>2° breakdown of tissue with normal developmental potential (eg, amniotic band syndrome).</td></tr><tr><td>Deformation</td><td>Extrinsic mechanical distortion (eg, congenital torticollis); occurs during fetal period.</td></tr><tr><td>Malformation</td><td>Intrinsic developmental defect (eg, cleft lip/palate); occurs during embryonic period.</td></tr><tr><td>Sequence</td><td>Abnormalities result from a single 1° embryologic event (eg, oligohydramnios + Potter sequence).</td></tr></table>
======================================
<table><thead><th>Pharyngeal pouch derivatives</th><th colspan="2">Ear, tonsils, bottom-to-top: | (ear), 2 (tonsils), 3 dorsal (bottom = inferior parathyroids), 3 ventral (to = thymus), 4 (top = superior parathyroids).</th></thead><tr><td>POUCH</td><td>DERIVATIVES</td><td>NOTES</td></tr><tr><td>Ist pharyngeal pouch</td><td>Middle ear cavity, eustachian tube, mastoid air cells</td><td>_Ist pouch contributes to endoderm-lined structures of ear</td></tr><tr><td>2nd pharyngeal pouch</td><td>Epithelial lining of palatine tonsil</td><td></td></tr><tr><td>3rd pharyngeal pouch</td><td>Dorsal wings &gt; inferior parathyroids Ventral wings &gt; thymus</td><td>Third pouch contributes to thymus and both inferior parathyroids Structures from 3rd pouch end up below those from 4th pouch</td></tr><tr><td>4th pharyngeal pouch</td><td>— Dorsal wings &gt; superior parathyroids Ventral wings &gt; ultimopharyngeal body &gt; parafollicular (C) cells of thyroid</td><td>a h pharyngeal pouch forms para“4”llicular cells</td></tr></table>
======================================
<table><thead><th>ARCH</th><th>NERVES*</th><th>MUSCLES</th><th>CARTILAGE</th><th>NOTES</th></thead><tr><td>1st pharyngeal arch</td><td>CN V, chew</td><td>Muscles of mastication (temporalis, masseter, ateral and medial pterygoids), mylohyoid, anterior belly of digastric, ensor tympani, anterior 2/3 of tongue, tensor veli palatini</td><td>Maxillary process &gt; maxilla, zygomatic bone Mandibular process &gt; meckel cartilage &gt; mandible, malleus and incus, sphenomandibular ligament</td><td>Pierre Robin sequence— micrognathia, glossoptosis, cleft palate, airway obstruction Treacher Collins syndrome—autosomal dominant neural crest dysfunction</td></tr><tr><td>2nd pharyngeal arch</td><td>—_CN VII (seven) smile (facial expression)</td><td>Muscles of facial expression, stapedius, stylohyoid, platysma, posterior belly of digastric</td><td>Reichert cartilage: stapes, styloid process, lesser horn of hyoid, stylohyoid ligament</td><td>&gt; craniofacial abnormalities (eg, zygomatic bone and mandibular hypoplasia), hearing loss, airway compromise</td></tr><tr><td>3rd pharyngeal arch</td><td>CN Ix swallow stylishly</td><td>Stylopharyngeus</td><td>Greater horn of hyoid</td><td></td></tr><tr><td>4th and 6th pharyngeal arches</td><td>4th arch: CN X (superior laryngeal branch) simply swallow 6th arch: CN X (recurrent/ inferior laryngeal branch) speak</td><td>4th arch: most pharyngeal constrictors; cricothyroid, _ levator veli palatini 6th arch: all intrinsic muscles of larynx except cricothyroid</td><td>Arytenoids, Cricoid, Corniculate, Cuneiform, Thyroid (used to sing and ACCCT)</td><td>Arches 3 and 4 form posterior 1/3 of tongue Arch 5 makes no major developmental contributions</td></tr></table>
======================================
<table><tr><td>Female</td><td>Default development. Mesonephric duct degenerates and paramesonephric duct develops.</td></tr><tr><td>Male</td><td>SRY gene on Y chromosome—produces testis- determining factor &gt; testes development. Sertoli cells secrete Miillerian inhibitory factor (MIF; also called antimullerian hormone) that suppresses development of paramesonephric ducts. Leydig cells secrete androgens that stimulate development of mesonephric ducts.</td></tr><tr><td>Paramesonephric (Millerian) duct</td><td>Develops into female internal structures— fallopian tubes, uterus, proximal vagina (distal vagina from urogenital sinus). Male remnant is appendix testis. Miullerian agenesis (Mayer-Rokitansky-Kister- Hauser syndrome)—1° amenorrhea with absent uterus, blind vaginal pouch, normal female external genitalia and 2° sexual characteristics (functional ovaries). Associated with urinary tract anomalies (eg, renal agenesis).</td></tr><tr><td></td><td></td></tr><tr><td>Mesonephric (Wolffian) duct</td><td>Develops into male internal structures (except prostate)—Seminal vesicles, Epididymis, Ejaculatory duct, Ductus deferens (SEED). Female remnant is Gartner duct.</td></tr></table>
======================================
<table><tr><td>Epispadias Waa</td><td>Abnormal opening of penile urethra on dorsal (top) surface due to faulty positioning of</td><td>Exstrophy of the bladder is associated with epispadias.</td></tr></table>
======================================
<table><thead><th></th><th>DESCRIPTION</th><th>MALE REMNANT</th><th>FEMALE REMNANT</th></thead><tr><td>Gubernaculum</td><td>Band of fibrous tissue</td><td>Anchors testes within scrotum</td><td>Ovarian ligament + round ligament of uterus</td></tr><tr><td>Processus vaginalis</td><td>Evagination of peritoneum</td><td>Forms tunica vaginalis Persistent patent processus vaginalis + hydrocele</td><td>Obliterated</td></tr></table>
======================================
<table><tr><td>Vulva</td><td>Stratified squamous epithelium</td></tr><tr><td>Vagina</td><td>Stratified squamous epithelium, nonkeratinized</td></tr><tr><td>Ectocervix</td><td>Stratified squamous epithelium, nonkeratinized</td></tr><tr><td>Transformation zone</td><td>Squamocolumnar junction (most common area for cervical cancer; sampled in Pap test)</td></tr><tr><td>Endocervix</td><td>Simp! e columnar epithe ium</td></tr><tr><td>Uterus</td><td>Simp! e columnar epithe ium with long tubular glands in proliferative phase; coiled glands in secretory phase</td></tr><tr><td>Fallopian tube</td><td>Simp! e columnar epithe ium, ciliated</td></tr><tr><td>Ovary, outer surface</td><td>Simp! epit! e cuboidal epithelium (germinal helium covering su rface of ovary)</td></tr></table>
======================================
<table><thead><th>URCE</th><th>Ovary (17B-estradiol), placenta (estriol), adipose tissue (estrone via aromatization).</th><th>Potency: estradiol &gt; estrone &gt; estriol. Estradiol is produced from 2 ovaries.</th></thead></table>
======================================
<table><tr><td>SOURCE</td><td>Corpus luteum, placenta, adrenal cortex, testes.</td><td>_ Fall in estrogen and progesterone after delivery disinhibits prolactin lactation. 1</td></tr></table>
======================================
<table><tr><td>Ovarian cycle</td><td>Follicular phase—follicular development; late stages are stimulated by F'SH; can fluctuate in length.</td><td>Luteal phase—corpus luteum formation from follicular remnants; stimulated by LH; lasts a fixed 14 days.</td></tr><tr><td>Uterine cycle</td><td>Proliferative phase— endometrial development;</td><td>Secretory phase—endometrial preparation for</td></tr></table>
======================================
<table><thead><th>in pregnancy</th><th>Mediated by t hormones (eg, estrogen, progesterone) and mechanical effects of gravid uterus.</th></thead><tr><td>CARDIOVASCULAR</td><td>+ SVR (4 afterload) and t blood volume (t preload) + t SV + t CO = t placental perfusion. t HR is the major contributor to t CO in late pregnancy. Hemodilution + 4 oncotic pressure &gt; peripheral edema.</td></tr><tr><td>ENDOCRINE</td><td>t insulin resistance and secretion &gt; tf lipolysis and fat utilization (to preserve glucose and amino acids for fetus). Pituitary enlargement (lactotroph hyperplasia). t TBG, t CBG, t SHBG.</td></tr><tr><td>GASTROINTESTINAL</td><td>+ GI motility, | LES tone, gallbladder stasis; predispose to constipation, GERD, gallstones.</td></tr><tr><td>HEMATOLOGIC</td><td>Dilutional anemia (tt plasma volume, t RBC mass), hypercoagulable state (to + blood loss at delivery). t micronutrient requirements predispose to deficiency (eg, iron, folate).</td></tr><tr><td>MUSCULOSKELETAL</td><td>Lordosis (to realign gravity center), joint laxity (to facilitate fetal descent).</td></tr><tr><td>SKIN</td><td>Hyperpigmentation (eg, melasma, linea nigra, areola darkening), striae gravidarum (stretch marks), vascular changes (eg, spider angiomas, palmar erythema, varicosities).</td></tr><tr><td>RENAL</td><td>Vasodilation &gt; t renal plasma flow + t GFR &gt; + BUN and § creatinine. Mild glucosuria, proteinuria, Hydronephrosis and hydroureter (more prominent on the right) predispose to pyelonephritis.</td></tr><tr><td>RESPIRATORY</td><td>Respiratory center stimulation + chronic hyperventilation (t V,,, unchanged RR) &gt; mild</td></tr></table>
======================================
<table><thead><th></th><th>Low birth weight</th><th>High birth weight (macrosomia)</th></thead><tr><td>DEFINITION</td><td>Birth weight &lt; 2500 g</td><td>Birth weight &gt; 4000 g</td></tr><tr><td>RISK FACTORS</td><td>Prematurity, FGR</td><td>Fetal: constitutional/genetic Maternal: obesity, diabetes mellitus</td></tr><tr><td>COMPLICATIONS</td><td>t mortality (SIDS), t morbidity</td><td>t risk of maternal or fetal trauma (eg, shoulder dystocia)</td></tr></table>
======================================
<table><tr><td>SOURCE</td><td>DHT and testosterone (testis), androstenedione (adrenal)</td><td>— Potency: DHT &gt; testosterone &gt; androstenedione.</td></tr><tr><td rowspan="2">FUNCTION</td><td>Testosterone: * Differentiation of epididymis, vas deferens, seminal vesicles (internal genitalia, except prostate) = Growth spurt: penis, seminal vesicles,</td><td>Testosterone is converted to DHT by 5a-reductase, which is inhibited by finasteride. In the male, androgens are converted to estrogens by aromatase (primarily in adipose tissue and testes).</td></tr><tr><td></td><td>prostate » Late—prostate growth, balding, sebaceous gland activity</td><td>— 4 intratesticular testosterone &gt; $ testicular size, | sperm count, azoospermia). Females may present with virilization (eg, hirsutism, acne,</td></tr></table>
======================================
<table><thead><th>development</th><th>by hormonal levels) and gonadal sex (testes vs ovaries, corresponds with Y chromosome).</th></thead><tr><td>46,XX DSD</td><td>Ovaries present, but external genitalia are virilized or atypical. Most commonly due to congenital adrenal hyperplasia (excessive exposure to androgens early in development).</td></tr><tr><td>46,XY DSD</td><td>Testes present, but external genitalia are feminized or atypical. Most commonly due to androgen insensitivity syndrome (defect in androgen receptor).</td></tr></table>
======================================
<table><tr><td>sex hormones</td><td>t</td><td>Androgen insensitivity syndrome</td></tr><tr><td></td><td>t</td><td>‘Testosterone-secreting tumor, exogenous androgenic steroids</td></tr><tr><td></td><td></td><td>Hypergonadotropic (1°) hypogonadism</td></tr><tr><td></td><td></td><td>Hypogonadotropic (2°) hypogonadism</td></tr></table>
======================================
<table><tr><td>isorders by physical</td><td>®</td><td>io)</td><td>Hypergonadotropic (1°) hypogonadism in genotypic female</td></tr><tr><td>raracteristics</td><td>iS)</td><td>i)</td><td>Hypogonadotropic (2°) hypogonadism genotypic Miillerian agenesis in genotypic female</td></tr></table>
======================================
<table><tr><td>KARYOTYPE</td><td>46,XX (most common); +6,XY</td><td>69,XXX; 69,XXY; 69,.XYY</td></tr><tr><td>COMPONENTS</td><td>Most commonly enucleated egg + single sperm (subsequently duplicates paternal DNA)</td><td>2 sperm + | egg</td></tr><tr><td>HISTOLOGY</td><td>Hydropic villi, circumferential and diffuse trophoblastic proliferation</td><td>Only some villi are hydropic, focal/minimal trophoblastic proliferation</td></tr><tr><td>FETAL PARTS</td><td>No</td><td>Yes (partial = fetal parts)</td></tr><tr><td>STAINING FOR P57 PROTEIN</td><td>© (paternally imprinted)</td><td>@ (maternally expressed) Partial mole is P57 positive</td></tr><tr><td>UTERINE SIZE</td><td>t</td><td></td></tr><tr><td>hcG</td><td>tttt</td><td>t</td></tr><tr><td>IMAGING</td><td>“Honeycombed” uterus or “clusters of grapes” EN, “snowstorm” [J on ultrasound</td><td>Fetal parts</td></tr><tr><td>RISK OF INVASIVE MOLE</td><td>15-20%</td><td>&lt;5%</td></tr></table>
======================================
<table><tr><td>Gestational hypertension</td><td>BP &gt; 140/90 mm Hg after 20 weeks of gestation. No preexisting hypertension. No proteinuria or end-organ damage. Hypertension prior to 20 weeks of gestation suggests chronic hypertension.</td></tr><tr><td rowspan="2">Preeclampsia</td><td>New-onset hypertension with either proteinuria or end-organ dysfunction after 20 weeks of gestation (onset of preeclampsia &lt; 20 weeks of gestation may suggest molar pregnancy). Caused by abnormal placental spiral arteries + endothelial dysfunction, vasoconstriction, ischemia. Risk factors: history of preeclampsia, multifetal gestation, chronic hypertension, diabetes, chronic kidney disease, autoimmune disorders (eg, antiphospholipid syndrome), obesity, age &gt; 35 years. Complications: placental abruption, coagulopathy, renal failure, pulmonary edema, uteroplacental insufficiency; may lead to eclampsia and/or HELLP syndrome. Treatment: antihypertensives, IV magnesium sulfate (to prevent seizure); definitive is delivery.</td></tr><tr><td></td><td>Prophylaxis: aspirin.</td></tr><tr><td>Eclampsia</td><td>Preeclampsia with seizures. Death due to stroke, intracranial hemorrhage, ARDS. Treatment: IV magnesium sulfate, antihypertensives, immediate delivery.</td></tr><tr><td>HELLP syndrome</td><td>Preeclampsia with thrombotic microangiopathy of the liver. Hemolysis, Elevated Liver enzymes, Low Platelets. May occur in the absence of hypertension and proteinuria. Blood smear shows schistocytes. Can lead to hepatic subcapsular hematomas (rupture &gt; severe hypotension) and DIC (due to release of tissue factor from injured placenta).</td></tr></table>
======================================
<table><thead><th colspan="2">Non-neoplastic</th></thead><tr><td>Bartholin cyst and abscess</td><td>Due to blockage of Bartholin gland duct causing accumulation of gland fluid. May lead to abscess 2° to obstruction and inflammation [[V. Usually in reproductive-age females.</td></tr><tr><td>Lichen sclerosus</td><td>Chronic, progressive inflammatory disease characterized by porcelain-white plaques [J that can be hemorrhagic, eroded, or ulcerated. May extend to anus producing figure-eight appearance. t incidence in prepubertal and peri-/postmenopausal females. Presents with intense pruritus, dyspareunia, dysuria, dyschezia. Benign, but slightly t risk for SCC.</td></tr><tr><td>Lichen simplex chronicus</td><td>Hyperplasia of vulvar squamous epithelium. Presents with leathery, thick vulvar skin with enhanced skin markings due to chronic rubbing or scratching. Benign, no risk of SCC.</td></tr><tr><td>Neoplastic</td><td></td></tr><tr><td>Vulvar carcinoma</td><td>Carcinoma from squamous epithelial lining of vulva [@. Rare. Presents with leukoplakia, biopsy often required to distinguish carcinoma from other causes. HPV-related vulvar carcinoma—associated with high-risk HPV types 16, 18. Risk factors: multiple partners, early coitarche. Usually in reproductive-age females. Non-HPV vulvar carcinoma—usually from long-standing lichen sclerosus. Females &gt; 70 years old</td></tr><tr><td>Extramammary Paget disease</td><td>Intraepithelial adenocarcinoma. Carcinoma in situ, low risk of underlying carcinoma (vs Paget disease of the breast, which is always associated with underlying carcinoma). Presents with pruritus, erythema, crusting, ulcers [).</td></tr></table>
======================================
<table><tr><td>Squamous cell carcinoma</td><td>Usually 2° to cervical SCC; 1° vaginal carcinoma rare.</td></tr><tr><td>Clear cell adenocarcinoma</td><td>Arises from vaginal adenosis (persistence of glandular columnar epithelium in proximal vagina), found in females who had exposure to diethylstilbestrol in utero.</td></tr><tr><td>Sarcoma botryoides</td><td>Embryonal rhabdomyosarcoma variant. Affects females &lt;4 years old; spindle-shaped cells; desmin ®. Presents with clear, grapelike, polypoid mass emerging from vagina.</td></tr></table>
======================================
<table><thead><th>Cervical pathology</th><th></th></thead><tr><td>Dysplasia and carcinoma in situ</td><td>Disordered epithelial growth; begins at basal layer of squamocolumnar junction (transformation zone) and extends outward. Classified as CIN 1, CIN 2, or CIN 3 (severe, irreversible dysplasia or carcinoma in situ), depending on extent of dysplasia. Associated with HPV-16 and HPV-18, which</td></tr><tr><td></td><td>pathognomonic of HPV infection. May progress slowly to invasive carcinoma if left untreated. Typically asymptomatic (detected with Pap smear) or presents as abnormal vaginal bleeding (often postcoital). Risk factors: multiple sexual partners, HPV, smoking, early coitarche, DES exposure, immunocompromise (eg, HIV, transplant).</td></tr><tr><td>Invasive carcinoma</td><td>Often squamous cell carcinoma. Pap smear can detect cervical dysplasia before it progresses to invasive carcinoma. Diagnose via colposcopy and biopsy. Lateral invasion can block ureters — hydronephrosis &gt; renal failure.</td></tr><tr><td>Primary ovarian insufficiency</td><td>Also called premature ovarian failure. Premature atresia of ovarian follicles in females of reproductive age. Most often idiopathic; associated with chromosomal abnormalities (eg, Turner syndrome, fragile X syndrome premutation), autoimmunity. Need karyotype screening. Patients present with signs of menopause after puberty but before age 40. 4 estrogen, t LH, t FSH.</td></tr></table>
======================================
<table><thead><th>Ovarian cysts</th><th>Usually asymptomatic, but may rupture, become hemorrhagic, or lead to adnexal torsion.</th></thead><tr><td>Follicular cyst</td><td>Functional (physiologic) cyst. Most common ovarian mass in young females. Caused by failure of mature follicle to rupture and ovulate. May produce excess estrogen. Usually resolves spontaneously.</td></tr><tr><td>Corpus luteal cyst</td><td>Functional cyst. Caused by failure of corpus luteum to involute after ovulation. May produce excess progesterone. Usually resolves spontaneously.</td></tr><tr><td>Theca lutein cyst</td><td>Also called hyperreactio luteinalis. Caused by hCG overstimulation. Often bilateral/multiple. Associated with gestational trophoblastic disease (eg, hydatidiform mole, choriocarcinoma).</td></tr></table>
======================================
<table><tr><td colspan="2">Epithelial tumors</td></tr><tr><td>Serous cystadenoma</td><td>Benign. Most common ovarian neoplasm. Lined by fallopian tube—like epithelium.</td></tr><tr><td>Mucinous</td><td>Benign. Multiloculated, large. Lined by mucus-secreting epithelium [.</td></tr><tr><td>cystadenoma</td><td></td></tr><tr><td>Brenner tumor</td><td>Usually benign. Nests of urothelial-like (bladderlike) epithelium with “coffee bean” nuclei.</td></tr><tr><td>Serous carcinoma</td><td>Most common malignant ovarian neoplasm. Psammoma bodies.</td></tr><tr><td>Mucinous carcinoma</td><td>Malignant. Rare. May be metastatic from appendiceal or other GI tumors. Can result in</td></tr></table>
======================================
<table><thead><th>TYPE</th><th>CHARACTERISTICS</th></thead><tr><td colspan="2">Germ cell tumors</td></tr><tr><td>Mature cystic teratoma</td><td>Also called dermoid cyst. Benign. Most common ovarian tumor in young females. Cystic mass with elements from all 3 germ layers (eg, teeth, hair, sebum) EJ. May be painful 2° to ovarian enlargement or torsion. Monodermal form with thyroid tissue (struma ovarii [§) may present with hyperthyroidism. Malignant transformation rare (usually to squamous cell carcinoma).</td></tr><tr><td>Immature teratoma</td><td>Malignant, aggressive. Contains fetal tissue, neuroectoderm. Commonly diagnosed before age 20. Typically represented by immature/embryoniclike neural tissue.</td></tr><tr><td>Dysgerminoma</td><td>Malignant. Most common in adolescents. Equivalent to male seminoma but rarer. Sheets of uniform “fried egg” cells B). Tumor markers: t hCG, t LDH.</td></tr><tr><td>Yolk sac tumor</td><td>Also called endodermal sinus tumor. Malignant, aggressive. Yellow, friable (hemorrhagic) mass. 50% have Schiller-Duval bodies (resemble glomeruli, arrow in [). Tumor marker: t AFP. Occurs in children and young adult females.</td></tr><tr><td colspan="2">Sex cord stromal tumors</td></tr><tr><td>Fibroma</td><td>Benign. Bundle of spindle-shaped fibroblasts. Meigs syndrome—triad of ovarian fibroma, ascites, pleural effusion. “Pulling” sensation in groin.</td></tr><tr><td>Thecoma</td><td>Benign. May produce estrogen. Usually presents as abnormal uterine bleeding in a postmenopausal female.</td></tr><tr><td>Sertoli-Leydig cell tumor Granulosa cell tumor</td><td>Benign. Gray to yellow-brown mass. Resembles testicular histology with tubules/cords lined by pink Sertoli cells. May produce androgens = virilization (eg, hirsutism, male pattern baldness, clitoral enlargement). Most common malignant sex cord stromal tumor. Predominantly occurs in females in their</td></tr></table>
======================================
<table><thead><th>TYPE</th><th>CHARACTERISTICS</th></thead><tr><td colspan="2">Non-neoplastic</td></tr><tr><td>Adenomyosis</td><td>Presence of endometrial tissue (glands and stroma) in myometrium. May be due to invagination of basal layer of endometrium or metaplasia of remnant progenitor cells. Presents with abnormal uterine bleeding, dysmenorrhea. Diffusely enlarged (“globular”), soft (“boggy”) uterus on exam.</td></tr><tr><td>Endometriosis</td><td>Presence of endometrial tissue (glands and stroma) outside uterus. May be due to ectopic implantation of endometrial tissue (via retrograde menses, blood vessels, lymphatics) or metaplasia of remnant progenitor cells. Typically involves pelvic sites, such as superficial eritoneum (yellow-brown “powder burn” lesions fi) and ovaries (forms blood-filled “chocolate” cyst called endometrioma). Presents with chronic pelvic pain (eg, dysmenorrhea, dyspareunia), abnormal uterine bleeding, infertility. Normal-sized uterus on exam.</td></tr><tr><td>Endometrial hyperplasia</td><td>Abnormal endometrial gland proliferation. Usually caused by excess estrogen unopposed by rogesterone. Associated with obesity, anovulation (eg, PCOS), hormone replacement therapy. Presents with abnormal uterine bleeding. t risk for endometrial carcinoma (especially with nuclear atypia).</td></tr><tr><td>Endometritis</td><td>Inflammation of endometrium EJ. Usually occurs after delivery due to inoculation of uterine cavity by vaginal microbiota. C-section is the most important risk factor (sutures and necrotic tissue act as nidus for polymicrobial infection). Presents with fever, uterine tenderness, purulent lochia.</td></tr><tr><td>Intrauterine adhesions</td><td>Fibrous bands/tissue within endometrial cavity. Caused by damage to basal layer of endometrium, usually after dilation and curettage. Presents with abnormal uterine bleeding (} menses), infertility, recurrent pregnancy loss, dysmenorrhea. Also called Asherman syndrome when symptomatic.</td></tr><tr><td colspan="2">Neoplastic</td></tr><tr><td>Leiomyoma</td><td>Benign tumor of myometrium (also called fibroid). Most common gynecological tumor. Arises in reproductive-age females. t incidence in Black population. Typically multiple; subtypes based on location: submucosal, intramural, or subserosal. Usually asymptomatic, but may present with abnormal uterine bleeding, pelvic pressure/pain, reproductive dysfunction. Estrogen sensitive; tumor size t with pregnancy and 4 with menopause. Enlarged uterus with nodular contour on exam [@. Histology: whorled pattern of smooth muscle bundles [5] and well-demarcated borders.</td></tr><tr><td>Endometrial carcinoma</td><td>Malignant tumor of endometrium. Most common gynecological cancer in resource-rich countries. Usually arises in postmenopausal females. Presents with abnormal uterine bleeding. Endometrioid carcinoma—most common subtype of endometrial carcinoma. Associated with long-term exposure to unopposed estrogen. Histology: confluent endometrial glands without intervening stroma GB.</td></tr></table>
======================================
<table><tr><td>Inflammatory processes</td><td>Fat necrosis—benign, usually painless, lump due to injury to breast tissue. Calcified oil cyst on mammography; necrotic fat and giant cells on biopsy. Up to 50% of patients may not report trauma. Lactational mastitis—occurs during breastfeeding, t risk of bacterial infection through cracks in nipple. S aureus is most common pathogen. ‘Treat with antibiotics and continue breastfeeding.</td></tr><tr><td>Gynecomastia</td><td>Breast enlargement in males due to t estrogen compared with androgen activity. Physiologic in newborn, pubertal, and older males, but may persist after puberty. Other causes include cirrhosis,</td></tr></table>
======================================
<table><thead><th>TYPE</th><th>CHARACTERISTICS</th><th>NOTES</th></thead><tr><td colspan="3">Noninvasive carcinomas</td></tr><tr><td>Ductal carcinoma in situ</td><td>Fills ductal lumen (black arrow in [J indicates neoplastic cells in duct; blue arrow shows engorged blood vessel). Arises from ductal atypia. Often seen early as microcalcifications on mammography.</td><td>Early malignancy without basement membrane penetration. Usually does not produce a mass.</td></tr><tr><td>Paget disease</td><td>Extension of underlying DCIS/invasive breast cancer up the lactiferous ducts and into the contiguous skin of nipple + eczematous patches over nipple and areolar skin [.</td><td>Paget cells = intraepithelial adenocarcinoma cells.</td></tr><tr><td>Lobular carcinoma in situ</td><td>+ E-cadherin expression. No mass or calcifications + incidental biopsy finding.</td><td>t risk of cancer in either breast (vs DCIS, same breast and quadrant).</td></tr><tr><td>Invasive carcinomas Invasive ductal</td><td>Firm, fibrous, “rock-hard” mass with sharp</td><td>Most common type of invasive breast cancer.</td></tr><tr><td>Invasive lobular</td><td>margins and small, glandular, ductlike desmoplastic stroma. + E-cadherin expression — orderly row of cells (“single file” B)) and no duct formation. Often</td><td>Often bilateral with multiple lesions in the same location.</td></tr><tr><td>Inflammatory</td><td>lacks desmoplastic response. Dermal lymphatic space invasion &gt; breast pain with warm, swollen, erythematous skin around exaggerated hair follicles (peau d’orange) 4.</td><td>Lines of cells = Lobular. Poor prognosis (50% survival at 5 years). Often mistaken for mastitis or Paget disease. Usually lacks palpable</td></tr></table>
======================================
<table><thead><th>TYPE</th><th>CHARACTERISTICS</th></thead><tr><td colspan="2">Germ cell tumors</td></tr><tr><td>Seminoma</td><td>Malignant. Painless, homogenous testicular enlargement. Most common testicular tumor. Analogous watery cytoplasm and “fried egg” appearance on histology, t placental alkaline phosphatase LAP). Highly radiosensitive. Late metastasis, excellent prognosis. (P. to ovarian dysgerminoma. Does not occur in infancy. Large cells in lobules with</td></tr><tr><td>Embryonal carcinoma</td><td>Ma “P. ignant. ainful, hemorrhagic mass with necrosis. Often glandular/papillary morphology. ure” embryonal carcinoma is rare; most commonly mixed with other tumor types. May present with metastases. May be associated with t hCG and normal AFP levels when pure (t AFP when mixed). Worse prognosis than seminoma.</td></tr><tr><td>Teratoma</td><td>Mai ure teral oma may be malignant in adult males. Benign in children and females.</td></tr><tr><td>Yolk sac tumor</td><td>Also called endodermal sinus tumor. Malignant, aggressive. Yellow, mucinous. Analogous to ovarian yo! ch aracteris k sac tumor. Schiller-Duval bodies resemble primitive glomeruli. t AFP is highly tic. Most common testicular tumor in children &lt; 3 years old.</td></tr><tr><td>Choriocarcinoma</td><td>Malignant. Disordered syncytiotrophoblastic and cytotrophoblastic elements. Hematogenous metastases to lungs and brain. t hCG. May produce gynecomastia, symptoms of hyperthyroidism (B subunit of hCG is similar to B subunit of TSH).</td></tr><tr><td colspan="2">Non-germ cell tumors</td></tr><tr><td>Leydig cell tumor</td><td>Mostly benign. Golden brown color; contains Reinke crystals (eosinophilic cytoplasmic inclusions) Produces androgens or estrogens &gt; precocious puberty, gynecomastia.</td></tr><tr><td>Sertoli cell tumor</td><td>Also called androblastoma (arises from sex cord stroma). Mostly benign.</td></tr><tr><td>Primary testicular lymphoma</td><td>Malignant, aggressive. ‘Typically diffuse large B-cell lymphoma. Often bilateral. Most common testicular cancer in males &gt; 60 years old.</td></tr></table>
======================================
<table><tr><td>PLAP</td><td>t</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>AFP</td><td>-</td><td>tt</td><td>-</td><td>-/t</td><td>-/t (when mixed)</td></tr><tr><td>B-hCG</td><td>-/t</td><td>-/t</td><td>tt</td><td>-</td><td>t</td></tr></table>
======================================
<table><thead><th>therapy</th><th>osteoporosis (t estrogen, + osteoclast activity). Unopposed estrogen replacement therapy ¢ risk of endometrial cancer, progesterone/progestin is added. Possible increased cardiovascular risk.</th></thead><tr><td colspan="2">Progestins Levonorgestrel, medroxyprogesterone, etonogestrel, norethindrone, megestrol.</td></tr><tr><td>MECHANISM</td><td>Bind progesterone receptors, + growth and t vascularization of endometrium, thicken cervical mucus.</td></tr><tr><td>CLINICAL USE</td><td>Contraception (forms include pill, intrauterine device, implant, depot injection), endometrial cancer, abnormal uterine bleeding. Progestin challenge: presence of bleeding upon withdrawal of progestins excludes anatomic defects (eg, Asherman syndrome) and chronic anovulation without estrogen.</td></tr><tr><td>Antiprogestins</td><td>Mifepristone, ulipristal.</td></tr><tr><td>MECHANISM</td><td>Competitive inhibitors of progestins at progesterone receptors.</td></tr><tr><td>CLINICAL USE</td><td>Termination of pregnancy (mifepristone with misoprostol); emergency contraception (ulipristal).</td></tr><tr><td></td><td>Progestins also inhibit endometrial proliferation + endometrium is less suitable to the implantation of an embryo. Adverse effects: breakthrough menstrual bleeding, breast tenderness, VTE, hepatic adenomas. Contraindications: people &gt; 35 years old who smoke tobacco (t risk of cardiovascular events), patients with t risk of cardiovascular disease (including history of venous thromboembolism, coronary artery disease, stroke), migraine (especially with aura), breast cancer, liver disease.</td></tr><tr><td colspan="2">Copper intrauterine device</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Synthetic androgen that acts as partial agonist at androgen receptors.</td></tr><tr><td>CLINICAL USE</td><td>Endometriosis, hereditary angioedema.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Weight gain, edema, acne, hirsutism, masculinization, | HDL levels, hepatotoxicity, idiopathic</td></tr></table>
======================================
<table><tr><td>MECHANISM</td><td>Agonists at androgen receptors.</td></tr><tr><td>CLINICAL USE</td><td>Treat hypogonadism and promote development of 2° sex characteristics.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Virilization in females; testicular atrophy in males. Premature closure of epiphyseal plates. t LDL, + HDL.</td></tr></table>
======================================
<table><thead><th>DRUG</th><th>MECHANISM</th><th>CLINICAL USE</th><th>ADVERSE EFFECTS</th></thead><tr><td>Abiraterone</td><td>17a-hydroxylase/17,20-lyase inhibitor (+ steroid synthesis)</td><td>rostate cancer</td><td>Hypertension, hypokalemia (t mineralocorticoids)</td></tr><tr><td>Finasteride</td><td>5a-reductase inhibitor (+ conversion of testosterone to DHT)</td><td>BPH, male-pattern baldness</td><td>Gynecomastia, sexual dysfunction</td></tr><tr><td>Flutamide, bicalutamide</td><td>Nonsteroidal competitive inhibitors at androgen receptor (+ steroid binding)</td><td>rostate cancer</td><td>Gynecomastia, sexual dysfunction</td></tr><tr><td>Ketoconazole</td><td>17a-hydroxylase/17,20-lyase inhibitor</td><td>rostate cancer</td><td>Gynecomastia</td></tr><tr><td>Spironolactone</td><td>Androgen receptor and 17a-hydroxylase/17,20-lyase</td><td>COS</td><td>Amenorrhea</td></tr></table>
======================================
<table><tr><td>Pulmonary hypoplasia</td><td colspan="2">Poorly developed bronchial tree with abnormal histology. Associated with congenital diaphragmatic hernia (usually left-sided), bilateral renal agenesis (Potter sequence).</td></tr><tr><td>Bronchogenic cysts</td><td colspan="2">Caused by abnormal budding of the foregut and dilation of terminal or large bronchi. Discrete, round, sharply defined, fluid-filled densities on CXR (air-filled if infected). Generally asymptomatic but can drain poorly + airway compression, recurrent respiratory infections.</td></tr><tr><td>Club cells</td><td colspan="2">Nonciliated; low columnar/cuboidal with secretory granules. Located in bronchioles. Degrade toxins via cytochrome P-450; secrete component of surfactant; progenitor cells for club and ciliated cells.</td></tr><tr><td colspan="3">Alveolar cell types</td></tr><tr><td>Type Il pneumocytes</td><td>Cuboidal and clustered F. 2 functions: 1. Serve as stem cell precursors for 2 cell types (type I and type II pneumocytes); proliferate during 2. Secrete surfactant (arrowheads in fF). Application of Law of La ung damage. from lamellar bodies place in alveoli—alveoli</td><td>fluid, phagocytes, and bacteria (in pneumonia). Surfactant—} alveolar surface tension, $ alveolar co. lapse, + lung recoil, and t compliance. Composed of multiple lecithins, mainly dipalmitoylphosphatidylcholine (DPPC). Syi ac G nthesis begins ~20 weeks of gestation and hieves mature levels ~35 weeks of gestation. ucocorticoids important for fetal surfactant</td></tr><tr><td>Alveolar macrophages</td><td>have t tendency to col radius 4. apse on expiration as Phagocytose foreign mal aterials; release cytokines</td><td>synthesis and lung development. Co! lapsing pressure = 2 (surface tension)/radius Hemosiderin-laden macrophages may be found</td></tr></table>
======================================
<table><thead><th rowspan="2">Tidal volume Inspiratory reserve</th><th rowspan="2">Air that moves into lung with each quiet inspiration, 6-8 mL/kg, typically ~500 mL. Air that can still be breathed in after normal</th><th colspan="3">Lung volumes (LITER)</th><th colspan="4">Lung capacities</th></thead><thead><th></th><th></th><th colspan="3" rowspan="2"></th><th rowspan="2">6.0 Volume</th><th rowspan="2">.</th><th rowspan="2"></th><th></th></thead><tr><td>volume Expiratory reserve</td><td>inspiration Air that can still be breathed out after normal</td><td colspan="3"></td><td></td><td></td><td></td><td rowspan="6">capacity 15]</td></tr><tr><td>volume</td><td>expiration</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Residual volume</td><td>Air in lung after maximal expiration; RV and any lung capacity that includes RV cannot be measured by spirometry</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Inspiratory capacity</td><td>IRV + Vr Air that can be breathed in after normal</td><td>IRV =</td><td>reserve</td><td>volume</td><td>IC =</td><td></td><td></td><td></td></tr><tr><td></td><td>exhalation</td><td>Vr = tidal</td><td>inspiratory volume</td><td></td><td>inspiratory FRC = functional</td><td>capacity</td><td>residual</td><td></td></tr><tr><td>Functional residual capacity</td><td>RV + ERV Volume of gas in lungs after normal expiration; outward pulling force of chest wall is balanced with inward collapsing force of lungs</td><td>ERV = RV = residual</td><td>expiratory reserve volume</td><td>volume</td><td>VC = vital TLC = total lung</td><td>capacity capacity</td><td></td><td></td></tr><tr><td>Vital capacity</td><td>IRV + Vr + ERV Maximum volume of gas that can be expired after a maximal inspiration</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Total lung capacity</td><td>IRV + Vr+ERV + RV = VC + RV Volume of gas present in lungs after a maximal inspiration</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>Jetermination of »yhysiologic dead</th><th>Vp =Vr x</th><th>Paco, — Peco, Paco,</th></thead><tr><td rowspan="5">pace</td><td>Vp = physiologic</td><td>dead space = anatomic dead</td></tr><tr><td></td><td>space of</td><td>conducting airways plus alveolar dead</td></tr><tr><td></td><td>space; apex</td><td>of healthy lung is largest contributo</td></tr><tr><td></td><td>of alveolar</td><td>dead space. Vp = volume of inspirec</td></tr><tr><td></td><td>air that does</td><td>not take part in gas exchange.</td></tr></table>
======================================
<table><tr><td>Ventilation</td><td></td><td></td><td></td></tr><tr><td>Minute ventilation</td><td>Abbreviated as Vr. Total volume of gas entering — lungs per minute. Ve=Vrx RR</td><td>= ®</td><td>Normal values: RR= 12-20 Vr = 500m</td></tr><tr><td>Alveolar ventilation</td><td>Abbreviated as Va. Volume of gas that reaches alveoli each minute. Va = (Vr—Vb) x RR</td><td>*</td><td>Vo = 150m</td></tr><tr><td>Lung and chest wall properties</td><td>Because of historical reasons and small pressures, pulmonary pressures are always presented in cm H,O.</td><td></td><td>Lung volume</td></tr><tr><td rowspan="2">Elastic recoil</td><td>Tendency for lungs to collapse inward and chest wall to spring outward. At FRC, airway and alveolar pressures equal . atmospheric pressure (PB; called zero), and is</td><td></td><td>Alveolar pressure (cmH,0)</td></tr><tr><td></td><td>intrapleural pressure negative (preventing atelectasis). ‘The inward pull of the lung is balanced by the outward pull of the chest wall. System pressure is atmospheric. Pulmonary vascular resistance (PVR) is ata minimum.</td><td></td><td>Inrapleur pressure (cmH,0 -———r</td></tr><tr><td>Compliance</td><td>Change in lung volume for a change in pressure (AV/AP). Inversely proportional to wall stiffness and increased by surfactant. * t compliance = lung easier to fill (eg, emphysema, older adults) Fs * 4 compliance = lung more difficult to fill 3 (eg, pulmonary fibrosis, pneumonia, ARDS, pulmonary edema)</td><td>ab 2</td><td>éLnc [fr a</td></tr><tr><td>Hysteresis</td><td>Lung inflation follows a different pressure- volume curve than lung deflation due to need to overcome surface tension forces in inflation.</td><td>o</td><td>4</td></tr></table>
======================================
<table><thead><th></th><th>Hb CONCENTRATION</th><th>Sao.</th><th>Pao.</th><th>TOTAL 0, CONTENT</th></thead><tr><td>CO poisoning</td><td>Normal</td><td>+ (CO competes with O,)</td><td>Normal</td><td>4</td></tr><tr><td>Anemia</td><td>t</td><td>Normal</td><td>Normal</td><td>1</td></tr><tr><td>Polycythemia</td><td>t</td><td>Normal</td><td>Normal</td><td>t</td></tr><tr><td>Methemoglobinemia</td><td>Normal</td><td>4 (Fe** poor at binding O,)</td><td>~~ Normal</td><td>1</td></tr><tr><td>Cyanide toxicity</td><td>Normal</td><td>Normal</td><td>Normal</td><td>Normal</td></tr></table>
======================================
<table><thead><th></th><th>Cyanide</th><th>Carbon monoxide</th></thead><tr><td>EXPOSURE</td><td>Synthetic product combustion, amygdalin ingestion (found in apricot seeds), cyanide ingestion (eg, in suicide attempts), fire victims.</td><td>Motor exhaust, gas heaters, fire victims.</td></tr><tr><td>PRESENTATION</td><td>Headache, dyspnea, drowsiness, seizure, coma. Skin may appear flushed (“cherry red”). Venules in retina appear bright red. Breath may have bitter almond odor.</td><td>Headache, vomiting, confusion, visual disturbances, coma. May have cherry-red skin with bullous skin lesions. Multiple victims may be involved (eg, family due to faulty furnace).</td></tr><tr><td></td><td>Normal Pao,. Elevated lactate + anion gap metabolic acidosis.</td><td>Normal Pao,. Elevated carboxyhemoglobin on co-oximetry. Classically associated with bilateral globus pallidus lesions on MRI ff, although can rarely be seen with cyanide toxicity.</td></tr><tr><td>EFFECT ON OXYGEN-HEMOGLOBIN CURVE</td><td>Curve normal. Oxygen saturation may appear normal initially. Despite ample O, supply, it be used due ineffective oxidative</td><td>Left shift in ODC = t affinity for O, + 4 O, unloading in tissues. Binds competitively Hb with 200x</td></tr><tr><td rowspan="2">TREATMENT</td><td>phosphorylation. Decontamination (eg, remove clothing). Hydroxocobalamin (binds cyanide =&gt; cyanocobalamin &gt; renal excretion). Nitrites (oxidize Hb + methemoglobin &gt; binds cyanide cyanomethemoglobin } toxicity).</td><td>affinity than O, to form carboxyhemoglobin &gt; 4%O, saturation of Hb. 100% ©,. Hyperbaric oxygen if severe.</td></tr><tr><td></td><td>Sodium thiosulfate (t cyanide conversion to thiocyanate &gt; renal excretion). 20 mL)</td><td>Normal (100% Hb)</td></tr></table>
======================================
<table><tr><td>Obstructive lung diseases</td><td>Obstruction of air flow (14 FEV,, 4} FVC $ FEV,/FVC ratio) + air trapping in lungs (t RV, +t FRC and t TLC) due to premature airway closure at high lung volumes. Includes COPD (chronic bronchitis and emphysema), asthma, and bronchiectasis.</td></tr><tr><td>Chronic obstructive pulmonary disease</td><td>Often due to tobacco use (most important risk factor), pollutants, or allergens. Includes chronic bronchitis and emphysema, which often co-exist. Exacerbation: acute worsening of symptoms, often associated with viral or bacterial upper respiratory tract infection.</td></tr><tr><td colspan="2">Chronic bronchitis</td></tr><tr><td>DIAGNOSIS</td><td>Clinical diagnosis. Criteria: productive cough for 2 3 months in a year for &gt; 2 consecutive years. May also have dyspnea, wheezes, crackles (due to mucus), cyanosis (hypoxemia due to shunting), 2° polycythemia. Leads to metaplasia of pseudostratified ciliated columnar epithelium into stratified squamous epithelium.</td></tr><tr><td>MECHANISMS</td><td>Hypertrophy and hyperplasia of mucus-secreting glands in bronchi.</td></tr><tr><td>NOTES</td><td>t Reid index (thickness of mucosal gland layer to thickness of wall between epithelium and cartilage) &gt; 50%.</td></tr><tr><td colspan="2">Emphysema</td></tr><tr><td>DIAGNOSIS</td><td>Radiologic or biopsy diagnosis. CXR: barrel chest, t AP diameter (best seen in lateral [i§), flattened diaphragm, t lung field lucency.</td></tr><tr><td>MECHANISMS</td><td>Alveolar wall destruction [J + t compliance of lung, 4 recoil, and damage to alveolar capillary membrane &gt; 4 DLCO; results in f air space. Centriacinar—spares distal alveoli, frequently in upper lobes. Associated with tobacco smoking [] 2). Panacinar—affects respiratory bronchioles and alveoli, frequently in lower lobes. Associated with o,-antitrypsin deficiency.</td></tr></table>
======================================
<table><tr><td>NOTES</td><td>Mediated by oxidative stress, chronic inflammation (CD8+ T cells, neutrophils, and macrophages), and imbalance of proteases and antiproteases (t elastase activity + t loss of elastic fibers &gt; alveolar destruction). Defect/deficiency/absence of o,-antitrypsin (antiprotease that inhibits neutrophil elastase( leads to unopposed elastase activity</td></tr><tr><td>Asthma</td><td>Intermittent obstructive lung disease often triggered by allergens, viral URIs, stress. Associated with atopy. NSAID- or aspirin-exacerbated respiratory disease—asthma, nasal polyps, and COX-inhibitor sensitivity (leukotriene overproduction —&gt; airway constriction) (Samter’s triad).</td></tr><tr><td>DIAGNOSIS</td><td>Clinical diagnosis. Intermittent episodes of dyspnea, coughing, wheezing, tachypnea. Diagnosis supported by spirometry (obstructive pattern with bronchodilator response, but may be normal when not in exacerbation) +/— methacholine challenge.</td></tr><tr><td>MECHANISMS</td><td>Type I hypersensitivity reaction + smooth muscle hypertrophy and hyperplasia. Hyperresponsive bronchi + reversible bronchoconstriction. Mucus plugging [3</td></tr><tr><td>OTHER</td><td>Curschmann spirals [§]—shed epithelium forms whorled mucus plugs. Charcot-Leyden crystals {S—eosinophilic, hexagonal, double-pointed crystals formed from breakdown of eosinophils in sputum.</td></tr><tr><td>Bronchiectasis</td><td>Obstructive lung disease. Most commonly associated with cystic fibrosis.</td></tr><tr><td>DIAGNOSIS</td><td>Characterized by chronic cough and daily purulent sputum production. Often have recurrent pulmonary infections. Confirmed by imaging demonstrating airway dilation and bronchial thickening. Supported by obstructive PF'T pattern.</td></tr><tr><td>PATHOPHYSIOLOGY</td><td>Initial insult of pulmonary infection combined with obstruction or impaired clearance — dysregulated host response + bronchial inflammation + permanently dilated airways.</td></tr><tr><td>NOTES</td><td>Many etiologies, including airway obstruction (eg, foreign body aspiration, mass), poor ciliary motility (eg, tobacco smoking, Kartagener syndrome), cystic fibrosis ([] shows a coughed up inspissated mucus me allergic bronchopulmonary aspergillosis, pulmonary infections (eg, Mycobacterium avium). Al i</td></tr></table>
======================================
<table><tr><td>Asbestos-related disease</td><td>Asbestos causes asbestosis (pulmonary fibrosis), pleural disease, malignancies. Associated with shipbuilding, roofing, plumbing. “Ivory white,” calcified, supradiaphragmatic and pleural [J plaques are pathognomonic. Risk of bronchogenic carcinoma &gt; risk of mesothelioma. tf risk of Caplan syndrome (rheumatoid arthritis and pneumoconioses</td><td>Affects lower lobes. Asbestos (ferruginous) bodies are golden-brown fusiform rods resembling dumbbells, found in alveolar sputum sample, visualized using Prussian blue stain [, often obtained by bronchoalveolar lavage. t risk of pleural effusions.</td></tr><tr><td>Berylliosis</td><td>with intrapulmonary nodules). Associated with exposure to beryllium in aerospace and manufacturing industries. Granulomatous (noncaseating) [§ on histology and therefore occasionally responsive to glucocorticoids. t risk of cancer and cor pulmonale.</td><td>Affects upper lobes.</td></tr><tr><td>Coal workers’ pneumoconiosis</td><td>Prolonged coal dust exposure + macrophages laden with carbon &gt; inflammation and fibrosis. Also called black lung disease. t risk of Caplan syndrome.</td><td>Affects upper lobes. Small, rounded nodular opacities seen on imaging. Anthracosis—asymptomatic condition found in many urban dwellers exposed to sooty air.</td></tr><tr><td>Silicosis</td><td>Associated with sandblasting, foundries, mines. Macrophages respond to silica and release fibrogenic factors, leading to fibrosis. It is thought that silica may disrupt phagolysosomes and impair macrophages, increasing susceptibility to TB. t risk of cancer, cor pulmonale, and Caplan syndrome.</td><td>Affects upper lobes. “Eggshell” calcification of hilar lymph nodes on CXR. The silly egg sandwich I found is mine!</td></tr></table>
======================================
<table><thead><th>Pulmonary hypertension</th><th>hypertrophy, intimal fibrosis of pulmonary arteries, plexiform lesions. t pulmonary vascular resistance + t RV pressure + RVH (parasternal heave on examination), RV failure.</th></thead><tr><td colspan="2">ETIOLOGIES</td></tr><tr><td>hypertension (group 1)</td><td>in BMPR2 gene (normally inhibits vascular smooth muscle proliferation); poor prognosis. Pulmonary vasculature endothelial dysfunction results in t vasoconstrictors (eg, endothelin) and 4 vasodilator: Other causes include drugs (eg, amphetamines, cocain portal hyper! s (eg, NO and prostacyclins). ension, congenital heart disease, schistos e), connective tissue disease, HIV infection, omiasis.</td></tr><tr><td>Left heart disease (group 2)</td><td>Causes includ e systolic/diastolic dysfunction and valvu ar disease.</td></tr><tr><td>Lung diseases or hypoxia (group 3)</td><td>Destruction o' diseases), hy f lung parenchyma (eg, COPD), lung infl poxemic vasoconstriction (eg, obstructive ammation/fibrosis (eg, interstitial lung sleep apnea, living in high altitude).</td></tr><tr><td>Chronic thromboembolic (group 4)</td><td>Recurrent microthrombi &gt; $ cross-sectional area of pu monary vascular bed.</td></tr><tr><td>Multifactorial (group 5)</td><td>Causes includ pulmonary vasculature by a tumor. e hematologic, systemic, and metabolic disorders, along with compression of the</td></tr></table>
======================================
<table><thead><th>ABNORMALITY</th><th>BREATH SOUNDS</th><th>PERCUSSION</th><th>FREMITUS</th><th>TRACHEAL DEVIATION</th></thead><tr><td>Pleural effusion</td><td>t</td><td>Dull</td><td>t</td><td>if small Away from side of lesion if large</td></tr><tr><td>Atelectasis</td><td>4</td><td>Dull</td><td>4</td><td>Toward side of lesion</td></tr><tr><td>Simple pneumothorax</td><td>+</td><td>Hyperresonant</td><td>+</td><td></td></tr><tr><td>Tension pneumothorax</td><td>+</td><td>Hyperresonant</td><td>+</td><td>Away from side of lesion</td></tr><tr><td>Consolidation (lobar pneumonia, pulmonary edema)</td><td>Bronchial breath sounds; late inspiratory crackles, egophony, whispered pectoriloquy</td><td>— Dull</td><td>t</td><td></td></tr></table>
======================================
<table><tr><td>Primary spontaneous pneumothorax</td><td>Due to rupture of apical subpleural bleb or cysts. Occurs most frequently in tall, thin, young males. Associated with tobacco smoking.</td></tr><tr><td>Secondary spontaneous pneumothorax</td><td>Due to diseased lung (eg, bullae in emphysema, Marfan syndrome, infections), mechanical ventilation with use of high pressures + barotrauma.</td></tr><tr><td>Traumatic pneumothorax</td><td>Caused by blunt (eg, rib fracture), penetrating (eg, gunshot), or iatrogenic (eg, central line placement, lung biopsy, barotrauma due to mechanical ventilation) trauma.</td></tr></table>
======================================
<table><tr><td>Bronchopneumonia</td><td>S pneumoniae, S aureus, H influenzae, Klebsiella</td><td>Acute inflammatory infiltrates from bronchioles into adjacent alveoli; patchy distribution involving = | lobe.</td></tr><tr><td>Interstitial (atypical) pneumonia</td><td>Mycoplasma, Chlamydophila pneumoniae, Chlamydophila psittaci, Legionella, Coxiella burnetii, viruses (RSV, CMV, influenza, adenovirus)</td><td>Diffuse patchy inflammation localized to interstitial areas at alveolar walls; CXR shows bilateral multifocal opacities [J]. Generally follows a more indolent course (“walking” pneumonia).</td></tr><tr><td>Cryptogenic organizing pneumonia</td><td>Etiology unknown. © sputum and blood cultures, often responds to glucocorticoids but not to antibiotics.</td><td>Formerly called bronchiolitis obliterans organizing pneumonia (BOOP). Noninfectious pneumonia characterized by inflammation of bronchioles and surrounding structure.</td></tr><tr><td>Aspiration pneumonia</td><td>Aspiration of oropharyngeal or gastric contents &gt; pulmonary infection. Risk factors: altered mental status (+ cough reflex or glottic closure), dysphagia, neurologic disorders (eg, stroke), invasive tubes (eg, nasogastric tube).</td><td>Presents days after aspiration event in dependent lung segment. More common in RLL if sitting up and RUL if lying down due to bronchial anatomy. Can progress to abscess. Aspiration (chemical) pneumonitis—presents hours after aspiration event. Due to gastric acid— mediated inflammation. Presents with infiltrates</td></tr></table>
======================================
<table><thead><th rowspan="2">TYPE</th><th colspan="2">neoplasms. Most often from breast, colon, prostate, and bladder cancer.</th><th colspan="2">smoking. Hamartomas are found incidentally on imaging, appearing as well-circumscribed mass.</th></thead><thead><th></th><th>LOCATION</th><th>CHARACTERISTICS</th><th></th><th>HISTOLOGY</th></thead><tr><td colspan="5">Small cell</td></tr><tr><td>Small cell (oat cell) carcinoma</td><td>© Central</td><td>Undifferentiated + very May cause neurologic Lambert-Eaton myasthenic myelitis, encephalitis, and endocrine paraneoplastic syndrome, SIADH). common. Managed with</td><td>aggressive. paraneoplastic syndromes (eg, syndrome, paraneoplastic subacute cerebellar degeneration) syndromes (Cushing Amplification of mye oncogenes chemotherapy +/— radiation.</td><td>Neoplasm of neuroendocrine Kulchitsky cells &gt; small _—_ dark blue cells [iV. Chromogranin A ®, neuron-specific enolase @, synaptophysin ©.</td></tr><tr><td>Non-small cell</td><td></td><td></td><td></td><td></td></tr><tr><td>Adenocarcinoma</td><td>Peripheral</td><td>Most common 1° lung cancer. in people who do not smoke. than males. Activating and ALK. Associated with (clubbing). Bronchioloalveolar subtype CXR often shows hazy better prognosis.</td><td>Most common subtype More common in females mutations include KRAS, EGFR, hypertrophic osteoarthropathy (adenocarcinoma in situ): infiltrates similar to pneumonia;</td><td>Glandular pattern, often stains mucin @ EJ. Bronchioloalveolar subtype: grows along alveolar septa &gt; apparent “thickening” of alveolar walls. Tall, columnar cells containing mucus.</td></tr><tr><td>Squamous cell carcinoma</td><td>Central</td><td>Hilar mass [@ arising from hypercalcemia (produces</td><td>bronchus; cavitation; cigarettes; PTHrP).</td><td>Keratin pearls [) and intercellular bridges (desmosomes).</td></tr><tr><td>Large cell carcinoma</td><td>Peripheral</td><td>Highly anaplastic undifferentiated association with tobacco &gt; gynecomastia (enlarged chemotherapy; removed</td><td>tumor. Strong smoking. May produce hCG breasts). Less responsive to surgically. Poor prognosis.</td><td>Pleomorphic giant cells</td></tr><tr><td>Bronchial carcinoid tumor</td><td>= Central or peripheral</td><td>Excellent prognosis; metastasis effect (wheezing) or carcinoid</td><td>rare. Symptoms. due to mass syndrome (flushing, diarrhea).</td><td>Nests of neuroendocrine cells; chromogranin A ©.</td></tr></table>
======================================
<table><tr><td>H,-blockers</td><td>Also called antihistamines. Reversible inhibitors antagonists or inverse agonists.</td><td>of H, histamine receptors. May function as neutral</td></tr><tr><td>First generation</td><td>Diphenhydramine, dimenhydrinate, chlorpheniramine, doxylamine.</td><td>Names usually contain “-en/-ine” or “-en/ate.”</td></tr><tr><td>CLINICAL USE</td><td>Allergy, motion sickness, vomiting in pregnancy, sleep aid.</td><td></td></tr><tr><td>ADVERSE EFFECTS</td><td>Sedation, antimuscarinic, anti-o-adrenergic.</td><td></td></tr><tr><td>Second generation</td><td>Loratadine, fexofenadine, desloratadine, cetirizine.</td><td>Names usually end in “-adine.” Setirizine (cetirizine) is second-generation agent.</td></tr><tr><td>CLINICAL USE</td><td>Allergy.</td><td></td></tr><tr><td>ADVERSE EFFECTS</td><td>Far less sedating than Ist generation because of</td><td></td></tr></table>
======================================
<table><tr><td>CLINICAL USE</td><td>Reduce hyperemia, edema (used as nasal decongestants); open obstructed eustachian tubes.</td></tr><tr><td>ADVERSE EFFECTS</td><td>Hypertension. Rebound congestion (rhinitis medicamentosa) if used more than 4-6 days. Associated with tachyphylaxis. Can also cause CNS stimulation/anxiety (pseudoephedrine)</td></tr></table>
======================================
<table><thead><th>DRUG</th><th>MECHANISM</th><th>CLINICAL NOTES</th></thead><tr><td>Endothelin receptor antagonists</td><td>Competitively antagonizes endothelin-1 receptors + $ pulmonary vascular resistance.</td><td>Hepatotoxic (monitor LF'Ts). Example: bosentan.</td></tr><tr><td>PDE-5 inhibitors</td><td>Inhibits PDE-5 + t cGMP = prolonged vasodilatory effect of NO.</td><td>Also used to treat erectile dysfunction. Contraindicated when taking nitroglycerin or other nitrates (due to risk of severe hypotension). Example: sildenafil.</td></tr><tr><td>Prostacyclin analogs</td><td>PGL, (prostacyclin) with direct vasodilatory effects on pulmonary and systemic arterial</td><td>Adverse effects: flushing, jaw pain. Examples: epoprostenol, iloprost.</td></tr></table>
======================================
<table><tr><td>Inhaled B,-agonists</td><td>Albuterol, salmeterol, formoterol—relax bronchial smooth muscle. Can cause tremor, arrhythmia. Albuterol is short-acting, used for acute symptoms. Salmeterol and formoterol are ong-acting.</td></tr><tr><td>Inhaled glucocorticoids</td><td>Fluticasone, budesonide—inhibit the synthesis of virtually all cytokines. Inactivate NF-«B, the ranscription factor that induces production of TNF-o and other inflammatory agents. Ist-line herapy for chronic asthma. Use a spacer or rinse mouth after use to prevent oral thrush.</td></tr><tr><td>Muscarinic antagonists</td><td>Tiotropium, ipratropium—competitively block muscarinic receptors, preventing bronchoconstriction. Also used for COPD. Tiotropium is long acting.</td></tr><tr><td>Antileukotrienes</td><td>Montelukast, zafirlukast—block leukotriene receptors (CysLT'l). Especially good for aspirin- induced and exercise-induced asthma. Zileuton—5-lipoxygenase inhibitor. | conversion of arachidonic acid to leukotrienes. Hepatotoxic.</td></tr><tr><td>Anti-IgE monoclonal therapy</td><td>Omalizumab—binds mostly unbound serum IgE and blocks binding to FceRI. Used in allergic asthma with t IgE levels resistant to inhaled glucocorticoids and long-acting B,-agonists.</td></tr><tr><td>Methylxanthines</td><td>Theophylline—likely causes bronchodilation by inhibiting phosphodiesterase + t cAMP levels due to } cAMP hydrolysis. Limited use due to narrow therapeutic index (cardiotoxicity, neurotoxicity); metabolized by cytochrome P-450. Blocks actions of adenosine.</td></tr><tr><td>PDE-4 Inhibitors</td><td>Roflumilast—inhibits phosphodiesterase + t cAMP &gt; bronchodilation, $ airway inflammation. Used in COPD to reduce exacerbations.</td></tr><tr><td>Chromones</td><td>Cromolyn—prevents mast cell degranulation. Prevents acute asthma symptoms. Rarely used.</td></tr><tr><td>Anti-IL-5 monoclonal therapy</td><td>Prevents eosinophil differentiation, maturation, activation, and survival mediated by IL-5 stimulation. For maintenance therapy in severe eosinophilic asthma. Mepolizumab, reslizumab—against IL-5. Benralizumab—against IL-5 receptor &amp;. Avoidance —S)— Exposure to allergen</td></tr></table><table>
  <tr>
    <td>Pathophysiology Important</td>
    <td></td>
    <td>of Diseases 710</td>
  </tr>
  <tr>
    <td>Classic</td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td>Presentations</td>
    <td></td>
    <td>722</td>
  </tr>
  <tr>
    <td>Findings</td>
    <td></td>
    <td>728</td>
  </tr>
  <tr>
    <td>Key</td>
    <td>Associations</td>
    <td>732</td>
  </tr>
  <tr>
    <td>Equation</td>
    <td></td>
    <td>Review 737</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>B-thalassemia</th>
    <th>
      Mutation at splice site or promoter sequences &gt; retained intron in mRNA
    </th>
    <th>38, 425</th>
  </thead>
  <tr>
    <td>Lynch syndrome</td>
    <td>
      Failure of mismatch repair during the S phase &gt; microsatellite
      instability
    </td>
    <td>37, 395</td>
  </tr>
  <tr>
    <td>I-cell disease</td>
    <td>
      N-acetylglucosaminyl-1-phosphotransferase defect + Golgi mediated mannose
      residues phosphorylation failure (} mannose-6-phosphate) &gt; t cellular
      debris in lysosomes
    </td>
    <td>45</td>
  </tr>
  <tr>
    <td>Osteogenesis imperfecta</td>
    <td>‘Type 1 collagen defect due to inability to form triple helices</td>
    <td>49</td>
  </tr>
  <tr>
    <td>Menkes disease</td>
    <td>
      Defective ATP7A protein &gt; impaired copper absorption and transport &gt;
      4 lysyl oxidase activity + 4 collagen cross-linking
    </td>
    <td>49</td>
  </tr>
  <tr>
    <td>Marfan syndrome</td>
    <td>
      FBNI mutation on chromosome 15 &gt; defective fibrillin (normally forms
      sheath around elastin)
    </td>
    <td>50</td>
  </tr>
  <tr>
    <td>Prader-Willi syndrome</td>
    <td>
      Uniparental disomy or imprinting leading to silencing of maternal gene.
      Disease expressed when paternal allele deleted or mutated
    </td>
    <td>56</td>
  </tr>
  <tr>
    <td>Angelman syndrome fibrosis</td>
    <td>
      Silenced gene leading to mutation, lack of expression, or deletion of
      UBE3A on maternal chromosome 15 Autosomal recessive AF'508 deletion in
      CFTR chromosome 7
    </td>
    <td>56 58</td>
  </tr>
  <tr>
    <td>Cystic</td>
    <td>
      gene on — impaired ATP-gated Cl channel (secretes Cl in lungs and GI tract
      and reabsorbs Cl- in sweat glands)
    </td>
    <td></td>
  </tr>
  <tr>
    <td>Duchenne muscular dystrophy</td>
    <td>
      Dystrophin gene frameshift mutations &gt; loss of anchoring protein to ECM
      (dystrophin) + myonecrosis
    </td>
    <td>59</td>
  </tr>
  <tr>
    <td>Myotonic dystrophy</td>
    <td>
      CTG trinucleotide repeat expansion in DMPK gene &gt; abnormal expression
      of myotonin protein kinase &gt; myotonia
    </td>
    <td>59</td>
  </tr>
  <tr>
    <td>Fragile X syndrome</td>
    <td>
      Trinucleotide repeat in FMRI gene &gt; hypermethylation &gt; $ expression
    </td>
    <td>60</td>
  </tr>
  <tr>
    <td>Bitot spots in vitamin A deficiency</td>
    <td>
      4 differentiation of epithelial cells into specialized tissue &gt;
      squamous metaplasia
    </td>
    <td>64</td>
  </tr>
  <tr>
    <td>Wernicke encephalopathy in alcoholic patient given glucose</td>
    <td>
      Thiamine deficiency &gt; impaired glucose breakdown &gt; ATP depletion
      worsened by glucose infusion
    </td>
    <td>64</td>
  </tr>
  <tr>
    <td>Pellagra in malignant carcinoid syndrome</td>
    <td>
      ‘Tryptophan is diverted towards serotonin synthesis + B, deficiency (B, is
      derived from tryptophan)
    </td>
    <td>65</td>
  </tr>
  <tr>
    <td>Kwashiorkor</td>
    <td>
      Protein malnutrition + 4 oncotic pressure (+ edema), $ apolipoprotein
      synthesis (— liver fatty change)
    </td>
    <td>69</td>
  </tr>
  <tr>
    <td>
      Lactic acidosis, fasting hypoglycemia, hepatic steatosis in alcoholism
    </td>
    <td>t NADH/NAD* ratio due to ethanol metabolism</td>
    <td>70</td>
  </tr>
  <tr>
    <td>Aspirin-induced hyperthermia</td>
    <td>
      t permeability of mitochondrial membrane &gt; 4 proton [H*] gradient and t
      O, consumption &gt; uncoupling
    </td>
    <td>76</td>
  </tr>
  <tr>
    <td>Hereditary fructose intolerance</td>
    <td>
      Aldolase B deficiency + Fructose-l-phosphate accumulates &gt; $ available
      phosphate + inhibition of glycogenolysis and gluconeogenesis
    </td>
    <td>78</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>Cataracts, retinopathy, peripheral neuropathy in DM</th>
    <th>
      Lens, retina, Schwann cells lack sorbitol dehydrogenase — intracellular
      sorbitol accumulation + osmotic damage
    </th>
    <th>79</th>
  </thead>
  <tr>
    <td>Recurrent Neisseria bacteremia</td>
    <td>
      Terminal complement deficiencies (C5—C9) &gt; failure of MAC formation
    </td>
    <td>05</td>
  </tr>
  <tr>
    <td>Hereditary angioedema</td>
    <td>
      Cl esterase inhibitor deficiency + unregulated activation of kallikrein =
      t bradykinin
    </td>
    <td>05</td>
  </tr>
  <tr>
    <td>Paroxysmal nocturnal hemoglobinuria</td>
    <td>
      PIGA gene mutation + + GPI anchors for complement inhibitors (DAF/ CD55,
      MIRL/CD59) + complement-mediated intravascular hemolysis
    </td>
    <td>05</td>
  </tr>
  <tr>
    <td>Type I hypersensitivity</td>
    <td>
      Immediate (minutes): antigen cross links IgE on mast cells + degranulation
      &gt; release of histamine and tryptase Late (hours): mast cells secrete
      chemokines (attract eosinophils) and leukotrienes + inflammation, tissue
      damage
    </td>
    <td></td>
  </tr>
  <tr>
    <td>Type II hypersensitivity</td>
    <td>
      Antibodies bind to cell-surface antigens &gt; cellular destruction,
      inflammation, cellular dysfunction
    </td>
    <td></td>
  </tr>
  <tr>
    <td>Type III hypersensitivity</td>
    <td>
      Antigen-antibody complexes + activate complement — attracts neutrophils
    </td>
    <td></td>
  </tr>
  <tr>
    <td>Type IV hypersensitivity</td>
    <td>
      T cell-mediated (no antibodies involved). CD8* directly kills target
      cells, CD+4* releases cytokines
    </td>
    <td></td>
  </tr>
  <tr>
    <td>Acute hemolytic transfusion reaction</td>
    <td>
      ‘Type II hypersensitivity reaction against donor RBCs (usually ABO
      antigens)
    </td>
    <td></td>
  </tr>
  <tr>
    <td>X-linked (Bruton) agammaglobulinemia</td>
    <td>
      Defect in BTK gene (tyrosine kinase) + no B-cell maturation &gt; absent B
      cells in peripheral blood, $ Ig of all classes
    </td>
    <td>114</td>
  </tr>
  <tr>
    <td>DiGeorge syndrome</td>
    <td>
      22q1] microdeletion &gt; failure to develop 3rd and 4th branchial
      (pharyngeal) pouches
    </td>
    <td>114</td>
  </tr>
  <tr>
    <td>Hyper-IgM syndrome</td>
    <td>Defective CD40L on Th cells + class switching defect</td>
    <td>115</td>
  </tr>
  <tr>
    <td>Leukocyte adhesion deficiency (type 1)</td>
    <td>LFA-1 integrin (CD18) defect + impaired phagocyte migration and</td>
    <td>115</td>
  </tr>
  <tr>
    <td>Chédiak-Higashi syndrome</td>
    <td>
      chemotaxis LYST mutation &gt; microtubule dysfunction + phagosome-lysosome
      fusion defect
    </td>
    <td>115</td>
  </tr>
  <tr>
    <td>Chronic granulomatous disease</td>
    <td>NADPH oxidase defect + | ROS, 4 respiratory burst in neutrophils</td>
    <td>115</td>
  </tr>
  <tr>
    <td>Candida infection in immunodeficiency</td>
    <td>+ granulocytes (systemic), + 'T cells (local)</td>
    <td>116</td>
  </tr>
  <tr>
    <td>Graft-versus-host disease</td>
    <td>Type IV HSR; HLA mismatch &gt; donor T cells attack host cells</td>
    <td>17</td>
  </tr>
  <tr>
    <td>Recurrent S aureus, Serratia, B cepacia infections in CGD</td>
    <td>
      Catalase ® organisms degrade H,O, before it can be converted to
      microbicidal products by the myeloperoxidase system
    </td>
    <td></td>
  </tr>
  <tr>
    <td>Hemolytic uremic syndrome</td>
    <td>
      Shiga/Shiga-like toxins inactivate 60S ribosome &gt; t cytokine release
    </td>
    <td>30</td>
  </tr>
  <tr>
    <td>‘Tetanus</td>
    <td>
      Tetanospasmin prevents release of inhibitory neurotransmitters (GABA and
      glycine) from Renshaw cells
    </td>
    <td>30</td>
  </tr>
  <tr>
    <td>Botulism</td>
    <td>
      Toxin (protease) cleaves SNARE &gt; $ neurotransmitter (ACh) release at
      NMJ
    </td>
    <td>30</td>
  </tr>
  <tr>
    <td>Gas gangrene</td>
    <td>
      Alpha toxin (phospholipase/lecithinase) degrades phospholipids &gt;
      myonecrosis
    </td>
    <td>31</td>
  </tr>
  <tr>
    <td>Toxic shock syndrome, scarlet fever</td>
    <td>
      TSST-1 and erythrogenic exotoxin A (scarlet) cross-link B region of TCR to
      MHC class II on APCs outside of antigen binding site &gt; tt IL-1, IL-2,
    </td>
    <td>31</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>Shock and DIC by gram © bacteria</th>
    <th>
      Lipid A of LPS + macrophage activation (TLR4/CD14), complement activation,
      tissue factor activation
    </th>
    <th></th>
  </thead>
  <tr>
    <td>Prosthetic device infection by S epidermidis</td>
    <td>Biofilm production</td>
    <td></td>
  </tr>
  <tr>
    <td>Endocarditis 2° to S sanguinis</td>
    <td>
      Dextrans (biofilm) production that bind to fibrin-platelet aggregates on
      damaged heart valves
    </td>
    <td></td>
  </tr>
  <tr>
    <td>Pseudomembranous colitis 2° to C difficile</td>
    <td>Toxins A and B damage enterocytes + watery diarrhea</td>
    <td></td>
  </tr>
  <tr>
    <td>Diphtheria</td>
    <td>Exotoxin inhibits protein synthesis via ADP-ribosylation of EF-2</td>
    <td>137</td>
  </tr>
  <tr>
    <td>Virulence of M tuberculosis</td>
    <td>
      Cord factor activates macrophages (promoting granuloma formation), induces
      release of TNF-o, sulfatides (surface glycolipids) inhibit phagolysosomal
      fusion
    </td>
    <td>38</td>
  </tr>
  <tr>
    <td>Tuberculoid leprosy</td>
    <td>Thl immune response &gt; mild</td>
    <td>139</td>
  </tr>
  <tr>
    <td>No effective vaccine for N gonorrhoeae</td>
    <td>Antigenic variation of pilus proteins</td>
    <td>40</td>
  </tr>
  <tr>
    <td>Cystitis and pyelonephritis by E coli</td>
    <td>Fimbriae (P pili)</td>
    <td>43</td>
  </tr>
  <tr>
    <td>Pneumonia, neonatal meningitis by E coli</td>
    <td>K capsule</td>
    <td>43</td>
  </tr>
  <tr>
    <td>Chlamydiae resistance to B-lactam antibiotics</td>
    <td>Lack of classic peptidoglycan (reduced muramic acid)</td>
    <td>46</td>
  </tr>
  <tr>
    <td>Influenza pandemics</td>
    <td>RNA segment reassortment &gt; antigenic shift</td>
    <td>66</td>
  </tr>
  <tr>
    <td>Influenza</td>
    <td>Mutations in neuraminidase &gt; drift</td>
    <td>66</td>
  </tr>
  <tr>
    <td>epidemics</td>
    <td>hemagglutinin, antigenic</td>
    <td></td>
  </tr>
  <tr>
    <td>CNS invasion by rabies</td>
    <td>Binds to ACh receptors + retrograde transport (dynein)</td>
    <td>69</td>
  </tr>
  <tr>
    <td>HIV infection</td>
    <td>
      Virus binds CD4 along with CCR5 on macrophages (early), or CXCR¢ on T’
      cells (late)
    </td>
    <td>173</td>
  </tr>
  <tr>
    <td>Granuloma</td>
    <td>
      Macrophages present antigens to CD4* and secrete IL-12 + CD4*
      differentiation into Thl which secrete IFN-y + macrophage activation
    </td>
    <td>213</td>
  </tr>
  <tr>
    <td>Limitless replicative potential of cancer cells</td>
    <td>
      Reactivation of telomerase + maintains and lengthens telomeres =
      prevention of chromosome shortening and aging
    </td>
    <td>217</td>
  </tr>
  <tr>
    <td>Tissue invasion by cancer</td>
    <td>
      4 E-cadherin function &gt; $ intercellular junctions + basement membrane
      and ECM degradation by metalloproteinases + cell attachment to ECM
      proteins (laminin, fibronectin) + locomotion ~ vascular dissemination
    </td>
    <td>217</td>
  </tr>
  <tr>
    <td>Persistent truncus arteriosus</td>
    <td>Failure of aorticopulmonary septum formation</td>
    <td>302</td>
  </tr>
  <tr>
    <td>D-transposition of great arteries</td>
    <td>Failure of the aorticopulmonary septum to spiral</td>
    <td>302</td>
  </tr>
  <tr>
    <td>Tet spells in tetralogy of Fallot</td>
    <td>
      Crying, fever, exercise + t RV outflow obstruction + t right-to-left flow
      across VSD; Squatting + t SVR &gt; $ right-to-left shunt + 4 cyanosis
    </td>
    <td>302</td>
  </tr>
  <tr>
    <td>Eisenmenger syndrome</td>
    <td>
      Uncorrected left-to-right shunt + t pulmonary blood flow + remodeling of
      vasculature + pulmonary hypertension + RVH = right to left shunting
    </td>
    <td>303</td>
  </tr>
  <tr>
    <td>Atherosclerosis</td>
    <td>Endothelial cell dysfunction + macrophage and LDL accumulation</td>
    <td>305</td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>Thoracic aortic aneurysm</td>
    <td>Cystic medial degeneration</td>
    <td>306</td>
  </tr>
  <tr>
    <td>Myocardial infarction</td>
    <td>
      Rupture of coronary artery atherosclerotic plaque + acute thrombosis
    </td>
    <td>308</td>
  </tr>
  <tr>
    <td>Non-ST-segment elevation MI</td>
    <td>Subendocardial infarcts (subendocardium vulnerable to ischemia)</td>
    <td>308</td>
  </tr>
  <tr>
    <td>ST-segment elevation MI</td>
    <td>Transmural infarcts</td>
    <td>308</td>
  </tr>
  <tr>
    <td>Death within 0-24 hours post MI</td>
    <td>Ventricular arrhythmia</td>
    <td>309, 314</td>
  </tr>
  <tr>
    <td>Death or shock within 3-14 days post MI</td>
    <td>
      Macrophage-mediated ruptures: papillary muscle (2-7 days),
      interventricular septum (3-5 days), free wall (5-14 days)
    </td>
    <td>309, 314</td>
  </tr>
  <tr>
    <td>Wolff-Parkinson-White</td>
    <td>
      Abnormal accessory pathway from atria to ventricle bypasses the AV node +
      ventricles begin to partially depolarize earlier + delta wave. Reentrant
      circuit + supraventricular tachycardia.
    </td>
    <td>311</td>
  </tr>
  <tr>
    <td>Hypertrophic obstructive cardiomyopathy</td>
    <td>
      Sarcomeric proteins gene mutations (myosin binding protein C and B-myosin
      heavy chain) &gt; concentric hypertrophy (sarcomeres added in parallel).
      Death due to arrhythmia
    </td>
    <td>315</td>
  </tr>
  <tr>
    <td>Syncope, dyspnea in HOCM</td>
    <td>
      Asymmetric septal hypertrophy, systolic anterior motion of mitral valve =
      outflow obstruction
    </td>
    <td>315</td>
  </tr>
  <tr>
    <td>Hypovolemic shock</td>
    <td>+ preload + | CO</td>
    <td>317</td>
  </tr>
  <tr>
    <td>Cardiogenic shock</td>
    <td>4 CO due to left heart dysfunction</td>
    <td>317</td>
  </tr>
  <tr>
    <td>Distributive shock</td>
    <td>+ SVR (afterload)</td>
    <td>317</td>
  </tr>
  <tr>
    <td>Rheumatic fever</td>
    <td>
      Antibodies against M protein cross react with self antigens; type II HSR
    </td>
    <td>319</td>
  </tr>
  <tr>
    <td>Most common form of congenital adrenal hyperplasia</td>
    <td>
      21-hydroxylase deficiency+ $ mineralocorticoids, } cortisol, t sex
      hormones, t 17-hydroxyprogesterone
    </td>
    <td>339</td>
  </tr>
  <tr>
    <td>Heat intolerance, weight loss in hyperthyroidism</td>
    <td>t Na’-K* ATPase &gt; t basal metabolic rate &gt; t calorigenesis</td>
    <td>344</td>
  </tr>
  <tr>
    <td>Myxedema in hypothyroidism</td>
    <td>t CAGs in interstitial space</td>
    <td>344</td>
  </tr>
  <tr>
    <td>Graves ophthalmopathy</td>
    <td>
      Lymphocytic infiltration, fibroblast secretion of GAGs &gt; t osmotic
      muscle swelling, inflammation
    </td>
    <td>346</td>
  </tr>
  <tr>
    <td>1° hyperparathyroidism</td>
    <td>Parathyroid adenoma or hyperplasia + t PTH</td>
    <td>349</td>
  </tr>
  <tr>
    <td>2° hyperparathyroidism</td>
    <td>+ Ca® and/or t PO, &gt; parathyroid hyperplasia &gt; t PTH, t ALP</td>
    <td>349</td>
  </tr>
  <tr>
    <td>Euvolemic hyponatremia in SIADH</td>
    <td>
      t ADH &gt; water retention &gt; $ aldosterone, t ANB, t BNP &gt; f urinary
      Na* secretion
    </td>
    <td>342</td>
  </tr>
  <tr>
    <td>Small/large vessel disease in DM</td>
    <td>Nonenzymatic glycation of proteins</td>
    <td>350</td>
  </tr>
  <tr>
    <td>Diabetic ketoacidosis</td>
    <td>
      + Insulin or t insulin requirement &gt; t fat breakdown &gt; t free fatty
      acids — t ketogenesis
    </td>
    <td>35]</td>
  </tr>
  <tr>
    <td>Hyperosmolar hyperglycemic state</td>
    <td>Hyperglycemia + ft serum osmolality, excessive osmotic diuresis</td>
    <td>35]</td>
  </tr>
  <tr>
    <td>Zollinger-Ellison syndrome</td>
    <td>
      Gastrin-secreting tumor (gastrinoma) of pancreas or duodenum &gt;
      recurrent ulcers in duodenum/jejunum and malabsorption
    </td>
    <td>357</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>CONDITION</th>
    <th>MECHANISM</th>
    <th>PAGE</th>
  </thead>
  <tr>
    <td>Superior mesenteric artery syndrome</td>
    <td>
      Compression of transverse (third) portion of duodenum by SMA and aorta
    </td>
    <td>370</td>
  </tr>
  <tr>
    <td>Achalasia</td>
    <td>
      Loss of postganglionic inhibitory neurons (contain NO and VIP) in
      myenteric plexus + failure of LES relaxation
    </td>
    <td>383</td>
  </tr>
  <tr>
    <td>Barrett esophagus</td>
    <td>
      Replacement (metaplasia) of nonkeratinized stratified squamous epithelium
      with intestinal epithelium (nonciliated columnar with goblet cells)
    </td>
    <td>385</td>
  </tr>
  <tr>
    <td>Acute gastritis 2° to NSAIDs</td>
    <td>+ PGE, &gt; 4 gastric protection</td>
    <td>386</td>
  </tr>
  <tr>
    <td>Celiac disease</td>
    <td>
      Autoimmune-mediated intolerance of gliadin (found in wheat) &gt;
      malabsorption (distal duodenum, proximal jejunum), steatorrhea
    </td>
    <td>388</td>
  </tr>
  <tr>
    <td>Fistula formation in Crohn</td>
    <td>Transmural inflammation</td>
    <td>389</td>
  </tr>
  <tr>
    <td>Meckel diverticulum</td>
    <td>Persistence of the vitelline (omphalomesenteric) duct</td>
    <td>391</td>
  </tr>
  <tr>
    <td>Hirschsprung disease</td>
    <td>
      Loss of function mutation in RET + failure of neural crest migration &gt;
      lack of ganglion cells/enteric nervous plexuses in distal colon
    </td>
    <td>391</td>
  </tr>
  <tr>
    <td>Adenoma-carcinoma sequence in colorectal cancer</td>
    <td>
      Loss of APC (4 intercellular adhesion, t proliferation) + KRAS mutation
      (unregulated intracellular signaling) + loss of tumor suppressor genes
      (TP53, DCC)
    </td>
    <td>395</td>
  </tr>
  <tr>
    <td>Fibrosis in cirrhosis</td>
    <td>Stellate cells</td>
    <td>396</td>
  </tr>
  <tr>
    <td></td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td>Reye syndrome</td>
    <td>
      Aspirin + B-oxidation by reversible inhibition of mitochondrial enzymes
    </td>
    <td>397</td>
  </tr>
  <tr>
    <td>Hepatic encephalopathy</td>
    <td>Cirrhosis &gt; portosystemic shunts + 4 NH, metabolism</td>
    <td>398</td>
  </tr>
  <tr>
    <td>o,-antitrypsin deficiency</td>
    <td>
      Misfolded proteins aggregate in hepatocellular ER &gt; cirrhosis. In
      lungs, + o,-antitrypsin &gt; uninhibited elastase in alveoli + panacinar
      emphysema
    </td>
    <td>400</td>
  </tr>
  <tr>
    <td>Wilson disease</td>
    <td>
      Mutated hepatocyte copper-transporting ATPase (ATP7B on chromosome 13)
      &gt; 4 copper incorporation into apoceruloplasmin, excretion into bile
      &gt; 4 serum ceruloplasmin, t copper in tissues and urine
    </td>
    <td>402</td>
  </tr>
  <tr>
    <td>Hemochromatosis</td>
    <td>
      HFE mutation on chromosome 6 4 hepcidin production, t intestinal
      absorption — iron overload (t ferritin,t iron, } TIBC &gt; f transferrin
      saturation)
    </td>
    <td>402</td>
  </tr>
  <tr>
    <td>Gallstone ileus</td>
    <td>
      Fistula between gallbladder and GI tract + stone enters GI lumen +
      obstructing ileocecal valve (narrowest point)
    </td>
    <td>403</td>
  </tr>
  <tr>
    <td>Acute cholangitis</td>
    <td>Biliary tree obstruction — stasis/bacterial overgrowth</td>
    <td>403</td>
  </tr>
  <tr>
    <td>Acute pancreatitis</td>
    <td>Autodigestion of pancreas by pancreatic enzymes</td>
    <td>404</td>
  </tr>
  <tr>
    <td>Rh hemolytic disease of the newborn</td>
    <td>
      Rh © mother form antibodies (maternal anti-D IgG) against RBCs of Rh ©
      fetus
    </td>
    <td>4ll</td>
  </tr>
  <tr>
    <td>Anemia in lead poisoning</td>
    <td>
      Lead inhibits ferrochelatase and ALA dehydratase &gt; + heme synthesis, t
      RBC protoporphyrin.
    </td>
    <td>425</td>
  </tr>
  <tr>
    <td>Anemia of chronic disease</td>
    <td>
      Inflammation &gt; t hepcidin &gt; 4 release of iron from macrophages, +
      iron absorption from gut
    </td>
    <td>427</td>
  </tr>
  <tr>
    <td>GO6PD deficiency</td>
    <td>
      Defect in G6PD + | NADPH + $ reduced glutathione + t RBC susceptibility
      oxidant
    </td>
    <td>428</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>CONDITION</th>
    <th>MECHANISM</th>
    <th>PAGE</th>
  </thead>
  <tr>
    <td>Glanzmann thrombasthenia</td>
    <td>
      4 GplIb/IIla + 4 platelet-to-platelet aggregation, defective platelet plug
      formation
    </td>
    <td>432</td>
  </tr>
  <tr>
    <td>Thrombotic thrombocytopenic purpura</td>
    <td>
      4 ADAMTS13 (a vWF metalloprotease) + + degradation of WWF multimers — t
      platelet adhesion and aggregation (microthrombi formation)
    </td>
    <td>432</td>
  </tr>
  <tr>
    <td>von Willebrand disease</td>
    <td>
      vWF = $ platelet-to-vWF adhesion, possibly t PT'T (vWF protects factor
      VIII)
    </td>
    <td>433</td>
  </tr>
  <tr>
    <td>Factor V Leiden</td>
    <td>
      Mutant factor V (Arg506GIn) that is resistant to degradation by protein C
    </td>
    <td>433</td>
  </tr>
  <tr>
    <td>Axillary nerve injury</td>
    <td>
      Fractured surgical neck or anterior dislocation of humerus &gt; flattened
      deltoid
    </td>
    <td>450</td>
  </tr>
  <tr>
    <td>Radial nerve injury (“Saturday night palsy”)</td>
    <td>
      Compression of axilla (use of crutches), midshaft humerus fracture,
      repetitive pronation/supination of forearm — wrist/finger drop, decreased
      grip strength
    </td>
    <td>450</td>
  </tr>
  <tr>
    <td>Median nerve injury (Ape’s hand/ Pope’s blessing)</td>
    <td>
      Proximal lesion: supracondylar fracture &gt; loss of sensation over thenar
      eminence, dorsal and palmar aspect of lateral 3% fingers Distal lesion:
      carpal tunnel syndrome
    </td>
    <td>450</td>
  </tr>
  <tr>
    <td>Ulnar nerve injury</td>
    <td>
      Proximal lesion: fractured medial epicondyle + radial deviation of wrist
      on flexion Distal lesion: fractured hook of hamate — ulnar claw on digital
      extension
    </td>
    <td>450</td>
  </tr>
  <tr>
    <td>Erb palsy (waiter’s tip)</td>
    <td>
      Traction/tear of C5-C6 roots during delivery on the neck of the infant,
      and due to trauma in adults
    </td>
    <td>452</td>
  </tr>
  <tr>
    <td>Klumpke palsy</td>
    <td>
      Traction/tear of C8-Tl roots during delivery on the arm of the infant, and
      on trying to grab a branch in adults
    </td>
    <td>452</td>
  </tr>
  <tr>
    <td>Winged scapula</td>
    <td>
      I njury to long thoracic nerve (C5-C7), like on axillary node dissection
      during mastectomy
    </td>
    <td>452</td>
  </tr>
  <tr>
    <td>Common peroneal nerve injury</td>
    <td>
      Trauma on lateral aspect of leg or fracture of fibular neck — foot drop
      with eppage gait a
    </td>
    <td>457</td>
  </tr>
  <tr>
    <td>Superior gluteal nerve injury</td>
    <td>
      Iatrogenic injury during IM injection at gluteal region + ‘Trendelenburg
      sign: lesion contralateral to side of hip that drops due to adductor
      weakness
    </td>
    <td>457</td>
  </tr>
  <tr>
    <td>Pudendal nerve injury</td>
    <td>
      I njury during horseback riding or prolonged cycling; can be blocked
      during delivery at the ischial spine
    </td>
    <td>457</td>
  </tr>
  <tr>
    <td>Radial head subluxation</td>
    <td>Nursemaid’s elbow; due to sudden pull on arm (in children)</td>
    <td>466</td>
  </tr>
  <tr>
    <td>Slipped capital femoral epiphysis</td>
    <td>
      Obese young adolescent with hip/knee pain. Increased axial force on
      femoral head + epiphysis displaces relative to femoral neck like a scoop
      of ice cream slips off a cone
    </td>
    <td>466</td>
  </tr>
  <tr>
    <td>Achondroplasia</td>
    <td>
      Constitutive activation of FGFR3 &gt; 4 chondrocyte proliferation &gt;
      failure of endochondral ossification + short limbs
    </td>
    <td>467</td>
  </tr>
  <tr>
    <td>Osteoporosis</td>
    <td>
      t osteoclast activity leading to t bone resorption secondary to 4 estrogen
      levels and old age.
    </td>
    <td>467</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>CONDITION</th>
    <th>MECHANISM</th>
    <th>PAGE</th>
  </thead>
  <tr>
    <td>Osteoarthritis</td>
    <td>
      Mechanical degeneration of articular cartilage causing inflammation with
      inadequate repair and osteophyte formation.
    </td>
    <td>472</td>
  </tr>
  <tr>
    <td>Rheumatoid arthritis</td>
    <td>
      Autoimmune inflammation due to HLA-DR¢4 causing pannus formation. ‘Type
      III Hypersensitivity reaction.
    </td>
    <td>472</td>
  </tr>
  <tr>
    <td>Sjogren syndrome</td>
    <td>
      Autoimmune Type IV hypersensitivity reaction leading to lymphocyte
      mediated damage of exocrine glands.
    </td>
    <td>474</td>
  </tr>
  <tr>
    <td>Systemic lupus erythematosus</td>
    <td>
      Predominantly a Type III hypersensitivity reaction with decreased
      clearance of immune complexes. Hematologic manifestations are a type II
      hypersensitivity reaction.
    </td>
    <td>476</td>
  </tr>
  <tr>
    <td>Blindness in giant cell (temporal) arteritis</td>
    <td>Ophthalmic artery occlusion</td>
    <td>478</td>
  </tr>
  <tr>
    <td>Myasthenia gravis</td>
    <td>Autoantibodies to postsynaptic nicotinic (ACh) receptors</td>
    <td>480</td>
  </tr>
  <tr>
    <td>Lambert-Eaton myasthenic syndrome</td>
    <td>_ Autoantibodies to presynaptic calcium channels + $ ACh release</td>
    <td>480</td>
  </tr>
  <tr>
    <td>Albinism</td>
    <td>Normal melanocyte number, + melanin production</td>
    <td>484</td>
  </tr>
  <tr>
    <td>Vitiligo Atopic dermatitis</td>
    <td>
      Autoimmune destruction of melanocytes Epidermal barrier dysfunction,
      genetic factors (ie, loss-of function mutations
    </td>
    <td>484 485</td>
  </tr>
  <tr>
    <td>Allergic contact dermatitis</td>
    <td>
      microbiome, environmental triggers of inflammation Type IV HSR. During the
      sensitization phase, Allergen activates Th] cells &gt; memory CD4* cells
      and CD8* form. Upon reexposure + CD4* cells release Cd8* cells kill cells
    </td>
    <td>485</td>
  </tr>
  <tr>
    <td>Psoriasis</td>
    <td>
      cytokines and targeted Disrupted skin barrier &gt; activation of dendritic
      cells via inflammatory cytokines (IL-1B, IL-6, TNF) &gt; activated
      dendritic cells release IL-23 &gt; Naive T cells form Thl (1L-12) and Th17
      (IL-23) cells that secrete IF'N-y and IL-I7A/IL-22 respectively +
      Acanthosis, parakeratosis, hypogranulosis
    </td>
    <td>485</td>
  </tr>
  <tr>
    <td>Pemphigus vulgaris</td>
    <td>
      Type IL HSR. IgG autoantibodies form against desmoglein | and 3 in
      desmosomes &gt; separation of keratinocytes in stratum spinosum from
      stratum basale
    </td>
    <td>489</td>
  </tr>
  <tr>
    <td>Bullous pemphigoid</td>
    <td>
      Type II HSR. IgG autoantibodies against hemidesmosomes — separation of
      epidermis from dermis
    </td>
    <td>489</td>
  </tr>
  <tr>
    <td>Spina bifida occulta, meningocele, myelomeningocele, myeloschisis</td>
    <td>Failure of caudal neuropore to fuse by 4th week of development</td>
    <td>501</td>
  </tr>
  <tr>
    <td>Anencephaly</td>
    <td>
      Failure of rostral neuropore to close + no forebrain, open calvarium
    </td>
    <td>501</td>
  </tr>
  <tr>
    <td>Holoprosencephaly</td>
    <td>
      Failure of the forebrain (prosencephalon) to divide into 2 cerebral
      hemispheres; developmental field defect typically occurring at weeks 3-4
      of development; associated with SHH mutations
    </td>
    <td>501</td>
  </tr>
  <tr>
    <td>Lissencephaly</td>
    <td>
      Failure of neuronal migration &gt; smooth brain surface lacking sulci and
      gyri
    </td>
    <td>501</td>
  </tr>
  <tr>
    <td>Chiari I malformation</td>
    <td>
      Downward displacement of cerebellar tonsils inferior to foramen magnum
    </td>
    <td>502</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>CONDITION</th>
    <th>MECHANISM</th>
    <th>PAGE</th>
  </thead>
  <tr>
    <td>Syringomyelia</td>
    <td>
      Fluid-filled, gliosis-lined cavity within spinal cord, associated with
      Chiari I malformation (low-lying cerebellar tonsils), less commonly with
      infections, tumors, trauma
    </td>
    <td>502</td>
  </tr>
  <tr>
    <td>Gerstmann syndrome</td>
    <td>
      Lesion in the dominant parietal cortex + agraphia, acalculia, finger
      agnosia, left-right disorientation
    </td>
    <td>526</td>
  </tr>
  <tr>
    <td>Hemispatial neglect syndrome</td>
    <td>Lesion in the nondominant parietal cortex</td>
    <td>526</td>
  </tr>
  <tr>
    <td>Kliiver-Bucy syndrome</td>
    <td>
      Bilateral lesions in the amygdala; seen in HSV-1 encephalitis =
      disinhibition, including hyperphagia, hypersexuality, hyperorality
    </td>
    <td>526</td>
  </tr>
  <tr>
    <td>Parinaud syndrome (inability to move eyes up and down)</td>
    <td>Lesion in the dorsal midbrain; often due to pineal gland tumors</td>
    <td>526</td>
  </tr>
  <tr>
    <td>Cerebral edema</td>
    <td>
      Fluid accumulation in the brain parenchyma &gt; t ICP; may be cytotoxic
      (intracellular fluid accumulation due to osmotic shift; associated with
      early ischemia, hyperammonemia, SIADH) or vasogenic (extracellular fluid
      accumulation due to increased permeability of BBB; associated with late
      ischemia, trauma, hemorrhage, inflammation, tumors)
    </td>
    <td>527</td>
  </tr>
  <tr>
    <td>Aphasia</td>
    <td>
      Stroke in dominant (usually left) hemisphere, in either the superior
      temporal gyrus of temporal lobe (Wernicke; receptive aphasia) or inferior
      frontal gyrus of frontal lobe (Broca; expressive aphasia)
    </td>
    <td>528, 531</td>
  </tr>
  <tr>
    <td>
      Locked-in syndrome (loss of horizontal, but not vertical, eye movements)
    </td>
    <td>Stroke of the basilar artery</td>
    <td>528</td>
  </tr>
  <tr>
    <td>Lateral pontine syndrome</td>
    <td>Stroke of the anterior inferior cerebellar artery</td>
    <td>528</td>
  </tr>
  <tr>
    <td>Lateral medullary (Wallenberg) syndrome</td>
    <td>Stroke of the posterior inferior cerebellar artery</td>
    <td>529</td>
  </tr>
  <tr>
    <td>Medial medullary syndrome</td>
    <td>Stroke of the anterior spinal artery</td>
    <td>529</td>
  </tr>
  <tr>
    <td>Neonatal intraventricular hemorrhage _</td>
    <td>
      Reduced glial fiber support and impaired autoregulation of BP in premature
      infants &gt; bleeding into the ventricles, originating in the germinal
      matrix (a highly vascularized layer within the subventricular zone)
    </td>
    <td>529</td>
  </tr>
  <tr>
    <td>Epidural hematoma</td>
    <td>
      Rupture of middle meningeal artery, often secondary to skull fracture
      involving the pterion
    </td>
    <td>530</td>
  </tr>
  <tr>
    <td>Subdural hematoma</td>
    <td>
      Rupture of bridging veins; acute (traumatic, high-energy impact, sudden
      deceleration injury) or chronic (mild trauma, cerebral atrophy, t age,
      chronic alcohol overuse, shaken baby syndrome)
    </td>
    <td>530</td>
  </tr>
  <tr>
    <td>Subarachnoid hemorrhage</td>
    <td>
      ‘Trauma, rupture of aneurysm (such as a saccular aneurysm), or
      arteriovenous malformation + bleeding
    </td>
    <td>—_ 530</td>
  </tr>
  <tr>
    <td>Intraparenchymal hemorrhage</td>
    <td>
      Systemic hypertension (most often occur in the putamen of basal ganglia,
      thalamus, pons, and cerebellum), amyloid angiopathy, arteriovenous
      malformation, vasculitis, neoplasm, or secondary to reperfusion injury in
      ischemic stroke &gt; bleeding
    </td>
    <td>530</td>
  </tr>
  <tr>
    <td>Phantom limb pain</td>
    <td>
      Most commonly following amputation &gt; reorganization of primary
      somatosensory present cortex &gt; sensation of pain in a limb that is no
      longer
    </td>
    <td>531</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>CONDITION</th>
    <th>MECHANISM</th>
    <th>PAGE</th>
  </thead>
  <tr>
    <td>Conduction aphasia</td>
    <td>Damage to the arcuate fasciculus</td>
    <td>531</td>
  </tr>
  <tr>
    <td>Global aphasia</td>
    <td>
      Damage to both Broca (inferior frontal gyrus of frontal lobe) and Wernicke
      (superior temporal gyrus of temporal lobe) areas
    </td>
    <td>531</td>
  </tr>
  <tr>
    <td>Heat stroke</td>
    <td>
      Inability of body to dissipate heat (eg, exertion) + CNS dysfunction (eg,
      confusion), rhabdomyolysis, acute kidney injury, ARDS, DIC
    </td>
    <td>532</td>
  </tr>
  <tr>
    <td>Migraine</td>
    <td>
      Irritation of CN V, meninges, or blood vessels (release of vasoactive
      neuropeptides [eg, substance P, calcitonin gene-related peptide])
    </td>
    <td>534</td>
  </tr>
  <tr>
    <td>Parkinson disease</td>
    <td>Loss of dopaminergic neurons of substantia nigra pars compacta</td>
    <td>536</td>
  </tr>
  <tr>
    <td>Huntington disease</td>
    <td>
      Trinucleotide (CAG) repeat expansion in huntingtin (HTT) gene on
      chromosome 4 + toxic gain of function &gt; atrophy of caudate and putamen
      with ex vacuo ventriculomegaly + t dopamine, | GABA, $ ACh in brain &gt;
      neuronal death via glutamate excitotoxicity
    </td>
    <td>536</td>
  </tr>
  <tr>
    <td>Alzheimer disease</td>
    <td>
      Widespread cortical atrophy, narrowing of gyri and widening of sulci;
      senile plaques in gray matter composed of beta-amyloid core (formed by
      cleavage of amyloid precursor protein); neurofibrillary tangles composed
      of intracellular, hyperphosphorylated tau protein; Hirano bodies
      (intracellular eosinophilic proteinaceous rods in hippocampus)
    </td>
    <td>536</td>
  </tr>
  <tr>
    <td>Frontotemporal dementia</td>
    <td>
      Frontotemporal lobe degeneration + 4 executive function and behavioral
      inhibition
    </td>
    <td>536</td>
  </tr>
  <tr>
    <td>Vascular dementia</td>
    <td>Multiple arterial infarcts and/or chronic ischemia</td>
    <td>537</td>
  </tr>
  <tr>
    <td>HIV-associated dementia</td>
    <td>Secondary to diffuse gray matter and subcortical atrophy</td>
    <td>537</td>
  </tr>
  <tr>
    <td>Idiopathic intracranial hypertension</td>
    <td>
      Increased ICP, associated with dural venous sinus stenosis; impaired optic
      nerve axoplasmic flow &gt; papilledema
    </td>
    <td>538</td>
  </tr>
  <tr>
    <td>Communicating hydrocephalus</td>
    <td>
      Reduced CSF absorption by arachnoid granulations (eg, arachnoid scarring
      post-meningitis) + t ICP, papilledema, herniation
    </td>
    <td>538</td>
  </tr>
  <tr>
    <td>Normal pressure hydrocephalus</td>
    <td>
      Idiopathic, CSF pressure elevated only episodically, no t subarachnoid
      space volume; expansion of ventricles distorts the fibers of the corona
      radiata
    </td>
    <td>538</td>
  </tr>
  <tr>
    <td>Noncommunicating hydrocephalus</td>
    <td>
      Structural blockage of CSF circulation within ventricular system (eg,
      stenosis of aqueduct of Sylvius, colloid cyst blocking foramen of Monro,
      tumor)
    </td>
    <td>538</td>
  </tr>
  <tr>
    <td>Ex vacuo ventriculomegaly</td>
    <td>
      Decreased brain tissue and neuronal atrophy + appearance of increased CSF
      on imaging
    </td>
    <td>538</td>
  </tr>
  <tr>
    <td>Multiple sclerosis</td>
    <td>
      Autoimmune inflammation and demyelination of CNS (brain and spinal cord) +
      axonal damage
    </td>
    <td>539</td>
  </tr>
  <tr>
    <td>Osmotic demyelination syndrome</td>
    <td>
      Rapid osmotic changes, most commonly iatrogenic correction of hyponatremia
      but also rapid shifts of other osmolytes (eg, glucose) &gt; massive axonal
      demyelination in pontine white matter
    </td>
    <td>540</td>
  </tr>
  <tr>
    <td>
      Acute inflammatory demyelinating polyneuropathy (subtype of Guillain-
      Barré syndrome)
    </td>
    <td>
      Autoimmune destruction of Schwann cells via inflammation and demyelination
      of motor and sensory fibers and peripheral nerves; likely facilitated by
      molecular mimicry and triggered by inoculations or stress
    </td>
    <td>540</td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>Sturge-Weber syndrome</td>
    <td>
      Somatic mosaicism of an activating mutation in one copy of the GNAQ gene +
      congenital anomaly of neural crest derivatives &gt; capillary vascular
      malformation, ipsilateral leptomeningeal angioma with calcifications,
      episcleral hemangioma
    </td>
    <td>541</td>
  </tr>
  <tr>
    <td>Pituitary adenoma</td>
    <td>
      Hyperplasia of only one type of endocrine cells found in pituitary (most
      commonly from lactotrophs, producing prolactin)
    </td>
    <td>542</td>
  </tr>
  <tr>
    <td>Spinal muscular atrophy</td>
    <td>Congenital degeneration of anterior horns</td>
    <td>546</td>
  </tr>
  <tr>
    <td>Amyotrophic lateral sclerosis</td>
    <td>Can be caused by defect in superoxide dismutase |</td>
    <td>546</td>
  </tr>
  <tr>
    <td>Tabes dorsalis</td>
    <td>
      Degeneration/demyelination of dorsal columns and roots &gt; progressive
      sensory ataxia (impaired proprioception &gt; poor coordination)
    </td>
    <td>546</td>
  </tr>
  <tr>
    <td>Poliomyelitis</td>
    <td>
      Poliovirus infection spreads from lymphoid tissue of oropharynx to small
      intestine and then to CNS via bloodstream — destruction of cells in
      anterior horn of spinal cord (LMN death)
    </td>
    <td>546</td>
  </tr>
  <tr>
    <td>Friedreich ataxia</td>
    <td>
      Trinucleotide repeat disorder (GAA) on chromosome 9 in gene that encodes
      rataxin (iron-binding protein) &gt; impairment in mitochondrial
      functioning — degeneration of lateral corticospinal tract, spinocerebellar
      tract, dorsal columns, and dorsal root ganglia
    </td>
    <td>547</td>
  </tr>
  <tr>
    <td>Noise-induced hearing loss</td>
    <td>
      Damage to stereociliated cells in organ of Corti + loss of high-frequency
      hearing first; sudden extremely loud noises can lead to tympanic membrane
      rupture &gt; hearing loss
    </td>
    <td>550</td>
  </tr>
  <tr>
    <td>Presbycusis</td>
    <td>
      Destruction of hair cells at the cochlear base (preserved low-frequency
      hearing at apex) + aging-related progressive bilateral/symmetric
      sensorineural hearing loss (often of higher frequencies)
    </td>
    <td>550</td>
  </tr>
  <tr>
    <td>Cholesteatoma</td>
    <td>Abnormal growth of keratinized squamous epithelium in middle ear</td>
    <td>550</td>
  </tr>
  <tr>
    <td>Ménieére disease</td>
    <td>
      Increased endolymph in inner ear &gt; vertigo, hearing loss, tinnitus and
      ear ullness
    </td>
    <td>550</td>
  </tr>
  <tr>
    <td>Hyperopia</td>
    <td>
      Eye too short for refractive power of cornea and lens &gt; light focused
      behind retina
    </td>
    <td>551</td>
  </tr>
  <tr>
    <td>Myopia</td>
    <td>
      Eye too long for refractive power of cornea and lens &gt; light focused in
      front of retina
    </td>
    <td>551</td>
  </tr>
  <tr>
    <td>Astigmatism</td>
    <td>
      Abnormal curvature of cornea &gt; different refractive power at different
      axes
    </td>
    <td>551</td>
  </tr>
  <tr>
    <td>Presbyopia</td>
    <td>
      Aging-related impaired accommodation, primarily due to + lens elasticity
    </td>
    <td>552</td>
  </tr>
  <tr>
    <td>Glaucoma</td>
    <td>
      Optic neuropathy causing progressive vision loss (peripheral + central),
      usually accompanied by increased intraocular pressure
    </td>
    <td>553</td>
  </tr>
  <tr>
    <td>Open-angle glaucoma</td>
    <td>
      Associated with increased resistance to aqueous humor drainage through
      trabecular meshwork
    </td>
    <td>553</td>
  </tr>
  <tr>
    <td>Angle-closure glaucoma</td>
    <td>
      Anterior chamber angle is narrowed or closed; associated with anatomic
      abnormalities (eg, anteriorly displaced lens resting against central iris)
      — 4 aqueous flow through pupil &gt; ft pressure in posterior chamber &gt;
      peripheral iris pushed against cornea &gt; obstruction of drainage
    </td>
    <td>553</td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>Diabetic retinopathy</td>
    <td>
      Chronic hyperglycemia + t permeability and occlusion of retinal vessels +
      microaneurysms, hemorrhages (nonproliferative); retinal neovascularization
      due to chronic hypoxia (proliferative)
    </td>
    <td>554</td>
  </tr>
  <tr>
    <td>Hypertensive retinopathy</td>
    <td>
      Chronic hypertension + spasm, sclerosis, and fibrinoid necrosis of retinal
      vessels
    </td>
    <td>554</td>
  </tr>
  <tr>
    <td>Retinal artery occlusion</td>
    <td>
      Blockage of central or branch retinal artery usually due to embolism
      (carotid artery atherosclerosis &gt; cardiogenic); less commonly due to
      giant cell arteritis
    </td>
    <td>554</td>
  </tr>
  <tr>
    <td>Retinal vein occlusion</td>
    <td>
      Primary thrombosis &gt; central retinal vein occlusion; secondary
      thrombosis at arteriovenous crossings (sclerotic arteriole compresses
      adjacent venule causing turbulent blood flow) &gt; branch retinal vein
      occlusion
    </td>
    <td>554</td>
  </tr>
  <tr>
    <td>Retinal detachment</td>
    <td>
      Separation of neurosensory retina from underlying retinal pigment
      epithelium — loss of choroidal blood supply + hypoxia and degeneration of
      photoreceptors; due to retinal tears (rhegmatogenous) or tractional or
      exudative (fluid accumulation) (nonrhegmatogenous)
    </td>
    <td>554</td>
  </tr>
  <tr>
    <td>Retinitis pigmentosa</td>
    <td>
      Progressive degeneration of photoreceptors and retinal pigment epithelium
    </td>
    <td>554</td>
  </tr>
  <tr>
    <td>Papilledema</td>
    <td>
      t ICP (eg, secondary to mass effect) + impaired axoplasmic flow in optic
      nerve + optic disc swelling (usually bilateral)
    </td>
    <td>554</td>
  </tr>
  <tr>
    <td>Relative afferent pupillary defect</td>
    <td>
      Unilateral or asymmetric lesions of afferent limb of pupillary reflex (eg,
      retina, optic nerve)
    </td>
    <td>556</td>
  </tr>
  <tr>
    <td>Horner syndrome</td>
    <td>
      Lesions along the sympathetic chain: Ist neuron (pontine hemorrhage,
      lateral medullary syndrome, spinal cord lesion above T1 like Brown-
      Sequard syndrome or late-stage syringomyelia); 2nd neuron (stellate
      ganglion compression by Pancoast tumor); 3rd neuron (carotid dissection)
    </td>
    <td>557</td>
  </tr>
  <tr>
    <td>Cavernous sinus syndrome</td>
    <td>
      Secondary to pituitary tumor mass effect, carotid-cavernous fistula, or
      cavernous sinus thrombosis related to infection (spreads due to lack of
      valves in dural venous sinuses)
    </td>
    <td>559</td>
  </tr>
  <tr>
    <td>Delirium</td>
    <td>
      Usually secondary to illnesses (eg, CNS disease, infection, trauma,
      substance use), or medications (eg, anticholinergics)
    </td>
    <td>577</td>
  </tr>
  <tr>
    <td>Schizophrenia</td>
    <td>
      Altered dopaminergic activity, t serotonergic activity, | dendritic
      activity
    </td>
    <td>579</td>
  </tr>
  <tr>
    <td>Distal RTA (type 1)</td>
    <td>
      Inability of @-intercalated cells to secrete Ht + no new HCO, generated +
      metabolic acidosis
    </td>
    <td>613</td>
  </tr>
  <tr>
    <td>Proximal RTA (type 2)</td>
    <td>
      Defective PCT HCO, reabsorption + t excretion of HCO, in urine + metabolic
      acidosis
    </td>
    <td>613</td>
  </tr>
  <tr>
    <td>Hyperkalemic tubular acidosis (type 4)</td>
    <td>
      Hypoaldosteronism/aldosterone resistance + t K* + NH, synthesis in PCT
      &gt; 4 NH,* excretion
    </td>
    <td>613</td>
  </tr>
  <tr>
    <td>Nephritic syndrome</td>
    <td>
      Glomerular inflammation + GBM damage — loss of RBCs in urine &gt;
      dysmorphic RBCs, hematuria
    </td>
    <td>615</td>
  </tr>
  <tr>
    <td>Nephrotic syndrome</td>
    <td>Podocyte damage &gt; impaired charge barrier + proteinuria</td>
    <td>615</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>Infection-associated glomerulonephritis</th>
    <th>‘Type III HSR with consumptive hypocomplementemia</th>
    <th>616</th>
  </thead>
  <tr>
    <td>Alport syndrome</td>
    <td>
      Type IV collagen mutation (X-linked dominant) &gt; irregular thinning and
      thickening and splitting of GBM — nephritic syndrome
    </td>
    <td>617</td>
  </tr>
  <tr>
    <td>Stress incontinence</td>
    <td>
      Outlet incompetence (urethral hypermobility/intrinsic sphincter
      deficiency) &gt; leak on t intraabdominal pressure
    </td>
    <td>620</td>
  </tr>
  <tr>
    <td>Urge incontinence</td>
    <td>Detrusor overactivity + leak with urge to void</td>
    <td>620</td>
  </tr>
  <tr>
    <td>Overflow incontinence</td>
    <td>
      Incomplete emptying (detrusor underactivity or outlet obstruction) + leak
      with overfillling
    </td>
    <td>620</td>
  </tr>
  <tr>
    <td>Prerenal azotemia</td>
    <td>+ RBF + | GFR = t reabsorption of Na*/H,O and urea</td>
    <td>622</td>
  </tr>
  <tr>
    <td>Intrinsic renal failure</td>
    <td>
      Patchy necrosis + debris obstructing tubules and fluid backflow + 4 GFR
    </td>
    <td>622</td>
  </tr>
  <tr>
    <td>Postrenal azotemia</td>
    <td>Outflow obstruction (bilateral)</td>
    <td>622</td>
  </tr>
  <tr>
    <td>Adnexal torsion</td>
    <td>
      ‘Twisting of ovary/fallopian tube around infundibulopelvic ligament and
      ovarian ligament + venous/lymphatic blockage — arterial inflow continued +
      edema + blockade of arterial inflow &gt; necrosis
    </td>
    <td>645</td>
  </tr>
  <tr>
    <td>Preeclampsia</td>
    <td>
      Abnormal placental spiral arteries + endothelial dysfunction,
      vasoconstriction, ischemia + new-onset HTN with proteinuria
    </td>
    <td>662</td>
  </tr>
  <tr>
    <td>Supine hypotensive syndrome</td>
    <td>
      Supine position + compressed abdominal aorta and IVC by gravid uterus &gt;
      4 and 4 return
    </td>
    <td>663</td>
  </tr>
  <tr>
    <td>Functional hypothalamic amenorrhea</td>
    <td>
      placental perfusion venous Severe caloric restriction, t energy
      expenditure, and/or stress + altered pulsatile GnRH secretion + + LH, FSH,
    </td>
    <td>665</td>
  </tr>
  <tr>
    <td>Polycystic ovarian syndrome</td>
    <td>
      estrogen Hyperinsulinemia and/or insulin resistance &gt; altered
      hypothalamic feedback response + t LH:FSH, t androgens, $ rate of
      follicular maturation &gt; unruptured follicles (cysts) + anovulation
    </td>
    <td>665</td>
  </tr>
  <tr>
    <td>Varicocele</td>
    <td>
      Dilated veins in pampiniform plexus due to t venous pressure + enlarged
      scrotum
    </td>
    <td>671</td>
  </tr>
  <tr>
    <td>Methemoglobin</td>
    <td>
      Oxidized Hb secondary to dapsone, local anesthetics, nitrites &gt; Hb
      oxidization (Fe) &gt; 4 O, binding but t cyanide affinity + tissue hypoxia
    </td>
    <td>690</td>
  </tr>
  <tr>
    <td>Deep venous thrombosis</td>
    <td>
      Stasis, hypercoagulability, endothelial damage (Virchow triad) &gt; blood
      clot within deep vein
    </td>
    <td>692</td>
  </tr>
  <tr>
    <td>Sarcoidosis associated hypercalcemia</td>
    <td>
      Noncaseating granulomas &gt; t macrophage activity + t lo-hydroxylase
      activity in macrophage &gt; vitamin D activation &gt; t Ca?*
    </td>
    <td>697</td>
  </tr>
  <tr>
    <td>Acute respiratory distress syndrome</td>
    <td>
      Alveolar injury + inflammation + capillary endothelial damage and t vessel
      permeability + leakage of protein-rich fluid into alveoli &gt;
      intra-alveolar hyaline membranes and noncardiogenic pulmonary edema &gt; 4
      compliance and V/Q mismatch &gt; hypoxic vasoconstriction &gt; t pulmonary
      vascular resistance
    </td>
    <td>699</td>
  </tr>
  <tr>
    <td>Sleep apnea</td>
    <td>
      Respiratory effort against airway obstruction (obstructive); impaired y,
      CHF, opioids (central); obesity respiratory effort due to CNS
      injury/toxici
    </td>
    <td>699</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>CLINICAL PRESENTATION</th>
    <th>DIAGNOSIS/DISEASE</th>
    <th>PAGE</th>
  </thead>
  <tr>
    <td>Gout, intellectual disability, selfmutilating behavior ina boy</td>
    <td>— Lesch-Nyhan syndrome (HGPRT deficiency, X-linked recessive)</td>
    <td>35</td>
  </tr>
  <tr>
    <td>
      Situs inversus, chronic ear infections, sinusitis, bronchiectasis,
      infertility
    </td>
    <td>Primary ciliary dyskinesia (Kartagener syndrome)</td>
    <td>47</td>
  </tr>
  <tr>
    <td>
      Blue sclera, multiple fractures, dental problems, conductive hearing loss
    </td>
    <td>Osteogenesis imperfecta (type I collagen defect)</td>
    <td>49</td>
  </tr>
  <tr>
    <td>Elastic skin, hypermobility of joints, t bleeding tendency</td>
    <td>
      _ Ehlers-Danlos syndrome (type V collagen defect, type III collagen defect
      seen in vascular subtype of ED)
    </td>
    <td>49</td>
  </tr>
  <tr>
    <td>
      Arachnodactyly, lens dislocation (upward and temporal), — aortic
      dissection, hyperflexible joints
    </td>
    <td>Marfan syndrome (fibrillin defect)</td>
    <td>50</td>
  </tr>
  <tr>
    <td>Arachnodactyly, pectus deformity, lens dislocation (downward)</td>
    <td>Homocystinuria (autosomal recessive)</td>
    <td>50</td>
  </tr>
  <tr>
    <td>
      Café-au-lait spots (unilateral), polyostotic fibrous dysplasia, precocious
      puberty, multiple endocrine abnormalities
    </td>
    <td>McCune-Albright syndrome (G -protein activating mutation)</td>
    <td>55</td>
  </tr>
  <tr>
    <td>
      Meconium ileus in neonate, recurrent pulmonary infections, nasal polyps,
      pancreatic insufficiency, infertility/subfertility
    </td>
    <td>Cystic fibrosis (CFTR gene defect, chromosome 7, AF508)</td>
    <td>58</td>
  </tr>
  <tr>
    <td>Calf pseudohypertrophy</td>
    <td>
      Muscular dystrophy (most commonly Duchenne, due to X-linked recessive
      frameshift mutation of dystrophin gene)
    </td>
    <td>59</td>
  </tr>
  <tr>
    <td>Child uses arms to stand up from squat</td>
    <td>Duchenne muscular dystrophy (Gowers sign)</td>
    <td>59</td>
  </tr>
  <tr>
    <td>Slow, progressive muscle weakness in boys</td>
    <td>
      Becker muscular dystrophy (X-linked non-frameshift deletions in
      dystrophin; less severe than Duchenne)
    </td>
    <td>59</td>
  </tr>
  <tr>
    <td>
      Infant with cleft lip/palate, microcephaly or holoprosencephaly,
      polydactyly, cutis aplasia
    </td>
    <td>Patau syndrome (trisomy 13)</td>
    <td>61</td>
  </tr>
  <tr>
    <td>
      Infant with microcephaly, rocker-bottom feet, clenched hands, and
      structural heart defect
    </td>
    <td>Edwards syndrome (trisomy 18)</td>
    <td>61</td>
  </tr>
  <tr>
    <td>Single palmar crease, intellectual disability</td>
    <td>Down syndrome</td>
    <td>61</td>
  </tr>
  <tr>
    <td>Microcephaly, high-pitched cry, intellectual disability</td>
    <td>Cri-du-chat (cry of the cat) syndrome</td>
    <td>62</td>
  </tr>
  <tr>
    <td>Confusion, ophthalmoplegia/nystagmus, ataxia</td>
    <td>
      Wernicke encephalopathy (add confabulation/memory loss for Korsakoff
      syndrome)
    </td>
    <td>64</td>
  </tr>
  <tr>
    <td>
      Dilated cardiomyopathy/high-output heart failure, edema, alcoholism or
      malnutrition
    </td>
    <td>Wet beriberi (thiamine [vitamin B,] deficiency)</td>
    <td>64</td>
  </tr>
  <tr>
    <td>Burning feet syndrome</td>
    <td>Vitamin B, deficiency</td>
    <td>65</td>
  </tr>
  <tr>
    <td>Dermatitis, dementia, diarrhea</td>
    <td>Pellagra (niacin [vitamin B,] deficiency)</td>
    <td>65</td>
  </tr>
  <tr>
    <td>
      Swollen gums, mucosal bleeding, poor wound healing, petechiae, corkscrew
      hairs, perifollicular hemorrhages
    </td>
    <td>
      Scurvy (vitamin C deficiency: can’t hydroxylate proline/ lysine for
      collagen synthesis); tea and toast diet
    </td>
    <td>67</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>LINICAL PRESENTATION</th>
    <th>DIAGNOSIS/DISEASE</th>
    <th>PAGE</th>
  </thead>
  <tr>
    <td>ntellectual disability, musty body odor, hypopigmented skin, eczema</td>
    <td>Phenylketonuria</td>
    <td>82</td>
  </tr>
  <tr>
    <td>
      3luish-black connective tissue, ear cartilage, sclerae; urine turns black
      on prolonged exposure to air
    </td>
    <td>Alkaptonuria (homogentisate oxidase deficiency; ochronosis)</td>
    <td>82</td>
  </tr>
  <tr>
    <td>nfant with hypoglycemia, hepatomegaly, cardiomyopathy</td>
    <td>
      Cori disease (debranching enzyme deficiency) or von Gierke disease
      (glucose-6-phosphatase deficiency, more severe)
    </td>
    <td>85</td>
  </tr>
  <tr>
    <td>
      Chronic exercise intolerance with myalgia, fatigue, painful cramps,
      myoglobinuria
    </td>
    <td>McArdle disease (skeletal muscle glycogen phosphorylase deficiency)</td>
    <td>85</td>
  </tr>
  <tr>
    <td>‘Cherry-red spots” on macula</td>
    <td>
      ‘Tay-Sachs (ganglioside accumulation; no hepatosplenomegaly); Niemann-Pick
      disease (sphingomyelin accumulation; hepatosplenomegaly); central retinal
      artery occlusion
    </td>
    <td>86 554</td>
  </tr>
  <tr>
    <td>
      Tepatosplenomegaly, pancytopenia, osteoporosis, avascular necrosis of
      femoral head, bone crises
    </td>
    <td>Gaucher disease (glucocerebrosidase [B-glucosidase| deficiency)</td>
    <td>86</td>
  </tr>
  <tr>
    <td>\chilles tendon xanthoma</td>
    <td>Familial hypercholesterolemia ($ LDL receptor signaling)</td>
    <td>92</td>
  </tr>
  <tr>
    <td>Male child, recurrent infections, no mature B cells</td>
    <td>Bruton disease (X-linked agammaglobulinemia)</td>
    <td>114</td>
  </tr>
  <tr>
    <td>\naphylaxis following blood transfusion</td>
    <td>IgA deficiency</td>
    <td>114</td>
  </tr>
  <tr>
    <td>
      Xecurrent cold (noninflamed) abscesses, eczema, high serum IgE, t
      eosinophils
    </td>
    <td>
      Hyper-IgE syndrome (Job syndrome: neutrophil chemotaxis abnormality)
    </td>
    <td>114</td>
  </tr>
  <tr>
    <td>uate separation (&gt;30 days) of umbilical cord, no pus,</td>
    <td>Leukocyte adhesion deficiency (type 1; defective LFA-1</td>
    <td>115</td>
  </tr>
  <tr>
    <td>
      recurrent skin and mucosal bacterial infections Xecurrent infections and
      granulomas with catalase ®
    </td>
    <td>integrin) Chronic granulomatous disease (defect of NADPH</td>
    <td>115</td>
  </tr>
  <tr>
    <td>organisms “ever, vomiting, diarrhea, desquamating rash following</td>
    <td>oxidase) Staphylococcal toxic shock syndrome</td>
    <td>133</td>
  </tr>
  <tr>
    <td>use of nasal pack or tampon ‘Strawberry tongue”</td>
    <td>
      Scarlet fever (sandpaper rash); Kawasaki disease (lymphadenopathy, high
      fever for 5 days)
    </td>
    <td>134, 478</td>
  </tr>
  <tr>
    <td>Solon cancer associated with infective endocarditis</td>
    <td>Streptococcus bovis</td>
    <td>35</td>
  </tr>
  <tr>
    <td>“laccid paralysis in newborn after ingestion of honey</td>
    <td>Clostridium botulinum infection (floppy baby syndrome)</td>
    <td>136</td>
  </tr>
  <tr>
    <td>\bdominal pain, diarrhea, leukocytosis, recent antibiotic use</td>
    <td>Clostridioides difficile infection</td>
    <td>136</td>
  </tr>
  <tr>
    <td>[onsillar pseudomembrane with “bull’s neck” appearance</td>
    <td>Corynebacterium diphtheria infection</td>
    <td></td>
  </tr>
  <tr>
    <td>3ack pain, fever, night sweats</td>
    <td>Pott disease (vertebral TB)</td>
    <td></td>
  </tr>
  <tr>
    <td>\drenal insufficiency, fever, bilateral adrenal hemorrhage</td>
    <td>Waterhouse-Friderichsen syndrome (meningococcemia)</td>
    <td></td>
  </tr>
  <tr>
    <td rowspan="2">
      Xed “currant jelly” sputum in patients with alcohol overuse or diabetes
      “ever, chills, headache, myalgia following antibiotic
    </td>
    <td>Klebsiella pneumoniae pneumonia</td>
    <td></td>
  </tr>
  <tr>
    <td></td>
    <td>Jarisch-Herxheimer reaction (due to host response to</td>
    <td></td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>CLINICAL PRESENTATION</th>
    <th>DIAGNOSIS/DISEASE</th>
    <th>PAGE</th>
  </thead>
  <tr>
    <td>Ulcerated genital lesion</td>
    <td>
      Nonpainful, indurated: chancre (1° syphilis, Treponema pallidum) Painful,
      with exudate: chancroid (Haemophilus ducreyi)
    </td>
    <td>145, 180</td>
  </tr>
  <tr>
    <td>Smooth, moist, painless, wartlike white lesions on genitals</td>
    <td>~Condylomata lata (2° syphilis)</td>
    <td>145</td>
  </tr>
  <tr>
    <td>Pupil accommodates but doesn’t react to light</td>
    <td>Neurosyphilis (Argyll Robertson pupil)</td>
    <td>145</td>
  </tr>
  <tr>
    <td>Dog or cat bite resulting in infection (cellulitis, osteomyelitis)</td>
    <td>Pasteurella multocida (cellulitis at inoculation site)</td>
    <td>147</td>
  </tr>
  <tr>
    <td>
      Atypical "walking pneumonia" with x-ray looking worse than the patient
    </td>
    <td>Mycoplasma pneumoniae infection</td>
    <td>148</td>
  </tr>
  <tr>
    <td>Rash on palms and soles</td>
    <td>Coxsackie A, 2° syphilis, Rocky Mountain spotted fever</td>
    <td>148</td>
  </tr>
  <tr>
    <td>
      Black eschar on face of patient with diabetic ketoacidosis | and/or
      neutropenia
    </td>
    <td>Mucor or Rhizopus fungal infection</td>
    <td>150</td>
  </tr>
  <tr>
    <td>Chorioretinitis, hydrocephalus, intracranial calcifications |</td>
    <td>Congenital toxoplasmosis</td>
    <td>153</td>
  </tr>
  <tr>
    <td>Pruritus, serpiginous rash after walking barefoot</td>
    <td>Hookworm (Ancylostoma spp, Necator americanus)</td>
    <td>156</td>
  </tr>
  <tr>
    <td>
      Child with fever later develops red rash on face that spreads to body
    </td>
    <td>
      Erythema infectiosum/fifth disease (“slapped cheeks” appearance, caused by
      parvovirus B19)
    </td>
    <td>161</td>
  </tr>
  <tr>
    <td>Fever, cough, conjunctivitis, coryza, diffuse rash</td>
    <td>Measles</td>
    <td>167</td>
  </tr>
  <tr>
    <td>
      Small, irregular red spots on buccal/lingual mucosa with __ blue-white
      centers
    </td>
    <td>Koplik spots (measles [rubeola] virus)</td>
    <td>167</td>
  </tr>
  <tr>
    <td>
      Bounding pulses, wide pulse pressure, diastolic heart murmur, head bobbing
    </td>
    <td>Aortic regurgitation</td>
    <td>296</td>
  </tr>
  <tr>
    <td>
      Systolic ejection murmur (crescendo-decrescendo), narrow pulse pressure,
      pulsus parvus et tardus
    </td>
    <td>Aortic stenosis</td>
    <td>296</td>
  </tr>
  <tr>
    <td>Continuous “machinelike” heart murmur</td>
    <td>PDA (close with indomethacin; keep open with PGE analogs)</td>
    <td>296</td>
  </tr>
  <tr>
    <td>Chest pain on exertion</td>
    <td>
      Angina (stable: with moderate exertion; unstable: with minimal exertion or
      at rest)
    </td>
    <td>308</td>
  </tr>
  <tr>
    <td>Chest pain with ST depressions on ECG</td>
    <td>Angina (© troponins) or NSTEMI (@ troponins)</td>
    <td>308</td>
  </tr>
  <tr>
    <td>
      Chest pain, pericardial effusion/friction rub, persistent fever following
      MI
    </td>
    <td>
      Postcardiac injury syndrome (autoimmune-mediated post-MI fibrinous
      pericarditis, 2 weeks to several months after acute episode)
    </td>
    <td>314</td>
  </tr>
  <tr>
    <td>Distant heart sounds, distended neck veins, hypotension _</td>
    <td>Beck triad of cardiac tamponade</td>
    <td>317</td>
  </tr>
  <tr>
    <td>
      Painful, raised red lesions on pads of fingers/toes Painless lesions and
      soles
    </td>
    <td>
      Osler nodes (infective endocarditis, immune complex deposition) lesions
      emboli/
    </td>
    <td>318 318</td>
  </tr>
  <tr>
    <td>erythematous on palms Splinter hemorrhages in fingernails</td>
    <td>
      Janeway (infective endocarditis, septic microabscesses) Infective
      endocarditis
    </td>
    <td>318</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>CLINICAL PRESENTATION</th>
    <th>DIAGNOSIS/DISEASE</th>
  </thead>
  <tr>
    <td>No lactation postpartum, absent menstruation, cold intolerance</td>
    <td>
      Sheehan syndrome (severe postpartum hemorrhage leading to pituitary
      infarction)
    </td>
  </tr>
  <tr>
    <td>Heat intolerance, weight loss, palpitations</td>
    <td>Hyperthyroidism</td>
  </tr>
  <tr>
    <td>Cold intolerance, weight gain, brittle hair</td>
    <td>Hypothyroidism</td>
  </tr>
  <tr>
    <td>
      Cutaneous/dermal edema due to deposition of mucopolysaccharides in
      connective tissue
    </td>
    <td>
      Myxedema (caused by hypothyroidism or hyperthyroidism [Graves disease])
    </td>
  </tr>
  <tr>
    <td>Facial muscle spasm upon tapping</td>
    <td>Chvostek sign (hypocalcemia)</td>
  </tr>
  <tr>
    <td>Carpal spasm upon inflation of BP cuff</td>
    <td>Trousseau sign (hypocalcemia)</td>
  </tr>
  <tr>
    <td>Rapid, deep, labored breathing/hyperventilation</td>
    <td>Diabetic ketoacidosis (Kussmaul respirations)</td>
  </tr>
  <tr>
    <td>
      Skin hyperpigmentation, orthostatic hypotension, fatigue, weakness, muscle
      aches, weight loss, GI disturbances
    </td>
    <td>
      Chronic 1° adrenal insufficiency (Addison disease) &gt; t ACTH, t MSH
    </td>
  </tr>
  <tr>
    <td>
      Shock, altered mental status, vomiting, abdominal pain, weakness, fatigue
      in patient under glucocorticoid herapy
    </td>
    <td>Acute adrenal insufficiency (adrenal crisis)</td>
  </tr>
  <tr>
    <td>Pancreatic, pituitary, parathyroid tumors</td>
    <td>MENI (autosomal dominant MEN] mutation)</td>
  </tr>
  <tr>
    <td>
      Medullary thyroid carcinoma, parathyroid hyperplasia, pheochromocytoma
    </td>
    <td>MEN2A (autosomal dominant RET mutation)</td>
  </tr>
  <tr>
    <td>
      Medullary thyroid carcinoma, pheochromocytoma, mucosal neuromas, marfanoid
      habitus
    </td>
    <td>MENZB (autosomal dominant RET mutation)</td>
  </tr>
  <tr>
    <td>Cutaneous flushing, diarrhea, bronchospasm, heart murmur</td>
    <td>
      Carcinoid syndrome (t urinary 5-HIAA); indicates systemic dissemination
      (eg, liver metastases)
    </td>
  </tr>
  <tr>
    <td>Jaundice, palpable distended non-tender gallbladder</td>
    <td>post Courvoisier sign (distal malignant obstruction of biliary</td>
  </tr>
  <tr>
    <td></td>
    <td>tree)</td>
  </tr>
  <tr>
    <td>Vomiting blood following gastroesophageal lacerations</td>
    <td>Mallory-Weiss syndrome (alcohol use disorder, bulimia nervosa)</td>
  </tr>
  <tr>
    <td>Dysphagia (esophageal webs), glossitis, iron deficiency anemia</td>
    <td>
      Plummer-Vinson syndrome (may progress to esophageal squamous cell
      carcinoma)
    </td>
  </tr>
  <tr>
    <td>Enlarged, hard left supraclavicular node</td>
    <td>Virchow node (metastasis from abdominal malignancy)</td>
  </tr>
  <tr>
    <td>Hematemesis, melena</td>
    <td>Upper GI bleeding (eg, peptic ulcer disease)</td>
  </tr>
  <tr>
    <td>Hematochezia</td>
    <td>Lower GI bleeding (eg, colonic diverticulosis)</td>
  </tr>
  <tr>
    <td>Arthralgias, cardiac and neurological symptoms, diarrhea</td>
    <td>| Whipple disease (Tropheryma whipplei)</td>
  </tr>
  <tr>
    <td>Severe RLQ pain with palpation of LLOQ</td>
    <td>Roysing sign (acute appendicitis)</td>
  </tr>
  <tr>
    <td>Severe RLQ pain with deep tenderness</td>
    <td>McBurney sign (acute appendicitis)</td>
  </tr>
  <tr>
    <td>
      Hamartomatous GI polyps, hyperpigmented macules on _ mouth, feet, hands,
      genitalia
    </td>
    <td>
      Peutz-Jeghers syndrome (inherited, benign polyposis can cause bowel
      obstruction; t breast/GI cancer risk)
    </td>
  </tr>
  <tr>
    <td rowspan="2">
      Multiple colon polyps, osteomas/soft tissue tumors, impacted/supernumerary
      teeth Severe jaundice in neonate
    </td>
    <td>Gardner syndrome (subtype of FAP)</td>
  </tr>
  <tr>
    <td></td>
    <td>
      Crigler-Najjar syndrome (congenital unconjugated hyperbilirubinemia)
    </td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>CLINICAL PRESENTATION</th>
    <th>DIAGNOSIS/DISEASE</th>
    <th>PAGE</th>
  </thead>
  <tr>
    <td>Female, fat (obese), fertile (multiparity), forty, fair</td>
    <td>Cholelithiasis (gallstones)</td>
    <td>403</td>
  </tr>
  <tr>
    <td>Painless jaundice with enlarged gallbladder</td>
    <td>Cancer of pancreatic head obstructing the bile duct</td>
    <td>405</td>
  </tr>
  <tr>
    <td>Bluish line on gingiva</td>
    <td>Burton line (lead poisoning)</td>
    <td>425</td>
  </tr>
  <tr>
    <td>
      Short stature, café-au-lait spots, thumb/radial defects, t incidence of
      tumors/leukemia, aplastic anemia
    </td>
    <td>
      Fanconi anemia (genetic loss of DNA crosslink repair; often progresses to
      AML)
    </td>
    <td>427</td>
  </tr>
  <tr>
    <td>Red/pink urine, fragile RBCs</td>
    <td>Paroxysmal nocturnal hemoglobinuria</td>
    <td>428</td>
  </tr>
  <tr>
    <td>Painful blue fingers/toes, hemolytic anemia</td>
    <td>
      Cold agglutinin disease (autoimmune hemolytic anemia caused by Mycoplasma
      pneumoniae, infectious mononucleosis, CLL)
    </td>
    <td>429</td>
  </tr>
  <tr>
    <td>Petechiae, mucosal bleeding, prolonged bleeding time</td>
    <td>
      Platelet disorders (eg, Glanzmann thrombasthenia, Bernard Soulier, HUS,
      TTP, ITP, uremic platelet dysfunction)
    </td>
    <td>432</td>
  </tr>
  <tr>
    <td>Fever, night sweats, weight loss</td>
    <td>B symptoms of malignancy</td>
    <td>434</td>
  </tr>
  <tr>
    <td>Skin patches/plaques, Pautrier microabscesses, atypical T cells</td>
    <td>
      Mycosis fungoides (cutaneous T-cell lymphoma) or Sézary syndrome (mycosis
      fungoides + malignant T cells in blood)
    </td>
    <td>435</td>
  </tr>
  <tr>
    <td>
      Neonate with arm paralysis following difficult birth, arm in “waiter’s
      tip” position
    </td>
    <td>Erb-Duchenne palsy (superior trunk [C5—C6] brachial plexus injury)</td>
    <td>452</td>
  </tr>
  <tr>
    <td>Anterior drawer ®</td>
    <td>Anterior cruciate ligament injury</td>
    <td></td>
  </tr>
  <tr>
    <td>sign Bone pain, bone enlargement, long bone chalk-stick</td>
    <td>Osteitis deformans (Paget disease of bone, t osteoblastic</td>
    <td></td>
  </tr>
  <tr>
    <td>
      fractures Swollen, hard, painful finger joints in an elderly individual,
      pain with activity
    </td>
    <td>
      and osteoclastic activity) Osteoarthritis (osteophytes on PIP [Bouchard
      nodes], DIP {Heberden nodes])
    </td>
    <td></td>
  </tr>
  <tr>
    <td>worse Sudden swollen/painful big toe joint, tophi</td>
    <td>Gout/podagra (hyperuricemia)</td>
    <td></td>
  </tr>
  <tr>
    <td>Dry eyes, dry mouth, arthritis</td>
    <td>Sjégren syndrome (autoimmune destruction of exocrine</td>
    <td></td>
  </tr>
  <tr>
    <td>Urethritis, conjunctivitis, arthritis in a male</td>
    <td>glands) Reactive arthritis associated with HLA-B27</td>
    <td></td>
  </tr>
  <tr>
    <td>
      “Butterfly” facial rash, arthritis, cytopenia, and fever in a female
    </td>
    <td>Systemic lupus erythematosus</td>
    <td></td>
  </tr>
  <tr>
    <td>
      young Cervical lymphadenopathy, desquamating rash, coronary aneurysms, red
      conjunctivae and tongue, hand-foot
    </td>
    <td>
      Kawasaki disease (mucocutaneous lymph node syndrome, treat with IVIG and
      aspirin)
    </td>
    <td>478</td>
  </tr>
  <tr>
    <td>
      changes Palpable purpura on buttocks/legs, joint pain, abdominal pain
      (child), hematuria
    </td>
    <td>
      Immunoglobulin A vasculitis (Henoch-Schénlein purpura, affects skin and
      kidneys)
    </td>
    <td>479</td>
  </tr>
  <tr>
    <td>
      Painful fingers/toes changing color from white to blue to red with cold or
      stress
    </td>
    <td>Raynaud phenomenon (vasospasm in extremities)</td>
    <td>480</td>
  </tr>
  <tr>
    <td rowspan="2">
      Dark purple skin/mouth nodules in a patient with AIDS Pruritic, purple,
      polygonal planar papules and plaques
    </td>
    <td>Kaposi sarcoma, associated with HHV-8</td>
    <td>486</td>
  </tr>
  <tr>
    <td></td>
    <td>Lichen planus</td>
    <td>491</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>CLINICAL PRESENTATION</th>
    <th>DIAGNOSIS/DISEASE</th>
    <th>PAGE</th>
  </thead>
  <tr>
    <td>Hyperphagia, hypersexuality, hyperorality</td>
    <td>Kliiver-Bucy syndrome (bilateral amygdala lesion)</td>
    <td>526</td>
  </tr>
  <tr>
    <td>Resting tremor, athetosis, chorea</td>
    <td>Basal ganglia lesion</td>
    <td>526</td>
  </tr>
  <tr>
    <td>
      Dysphagia, hoarseness, + gag reflex, nystagmus, ipsilateral Horner
      syndrome
    </td>
    <td>
      Lateral medullary (Wallenberg) syndrome (posterior inferior cerebellar
      artery lesion)
    </td>
    <td>529</td>
  </tr>
  <tr>
    <td>Lucid interval after traumatic brain injury</td>
    <td>
      Epidural hematoma (middle meningeal artery rupture; branch of maxillary
      artery)
    </td>
    <td>530</td>
  </tr>
  <tr>
    <td>“Worst headache of my life”</td>
    <td>Subarachnoid hemorrhage</td>
    <td>530</td>
  </tr>
  <tr>
    <td>
      Resting tremor, rigidity, akinesia, postural instability, shuffling gait,
      micrographia
    </td>
    <td>
      Parkinson disease (loss of dopaminergic neurons in substantia nigra pars
      compacta)
    </td>
    <td>536</td>
  </tr>
  <tr>
    <td>Chorea, dementia, caudate degeneration</td>
    <td>Huntington disease (autosomal dominant CAG repeat expansion)</td>
    <td>536</td>
  </tr>
  <tr>
    <td>Urinary incontinence, gait apraxia, cognitive dysfunction</td>
    <td>Normal pressure hydrocephalus</td>
    <td>538</td>
  </tr>
  <tr>
    <td>
      Relapsing and remitting nystagmus, intention tremor, scanning speech,
      bilateral internuclear ophthalmoplegia
    </td>
    <td>Multiple sclerosis</td>
    <td>539</td>
  </tr>
  <tr>
    <td>
      Rapidly progressive limb weakness that ascends following — Gl/upper
      respiratory infection
    </td>
    <td>
      Guillain-Barré syndrome (acute inflammatory demyelinating polyneuropathy)
    </td>
    <td>540</td>
  </tr>
  <tr>
    <td>
      Café-au-lait spots, Lisch nodules (iris hamartoma), cutaneous
      neurofibromas, pheochromocytomas, optic gliomas
    </td>
    <td>Neurofibromatosis type I</td>
    <td>541</td>
  </tr>
  <tr>
    <td>Vascular birthmark (port-wine stain) of the face</td>
    <td>Nevus flammeus (benign, but associated with Sturge- Weber syndrome)</td>
    <td>541</td>
  </tr>
  <tr>
    <td>
      Renal cell carcinoma (bilateral), hemangioblastomas, angiomatosis,
      pheochromocytoma
    </td>
    <td>von Hippel-Lindau disease (deletion of VHL on chromosome 3p)</td>
    <td>541</td>
  </tr>
  <tr>
    <td>Bilateral vestibular schwannomas</td>
    <td>Neurofibromatosis type II</td>
    <td>541</td>
  </tr>
  <tr>
    <td>Hyperreflexia, hypertonia, Babinski sign present</td>
    <td>UMN damage</td>
    <td>545</td>
  </tr>
  <tr>
    <td>Hyporeflexia, hypotonia, atrophy, fasciculations</td>
    <td>LMN damage</td>
    <td>545</td>
  </tr>
  <tr>
    <td>
      Staggering gait, frequent falls, nystagmus, hammer toes, __ diabetes
      mellitus, hypertrophic cardiomyopathy
    </td>
    <td>Friedreich ataxia</td>
    <td>547</td>
  </tr>
  <tr>
    <td>Unilateral facial drooping involving forehead</td>
    <td>LMN facial nerve (CN VII) palsy; UMN lesions spare the forehead</td>
    <td>548</td>
  </tr>
  <tr>
    <td>Episodic vertigo, tinnitus, sensorineural hearing loss</td>
    <td>Méniére disease</td>
    <td>550</td>
  </tr>
  <tr>
    <td>Ptosis, miosis, anhidrosis</td>
    <td>Horner syndrome (sympathetic chain lesion)</td>
    <td>557</td>
  </tr>
  <tr>
    <td>Conjugate horizontal gaze palsy, horizontal diplopia</td>
    <td>
      Internuclear ophthalmoplegia (damage to MLF; may be unilateral or
      bilateral)
    </td>
    <td>560</td>
  </tr>
  <tr>
    <td>
      “Waxing and waning” level of consciousness (acute onset), $ attention
      span, $ level of arousal
    </td>
    <td>Delirium (usually 2° to other cause)</td>
    <td>577</td>
  </tr>
  <tr>
    <td>
      Polyuria, renal tubular acidosis type II, growth retardation, electrolyte
      imbalances, hypophosphatemic rickets
    </td>
    <td>
      Fanconi syndrome (multiple combined dysfunction of the proximal convoluted
      tubule)
    </td>
    <td>606</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>
      Wilms tumor, macroglossia, organomegaly, hemihyperplasia, omphalocele
    </th>
    <th>Beckwith-Wiedemann syndrome (WT2 mutation)</th>
    <th>626</th>
  </thead>
  <tr>
    <td>
      Streak ovaries, congenital heart disease, horseshoe kidney, cystic
      hygroma, short stature, webbed neck, lymphedema
    </td>
    <td>Turner syndrome (45,XO)</td>
    <td>657</td>
  </tr>
  <tr>
    <td>Ovarian fibroma, ascites, pleural effusion</td>
    <td>Meigs syndrome</td>
    <td>667</td>
  </tr>
  <tr>
    <td>Red, itchy, swollen rash of nipple/areola</td>
    <td>Paget disease of the breast (sign of underlying neoplasm)</td>
    <td>670</td>
  </tr>
  <tr>
    <td>
      Fibrous plaques in tunica albuginea of penis with abnormal curvature
    </td>
    <td>Peyronie disease (connective tissue disorder)</td>
    <td>671</td>
  </tr>
  <tr>
    <td>Pink complexion, dyspnea, hyperventilation</td>
    <td>
      Emphysema (“pink puffer,” centriacinar [tobacco smoking] or panacinar
      |o,,-antitrypsin deficiency])
    </td>
    <td>694</td>
  </tr>
  <tr>
    <td>Hypoxemia, polycythemia, hypercapnia</td>
    <td>
      Chronic bronchitis (hypertrophy and hyperplasia of mucus-secreting glands,
      “blue bloater”)
    </td>
    <td>695</td>
  </tr>
  <tr>
    <td>Bilateral hilar adenopathy, uveitis</td>
    <td>Sarcoidosis (noncaseating granulomas)</td>
    <td>697</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>LAB/DIAGNOSTIC FINDING</th>
    <th>DIAGNOSIS/DISEASE</th>
    <th>PAGE</th>
  </thead>
  <tr>
    <td>Colonies of Pseudomonas in lungs</td>
    <td>
      Cystic fibrosis (autosomal recessive mutation in CFTR gene — fat-soluble
      vitamin deficiency and mucous plugs)
    </td>
    <td>58</td>
  </tr>
  <tr>
    <td>+ AFP on second trimester screening</td>
    <td>Down syndrome, Edwards syndrome</td>
    <td>61</td>
  </tr>
  <tr>
    <td>t B-hCG, + PAPP-A on first trimester screening</td>
    <td>Down syndrome</td>
    <td>61</td>
  </tr>
  <tr>
    <td>t serum homocysteine, t methylmalonic acid, $ folate</td>
    <td>Vitamin B,, deficiency</td>
    <td>67</td>
  </tr>
  <tr>
    <td>Anti-histone antibodies</td>
    <td>Drug-induced lupus</td>
    <td>113</td>
  </tr>
  <tr>
    <td>+ T cells, } PTH, $ Ca**, absent thymic shadow on CXR</td>
    <td>Thymic aplasia (DiGeorge syndrome, velocardiofacial syndrome)</td>
    <td>114</td>
  </tr>
  <tr>
    <td>Recurrent infections, eczema, thrombocytopenia</td>
    <td>Wiskott-Aldrich syndrome</td>
    <td>115</td>
  </tr>
  <tr>
    <td>Large granules in phagocytes, immunodeficiency</td>
    <td>
      Chédiak-Higashi disease (congenital failure of phagolysosome formation)
    </td>
    <td>115</td>
  </tr>
  <tr>
    <td>Optochin sensitivity</td>
    <td>
      Sensitive: S pneumoniae; resistant: viridans streptococci (S mutans, S
      sanguis)
    </td>
    <td>132</td>
  </tr>
  <tr>
    <td>Novobiocin response</td>
    <td>Sensitive: S epidermidis; resistant: S saprophyticus</td>
    <td>132</td>
  </tr>
  <tr>
    <td>Bacitracin response</td>
    <td>Sensitive: S pyogenes (group A); resistant: S agalactiae (group B)</td>
    <td>132</td>
  </tr>
  <tr>
    <td>Branching gram © rods with sulfur granules</td>
    <td>Actinomyces israeli</td>
    <td>137</td>
  </tr>
  <tr>
    <td>
      Hilar lymphadenopathy, peripheral granulomatous lesion in middle or lower
      lung lobes (can calcify)
    </td>
    <td>Ghon complex (1° TB: Mycobacterium bacilli)</td>
    <td>138</td>
  </tr>
  <tr>
    <td>“Thumb sign” on lateral neck x-ray</td>
    <td>Epiglottitis (Haemophilus influenzae)</td>
    <td>140</td>
  </tr>
  <tr>
    <td>Bacteria-covered vaginal epithelial cells, ® whiff test</td>
    <td>“Clue cells” (Gardnerella vaginalis)</td>
    <td>147</td>
  </tr>
  <tr>
    <td>Ring-enhancing brain lesion on CT/MRI in AIDS</td>
    <td>Toxoplasma gondii (multiple), CNS lymphoma (may be</td>
    <td>153,</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>LAB/DIAGNOSTIC FINDING</th>
    <th>DIAGNOSIS/DISEASE</th>
    <th>PAGE</th>
  </thead>
  <tr>
    <td>
      Dilated cardiomyopathy with apical atrophy, megacolon, megaesophagus
    </td>
    <td>Chagas disease (‘Trypanosoma cruzi)</td>
    <td>155</td>
  </tr>
  <tr>
    <td>Atypical lymphocytes, heterophile antibodies</td>
    <td>Infectious mononucleosis (EBV infection)</td>
    <td>162</td>
  </tr>
  <tr>
    <td>Narrowing of upper trachea and subglottis (Steeple sign) on x-ray</td>
    <td>Croup (parainfluenza virus)</td>
    <td>167</td>
  </tr>
  <tr>
    <td>
      Eosinophilic inclusion bodies in cytoplasm of hippocampal and cerebellar
      neurons
    </td>
    <td>Negri bodies of rabies</td>
    <td>169</td>
  </tr>
  <tr>
    <td>Psammoma bodies</td>
    <td>
      Meningiomas, papillary thyroid carcinoma, mesothelioma, papillary serous
      carcinoma of the endometrium and ovary
    </td>
    <td>207</td>
  </tr>
  <tr>
    <td>“Boot-shaped” heart on x-ray</td>
    <td>Tetralogy of Fallot (due to RVH)</td>
    <td>302</td>
  </tr>
  <tr>
    <td>Rib notching (inferior surface, on x-ray)</td>
    <td>Coarctation of the aorta</td>
    <td>304</td>
  </tr>
  <tr>
    <td>
      “Delta wave” on ECG, short PR interval, supraventricular tachycardia
    </td>
    <td>Wolff-Parkinson-White syndrome (bundle of Kent bypasses AV node)</td>
    <td>311</td>
  </tr>
  <tr>
    <td>Electrical alternans (alternating amplitude on ECG)</td>
    <td>Cardiac tamponade</td>
    <td>317</td>
  </tr>
  <tr>
    <td>Granuloma with giant cells after pharyngeal infection</td>
    <td>Aschoff bodies (rheumatic fever)</td>
    <td>319</td>
  </tr>
  <tr>
    <td>Empty-appearing nuclei with central clearing of thyroid cells</td>
    <td>“Orphan Annie” eyes nuclei (papillary carcinoma of the thyroid)</td>
    <td>347</td>
  </tr>
  <tr>
    <td>“Brown” tumor of bone</td>
    <td>
      Hyperparathyroidism or osteitis fibrosa cystica (deposited hemosiderin
      from hemorrhage gives brown color)
    </td>
    <td>349 469</td>
  </tr>
  <tr>
    <td>Hypertension, hypokalemia, metabolic alkalosis</td>
    <td>1° hyperaldosteronism (eg, Conn syndrome)</td>
    <td>354</td>
  </tr>
  <tr>
    <td>Mucin-filled cell with peripheral nucleus</td>
    <td>“Signet ring” cells (diffuse gastric carcinoma)</td>
    <td>386</td>
  </tr>
  <tr>
    <td>Anti-transglutaminase/anti-gliadin/anti-endomysial antibodies</td>
    <td>Celiac disease (diarrhea, weight loss)</td>
    <td>388</td>
  </tr>
  <tr>
    <td>Narrowing of bowel lumen on barium x-ray</td>
    <td>“String sign” (Crohn disease)</td>
    <td>389</td>
  </tr>
  <tr>
    <td>“Lead pipe” appearance of colon on abdominal imaging</td>
    <td>Ulcerative colitis (loss of haustra)</td>
    <td>389</td>
  </tr>
  <tr>
    <td>Thousands of polyps on colonoscopy</td>
    <td>
      Familial adenomatous polyposis (autosomal dominant, mutation of APC gene)
    </td>
    <td>394</td>
  </tr>
  <tr>
    <td>‘Apple core” lesion on barium enema x-ray</td>
    <td>Colorectal cancer (usually left-sided)</td>
    <td>395</td>
  </tr>
  <tr>
    <td>Eosinophilic cytoplasmic inclusion in liver cell</td>
    <td>Mallory body (alcoholic liver disease)</td>
    <td>398</td>
  </tr>
  <tr>
    <td>Triglyceride accumulation in liver cell vacuoles</td>
    <td>Fatty liver disease (alcoholic or metabolic syndrome)</td>
    <td>398</td>
  </tr>
  <tr>
    <td>
      Anti-smooth muscle antibodies (ASMAs), anti-liver/ kidney microsomal-1
      (anti-LKM1) antibodies
    </td>
    <td>Autoimmune hepatitis</td>
    <td>398</td>
  </tr>
  <tr>
    <td>“Nutmeg” appearance of liver</td>
    <td>
      Chronic passive congestion of liver due to right heart failure or
      Budd-Chiari syndrome
    </td>
    <td>399</td>
  </tr>
  <tr>
    <td>Antimitochondrial antibodies (AMAs)</td>
    <td>1° biliary cholangitis (female, cholestasis, portal hypertension)</td>
    <td>402</td>
  </tr>
  <tr>
    <td>Low serum ceruloplasmin</td>
    <td>
      Wilson disease (hepatolenticular degeneration; Kayser- Fleischer rings due
      to copper accumulation)
    </td>
    <td>402</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>LAB/DIAGNOSTIC FINDING</th>
    <th>DIAGNOSIS/DISEASE</th>
    <th>PAGE</th>
  </thead>
  <tr>
    <td>Basophilic nuclear remnants in RBCs</td>
    <td>Howell-Jolly bodies (due to splenectomy or nonfunctional spleen)</td>
    <td>422</td>
  </tr>
  <tr>
    <td>Basophilic stippling of RBCs</td>
    <td>Sideroblastic anemias, thalassemias</td>
    <td>422</td>
  </tr>
  <tr>
    <td>Hypochromic, microcytic anemia</td>
    <td>
      Iron deficiency anemia, lead poisoning, thalassemia (fetal hemoglobin
      sometimes present)
    </td>
    <td>424, 425</td>
  </tr>
  <tr>
    <td>“Hair on end” (“crew cut”) appearance on x-ray</td>
    <td>B-thalassemia, sickle cell anemia (marrow expansion)</td>
    <td>425, 428</td>
  </tr>
  <tr>
    <td>Anti-GplIb/IIIa antibodies</td>
    <td>Immune thrombocytopenia</td>
    <td>432</td>
  </tr>
  <tr>
    <td>High level of p-dimers</td>
    <td>DVT, DIC</td>
    <td>433, 692</td>
  </tr>
  <tr>
    <td>
      Giant B cells with bilobed nucleus with prominent inclusions (“owl’s eye”)
    </td>
    <td>Reed-Sternberg cells (Hodgkin lymphoma)</td>
    <td>434</td>
  </tr>
  <tr>
    <td>
      Sheets of medium-sized lymphoid cells with scattered pale, tingible
      body—laden macrophages (“starry sky” histology)
    </td>
    <td>
      Burkitt lymphoma (t[8:14] c-myc activation, associated with EBV; “starry
      sky” made up of malignant cells)
    </td>
    <td>435</td>
  </tr>
  <tr>
    <td>Lytic (“punched-out”) bone lesions on x-ray</td>
    <td>Multiple myeloma</td>
    <td>436</td>
  </tr>
  <tr>
    <td>Monoclonal spike on serum protein electrophoresis</td>
    <td>
      Multiple myeloma (usually IgG or IgA) Waldenstrém macroglobulinemia (IgM)
      Monoclonal gammopathy of undetermined significance
    </td>
    <td>436</td>
  </tr>
  <tr>
    <td>Stacks of RBCs</td>
    <td>Rouleaux formation (high ESR, multiple myeloma)</td>
    <td>436</td>
  </tr>
  <tr>
    <td>
      Myeloperoxidase ® cytoplasmic inclusions in myeloblasts, with tt
      circulating myeloblasts
    </td>
    <td>Auer rods (APL)</td>
    <td></td>
  </tr>
  <tr>
    <td>WBGs that look “smudged”</td>
    <td>CLL</td>
    <td></td>
  </tr>
  <tr>
    <td>
      “Tennis racket”-shaped cytoplasmic organelles (EM) in Langerhans cells
    </td>
    <td>Birbeck granules (Langerhans cell histiocytosis)</td>
    <td></td>
  </tr>
  <tr>
    <td>“Soap bubble” in femur or tibia on x-ray</td>
    <td>Giant cell tumor of bone (generally benign)</td>
    <td></td>
  </tr>
  <tr>
    <td>Raised periosteum (creating a “Codman triangle”)</td>
    <td>Aggressive bone lesion (eg, osteosarcoma, Ewing sarcoma)</td>
    <td></td>
  </tr>
  <tr>
    <td>“Onion skin” periosteal reaction</td>
    <td>Ewing sarcoma (malignant small blue cell tumor)</td>
    <td></td>
  </tr>
  <tr>
    <td>IgM antibody that targets IgG Fc region</td>
    <td>
      Rheumatoid arthritis (systemic inflammation, joint pannus, boutonniere and
      swan neck deformities)
    </td>
    <td></td>
  </tr>
  <tr>
    <td>Rhomboid crystals, ® birefringent</td>
    <td>Pseudogout (calcium pyrophosphate dihydrate crystals)</td>
    <td>473</td>
  </tr>
  <tr>
    <td>Needle-shaped, © birefringent crystals</td>
    <td>Gout (monosodium urate crystals)</td>
    <td>473</td>
  </tr>
  <tr>
    <td>t uric acid levels</td>
    <td>
      Gout, Lesch-Nyhan syndrome, tumor lysis syndrome, loop and thiazide
      diuretics
    </td>
    <td>473</td>
  </tr>
  <tr>
    <td>“Bamboo spine” on x-ray</td>
    <td>Ankylosing spondylitis (chronic inflammatory arthritis: HLA-B27)</td>
    <td>475</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>LAB/DIAGNOSTIC FINDING</th>
    <th>DIAGNOSIS/DISEASE</th>
    <th>PAGE</th>
  </thead>
  <tr>
    <td>Anticentromere antibodies</td>
    <td>Limited scleroderma (CREST syndrome)</td>
    <td>481</td>
  </tr>
  <tr>
    <td>
      Anti-Scl-70 (anti-DNA topoisomerase-I) and anti-RNA polymerase III
      antibodies
    </td>
    <td>Diffuse scleroderma</td>
    <td>481</td>
  </tr>
  <tr>
    <td>Anti-desmoglein (anti-desmosome) antibodies</td>
    <td>Pemphigus vulgaris</td>
    <td>489</td>
  </tr>
  <tr>
    <td>Antihemidesmosome antibodies</td>
    <td>Bullous pemphigoid</td>
    <td>489</td>
  </tr>
  <tr>
    <td>Keratin pearls on a skin biopsy</td>
    <td>Squamous cell carcinoma</td>
    <td>493</td>
  </tr>
  <tr>
    <td>t AFP in amniotic fluid/maternal serum</td>
    <td>Dating error, anencephaly, spina bifida (open neural tube defects)</td>
    <td>501</td>
  </tr>
  <tr>
    <td>Bloody or yellow tap on lumbar puncture</td>
    <td>Xanthochromia (due to subarachnoid hemorrhage)</td>
    <td>530</td>
  </tr>
  <tr>
    <td>Eosinophilic cytoplasmic inclusion in neuron</td>
    <td>Lewy body (Parkinson disease and Lewy body dementia)</td>
    <td>536</td>
  </tr>
  <tr>
    <td>Extracellular amyloid deposition in gray matter of brain _</td>
    <td>Senile plaques (Alzheimer disease)</td>
    <td>536</td>
  </tr>
  <tr>
    <td>Depigmentation of neurons in substantia nigra</td>
    <td>
      Parkinson disease (basal ganglia disorder: rigidity, resting tremor,
      bradykinesia)
    </td>
    <td>536</td>
  </tr>
  <tr>
    <td>
      Protein aggregates in neurons from hyperphosphorylation of tau protein
    </td>
    <td>
      Neurofibrillary tangles (Alzheimer disease) and Pick bodies (Pick disease)
    </td>
    <td>536</td>
  </tr>
  <tr>
    <td>Silver-staining spherical aggregation of tau proteins in neurons</td>
    <td>
      Pick bodies (frontotemporal dementia: progressive dementia, changes in
      personality)
    </td>
    <td>536</td>
  </tr>
  <tr>
    <td>Pseudopalisading pleomorphic tumor cells on brain biopsy</td>
    <td>Glioblastoma</td>
    <td>542</td>
  </tr>
  <tr>
    <td>Small blue cells surrounding central area of neuropil</td>
    <td>Homer-Wright rosettes (neuroblastoma, medulloblastoma)</td>
    <td>544</td>
  </tr>
  <tr>
    <td>“Waxy” casts with very low urine flow</td>
    <td>Chronic end-stage renal disease</td>
    <td>614</td>
  </tr>
  <tr>
    <td>WBC casts in urine</td>
    <td>
      Acute pyelonephritis, transplant rejection, tubulointerstitial
      inflammation
    </td>
    <td>614</td>
  </tr>
  <tr>
    <td>RBC casts in urine</td>
    <td>Glomerulonephritis</td>
    <td></td>
  </tr>
  <tr>
    <td>Anti-glomerular basement membrane antibodies</td>
    <td>Goodpasture syndrome (glomerulonephritis and hemoptysis)</td>
    <td></td>
  </tr>
  <tr>
    <td>Cellular crescents in Bowman capsule</td>
    <td>Rapidly progressive (crescentic) glomerulonephritis</td>
    <td>616</td>
  </tr>
  <tr>
    <td>“Wire loop” glomerular capillary appearance on light microscopy</td>
    <td>Diffuse proliferative glomerulonephritis (usually seen with lupus)</td>
    <td>617</td>
  </tr>
  <tr>
    <td>
      Linear appearance of IgG deposition on glomerular and — alveolar basement
      membranes
    </td>
    <td>Goodpasture syndrome</td>
    <td>616</td>
  </tr>
  <tr>
    <td>“Lumpy bumpy” appearance of glomeruli on immunofluorescence</td>
    <td>
      Infection-related glomerulonephritis (due to deposition of IgG, IgM, and
      C3)
    </td>
    <td>616</td>
  </tr>
  <tr>
    <td>Necrotizing vasculitis (lungs) and necrotizing glomerulonephritis</td>
    <td>
      Granulomatosis with polyangiitis (PR3-ANCA/c-ANCA) and Goodpasture
      syndrome (anti-basement membrane antibodies)
    </td>
    <td>616, 479</td>
  </tr>
  <tr>
    <td>
      “Tram-track” appearance of capillary loops of glomerular basement
      membranes on light microscopy Nodular hyaline deposits in glomeruli
    </td>
    <td>
      Membranoproliferative glomerulonephritis Kimmelstiel-Wilson nodules
      (diabetic
    </td>
    <td>617 618</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>LAB/DIAGNOSTIC FINDING</th>
    <th>DIAGNOSIS/DISEASE</th>
    <th>PAGE</th>
  </thead>
  <tr>
    <td>Thyroidlike appearance of kidney</td>
    <td>Chronic pyelonephritis (usually due to recurrent infections)</td>
    <td>621</td>
  </tr>
  <tr>
    <td>Granular casts in urine</td>
    <td>Acute tubular necrosis (eg, ischemia or toxic injury)</td>
    <td>623</td>
  </tr>
  <tr>
    <td>hCG elevated</td>
    <td>
      Multifetal gestation, hydatidiform moles, choriocarcinomas, Down syndrome
    </td>
    <td>654</td>
  </tr>
  <tr>
    <td>
      Dysplastic squamous cervical cells with “raisinoid” nuclei and
      hyperchromasia
    </td>
    <td>Koilocytes (HPV: predisposes to cervical cancer)</td>
    <td>664</td>
  </tr>
  <tr>
    <td>Sheets of uniform “fried egg” cells, t hCG, t LDH</td>
    <td>Dysgerminoma</td>
    <td>667</td>
  </tr>
  <tr>
    <td>Glomeruluslike structure surrounding vessel in germ cells</td>
    <td>Schiller-Duval bodies (yolk sac tumor)</td>
    <td>667</td>
  </tr>
  <tr>
    <td>
      Disarrayed granulosa cells arranged around collections of eosinophilic
      fluid
    </td>
    <td>Call-Exner bodies (granulosa cell tumor of the ovary)</td>
    <td>667</td>
  </tr>
  <tr>
    <td>“Chocolate cyst” of ovary</td>
    <td>Endometriosis (frequently involves both ovaries)</td>
    <td>668</td>
  </tr>
  <tr>
    <td>Mammary gland (“blue domed”) cyst</td>
    <td>Fibrocystic change of the breast</td>
    <td>669</td>
  </tr>
  <tr>
    <td>Rectangular, crystal-like, cytoplasmic inclusions in Leydig cells</td>
    <td>Reinke crystals (Leydig cell tumor)</td>
    <td>673</td>
  </tr>
  <tr>
    <td>Thrombi made of white/red layers</td>
    <td>Lines of Zahn (arterial thrombus, layers of platelets/ RBCs)</td>
    <td>693</td>
  </tr>
  <tr>
    <td>
      Hexagonal, double-pointed, needlelike crystals in bronchial secretions
    </td>
    <td>Bronchial asthma (Charcot-Leyden crystals: eosinophilic granules)</td>
    <td>695</td>
  </tr>
  <tr>
    <td>Desquamated epithelium casts in sputum</td>
    <td>
      Curschmann spirals (bronchial asthma; can result in whorled mucous plugs)
    </td>
    <td>695</td>
  </tr>
  <tr>
    <td>“Honeycomb lung” on x-ray or CT’</td>
    <td>Idiopathic pulmonary fibrosis</td>
    <td>696</td>
  </tr>
  <tr>
    <td>Iron-containing nodules in alveolar septum</td>
    <td>Ferruginous bodies (asbestosis: t chance of lung cancer)</td>
    <td>698</td>
  </tr>
  <tr>
    <td>Bronchogenic apical lung tumor on imaging</td>
    <td>
      Pancoast tumor (can compress cervical sympathetic chain and cause Horner
      syndrome)
    </td>
    <td>706</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>DISEASE/FINDING</th>
    <th>MOST COMMON/IMPORTANT ASSOCIATIONS.</th>
    <th>PAGE</th>
  </thead>
  <tr>
    <td>Mitochondrial inheritance</td>
    <td>
      Disease occurs in all offspring of affected females (maternal inheritance
      pattern), heteroplasmy
    </td>
    <td>55, 57</td>
  </tr>
  <tr>
    <td>Intellectual disability</td>
    <td>Down syndrome, fragile X syndrome</td>
    <td>60, 6l</td>
  </tr>
  <tr>
    <td>Vitamin deficiency (USA)</td>
    <td>
      Folate (pregnant women are at high risk; body stores only 3- to 4-month
      supply)
    </td>
    <td>66</td>
  </tr>
  <tr>
    <td>Lysosomal storage disease</td>
    <td>Gaucher disease</td>
    <td>86</td>
  </tr>
  <tr>
    <td>HLA-DR3</td>
    <td>
      DM type 1, SLE, Graves disease, Hashimoto thyroiditis, Addison disease
    </td>
    <td>98</td>
  </tr>
  <tr>
    <td>HLA-DR4</td>
    <td>Rheumatoid arthritis, type 1 DM, Addison disease</td>
    <td>98</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>DISEASE/FINDING</th>
    <th>MOST COMMON/IMPORTANT ASSOCIATIONS.</th>
    <th>PAGE</th>
  </thead>
  <tr>
    <td>
      Bacteria associated with gastritis, peptic ulcer disease, and gastric
      malignancies (eg, adenocarcinoma, MAL‘Toma)
    </td>
    <td>_H pylori</td>
    <td>44</td>
  </tr>
  <tr>
    <td>Opportunistic respiratory infection in AIDS</td>
    <td>Pneumocystis jirovecii</td>
    <td>51</td>
  </tr>
  <tr>
    <td>Viral encephalitis affecting temporal lobe</td>
    <td>HSV-1</td>
    <td>62</td>
  </tr>
  <tr>
    <td>Viral infection 2° to blood transfusion</td>
    <td>Hepatitis C</td>
    <td>71</td>
  </tr>
  <tr>
    <td>Food poisoning (exotoxin mediated)</td>
    <td>S aureus, B cereus</td>
    <td>175</td>
  </tr>
  <tr>
    <td>Healthcare-associated pneumonia</td>
    <td>S aureus, Pseudomonas, other gram © rods</td>
    <td>176</td>
  </tr>
  <tr>
    <td>Bacterial meningitis (&gt; 6 months old)</td>
    <td>S pneumoniae</td>
    <td>177</td>
  </tr>
  <tr>
    <td>Bacterial meningitis (newborns 0-6 months old)</td>
    <td>Group B streptococcus/E coli/Listeria (newborns)</td>
    <td>177</td>
  </tr>
  <tr>
    <td>Osteomyelitis</td>
    <td>S aureus (most common overall)</td>
    <td>177</td>
  </tr>
  <tr>
    <td>Osteomyelitis in sickle cell disease</td>
    <td>Salmonella and S aureus</td>
    <td>177</td>
  </tr>
  <tr>
    <td>Osteomyelitis with injection drug use</td>
    <td>S aureus, Pseudomonas, Candida</td>
    <td>177</td>
  </tr>
  <tr>
    <td>UTI</td>
    <td>E coli, Staphylococcus saprophyticus</td>
    <td>79</td>
  </tr>
  <tr>
    <td>Bacterial STI</td>
    <td>C trachomatis</td>
    <td>80</td>
  </tr>
  <tr>
    <td>Pelvic disease</td>
    <td>C trachomatis N</td>
    <td>82</td>
  </tr>
  <tr>
    <td>inflammatory</td>
    <td>(subacute), gonorrhoeae (acute)</td>
    <td></td>
  </tr>
  <tr>
    <td>Metastases to bone</td>
    <td>Prostate, breast &gt;&gt; lung &gt; kidney, colon</td>
    <td>219</td>
  </tr>
  <tr>
    <td>Metastases to brain Metastases to liver</td>
    <td>
      Lung &gt; breast &gt;&gt; melanoma &gt; colon, prostate Colon &gt; breast
      &gt;&gt; lung, prostate
    </td>
    <td>219 219</td>
  </tr>
  <tr>
    <td>S3 heart sound</td>
    <td>
      pancreas, t ventricular filling pressure (eg, MR, AR, HF, in dilated
      ventricles
    </td>
    <td>292</td>
  </tr>
  <tr>
    <td>S4 heart sound</td>
    <td>
      thyrotoxicosis), common Stiff/hypertrophic ventricle (aortic stenosis,
      restrictive cardiomyopathy)
    </td>
    <td>292</td>
  </tr>
  <tr>
    <td>Holosystolic murmur</td>
    <td>VSD, tricuspid regurgitation, mitral regurgitation</td>
    <td>296</td>
  </tr>
  <tr>
    <td>Ejection click</td>
    <td>Aortic stenosis</td>
    <td>296</td>
  </tr>
  <tr>
    <td>Mitral stenosis</td>
    <td>
      Rheumatic heart disease (late and highly specific sequelae of rheumatic
      fever)
    </td>
    <td>296</td>
  </tr>
  <tr>
    <td>Opening snap</td>
    <td>Mitral stenosis</td>
    <td>296</td>
  </tr>
  <tr>
    <td>Heart murmur, congenital</td>
    <td>Mitral valve prolapse</td>
    <td>296</td>
  </tr>
  <tr>
    <td>Cyanotic heart disease (early)</td>
    <td>
      Tetralogy of Fallot (most common), D-transposition of great arteries,
      persistent truncus arteriosus, total anomalous pulmonary venous return,
      tricuspid atresia
    </td>
    <td>302</td>
  </tr>
  <tr>
    <td>
      Late cyanotic shunt (uncorrected left to right becomes right to left)
    </td>
    <td>Eisenmenger syndrome (caused by VSD, ASD, PDA)</td>
    <td>303</td>
  </tr>
  <tr>
    <td>Congenital heart disease (left-to-right shunts)</td>
    <td>VSD &gt; ASD &gt; PDA</td>
    <td>303</td>
  </tr>
  <tr>
    <td>Hypertension, 2°</td>
    <td>
      Renal/renovascular diseases (eg, fibromuscular dysplasia), atherosclerotic
      renal artery stenosis, 1° hyperaldosteronism, or obstructive sleep apnea
    </td>
    <td>304</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>Sites of atherosclerosis</th>
    <th>
      Abdominal aorta &gt; coronary artery &gt; popliteal artery &gt; carotid
      artery
    </th>
    <th>305</th>
  </thead>
  <tr>
    <td>Aortic dissection</td>
    <td>Hypertension (most important risk factor)</td>
    <td>307</td>
  </tr>
  <tr>
    <td>Irregularly irregular rhythm on ECG with no discrete P waves</td>
    <td>Atrial fibrillation (associated with high risk of emboli)</td>
    <td>311</td>
  </tr>
  <tr>
    <td>Right heart failure due to a pulmonary cause</td>
    <td>Cor pulmonale</td>
    <td>316</td>
  </tr>
  <tr>
    <td>Heart valve in infective endocarditis</td>
    <td>Mitral &gt; aortic, tricuspid (injection drug use)</td>
    <td>318</td>
  </tr>
  <tr>
    <td>Infective endocarditis presentation associated with bacterium</td>
    <td>
      S aureus (acute, injection drug use, tricuspid valve), viridans
      streptococci (subacute, dental procedure), S gallolyticus (colon cancer),
      gram © (HACEK), culture © (Coxiella, Bartonella)
    </td>
    <td>318</td>
  </tr>
  <tr>
    <td>Cardiac tumor (adults)</td>
    <td>Metastasis, myxoma (90% in left atrium; “ball valve”)</td>
    <td>320</td>
  </tr>
  <tr>
    <td>Cardiac 1° tumor (kids)</td>
    <td>Rhabdomyoma (associated with tuberous sclerosis)</td>
    <td>320</td>
  </tr>
  <tr>
    <td>Congenital adrenal hyperplasia, hypotension</td>
    <td>21-hydroxylase deficiency</td>
    <td>339</td>
  </tr>
  <tr>
    <td>Hypopituitarism</td>
    <td>Pituitary adenoma (usually benign tumor)</td>
    <td>343</td>
  </tr>
  <tr>
    <td>Congenital hypothyroidism (cretinism)</td>
    <td>Thyroid dysgenesis/dyshormonogenesis, iodine deficiency</td>
    <td>345</td>
  </tr>
  <tr>
    <td>Thyroid cancer</td>
    <td>Papillary carcinoma (RET/PTC rearrangements, BRAF’</td>
    <td>347</td>
  </tr>
  <tr>
    <td>Hypoparathyroidism</td>
    <td>mutations) Accidental excision during thyroidectomy</td>
    <td>348</td>
  </tr>
  <tr>
    <td>1° hyperparathyroidism</td>
    <td>Adenomas, hyperplasia, carcinoma</td>
    <td>349</td>
  </tr>
  <tr>
    <td>2° hyperparathyroidism</td>
    <td>Hypocalcemia of chronic kidney disease</td>
    <td>349</td>
  </tr>
  <tr>
    <td>Cushing syndrome</td>
    <td>
      * Exogenous glucocorticoids = Adrenocortical adenoma (secretes excess
      cortisol) » ACTH-secreting pituitary adenoma (Cushing disease) =
      Paraneoplastic (due to ACTH secretion by tumors)
    </td>
    <td>352</td>
  </tr>
  <tr>
    <td>1° hyperaldosteronism</td>
    <td>Bilateral adrenal hyperplasia or adenoma (Conn syndrome)</td>
    <td>354</td>
  </tr>
  <tr>
    <td>Tumor of the adrenal medulla (kids)</td>
    <td>Neuroblastoma (malignant)</td>
    <td>354</td>
  </tr>
  <tr>
    <td>Tumor of the adrenal medulla (adults)</td>
    <td>Pheochromocytoma (usually benign)</td>
    <td>355</td>
  </tr>
  <tr>
    <td>Refractory peptic ulcers and high gastrin levels</td>
    <td>
      Zollinger-Ellison syndrome (gastrinoma of duodenum or pancreas),
      associated with MEN]
    </td>
    <td>357</td>
  </tr>
  <tr>
    <td>Esophageal cancer</td>
    <td>Squamous cell carcinoma (worldwide); adenocarcinoma (US)</td>
    <td>385</td>
  </tr>
  <tr>
    <td>Acute gastric ulcer associated with CNS injury</td>
    <td>Cushing ulcer (t vagal stimulation + t ACh &gt; t H' production)</td>
    <td>386</td>
  </tr>
  <tr>
    <td>Acute gastric ulcer associated with severe burns</td>
    <td>Curling ulcer (hypovolemia + mucosal ischemia)</td>
    <td>386</td>
  </tr>
  <tr>
    <td>Bilateral ovarian metastases from gastric carcinoma</td>
    <td>Krukenberg tumor (mucin-secreting signet ring cells)</td>
    <td>386</td>
  </tr>
  <tr>
    <td>Chronic atrophic gastritis (autoimmune)</td>
    <td>
      Predisposition to gastric carcinoma (can also cause pernicious anemia)
    </td>
    <td>386</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>DISEASE/FINDING</th>
    <th>MOST COMMON/IMPORTANT ASSOCIATIONS.</th>
    <th>PAGE</th>
  </thead>
  <tr>
    <td>Diverticulum in pharynx</td>
    <td>Zenker diverticulum</td>
    <td>391</td>
  </tr>
  <tr>
    <td>Hepatocellular carcinoma</td>
    <td>
      HBV (+/ cirrhosis) or other causes of cirrhosis (eg, alcoholic liver
      disease, hemochromatosis), aflatoxins
    </td>
    <td>399</td>
  </tr>
  <tr>
    <td>Congenital conjugated hyperbilirubinemia (black liver)</td>
    <td>
      Dubin-Johnson syndrome (inability of hepatocytes to secrete conjugated
      bilirubin into bile)
    </td>
    <td>401</td>
  </tr>
  <tr>
    <td>Hereditary harmless jaundice</td>
    <td>
      Gilbert syndrome (benign congenital unconjugated hyperbilirubinemia)
    </td>
    <td>401</td>
  </tr>
  <tr>
    <td>Wilson disease</td>
    <td>
      Hereditary ATP7B mutation (copper buildup in liver, brain, cornea
      [Kayser-Fleischer rings], kidneys)
    </td>
    <td>402</td>
  </tr>
  <tr>
    <td>Hemochromatosis</td>
    <td>
      Multiple blood transfusions or hereditary HFE mutation (can result in
      heart failure, “bronze diabetes,” and t risk of hepatocellular carcinoma)
    </td>
    <td>402</td>
  </tr>
  <tr>
    <td>Pancreatitis (acute)</td>
    <td>Gallstones, alcohol</td>
    <td>404</td>
  </tr>
  <tr>
    <td>Pancreatitis (chronic)</td>
    <td>Alcohol (adults), cystic fibrosis (children)</td>
    <td>404</td>
  </tr>
  <tr>
    <td>Microcytic anemia</td>
    <td>Iron deficiency, thalassemias, lead poisoning, sideroblastic anemia</td>
    <td>424, 425</td>
  </tr>
  <tr>
    <td>Autosplenectomy (fibrosis and shrinkage), Howell-Jolly bodies</td>
    <td>Sickle cell anemia (hemoglobin S)</td>
    <td>428</td>
  </tr>
  <tr>
    <td>Platelet disorder with GpIb deficiency</td>
    <td>
      Bernard-Soulier syndrome (defect in platelet adhesion to von Willebrand
    </td>
    <td>432</td>
  </tr>
  <tr>
    <td>Platelet disorder with GpIIb/IIla deficiency</td>
    <td>factor) Glanzmann thrombasthenia (defect in platelet-to-platelet</td>
    <td>432</td>
  </tr>
  <tr>
    <td>Inherited bleeding disorder</td>
    <td>aggregation and platelet plug formation) von Willebrand disease</td>
    <td>433</td>
  </tr>
  <tr>
    <td>Hereditary thrombophilia</td>
    <td>Leiden (also associated with recurrent pregnancy loss)</td>
    <td>433</td>
  </tr>
  <tr>
    <td>DIC</td>
    <td>
      Stroke, snake bite, sepsis, trauma, obstetric complications, acute
      pancreatitis, malignancy, nephrotic syndrome,
    </td>
    <td>433</td>
  </tr>
  <tr>
    <td>Malignancy associated with noninfectious fever</td>
    <td>transfusion Hodgkin lymphoma</td>
    <td>434</td>
  </tr>
  <tr>
    <td>Type of Hodgkin lymphoma (most common)</td>
    <td>Nodular sclerosis</td>
    <td>434</td>
  </tr>
  <tr>
    <td>(14518)</td>
    <td>Follicular lymphoma (BCL-2 activation, anti-apoptotic oncogene)</td>
    <td>435, 439</td>
  </tr>
  <tr>
    <td>(8; 14)</td>
    <td>Burkitt lymphoma (c-myc fusion, transcription factor oncogene)</td>
    <td>435, 439</td>
  </tr>
  <tr>
    <td>Type of non-Hodgkin lymphoma (most common in adults)</td>
    <td>Diffuse large B-cell lymphoma</td>
    <td>435</td>
  </tr>
  <tr>
    <td>1° bone tumor (older adults)</td>
    <td>Multiple myeloma</td>
    <td>436</td>
  </tr>
  <tr>
    <td rowspan="2">
      Age ranges for patient with ALL/CLL/AML/CML Malignancy (kids)
    </td>
    <td>ALL: child, CLL: adult &gt; 60, AML: adult ~ 65, CML: adult 45-85</td>
    <td>437</td>
  </tr>
  <tr>
    <td></td>
    <td>Leukemia, brain tumors</td>
    <td>437</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>HLA-B27</th>
    <th>
      soriatic arthritis, ankylosing spondylitis, IBD-associated arthritis,
      reactive arthritis
    </th>
    <th>475</th>
  </thead>
  <tr>
    <td>Death in SLE</td>
    <td>
      Renal disease (most common), infections, cardiovascular disease
      (accelerated CAD)
    </td>
    <td>476</td>
  </tr>
  <tr>
    <td>Giant cell arteritis</td>
    <td>
      Risk of ipsilateral blindness due to occlusion of ophthalmic artery;
      polymyalgia rheumatica
    </td>
    <td>478</td>
  </tr>
  <tr>
    <td>Recurrent inflammation/thrombosis of medium-vessels in extremities</td>
    <td>
      Buerger disease (strongly associated with tobacco smoking, Raynaud
      phenomenon)
    </td>
    <td>478</td>
  </tr>
  <tr>
    <td>Benign vascular tumor of infancy</td>
    <td>
      Strawberry hemangioma (grows rapidly and regresses spontaneously by 5-8
      years of age)
    </td>
    <td>486</td>
  </tr>
  <tr>
    <td>Herald patch (Christmas tree distribution)</td>
    <td>ityriasis rosea</td>
    <td>491</td>
  </tr>
  <tr>
    <td>Actinic keratosis</td>
    <td>recursor to squamous cell carcinoma</td>
    <td>493</td>
  </tr>
  <tr>
    <td>Cerebellar tonsillar herniation</td>
    <td>
      Chiari I malformation (associated with spinal cord cavitations [eg,
      syringomyelia])
    </td>
    <td>502</td>
  </tr>
  <tr>
    <td>Bilateral mamillary body lesions with thiamine deficiency</td>
    <td>Wernicke-Korsakoff syndrome (with bilateral lesions)</td>
    <td>526</td>
  </tr>
  <tr>
    <td>Epidural hematoma</td>
    <td>Rupture of middle meningeal artery (trauma; lentiform shaped)</td>
    <td>530</td>
  </tr>
  <tr>
    <td>Subdural hematoma</td>
    <td>Rupture of bridging veins (crescent shaped)</td>
    <td>530</td>
  </tr>
  <tr>
    <td>Dementia</td>
    <td>Alzheimer disease, vascular dementia (multiple infarcts)</td>
    <td>536, 537</td>
  </tr>
  <tr>
    <td>Demyelinating disease in young women</td>
    <td>Multiple sclerosis</td>
    <td>539</td>
  </tr>
  <tr>
    <td>Brain tumor (adults)</td>
    <td>Metastasis, glioblastoma (malignant), meningioma, hemangioblastoma</td>
    <td>542</td>
  </tr>
  <tr>
    <td>Galactorrhea, amenorrhea</td>
    <td>Prolactinoma</td>
    <td>542</td>
  </tr>
  <tr>
    <td>Brain tumor (children)</td>
    <td>
      Infratentorial: medulloblastoma (cerebellum) or supratentorial:
      craniopharyngioma
    </td>
    <td>544</td>
  </tr>
  <tr>
    <td>Combined (UMN and LMN) motor neuron degeneration</td>
    <td>Amyotrophic lateral sclerosis</td>
    <td>546</td>
  </tr>
  <tr>
    <td>Degeneration of dorsal column fibers</td>
    <td>
      Tabes dorsalis (3° syphilis), subacute combined degeneration (dorsal
      columns, lateral corticospinal, spinocerebellar tracts affected)
    </td>
    <td>546</td>
  </tr>
  <tr>
    <td>Nephrotic syndrome (children)</td>
    <td>Minimal change disease</td>
    <td>618</td>
  </tr>
  <tr>
    <td>Kidney stones (radiolucent)</td>
    <td>Uric acid</td>
    <td>619</td>
  </tr>
  <tr>
    <td>Kidney stones (radiopaque)</td>
    <td>
      Calcium (most common), struvite (ammonium), cystine (faintly radiopaque)
    </td>
    <td>619</td>
  </tr>
  <tr>
    <td>Renal malignancy (in males)</td>
    <td>
      Renal cell carcinoma: associated with tobacco smoking and VHL (clear cell
      subtype); paraneoplastic syndromes (EPO, renin, PTHrP, ACTH)
    </td>
    <td>625</td>
  </tr>
  <tr>
    <td>1° amenorrhea</td>
    <td>Turner syndrome (45,XO or 45,XO/46,XX mosaic)</td>
    <td>657</td>
  </tr>
  <tr>
    <td>Hypogonadotropic hypogonadism with anosmia</td>
    <td>Kallmann syndrome (neuron migration failure)</td>
    <td>658</td>
  </tr>
  <tr>
    <td>Clear cell adenocarcinoma of the vagina</td>
    <td>DES exposure in utero</td>
    <td>664</td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>Ovarian tumor (malignant)</td>
    <td>Serous carcinoma</td>
    <td>666</td>
  </tr>
  <tr>
    <td>Benign tumor of myometrium</td>
    <td>Leiomyoma (estrogen dependent, not precancerous)</td>
    <td>668</td>
  </tr>
  <tr>
    <td>Gynecologic malignancy (most common)</td>
    <td>
      Endometrial carcinoma (most common in resource-rich countries); cervical
      cancer (most common worldwide)
    </td>
    <td>663- 668</td>
  </tr>
  <tr>
    <td>Breast mass</td>
    <td>
      Fibrocystic change (in premenopausal females); carcinoma (in
      postmenopausal females)
    </td>
    <td>669, 670</td>
  </tr>
  <tr>
    <td>Breast tumor (benign, young woman)</td>
    <td>Fibroadenoma</td>
    <td>669</td>
  </tr>
  <tr>
    <td>Breast cancer</td>
    <td>nvasive ductal carcinoma</td>
    <td>670</td>
  </tr>
  <tr>
    <td>Testicular tumor</td>
    <td>Seminoma (malignant, radiosensitive), t PLAP</td>
    <td>672, 673</td>
  </tr>
  <tr>
    <td>Bladder outlet obstruction in men</td>
    <td>BPH</td>
    <td>674</td>
  </tr>
  <tr>
    <td>Hypercoagulability, endothelial damage, blood stasis</td>
    <td>Virchow triad (t risk of thrombosis)</td>
    <td>692</td>
  </tr>
  <tr>
    <td>Pulmonary hypertension</td>
    <td>
      diopathic, left heart disease, lung diseases/hypoxia, chronic
      thromboembolism, multifactorial
    </td>
    <td>700</td>
  </tr>
  <tr>
    <td>SIADH</td>
    <td>Small cell carcinoma of the lung</td>
    <td>705</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>TOPIC</th>
    <th></th>
    <th>PAGE</th>
  </thead>
  <tr>
    <td>Volume of distribution</td>
    <td>amount of drug in the body plasma drug concentration</td>
    <td>229</td>
  </tr>
  <tr>
    <td>Half-life</td>
    <td>0.7 x Vy CL</td>
    <td>229</td>
  </tr>
  <tr>
    <td>Drug clearance</td>
    <td>
      4 K, (elimination constant) tate of elimination of drug _ plasma drug
      concentration
    </td>
    <td>229</td>
  </tr>
  <tr>
    <td>Loading dose</td>
    <td>C\xV, po td F</td>
    <td>229</td>
  </tr>
  <tr>
    <td>Maintenance dose</td>
    <td>C,xCLxt Maintenance dose = +&gt;</td>
    <td>229</td>
  </tr>
  <tr>
    <td>Therapeutic index</td>
    <td>median toxic dose/median effective dose = TD,,/ED,,</td>
    <td>233</td>
  </tr>
  <tr>
    <td>Od4ds ratio (for case-control studies)</td>
    <td>/c _ ad 26 _ 2 b/d be</td>
    <td>258</td>
  </tr>
  <tr>
    <td>Relative risk</td>
    <td>/(a +b) cl(c + d)</td>
    <td>258</td>
  </tr>
  <tr>
    <td>Attributable risk</td>
    <td>AR=—2 c “a+b c+d</td>
    <td>258</td>
  </tr>
  <tr>
    <td>Relative risk reduction</td>
    <td>(ARC — ART)/ARC</td>
    <td>258</td>
  </tr>
  <tr>
    <td>Absolute risk reduction</td>
    <td>c a c+td a+b</td>
    <td>258</td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>Number needed to treat</td>
    <td>NNT = L/ARR</td>
    <td>258</td>
  </tr>
  <tr>
    <td>Number needed to harm</td>
    <td>NNH = I/AR</td>
    <td>258</td>
  </tr>
  <tr>
    <td>Likelihood ratio +</td>
    <td>LR+ = sensitivity/(1 — specificity) = TP rate/FP rate</td>
    <td>259</td>
  </tr>
  <tr>
    <td>Likelihood ratio —</td>
    <td>LR-= 1 — sensitivity)/specificity = F'N rate/TN rate</td>
    <td>259</td>
  </tr>
  <tr>
    <td>Sensitivity</td>
    <td>Sensitivity = TP / (TP + FN)</td>
    <td>260</td>
  </tr>
  <tr>
    <td>Specificity</td>
    <td>Specificity = TN / (‘TN + FP)</td>
    <td>260</td>
  </tr>
  <tr>
    <td>Positive predictive value</td>
    <td>PPV =TP/(TP + FP)</td>
    <td>260</td>
  </tr>
  <tr>
    <td>Negative predictive value</td>
    <td>NPV =TN/(TN + FN)</td>
    <td>260</td>
  </tr>
  <tr>
    <td rowspan="3">Cardiac output</td>
    <td>rate of O, consumption</td>
    <td rowspan="3">290</td>
  </tr>
  <tr>
    <td></td>
    <td>CO = (arterial O, content - venous O, content)</td>
    <td></td>
  </tr>
  <tr>
    <td></td>
    <td>CO = stroke volume x heart rate</td>
    <td></td>
  </tr>
  <tr>
    <td rowspan="3">Mean arterial pressure</td>
    <td>MAP = CO x total peripheral resistance (TPR)</td>
    <td rowspan="3">290</td>
  </tr>
  <tr>
    <td></td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td></td>
    <td>MAP (at resting HR) = 74 DBP + 4 SBP = DBP + '4 PP</td>
    <td></td>
  </tr>
  <tr>
    <td rowspan="4">Stroke volume Ejection fraction</td>
    <td></td>
    <td>SV = EDV - ESV</td>
    <td>290</td>
  </tr>
  <tr>
    <td></td>
    <td>SV. _ EDV-ESV</td>
    <td rowspan="4">290</td>
    <td></td>
  </tr>
  <tr>
    <td>EF =</td>
  </tr>
  <tr>
    <td></td>
    <td>EDV EDV</td>
    <td></td>
  </tr>
  <tr>
    <td rowspan="3">Resistance</td>
    <td>driving pressure (AP) 81 (viscosity) x length</td>
    <td rowspan="3">291</td>
    <td></td>
  </tr>
  <tr>
    <td></td>
    <td>Resistance = = flow mt</td>
    <td></td>
  </tr>
  <tr>
    <td></td>
    <td>(Q)</td>
    <td></td>
  </tr>
  <tr>
    <td>Capillary fluid exchange</td>
    <td>J, = net fluid flow = K(P.— P,) — o(x, — 1)</td>
    <td>301</td>
  </tr>
  <tr>
    <td>Reticulocyte production index</td>
    <td>
      RPI = % reticulocytes x ( actual Het normal Het, ) / maturation time
    </td>
    <td>423</td>
  </tr>
  <tr>
    <td>Renal clearance</td>
    <td>C.=(UN)/P.</td>
    <td>602</td>
  </tr>
  <tr>
    <td>Glomerular filtration rate</td>
    <td>=GFR=U,,,,,. x V/P. inulin inulin = ~ ~ ~ inulin</td>
    <td>602</td>
  </tr>
  <tr>
    <td>Effective renal plasma flow</td>
    <td>K, (Pec P3s) ec T,5)| V eRPF = Upagy =Cpay Poa</td>
    <td>602</td>
  </tr>
  <tr>
    <td>Filtration fraction</td>
    <td>SFR rr-© RPF</td>
    <td>603</td>
  </tr>
  <tr>
    <td>Fractional excretion of sodium</td>
    <td>Fey. = Vx Ux, /GFR x Py, =P. x Uy, / Ug, x Py,</td>
    <td>604</td>
  </tr>
  <tr>
    <td>Henderson-Hasselbalch equation (for extracellular pH)</td>
    <td>[HCO,-] H=6.1 + log Hos! P °5 0.03 Peo,</td>
    <td>612</td>
  </tr>
  <tr>
    <td>Winters formula</td>
    <td>Poo, = 1.5 [HCO,|+ 8 + 2</td>
    <td>612</td>
  </tr>
  <tr>
    <td>Anion gap</td>
    <td>Na*— (Cl + HCO,)</td>
    <td>612</td>
  </tr>
  <tr>
    <td>Physiologic dead space</td>
    <td>Paco, — PEco, Vp Vr x —— =</td>
    <td>684</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>TOPIC</th>
    <th>EQUATION</th>
    <th>PAGE</th>
  </thead>
  <tr>
    <td>Pulmonary vascular resistance</td>
    <td>pulm artery 7 PL atrium PVR = Cardiac output</td>
    <td>686</td>
  </tr>
  <tr>
    <td>Alveolar gas equation</td>
    <td>Paco, Pao, = Pio, — = 150 mm Hg? — Paco, / 0.8</td>
    <td>687</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>DRUG</th>
    <th>CLINICAL USE/MECHANISM OF ACTION</th>
  </thead>
  <tr>
    <td>Amiloride</td>
    <td>K'-sparing diuretic</td>
  </tr>
  <tr>
    <td>Amiodarone</td>
    <td>Kk’ channel blocker (class HI antiarrhythmic)</td>
  </tr>
  <tr>
    <td>Amlodipine</td>
    <td>Dihydropyridine Ca** channel blocker</td>
  </tr>
  <tr>
    <td>Benztropine</td>
    <td>Parkinson disease (cholinergic antagonist)</td>
  </tr>
  <tr>
    <td>Bromocriptine</td>
    <td>Parkinson disease (dopamine agonist; rarely used)</td>
  </tr>
  <tr>
    <td>Buspirone</td>
    <td>Generalized anxiety disorder (partial 5-H, -receptor agonist)</td>
  </tr>
  <tr>
    <td>Bupropion</td>
    <td>Depression, smoking cessation (NE-DA reuptake inhibitor)</td>
  </tr>
  <tr>
    <td>Cimetidine</td>
    <td>Gastritis, peptic ulcer (H,-receptor antagonist)</td>
  </tr>
  <tr>
    <td>Cetirizine</td>
    <td>Allergy (2nd-generation antihistamine)</td>
  </tr>
  <tr>
    <td>Chloramphenicol</td>
    <td>Antibiotic (blocks 50S subunit)</td>
  </tr>
  <tr>
    <td>Chlordiazepoxide</td>
    <td>Long-acting benzodiazepine</td>
  </tr>
  <tr>
    <td>Chlorpromazine</td>
    <td>Typical antipsychotic</td>
  </tr>
  <tr>
    <td>Chlorpropamide</td>
    <td>st-generation sulfonylurea</td>
  </tr>
  <tr>
    <td>Chlorpheniramine</td>
    <td>st-generation antihistamine</td>
  </tr>
  <tr>
    <td>Chlorthalidone</td>
    <td>Thiazide diuretic</td>
  </tr>
  <tr>
    <td>Clozapine</td>
    <td>Atypical antipsychotic</td>
  </tr>
  <tr>
    <td>Clomipramine</td>
    <td>Tricyclic antidepressant</td>
  </tr>
  <tr>
    <td>Clomiphene</td>
    <td>
      Infertility due to anovulation (selective estrogen receptor modulator in
      hypothalamus)
    </td>
  </tr>
  <tr>
    <td>Clonidine</td>
    <td>Hypertensive urgency, ADHD (0,-agonist)</td>
  </tr>
  <tr>
    <td>Doxepin</td>
    <td>Tricyclic antidepressant</td>
  </tr>
  <tr>
    <td>Doxazosin</td>
    <td>BPH, HTN (q,-antagonist)</td>
  </tr>
  <tr>
    <td>Eplerenone</td>
    <td>K’-sparing diuretic</td>
  </tr>
  <tr>
    <td>Propafenone</td>
    <td>Na* channel blocker (class Ic antiarrhythmic)</td>
  </tr>
  <tr>
    <td>Fluoxetine</td>
    <td>Depression (selective serotonin reuptake inhibitor)</td>
  </tr>
  <tr>
    <td>Fluphenazine</td>
    <td>Typical antipsychotic</td>
  </tr>
  <tr>
    <td>Mifepristone</td>
    <td>Pregnancy termination (progesterone receptor antagonist)</td>
  </tr>
  <tr>
    <td>Misoprostol</td>
    <td>
      Used with mifepristone for pregnancy termination (PGE,-synthetic analog)
    </td>
  </tr>
  <tr>
    <td>Naloxone</td>
    <td>Opioid receptor antagonist (treats toxicity)</td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>Nitroprusside</td>
    <td>Hypertensive emergency (t cGMP/NO)</td>
  </tr>
  <tr>
    <td>Nitroglycerin</td>
    <td>Antianginal (t cGMP/NO)</td>
  </tr>
  <tr>
    <td>Omeprazole</td>
    <td>Proton pump inhibitor (inhibits H'/K'-ATPase in parietal cells)</td>
  </tr>
  <tr>
    <td>Ketoconazole</td>
    <td>Antifungal (inhibits fungal sterol synthesis)</td>
  </tr>
  <tr>
    <td>Aripiprazole</td>
    <td>Atypical antipsychotic (D, partial agonist)</td>
  </tr>
  <tr>
    <td>Anastrozole</td>
    <td>ER @ breast cancer in postmenopausal women (aromatase inhibitor)</td>
  </tr>
  <tr>
    <td>Rifaximin</td>
    <td>Hepatic encephalopathy (! ammoniagenic bacteria)</td>
  </tr>
  <tr>
    <td>Rifampin</td>
    <td>
      Antituberculous drug/antimicrobial (inhibits DNA-dependent RNA polymerase)
    </td>
  </tr>
  <tr>
    <td>Sertraline</td>
    <td>Depression, PT'SD (selective serotonin reuptake inhibitor)</td>
  </tr>
  <tr>
    <td>Selegiline</td>
    <td>Parkinson disease (MAO-B inhibitor)</td>
  </tr>
  <tr>
    <td>Trazodone</td>
    <td>
      Insomnia (blocks 5-HT’,, o,-adrenergic, and H, receptors); also weakly
      inhibits 5-HT reuptake
    </td>
  </tr>
  <tr>
    <td>Tramadol</td>
    <td>Chronic pain (weak opioid agonist)</td>
  </tr>
  <tr>
    <td>Varenicline</td>
    <td>Smoking cessation (nicotinic ACh receptor partial agonist)</td>
  </tr>
  <tr>
    <td>Venlafaxine</td>
    <td>Serotonin-norepinephrine reuptake inhibitor</td>
  </tr>
</table>
<table>
  <tr>
    <td>» How to Use</td>
    <td>the</td>
    <td></td>
  </tr>
  <tr>
    <td>Database</td>
    <td></td>
    <td>742</td>
  </tr>
  <tr>
    <td></td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td>&gt; Question » Web and</td>
    <td>Banks Mobile</td>
    <td>744</td>
  </tr>
  <tr>
    <td>Apps</td>
    <td></td>
    <td>744</td>
  </tr>
  <tr>
    <td>&gt;» Comprehensive » Anatomy,</td>
    <td>Embryology,</td>
    <td>745</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>A*</th>
    <th>= ©UWorld Qbank</th>
    <th>UWorld</th>
    <th>uworld.com</th>
    <th>est/3600+.q</th>
    <th>$299-$719</th>
  </thead>
  <tr>
    <td>A</td>
    <td>AMBOSS</td>
    <td>Amboss</td>
    <td>amboss.com</td>
    <td>est/2700+ q</td>
    <td>$99-$398</td>
  </tr>
  <tr>
    <td>A</td>
    <td>NBME Practice Exams</td>
    <td>National Board of Medical Examiners</td>
    <td>nbme.org/examinees/self- assessments</td>
    <td>est/200 q</td>
    <td>$60</td>
  </tr>
  <tr>
    <td>A”</td>
    <td>OUSMLE-Rx Qmax</td>
    <td>USMLE-Rx</td>
    <td>usmle-rx.com/products/step-1-qmax/</td>
    <td>Test/2750+q</td>
    <td>$79-$299</td>
  </tr>
  <tr>
    <td>B*</td>
    <td>Kaplan Qbank</td>
    <td>Kaplan</td>
    <td>kaptest.com</td>
    <td>est/3300+q</td>
    <td>$159-$499</td>
  </tr>
  <tr>
    <td>Bs</td>
    <td>TrueLearn Review</td>
    <td></td>
    <td>truelearn.com</td>
    <td>est/2600+ q</td>
    <td>$149-$419</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>A*</th>
    <th>Free 120</th>
    <th>orientation.nbme.org/launch/usmle/ stpfl</th>
    <th>—_Test/120 q</th>
    <th>Free</th>
  </thead>
  <tr>
    <td>A</td>
    <td>AMBOSS Library</td>
    <td>amboss.com</td>
    <td>eview</td>
    <td>$129</td>
  </tr>
  <tr>
    <td>A</td>
    <td>Anki</td>
    <td>ankiweb.net</td>
    <td>Flash cards</td>
    <td>Free</td>
  </tr>
  <tr>
    <td>A</td>
    <td>Boards and Beyond</td>
    <td>boardsbeyond.com</td>
    <td>eview/ est/2300+ q</td>
    <td>$24-$399</td>
  </tr>
  <tr>
    <td>A</td>
    <td>OnlineMedEd</td>
    <td>onlinemeded.org</td>
    <td>‘eview</td>
    <td>Free-$365</td>
  </tr>
  <tr>
    <td>A</td>
    <td>Pixorize</td>
    <td>pixorize.com</td>
    <td>‘eview</td>
    <td>$185-$249</td>
  </tr>
  <tr>
    <td>A</td>
    <td>Rx Bricks</td>
    <td>usmle-rx.com/products/rx-bricks</td>
    <td>Study plan</td>
    <td>$99-$399</td>
  </tr>
  <tr>
    <td>A</td>
    <td>SketchyMedical</td>
    <td>sketchy.com</td>
    <td>‘eview</td>
    <td>$300-$600</td>
  </tr>
  <tr>
    <td>A</td>
    <td>Dirty Medicine</td>
    <td>youtube.com/DirtyMedicine</td>
    <td></td>
    <td>Free</td>
  </tr>
  <tr>
    <td>A-</td>
    <td>Osmosis</td>
    <td>osmosis.org</td>
    <td>est</td>
    <td>$179-$279</td>
  </tr>
  <tr>
    <td>A”</td>
    <td>Physeo</td>
    <td>physeo.com</td>
    <td>eview</td>
    <td>Free-$450</td>
  </tr>
  <tr>
    <td>A&gt;</td>
    <td>USMLE-Rx Step 1 Express</td>
    <td>usmle-rx.com/products/step-1- express-videos</td>
    <td>‘eview/Test</td>
    <td>$49-$179</td>
  </tr>
  <tr>
    <td>A-</td>
    <td>USMLE-Rx Step 1 Flash Facts</td>
    <td>usmle-rx.com/products/step-1-flash- facts</td>
    <td>Flash cards</td>
    <td>$29-$99</td>
  </tr>
  <tr>
    <td>B*</td>
    <td>Armando Hasudungan</td>
    <td>youtube.com/user/ armandohasudungan</td>
    <td>eview</td>
    <td>Free</td>
  </tr>
  <tr>
    <td>B*</td>
    <td>Cram Fighter</td>
    <td>cramfighter.com</td>
    <td>Study plan</td>
    <td>$29-$149</td>
  </tr>
  <tr>
    <td>B*</td>
    <td>Firecracker</td>
    <td>
      wolterskluwer.com/en/solutions/ lippincott-medicine/medical-
      education/firecracker
    </td>
    <td>eview/ est/2300 q</td>
    <td>$99-$149</td>
  </tr>
  <tr>
    <td>B*</td>
    <td>Kaplan USMLE? Step 1 Prep</td>
    <td>kaptest.com/usmle-step-1</td>
    <td>eview/ est/3300+ q</td>
    <td>$1999</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>B*</th>
    <th>Ninja Nerd Medicine</th>
    <th>youtube.com/ninjanerdscience</th>
    <th>eview</th>
    <th>Free</th>
  </thead>
  <tr>
    <td>B*</td>
    <td>Picmonic</td>
    <td>picmonic.com</td>
    <td>‘eview</td>
    <td>$528-$1019</td>
  </tr>
  <tr>
    <td>B*</td>
    <td>Radiopaedia.org</td>
    <td>radiopaedia.org</td>
    <td>Cases/Test</td>
    <td>Free</td>
  </tr>
  <tr>
    <td></td>
    <td>Dr. Najeeb Lectures</td>
    <td>drnajeeblectures.com</td>
    <td>eview</td>
    <td>$499</td>
  </tr>
  <tr>
    <td></td>
    <td>KISSPrep</td>
    <td>kissprep.com</td>
    <td>‘eview</td>
    <td>$30-$150</td>
  </tr>
  <tr>
    <td></td>
    <td>Medbullets</td>
    <td>step1.medbullets.com</td>
    <td>‘eview/ est/1000+ q</td>
    <td>$80-$250</td>
  </tr>
  <tr>
    <td></td>
    <td>Memorang</td>
    <td>memorang.com</td>
    <td>Flash cards</td>
    <td>$20-$240</td>
  </tr>
  <tr>
    <td></td>
    <td>WebPath: The Internet Pathology Laboratory</td>
    <td>webpath.med.utah.edu</td>
    <td>‘eview/ est/1300+ q</td>
    <td>Free</td>
  </tr>
  <tr>
    <td></td>
    <td>B-Innerbody Research</td>
    <td>innerbody.com/htm/body.html</td>
    <td>eview</td>
    <td>Free</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>A</th>
    <th>First Aid Cases for the USMLE Step 1</th>
    <th>Le</th>
    <th>McGraw-Hill, 2019, 496 pages, ISBN 9781260143133</th>
    <th>Cases</th>
    <th>$50</th>
  </thead>
  <tr>
    <td>A</td>
    <td>First Aid for the Basic Sciences: General Principles</td>
    <td>Le</td>
    <td>McGraw-Hill, 2017, 528 pages, ISBN 9781259587016</td>
    <td>‘eview</td>
    <td>$75</td>
  </tr>
  <tr>
    <td>A</td>
    <td>First Aid for the Basic Sciences: Organ Systems</td>
    <td>Le</td>
    <td>McGraw-Hill, 2017, 912 pages, ISBN 9781259587030</td>
    <td>‘eview</td>
    <td>$72</td>
  </tr>
  <tr>
    <td>A</td>
    <td>USMLE Step 1 Secrets in Color</td>
    <td>O'Connell</td>
    <td>Elsevier, 2021, 5th ed., 736 pages, ISBN 9780323810609</td>
    <td>Review</td>
    <td>$45</td>
  </tr>
  <tr>
    <td>B*</td>
    <td>USMLE Step 1 Lecture Notes 2022</td>
    <td>Kaplan</td>
    <td>Kaplan Test Prep, 2022, 2000 pages, ISBN 9781506272967</td>
    <td>‘eview</td>
    <td>$350</td>
  </tr>
  <tr>
    <td>Bt</td>
    <td>Crush Step 1: The Ultimate USMLE Step 1 Review</td>
    <td>O'Connell</td>
    <td>Elsevier, 2018, 704 pages, 9780323481632</td>
    <td>eview</td>
    <td>$45</td>
  </tr>
  <tr>
    <td>B_</td>
    <td>USMLE Step 1 Made Ridiculously Simple</td>
    <td>Carl</td>
    <td>MedMaster, 2020, 416 pages, ISBN 9781935660224</td>
    <td>eview</td>
    <td>$30</td>
  </tr>
  <tr>
    <td>B_</td>
    <td>Kaplan USMLE Step 1 Qbook</td>
    <td>Kaplan</td>
    <td>Kaplan Test Prep, 2022, 10th ed., 456 pages, ISBN 9781506276410</td>
    <td>est/850 q</td>
    <td>$55</td>
  </tr>
  <tr>
    <td></td>
    <td>B__medEssentials for the USMLE Step 1</td>
    <td>Kaplan</td>
    <td>Kaplan Medical, 2022, 6th ed., 536 pages, ISBN 9781506254609</td>
    <td>‘eview</td>
    <td>$60</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th></th>
    <th></th>
    <th>AUTHOR</th>
    <th>PUBLISHER</th>
    <th>TYPE</th>
    <th>PRICE</th>
  </thead>
  <tr>
    <td>A~</td>
    <td>High-Yield Gross Anatomy</td>
    <td>Dudek</td>
    <td>
      Lippincott Williams &amp; Wilkins, 2015, 320 pages, ISBN 9781451190236
    </td>
    <td>Review</td>
    <td>$53</td>
  </tr>
  <tr>
    <td>B*</td>
    <td>BRS Embryology</td>
    <td>Dudek</td>
    <td>
      Lippincott Williams &amp; Wilkins, 2014, 336 pages, ISBN 9781451190380
    </td>
    <td>Review/ Test/220 q</td>
    <td>$60</td>
  </tr>
  <tr>
    <td>B*</td>
    <td>High-Yield Neuroanatomy</td>
    <td>Gould</td>
    <td>
      Lippincott Williams &amp; Wilkins, 2016, 208 pages, ISBN 9781451193435
    </td>
    <td>Review/ Test/50 q</td>
    <td>$49</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th></th>
    <th></th>
    <th>AUTHOR</th>
    <th>PUBLISHER</th>
    <th>TYPE</th>
    <th>PRICE</th>
  </thead>
  <tr>
    <td>B*</td>
    <td>Netter’s Anatomy Flash Cards</td>
    <td>Hansen</td>
    <td>Elsevier, 2022, 6th ed., 680 pages, ISBN 9789323834179</td>
    <td>Flash cards</td>
    <td>S41</td>
  </tr>
  <tr>
    <td>B*</td>
    <td>Crash Course: Anatomy and Physiology</td>
    <td>Stephens</td>
    <td>Elsevier, 2019, 350 pages, ISBN 9780702073755</td>
    <td>Review</td>
    <td>$40</td>
  </tr>
  <tr>
    <td>B=</td>
    <td>Anatomy—An Essential Textbook</td>
    <td>Gilroy</td>
    <td>Thieme, 2017, 528 pages, ISBN 9781626234390</td>
    <td>Text/ Test/400 q</td>
    <td>$50</td>
  </tr>
  <tr>
    <td>B-</td>
    <td>Complete Anatomy</td>
    <td></td>
    <td>3d4medical.com</td>
    <td>Review</td>
    <td>$75</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th></th>
    <th></th>
    <th>AUTHOR</th>
    <th>PUBLISHER</th>
    <th>TYPE</th>
    <th>PRICE</th>
  </thead>
  <tr>
    <td>A”</td>
    <td>BRS Behavioral Science</td>
    <td>Fadem</td>
    <td>
      Lippincott Williams &amp; Wilkins, 2021, 384 pages, ISBN 9781975188856
    </td>
    <td>Review/ Test/600 q</td>
    <td>$60</td>
  </tr>
  <tr>
    <td>B</td>
    <td>
      Biostatistics and Epidemiology: A Primer for Health and Biomedical
      Professionals
    </td>
    <td>—_ \Wassertheil- Smoller</td>
    <td>Springer, 2015, 280 pages, 9781493921331</td>
    <td>Review</td>
    <td>$90</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th></th>
    <th></th>
    <th>AUTHOR</th>
    <th>PUBLISHER</th>
    <th>TYPE</th>
    <th>PRICE</th>
  </thead>
  <tr>
    <td>B*</td>
    <td>Lippincott Illustrated Reviews: Biochemistry</td>
    <td>Abali</td>
    <td>
      Lippincott Williams &amp; Wilkins, 8th ed. 2021, 649 pages, ISBN
      9789960717319
    </td>
    <td>Review/ Test/200 q</td>
    <td>$82</td>
  </tr>
  <tr>
    <td>B*</td>
    <td>BRS Biochemistry, Molecular Biology, and Genetics</td>
    <td>Lieberman</td>
    <td>
      Lippincott Williams &amp; Wilkins, 2020, 448 pages, ISBN 9781496399236
    </td>
    <td>Review/ Test/500 q</td>
    <td>$58</td>
  </tr>
  <tr>
    <td>B</td>
    <td>Lange Flashcards: Biochemistry and Genetics</td>
    <td>Baron</td>
    <td>McGraw-Hill, 2017, 184 flash cards, ISBN 9781259837210</td>
    <td>Flash cards</td>
    <td>$38</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th></th>
    <th></th>
    <th>AUTHOR</th>
    <th>PUBLISHER</th>
    <th>TYPE</th>
    <th>PRICE</th>
  </thead>
  <tr>
    <td>B*</td>
    <td>Blue Histology</td>
    <td></td>
    <td>
      lecannabiculteur-free.fr/SITES/ UNIV%20W.AUSTRALIA/mb140/ Lectures.htm
    </td>
    <td>Test</td>
    <td>Free</td>
  </tr>
  <tr>
    <td>B*</td>
    <td>Crash Course: Cell Biology and Genetics</td>
    <td>Stubbs</td>
    <td>Mosby, 2015, 216 pages, ISBN 9780723438762</td>
    <td>Review/Print + online</td>
    <td>$47</td>
  </tr>
  <tr>
    <td>B</td>
    <td>BRS Cell Biology and Histology</td>
    <td>Gartner</td>
    <td>
      Lippincott Williams &amp; Wilkins, 2018, 448 pages, ISBN 9781496396358
    </td>
    <td>Review/ Test/320 q</td>
    <td>$59</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th></th>
    <th></th>
    <th>AUTHOR</th>
    <th>PUBLISHER</th>
    <th>TYPE</th>
    <th>PRICE</th>
  </thead>
  <tr>
    <td>A”</td>
    <td>Medical Microbiology and Immunology Flash Cards</td>
    <td>Rosenthal</td>
    <td>Elsevier, 2016, 192 flash cards, ISBN 9780323462242</td>
    <td>Flash cards</td>
    <td>$41</td>
  </tr>
  <tr>
    <td>B*</td>
    <td>Basic Immunology</td>
    <td>Abbas</td>
    <td>Elsevier, 2020, 336 pages, ISBN 9780323549431</td>
    <td>Review</td>
    <td>$72</td>
  </tr>
  <tr>
    <td>B*</td>
    <td>Clinical Microbiology Made Ridiculously Simple</td>
    <td>— Gladwin</td>
    <td>MedMaster, 2021, 448 pages, ISBN 9781935660453</td>
    <td>Review</td>
    <td>$45</td>
  </tr>
  <tr>
    <td>B*</td>
    <td>Microcards: Microbiology Flash Cards</td>
    <td>Harpavat</td>
    <td>
      Lippincott Williams &amp; Wilkins, 2015, 156 flash cards, ISBN
      9781451192353
    </td>
    <td>Flash cards</td>
    <td>$62</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th></th>
    <th></th>
    <th>AUTHOR</th>
    <th>PUBLISHER</th>
    <th>TYPE</th>
    <th>PRICE</th>
  </thead>
  <tr>
    <td>B*</td>
    <td>Lange Microbiology and Infectious Diseases Flash Cards, 3e</td>
    <td>Somers</td>
    <td>McGraw-Hill, 2018, ISBN 9781259859823</td>
    <td>Flash cards</td>
    <td>$55</td>
  </tr>
  <tr>
    <td>B</td>
    <td>Lippincott Illustrated Reviews: Microbiology</td>
    <td>Cornelissen</td>
    <td>
      Lippincott Williams &amp; Wilkins, 2019, 448 pages, ISBN 9781496395856
    </td>
    <td>eview/Test/ Few q</td>
    <td>$78</td>
  </tr>
  <tr>
    <td>B_</td>
    <td>Case Studies in Immunology: A Clinical Companion</td>
    <td>Geha</td>
    <td>W.W. Norton &amp; Company, 2016, 384 pages, ISBN 9780815345121</td>
    <td>Cases</td>
    <td>$62</td>
  </tr>
  <tr>
    <td>B__</td>
    <td>Review of Medical Microbiology and Immunology</td>
    <td>Levinson</td>
    <td>McGraw-Hill, 2022, 848 pages, ISBN 9781264267088</td>
    <td>‘eview/ est/650 q</td>
    <td>S69</td>
  </tr>
  <tr>
    <td>B-</td>
    <td>How the Immune System Works</td>
    <td>Sompayrac</td>
    <td>Wiley-Blackwell, 2019, 168 pages, ISBN 9781119542124</td>
    <td>Review</td>
    <td>$50</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>A*</th>
    <th>Pathoma: Fundamentals of Pathology</th>
    <th>Sattar</th>
    <th>athoma, 2021, 218 pages, ISBN 9780983224631</th>
    <th>‘eview/ Lecture</th>
    <th>$85-$125</th>
  </thead>
  <tr>
    <td>A-</td>
    <td>Rapid Review: Pathology</td>
    <td>Goljan</td>
    <td>Elsevier, 2019, 864 pages, ISBN 9780323476683</td>
    <td>eview/ est/500 q</td>
    <td>$69</td>
  </tr>
  <tr>
    <td>A~</td>
    <td>Robbins and Cotran Review of Pathology</td>
    <td>Klatt</td>
    <td>Elsevier, 2022, 488 pages, ISBN 9780323640220</td>
    <td>est/1500 q</td>
    <td>$57</td>
  </tr>
  <tr>
    <td>A-</td>
    <td>Crash Course: Pathology</td>
    <td>McKinney</td>
    <td>Elsevier, 2019, 438 pages, ISBN 9780702073540</td>
    <td>eview</td>
    <td>$40</td>
  </tr>
  <tr>
    <td>B*</td>
    <td>Pocket Companion to Robbins and Cotran Pathologic Basis of Disease</td>
    <td>Mitchell</td>
    <td>Elsevier, 2016, 896 pages, ISBN 9781455754168</td>
    <td>‘eview</td>
    <td>$41</td>
  </tr>
  <tr>
    <td>B</td>
    <td>BRS Pathology</td>
    <td>Gupta</td>
    <td>
      Lippincott Williams &amp; Wilkins, 2021, 496 pages, ISBN 9781975136628
    </td>
    <td>eview/ est/450 q</td>
    <td>$58</td>
  </tr>
  <tr>
    <td>Bs</td>
    <td>Pathophysiology of Disease: Introduction to Clinical Medicine</td>
    <td>© Hammer</td>
    <td>McGraw-Hill, 2019, 832 pages, ISBN 9781260026504</td>
    <td>ext</td>
    <td>$90</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>B*</th>
    <th>Crash Course: Pharmacology</th>
    <th>Page</th>
    <th>Elsevier, 2019, 336 pages, ISBN 9780702073441</th>
    <th>eview</th>
    <th>$40</th>
  </thead>
  <tr>
    <td>B*</td>
    <td>Katzung &amp; Trevor's Pharmacology: Examination and Board Review</td>
    <td>Trevor</td>
    <td>McGraw-Hill, 2021, 608 pages, ISBN 9781260117127</td>
    <td>‘eview/ est/1000 q</td>
    <td>$62</td>
  </tr>
  <tr>
    <td>B</td>
    <td>Lange Pharmacology Flash Cards</td>
    <td>Baron</td>
    <td>McGraw-Hill, 2018, 266 flash cards, ISBN 9781259837241</td>
    <td>Flash cards</td>
    <td>$39</td>
  </tr>
  <tr>
    <td>Bs</td>
    <td>Pharmacology Flash Cards</td>
    <td>Brenner</td>
    <td>Elsevier, 2017, 277 flash cards, ISBN 9780323355643</td>
    <td>Flash cards</td>
    <td>$46</td>
  </tr>
  <tr>
    <td>B_</td>
    <td>BRS Pharmacology</td>
    <td>Lerchenfeldt</td>
    <td>
      Lippincott Williams &amp; Wilkins, 2019, 384 pages, ISBN 9781975105495
    </td>
    <td>eview/ est/200 q</td>
    <td>$59</td>
  </tr>
  <tr>
    <td>B-</td>
    <td>Lippincott Illustrated Reviews: Pharmacology</td>
    <td>Whalen</td>
    <td>
      Lippincott Williams &amp; Wilkins, 2022, 8th ed., 704 pages, ISBN
      9781975170554
    </td>
    <td>‘eview/ est/380 q</td>
    <td>$78</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>A</th>
    <th>Physiology</th>
    <th>Costanzo</th>
    <th>Elsevier, 2022, 7th ed., 528 pages, ISBN 9780323793339</th>
    <th>ext</th>
    <th>$70</th>
  </thead>
  <tr>
    <td>A”</td>
    <td>Color Atlas of Physiology</td>
    <td>Silbernag|</td>
    <td>Thieme, 2015, 472 pages, ISBN 9783135450070</td>
    <td>eview</td>
    <td>$50</td>
  </tr>
  <tr>
    <td>A~</td>
    <td>Pulmonary Pathophysiology: The Essentials</td>
    <td>West</td>
    <td>
      Lippincott Williams &amp; Wilkins, 2022, 272 pages, ISBN 9781975152819
    </td>
    <td>‘eview/ est/75 q</td>
    <td>$58</td>
  </tr>
  <tr>
    <td>B*</td>
    <td>BRS Physiology</td>
    <td>Costanzo</td>
    <td>
      Lippincott Williams &amp; Wilkins, 2022, 8th ed., 336 pages, SBN
      9781975153601
    </td>
    <td>eview/ est/350 q</td>
    <td>$55</td>
  </tr>
  <tr>
    <td>B*</td>
    <td>Pathophysiology of Heart Disease</td>
    <td>Lilly</td>
    <td>
      Lippincott Williams &amp; Williams, 2020, 480 pages, ISBN 9781975120597
    </td>
    <td>eview</td>
    <td>$59</td>
  </tr>
  <tr>
    <td>B*</td>
    <td>Acid-Base, Fluids, and Electrolytes Made Ridiculously Simple</td>
    <td>Preston</td>
    <td>MedMaster, 2017, 166 pages, ISBN 9781935660293</td>
    <td>‘eview</td>
    <td>$24</td>
  </tr>
  <tr>
    <td>B*</td>
    <td>Lippincott Illustrated Reviews: Physiology</td>
    <td>Preston</td>
    <td>
      Lippincott Williams &amp; Wilkins, 2018, 544 pages, ISBN 9781496385826
    </td>
    <td>eview</td>
    <td>$79</td>
  </tr>
  <tr>
    <td>B_</td>
    <td>Vander's Renal Physiology</td>
    <td>Eaton</td>
    <td>McGraw-Hill, 2018, 224 pages, ISBN 9781260019377</td>
    <td>ext</td>
    <td>$49</td>
  </tr>
  <tr>
    <td>B_</td>
    <td>Endocrine Physiology</td>
    <td>Molina</td>
    <td>McGraw-Hill, 2018, 320 pages, ISBN 9781260019353</td>
    <td>‘eview</td>
    <td>$59</td>
  </tr>
  <tr>
    <td></td>
    <td>B_Netter’s Physiology Flash Cards</td>
    <td>Mulroney</td>
    <td>Saunders, 2015, 200+ flash cards, ISBN 9780323359542</td>
    <td>Flash cards</td>
    <td>$40</td>
  </tr>
</table>
<table>
  <thead>
    <th>ABBREVIATION</th>
    <th>MEANING</th>
  </thead>
  <tr>
    <td>Ist MC*</td>
    <td>Ist metacarpal</td>
  </tr>
  <tr>
    <td>Aa</td>
    <td>alveolar-arterial [gradient]</td>
  </tr>
  <tr>
    <td>AA</td>
    <td>Alcoholics Anonymous, amyloid A</td>
  </tr>
  <tr>
    <td>AAMC</td>
    <td>Association of American Medical Colleges</td>
  </tr>
  <tr>
    <td>AAo*</td>
    <td>ascending aorta</td>
  </tr>
  <tr>
    <td>Ab</td>
    <td>antibody</td>
  </tr>
  <tr>
    <td>ABPA</td>
    <td>allergic bronchopulmonary aspergillosis</td>
  </tr>
  <tr>
    <td>AC</td>
    <td>adenylyl cyclase</td>
  </tr>
  <tr>
    <td>ACA</td>
    <td>anterior cerebral artery</td>
  </tr>
  <tr>
    <td>Acetyl-CoA</td>
    <td>acetyl coenzyme A</td>
  </tr>
  <tr>
    <td>ACD</td>
    <td>anemia of chronic disease</td>
  </tr>
  <tr>
    <td>ACE</td>
    <td>angiotensin-converting enzyme</td>
  </tr>
  <tr>
    <td>ACh</td>
    <td>acetylcholine</td>
  </tr>
  <tr>
    <td>AChE</td>
    <td>acetylcholinesterase</td>
  </tr>
  <tr>
    <td>ACL</td>
    <td>anterior cruciate ligament</td>
  </tr>
  <tr>
    <td>ACom</td>
    <td>anterior communicating [artery]</td>
  </tr>
  <tr>
    <td>ACTH</td>
    <td>adrenocorticotropic hormone</td>
  </tr>
  <tr>
    <td>AD</td>
    <td>Alzheimer disease, autosomal dominant</td>
  </tr>
  <tr>
    <td>ADA</td>
    <td>adenosine deaminase, Americans with Disabilities Act</td>
  </tr>
  <tr>
    <td>ADH</td>
    <td>antidiuretic hormone</td>
  </tr>
  <tr>
    <td>ADHD</td>
    <td>attention-deficit hyperactivity disorder</td>
  </tr>
  <tr>
    <td>ADP.</td>
    <td>adenosine diphosphate</td>
  </tr>
  <tr>
    <td>ADPKD</td>
    <td>autosomal-dominant polycystic kidney disease</td>
  </tr>
  <tr>
    <td>AFP</td>
    <td>a-fetoprotein</td>
  </tr>
  <tr>
    <td></td>
    <td>silver</td>
  </tr>
  <tr>
    <td>Ag</td>
    <td>antigen,</td>
  </tr>
  <tr>
    <td>AICA</td>
    <td>anterior inferior cerebellar artery</td>
  </tr>
  <tr>
    <td>AIDS</td>
    <td>acquired immunodeficiency syndrome</td>
  </tr>
  <tr>
    <td>AIHA</td>
    <td>autoimmune hemolytic anemia</td>
  </tr>
  <tr>
    <td>AKI</td>
    <td>acute kidney injury</td>
  </tr>
  <tr>
    <td>AKT</td>
    <td>protein kinase B</td>
  </tr>
  <tr>
    <td></td>
    <td>amyloid light [chain]</td>
  </tr>
  <tr>
    <td></td>
    <td>aminolevulinate</td>
  </tr>
  <tr>
    <td></td>
    <td>acute lung injury</td>
  </tr>
  <tr>
    <td></td>
    <td>anaplastic lymphoma kinase</td>
  </tr>
  <tr>
    <td></td>
    <td>acute lymphoblastic (lymphocytic) leukemia</td>
  </tr>
  <tr>
    <td></td>
    <td>alkaline phosphatase</td>
  </tr>
  <tr>
    <td></td>
    <td>amyotrophic lateral sclerosis</td>
  </tr>
  <tr>
    <td></td>
    <td>alanine transaminase</td>
  </tr>
  <tr>
    <td>AMA</td>
    <td>American Medical Association, antimitochondrial antibody</td>
  </tr>
  <tr>
    <td>AML</td>
    <td>acute myelogenous (myeloid) leukemia</td>
  </tr>
  <tr>
    <td>AMP</td>
    <td>adenosine monophosphate</td>
  </tr>
  <tr>
    <td>ANA</td>
    <td>antinuclear antibody</td>
  </tr>
  <tr>
    <td>ANCA</td>
    <td>antineutrophil cytoplasmic antibody</td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>ANOVA</td>
    <td>analysis of variance</td>
  </tr>
  <tr>
    <td>ANP</td>
    <td>atrial natriuretic peptide</td>
  </tr>
  <tr>
    <td>ANS</td>
    <td>autonomic nervous system</td>
  </tr>
  <tr>
    <td>Ant*</td>
    <td>anterior</td>
  </tr>
  <tr>
    <td>Ao*</td>
    <td>aorta</td>
  </tr>
  <tr>
    <td>AOA</td>
    <td>American Osteopathic Association</td>
  </tr>
  <tr>
    <td>AP</td>
    <td>action potential, A &amp; P [ribosomal binding sites]</td>
  </tr>
  <tr>
    <td>APC</td>
    <td>antigen-presenting cell, activated protein C</td>
  </tr>
  <tr>
    <td>APL</td>
    <td>Acute promyelocytic leukemia</td>
  </tr>
  <tr>
    <td>Apo</td>
    <td>apolipoprotein</td>
  </tr>
  <tr>
    <td>APP</td>
    <td>amyloid precursor protein</td>
  </tr>
  <tr>
    <td>APRT</td>
    <td>adenine phosphoribosyltransferase</td>
  </tr>
  <tr>
    <td>aPTT</td>
    <td>activated partial thromboplastin time</td>
  </tr>
  <tr>
    <td>AR</td>
    <td>attributable risk, autosomal recessive, aortic regurgitation</td>
  </tr>
  <tr>
    <td>ARB</td>
    <td>angiotensin receptor blocker</td>
  </tr>
  <tr>
    <td>ARDS</td>
    <td>acute respiratory distress syndrome</td>
  </tr>
  <tr>
    <td>Arg</td>
    <td>arginine</td>
  </tr>
  <tr>
    <td>ARPKD</td>
    <td>autosomal-recessive disease</td>
  </tr>
  <tr>
    <td></td>
    <td>polycystic kidney</td>
  </tr>
  <tr>
    <td>ART</td>
    <td>antiretroviral therapy</td>
  </tr>
  <tr>
    <td>AS</td>
    <td>aortic stenosis</td>
  </tr>
  <tr>
    <td>ASA</td>
    <td>anterior</td>
  </tr>
  <tr>
    <td>Asc*</td>
    <td>spinal artery ascending</td>
  </tr>
  <tr>
    <td>Asc Ao*</td>
    <td>ascending aorta</td>
  </tr>
  <tr>
    <td>ASD</td>
    <td>atrial septal defect</td>
  </tr>
  <tr>
    <td>ASO</td>
    <td>anti-streptolysin O</td>
  </tr>
  <tr>
    <td>AST</td>
    <td>transaminase</td>
  </tr>
  <tr>
    <td></td>
    <td>aspartate</td>
  </tr>
  <tr>
    <td>AT</td>
    <td>angiotensin, antithrombin</td>
  </tr>
  <tr>
    <td>ATN</td>
    <td>acute tubular necrosis</td>
  </tr>
  <tr>
    <td>ATP</td>
    <td>adenosine triphosphate</td>
  </tr>
  <tr>
    <td>ATPase</td>
    <td>adenosine triphosphatase</td>
  </tr>
  <tr>
    <td>ATTR</td>
    <td>transthyretin-mediated amyloidosis</td>
  </tr>
  <tr>
    <td>AV</td>
    <td>atrioventricular</td>
  </tr>
  <tr>
    <td>AZT</td>
    <td>azidothymidine</td>
  </tr>
  <tr>
    <td>BAL</td>
    <td>British anti-Lewisite [dimercaprol]</td>
  </tr>
  <tr>
    <td>BBB</td>
    <td>blood-brain barrier</td>
  </tr>
  <tr>
    <td>BCG</td>
    <td>bacille Calmette-Guérin</td>
  </tr>
  <tr>
    <td>bd*</td>
    <td>bile duct</td>
  </tr>
  <tr>
    <td>BH,</td>
    <td>tetrahydrobiopterin</td>
  </tr>
  <tr>
    <td>BM</td>
    <td>basement membrane</td>
  </tr>
  <tr>
    <td>BOOP</td>
    <td>bronchiolitis obliterans organizing pneumonia</td>
  </tr>
  <tr>
    <td>BP</td>
    <td>bisphosphate, blood pressure</td>
  </tr>
  <tr>
    <td>BPG</td>
    <td>bisphosphoglycerate</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>ABBREVIATION</th>
    <th>MEANING</th>
  </thead>
  <tr>
    <td>BT</td>
    <td>bleeding time</td>
  </tr>
  <tr>
    <td></td>
    <td>blood urea nitrogen</td>
  </tr>
  <tr>
    <td></td>
    <td>caudate</td>
  </tr>
  <tr>
    <td></td>
    <td>capillary</td>
  </tr>
  <tr>
    <td></td>
    <td>calcium ion</td>
  </tr>
  <tr>
    <td></td>
    <td>coronary artery disease</td>
  </tr>
  <tr>
    <td></td>
    <td>common application form</td>
  </tr>
  <tr>
    <td></td>
    <td>cyclic adenosine monophosphate</td>
  </tr>
  <tr>
    <td></td>
    <td>corticosteroid-binding globulin</td>
  </tr>
  <tr>
    <td></td>
    <td>Comprehensive Basic Science Examination</td>
  </tr>
  <tr>
    <td></td>
    <td>Comprehensive Basic Science Self-Assessment</td>
  </tr>
  <tr>
    <td></td>
    <td>computer-based test, cognitive behavioral therapy</td>
  </tr>
  <tr>
    <td></td>
    <td>cholecystokinin</td>
  </tr>
  <tr>
    <td></td>
    <td>computer-based case simulation</td>
  </tr>
  <tr>
    <td></td>
    <td>cluster of differentiation</td>
  </tr>
  <tr>
    <td></td>
    <td>cyclin-dependent kinase</td>
  </tr>
  <tr>
    <td></td>
    <td>complementary deoxyribonucleic acid</td>
  </tr>
  <tr>
    <td></td>
    <td>carcinoembryonic antigen</td>
  </tr>
  <tr>
    <td></td>
    <td>cholesteryl-ester transfer protein</td>
  </tr>
  <tr>
    <td></td>
    <td>cystic fibrosis</td>
  </tr>
  <tr>
    <td></td>
    <td>cystic fibrosis transmembrane conductance regulator</td>
  </tr>
  <tr>
    <td></td>
    <td>chronic granulomatous disease</td>
  </tr>
  <tr>
    <td></td>
    <td>cyclic guanosine monophosphate</td>
  </tr>
  <tr>
    <td></td>
    <td>calcitonin gene-related peptide</td>
  </tr>
  <tr>
    <td></td>
    <td>constant regions, heavy chain [antibody]</td>
  </tr>
  <tr>
    <td></td>
    <td>choline acetyltransferase</td>
  </tr>
  <tr>
    <td></td>
    <td>common hepatic duct</td>
  </tr>
  <tr>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td></td>
    <td>chi-squared</td>
  </tr>
  <tr>
    <td></td>
    <td>confidence interval</td>
  </tr>
  <tr>
    <td></td>
    <td>candidate identification number, carcinoma in situ, cervical</td>
  </tr>
  <tr>
    <td></td>
    <td>intraepithelial neoplasia</td>
  </tr>
  <tr>
    <td>CIS</td>
    <td>Communication and Interpersonal Skills</td>
  </tr>
  <tr>
    <td>CK</td>
    <td>clinical knowledge, creatine kinase</td>
  </tr>
  <tr>
    <td>CKD</td>
    <td>chronic disease</td>
  </tr>
  <tr>
    <td></td>
    <td>kidney</td>
  </tr>
  <tr>
    <td>CK-MB</td>
    <td>creatine kinase, MB fraction</td>
  </tr>
  <tr>
    <td></td>
    <td>constant region, light chain [antibody]</td>
  </tr>
  <tr>
    <td>L</td>
    <td></td>
  </tr>
  <tr>
    <td>CL</td>
    <td>clearance</td>
  </tr>
  <tr>
    <td></td>
    <td>chloride ion</td>
  </tr>
  <tr>
    <td>CLL</td>
    <td>chronic lymphocytic leukemia</td>
  </tr>
  <tr>
    <td>CMC.</td>
    <td>carpometacarpal (joint)</td>
  </tr>
  <tr>
    <td>CML</td>
    <td>chronic myelogenous (myeloid) leukemia</td>
  </tr>
  <tr>
    <td>CMV</td>
    <td>cytomegalovirus</td>
  </tr>
  <tr>
    <td>CN</td>
    <td>cranial nerve</td>
  </tr>
  <tr>
    <td>CN-</td>
    <td>cyanide ion</td>
  </tr>
  <tr>
    <td>CNS</td>
    <td>central nervous system</td>
  </tr>
  <tr>
    <td>CNV</td>
    <td>copy number variation</td>
  </tr>
  <tr>
    <td>co</td>
    <td>carbon monoxide, cardiac output</td>
  </tr>
  <tr>
    <td>co,</td>
    <td>carbon dioxide</td>
  </tr>
  <tr>
    <td>CoA</td>
    <td>coenzyme A</td>
  </tr>
  <tr>
    <td>Coarct*</td>
    <td>coarctation</td>
  </tr>
  <tr>
    <td>COLIA1</td>
    <td>collagen, type I, alpha 1</td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>COPD</td>
    <td>chronic obstructive pulmonary disease</td>
  </tr>
  <tr>
    <td>CoQ</td>
    <td>coenzyme O</td>
  </tr>
  <tr>
    <td>COVID-19</td>
    <td>Coronavirus disease 2019</td>
  </tr>
  <tr>
    <td>COX</td>
    <td>cyclooxygenase</td>
  </tr>
  <tr>
    <td>Cc,</td>
    <td>plasma concentration</td>
  </tr>
  <tr>
    <td>CPAP</td>
    <td>continuous positive airway pressure.</td>
  </tr>
  <tr>
    <td>CPR</td>
    <td>cardiopulmonary resuscitation</td>
  </tr>
  <tr>
    <td>Cr</td>
    <td>creatinine</td>
  </tr>
  <tr>
    <td>CRC</td>
    <td>colorectal cancer</td>
  </tr>
  <tr>
    <td>CREST</td>
    <td>
      calcinosis, Raynaud phenomenon, esophageal dysfunction, sclerosis, and
      telangiectasias [syndrome]
    </td>
  </tr>
  <tr>
    <td>CRH</td>
    <td>corticotropin-releasing hormone</td>
  </tr>
  <tr>
    <td>CRP</td>
    <td>C-reactive protein</td>
  </tr>
  <tr>
    <td>cs</td>
    <td>clinical skills</td>
  </tr>
  <tr>
    <td>C-section</td>
    <td>cesarean section</td>
  </tr>
  <tr>
    <td>CSF</td>
    <td>cerebrospinal fluid</td>
  </tr>
  <tr>
    <td>cT</td>
    <td>computed tomography</td>
  </tr>
  <tr>
    <td>CTP</td>
    <td>cytidine triphosphate</td>
  </tr>
  <tr>
    <td>CXR</td>
    <td>chest x-ray</td>
  </tr>
  <tr>
    <td>DA</td>
    <td>lopamine</td>
  </tr>
  <tr>
    <td>DAF</td>
    <td>jecay-accelerating factor</td>
  </tr>
  <tr>
    <td>DAG.</td>
    <td>iacylglycerol</td>
  </tr>
  <tr>
    <td>DAo*</td>
    <td>lescending aorta</td>
  </tr>
  <tr>
    <td>dATP</td>
    <td>leoxyadenosine triphosphate</td>
  </tr>
  <tr>
    <td>DCIS</td>
    <td>uctal carcinoma in situ</td>
  </tr>
  <tr>
    <td>DCT</td>
    <td>istal convoluted tubule</td>
  </tr>
  <tr>
    <td>ddI</td>
    <td>idanosine</td>
  </tr>
  <tr>
    <td>DES</td>
    <td>icthylstilbestrol</td>
  </tr>
  <tr>
    <td>Desc Ao*</td>
    <td>lescending aorta</td>
  </tr>
  <tr>
    <td>DEXA</td>
    <td>ual-energy x-ray absorptiometry</td>
  </tr>
  <tr>
    <td>DHAP</td>
    <td></td>
  </tr>
  <tr>
    <td></td>
    <td>ihydroxyacetone phosphate</td>
  </tr>
  <tr>
    <td>DHEA</td>
    <td>ichydroepiandrosterone</td>
  </tr>
  <tr>
    <td>DHF</td>
    <td>ihydrofolic acid</td>
  </tr>
  <tr>
    <td>DHT</td>
    <td>ihydrotestosterone</td>
  </tr>
  <tr>
    <td>DI</td>
    <td>iabetes insipidus</td>
  </tr>
  <tr>
    <td>DIC</td>
    <td>jisseminated intravascular coagulation</td>
  </tr>
  <tr>
    <td>DIP</td>
    <td>istal interphalangeal [joint]</td>
  </tr>
  <tr>
    <td>DKA</td>
    <td>iabetic ketoacidosis</td>
  </tr>
  <tr>
    <td>DLCO</td>
    <td>iffusing capacity for carbon monoxide</td>
  </tr>
  <tr>
    <td>DM</td>
    <td>iabetes mellitus</td>
  </tr>
  <tr>
    <td>DNA</td>
    <td>eoxyribonucleic acid</td>
  </tr>
  <tr>
    <td>DNR</td>
    <td>lo not resuscitate</td>
  </tr>
  <tr>
    <td>dNTP</td>
    <td>leoxynucleotide triphosphate</td>
  </tr>
  <tr>
    <td>DO</td>
    <td>loctor of osteopathy</td>
  </tr>
  <tr>
    <td>DPGN</td>
    <td>iffuse proliferative glomerulonephritis</td>
  </tr>
  <tr>
    <td>DPM</td>
    <td>loctor of podiatric medicine</td>
  </tr>
  <tr>
    <td>DPP4</td>
    <td>jipeptidyl peptidase-4</td>
  </tr>
  <tr>
    <td>DPPC</td>
    <td>jipalmitoylphosphatidylcholine</td>
  </tr>
  <tr>
    <td>DS</td>
    <td>louble stranded</td>
  </tr>
  <tr>
    <td>dsDNA</td>
    <td>louble-stranded deoxyribonucleic acid</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>ABBREVIATION</th>
    <th>MEANING</th>
  </thead>
  <tr>
    <td>DTs</td>
    <td>delirium tremens</td>
  </tr>
  <tr>
    <td>dUDP</td>
    <td>deoxyuridine diphosphate</td>
  </tr>
  <tr>
    <td>dUMP</td>
    <td>deoxyuridine monophosphate</td>
  </tr>
  <tr>
    <td>DVT</td>
    <td>deep venous thrombosis</td>
  </tr>
  <tr>
    <td>E*</td>
    <td>euthromatin, esophagus</td>
  </tr>
  <tr>
    <td>EBV</td>
    <td>Epstein-Barr virus</td>
  </tr>
  <tr>
    <td>ECA*</td>
    <td>external carotid artery</td>
  </tr>
  <tr>
    <td>ECF</td>
    <td>extracellular fluid</td>
  </tr>
  <tr>
    <td>ECFMG</td>
    <td>Educational Commission for Foreign Medical Graduates</td>
  </tr>
  <tr>
    <td>ECG</td>
    <td>electrocardiogram</td>
  </tr>
  <tr>
    <td>ECL</td>
    <td>enterochromaffhin-like [cell]</td>
  </tr>
  <tr>
    <td>ECM</td>
    <td>extracellular matrix</td>
  </tr>
  <tr>
    <td>ECT</td>
    <td>electroconvulsive therapy</td>
  </tr>
  <tr>
    <td>ED,,</td>
    <td>median effective dose</td>
  </tr>
  <tr>
    <td>EDRF</td>
    <td>endothelium-derived relaxing factor</td>
  </tr>
  <tr>
    <td>EDTA</td>
    <td>ethylenediamine tetra-acetic acid</td>
  </tr>
  <tr>
    <td>EDV</td>
    <td>end-diastolic volume</td>
  </tr>
  <tr>
    <td>EEG</td>
    <td></td>
  </tr>
  <tr>
    <td></td>
    <td>electroencephalogram</td>
  </tr>
  <tr>
    <td>EF</td>
    <td>ejection fraction</td>
  </tr>
  <tr>
    <td>EGF</td>
    <td>epidermal growth factor</td>
  </tr>
  <tr>
    <td>EHEC</td>
    <td>enterohemorrhagic E coli</td>
  </tr>
  <tr>
    <td>EIEC</td>
    <td>enteroinvasive E coli</td>
  </tr>
  <tr>
    <td>ELISA</td>
    <td>enzyme-linked immunosorbent assay</td>
  </tr>
  <tr>
    <td>EM</td>
    <td>electron micrograph/microscopy</td>
  </tr>
  <tr>
    <td>EMB</td>
    <td>eosin-methylene blue</td>
  </tr>
  <tr>
    <td>EPEC</td>
    <td>eneteropathogenic E coli</td>
  </tr>
  <tr>
    <td>Epi</td>
    <td>epinephrine</td>
  </tr>
  <tr>
    <td>EPO</td>
    <td>erythropoietin</td>
  </tr>
  <tr>
    <td>EPS</td>
    <td>extrapyramidal system</td>
  </tr>
  <tr>
    <td>ER</td>
    <td>endoplasmic reticulum, estrogen receptor</td>
  </tr>
  <tr>
    <td></td>
    <td>Electronic Residency Application Service</td>
  </tr>
  <tr>
    <td>ERAS</td>
    <td></td>
  </tr>
  <tr>
    <td>ERCP</td>
    <td>endoscopic retrograde cholangiopancreatography</td>
  </tr>
  <tr>
    <td>ERP</td>
    <td>effective refractory period</td>
  </tr>
  <tr>
    <td></td>
    <td>effective renal flow</td>
  </tr>
  <tr>
    <td>eRPF</td>
    <td>plasma</td>
  </tr>
  <tr>
    <td>ERT</td>
    <td>estrogen replacement therapy</td>
  </tr>
  <tr>
    <td>ERV</td>
    <td>volume</td>
  </tr>
  <tr>
    <td></td>
    <td>expiratory reserve</td>
  </tr>
  <tr>
    <td>ESR</td>
    <td>erythrocyte sedimentation rate</td>
  </tr>
  <tr>
    <td>ESRD</td>
    <td>end-stage renal disease</td>
  </tr>
  <tr>
    <td>ESV</td>
    <td>end-systolic volume</td>
  </tr>
  <tr>
    <td>ETEC</td>
    <td>enterotoxigenic E coli</td>
  </tr>
  <tr>
    <td>EtOH</td>
    <td>ethyl alcohol</td>
  </tr>
  <tr>
    <td>EV</td>
    <td>esophageal vein</td>
  </tr>
  <tr>
    <td>F</td>
    <td>bioavailability</td>
  </tr>
  <tr>
    <td>FA</td>
    <td>fatty acid</td>
  </tr>
  <tr>
    <td>Fab</td>
    <td>fragment, antigen-binding</td>
  </tr>
  <tr>
    <td>FAD</td>
    <td>flavin adenine dinucleotide</td>
  </tr>
  <tr>
    <td>FADH,</td>
    <td>reduced flavin adenine dinucleotide</td>
  </tr>
  <tr>
    <td>FAP</td>
    <td>familial adenomatous polyposis</td>
  </tr>
  <tr>
    <td>F1,6BP</td>
    <td>fructose-1,6-bisphosphate</td>
  </tr>
  <tr>
    <td>F2,6BP</td>
    <td>fructose-2,6-bisphosphate</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>ABBREVIATION</th>
    <th>MEANING</th>
  </thead>
  <tr>
    <td>5f£dUMP</td>
    <td>5-fluorodeoxyuridine monophosphate</td>
  </tr>
  <tr>
    <td>Fe*</td>
    <td>ferrous ion</td>
  </tr>
  <tr>
    <td>Fe*</td>
    <td>ferric ion</td>
  </tr>
  <tr>
    <td>Fem*</td>
    <td>femur</td>
  </tr>
  <tr>
    <td>FENa</td>
    <td>excreted fraction of filtered sodium</td>
  </tr>
  <tr>
    <td>FEV,</td>
    <td>forced expiratory volume in | second</td>
  </tr>
  <tr>
    <td>FF</td>
    <td>filtration fraction</td>
  </tr>
  <tr>
    <td>FFA</td>
    <td>free fatty acid</td>
  </tr>
  <tr>
    <td>FGF</td>
    <td>fibroblast growth factor</td>
  </tr>
  <tr>
    <td>FGFR</td>
    <td>fibroblast growth factor receptor</td>
  </tr>
  <tr>
    <td>FGR</td>
    <td>fetal growth restriction</td>
  </tr>
  <tr>
    <td>FISH</td>
    <td>fluorescence in situ hybridization</td>
  </tr>
  <tr>
    <td></td>
    <td>fraction of inspired oxygen</td>
  </tr>
  <tr>
    <td></td>
    <td>fecal immunochemical testing</td>
  </tr>
  <tr>
    <td></td>
    <td>FK506 binding protein</td>
  </tr>
  <tr>
    <td></td>
    <td>formylmethionine</td>
  </tr>
  <tr>
    <td></td>
    <td>foreign medical graduate</td>
  </tr>
  <tr>
    <td></td>
    <td>flavin mononucleotide</td>
  </tr>
  <tr>
    <td></td>
    <td>false</td>
  </tr>
  <tr>
    <td></td>
    <td>negative</td>
  </tr>
  <tr>
    <td>FP, FP*</td>
    <td>false positive, foot process</td>
  </tr>
  <tr>
    <td>FRC</td>
    <td>functional residual capacity</td>
  </tr>
  <tr>
    <td>FSH</td>
    <td>follicle-stimulating hormone</td>
  </tr>
  <tr>
    <td>FSMB</td>
    <td>Federation of State Medical Boards</td>
  </tr>
  <tr>
    <td>FTA-ABS</td>
    <td>fluorescent treponemal antibody—absorbed</td>
  </tr>
  <tr>
    <td>FTD*</td>
    <td>frontotemporal dementia</td>
  </tr>
  <tr>
    <td>5-FU</td>
    <td>5-fluorouracil</td>
  </tr>
  <tr>
    <td>FVC</td>
    <td>forced vital</td>
  </tr>
  <tr>
    <td></td>
    <td>capacity</td>
  </tr>
  <tr>
    <td>GABA</td>
    <td>yraminobutyric acid</td>
  </tr>
  <tr>
    <td>GAG</td>
    <td>glycosaminoglycan</td>
  </tr>
  <tr>
    <td>Gal</td>
    <td>galactose</td>
  </tr>
  <tr>
    <td>GBM</td>
    <td>basement membrane</td>
  </tr>
  <tr>
    <td></td>
    <td>glomerular</td>
  </tr>
  <tr>
    <td>GC</td>
    <td>glomerular capillary</td>
  </tr>
  <tr>
    <td>G-CSF</td>
    <td>granulocyte colony-stimulating factor</td>
  </tr>
  <tr>
    <td>GERD</td>
    <td>gastroesophageal reflux disease</td>
  </tr>
  <tr>
    <td>GFAP</td>
    <td>glial fibrillary acid protein</td>
  </tr>
  <tr>
    <td>GFR</td>
    <td>glomerular filtration rate</td>
  </tr>
  <tr>
    <td>GGT</td>
    <td>-glutamyl transpeptidase</td>
  </tr>
  <tr>
    <td>GH</td>
    <td>growth hormone</td>
  </tr>
  <tr>
    <td>GHB</td>
    <td>y-hydroxybutyrate</td>
  </tr>
  <tr>
    <td>GHRH</td>
    <td>growth hormone-teleasing hormone</td>
  </tr>
  <tr>
    <td>G,</td>
    <td>G protein, I polypeptide</td>
  </tr>
  <tr>
    <td>GI</td>
    <td>gastrointestinal</td>
  </tr>
  <tr>
    <td>GIP</td>
    <td>gastric inhibitory peptide</td>
  </tr>
  <tr>
    <td>GIST</td>
    <td>gastrointestinal stromal tumor</td>
  </tr>
  <tr>
    <td>GLUT</td>
    <td>glucose transporter</td>
  </tr>
  <tr>
    <td>GM</td>
    <td>granulocyte macrophage</td>
  </tr>
  <tr>
    <td>GM-CSF</td>
    <td>granulocyte-macrophage colony stimulating factor</td>
  </tr>
  <tr>
    <td>GMP</td>
    <td>guanosine monophosphate</td>
  </tr>
  <tr>
    <td>GnRH</td>
    <td>gonadotropin-releasing hormone</td>
  </tr>
  <tr>
    <td>Gp</td>
    <td>glycoprotein</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>ABBREVIATION</th>
    <th>MEANING</th>
  </thead>
  <tr>
    <td>GPI</td>
    <td>glycosyl phosphatidylinositol</td>
  </tr>
  <tr>
    <td>GRP.</td>
    <td>gastrin-releasing peptide</td>
  </tr>
  <tr>
    <td>Gy</td>
    <td>G protein, S polypeptide</td>
  </tr>
  <tr>
    <td>GSH</td>
    <td>reduced glutathione</td>
  </tr>
  <tr>
    <td>GSSG</td>
    <td>oxidized glutathione</td>
  </tr>
  <tr>
    <td>GTP</td>
    <td>guanosine triphosphate</td>
  </tr>
  <tr>
    <td>GTPase</td>
    <td>guanosine triphosphatase</td>
  </tr>
  <tr>
    <td>GU</td>
    <td>genitourinary</td>
  </tr>
  <tr>
    <td>H*</td>
    <td>heterochromatin</td>
  </tr>
  <tr>
    <td>He</td>
    <td>hydrogen ion</td>
  </tr>
  <tr>
    <td>H,, H,</td>
    <td>histamine receptors</td>
  </tr>
  <tr>
    <td>H,S</td>
    <td>hydrogen sulfide</td>
  </tr>
  <tr>
    <td>ha*</td>
    <td>hepatic artery</td>
  </tr>
  <tr>
    <td>HAV</td>
    <td>hepatitis A virus</td>
  </tr>
  <tr>
    <td>HAVAb</td>
    <td>hepatitis A antibody</td>
  </tr>
  <tr>
    <td>Hb</td>
    <td>hemoglobin</td>
  </tr>
  <tr>
    <td>HBcAb/HBcAg</td>
    <td>hepatitis B core antibody/antigen</td>
  </tr>
  <tr>
    <td></td>
    <td>B</td>
  </tr>
  <tr>
    <td>HBeAb/HBeAg</td>
    <td>hepatitis early antibody/antigen</td>
  </tr>
  <tr>
    <td>HBsAb/HBsAg</td>
    <td>hepatitis B surface antibody/antigen</td>
  </tr>
  <tr>
    <td>HbCO,</td>
    <td>carbaminohemoglobin</td>
  </tr>
  <tr>
    <td>HBV</td>
    <td>hepatitis B virus</td>
  </tr>
  <tr>
    <td>HCC</td>
    <td>hepatocellular carcinoma</td>
  </tr>
  <tr>
    <td>hCG</td>
    <td>human chorionic gonadotropin</td>
  </tr>
  <tr>
    <td>HCO,</td>
    <td>bicarbonate</td>
  </tr>
  <tr>
    <td>Het</td>
    <td>hematocrit</td>
  </tr>
  <tr>
    <td>HCTZ</td>
    <td>hydrochlorothiazide</td>
  </tr>
  <tr>
    <td>HCV</td>
    <td>C virus</td>
  </tr>
  <tr>
    <td></td>
    <td>hepatitis</td>
  </tr>
  <tr>
    <td>HDL</td>
    <td>high-density lipoprotein</td>
  </tr>
  <tr>
    <td>HDN</td>
    <td>hemolytic disease of the newborn</td>
  </tr>
  <tr>
    <td>HDV</td>
    <td>hepatitis D virus</td>
  </tr>
  <tr>
    <td>H&amp;E</td>
    <td>and eosin</td>
  </tr>
  <tr>
    <td></td>
    <td>hematoxylin</td>
  </tr>
  <tr>
    <td>HEV</td>
    <td>hepatitis E. virus</td>
  </tr>
  <tr>
    <td>HF</td>
    <td>heart failure</td>
  </tr>
  <tr>
    <td>Hfr</td>
    <td>high-frequency recombination [cell]</td>
  </tr>
  <tr>
    <td>HFpEF</td>
    <td>heart failure with preserved ejection fraction</td>
  </tr>
  <tr>
    <td>HFYEF</td>
    <td>heart failure with reduced ejection fraction</td>
  </tr>
  <tr>
    <td>HGPRT</td>
    <td>hypoxanthine-guanine phosphoribosyltransferase</td>
  </tr>
  <tr>
    <td>HHb</td>
    <td>deoxygenated hemoglobin</td>
  </tr>
  <tr>
    <td>HHS</td>
    <td>hyperosmolar hyperglycemic state</td>
  </tr>
  <tr>
    <td>HHV</td>
    <td>human herpesvirus</td>
  </tr>
  <tr>
    <td>5-HIAA</td>
    <td>5-hydroxyindoleacetic acid</td>
  </tr>
  <tr>
    <td>HIT</td>
    <td>heparin-induced thrombocytopenia</td>
  </tr>
  <tr>
    <td>HIV</td>
    <td>human immunodeficiency virus</td>
  </tr>
  <tr>
    <td>HL</td>
    <td>hepatic lipase</td>
  </tr>
  <tr>
    <td>HLA</td>
    <td>human leukocyte antigen</td>
  </tr>
  <tr>
    <td>HMG-CoA.</td>
    <td>hydroxymethylglutaryl-coenzyme A</td>
  </tr>
  <tr>
    <td>HMP</td>
    <td>hexose monophosphate</td>
  </tr>
  <tr>
    <td>HMWK</td>
    <td>high-molecular-weight kininogen</td>
  </tr>
  <tr>
    <td>HNPCC</td>
    <td>hereditary nonpolyposis colorectal cancer</td>
  </tr>
  <tr>
    <td>hnRNA</td>
    <td>heterogeneous nuclear ribonucleic acid</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>HPV</th>
    <th>human papillomavirus</th>
  </thead>
  <tr>
    <td>HR</td>
    <td>heart rate</td>
  </tr>
  <tr>
    <td>HSP</td>
    <td>Henoch-Schénlein purpura</td>
  </tr>
  <tr>
    <td>HSV</td>
    <td>herpes simplex virus</td>
  </tr>
  <tr>
    <td>5-HT</td>
    <td>5-hydroxytryptamine (serotonin)</td>
  </tr>
  <tr>
    <td>HTLV</td>
    <td>human T-cell leukemia virus</td>
  </tr>
  <tr>
    <td>HTN</td>
    <td>hypertension</td>
  </tr>
  <tr>
    <td>HUS</td>
    <td>hemolytic-uremic syndrome</td>
  </tr>
  <tr>
    <td>HVA</td>
    <td>homovanillic acid</td>
  </tr>
  <tr>
    <td>IBD</td>
    <td>inflammatory bowel disease</td>
  </tr>
  <tr>
    <td>IBS</td>
    <td>irritable bowel syndrome</td>
  </tr>
  <tr>
    <td>IC</td>
    <td>inspiratory capacity, immune complex</td>
  </tr>
  <tr>
    <td>They</td>
    <td>calcium current [heart]</td>
  </tr>
  <tr>
    <td>I</td>
    <td>funny current [heart]</td>
  </tr>
  <tr>
    <td>ICA</td>
    <td>internal carotid artery</td>
  </tr>
  <tr>
    <td>ICAM.</td>
    <td>intercellular adhesion molecule</td>
  </tr>
  <tr>
    <td>ICD</td>
    <td>implantable cardioverter-defibrillator</td>
  </tr>
  <tr>
    <td>ICE</td>
    <td>Integrated Clinical Encounter</td>
  </tr>
  <tr>
    <td></td>
    <td>intracellular fluid</td>
  </tr>
  <tr>
    <td>ICF</td>
    <td></td>
  </tr>
  <tr>
    <td>ICP</td>
    <td>intracranial pressure</td>
  </tr>
  <tr>
    <td>ID</td>
    <td>identification</td>
  </tr>
  <tr>
    <td>ID,,</td>
    <td>median infective dose</td>
  </tr>
  <tr>
    <td>IDL</td>
    <td>intermediate-density lipoprotein</td>
  </tr>
  <tr>
    <td>IF</td>
    <td>immunofluorescence, initiation factor</td>
  </tr>
  <tr>
    <td>IFN</td>
    <td>interferon</td>
  </tr>
  <tr>
    <td>Ig</td>
    <td>immunoglobulin</td>
  </tr>
  <tr>
    <td>IGF</td>
    <td>insulinlike growth factor</td>
  </tr>
  <tr>
    <td>Ihe</td>
    <td>current [heart]</td>
  </tr>
  <tr>
    <td></td>
    <td>potassium</td>
  </tr>
  <tr>
    <td>IL</td>
    <td>interleukin</td>
  </tr>
  <tr>
    <td>IM</td>
    <td>intramuscular</td>
  </tr>
  <tr>
    <td>IMA</td>
    <td>inferior mesenteric artery</td>
  </tr>
  <tr>
    <td>IMG</td>
    <td>international medical graduate</td>
  </tr>
  <tr>
    <td>IMP</td>
    <td>inosine monophosphate</td>
  </tr>
  <tr>
    <td>IMV</td>
    <td>inferior mesenteric vein</td>
  </tr>
  <tr>
    <td>I,</td>
    <td>sodium current [heart]</td>
  </tr>
  <tr>
    <td>INH</td>
    <td>isoniazid</td>
  </tr>
  <tr>
    <td>INO</td>
    <td>internuclear ophthalmoplegia</td>
  </tr>
  <tr>
    <td>INR</td>
    <td>International Normalized Ratio</td>
  </tr>
  <tr>
    <td>s(@)</td>
    <td>inferior oblique [muscle]</td>
  </tr>
  <tr>
    <td>IOP</td>
    <td>intraocular pressure</td>
  </tr>
  <tr>
    <td>IP,</td>
    <td>inositol triphosphate</td>
  </tr>
  <tr>
    <td>IPV</td>
    <td>inactivated polio vaccine</td>
  </tr>
  <tr>
    <td>IR</td>
    <td>current X resistance [Ohm’s law], inferior rectus [muscle]</td>
  </tr>
  <tr>
    <td>IRV</td>
    <td>inspiratory reserve volume</td>
  </tr>
  <tr>
    <td>ITP</td>
    <td>idiopathic thrombocytopenic purpura</td>
  </tr>
  <tr>
    <td>IUD</td>
    <td>intrauterine device</td>
  </tr>
  <tr>
    <td>IV</td>
    <td>intravenous</td>
  </tr>
  <tr>
    <td>IVC</td>
    <td>inferior vena cava</td>
  </tr>
  <tr>
    <td>IVIG.</td>
    <td>intravenous immunoglobulin</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>ABBREVIATION</th>
    <th>MEANING</th>
  </thead>
  <tr>
    <td>K</td>
    <td>potassium ion</td>
  </tr>
  <tr>
    <td>KatG</td>
    <td>catalase-peroxidase produced by M tuberculosis</td>
  </tr>
  <tr>
    <td></td>
    <td>elimination constant</td>
  </tr>
  <tr>
    <td></td>
    <td>filtration constant</td>
  </tr>
  <tr>
    <td></td>
    <td>ctoglutarate</td>
  </tr>
  <tr>
    <td></td>
    <td>idney</td>
  </tr>
  <tr>
    <td></td>
    <td>Michaelis-Menten constant</td>
  </tr>
  <tr>
    <td></td>
    <td>potassium hydroxide</td>
  </tr>
  <tr>
    <td></td>
    <td>eft, lentiform, liver</td>
  </tr>
  <tr>
    <td></td>
    <td>eft atrial, left atrium</td>
  </tr>
  <tr>
    <td></td>
    <td>eft anterior descending coronary artery</td>
  </tr>
  <tr>
    <td></td>
    <td>leukocyte alkaline phosphatase</td>
  </tr>
  <tr>
    <td>Lat cond*</td>
    <td>jateral condyle</td>
  </tr>
  <tr>
    <td>Lb*</td>
    <td>jamellar body</td>
  </tr>
  <tr>
    <td>LCA</td>
    <td>eft</td>
  </tr>
  <tr>
    <td></td>
    <td>coronary artery</td>
  </tr>
  <tr>
    <td>LCAT</td>
    <td>ecithin-cholesterol acyltransferase</td>
  </tr>
  <tr>
    <td>LCC*</td>
    <td>jeft common carotid artery</td>
  </tr>
  <tr>
    <td>LCFA</td>
    <td>long-chain fatty acid</td>
  </tr>
  <tr>
    <td>LCL</td>
    <td>ateral collateral ligament</td>
  </tr>
  <tr>
    <td>LCME</td>
    <td>Liaison Committee Medical Education</td>
  </tr>
  <tr>
    <td></td>
    <td>on</td>
  </tr>
  <tr>
    <td>LCMV</td>
    <td>lymphocytic choriomeningitis virus</td>
  </tr>
  <tr>
    <td>LCX</td>
    <td>left circumflex coronary artery</td>
  </tr>
  <tr>
    <td>LD</td>
    <td>loading dose</td>
  </tr>
  <tr>
    <td>LD,,</td>
    <td>median lethal dose</td>
  </tr>
  <tr>
    <td>LDH</td>
    <td>lactate dehydrogenase</td>
  </tr>
  <tr>
    <td>LDL</td>
    <td>low-density lipoprotein</td>
  </tr>
  <tr>
    <td>LES</td>
    <td>lower esophageal sphincter</td>
  </tr>
  <tr>
    <td>LFA</td>
    <td>cukocyte function-associated antigen</td>
  </tr>
  <tr>
    <td>LFT</td>
    <td>iver function test</td>
  </tr>
  <tr>
    <td>LH</td>
    <td>uteinizing hormone</td>
  </tr>
  <tr>
    <td>Liv*</td>
    <td>iver</td>
  </tr>
  <tr>
    <td>LLL*</td>
    <td>eft lower lobe (of lung)</td>
  </tr>
  <tr>
    <td>LLO</td>
    <td>eft lower quadrant</td>
  </tr>
  <tr>
    <td>LM</td>
    <td>jateral meniscus, left main light microscopy</td>
  </tr>
  <tr>
    <td></td>
    <td>coronary artery,</td>
  </tr>
  <tr>
    <td>LMN</td>
    <td>lower motor neuron</td>
  </tr>
  <tr>
    <td>LOS</td>
    <td>ipooligosaccharide</td>
  </tr>
  <tr>
    <td>LPA*</td>
    <td>eft pulmonary artery</td>
  </tr>
  <tr>
    <td>LPL</td>
    <td>ipoprotein lipase</td>
  </tr>
  <tr>
    <td>LPS</td>
    <td>ipopolysaccharide</td>
  </tr>
  <tr>
    <td>LR</td>
    <td>lateral rectus [muscle]</td>
  </tr>
  <tr>
    <td></td>
    <td>labile toxin, leukotriene</td>
  </tr>
  <tr>
    <td>LUL*</td>
    <td>eft upper lobe (of lung)</td>
  </tr>
  <tr>
    <td></td>
    <td>eft ventricle, left ventricular</td>
  </tr>
  <tr>
    <td></td>
    <td>muscarinic (parasympathetic) ACh receptors</td>
  </tr>
  <tr>
    <td>MAC</td>
    <td>membrane attack complex, minimum alveolar concentration</td>
  </tr>
  <tr>
    <td>MALT</td>
    <td>mucosa-associated lymphoid tissue</td>
  </tr>
  <tr>
    <td>MAO</td>
    <td>monoamine oxidase</td>
  </tr>
  <tr>
    <td>MAP.</td>
    <td>mean arterial pressure, mitogen-activated protein</td>
  </tr>
  <tr>
    <td>Max*</td>
    <td>maxillary sinus</td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>MCL</td>
    <td>medial collateral ligament</td>
  </tr>
  <tr>
    <td>MCP</td>
    <td>metacarpophalangeal [joint]</td>
  </tr>
  <tr>
    <td>MCV</td>
    <td>mean corpuscular volume</td>
  </tr>
  <tr>
    <td>MD</td>
    <td>maintenance dose</td>
  </tr>
  <tr>
    <td>MDD</td>
    <td>major depressive disorder</td>
  </tr>
  <tr>
    <td>Med cond*</td>
    <td>medial condyle</td>
  </tr>
  <tr>
    <td>MELAS syndrome</td>
    <td>
      mitochondrial encephalopathy, lactic acidosis, and stroke- like episodes
    </td>
  </tr>
  <tr>
    <td>MEN</td>
    <td>multiple endocrine neoplasia</td>
  </tr>
  <tr>
    <td>MERS</td>
    <td>Middle East respiratory syndrome</td>
  </tr>
  <tr>
    <td>Mg</td>
    <td>magnesium ion</td>
  </tr>
  <tr>
    <td>MgSO,</td>
    <td>magnesium sulfate</td>
  </tr>
  <tr>
    <td>MHC</td>
    <td>major histocompatibility complex</td>
  </tr>
  <tr>
    <td>MI</td>
    <td>myocardial infarction</td>
  </tr>
  <tr>
    <td>MIF</td>
    <td>miillerian inhibiting factor</td>
  </tr>
  <tr>
    <td>MIRL</td>
    <td>membrane inhibitor of reactive lysis</td>
  </tr>
  <tr>
    <td>MLCK</td>
    <td>kinase</td>
  </tr>
  <tr>
    <td></td>
    <td>myosin light-chain</td>
  </tr>
  <tr>
    <td>MLF</td>
    <td>medial longitudinal fasciculus</td>
  </tr>
  <tr>
    <td>MMC</td>
    <td>migrating motor complex</td>
  </tr>
  <tr>
    <td>MMR</td>
    <td>measles, mumps, rubella [vaccine]</td>
  </tr>
  <tr>
    <td>MODY</td>
    <td>maturity-onset diabetes of the young</td>
  </tr>
  <tr>
    <td>6-MP</td>
    <td>6-mercaptopurine</td>
  </tr>
  <tr>
    <td>MPGN</td>
    <td>membranoproliferative glomerulonephritis</td>
  </tr>
  <tr>
    <td>MPO</td>
    <td>myeloperoxidase</td>
  </tr>
  <tr>
    <td>MPO-ANCA/</td>
    <td>myeloperoxidase/perinuclear antineutrophil cytoplasmic</td>
  </tr>
  <tr>
    <td>p-ANCA</td>
    <td>antibody</td>
  </tr>
  <tr>
    <td>MR</td>
    <td>medial rectus [muscle], mitral regurgitation</td>
  </tr>
  <tr>
    <td>MRI</td>
    <td>magnetic resonance imaging</td>
  </tr>
  <tr>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td>miRNA</td>
    <td>microribonucleic acid</td>
  </tr>
  <tr>
    <td>mRNA</td>
    <td>ribonucleic acid</td>
  </tr>
  <tr>
    <td></td>
    <td>messenger</td>
  </tr>
  <tr>
    <td>MRSA</td>
    <td>methicillin-resistant S aureus</td>
  </tr>
  <tr>
    <td>MS</td>
    <td>mitral stenosis, multiple sclerosis</td>
  </tr>
  <tr>
    <td>MSH</td>
    <td>melanocyte-stimulating hormone</td>
  </tr>
  <tr>
    <td>mtDNA</td>
    <td>mitochondrial DNA</td>
  </tr>
  <tr>
    <td>mTOR</td>
    <td>mammalian target of rapamycin</td>
  </tr>
  <tr>
    <td>MTP</td>
    <td>metatarsophalangeal [joint]</td>
  </tr>
  <tr>
    <td>MTX</td>
    <td>methotrexate</td>
  </tr>
  <tr>
    <td></td>
    <td>myocardial</td>
  </tr>
  <tr>
    <td>MVO,</td>
    <td>oxygen consumption</td>
  </tr>
  <tr>
    <td>MVP</td>
    <td>mitral valve prolapse</td>
  </tr>
  <tr>
    <td>Ne</td>
    <td>nucleus</td>
  </tr>
  <tr>
    <td>Na*</td>
    <td>sodium ion</td>
  </tr>
  <tr>
    <td>NAAT</td>
    <td>nucleic acid amplification test</td>
  </tr>
  <tr>
    <td>NAD</td>
    <td>nicotinamide adenine dinucleotide</td>
  </tr>
  <tr>
    <td>NAD*</td>
    <td>ized nicotinamide adenine dinucleotide ox</td>
  </tr>
  <tr>
    <td>NADH</td>
    <td>reduced nicotinamide adenine dinucleotide</td>
  </tr>
  <tr>
    <td>NADP*</td>
    <td>oxidized nicotinamide adenine dinucleotide phosphate</td>
  </tr>
  <tr>
    <td>NADPH</td>
    <td>reduced nicotinamide adenine dinucleotide phosphate</td>
  </tr>
  <tr>
    <td>NBME</td>
    <td>National Board of Medical Examiners</td>
  </tr>
  <tr>
    <td>NBOME</td>
    <td>National Board of Osteopathic Medical Examiners</td>
  </tr>
  <tr>
    <td>NBPME</td>
    <td>National Board of Podiatric Medical Examiners</td>
  </tr>
  <tr>
    <td>NE</td>
    <td>norepinephrine</td>
  </tr>
  <tr>
    <td>NF</td>
    <td>neurofibromatosis</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>ABBREVIATION</th>
    <th>MEANING</th>
    <th>ABBREVIATION</th>
    <th>MEANING</th>
  </thead>
  <tr>
    <td>NH,*</td>
    <td>ammonium</td>
    <td>PCL</td>
    <td>posterior cruciate ligament</td>
  </tr>
  <tr>
    <td>NK</td>
    <td>natural killer [cells]</td>
    <td>Pco,</td>
    <td>partial pressure of carbon dioxide</td>
  </tr>
  <tr>
    <td>Ny</td>
    <td>muscarinic ACh receptor in neuromuscular junction</td>
    <td>PCom</td>
    <td>posterior communicating [artery]</td>
  </tr>
  <tr>
    <td>NMDA</td>
    <td>N-nethyl-d-aspartate</td>
    <td rowspan="2">PCOS PCP</td>
    <td>polycystic ovarian syndrome</td>
  </tr>
  <tr>
    <td>NMJ</td>
    <td>neuromuscular junction</td>
    <td></td>
    <td>phencyclidine hydrochloride, Pneumocystis jirovecii</td>
  </tr>
  <tr>
    <td>NMS</td>
    <td>neuroleptic malignant syndrome</td>
    <td></td>
    <td>pneumonia</td>
  </tr>
  <tr>
    <td>Ny</td>
    <td>nicotinic ACh receptor in autonomic ganglia</td>
    <td>PCR</td>
    <td>polymerase chain reaction</td>
  </tr>
  <tr>
    <td>NRMP</td>
    <td>National Residency Matching Program</td>
    <td>PCT</td>
    <td>proximal convoluted tubule</td>
  </tr>
  <tr>
    <td>NNRTI</td>
    <td>non-nucleoside reverse transcriptase inhibitor</td>
    <td>PCVI13</td>
    <td>pneumococcal conjugate vaccine</td>
  </tr>
  <tr>
    <td>NO</td>
    <td>nitric oxide</td>
    <td>PCWP</td>
    <td>pulmonary capillary wedge pressure</td>
  </tr>
  <tr>
    <td>N,O</td>
    <td>nitrous oxide</td>
    <td>PDA</td>
    <td>patent ductus arteriosus, posterior descending artery</td>
  </tr>
  <tr>
    <td>NPH</td>
    <td>neutral protamine Hagedorn, normal</td>
    <td>PDE</td>
    <td>phosphodiesterase</td>
  </tr>
  <tr>
    <td></td>
    <td>pressure hydrocephalus</td>
    <td>PDGF</td>
    <td>platelet-derived growth factor</td>
  </tr>
  <tr>
    <td>NPV</td>
    <td>negative predictive value</td>
    <td>PDH</td>
    <td>dehydrogenase</td>
  </tr>
  <tr>
    <td></td>
    <td></td>
    <td></td>
    <td>pytuvate</td>
  </tr>
  <tr>
    <td>NRITI</td>
    <td>nucleoside reverse transcriptase inhibitor</td>
    <td>PE</td>
    <td>pulmonary embolism</td>
  </tr>
  <tr>
    <td>NSAID</td>
    <td>nonsteroidal anti-inflammatory drug</td>
    <td>PECAM</td>
    <td>platelet-endothelial cell adhesion molecule</td>
  </tr>
  <tr>
    <td>NSE</td>
    <td>neuron-specific enolase</td>
    <td>PEco,</td>
    <td>expired air Pco,</td>
  </tr>
  <tr>
    <td>NSTEMI</td>
    <td>non-ST-segment elevation myocardial infarction</td>
    <td>PEP</td>
    <td>phosphoenolpyruvate</td>
  </tr>
  <tr>
    <td>NTD</td>
    <td>neural tube defect</td>
    <td>PF</td>
    <td>platelet factor</td>
  </tr>
  <tr>
    <td>Nu*</td>
    <td>nucleolus</td>
    <td>PFK</td>
    <td>phosphofructokinase</td>
  </tr>
  <tr>
    <td>OAA</td>
    <td>oxaloacetic acid</td>
    <td>PFK-2</td>
    <td>phosphofructokinase-2</td>
  </tr>
  <tr>
    <td>OCD</td>
    <td>obsessive-compulsive disorder</td>
    <td>PFT</td>
    <td>pulmonary function test</td>
  </tr>
  <tr>
    <td>OCP.</td>
    <td>oral contraceptive pill</td>
    <td>PG</td>
    <td>phosphoglycerate</td>
  </tr>
  <tr>
    <td>ODC</td>
    <td>oxygen-hemoglobin dissociation curve</td>
    <td>Pu,o</td>
    <td>water pressure</td>
  </tr>
  <tr>
    <td>OH</td>
    <td>hydroxy</td>
    <td>ia</td>
    <td>plasma interstitial osmotic pressure, inorganic phosphate</td>
  </tr>
  <tr>
    <td>1,25-OH D,</td>
    <td>calcitriol (active form of vitamin D)</td>
    <td>PICA</td>
    <td>posterior inferior cerebellar artery</td>
  </tr>
  <tr>
    <td>25-OH D,</td>
    <td>storage form of vitamin D</td>
    <td>PID</td>
    <td>pelvic inflammatory disease</td>
  </tr>
  <tr>
    <td>OPV</td>
    <td>oral polio vaccine</td>
    <td>Pio,</td>
    <td>Po, in inspired air</td>
  </tr>
  <tr>
    <td>OR</td>
    <td>odds ratio</td>
    <td>PIP</td>
    <td>proximal interphalangeal [joint]</td>
  </tr>
  <tr>
    <td>ori</td>
    <td>origins of replication</td>
    <td>PIP,</td>
    <td>phosphatidylinositol 4,5-bisphosphate</td>
  </tr>
  <tr>
    <td>OS</td>
    <td>opening snap</td>
    <td>PIP,</td>
    <td>phosphatidylinositol 3,4,5-bisphosphate</td>
  </tr>
  <tr>
    <td>OSA</td>
    <td>obstructive sleep apnea</td>
    <td>PKD</td>
    <td>polycystic kidney disease</td>
  </tr>
  <tr>
    <td>OTC</td>
    <td>Omithine transcarbamylase</td>
    <td>PKR</td>
    <td>interferon-o-induced protein kinase</td>
  </tr>
  <tr>
    <td>OVLT</td>
    <td>vasculosum of the lamina terminalis</td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td></td>
    <td>organum</td>
    <td>PKU</td>
    <td>phenylketonuria</td>
  </tr>
  <tr>
    <td>P-body</td>
    <td>processing body (cytoplasmic)</td>
    <td>PLAP</td>
    <td>placental alkaline phosphatase</td>
  </tr>
  <tr>
    <td>P-450</td>
    <td>cytochrome P-450 family of enzymes</td>
    <td>PLP</td>
    <td>pyridoxal phosphate</td>
    ======================================
  </tr>
  <tr>
    <td>PA</td>
    <td>posteroanterior, pulmonary artery</td>
    <td>PML</td>
    <td>progressive multifocal leukoencephalopathy</td>
  </tr>
  <tr>
    <td>PABA</td>
    <td>para-aminobenzoic acid</td>
    <td>PMN</td>
    <td>polymorphonuclear [leukocyte]</td>
  </tr>
  <tr>
    <td>Paco,</td>
    <td>arterial Pco,</td>
    <td>Pp.</td>
    <td>net filtration</td>
  </tr>
  <tr>
    <td>Paco,</td>
    <td>alveolar Pco,</td>
    <td>PNET</td>
    <td>pressure primitive neuroectodermal tumor</td>
  </tr>
  <tr>
    <td>PAH</td>
    <td>para-aminohippuric acid</td>
    <td>PNS</td>
    <td>peripheral nervous</td>
  </tr>
  <tr>
    <td>PAN</td>
    <td>polyarteritis nodosa</td>
    <td>Po,</td>
    <td>system partial of</td>
  </tr>
  <tr>
    <td>Pao,</td>
    <td>partial pressure of oxygen in arterial blood</td>
    <td>POs</td>
    <td>pressure oxygen phosphate</td>
  </tr>
  <tr>
    <td>Pao,</td>
    <td>partial pressure of oxygen in alveolar blood</td>
    <td>Pop*</td>
    <td>popliteal artery</td>
  </tr>
  <tr>
    <td rowspan="2">PAP</td>
    <td></td>
    <td>Papanicolaou [smear], prostatic acid phosphatase,</td>
    <td>Pop a*</td>
    <td>popliteal artery</td>
  </tr>
  <tr>
    <td>posteromedial papillary muscle</td>
    <td>Post®</td>
    <td>posterior</td>
  </tr>
  <tr>
    <td>RAID</td>
    <td>pregnancy-associated plasma protein A</td>
    <td>PPAR</td>
    <td>peroxisome proliferator-activated receptor</td>
  </tr>
  <tr>
    <td>PAS</td>
    <td>periodic acid-Schiff</td>
    <td>PPD</td>
    <td>purified protein derivative</td>
  </tr>
  <tr>
    <td>Lat</td>
    <td>patella</td>
    <td>PPI</td>
    <td>proton pump inhibitor</td>
  </tr>
  <tr>
    <td>PB</td>
    <td>Barometric (atmospheric) pressure</td>
    <td>PPM</td>
    <td>parts per million</td>
  </tr>
  <tr>
    <td>a?</td>
    <td>penicillin-binding protein</td>
    <td>PPSV23</td>
    <td>pneumococcal polysaccharide vaccine</td>
  </tr>
  <tr>
    <td>PC</td>
    <td>platelet count, pyruvate carboxylase</td>
    <td>PPV</td>
    <td>positive predictive value</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>ABBREVIATION</th>
    <th>MEANING</th>
  </thead>
  <tr>
    <td>PrP</td>
    <td>prion protein</td>
  </tr>
  <tr>
    <td>PRPP</td>
    <td>phosphoribosylpyrophosphate</td>
  </tr>
  <tr>
    <td>PSA</td>
    <td>prostate-specific antigen</td>
  </tr>
  <tr>
    <td>PSS</td>
    <td>progressive systemic sclerosis</td>
  </tr>
  <tr>
    <td>PT</td>
    <td>prothrombin time, proximal tubule</td>
  </tr>
  <tr>
    <td>PTEN</td>
    <td>phosphatase and tensin homolog</td>
  </tr>
  <tr>
    <td>PTH</td>
    <td>parathyroid hormone</td>
  </tr>
  <tr>
    <td>PTHrP</td>
    <td>parathyroid hormone-related protein</td>
  </tr>
  <tr>
    <td>PTSD</td>
    <td>post-traumatic stress disorder</td>
  </tr>
  <tr>
    <td>PIT</td>
    <td>partial thromboplastin time</td>
  </tr>
  <tr>
    <td>PV</td>
    <td>plasma volume, venous pressure, portal vein</td>
  </tr>
  <tr>
    <td>pv"</td>
    <td>pulmonary vein</td>
  </tr>
  <tr>
    <td>PVC</td>
    <td>polyvinyl chloride</td>
  </tr>
  <tr>
    <td></td>
    <td>pulmonary vascular resistance</td>
  </tr>
  <tr>
    <td></td>
    <td>pytrolidonyl aminopeptidase</td>
  </tr>
  <tr>
    <td></td>
    <td>correlation coefficient, right, R variable</td>
  </tr>
  <tr>
    <td>PRU</td>
    <td>[group]</td>
  </tr>
  <tr>
    <td></td>
    <td>Registration, Ranking, &amp; Results [system]</td>
  </tr>
  <tr>
    <td>Sele</td>
    <td>atrial</td>
  </tr>
  <tr>
    <td></td>
    <td>right atrium, right</td>
  </tr>
  <tr>
    <td>RAAS</td>
    <td>renin-angiotensin-aldosterone</td>
  </tr>
  <tr>
    <td></td>
    <td>system</td>
  </tr>
  <tr>
    <td>RANK-L</td>
    <td>receptor activator of nuclear factor-« B ligand</td>
  </tr>
  <tr>
    <td></td>
    <td>reticular activating system</td>
  </tr>
  <tr>
    <td>RBF</td>
    <td>renal blood flow</td>
  </tr>
  <tr>
    <td>RCA</td>
    <td>right coronary artery</td>
  </tr>
  <tr>
    <td>REM</td>
    <td>rapid eye movement</td>
  </tr>
  <tr>
    <td>RER</td>
    <td>rough endoplasmic reticulum</td>
  </tr>
  <tr>
    <td></td>
    <td>rhesus antigen</td>
  </tr>
  <tr>
    <td></td>
    <td>lower lobe (of</td>
  </tr>
  <tr>
    <td></td>
    <td>right lungs)</td>
  </tr>
  <tr>
    <td></td>
    <td>right lower quadrant</td>
  </tr>
  <tr>
    <td></td>
    <td>right middle lobe (of lung)</td>
  </tr>
  <tr>
    <td></td>
    <td>ribonucleic acid</td>
  </tr>
  <tr>
    <td></td>
    <td>ribonucleoprotein</td>
  </tr>
  <tr>
    <td></td>
    <td>reactive oxygen species</td>
  </tr>
  <tr>
    <td></td>
    <td>renal plasma flow</td>
  </tr>
  <tr>
    <td></td>
    <td>rapidly progressive glomerulonephritis</td>
  </tr>
  <tr>
    <td></td>
    <td>rapid plasma reagin</td>
  </tr>
  <tr>
    <td></td>
    <td>relative</td>
  </tr>
  <tr>
    <td></td>
    <td>risk, respiratory rate</td>
  </tr>
  <tr>
    <td></td>
    <td>ribosomal ribonucleic acid</td>
  </tr>
  <tr>
    <td></td>
    <td>Reed-Sternberg [cells</td>
  </tr>
  <tr>
    <td></td>
    <td>right subclavian artery</td>
  </tr>
  <tr>
    <td></td>
    <td>respiratory syncytial virus</td>
  </tr>
  <tr>
    <td></td>
    <td>renal tubular acidosis</td>
  </tr>
  <tr>
    <td></td>
    <td>right upper lobe (of lung)</td>
  </tr>
  <tr>
    <td></td>
    <td>right upper quadrant</td>
  </tr>
  <tr>
    <td></td>
    <td>residual volume, right ventricle, right ventricular</td>
  </tr>
  <tr>
    <td></td>
    <td>right ventricular hypertrophy</td>
  </tr>
  <tr>
    <td></td>
    <td>substrate concentration</td>
  </tr>
  <tr>
    <td></td>
    <td>sinoatrial</td>
  </tr>
  <tr>
    <td></td>
    <td>serum amyloid-associated [protein]</td>
  </tr>
  <tr>
    <td>SAM</td>
    <td>S-adenosylmethionine</td>
  </tr>
  <tr>
    <td>SARS.</td>
    <td>severe acute respiratory syndrome</td>
  </tr>
</table>
======================================
<table>
  <thead>
    <th>ABBREVIATION</th>
    <th>MEANING</th>
  </thead>
  <tr>
    <td>SCJ</td>
    <td>squamocolumnar junction</td>
  </tr>
  <tr>
    <td>SCM</td>
    <td>sternocleidomastoid muscle</td>
  </tr>
  <tr>
    <td>SCN</td>
    <td>suprachiasmatic nucleus</td>
  </tr>
  <tr>
    <td>sD</td>
    <td>standard deviation</td>
  </tr>
  <tr>
    <td>SE,</td>
    <td>standard error [of the mean]</td>
  </tr>
  <tr>
    <td>SEP</td>
    <td>Spoken English Proficiency</td>
  </tr>
  <tr>
    <td>SER</td>
    <td>smooth endoplasmic reticulum</td>
  </tr>
  <tr>
    <td>SERM</td>
    <td>selective estrogen receptor modulator</td>
  </tr>
  <tr>
    <td>SGLT</td>
    <td>sodium-glucose transporter</td>
  </tr>
  <tr>
    <td>SHBG</td>
    <td>sex hormone-binding globulin</td>
  </tr>
  <tr>
    <td>SIADH</td>
    <td>syndrome of inappropriate [secretion of] antidiuretic hormone</td>
  </tr>
  <tr>
    <td>SIDS</td>
    <td>sudden infant death syndrome</td>
  </tr>
  <tr>
    <td>SJS</td>
    <td>Stevens-Johnson syndrome</td>
  </tr>
  <tr>
    <td>SLE</td>
    <td>systemic lupus erythematosus</td>
  </tr>
  <tr>
    <td>SLL</td>
    <td>small lymphocytic lymphoma</td>
  </tr>
  <tr>
    <td>SLT</td>
    <td>Shiga-like toxin</td>
  </tr>
  <tr>
    <td>SMA</td>
    <td>superior mesenteric artery</td>
  </tr>
  <tr>
    <td>SMX</td>
    <td>sulfamethoxazole</td>
  </tr>
  <tr>
    <td></td>
    <td>soluble NSF attachment</td>
  </tr>
  <tr>
    <td>SNARE</td>
    <td>protein receptor</td>
  </tr>
  <tr>
    <td>SNe</td>
    <td>substantia nigra pars compacta</td>
  </tr>
  <tr>
    <td>SNP</td>
    <td>single nucleotide polymorphism</td>
  </tr>
  <tr>
    <td>SNr</td>
    <td>substantia nigra reticulata</td>
  </tr>
  <tr>
    <td></td>
    <td>pars</td>
  </tr>
  <tr>
    <td>SNRI</td>
    <td>serotonin and norepinephrine receptor inhibitor</td>
  </tr>
  <tr>
    <td>snRNA</td>
    <td>small nuclear RNA</td>
  </tr>
  <tr>
    <td>snRNP</td>
    <td>small nuclear</td>
  </tr>
  <tr>
    <td></td>
    <td>ribonucleoprotein</td>
  </tr>
  <tr>
    <td>sO</td>
    <td>superior oblique [muscle]</td>
  </tr>
  <tr>
    <td>SOAP</td>
    <td>Supplemental Offer and Acceptance Program</td>
  </tr>
  <tr>
    <td>Sp*</td>
    <td>spleen</td>
  </tr>
  <tr>
    <td>spp</td>
    <td>species</td>
  </tr>
  <tr>
    <td>SR</td>
    <td>superior rectus [muscle]</td>
  </tr>
  <tr>
    <td>SS</td>
    <td>stranded</td>
  </tr>
  <tr>
    <td></td>
    <td>single</td>
  </tr>
  <tr>
    <td>ssDNA</td>
    <td>single-stranded deoxyribonucleic acid</td>
  </tr>
  <tr>
    <td>SSPE</td>
    <td>subacute sclerosing panencephalitis</td>
  </tr>
  <tr>
    <td>SSRI</td>
    <td>selective serotonin reuptake inhibitor</td>
  </tr>
  <tr>
    <td>ssRNA</td>
    <td>single-stranded ribonucleic acid</td>
  </tr>
  <tr>
    <td>St*</td>
    <td>stomach</td>
  </tr>
  <tr>
    <td>sT</td>
    <td>Shiga toxin</td>
  </tr>
  <tr>
    <td>StAR</td>
    <td>steroidogenic acute regulatory protein</td>
  </tr>
  <tr>
    <td>STEMI</td>
    <td>ST-segment elevation myocardial infarction</td>
  </tr>
  <tr>
    <td>STI</td>
    <td>sexually transmitted infection</td>
  </tr>
  <tr>
    <td>STN</td>
    <td>subthalamic nucleus</td>
  </tr>
  <tr>
    <td>SV</td>
    <td>splenic vein, stroke volume</td>
  </tr>
  <tr>
    <td>SVC</td>
    <td>superior vena cava</td>
  </tr>
  <tr>
    <td>SVR</td>
    <td>systemic vascular resistance</td>
  </tr>
  <tr>
    <td>SVT</td>
    <td>supraventricular tachycardia</td>
  </tr>
  <tr>
    <td>T*</td>
    <td>thalamus, trachea</td>
  </tr>
  <tr>
    <td>tin</td>
    <td>half-life</td>
  </tr>
  <tr>
    <td>T,;</td>
    <td>triiodothyronine</td>
  </tr>
  <tr>
    <td>T,</td>
    <td>thyroxine</td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>TCA</td>
    <td>tricarboxylic acid [cycle], tricyclic antidepressant</td>
  </tr>
  <tr>
    <td>Tc cell</td>
    <td>cytotoxic T cell</td>
  </tr>
  <tr>
    <td>TCR</td>
    <td>T-cell receptor</td>
  </tr>
  <tr>
    <td>TDF</td>
    <td>tenofovir disoproxil fumarate</td>
  </tr>
  <tr>
    <td>TdT</td>
    <td>terminal deoxynucleotidyl transferase</td>
  </tr>
  <tr>
    <td>TE</td>
    <td>tracheoesophageal</td>
  </tr>
  <tr>
    <td>TFT</td>
    <td>thyroid function test</td>
  </tr>
  <tr>
    <td>TG</td>
    <td>triglyceride</td>
  </tr>
  <tr>
    <td>TGF</td>
    <td>transforming growth factor</td>
  </tr>
  <tr>
    <td>Th cell</td>
    <td>helper T cell</td>
  </tr>
  <tr>
    <td>THF</td>
    <td>tetrahydrofolic acid</td>
  </tr>
  <tr>
    <td>TI</td>
    <td>therapeutic index</td>
  </tr>
  <tr>
    <td>TIA</td>
    <td>transient ischemic attack</td>
  </tr>
  <tr>
    <td>Tib*</td>
    <td>tibia</td>
  </tr>
  <tr>
    <td>TIBC</td>
    <td>total iron-binding capacity</td>
  </tr>
  <tr>
    <td>TIPS</td>
    <td>transjugular intrahepatic portosystemic shunt</td>
  </tr>
  <tr>
    <td>TLC</td>
    <td>total lung</td>
  </tr>
  <tr>
    <td></td>
    <td>capacity</td>
  </tr>
  <tr>
    <td>uf</td>
    <td>maximum rate of transport</td>
  </tr>
  <tr>
    <td>TMP</td>
    <td></td>
  </tr>
  <tr>
    <td></td>
    <td>trimethoprim</td>
  </tr>
  <tr>
    <td>™N</td>
    <td>true negative</td>
  </tr>
  <tr>
    <td>TNF</td>
    <td>tumor necrosis factor</td>
  </tr>
  <tr>
    <td>TNM</td>
    <td>tumor, node, metastases [staging]</td>
  </tr>
  <tr>
    <td>TOP</td>
    <td>topoisomerase</td>
  </tr>
  <tr>
    <td>ToRCHeS</td>
    <td>Toxoplasma gondii, rubella, CMV, HIV, HSV-2, syphilis</td>
  </tr>
  <tr>
    <td>TP</td>
    <td>true positive</td>
  </tr>
  <tr>
    <td>tPA</td>
    <td>tissue plasminogen activator</td>
  </tr>
  <tr>
    <td>TPO</td>
    <td>thyroid peroxidase, thrombopoietin</td>
  </tr>
  <tr>
    <td>TPP</td>
    <td>thiamine pyrophosphate</td>
  </tr>
  <tr>
    <td>TPPA</td>
    <td>Treponema pallidum particle agglutination assay</td>
  </tr>
  <tr>
    <td>TPR</td>
    <td>total peripheral resistance</td>
  </tr>
  <tr>
    <td></td>
    <td>tricuspid regurgitation</td>
  </tr>
  <tr>
    <td></td>
    <td>tartrate-resistant acid phosphatase</td>
  </tr>
  <tr>
    <td></td>
    <td>T-cell receptor excision circles</td>
  </tr>
  <tr>
    <td></td>
    <td>thyrotropin-releasing hormone</td>
  </tr>
  <tr>
    <td></td>
    <td>transfer ribonucleic acid</td>
  </tr>
  <tr>
    <td></td>
    <td>thyroid-stimulating hormone</td>
  </tr>
  <tr>
    <td></td>
    <td>triple sugar iron</td>
  </tr>
  <tr>
    <td></td>
    <td>toxic shock syndrome</td>
  </tr>
  <tr>
    <td></td>
    <td>toxic shock syndrome toxin</td>
  </tr>
  <tr>
    <td></td>
    <td>thrombotic thrombocytopenic purpura</td>
  </tr>
  <tr>
    <td></td>
    <td>transthyretin</td>
  </tr>
  <tr>
    <td></td>
    <td>thromboxane A,</td>
  </tr>
  <tr>
    <td></td>
    <td>uridine diphosphate</td>
  </tr>
</table>
======================================
<table>
  <tr>
    <td>UMN</td>
    <td>upper motor neuron</td>
  </tr>
  <tr>
    <td>UMP</td>
    <td>uridine monophosphate</td>
  </tr>
  <tr>
    <td>UPD</td>
    <td>uniparental disomy</td>
  </tr>
  <tr>
    <td>URI</td>
    <td>upper respiratory infection</td>
  </tr>
  <tr>
    <td>USMLE</td>
    <td>United States Medical Licensing Examination</td>
  </tr>
  <tr>
    <td>UTI</td>
    <td>urinary tract infection</td>
  </tr>
  <tr>
    <td>UTP</td>
    <td>uridine triphosphate</td>
  </tr>
  <tr>
    <td>UV</td>
    <td>ultraviolet</td>
  </tr>
  <tr>
    <td>V,V,</td>
    <td>vasopressin receptors</td>
  </tr>
  <tr>
    <td>Va</td>
    <td>alveolar ventilation</td>
  </tr>
  <tr>
    <td>VC</td>
    <td>vital capacity</td>
  </tr>
  <tr>
    <td></td>
    <td>volume of distribution</td>
  </tr>
  <tr>
    <td></td>
    <td>physiologic dead space</td>
  </tr>
  <tr>
    <td></td>
    <td>
      variable, (diversity), joining gene segments rearranged to form Ig genes
    </td>
  </tr>
  <tr>
    <td>VDRL</td>
    <td>Venereal Disease Research Laboratory</td>
  </tr>
  <tr>
    <td>VE</td>
    <td>minute ventilation</td>
  </tr>
  <tr>
    <td>VEGF</td>
    <td>vascular endothelial growth factor</td>
  </tr>
  <tr>
    <td>Vu</td>
    <td>variable region, heavy chain [antibody]</td>
  </tr>
  <tr>
    <td>VHL</td>
    <td>von Hippel-Lindau [disease]</td>
  </tr>
  <tr>
    <td>VIP</td>
    <td>vasoactive intestinal peptide</td>
  </tr>
  <tr>
    <td>VIPoma</td>
    <td>vasoactive intestinal polypeptide-secreting tumor</td>
  </tr>
  <tr>
    <td>yj</td>
    <td>light-chain hypervariable region [antibody]</td>
  </tr>
  <tr>
    <td>Vv,</td>
    <td>variable region, light chain [antibody]</td>
  </tr>
  <tr>
    <td>VLCFA</td>
    <td>very-long-chain fatty acids</td>
  </tr>
  <tr>
    <td>VLDL</td>
    <td>very low density lipoprotein</td>
  </tr>
  <tr>
    <td>VMA</td>
    <td>vanillylmandelic acid</td>
  </tr>
  <tr>
    <td>VMAT</td>
    <td>vesicular monoamine transporter</td>
  </tr>
  <tr>
    <td>Ves</td>
    <td>maximum velocity</td>
  </tr>
  <tr>
    <td>VPL</td>
    <td>ventral posterior nucleus, lateral</td>
  </tr>
  <tr>
    <td>VPM</td>
    <td>ventral posterior nucleus, medial</td>
  </tr>
  <tr>
    <td>VPN</td>
    <td>vancomycin, polymyxin, nystatin [media]</td>
  </tr>
  <tr>
    <td>VIO</td>
    <td>ventilation/perfusion [ratio]</td>
  </tr>
  <tr>
    <td>VRE</td>
    <td>vancomycin-resistant enterococcus</td>
  </tr>
  <tr>
    <td>VSD</td>
    <td>ventricular septal defect</td>
  </tr>
  <tr>
    <td>Vr</td>
    <td>tidal volume</td>
  </tr>
  <tr>
    <td>VTE</td>
    <td>venous thromboembolism</td>
  </tr>
  <tr>
    <td>vWF</td>
    <td>von Willebrand factor</td>
  </tr>
  <tr>
    <td>VZV</td>
    <td>varicella-zoster virus</td>
  </tr>
  <tr>
    <td>VMAT</td>
    <td>vesicular monoamine transporter</td>
  </tr>
  <tr>
    <td>XR</td>
    <td>X-linked recessive</td>
  </tr>
  <tr>
    <td>XX/XY</td>
    <td>normal complement of sex chromosomes for female/male</td>
  </tr>
</table>
